1. business and industrial
2. business operations
3. business plans

62nd AAN Annual Meeting
A p r i l 1 0 — A p r i l 1 7, 2 0 1 0
Scientific Abstract
Listing and
Annual Meeting
Information
Early Registration Deadline:
March 10, 2010
Science · Education · People · Progress
2010 Locations and Deadlines-At-A-Glance
Highlights of the 2010 Annual Meeting
Dates and Deadlines
Integrated Neuroscience Sessions
NEW! Highlights in the Field
MARCH 10, 2010
Sunday, April 11–Friday, April 16
Annual Meeting Early Registration and Housing Deadline
Visit www.aan.com/am
Provides in-depth subspecialty concentration around a topic using a
combination of presentations, such as scientific sessions, case studies,
short poster talks, discussions, invited speakers, and poster sessions.
MAY 13, 2010
xx Emerging Concepts in Genetics (see page 25)
xx Pediatric Demyelinating Disorders (see page 26)
xx Global Neurology: Toxins and Infections (see page 29)
xx Current Concepts in Cognitive Neuroscience: Implications for
Neurological Disease (see page 30)
xx Proteins, Genes, Neurodegeneration, and the Clinical
Presentations (see page 41)
xx Emerging Treatments in Neuromuscular Disease (see page 64)
xx Multiple Sclerosis Imaging (see page 65)
xx Deep Brain Stimulation: Where Are We and Where Do We Go
From Here? (see page 89)
xx Ischemic Stroke, Interventional, and Endovascular Therapies/Large
Vessel Disease (see page 102)
xx Molecular Markers and Targets in Neuro-oncology (see page 103)
These new sessions bring you all you need to know for your
subspecialty or area of special interest. Get overviews in subspecialty
topics from the past year featuring scientific and educational abstracts,
journal articles, subspecialty society updates, tips, resources, and
more. Look for highlights from AAN Sections. See page 79 for list of
participating sections and details.
Course Proposal Deadline for 2011 Annual Meeting
Locations
Metro Toronto Convention Centre
Co-Headquarters Hotels:
ƒƒFairmont Royal York
ƒƒSheraton Centre Toronto Hotel
www.aan.com/am
Table of Contents
New! Clinical Trials Session
Meeting-at-a-Glance. . . . . . . . . . . . . . . . . . . . . . . . . 2
Thursday, April 15 Highlights. . . . . . . . . . . . . . . . 78
Industry Relations Message . . . . . . . . . . . . . . . . . . . 4
Thursday Poster Session V. . . . . . . . . . . . . . . . . . . 80
Program Legend. . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Thursday Integrated Neuroscience Session. . . . . . 89
Meeting Overview. . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Thursday Scientific Sessions. . . . . . . . . . . . . . . . . . 90
Scientific Sessions-At-A-Glance. . . . . . . . . . . . . . . 15
Thursday Poster Session VI . . . . . . . . . . . . . . . . . . 94
Award Recipients. . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Friday, April 16 Highlights . . . . . . . . . . . . . . . . . 101
Saturday, April 10 Highlights. . . . . . . . . . . . . . . . 23
Friday Integrated Neuroscience Session. . . . . . . . 102
Sunday, April 11 Highlights. . . . . . . . . . . . . . . . . 24
Friday Integrated Neuroscience Session. . . . . . . . 103
Sunday Integrated Neuroscience Session . . . . . . . 25
2010 Virtual Annual Meeting Products
(Syllabi CD, Webcast-on-Demand,
Practice CD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Sunday Integrated Neuroscience Session . . . . . . . 26
Monday, April 12 Highlights. . . . . . . . . . . . . . . . . 27
Monday Integrated Neuroscience Session. . . . . . . 29
Monday Integrated Neuroscience Session. . . . . . . 30
Tuesday, April 13 Highlights . . . . . . . . . . . . . . . . 31
Poster Session Floor Plan. . . . . . . . . . . . . . . . . . . . 33
Tuesday Poster Session I. . . . . . . . . . . . . . . . . . . . 34
Tuesday Integrated Neuroscience Session. . . . . . . 41
Tuesday Scientific Sessions. . . . . . . . . . . . . . . . . . 42
Tuesday Poster Session II. . . . . . . . . . . . . . . . . . . . 44
Tuesday Scientific Sessions. . . . . . . . . . . . . . . . . . 52
Wednesday, April 14 Highlights. . . . . . . . . . . . . . 54
Wednesday Poster Session III . . . . . . . . . . . . . . . . 56
Wednesday Integrated Neuroscience Session. . . . 64
Wednesday Integrated Neuroscience Session. . . . 65
Wednesday Scientific Sessions. . . . . . . . . . . . . . . . 66
Wednesday Poster Session IV . . . . . . . . . . . . . . . . 68
Wednesday Scientific Sessions. . . . . . . . . . . . . . . . 76
General Information. . . . . . . . . . . . . . . . . . . . . . . . 106
CME/Accreditation. . . . . . . . . . . . . . . . . . . . . 106
Disclaimers/Disclosures . . . . . . . . . . . . . . . . 106
Services. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Volunteer Opportunities. . . . . . . . . . . . . . . . . 107
Weather/Attire. . . . . . . . . . . . . . . . . . . . . . . . 107
Registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
What’s Free With Your Badge. . . . . . . . . . . . . . . . 110
Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . 114
Travel Information. . . . . . . . . . . . . . . . . . . . . . . . . 116
Alliance Tour Information. . . . . . . . . . . . . . . . . . . . 116
Students, Residents, and Fellows Events. . . . . . . 117
Education Programs and Scientific Sessions .
by Topic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Annual Meeting Exhibitors. . . . . . . . . . . . . . . . . . . 122
Committee Members and Staff. . . . . . . . . . . . . . . 124
Offices and Hours of Operation. . . . . . . . . . . . . . . 126
Friday, April 16, 12:00 p.m.–1:30 p.m.
MTCC, Theatre 102
This midday seminar covers important clinical topics identified from
other society meetings that affect patient care. The latest updates
within several clinical trials conducted over the course of the last year
will be presented with a question and answer period following. The
session will cover several scientific topics.
NEW! The AAN Awards Plenary Session
Thursday, April 15, 4:00 p.m.–6:00 p.m.
MTCC, Exhibit Hall FG
This session highlights some of the best and brightest in the field
today, featuring presentations by the recipients of four top 2010
awards: The Potamkin Prize for Research in Pick’s, Alzheimer’s, and
Related Diseases, the Sheila Essey Award—An Award for ALS
Research, the John Dystel Prize for Multiple Sclerosis Research, and
the Dreifuss-Penry Epilepsy Award in a rotating slot. (See page 78)
NEW! Thursday Afternoon Half-Day Course
Times
Thursday afternoon half-day courses begin at 1:15 p.m. and end
at 5:00 p.m. to allow time to attend Plenary Sessions.
Academy Central
Saturday, April 10–Friday, April 16
Academy Central offers a variety of resources central to the career of
any neurology professional. Explore science and education publications
such as Neurology ® and Continuum: Lifelong Learning in Neurology ®.
Learn about clinical guidelines and shop for tools that can make your
practice more effective and efficient. Find out how social networking is
revolutionizing health care, and why the Academy is advocating on your
behalf in Washington, DC. Enjoy a range of speakers who will address
a variety of topics. Watch for a list of events and speakers. Academy
Central helps demonstrate how the Academy is delivering on its promise
to be an indispensable part of your career, each step of the way.
Changes to Syllabi Process—Download in
Advance
Obtaining your Education Program syllabi is quicker and easier
than ever. All registered attendees will be able to download the
full syllabi for their selected programs, starting in late March.
All registered attendees will receive an email notification once
syllabi are available.
Printed syllabi will not be available. Printed slides will be
available in program rooms.
Future of Neuroscience Conference: Frontiers
in Neuroimaging: Coming Soon to a Scanner
Near You
Friday, April 16, 9:00 a.m.–5:00 p.m.
MTCC, Room 718A
This interactive day-long program focuses on neuroimaging. The
program will feature poster sessions, platform presentations, a
series of case vignettes, and several invited lecturers discussing new
developments in the field. The presenters will combine high-level
science with practical clinical application. Registration is required.
Attendees may register to attend the Future of Neuroscience
Conference only. This fee includes Thursday and Friday scientific
events. Medical Students and PhD candidates may attend at no charge
but MUST register.
New! Platform Session Times
New time slots this year allow registrants to attend the Highlights in
the Field program of their choice.
3
Meeting At-A-Glance
7:00 a.m.
8:00 a.m.
Programs and dates of presentation are subject to change.
Current as of 2/8/2010
9:00 a.m.
10:00 a.m.
11:00 a.m.
12:00 p.m.
1:00 p.m.
2:00 p.m.
3:00 p.m.
4:00 p.m.
5:00 p.m.
6:00 p.m.
7:00 p.m.
8:00 p.m.
9:00 p.m.
10:00 p.m.
Clerkship and Program Directors’ Conference
BRAINS Colloquium
Basic Science Resident Program
APRIL
10
th
Basic Science Resident Program
Neurology Skills Pavilion
Breakfast Seminars
Full-Day Courses
Skills Workshop
SUN
A.M. Half-Day Courses
APRIL
11
th
Scientific Program:
P.M. Half-Day Courses
Neurology Skills Pavilion
Skills Workshop
Dinner Seminars
Full-Day Courses
Scientific Program: Integrated Neuroscience
APRIL
th
Luncheon Seminar
Education Colloquium
P.M. Half-Day Courses
ABPN
MOC
Exhibits Opening and Reception
ABPN Resident
Session
Exhibits
NIH Sponsored Clinical Trials Collo
Poster Session I (With Discussion Session)
Breakfast Seminars
th
-quium
Scientific Program:
Presidential Plenary Session
13
AAN/
AANPA
Business
Meeting
Poster Session II (With Discussion Session)
Integrated Neuroscience
Luncheon Seminar
Corporate Therapeutic Updates
Hot Topics
Plenary Session
Scientific Sessions
P.M. Half-Day Courses
Ethics Colloquium
Neurology Skills Pavilion
Breakfast Seminars
Exhibits
Poster Session III (With Discussion Session)
Skills Workshop
Contemporary Clinical Issues & Case Studies Plenary Session
APRIL
After-Dinner Seminars
Web Wonders
Run/Walk for Brain Research
WED
Neuro Flashes
Best Care Expo
International
Attendee Summit
APRIL
Residents & Fellows Career Forum & Reception
Scientific Program: Integrated Neuroscience
A.M. Half-Day Courses
TUE
Dinner Seminars
Practice Colloquium
Luncheon Seminars
Morning Reports
MON
Celebration for Research
Integrated Neuroscience
Patient Safety Colloquium
Scientific Program: Integrated Neuroscience
Breakfast Seminars
12
Kick-Off Programs
Full-Day Course
SAT
Awards Luncheon
Case Study Programs
Scientific Program: Integrated Neuroscience
14
th
Scientific Program: Integrated Neuroscience
P.M. Half-Day Courses
Poster Session IV (With Discussion Session)
Scientific Sessions
Current Practice Issues in
Neurology: Health Reform
Breakfast Seminars
THU
APRIL
15
th
Exhibits
Poster Session V (With Discussion Session)
Scientific Program: Integrated
Frontiers in Clinical Neuroscience
Plenary Session
Scientific
Clinical Trials Session
Scientific Program: Integrated Neuroscience
P.M. Skills Workshop
Scientific Program:
th
17
4
Scientific Program
Highlights
Plenary Session
P.M. Half-Day Courses
Neurology Skills Pavilion
SAT
Breakfast Seminars
7:00 a.m.
8:00 a.m.
Educational Program
Scientific Program
Other Event
Plenary Session
Exhibits
Events
Neuro Flashes
Future of Neuroscience Conference
A.M. Half-Day Courses
Color Key:
Integrated Neuroscience
Full-Day Courses
APRIL
th
Case Study Programs
Therapy Programs
Poster Session VI (With Discussion Session)
FRI
APRIL
AAN Awards Plenary Session
Sessions
P.M. Half-Day Courses
Breakfast Seminars
16
Neuroscience
Therapy Programs
A.M. Half-Day Courses
9:00 a.m.
10:00 a.m.
11:00 a.m.
12:00 p.m.
1:00 p.m.
2:00 p.m.
3:00 p.m.
4:00 p.m.
5:00 p.m.
6:00 p.m.
7:00 p.m.
8:00 p.m.
9:00 p.m.
10:00 p.m.
Industry Relations Message
Continuing medical education is one of the most important and
well-regarded member services provided by the American Academy
of Neurology (AAN). The Annual Meeting is the AAN’s premier
continuing medical education event. It is internationally recognized in
the neurologic community for the quality of its education and scientific
programs as well as many networking opportunities.
The AAN benefits from its relationship with corporate sponsors who
provide financial support for a variety of Annual Meeting events and
programs. The AAN recognizes members’ concerns regarding industry
involvement in the Annual Meeting and the potential for commercial
bias, overt, or otherwise. The AAN annually reviews and revises
its guidelines that govern industry participation to ensure that they
are appropriate, comprehensive, and unambiguous. The AAN’s zero
tolerance policy for any real or perceived commercial bias in AAN
education or scientific programs is the fundamental and unwavering
principle that guides its interactions with industry.
Note: All programs have limited enrollment. Register early to ensure your selection.
with infractions and perceptions of bias in a rigorous and impartial
manner, the Committee frequently seeks input on these issues from
the AAN’s Ethics, Law, and Humanities Committee.
The AAN values its relationship with industry. However, the AAN
cannot and will not compromise the independence and credibility
of its programs through its relationships with corporate sponsors.
Appropriate guidelines and input from attendees are essential
components of managing these relationships so that the AAN
maintains its integrity as an organization and the confidence of the
medical profession.
The AAN’s Annual Meeting policies and processes are based on, and
closely follow, guidelines established by the Accreditation Council for
Continuing Medical Education, American Medical Association, and US
Food and Drug Administration.
Programs at the Annual Meeting are developed and implemented
solely by the AAN’s Education Committee, Science Committee, their
respective subcommittees, and AAN staff. Industry has absolutely
no role in selecting program topics, faculty and directors, or planning
program content. Industry influence or promotion on slides or
computer-based presentations is prohibited, and any use of product
brand names should be avoided. All speakers must personally disclose,
in writing, any actual or perceived relationships with industry,
regardless of whether these relate to a specific presentation or not.
These disclosures are published in Neurology ® and AAN Annual
Meeting publications. Industry and presenters are required to sign
letters of agreement explicitly stating that they understand and
will adhere to the AAN guidelines. The AAN Foundation sponsors a
Corporate Roundtable, comprised of representatives from both the
AAN and industry, which promotes awareness of, and compliance
with, the AAN’s policies governing industry participation in the Annual
Meeting and other activities.
The great majority of the AAN’s industry supporters and presenters
abide by the AAN guidelines, but occasional infractions do occur.
Although most of these are minor, the AAN’s zero-tolerance policy
specifies sanctions for those who violate its guidelines. In addition,
the AAN has revised all education and scientific evaluation forms
to provide attendees with an opportunity to report any perceived
commercial bias. Although the Meeting Management Committee deals
6
Education Program Legend
First Digit = Day of Program
EC
2 Day Two: Sunday, April 11
Didactic program offered as morning or
afternoon half-day programs. Free to all
registered attendees.
7 Day Seven: Friday, April 16
8 Day Eight: Saturday, April 17
FC
PC
Letters = Type of Program
Didactic program begins at 9:00 a.m. and ends
at 5:00 p.m. Refreshments will be served
during the morning and afternoon break.
Lunch will not be served.
6 Day Six: Thursday, April 15
AC
Cynthia L. Comella, MD, FAAN, Chair, Education Committee and Chair,
Annual Meeting Subcommittee
NP
NEW! Neurology Skills
Pavilion
Interactive program offered only on Saturday,
April 10. Program begins at 8:30 a.m. and
ends at 4:00 p.m.
4 Day Four: Tuesday, April 13
5 Day Five: Wednesday, April 14
Stefan M. Pulst, MD, FAAN, Chair, Science Committee and Scientific
Program Subcommittee
Colloquium
Hands-on, interactive program beginning at
2:15 p.m. and ending at 6:00 p.m. Participants
rotate through multiple learning stations in
small groups. Refreshments will be served
during the break. Note: The Friday Neurology
Skills Pavilion begins at 1:15 p.m. and ends at
5:00 p.m. to allow time to attend the Scientific
Program Highlights Plenary Session.
3 Day Three: Monday, April 12
The Principles Governing AAN Relationships with External Sources of
Support state:
It is the AAN’s policy to avoid
even the appearance of a conflict
of interest between the AAN
and industry.
Visit www.aan.com/go/am/education for complete course listings.
1 Day One: Saturday, April 10
Stanley Fahn, MD, FAAN, Chair, Meeting Management Committee
Education Program Legend
Morning Half-Day Course
Didactic program begins at 9:00 a.m. and ends
at 12:45 p.m. Refreshments will be served
during the break.
AS
After-Dinner Seminar
Interactive program begins at 7:30 p.m. and
ends at 10:30 p.m. Desserts, light snacks, and
beverages will be served.
BS
Breakfast Seminar
Interactive program begins at 6:45 a.m. and
ends at 8:30 a.m. A plated breakfast will
be available at the start of the program.
Participants are encouraged to arrive early.
CS
Case Studies Program
Interactive program begins at 7:00 p.m. and
ends at 10:00 p.m. Desserts, light snacks, and
beverages will be served.
DS
Dinner Seminar
Interactive program begins at 6:00 p.m. and
ends at 9:00 p.m. on Sunday, April 11, and
begins at 6:30 p.m. and ends at 9:30 p.m.
on Monday, April 12. A plated dinner will be
available at the beginning of the program.
Participants are encouraged to arrive early.
EPClerkship and Program
Directors Conference
KP
Full-Day Course
Kick-Off Program
Interactive program offered only on Saturday,
April 10. Program begins at 6:00 p.m. and
ends at 8:00 p.m. A light snack will be served.
LS
Luncheon Seminar
Interactive program begins at 12:00 p.m.
and ends at 1:30 p.m. A plated lunch will be
available at the beginning of the program.
Participants are encouraged to arrive early.
MR
NEW! Morning Report
Interactive program beginning at 7:00 a.m.
and ending at 8:30 a.m. The director will
present a case with focused questions
directed to the program attendees. All
Morning Report programs will be utilizing the
Audience Response System. Coffee and a
light snack will be served.
NF
NEW! Neuro Flash
Quick updates on the pertinent issues about
a clinical topic beginning at 6:30 p.m. and
ending at 8:00 p.m. Three half-hour talks will
be interspersed with interactive Q&A. All
Neuro Flash programs will be utilizing the
Audience Response System. A light snack will
be served.
Afternoon Half-Day Course
Didactic program begins at 2:15 p.m. and ends
at 6:00 p.m. Refreshments will be served
during the break. Note: Thursday and Friday
afternoon half-day courses begin at 1:15 p.m.
and end at 5:00 p.m. to allow time to attend
Plenary Sessions.
PW
Afternoon Skills Workshop
Hands-on, interactive program begins at
1:30 p.m. and ends at 6:00 p.m. Available to
physicians only. Lunch will not be provided.
SC
Science Conference
Interactive program offered only on Friday,
April 16. Program begins at 9:00 a.m. and
ends at 5:00 p.m. Lunch will be served.
SW
Skills Workshop
Hands-on, interactive program begins at 9:00
a.m. and ends at 6:00 p.m. Box lunches will be
provided. Available to physicians only.
Note: Wednesday Skills Workshop begins at
noon and ends at 7:00 p.m. to allow time to
attend the Contemporary Clinical Issues and
Case Studies Plenary Session.
TP
Therapy Program
Didactic program begins at 7:00 p.m. and
ends at 9:00 p.m. Desserts, light snacks, and
beverages will be served.
7
Meeting Overview
SATURDAY, APRIL 10
Education Directors Program
8:30 a.m.–4:00 p.m.
1EP.001 Clerkship and Program Directors Conference
A.M. Half-Day Course
9:00 a.m.–12:45 p.m.
1AC.001 Resident Basic Science I: Neuropathology
Full-Day Course
9:00 a.m.–5:00 p.m.
1FC.001 The Practice of Neurology: Issues in Coding and
Reimbursement
Colloquium
1:00 p.m.–5:00 p.m.
Developing Countries
2BS.004 Canalith Repositioning for Benign Paroxysmal Positional
Vertigo
2BS.005 Clinical Grant Writing
2BS.006 Peripheral Nerve Blocks and Other Interventional
Procedures for Headache and Facial Pain
Integrated Neuroscience Session: Emerging
Concepts in Genetics
8:00 a.m.–12:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
8:00 a.m.–9:30 a.m.
Platform Session
9:30 a.m.–10:30 a.m.
Poster Session/Poster Rounds
10:30 a.m.–12:00 p.m.
Invited Speaker Session
1EC.001 BRAINS (Business and Research Administrators in
Neurology Society) Colloquium
Colloquium
9:00 a.m.–12:00 p.m.
P.M. Half-Day Course
2:15 p.m.–6:00 p.m.
2EC.001 Patient Safety Colloquium: Diagnostic Errors in Neurology
1PC.001 Resident Basic Science II: Clinical Application of
Neuropathology
Neurology Skills Pavilion
2:15 p.m.–6:00 p.m.
1NP.001 Neurology Skills Pavilion: Health Information Technology for
Neurology: The Electronic Frontier
Kick-Off Programs
6:00 p.m.–8:00 p.m.
1KP.001 Assessment of Rapidly Progressive Dementias and Related
Neurologic Conditions
1KP.002 Diagnosis and Management of Motor Neuron Disease: ALS
1KP.003 Movement Disorder Emergencies: Adults and Children
1KP.004 Surviving Stroke Call: A Guide for Non-vascular
Neurologists
1KP.005 Starting Your Career: The Early Years
1KP.006 Intractable Epilepsy: What to Do When Nothing Works
1KP.007 Multiple Sclerosis (Quint)Essentials
1KP.008 Top 10 Neuro-ophthalmic Diagnoses You Can’t
Afford to Miss
1KP.009 Biological Rhythms and Neurologic Disease
SUNDAY, APRIL 11
Breakfast Seminars
6:45 a.m.–8:30 a.m.
2BS.001 Attention Deficit Hyperactivity Disorder Across the
Lifespan
2BS.002 Update on Myotonias
2BS.003 Global Health Challenges: Neurology in
A.M. Half-Day Courses
9:00 a.m.–12:45 p.m.
2AC.001 Structure Function Correlations in Behavioral Neurology
2AC.002 Making Sure Your Electronic Health Record System
is a Success
2AC.003 Update on Multiple Sclerosis I: Basic Science
2AC.004 Clinical Research Methods I
2AC.005 Neuromuscular Junction Disorders
2AC.006 Advanced Topics in Pediatric Neurology I:
Neurodegenerative Diseases
Full-Day Courses
9:00 a.m.–5:00 p.m.
2FC.001
2FC.002
2FC.003
2FC.004
2FC.005
Movement Disorders
Neurology Update I
Neurology of Sleep
Update in Neuroimaging: Essentials and Beyond–Part I
Continuum Test Your Knowledge: A Multiple-Choice
Question Review
2FC.006 Cerebrovascular Diseases
Skills Workshop
9:00 a.m.–6:00 p.m.
2SW.001 EMG Skills Workshop: Basic
Luncheon Seminars
12:00 p.m.–1:30 p.m.
2LS.001 E/M: Minimize Mistakes, Maximize Reimbursement
2LS.002 Bulletproof Your Practice: What You Need to Know
About Compliance and Regulatory Issues to Stay Ahead
of the Curve
9
Meeting Overview
Integrated Neuroscience Session: Pediatric Demyelinating
Disorders
1:00 p.m.–5:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
1:00 p.m.–2:45 p.m.
Invited Speaker Session
2:45 p.m.–3:45 p.m.
Poster Session
3:45 p.m.–5:00 p.m.
Platform Session
Colloquium
1:30 p.m.–4:30 p.m.
2EC.002 Practice Colloquium: Dialogue with the Insurer Medical
Directors: A Conversation You Don’t Have Every Day
P.M. Half-Day Courses
2:15 p.m.–6:00 p.m.
2PC.001
2PC.002
2PC.003
2PC.004
2PC.005
2PC.006
How to Analyze Spells by Video-EEG
Genetic Testing in Clinical Neurology
Update on Multiple Sclerosis II: Clinical
Clinical Research Methods II
Myelopathies
Bedside Evidence-Based Medicine: How to Deconstruct
Articles in Order to Take Care of Patients
Neurology Skills Pavilion
2:15 p.m.–6:00 p.m.
2NP.001 Neurology Skills Pavilion: Neuromuscular Bedside Rounds
Dinner Seminars
6:00 p.m.–9:00 p.m.
2DS.001 Mild Cognitive Impairment: Implications for Clinicians
2DS.002 The Dystonias: Diagnosis, Treatment, and Update on
Causes
2DS.003 Practice Survival for Neurologists: Business Strategies for
Success
2DS.004 The Interface of Sleep and Neurologic Disorders
2DS.005 Important Drug Interactions for Neurologists and
Psychiatrists
2DS.006 Implications of Combat Related Traumatic Brain Injury
Celebration for Research
6:00 p.m.–11:00 p.m.
Neurobowl®
6:00 p.m.–8:00 p.m.
Main Stage: Featuring Second City and Billy McLaughlin
8:30 p.m.–10:30 p.m.
10
Neuro Film Festival
8:30 p.m.–10:30 p.m.
Neuro Hop
8:30 p.m.–11:00 p.m.
Meeting Overview
MONDAY, APRIL 12
Breakfast Seminars
6:45 a.m.–8:30 a.m.
3BS.001 Can I Drive? Can I Fly?
3BS.002 Career Development for Clinician Educators
3BS.003 Blink and You Live: Coma Prognosis in Child Neurology
Kenneth M. Viste, Jr., MD, Neurology Public Policy Fellowship
Informational Session
12:00 p.m.–1:00 p.m.
3DS.004 Mitochondrial Disorders in Neurology
International Attendee Summit
12:00 p.m.–1:00 p.m.
3NF.001
3NF.002
3NF.003
3NF.004
Luncheon Seminar
12:00 p.m.–1:30 p.m.
State Society Leadership Roundtable
7:00 a.m.–9:30 a.m.
3LS.001 Primary and Comprehensive Stroke Centers: The Future
of Stroke Care
Morning Reports
7:00 a.m.–8:30 a.m.
Integrated Neuroscience Session: Current Concepts in
Cognitive Neuroscience: Implications for Neurological
Disease
2:00 p.m.–6:00 p.m.
3MR.001 Morning Report: Behavioral Neurology
3MR.002 Morning Report: Chronic Migraine: Basis and Tools for
Management
3MR.003 Morning Report: Multiple Sclerosis
Integrated Neuroscience Session: Global Neurology: Toxins
and Infections
8:00 a.m.–12:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
8:00 a.m.–9:30 a.m.
Platform Session
9:30 a.m.–10:30 p.m.
Poster Session/Poster Rounds
10:30 a.m.–12:00 p.m.
Invited Speaker Session
Colloquium
8:30 a.m.–12:00 p.m.
3EC.001 Education Colloquium: International Education
A.M. Half-Day Courses
9:00 a.m.–12:45 p.m.
3AC.001
3AC.002
3AC.003
3AC.004
Advanced Topics in Pediatric Neurology II: Neuro-oncology
Update in Neuroimaging: Essentials and Beyond–Part II
Traumatic Brain Injury
Update on Endovascular Treatment of Cerebrovascular
Diseases
Full-Day Courses
9:00 a.m.–5:00 p.m.
3FC.001
3FC.002
3FC.003
3FC.004
3FC.005
3FC.006
3FC.007
Challenging Pain Patients
Therapy in Neurology
Clinical Epilepsy
Headaches in Adults
Infections of the Nervous System
Peripheral Neuropathy
Neuro-ophthalmology
Skills Workshop
9:00 a.m.–6:00 p.m.
3SW.001 Advanced Techniques in EMG and Neuromuscular Disease
Scientific platform and poster presentations along with an invited
speaker session.
2:00 p.m.–3:30 p.m.
Invited Speaker Session
3:30 p.m.–4:30 p.m.
Poster Session
4:30 p.m.–6:00 p.m.
Platform Session
P.M. Half-Day Courses
2:15 p.m.–6:00 p.m.
3PC.001
3PC.002
3PC.003
3PC.004
Diagnostic Dilemmas in Multiple Sclerosis
Traumatic Spinal Cord Injury
Non-Alzheimer’s Dementia
Stroke Prevention in 2010
Web Wonders: The Must-Have Technologies for Neurologists
in 2010
2:30 p.m.–5:30 p.m.
Neuro Flashes
6:30 p.m.–8:00 p.m.
Neuro Flash: Acute Stroke Management
Neuro Flash: Neurogenetics
Neuro Flash: Multiple Sclerosis
Neuro Flash: Neuro-ophthalmology
After-Dinner Seminars
7:30 p.m.–10:30 p.m.
3AS.001 Improving Accuracy of Dementia Diagnosis: Case Studies
with Both Imaging and Neuropathology
3AS.002 Stroke Rehabilitation for Spatial Neglect: Win-Win
Treatment Science
3AS.003 Clinical Pearls in Bedside Neurology
3AS.004 EEG in Children: Developmental Maturation, Variants,
Epilepsy Syndromes, and Identification of Surgical
Candidates
3AS.005 Brain Computer Interfaces: Frontiers in Neurology
and Neuroscience
3AS.006 Diagnosis and Management of Leukodystrophies
TUESDAY, APRIL 13
Run/Walk for Brain Research
6:30 a.m.–8:30 a.m.
Breakfast Seminars
6:45 a.m.–8:30 a.m.
Student Interest Group in Neurology (SIGN) Meeting
5:00 p.m.–6:30 p.m.
4BS.001 The Neurology of Social Behavior
4BS.002 Introduction to the Evaluation and Therapy of Restless Legs
Syndrome and Periodic Limb Movements in Sleep
4BS.003 Advanced Palliative Care and Symptom Management of
ALS, Alzheimer’s Disease, or Parkinson’s Disease
4BS.004 Approach to Acute CNS Infections
4BS.005 Recognition and Management of the Many Types
of Status Epilepticus
4BS.006 Bone Disease for the Practicing Neurologist
Consortium of Neurology Residents and Fellows Meeting
5:00 p.m.–6:00 p.m.
Palatucci Advocacy Action Planning Roundtable
7:30 a.m.–9:30 a.m.
Exhibit Hall Opening Reception
5:00 p.m.–7:00 p.m.
Poster Session I (With Discussion Session)
7:30 a.m.–12:00 p.m.
Residents and Fellows Career Forum and Reception
6:30 p.m–9:00 p.m.
Presidential Plenary Session
9:00 a.m.–12:00 p.m.
Dinner Seminars
6:30 p.m.–9:30 p.m.
AAN/AAN Professional Association Business Meeting
Best Care Expo: Guidelines, Government Relations
and Getting Paid
3:00 p.m.–5:00 p.m.
ABPN Resident Informational Session
4:00 p.m.–5:00 p.m.
3DS.001 Top 10 Pitfalls in the Diagnosis of Parkinson’s Disease
3DS.002 Stroke in Children and Neonates
3DS.003 Common and Important Ophthalmoscopic Findings
(Immediately follows the last Presidential Plenary Session lecture)
11
Meeting Overview
4NP.001 Neurology Skills Pavilion: Acute Stroke Alert
American Academy of Neurology and American Academy of
Neurology Foundation Awards Luncheon
12:00 p.m.–1:30 p.m.
Poster Session II (With Discussion Session)
3:00 p.m.–7:30 p.m.
Skills Workshop
12:00 p.m.–7:00 p.m.
Neurology Skills Pavilion
2:15 p.m.–6:00 p.m.
Exhibits
11:30 a.m.–5:00 p.m.
Exhibit Hall Lunch
12:00 p.m.–2:00 p.m.
Luncheon Seminar
12:00 p.m.–1:30 p.m.
4LS.001 Telemedicine Increases Options for Successful Stroke
Treatment: Nuts and Bolts
Scientific Platform Sessions
4:00 p.m.–5:15 p.m.
S11 Multiple Sclerosis: Clinical Trials I
S12 Cerebrovascular Disease: Acute Stroke Therapy
Colloquium
12:30 p.m.–2:00 p.m.
4EC.001 Ethics Colloquium
Colloquium
1:00 p.m.–3:00 p.m.
S13 Movement Disorders: Huntington’s Disease: Pathophysiology
and Clinical Assessment
S14 Aging and Dementia: Epidemiology
S15 Epilepsy: Clinical Neurophysiology and Imaging
4EC.002 NIH Sponsored Clinical Trials in Neurology: What’s Going
On? How to Participate? How Can We Do Better?
S16 Anterior Horn: Clinical Studies
Integrated Neuroscience Session: Proteins, Genes,
Neurodegeneration, and the Clinical Presentations
1:00 p.m.–5:00 p.m.
S18 Interventional Neurology
Scientific platform and poster presentations along with an invited
speaker session.
1:00 p.m.–3:00 p.m.
Invited Speaker Session
3:00 p.m.–3:30 p.m.
Poster Session
3:30 p.m.–5:00 p.m.
Platform Session
S17 Critical Care, Trauma, and Inpatient Neurology
S19 Movement Disorders: Dystonia
S20 Neurologic Education
Hot Topics Plenary Session
5:30 p.m.–6:30 p.m.
Corporate Therapeutic Updates
7:30 p.m.–10:00 p.m.
Scientific Platform Sessions
1:45 p.m.–3:45 p.m.
WEDNESDAY, APRIL 14
S01 Multiple Sclerosis: Clinical Research I
Breakfast Seminars
6:45 a.m.–8:30 a.m.
S02 Cerebrovascular Disease: Stroke Epidemiology I
S03 Movement Disorders: Epidemiology of Parkinson’s Disease
S04 Sleep Disorders
S05 Epilepsy: Clinical Epilepsy
S06 Neuromuscular Junction and Muscle Disorders
S07 Headache I
S08 Behavioral Neurology: From Genetics to Brain Function
to Behavior
S09 History of Neurology
S10 Multiple Sclerosis: MRI I
P.M. Half-Day Courses
2:15 p.m.–6:00 p.m.
4PC.001
4PC.002
4PC.003
4PC.004
4PC.005
12
Meeting Overview
Spine Neuroimaging: Clinical-Radiologic Correlation
Evaluation and Management of Autonomic Disorders
Localization in Clinical Neurology
Practical Legal Issues for Neurologists
Neurotoxicology
5BS.001 Anosognosia and Anosodiaphoria in Stroke and Dementia
5BS.002 Archival Neurologic Films
5BS.003 Eye Movement Disorders: A Systematic Approach to the
Evaluation of Diplopia
5BS.004 Case Studies: Clinical Ethics, Professionalism, and
Evidence-Based Care of Patients with Severe Life-Limiting
Neurologic Disease
5BS.005 Hyperkinetic Movement Disorders: Diagnosis
and Treatment
Poster Session III (With Discussion Session)
7:30 a.m.–12:00 p.m.
Contemporary Clinical Issues and Case Studies Plenary
Session
9:00 a.m.–12:00 p.m.
Exhibits
11:30 a.m.–5:00 p.m.
Exhibit Hall Lunch
12:00 p.m.–2:00 p.m.
5SW.001 Neurophysiologic Intraoperative Monitoring
Scientific Platform Sessions
2:00 p.m.–4:00 p.m.
S21 Multiple Sclerosis: Clinical Trials II
S22 Cerebrovascular Disease I
S23 Movement Disorders: Parkinson’s Disease / Non-Motor
Symptoms
5PC.004 History of Neurology: Landmark Case Studies of
Neurological Giants
5PC.005 Perioperative Stroke: A Practical Approach to Risk
Stratification and Modification During the Preoperative
Evaluation
Poster Session IV (With Discussion Session)
3:00 p.m.–7:30 p.m.
Scientific Platform Sessions
4:15 p.m.–5:30 p.m.
S31 Multiple Sclerosis: Biomarkers
S32 Cerebrovascular Disease: Stroke Imaging
S33 Current and Future Treatment of Parkinson’s Disease
S24 Aging and Dementia: Imaging
S34 Aging and Dementia: Recognition and Treatment
S25 Epilepsy: Antiepileptic Drug Therapy
S35 Headache II
S26 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy
S36 Anterior Horn: Spinal Muscular Atrophy
S27 Infections
S37 Neurologic Manifestations: Imaging and Therapeutics
S28 Neuro-ophthalmology/ Neuro-otology
S38 Neurogenetics: Basic Science and Therapeutics
S29 Neuroepidemiology
S39 Neuro-oncology: Paraneoplastic Disorders
S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis
S40 Multiple Sclerosis: Epidemiology
Integrated Neuroscience Sessions: Emerging Treatments in
Neuromuscular Disease
2:00 p.m.–6:00 p.m.
Current Practice Issues in Neurology: Health Care Reform
5:30 p.m.–7:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
2:00 p.m.–3:15 p.m.
Platform Session
3:15 p.m.–4:30 p.m.
Poster Session
4:30 p.m.–5:00 p.m.
Invited Speaker Session
5:00 p.m.–6:00 p.m.
Platform Session
Integrated Neuroscience Sessions: Multiple Sclerosis
Imaging
2:00 p.m.–6:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
2:00 p.m.–3:30 p.m.
Platform Session
3:30 p.m.–4:30 p.m.
Poster Session
4:30 p.m.–6:00 p.m.
Invited Speaker Session
P.M. Half-Day Courses
2:15 p.m.–6:00 p.m.
5PC.001 Primer of Cognitive Neurology
5PC.002 Diagnosis and Management of Movement Disorders in
Children
5PC.003 Emergency Neurology
Case Study Programs
7:00 p.m.–10:00 p.m.
5CS.001 Case Studies: Dementia
5CS.002 Case Studies: Unusual Diagnostic and Management of
Cases in Neuromuscular Disease
5CS.003 Case Studies: Unusual Movement Disorders
5CS.004 Case Studies: Multiple Sclerosis
THURSDAY, APRIL 15
Breakfast Seminars
6:45 a.m.–8:30 a.m.
6BS.001 Differential Diagnosis of Dementia: Linking Clinical
Syndromes to Pathology
6BS.002 Critical Care Epilepsy/EEG
6BS.003 Criteria for Stopping and Starting Multiple Sclerosis
Therapy
6BS.004 Nystagmus: An Organized Approach
6BS.005 Small Fiber Neuropathies: Somatic, Autonomic, or a
Mixture of Both
Poster Session V (With Discussion Session)
7:30 a.m.–12:00 p.m.
Frontiers in Clinical Neuroscience Plenary Session
9:00 a.m.–11:00 a.m.
13
Meeting Overview
Exhibits
11:30 a.m.–4:00 p.m.
S56 Anterior Horn: Basic Science
S57 Neural Repair and Neurorehabilitation
Exhibit Hall Lunch
S58 Behavioral Neurology: Language, Action, and Memory
12:00 p.m.–2:00 p.m.
S59 Ethics
Integrated Neuroscience Session: Deep Brain Stimulation:
Where Are We and Where Do We Go From Here?
12:00 p.m.–4:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
12:00 p.m.–1:30 p.m.
Invited Speaker Session
1:30 p.m.–2:30 p.m.
Poster Session
2:30 p.m.–4:00 p.m.
Platform Session
Scientific Platform Sessions
1:15 p.m.–2:30 p.m.
S41 Multiple Sclerosis: Clinical Immunology
S42 Cerebrovascular Disease: Stroke Prevention
S43 Movement Disorders: Essential Tremor and Ataxia
S60 Multiple Sclerosis: MRI II
Poster Session VI (With Discussion Session)
3:00 p.m.–7:30 p.m.
NEW! AAN Awards Plenary Session
4:00 p.m.–6:00 p.m.
Therapy Programs
7:00 p.m.–9:00 p.m.
6TP.001 Therapy Program: Epilepsy
6TP.002 Therapy Program: Multiple Sclerosis
6TP.003 Therapy Program: Stroke
Case Study Programs
7:00 p.m.–10:00 p.m.
S46 Peripheral Nerve: Molecular Mechanisms of Peripheral
Neuropathy
6CS.001 Now You See It, Now You Know It; (Nearly) Pathognomonic
Signs in Neuro-ophthalmology Findings
6CS.002 Case Studies: Sleep Medicine
6CS.003 Case Studies: Adult Metabolic Disorders
6CS.004 Case Studies: Neuroimaging
S47 Neurologic Manifestations: Clinical Neurophysiology and
Epidemiology
FRIDAY, APRIL 16
S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology
S45 Child Neurology: Developmental Neurobiology
S48 Autonomic Disorders: Frontiers of Autonomic Neurology
S49 Cerebrovascular Disease: Hemorrhagic Stroke
S50 Multiple Sclerosis: EAE/Animal Models
P.M. Half-Day Courses
1:15 p.m.–5:00 p.m. (Note time change)
6PC.001
6PC.002
6PC.003
6PC.004
6PC.005
Psychiatry for the Neurologist
Neurologic Consultations in the ICU
Neuro-oncology Update I: Primary Brain Tumors
Women’s Neurologic Issues in Pregnancy
Common Spine Disorders
Scientific Platform Sessions
2:45 p.m.–3:45 p.m.
S51 Multiple Sclerosis: Clinical Research II
S52 Cerebrovascular Disease II
S53 Movement Disorders: Parkinson’s Disease and Atypical
Parkinsonism
S54 Aging and Dementia: Genetics
S55 Clinical Neurophysiology: Intraoperative Neurophysiologic
Monitoring; Evoked Potentials
14
Meeting Overview
Breakfast Seminars
6:45 a.m.–8:30 a.m.
7BS.001 Diagnosing Spells in Older Adults
7BS.002 Rapid Quantitation in EMG: Learning Accurate and Efficient
Motor Unit Potential Analysis
7BS.003 Neurologic Complications of Nutritional Deficiencies
7BS.004 Unruptured Intracranial Aneurysms and Intracranial
Vascular Malformations: What a Practicing Neurologist
Needs to Know
7BS.005 Case Studies in Neuro-oncology
7BS.006 Update on Ataxias
A.M. Half-Day Courses
9:00 a.m.–12:45 p.m.
P.M. Skills Workshop
1:30 p.m.–6:00 p.m.
7AC.001 Deep Brain Stimulation Management
7AC.002 Botulinum Toxins: Practical Issues and Clinical Uses for
Neurologists
7AC.003 Clinical Issues in Multiple Sclerosis
7AC.004 Neuro-oncology Update II: Systemic Cancer
7AC.005 Clinical EMG I
7AC.006 Child Neurology I
7PW.001 Clinical Usefulness of Botulinum Toxin and Treatment of
Dystonia
Full-Day Courses
9:00 a.m.–5:00 p.m.
7FC.001
7FC.002
7FC.003
7FC.004
7FC.005
Genetics in Neurology
Dementia Update
Neurology Update II
Neurologic Intensive Care
Clinical EEG
Scientific Program Highlights Plenary Session
5:15 p.m.–6:15 p.m.
Neuro Flashes
6:30 p.m.–8:00 p.m.
7NF.001 Neuro Flash: Child Neurology
7NF.002 Neuro Flash: Epilepsy
Therapy Programs
7:00 p.m.–9:00 p.m.
7TP.001 Therapy Program: Neuromuscular Disease
7TP.002 Therapy Program: Movement Disorders
7TP.003 Therapy Program: Headache
SATURDAY, APRIL 17
Neuroscience Conference
9:00 a.m.–5:00 p.m.
7SC.001 Future of Neuroscience Conference: Frontiers in
Neuroimaging: Coming Soon to a Scanner Near You
New! Clinical Trials Session
12:00 p.m.–1:30 p.m.
Integrated Neuroscience Session: Molecular Markers and
Targets in Neuro-oncology
1:00 p.m.–5:00 p.m.
Scientific platform and poster presentations along with an invited
speaker session.
1:00 p.m.–2:30 p.m.
Platform Session
2:30 p.m.–3:30 p.m.
Poster Session
3:30 p.m.–5:00 p.m.
Invited Speaker Session
P.M. Half-Day Courses
1:15 p.m.–5:00 p.m.
Integrated Neuroscience Session: Ischemic Stroke,
Interventional, and Endovascular Therapies/Large Vessel
Disease
8:00 a.m.–12:00 p.m.
7PC.001
7PC.002
7PC.003
7PC.004
7PC.005
7PC.006
Scientific platform and poster presentations along with an invited
speaker session.
Neurology Skills Pavilion
1:15 p.m.–5:00 p.m.
8:00 a.m.–9:30 a.m.
Invited Speaker Session
9:30 a.m.–10:30 a.m.
Poster Session
7NP.001 Neurology Skills Pavilion: Neuro-ophthalmology and
Neurovestibular Exam Lab
10:30 a.m.–12:00 p.m.
Platform Session
Behavioral Neurology: Contemporary Topics: Vision
Emergency Room Neuro-ophthalmology
MRI and Multiple Sclerosis
Stroke In Young Adults
Clinical EMG II
Child Neurology II
Breakfast Seminars
6:45 a.m.–8:30 a.m.
8BS.001 Vascular Cognitive Impairment and Dementia: Current
Status and Future
8BS.002 Autoimmune Testing in Neuropathy: Indications for the
Practicing Clinician
8BS.003 Balance and Gait Disorders
8BS.004 Neurologic Complications of Immunosuppressive and
Immunomodulatory Therapy
8BS.005 Advances in the Care of Brain Injury After Resuscitation
from Cardiac Arrest
A.M. Half-Day Courses
9:00 a.m.–12:45 p.m.
8AC.001
8AC.002
8AC.003
8AC.004
8AC.005
8AC.006
8AC.007
Neurologic Complications of Medical Disease
Women’s Issues In Cerebrovascular Diseases
Neuromyelitis Optica: Scientific and Clinical Update
Hot Topics in Headaches and Related Disorders
Clinical Approach to Muscle Disease
Parkinson’s Disease and Movement Disorders Update
Neuro-otology
15
Scientific Sessions-at-a-Glance
All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted)
Sunday, April 11, 2010
8:00 a.m.–12:00 p.m.
Integrated Neuroscience Session: Emerging Concepts in Genetics . . . . . . . . . . . . . . Reception Hall 104A–D
8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session/Poster Rounds
10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
1:00 p.m.–5:00 p.m.
Integrated Neuroscience Session: Pediatric Demyelinating Disorders . . . . . . . . . . Reception Hall 104A–D
1:00 p.m.–2:45 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
2:45 p.m.–3:45 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
3:45 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
Monday, April 12, 2010
8:00 a.m.–12:00 p.m.
Integrated Neuroscience Session: Global Neurology: Toxins and Infections . . . . . Reception Hall 104A–D
8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session/Poster Rounds
10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
2:00 p.m.–6:00 p.m.
Integrated Neuroscience Session: Current Concepts in Cognitive
Neuroscience: Implications for Neurological Disease . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
2:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
3:30 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
4:30 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
Tuesday, April 13, 2010
7:30 a.m.–12:00 p.m.
Poster Session I (with Aging and Dementia: Risk Factors Poster Discussion Session) . . . . . . . . . Room 808
9:00 a.m.–12:00 p.m.
Presidential Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG
1:00 p.m.–5:00 p.m.
Integrated Neuroscience Session: Proteins, Genes, Neurodegeneration,
and the Clinical Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
1:00 p.m.–3:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
3:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
3:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
1:45 p.m.–3:45 p.m.
Scientific Sessions
S01 Multiple Sclerosis: Clinical Research I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S02 Cerebrovascular Disease: Stroke Epidemiology I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
S03 Movement Disorders: Epidemiology of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB
Presentation of the Movement Disorders Research Award
S04 Sleep Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
Presentation of the Sleep Science Award
S05 Epilepsy: Clinical Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
S06 Neuromuscular Junction and Muscle Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105
S07 Headache I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B
S08 Behavioral Neurology: From Genetics to Brain Function to Behavior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A
Presentation of the Norman Geschwind Prize in Behavioral Neurology
S09 History of Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
Presentation of the Lawrence C. McHenry Award
S10 Multiple Sclerosis: MRI I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
3:00 p.m.–7:30 p.m.
Poster Session II (with Epilepsy Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808
4:00 p.m.–5:15 p.m.
Scientific Sessions
S11 Multiple Sclerosis: Clinical Trials I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S12 Cerebrovascular Disease: Acute Stroke Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
S13 Movement Disorders: Huntington’s Disease: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . 718AB
Presentation of the Jon Stolk Award in Movement Disorders for Young Investigators
S14 Aging and Dementia: Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
S15 Epilepsy: Clinical Neurophysiology and Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
S16 Anterior Horn: Clinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105
17
Scientific Sessions-at-a-Glance
Scientific Sessions-at-a-Glance
All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted)
S17 Critical Care, Trauma, and Inpatient Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B
Presentation of the AAN Alliance: Founders Award
S18 Interventional Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A
S19 Movement Disorders: Dystonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
S20 Neurologic Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
12:00 p.m.–4:00 p.m.
Integrated Neuroscience Session: Deep Brain Stimulation:
Where Are We and Where Do We Go From Here? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
12:00 p.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
1:30 p.m.–2:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
2:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
5:30 p.m.–6:30 p.m.
Hot Topics Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG
1:15 p.m.–2:30 p.m.
Scientific Sessions
S41 Multiple Sclerosis: Clinical Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S42 Cerebrovascular Disease: Stroke Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
S43 Movement Disorders: Essential Tremor and Ataxia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB
S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
S45 Child Neurology: Developmental Neurobiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B
S46 Peripheral Nerve: Molecular Mechanisms of Peripheral Neuropathy . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105
S47 Neurologic Manifestations: Clinical Neurophysiology and Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
S48 Autonomic Disorders: Frontiers of Autonomic Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
S49 Cerebrovascular Disease: Hemorrhagic Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A
S50 Multiple Sclerosis: EAE/Animal Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
2:45 p.m.–3:45 p.m. Scientific Sessions
S51 Multiple Sclerosis: Clinical Research II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S52 Cerebrovascular Disease II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
Presentation of the Michael S. Pessin Stroke Leadership Prize
S53 Movement Disorders: Parkinson’s Disease and Atypical Parkinsonism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB
S54 Aging and Dementia: Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
S55 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials . . . . . . . . . . . . . . . . . 701B
S56 Anterior Horn: Basic Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105
S57 Neural Repair and Neurorehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
S58 Behavioral Neurology: Language, Action, and Memory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
S59 Ethics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A
S60 Multiple Sclerosis: MRI II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
3:00 p.m.–7:30 p.m.
Poster Session VI (with Cerebrovascular Disease:
Acute Stroke Therapy Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808
4:00 p.m.–6:00 p.m.
New! AAN Awards Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG
Presentation of the Sheila Essey Award: An Award for ALS Research
Presentation of the Dreifuss-Penry Epilepsy Award
Presentation of the Potamkin Prize for Research in Picks, Alzheimers, and Related Diseases
Presentation of the John Dystel Prize for Multiple Sclerosis Research
Wednesday, April 14, 2010
7:30 a.m.–12:00 p.m.
Poster Session III (with Anterior Horn: Therapeutics Poster Discussion Session) . . . . . . . . . . . . . Room 808
9:00 a.m.–12:00 p.m.
Contemporary Clinical Issues and Case Studies Plenary Session . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG
2:00 p.m.–4:00 p.m.
Scientific Sessions
S21 Multiple Sclerosis: Clinical Trials II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S22 Cerebrovascular Disease I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
S23 Movement Disorders: Parkinson’s Disease / Non-Motor Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB
S24 Aging and Dementia: Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
S25 Epilepsy: Antiepileptic Drug Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716A
S26 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B
S27 Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
S28 Neuro-ophthalmology/ Neuro-otology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714B
S29 Neuroepidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
Presentation of the Bruce S. Schoenberg International Award in Neuroepidemiology
S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
2:00 p.m.–6:00 p.m.
Integrated Neuroscience Session: Emerging Treatments
in Neuromuscular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
2:00 p.m.–3:15 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
3:15 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
4:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
5:00 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
2:00 p.m.–6:00 p.m.
Integrated Neuroscience Session: Multiple Sclerosis Imaging . . . . . . . . . . . . . . . . . . . . Constitution Hall 105
2:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
3:30 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
4:30 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
3:00 p.m.–7:30 p.m.
Poster Session IV (with Movement Disorders: Parkinson’s Disease:
Treatment Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808
4:15 p.m.–5:30 p.m.
Scientific Sessions
S31 Multiple Sclerosis: Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
S32 Cerebrovascular Disease: Stroke Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106
S33 Current and Future Treatment of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB
S34 Aging and Dementia: Recognition and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107
S35 Headache II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716A
Presentation of the Harold Wolff-John Graham Award
S36 Anterior Horn: Spinal Muscular Atrophy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B
S37 Neurologic Manifestations: Imaging and Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A
S38 Neurogenetics: Basic Science and Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714B
Presentation of the AAN Alliance: S. Weir Mitchell Award
S39 Neuro-oncology: Paraneoplastic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB
S40 Multiple Sclerosis: Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB
Thursday, April 15, 2010
18
All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted)
7:30 a.m.–12:00 p.m.
Poster Session V (with Multiple Sclerosis and Related Diseases:
Drug Mechanisms Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808
9:00 a.m.–11:00 a.m.
Frontiers in Clinical Neuroscience Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG
Friday, April 16, 2010
8:00 a.m.–12:00 p.m. Integrated Neuroscience Session: Ischemic Stroke, Interventional,
and Endovascular Therapies / Large Vessel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
9:00 a.m.–5:00 p.m. Future of Neuroscience Conference: Frontiers in Neuroimaging:
Coming Soon to a Scanner Near You . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718A
12:00 p.m.–1:30 p.m.
NEW! Clinical Trials Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
1:00 p.m.–5:00 p.m. Integrated Neuroscience Session: Molecular Markers and Targets
in Neuro-oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D
1:00 p.m.–2:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session
2:30 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session
3:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session
5:15 p.m.–6:15 p.m. Scientific Program Highlights Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102
19
2010 Award Recipients
2010 Award Recipients
Rooms and locations are subject to change.
AAN Alliance Awards
xx Founders Award
Sponsored by the American Academy of Neurology Alliance.
Recipient: Farrah Mateen, MD / Baltimore, MD
Presentation: S17: Critical Care, Trauma, and Inpatient Neurology
Date and Time: Tuesday, April 13, 4:00 p.m., Room 701B
Title: “Long-Term Cognitive and Neurological Outcomes following
Successful Cardiac Defibrillation for Out-of-Hospital Cardiac Arrest:
A Population-based Study”
xx S. Weir Mitchell Award
Sponsored by the American Academy of Neurology Alliance.
Recipient: Peter Todd, MD, PhD / Ann Arbor, MI
Presentation: S38: Neurogenetics: Basic Science and Therapeutics
Date and Time: Wednesday, April 14, 4:15 p.m., Room 714B
Title: “Histone Deacetylases Suppress CGG Repeat Induced
Neurodegeneration in Drosophila Model of FXTAS”
A. B. Baker Award for Lifetime Achievement in
Neurologic Education
Supported by the AAN, the AAN Foundation, and the generous donors
to the Doctors Vincent Di Carlo, Milton Alter, and Lawrence Brass Stroke
Research Funds, the Peter S. Y. Lee Stroke Research Fund, the Stroke
Research Fund, and the Fund for Brain Research.
Recipient: Sharon Poisson, MD
University of California San Francisco, San Francisco, CA
AAN Foundation Practice Research Training
Fellowship
Funded by the American Academy of Neurology and the AAN
Foundation.
Recipient: Farrah Mateen, MD
Johns Hopkins University, Baltimore, MD
Funded by an endowment created by matching funds from the A. B.
Baker Family Trust and Novartis Pharmaceuticals.
AAN Foundation Robert Katzman, MD, Clinical
Research Training Fellowship in Alzheimer’s
Research
Recipient: Ralph F. Józefowicz, MD, FAAN / Rochester, NY
Presentation: The Globalization of Neurologic Education
Date and Time: Monday, April 12, 9:00 a.m.
Supported by the AAN Foundation and the Alzheimer’s Association.
Recipient: Winston Chiong, MD
University of California San Francisco, San Francisco, CA
AAN Foundation Clinical Research Training
Fellowships
AAN Foundation/Myasthenia Gravis Foundation
of America Clinician-Scientist Development
Award
Funded by the American Academy of Neurology and the AAN Foundation.
Recipients:
Vikram Khurana, MD, PhD
Massachusetts General Hospital, Cambridge, MA
Suzanne Goh, MD
Columbia University Medical Center, New York, NY
Jackie Whitesell, MD
University of Utah, Salt Lake City, UT
Khalid A. Hanafy, MD, PhD
Columbia University Medical Center, New York, NY
Michael Kruer, MD
Oregon Health and Science University, Portland, OR
Eugenia Ho, MD
Children’s Hospital Boston, Boston, MA
These fellowships are supported by the American Academy of
Neurology, the AAN Foundation, and the AAN Foundation Corporate
Roundtable
Kevin Sheth, MD
University of Maryland School of Medicine, Baltimore, MD
Nicte Mejia, MD
Massachusetts General Hospital, Cambridge, MA
20
AAN Foundation Clinical Research Training
Fellowship In Stroke
Co-sponsored by The Myasthenia Gravis Foundation of America and
AAN Foundation.
Recipient: Jeffrey Guptill, MD
Duke University Medical Center, Raleigh, NC
AAN Foundation/Consortium of Multiple
Sclerosis Centers John F. Kurtzke, MD, FAAN
Clinician-Scientist Development Three-Year
Award
Supported by the American Academy of Neurology, the AAN
Foundation, the Consortium of MS Centers, and donations from
Bayer Healthcare Pharmaceuticals, EMD Serono, Inc., and Questcor
Pharmaceuticals, Inc.
Recipient: Gabriele De Luca, MD, PhD
Mayo Clinic College of Medicine, Rochester, MN
AAN Foundation/National MS Society Clinician
Development Award
Funded by the AAN Foundation and the National Multiple
Sclerosis Society.
Recipient: Zongqi Xia, MD, PhD
Brigham and Women’s Hospital, Boston, MA
AAN Award For Creative Expression of Human
Values in Neurology
Sponsored by the Ethics, Law and Humanities Committee.
Recipient: Mitchell S. V. Elkind, MD, MS, FAAN / New York, NY
Title: “If I Had Time”
Dreifuss-Penry Epilepsy Award
Sponsored by the American Academy of Neurology and endowed
by members of the AAN Epilepsy Section; Abbott Laboratories,
Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.;
GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Neurologics;
Pfizer Inc; Shire US, Inc; and UCB Pharma.
Recipient: Martin Gallagher, MD, PhD / Nashville, TN
Presentation: Awards Plenary Session
Date and Time: Thursday, April 15, 4:30 p.m., Exhibit Hall FG
John Dystel Prize for Multiple Sclerosis
Research
Presented by the American Academy of Neurology and the National
Multiple Sclerosis Society and made possible through a special
contribution from the John Dystel Multiple Sclerosis Research Fund at
the National Multiple Sclerosis Society.
Recipient: David Hafler, MD, MSc / New Haven, CT
Presentation: Awards Plenary Session
Date and Time: Thursday, April 15, 5:30 p.m., Exhibit Hall FG
Sheila Essey Award: An Award for
ALS Research
Presented by the American Academy of Neurology and the ALS
Association and supported through the philanthropy of the Essey Family
Fund and the ALS Association.
Recipient: Clive Svendsen, PhD / Madison, WI
Presentation: Awards Plenary Session
Date and Time: Thursday, April 15, 4:00 p.m., Exhibit Hall FG
American Academy of Neurology Foundation
Chair’s Award
Sponsored by the AAN Foundation.
Recipient: TBD
Norman Geschwind Prize in Behavioral
Neurology
Sponsored by the American Academy of Neurology and the AAN
Behavioral Neurology Section and endowed through Dr. Geschwnd’s
family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral
and Cognitive Neurology.
Recipient: Keith Josephs, MD, MST, MS / Rochester, MN
Presentation: S08: Behavioral Neurology: From Genetics to Brain
Function to Behavior
Date and Time: Tuesday, April 13, 1:45 p.m., Room 714A
Jon Stolk Award in Movement Disorders for
Young Investigators
Sponsored by the American Academy of Neurology and endowed by
Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis
Gillings, and Vela Pharma.
Recipient: E. Ray Dorsey, MD / Rochester, NY
Presentation: S13: Movement Disorders: Huntington’s Disease:
Pathophysiology and Clinical Assessment
Date and Time: Tuesday, April 13, 4:00 p.m., Room 718AB
Association of Indian Neurologists in America
(AINA) Lifetime Achievement Award
Endowed by the Association of Indian Neurologists in America (AINA).
Recipient: Sudhansu Chokroverty, MD, FAAN / Edison, NJ
Presentation: AINA Annual Meeting - Radisson Admiral Hotel
Date and Time: Monday, April 12, 6:30 p.m.
International Scholarship Award
Sponsored by the American Academy of Neurology International
Subcommittee.
Recipients:
Mariya Ivanova Petrova, MD
Sofia, Bulgaria
Hamid Suhail
New Delhi, India
Jelena Nikodinovic, MD
Belgrade, Serbia
Renato Oliveira dos Santos
Campinas, Sao Paulo, Brazil
Daniel Kaganovich, PhD
Rehovot, Israel
Emmanuel Olatunde Sanya, MB MBChB
Kwara, Nigeria
Xin Cheng, MD, PhD
Shanghai, China
Qi Li
Chongqing, China
Marina Coelho Gonsales, PhD
Campinas, Sao Paulo, Brazil
Hacer Durmus, MD
Istanbul, Turkey
Andre Carvalho Felicio
Sao Paulo, Brazil
Clarissa Yasuda, MD, PhD
Campinas, Sao Paulo, Brazil
21
2010 Award Recipients
Lawrence C. McHenry Award: An Award for the
History of Neurology
Sponsored by the American Academy of Neurology.
Recipient: Elan Louis, MD, MS / New York, NY
Presentation: S09: History of Neurology
Date and Time: Tuesday, April 13, 1:45 p.m., Room 717AB
Title: “The Coming of Age of Neurology: The Conceptualization and
Organization of the First International Neurological Congress (1931)”
Medical Student Essay Awards
Sponsored by the American Academy of Neurology.
xx Extended Neuroscience Award
Recipient: Amanda Rowlands / Hershey, PA
Presentation: Poster Session IV
Date and Time: Wednesday, April 14, 3:00 p.m., Room 808
Title: “Immunological Aspects of Cell Transplantation in
Parkinson’s Disease”
xx G. Milton Shy Award in Clinical Neurology
Recipient: Deanna Cettomai / Baltimore, MD
Presentation: Poster Session IV
Date and Time: Wednesday, April 14, 3:00 p.m., Room 808
Title: “Utility of Quantitative Sensory Testing and Neuropathy
Screening Tools in Identifying HIV-Associated Peripheral Neurology
in Western Kenya: A Pilot Testing”
xx Roland P. Mackay Award in Historical Aspects
Recipient: Lauren Bowen / Gainesville, FL
Presentation: Poster Session IV
Date and Time: Wednesday, April 14, 3:00 p.m., Room 808
Title: “Elementary My Dear Dr. Allen: the Case of Barium Toxicity and
Pa Ping”
xx Saul R. Korey Award in Experimental Neurology
Recipient: Benjamin Kwan / Windsor, ON, Canada
Presentation: Poster Session IV
Date and Time: Wednesday, April 14, 3:00 p.m., Room 808
Title: “Neurogenetics: Parent of Origin Effects in Autistic Copy
Number Variation, a Possible Mechanism for Autism Pathogenesis”
Movement Disorders Research Award
Sponsored by the American Academy of Neurology, the Parkinson’s
Disease Foundation, and the AAN Movement Disorders Section and
endowed by the Parkinson’s Disease Foundation.
Recipient: David Eidelberg, MD / Manhasset, NY
Presentation: S03: Movement Disorders: Epidemiology of
Parkinson’s Disease
Date and Time: Tuesday, April 13, 1:45 p.m., Room 718AB
22
2010 Award Recipients
Neuroscience Research Prize
Preuss Award in Clinical Neuro-oncology
Recipients:
Jan Gong / Garden City, NY
Anouva Kalra-Lall / Roslyn, NY
Theresa Tharakan / Bronx, NY
Recipient: Antonio Omuro, MD / New York, NY
Presentation: Neuro-oncology Section Meeting
Date and Time: Thursday, April 15, 12:15 p.m.
Sponsored by the American Academy of Neurology, American Academy
of Neurology Foundation, and the Child Neurology Society.
Child Neurology Neuroscience Research Prize
Sponsored by the American Academy of Neurology, American Academy
of Neurology Foundation, and the Child Neurology Society.
Recipient: Pragya Kakani / Jericho, NY
Note: The recipient will attend the Child Neurology Society Annual
Meeting, October 13–16, 2010, in Providence, RI.
Palatucci Advocacy Leadership Forum
Advocates of the Year.
Sponsored by the AAN Government Relations Committee.
Recipients:
Teshamae Monteith, MD / San Francisco, CA
Mamta Bhushan Singh, MBBS, MD, DM / New Delhi, India
Michael S. Pessin Stroke Leadership Prize
Sponsored by the American Academy of Neurology and endowed by
Dr. Pessin’s family, friends, and colleagues.
Recipient: Shelagh Coutts, MD / Calgary, AB, Canada
Presentation: S52: Cerebrovascular Disease II
Date and Time: Thursday, April 15, 2:45 p.m., Constitution Hall 106
Potamkin Prize for Research in Pick’s,
Alzheimer’s, and Related Diseases
Supported by the American Academy of Neurology and the AAN Neurooncology Section and awarded through a gift from Dr. Preuss’ family,
friends, and colleagues.
Research Award in Geriatric Neurology
Sponsored by the American Academy of Neurology and the AAN
Geriatric Neurology Section and supported by the American Geriatrics
Society and the John J. Hartford Foundation.
Recipient: Liana Apostolova, MD / Los Angeles, CA
Presentation: Geriatric Neurology Section Meeting
Date and Time: Wednesday, April 14, 1:00 p.m.
Bruce S. Schoenberg International Award
in Neuroepidemiology
Endowed by GlaxoSmithKline, Inc.
Recipient: Judith Kwasa, MD / Kisumu, Kenya
Presentation: S29: Neuroepidemiology
Date and Time: Wednesday, April 14, 2:00 p.m., Room 713AB
Title: “Status of Bone Health in Pre-Menopaused Women Living with
Epilepsy on Anticonvulsant Drug Therapy in Kenya”
H. Richard Tyler Award
Sponsored by the American Academy of Neurology and the AAN
Archive Committee.
Not given in 2010.
Kenneth M. Viste, Jr., MD, Patient Advocate
of the Year Award
Endowed by gifts from Dr. Viste’s colleagues, friends, and patients.
Recipient: Enawgaw Mehari, MD / Morehead, KY
Presentation: Palatucci Advocacy Leadership Forum Graduate
Reception
Date and Time: Monday, April 12, 5:00 p.m., Intercontinental Toronto
Centre
Harold Wolff-John Graham: An Award for
Headache/Facial Pain Research
Sponsored by the American Academy of Neurology and endowed by
Endo Pharmaceuticals, Inc.
Recipient: Ana Recober, MD / Iowa City, IA
Presentation: S35: Headache II
Date and Time: Wednesday, April 14, 4:15 p.m., Room 716A
Sleep Science Award
Sponsored by the American Academy of Neurology and the AAN Sleep
Section and endowed by Cephalon, Inc.
Recipient: Arthur Walters, MD / Nashville, TN
Presentation: S04: Sleep Disorders
Date and Time: Tuesday, April 13, 1:45 p.m., Constitution Hall 107
Sponsored by the American Academy of Neurology, the
AAN Foundation, and funded through the philanthropy of the
Potamkin Family.
Recipients:
Bruce L. Miller, MD / San Francisco, CA
Lennart Mucke, MD / San Francisco, CA
Presentation: Awards Plenary Session
Date and Time: Thursday, April 15, 5:00 p.m., Exhibit Hall FG
American Academy of Neurology President’s
Award
Sponsored by the American Academy of Neurology.
Recipient: Isabelle Rapin, MD, FAAN / Bronx, NY
Vote for Your Favorite
Neuro Film Festival Entry by March 17
The entries for the 2010 Neuro Film Festival are in and public voting for “Fan Favorite” has begun. The event
highlights compelling stories from patients and their families and caregivers about living with a neurologic
condition. The winner of the Fan Favorite award will receive a $500 prize. Two other winners will also be
awarded for their filmmaking skills and creativity, as decided by the festival’s jury. Eligible entries are now
online available to be voted on at www.youtube.com/neurofilmfest. For more information, contact
Andrew Halverson at ahalverson@aan.com or (651) 695-2757.
23
Saturday, April 10 Highlights
2010 AAN Clerkship and Program Directors
Academy Central
Conference: Career Development and Resources Saturday, April 10–Friday, April 16
8:30 a.m.–4:00 p.m.
Education is one of the most important elements of medical science.
Fostering the teaching, assessment, feedback, and administrative skills
of medical educators is important for a successful career. Medical
educators also must learn to document and use their accomplishments
in education for career advancement and promotion. The process of
recognizing educational contribution and enhancing teaching skills of
teachers at all levels will be discussed. In addition, areas of interest to
the educational community such as duty hours for residents and CME
requirements and their impact on medical student education will be
discussed.
Basic Science Resident Curriculum
9:00 a.m.–12:45 p.m.
2:15 p.m.–6:00 p.m.
The resident neuroscience initiative is a three-year basic science
curriculum for neurology residents offered at the Annual Meeting.
The curriculum is primarily intended to help neurology residents learn
the basic sciences on which clinical neurology is founded. Topics
that will be covered over the three-year cycle include neuroanatomy,
neurophysiology, neuropharmacology, neuropathology, development,
and genetics. This curriculum will also help residents prepare for the
AAN’s RITETM Exam (Residency In-service Training Examination).
This year’s program topics include:
1AC.001 Resident Basic Science I: Neuropathology
1PC.001 Resident Basic Science II: Clinical Application of
Neuropathology
Registration is required.
BRAINS Colloquium: Critical Thinking for
Critical Issues
1:00 p.m.–5:00 p.m.
The BRAINS Colloquium is intended to provide attendees with up-todate information on the “business” of neurology and an opportunity to
further develop practice management skill sets. Faculty will address
how to recruit and retain physicians, adding ancillary services to your
practice, physician productivity and tracking, benchmarking, and
current hot topics relevant to neurology practice management.
Neurology Skills Pavilion: Health Information
Technology for Neurology: The Electric Frontier
Academy Central offers a variety of resources central to the career of
any neurology professional. Explore science and education publications
such as Neurology ® and Continuum: Lifelong Learning in Neurology ®.
Learn about clinical guidelines and shop for tools that can make your
practice more effective and efficient. Find out how social networking
is revolutionizing health care, and why the Academy is advocating on
your behalf in Washington, DC. Enjoy a range of speakers who will
address a variety of topics. Watch for a list of events and speakers.
Academy Central helps demonstrate how the Academy is delivering on
its promise to be an indispensable part of your career, each step of the
way.
Changes to Syllabi Process—Download
in Advance
Obtaining your Education Program syllabi is quicker and easier
than ever. All registered attendees will be able to download the
full syllabi for their selected programs, starting in late March.
All registered attendees will receive an email notification once
syllabi are available.
Printed syllabi will not be available. Printed slides will be
available in program rooms.
AAN Foundation Research Area
Saturday, April 10–Friday, April 16
Learn about the AAN Foundation’s Clinical Research Training
Fellowship program and how donations help fund the next generation
of researchers in neurology. Visit with Foundation staff and learn more
about fundraising initiatives including the Art for Research gallery, the
Foundation Silent Auction, and the Buy a Brain program.
Research Career Development Symposium:
Transitioning from Residency to Research
This new full day conference provides information to assist young
researchers transition from residency to investigative independence
in academic neurology. The morning sessions are for and open to
everyone. The afternoon sessions are invitations only. For additional
information contact Terry Heinz at (651) 695-2746 or theinz@aan.com.
Sponsored by American Academy of Neurology, the AAN Foundation,
and NINDS.
2:15 p.m.–6:00 p.m.
Brush up on or learn new skills in an interactive, hands-on environment.
Participants in small groups will rotate through multiple learning
stations and participate in skills demonstrations. Most programs
will begin at 2:15 p.m. and end at 6:00 p.m. Friday’s Neurology Skills
Pavilion begins at 1:15 p.m. and ends at 5:00 p.m. to allow time to
attend the Scientific Program Highlights Plenary Session.
25
Sunday, April 11 Highlights
AUPN Clerkship Directors’ Boot Camp
Celebration for Research
8:00 a.m.–11:00 a.m.
6:00 p.m.–11:00 p.m.
This three-hour session is designed to be an interactive meeting
for Neurology Clerkship Directors, both those new to the position
and veterans. Also welcome are any Residents, Fellows, or Faculty
interested in improving teaching and curriculum writing skills. To
register visit www.aupn.org.
Join us for an exciting evening filled with music, dancing, laughter,
and more! Enjoy a buffet of Toronto favorites with your friends and
colleagues. Extra tickets are available through registration. Proceeds
from the evening are dedicated to AAN Foundation initiatives,
including Clinical Research Training Fellowships.
Patient Safety Colloquium: Diagnostic Errors
in Neurology
Neurobowl®
9:00 a.m.–12:00 p.m.
There is no better way to begin the 62nd Annual Meeting than by
attending Neurobowl. AAN former president Thomas R. Swift,
MD, FAAN, hosts another year of competition by the best and
brightest in neurology for the enviable Neurobowl title. This
popular quiz show focuses on the process of neurological diagnosis
with common and rare neurologic case histories, video clips,
investigations, and movie segments. Seating is limited and is
available on a first-come, first-served basis.
The objective of this colloquium is to improve patient safety by
reducing the likelihood of diagnostic errors in neurology. Faculty will
cover the breadth of diagnostic errors in neurology and strategies
for preventing misdiagnosis and misdiagnosis-related harm. Future
opportunities in simulation and diagnostic technology will be
introduced to promote diagnostic clarity.
6:00 p.m.–8:00 p.m.
Practice Colloquium: Dialogue with the Insurer
Medical Directors: A Conversation You Don’t
Have Every Day
Sponsored by UCB, Inc.
1:30 p.m.–4:30 p.m.
8:30 p.m.–10:30 p.m.
Attendees will have a chance to dialogue with medical directors
from major insurers at this free session. Attendees will gain a better
understanding of what insurers are contemplating, so they are a step
ahead of everyone else with new programs, and will understand
how to take advantage of insurer programs that can increase their
reimbursement and reduce administrative hassle. Attendees will have
an opportunity to ask questions and provide feedback.
Billy McLaughlin is recognized internationally as an innovative
world-class acoustic guitarist, composer, and producer. He is a
five-time Minnesota Music Award winner with 12 CD releases
and a history on the Billboard Top Ten Chart. Recently diagnosed
with focal dystonia, he has launched a remarkable comeback as a
left-handed performer, a story recently featured with a one-hour
documentary on PBS.
Neurology Skills Pavilion: Neuromuscular
Bedside Rounds
Toronto comedy troupe The Second City returns to the Annual
Meeting! Laugh out loud at this two-hour show tailored for
neurology. The Second City’s alumni have gone on to become stars
of movies and television, and garner awards galore. Notable grads
include: Dan Aykroyd, Gilda Radner, Bill Murray, Mike Myers, Tina
Fey, Steve Carell, and Stephen Colbert. This is sure to be a laugh
riot—but seating is limited and is available on a first-come, firstserved basis—so get there early!
2:15 p.m.–6:00 p.m.
Brush up on or learn new skills in an interactive, hands-on environment.
Participants in small groups will rotate through multiple learning
stations and participate in skills demonstrations. Most programs
will begin at 2:15 p.m. and end at 6:00 p.m. Friday’s Neurology Skills
Pavilion begins at 1:15 p.m. and ends at 5:00 p.m. to allow time to
attend the Scientific Program Highlights Plenary Session.
26
Integrated Neuroscience Session: Emerging Concepts in Genetics
Main Stage: The Second City and Billy
McLaughlin
Sponsored by Teva Neuroscience, Inc.
NEW! Neuro Film Festival
NEW! Specialists in Focus: Child Neurology
8:30 p.m.–10:30 p.m.
This special, intensive program offers an in-depth look into child
neurology focused topics. While primarily intended for child neurology
specialists, generalists will also find useful information. This Sunday to
Monday program includes:
Join us for the “best of the fest,” a collection of inspirational
stories revealing why brain research is so important.
xx 2AC.006 Advanced Topics in Pediatric Neurology I:
Neurodegenerative Diseases (Registration Required)
xx Integrated Neuroscience Program: Pediatric Demyelinating Disorders
xx 3AC.001 Advanced Topics in Pediatric Neurology II: Neuro-oncology
(Registration Required)
Neuro Hop
Sunday, April 11 | 8:00 a.m.–12:00 p.m.
Coordinators: Massimo Pandolfo, MD and Natalia Rost, MD
Platform Session / 8:00 a.m.–9:30 a.m. / Reception Hall 104A–D
8:00 a.m.
Introduction to INS: Concepts and
Evolving Science
8:15 a.m.
IN1-1.001
rAAV5 Mediated Delivery of Dysferlin
as a Therapeutic Strategy for LGMD2B
and Miyoshi Myopathy Louise RodinoKlapac, Kimberly Shontz, Chrystal
Montgomery, Vinod Malik, Nancy Davis,
Paul Janssen, K. Reed Clark, Robert
Brown, Jerry Mendell
8:30 a.m.
IN1-1.002
Meta-Analysis of MS Genome Scans
V2.0 Implicates New Susceptibility
Genes Involved in Proliferation and
Differentiation Philip De Jager,
Nikolaos Patsopoulos, Joachim Reischl,
Stephan Lehr, David Bauer, Committees
of BENEFIT, BEYOND, LTF, CCR1 Studies,
Juergen Heubach, Rupert Sandbrink,
Christoph Pohl, Paul De Bakker, David
Hafler
8:45 a.m.
IN1-1.003
Frequency and Phenotypic
Characteristics of PRKN, LRRK2, GBA,
PINK1 and DJ1 Mutation Carriers
in Early Onset PD: The CORE-PD
Study Roy Alcalay, Elise Caccappolo,
Helen Mejia-Santana, Ming Tang,
Llency Rosado, Miguel Verbitsky,
Barbara Ross, Sergey Kisselev, Elan
Louis, Cynthia Comella, Amy Colcher,
Danna Jennings, Martha Nance,
Susan Bressman, William Scott,
Caroline Tanner, Susan Mickel, Howard
Andrews, Cheryl Waters, Stanley Fahn,
Lucien Cote, Steven Frucht, Blair Ford,
Michael Rezak, Kevin Novak, Joseph
Friedman, Ronald Pfeiffer, Laura Marsh,
Bradley Hiner, Andrew Siderowf, Ruth
Ottman, Karen Marder, Lorraine Clark
9:00 a.m.
IN1-1.004
Single Nucleotide Polymorphisms of
the ADRB2 Gene Modulate Migraine
Phenotypes Bettina Bayerer, Volker
Limmroth, Hans-Christopher Diener
9:15 a.m.
IN1-1.005
Cigarette Smoking, CYP2A6 Genetic
Variants, and Parkinson Disease: A
Case-Control Study Maurizio Facheris,
Timothy Lesnick, Julie Cunningham,
Walter Rocca, Demetrius Maraganore
Poster Session / Poster Rounds / 9:30 a.m.–10:30 a.m. / Reception Hall 104A–D
IN1-2.001 Mutant LRRK2 and Cell
Death-Signaling Complex Formation:
Implications for Neurodegeneration in
Parkinson’s Disease Hardy Rideout,
Nasia Antoniou, Polena Valkimadi,
William Dauer
IN1-2.002 Gene Therapy for
Mitochondrial Disease John Guy,
Rajeshwari Koilkonda, Vittorio Porciatti,
William Hauswirth, Hong Yu
IN1-2.003 The 6p12.2-p21.1 Migraine
Locus Is Associated with Migraine
with and without Aura in General
Pedigrees Agustin Oterino Duran,
María Toriello, Nuria Ruiz-Lavilla, Ana
Alonso-Arranz, Jesús Castillo, Pablo
Sanchez-Velasco, Julio Pascual
IN1-2.004 Sirtuin and
Mitochondrial Uncoupling Protein
Polymorphisms in Subclinical Carotid
Atherosclerosis David Della-Morte,
Chuanhui Dong, Mark McClendon,
Ashley Beecham, Liyong Wang, Susan
Blanton, Ralph Sacco, Tatjana Rundek
IN1-2.005 Gene Identification Via
Exome Sequencing in Hereditary
Spastic Paraplegia Families Jia Huang,
Eric Powell, Cherylyn Almonte, Gladys
Montenegro, Stuart Young, Daniel
Burges, Mike Schmidt, Benjamin Boese,
Ed Szekeres, Xinmin Zhang, Jeffery
Vance, Margaret Pericak-Vance, Eden
Martin, Tim Harkins, Dale Hedges,
Stephan Zuchner
IN1-2.007 Dynamic Transcriptomes
during Neural Differentiation of Human
Embryonic Stem Cells Revealed
by Short, Long, and Paired-End
Sequencing Anna Szekely, Jia Qian
Wu, Lukas Habegger, Parinya Noisa,
Caihong Qiu, Stephen Hutchison,
Debasish Raha, Michael Egholm, Haifan
Lin, Sherman Weissman, Wei Cui, Mark
Gerstein, Michael Snyder
IN1-2.008 Association of Brain
Derived Neurotrophic Factor SNPs and
Imaging Phenotypes of Alzheimer’s
Disease in the ADNI Cohort Robyn
Honea, Amith Harsha, Eric Vidoni, Carlos
Cruchaga, Russell Swerdlow, Andrew
Saykin, Alison Goate, Jeffrey Burns
IN1-2.009 Genome-Wide Association
Study in Musician’s Dystonia Katja
Lohmann, Alexander Schmidt, Claudia
Hemmelmann, Hans-Christian Jabusch,
Susen Winkler, Stefan Schreiber, Eckart
Altenmüller, Andreas Ziegler, Christine
Klein
IN1-2.010 Development of
Biomarkers for HDAC Inhibitor
Treatment of Friedreich’s
Ataxia Massimo Pandolfo, Heather
Plasterer, Myriam Rai, Sushil Sharma,
Carly Therkelsen, Andrew Cooper,
Jennifer Farmer, David Lynch, James
Rusche
IN1-2.006 Autistic Copy Number
Variations: Parent of Origin and Child
Gender Effects Benjamin Kwan, Brett
Abrahams, Daniel Geschwind
Invited Speaker Session* / Time 10:30 a.m.–12:00 p.m. / Reception Hall 104A–D
10:30 a.m.–10:50 a.m. Genetic Basis of Neurological Disease Margaret Pericak-Vance, PhD
10:50 a.m.–11:10 a.m. Recent Discoveries in Neurogenetics Bryan Traynor, MD
11:10 a.m.–11:15 a.m. Questions and Answers
11:15 a.m.–11:35 a.m. Genes and Fuction: the Rewriting of our Textbooks of Pathology David Hafler, MD
11:35 a.m.–11:55 a.m. Epigenetics: A New Science Underlying Gene-Environmental Interactions, Regenerative Medicine and Multigenerational Inheritance Mark Mehler, MD
11:55 a.m.–12:00 p.m. Questions and Answers
Sponsored by PSAV ® Presentation Services
8:30 p.m.–11:00 p.m.
Dance the night away to classic hits from today and yesteryear. DJ
Kyle spins the tunes. You provide the wild dance moves!
*Current as of February 1, 2010
27
Integrated Neuroscience Session: Pediatric Demyelinating Disorders
Sunday, April 11 | 1:00 p.m.–5:00 p.m.
Monday, April 12 Highlights
Morning Reports
Coordinators: Brenda Banwell, MD and Ann Yeh, MD
Invited Speaker Session* / 1:00 p.m.–2:45 p.m. / Reception Hall 104A–D
7:00 a.m–8:30 a.m.
1:00 p.m.–1:15 p.m.
Directors present a case study in this new interactive program to elicit
questions and answers from participants. All Morning Report programs
will use the interactive audience response system. Morning Report
programs will begin at 7:00 a.m. and run until 8:30 a.m. on select days.
Introduction Ann Yeh, MD
1:15 p.m.–1:40 p.m.
Pediatric Multiple Sclerosis: Diagnosis and Management in 2010 Jayne Ness, MD
1:40 p.m.–2:05 p.m.
ADEM & NMO: Approach Diagnosis and Distinct Aspects of Care Tim Lotze, MD
2:05 p.m.–2:25 p.m.
Environmental Exposures: Vitamin D, Microbial Infection, and Environmental Pollution and Risk of MS in Children Marc Tardieu, MD
2:25 p.m.–2:45 p.m.
Controversies and Considerations in Childhood Demyelination: Age, Maturation, and the Developing Immune and CNS Systems Amit Bar-Or, MD
Poster Session / 2:45 p.m.–3:45 p.m. / Reception Hall 104A–D
IN2-1.001 Clinical and MRI
Distinctions between Tumefactive
Demyelination and Brain Tumors in
Children Eppie Yiu, Suzanne Laughlin,
Leonard Verhey, Sandra Magalhaes,
Sridar Narayanan, Amit Bar-Or, Dessa
Sadovnick, Douglas Arnold, Brenda
Banwell
IN2-1.002 Increasing the Sensitivity
of the National MS Society
Consensus Neuropsychological
Battery for Pediatric MS
(NBPMS) with Regression-Based
Normalization Audrey Smerbeck,
Joy Parrish, Marietta Hoogs, Bianca
Weinstock-Guttman, E. Ann Yeh, Ralph
Benedict
7:00 a.m–9:30 a.m.
IN2-1.003 Executive Functioning in
Children and Adolescents with Multiple
Sclerosis Ameeta Dudani, Rezwan
Ghassemi, Sridar Narayanan, Douglas
Arnold, John Sled, Brenda Banwell,
Christine Till
IN2-1.006 Recurrent Demyelinating
Episodes in Pediatric Patients with
Acute Disseminated Encephalomyelitis
(ADEM) Thitiwan Simasathien,
Khurram Bashir, John Rinker, Jayne
Ness
IN2-1.004 Quality of Life, Cognitive
Function, and Mood in Young Adults
with Pediatric-Onset Multiple
Sclerosis Kristen Krysko, Paul O’Connor
IN2-1.007 Lower Risk for Developing
Neutralizing Antibodies to Interferon
in Children with MS on Interferon
Treatment E. Ann Yeh, Murali
Ramanathan, Rachael Heim, Bianca
Weinstock-Guttman
IN2-1.005 Screening for Depression
in Pediatric Clinically Isolated
Syndrome and Multiple Sclerosis
Populations; Patient and Parent
Report David Rintell, Natalie Baruch,
Brian Healy, Ellen O’Donnell, Mark
Gorman, Tanuja Chitnis
IN2-1.008 Effector B Cell Responses
in Pediatric Multiple Sclerosis Lama
Fawaz, Viviane Poupon, Brenda Banwell,
Ciro Piccirillo, Anne Griffiths, M.
Silverberg, Upton Allen, Amit Bar-Or
IN2-1.009 Biomarkers in Pediatric
MS: Predicting Recurrent Disease
at Time of the First Demyelinating
Episode Sandra Magalhaes, Sunita
Venkateswaran, Chahrazed Belabani,
Nadia Ouamara, Douglas Arnold, Dessa
Sadovnick, Viviane Poupon, Brenda
Banwell, Amit Bar-Or
Platform Sessions / 3:45 p.m.–5:00 p.m. / Reception Hall 104A–D
3:45 p.m.
IN2-2.001
Severity and Recovery of
Exacerbations in Early Pediatric
Multiple Sclerosis Alex Fay, Ellen
Mowry, Dorothee Chabas-Chanezon,
Jonathan Strober, Emmanuelle
Waubant
4:00 p.m.
IN2-2.002
Anti-Myelin Oligodendrocyte
(MOG) Autoantibodies in Childhood
Demyelination: Comparison of Assays
and Longitudinal Analysis Anne-Katrin
Proebstel, Klaus Dornmair, Constanze
Breithaupt, Robert Weissert, Uwe
Jacob, Amit Bar-Or, Brenda Banwell,
Russell Dale, Fabienne Brilot-Turville,
Esther Tantsis, Mohsen Khademi,
Tomas Olsson, Daniela Pohl, Kevin
Rostasy, Astrid Blaschek , Tania
Kuempfel, Frank Weber, Hartmut
Wekerle, Reinhard Hohlfeld, Edgar
Meinl, Tobias Derfuss
State Society Leadership Roundtable
4:15 p.m.
IN2-2.003
Gestational Vitamin D and the
Risk of Multiple Sclerosis in the
Offspring Fariba Mirzaei, Karin
Michels, Kassandra Munger, Eilis
O’Reilly, Tanuja Chitnis, Edward
Giovannucci, Alberto Ascherio
4:30 p.m.
IN2-2.004
Lower Vitamin D Levels Are Associated
with a Higher Rate of Subsequent
Relapse in Pediatric-Onset Multiple
Sclerosis Ellen Mowry, Lauren Krupp,
Maria Milazzo, Dorothee Chabas,
Jonathan Strober, Anita Belman, Jamie
McDonald, Jorge Oksenberg, Peter
Bacchetti, Emmanuelle Waubant
4:45 p.m.
IN2-2.005
Cognitive and Behavioural Outcomes in
Individuals with a History of Childhood
Acute Disseminated Encephalomyelitis
(ADEM) Bravina Bala, Brenda Banwell,
Christine Till
Leadership representatives of state neurological societies are invited
to discuss challenges, strategies, and practices related to state society
creation and maintenance. Discussion will be facilitated by Academy
staff. Participants will learn from the experiences of established
societies and be introduced to the resources available from the
Academy.
Education Colloquium: International Education
8:30 a.m.–12:00 p.m.
The world grows smaller and more interconnected every day. It is
global, multicultural, multilingual, and digitally connected. Neurologists
need knowledge about other countries, regions, cultures, and global
systems to foster the development of health care systems to service
patients with neurological disease throughout the world. In an
increasingly interdependent world, it is essential to foster global and
cross-cultural knowledge and understanding.
This colloquium will provide attendees with a greater understanding
of the challenges, successes and opportunities providing neurology
training in India, Africa, and Latin America. Attendees will have
a greater understanding of the role of the World Federation of
Neurology. Attendees will understand the challenges and opportunities
of Canadian neurology residency and fellowship programs in providing
training for foreign nationals.
International Attendee Summit
12:00 p.m.–1:00 p.m.
This exclusive, free event for international meeting attendees
provides an excellent opportunity to socialize and network with your
international colleagues, make your voice heard on matters most
important to you, and get answers to your most pressing AAN-related
questions. Reserve your space today by contacting Lynee Koester at
lkoester@aan.com or (651) 695-2739.
Kenneth M. Viste, Jr., MD, Neurology Public
Policy Fellowship Information Session
12:00 p.m.–1:00 p.m.
The Kenneth M. Viste, Jr., MD, Neurology Public Policy Fellowship
provides an excellent opportunity to gain hands-on experience in
federal policy and develop political relationships that help promote
the interests of neurology. Meet with past fellows and selection
committee members to learn more about the yearlong paid fellowship
in Washington, DC, offered by the AAN Professional Association, the
American Neurological Association, and the Child Neurology Society.
Web Wonders: The Must-Have Technologies
for Neurologists in 2010
2:30 p.m.–5:30 p.m.
Web Wonders will feature six member presentations highlighting
products and technologies that simplify office workflow, improve
physician/patient communication, and prepare members for federally
mandated changes and incentives with health information technology
and reimbursement issues. The presentations will include: revenue
cycle management, registries for quality reporting, social networking in
your medical practice, “meaningful use”, incentives, patient portals and
e-prescribing.
Best Care Expo: Guidelines, Government
Relations, and Getting Paid
3:00 p.m.–5:00 p.m.
Attend the 2010 “Best Care Expo” where your colleagues will discuss
ways the Academy helps you use the latest research, technology and
tools to streamline your practice and provide the best possible care to
your patients.
Joel M. Kaufman, MD, FAAN, chair of the Academy’s Payment Policy
Subcommittee, speaks about Academy relationships with private
insurance companies, and tips for developing relationships with those
with whom you work most.
Laurence Kinsella, MD, FAAN, co-chair of the Government Relations
Committee, speaks about Academy activities on Capitol Hill, why it is
important to get involved, resources and opportunities.
Hans D. Katzberg, MD, lead author of “Assessment: Symptomatic
Treatment for Muscle Cramps” shares his experience of developing an
Academy guideline.
Activities include:
xx Debate the nuances of evaluation and management coding with
colleagues
xx Discuss recommendations with authors of recently published
guidelines
xx Network with members who have participated in Academy programs
designed to help you become a better advocate for neurology and
your patients’ care
Free to all Annual Meeting Attendees.
*Current as of February 1, 2010
28
29
Monday, April 12 Highlights
ABPN Resident Informational Session
4:00 p.m.–5:00 p.m.
This is an interactive opportunity for residents and fellows to meet
members of the ABPN. The panel will discuss all aspects of the
neurology boards and what is expected from candidates. Free and
open to all interested persons.
Consortium of Neurology Residents
and Fellows (CNRF) Meeting
5:00 p.m.–6:00 p.m.
Come and learn about the consortium, meet officers, and participate in
discussions on a variety of topics related to residents and fellows.
Student Interest Group in Neurology
(SIGN) Meeting
5:00 p.m.–6:30 p.m.
Student and faculty representatives from existing SIGN chapters and
those interested in starting chapters will gather for presentations and
discussions.
Exhibit Hall Opening Reception
5:00 p.m.–7:00 p.m.
MTCC, Exhibit Halls DE
Attend the opening reception to mingle with fellow attendees and
preview the latest products and services available in the neurologic
industry. Light hors d’oeuvres and beverages will be served. The
exhibits will be open at this time.
Sponsored by EMD Serono, Inc. and Pfizer Inc
Neuro Flash
6:30 p.m.–8:00 p.m.
Neuro Flash is a new interactive program featuring quick updates in
the evenings on pertinent issues about a clinical topic. Three half-hour,
case-by-case talks will be followed by questions and answers. All
Neuro Flash programs will utilize the audience response system. Neuro
Flash programs start at 6:30 p.m. and end at 8:00 p.m. on select days.
Residents and Fellows Career Forum and
Reception
6:30 p.m.–9:00 p.m.
This career night for residents and fellows features three panel rooms
including fellowship, private practice, and academic/research, as
well as a poster forum and reception that includes exhibits of private
practice groups and opportunities to learn about potential positions
from Dendrite™ Careers in Neurology advertisers. For more information
email dendrite@aan.com.
Integrated Neuroscience Session: Global Neurology:
Toxins and Infections
Monday, April 12 | 8:00 a.m.–12:00 p.m.
Coordinators: Michael Dobbs, MD and Gustavo Roman, MD, FAAN
Platform Session / 8:00 a.m–9:30 a.m. / Reception Hall 104A–D
8:00 a.m.
IN3-1.001
Neurology of the H1N1 Pandemic in
Singapore Asha Prerna, Natalie Tan,
Jocelyn Lim, Chia-Yin Chong, Derrick
Chan, Kevin Tan
Panel Forums
6:30 p.m.–7:30 p.m.
xx Fellowship Panel
Find out how to search for a fellowship, how program directors
select fellows, and how a fellowship could benefit your career.
xx Academic/Research Panel
Learn how to start a career in academics/research.
xx Private Practice Panel
Learn about beginning a career in private practice.
Poster Forum and Reception
7:30 p.m.–9:00 p.m.
Socialize with other residents and representatives from various
neurology programs and address questions regarding fellowships,
academic research, and private practice career opportunities.
International Component Posters
Neurology Residency Programs that feature an international
element will have the opportunity to showcase their programs
during the poster forum and reception, and to share information
about their international outreach. Neurology Residency
Programs that have a formal affiliation with foreign programs
that encompass teaching and research are encouraged to submit a
poster.
For questions about the Residents and Fellows Career Forum
and Reception, contact Cheryl Alementi at calementi@aan.com
or (651) 695-2737.
8:15 a.m.
IN3-1.002
Progressive Multifocal
Leukoencephalopathy in Transplant
Recipients: A Multi-Center Study
of Clinical Characteristics and
Outcomes Farrah Mateen, RajaNandini
Muralidharan, Daniel Harrison, David
Clifford, Marco Carone, Eelco Wijdicks,
Avindra Nath
8:30 a.m.
IN3-1.003
Stroke in Asymptomatic Trypanosome
cruzi Infected Patients Francisco Javier
Carod-Artal, Antonio Pedro Vargas,
Thiago Falcao
8:45 a.m.
IN3-1.004
African Dust-Laden Atmospheric
Conditions Activate the
Trigeminovascular System Hayrunnisa
Bolay, Hacer Doganay, Didem Akcali,
Tayfun Goktas, Kayhan Caglar, Deniz
Erbas, Cemal Saydam
9:00 a.m.
IN3-1.005
Longitudinal Evaluation of Diffusion
Tensor Imaging from Acute Carbon
Monoxide Poisoning to Delayed
Encephalopathy Hiroshi Kuroda,
Kazuo Fujihara, Shuichi Higano, Yotaro
Shinozawa, Yasuto Itoyama
9:15 a.m.
IN3-1.006
Intracranial Complications of Sinusitis
in Children Caitlin Hicks, Joseph
Weber, Manikum Moodley
Poster Session / Poster Rounds / 9:30 a.m–10:30 a.m. / Reception Hall 104A–D
IN3-2.001 Utility of Quantitative
Sensory Testing in Characterizing HIVAssociated Peripheral Neuropathy in
Western Kenya: Pilot Testing Deanna
Cettomai, Judith Kwasa, Caroline
Kendi, Gretchen Birbeck, Richard Price,
Elizabeth Bukusi, Craig Cohen, AnaClaire Meyer
IN3-2.002 Acute Cerebellitis
Associated with Novel H1N1
Infection Diana Castro, Benjamin
Greenberg
IN3-2.003 Adipokines and
Metabolic Abnormalities in HIV
Patients on Nucleoside Reverse
Transcriptase Inhibitor Containing
Regimens Sivakumar Rajappa
IN3-2.004 Neurocysticercosis. FiveYear Experience at Loyola University
Medical Center Adolfo RamirezZamora, Esteban Golombievski
IN3-2.005 Primary Amebic
Encephalitis by Naegleria
fowleri: Chimaera of Bacterial
Meningitis Herbert Manosalva, Cesar
Ponce, Ilmic Davelaar, Ana Waalkens,
Richard Pladdet
IN3-2.006 Neurological
Complications of Influenza Viruses:
The Role of Dysregulation of Immune
System Sidney Houff, Joseph Berger
IN3-2.007 Headache in Residents
and Workers Exposed to World Trade
Center (WTC) Dust, Gas, and Fumes
Presenting for Medical Care Sara
Crystal, Joan Reibman, Mengling Liu,
Kristen Babinski, Alexandra Milin,
Katherine Henry
IN3-2.009 Chronic Neurological
Symptoms and Disorders Occasionally
Associated with Seafood Poisonings
Occuring in French Polynesia: A FiveCase Exploration Clémence Mahana
iti Gatti, Laurent Maurs, Stéphane Rihet,
Anne-Marie Legrand
IN3-2.008 Brain Blood Regional
Flow Measured by 99Tc EDC SPECT in
’PACO’ Abusers Hugo Videla, David
Huanambal, Juan Ollari, Monica Diez,
Hector D’Onofrio, Juan Maegli, Jorge
Ure
IN3-2.010 HTLV-1 Proviral Load as
a Surrogate Marker for Neurological
Deterioration in HTLV-1-Infected
Individuals: 10 Years of FollowUp Abelardo Araujo, Isa Martins,
Cecília Longo, Raquel de Oliveira,
Suzana Greffin, Maria José AndradaSerpa, Marcus Tulius Silva
Invited Speaker Session* / 10:30 a.m–12:00 p.m. / Reception Hall 104A–D
10:30 a.m.–11:00 a.m. PML-IRIS: Diagnostic and Therapeutic Challenges Avindra Nath, MBBS, FAAN
11:00 a.m.–11:30 a.m. Immunoneurotoxicology in Carbon Monoxide Exposure Sidney Houff, MD, PhD
11:30 a.m.–12:00 p.m. Neurological Complications of Influenza Sidney Houff, MD, PhD
*Current as of February 1, 2010
30
31
Integrated Neuroscience Session: Current Concepts in
Cognitive Neuroscience: Implications for Neurological Disease
Monday, April 12 | 2:00 p.m.–6:00 p.m.
2:00 p.m.–2:30 p.m.
Network Approach to Spatial Attention M. Marsel Mesulam, MD, FAAN
2:30 p.m.–3:00 p.m.
Network-Based Neurodegeneration William Seeley, MD
3:00 p.m.–3:30 p.m.
The Effect of Focal Lesions on Cortical Networks Mark D’Esposito, MD
Poster Session / 3:30 p.m.–4:30 p.m. / Reception Hall 104A–D
IN4-1.002 Theory of Mind Deficits in
Patients with Frontal and Parietal Lobe
Syndromes Brianna Morgan, Rachel
Gross, Paul Eslinger, Ashley Boller,
Murray Grossman
IN4-1.005 Imaging Cognitive
Reserve: Fronto-Parietal Connectivity
Increases with PIB Retention in Healthy
Elderly Subjects Michael Greicius,
Elizabeth Mormino, William Jagust
IN4-1.006 Effect of Propranolol
on Eye Contact in Autism Sepctrum
Disorder David Beversdorf, Sanjida
Saklayen, Ananth Narayanan, Katherine
Higgins, Shawn Christ
IN4-1.007 In ADHD Children, Motor
Subtle Signs Correlate with Reduced
Motor Cortex Inhibition Donald Gilbert,
Kelly Isaacs, Priya Xavier, Lindsay
MacNeil, Amanda Lewis, Martha
Denckla, Stewart Mostofsky
IN4-1.003 Post-Stroke Spatial Bias
and Spatial Neglect in Near and Far
Space Anna Barrett, Elizabeth Murray,
Siby Varughese, Jenny Masmela, Karen
Kelly, Shpresa Ahmeti
IN4-1.008 Connected Speech
Production in Three Variants of Primary
Progressive Aphasia: Linguistic
Features and Neuroanatomical
Correlates Stephen Wilson, Maya
Henry, Max Besbris, Jennifer Ogar,
Bruce Miller, Maria Gorno-Tempini
Bus service to and from the race site will be provided. For registration
and details, visit www.aan.com/view/runwalk or contact Andrew
Halverson at ahalverson@aan.com or (651) 695-2757.
IN4-1.009 Ego and Allocentric
Hypometric Computations in Parkinson
Disease Tigran Kesayan, Anahid
Kabasakalian, John Williamson, Frank
Skidmore, Kenneth Heilman
7:30 a.m.–9:30 a.m.
Now a tradition, the Action Planning Roundtable returns to provide
Donald M. Palatucci Advocacy Leadership Forum graduates a chance
to share with their peers the challenges and successes they’ve
encountered while implementing their action plans. Graduates from all
years are encouraged to attend.
9:00 a.m.–12:00 p.m.
MTCC, Exhibit Hall FG
Platform Session / 4:30 p.m.–6:00 p.m. / Reception Hall 104A–D
5:00 p.m.
IN4-2.003
Fractionating Episodic Memory:
Dissociable Neuroanatomic Correlates
of Impairment of Specific Memory
Processes in AD, a Perspective from
ADNI David Wolk, Bradford Dickerson
4:45 p.m.
IN4-2.002
Motor Extinction in Distinct Reference
Frames: Double Dissociations and
Associated Cortical Lesions Jennifer
Heidler-Gary, Cameron Davis, Melissa
Newhart, John Molitoris, Argye Hillis
5:15 p.m.
IN4-2.004
Drug-Induced Deactivation of Inhibitory
Networks Predicts Pathological
Gambling in PD Thilo van Eimeren,
Giovanna Pellecchia, Roberto Cilia,
Bénédicte Ballanger, Thomas Steeves,
Sylvain Houle, Janis Miyasaki, Mateusz
Zurowski, Anthony Lang, Antonio
Strafella
5:30 p.m.
IN4-2.005
The Human Dopaminergic VTAHippocampal Loop Evidenced by the
Effect of BDNF Genotype Joseph
Masdeu, Philip Kohn, Erica Baller, Joel
Bronstein, Shau-Ming Wei, Angela
Ianni, Andreas Meyer-Lindenberg,
Bhaskar Kolachana, Jasmine Czarapata,
Daniel Weinberger, Karen Berman
Pediatric Stroke: Recent Insights From an Emerging
Field
5:45 p.m.
IN4-2.006
Shared Neural Substrates of Reading
and Spelling in Left Fusiform Gyrus:
Converging Evidence from LesionDeficit and Functional Imaging
Studies Steven Rapcsak, Esther
Kim, Maya Henry, Hyesuk Cho, Sarah
Andersen, Pelagie Beeson
Gabrielle A. DeVeber, MD
Hospital for Sick Children, Toronto, ON, Canada
George C. Cotzias Lecture
Endowed by Roche Pharmaceuticals, Inc.
Deciphering the Molecular Mechanisms of
Alzheimer’s Disease Predicts Novel Therapies
Dennis J. Selkoe, MD, FAAN
Brigham & Women’s Hospital, Boston, MA
Palatucci Advocacy Action Planning Roundtable
Presidential Plenary Session
4:30 p.m.
IN4-2.001
Lesions to the Ventromedial Frontal
Lobe Impair the Ability To Make
Preference Judgments Alexandre
Henri-Bhargava, Alison Simioni, Lesley
Fellows
Sidney Carter Award in Child Neurology
Endowed by an anonymous donor.
Support research in neurology and join us for a 5k run or one mile walk
in downtown Toronto along the scenic waterfront. Whether you’re an
occasional or seasoned runner, or just enjoy a walk, you’ll enjoy this
beautiful trek—for a good cause. All proceeds go to support Clinical
Research Training Fellowships in neurology. The race is open to all
meeting attendees and their families. Water and refreshments will be
available following the race. The registration fee is $25.
Invited Speaker Session* / 2:00 p.m.–3:30 p.m. / Reception Hall 104A–D
IN4-1.004 Cognitive Impairment
in ARCA-1, a Newly Discovered Pure
Cerebellar Ataxia Syndrome Robert
Laforce, James Buteau, Jean-Pierre
Bouchard, Guy Rouleau, Lefebvre
Bernard, Rémi Bouchard, Nicolas Dupré
Run/Walk For Brain Research
6:30 a.m.–8:30 a.m.
Coordinators: Anjan Chatterjee, MD, FAAN and Mark D’Esposito, MD
IN4-1.001 Visual Search in Dementia:
Evidence for Paradoxical Facilitation
of Binding Processes in Semantic
Dementia Adam Boxer, Indre Viskontas,
Alisa Matlin, John Fesenko, Bruce
Miller
Tuesday, April 13 Highlights
Moderator: Stefan M. Pulst, MD, FAAN,
Chair, Science Committee and Scientific
Program Subcommittee
The Presidential Plenary Session features the
Academy’s premier lecture awards for clinically
relevant research and a presentation by a leading
lecturer. Top researchers speak on some of the
most significant findings in neurology in 2010. The session concludes
with the annual AAN Business Meeting.
Lectures include:
Presidential Lecture
Stem and Progenitor Cell-Based Treatment of
Neurological Disease
Steven A. Goldman, MD, PhD
University of Rochester, Rochester, NY
Get Involved in Your Academy and
Professional Association
Stay for the annual AAN/AAN Professional Association Business
Meeting immediately following the final lecture to find out the
latest on Academy business and information.
Meeting will take place in Exhibit Hall FG of the Metro Toronto
Convention Centre.
Exhibits
11:30 a.m.–5:00 p.m.
Complimentary Luncheon
12:00 p.m.–2:00 p.m.
MTCC, Exhibit Hall DE
See the latest in pharmaceutical products, medical equipment,
publications, and products to assist with practice management,
teaching methods, and research activities.
Ethics Colloquium
12:30 p.m.–2:00 p.m.
Participants will have the opportunity to identify emerging ethical
issues affecting the practice of neurology that they would like the
Ethics, Law, and Humanities Committee (ELHC) to consider for future
reports or policies. Attendees will be encouraged to submit topics,
along with related articles, opinions, or guidelines, in advance of the
Colloquium.
Robert Wartenberg Lecture
Midlife Risk Profile and Later Life Cognitive Decline
and Dementia
Philip A. Wolf, MD, FAAN
Boston University School of Medicine, Boston, MA
*Current as of February 1, 2010
32
33
Tuesday, April 13 Highlights
Poster Discussion Session
Hot Topics Plenary Session
7:30 a.m.–12:00 p.m.
(Author stand by poster from 7:30 a.m.–9:00 a.m.)
5:30 p.m.–6:30 p.m.
3:00 p.m.–7:30 p.m.
(Author stand by poster from 6:00 p.m.–7:30 p.m.)
Ten posters in six neurologic topics have been selected for discussion.
Posters will be grouped in a separate area where topic experts will
facilitate questions and answers with attendees and poster authors
during the 90-minute author standby time.
NIH Sponsored Clinical Trials in Neurology:
What’s Going On? How to Participate?
How Can We Do Better?
1:00 p.m.–3:00 p.m.
The National Institutes of Health is the world’s largest funding agency
for medical research. In the amount of research dollars going to major
areas, neuroscience research is second only to cancer. The final goal
of the taxpayer’s investment in neuroscience research is clinical trials
that test new therapies. Many trials are performed by industry based
upon NIH funded neuroscience discoveries, but many are funded by the
NIH. The program will review NIH clinical trials currently in progress or
just completed. A major new emphasis has been placed on obtaining
evidence to inform medical decision-making, so called comparative
effectiveness research. The focus will be on how the results of
these trials might impact practice and also to obtain feedback
from practitioners on what are the major questions that need to be
addressed by future trials.
Free to all attendees.
New! Platform Session Times
1:45 p.m.–3:45 p.m.
4:00 p.m.–5:15 p.m.
New time slots this year allow registrants to attend the Highlights in
the Field program of their choice while still being able to attend the
evening’s Hot Topics Plenary Session.
34
Poster Session Floor Plan
Metro Toronto Convention Centre, Room 808
242
243
244
245
246
247
248
249
250
251
MTCC, Exhibit Hall FG
Moderator: Raymond P. Roos, MD, FAAN,
Member, Science Committee
This session highlights important and interesting
abstracts presented at subspecialty meetings
leading up to the Annual Meeting that are not
on the program but should be heard by a wide
audience at the Annual Meeting. Topics are
selected by the AAN Science Committee and AAN Scientific Program
Subcommittee.
Topic: Whole Exome Sequencing
Jeffrey M. Vance, MD, PhD
University of Miami, Miami, FL
257 258
269 270
281 282
293 294
241
256 259
268 271
280 283
292 295
240
255 260
267 272
279 284
291 296
239
254 261
266 273
278 285
290 297
238
253 262
265 274
277 286
289 298
237
252 263
264 275
276 287
288 299
70 71
90 91
110 111
130 131
186 187
206 207
226 227
69 72
89 92
109 112
129 132
149 150
167 168
185 188
205 208
225 228
68 73
88 93
108 113
128 133
148 151
166 169
184 189
204 209
224 229
67 74
87 94
107 114
127 134
147 152
165 170
183 190
203 210
223 230
66 75
86 95
106 115
126 135
146 153
164 171
182 191
202 211
222 231
65 76
85 96
105 116
125 136
145 154
163 172
181 192
201 212
221 232
64 77
84 97
104 117
124 137
144 155
162 173
180 193
200 213
220 233
63 78
83 98
103 118
123 138
143 156
161 174
179 194
199 214
219 234
Corporate Therapeutic Updates
62 79
82 99
102 119
122 139
142 157
160 175
178 195
198 215
218 235
Sheraton Centre Toronto Hotel
61 80
81 100
101 120
121 140
141 158
159 176
177 196
197 216
217 236
Topic: CREST Trial
Thomas G. Brott, MD, FAAN
Mayo Clinic-Jacksonville, Jacksonville, FL
Title: “Devices for Epilepsy”
Gregory A. Worrell, MD
May Clinic-Rochester, Rochester, MN
Title: “Comparative Effectiveness Research”
S. Claiborne Johnston, MD, PhD
University of San Francisco, San Francisco, CA
Tuesday, April 13
Poster Session I
7:30 a.m.–12:00 p.m. .
7:30 a.m.–9:00 a.m.*
Poster Session II
3:00 p.m.–7:30 p.m..
6:00 p.m.–7:30 p.m.*
Wednesday, April 14
Poster Session III
7:30 a.m.–12:00 p.m..
7:30 a.m.–9:00 a.m.*
Poster Session IV
3:00 p.m.–7:30 p.m..
6:00 p.m.–7:30 p.m.*
Thursday, April 15
Poster Session V
7:30 a.m.–12:00 p.m..
7:30 a.m.–9:00 a.m.*
Poster Session VI
3:00 p.m.–7:30 p.m..
6:00 p.m.–7:30 p.m.*
*Authors stand by posters.
7:30 p.m.–10:00 p.m.
Industry-sponsored, non-CME programs will be offered and are
open to attendees at no charge. They will provide an opportunity for
pharmaceutical companies, device companies, or other neurologic
related organizations to share information regarding their current
therapies and projects in the pipeline in accordance with standards set
for industry by the FDA.
See page 88 for more details.
10 11
30 31
50 51
9 12
29 32
49 52
8 13
28 33
48 53
7 14
27 34
47 54
6 15
26 35
46 55
5 16
25 36
45 56
4 17
24 37
44 57
3 18
23 38
43 58
2 19
22 39
42 59
1 20
21 40
41 60
35
Poster Session I
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
Poster Discussion Session: Aging and Dementia: Risk Factors
Location: 800 Level
Moderator: Andrea Bozoki, MD
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
PD1.001 Subjective Memory
Complaints Are Associated with
Impending Cognitive Decline Isabel
Hernandez Ruiz, Pablo Martinez-Lage,
Monserrat Alegret Llorens, Sergi Valero
Ventura, James Becker, Oscar Lopez, Lluis
Tarraga Mestre, Merce Boada Rovira
PD1.003 Effect of Age, Gender,
Marital Status, and Education on
Behavioral Symptoms in Mild Cognitive
Impairment and Mild Alzheimer’s Disease
Subjects Liana Apostolova, Chi-Hong
Tseng, Lynn Fairbanks, David Elashoff,
Jeffrey Cummings
PD1.002 White Matter
Hyperintensities Volume Is a
Stronger Predictor of Dementia Than
Silent Infarcts. A Population-Based
Cohort Study: The 3C-Dijon MRI
Study Christophe Tzourio, Yi-Cheng Zhu,
Aicha Soumaré, Ophelia Godin, Bernard
Mazoyer, Olivier Rouaud, Hugues Chabriat,
Carole Dufouil
PD1.004 Anxiety Affects
Executive Functioning Differently in
Asymptomatic APOEe4 Homozygotes and
Noncarriers Cynthia Stonnington, Richard
Caselli, Dona Locke, Amylou Dueck
PD1.007 A Simple Risk Model Based
on Age at Diagnosis, MMSE, and Gender
for the Prediction of Survival in Persons
with Alzheimer’s Disease: “Tell Me
Doc, How Long Do I Have?” Gregory
Jicha, Peter Nelson, Erin Abner, Marta
Mendiondo, Frederick Schmitt, William
Markesbery, Richard Kryscio
PD1.005 Education Mitigates Effects
of Frontal Inhibitory Network Atrophy To
Maintain Executive Function in Normal
Elders Jacob Mirsky, Hilary Heuer, Aria
Jafari, Joel Kramer, Indre Viskontas, Bruce
Miller, Adam Boxer
PD1.008 Apoliprotein E Status
Modulates the Clinical and
Neuroanatomic Phenotype of Alzheimer’s
Disease: Data from ADNI David Wolk,
Bradford Dickerson
Neurologic Education: Resident
and Student Education
Neurologic Education: Stroke
Education
P01.001 What Is the Effect of Logging
Abnormal Clinical Signs on Medical
Student Knowledge Acquisition during the
Neurology Clerkship? David Tabby
P01.009 Development,
Implementation, and Evaluation of a
Training Video To Instruct Healthcare
Providers on a Formal Bedside Dysphagia
Assessment for Stroke Patients Cathy
Sila, Gina Nicastro, Natalie Rudd, Margaret
Stecker, Erin Supan, LeighAnn McCartney
P01.015 Median Nerve
Ultrasonography in Carpal Tunnel
Syndrome: A Blinded Case-Control
Study Andrea Leep Hunderfund, Andrea
Boon, Eric Sorenson
P01.002 Effectiveness of a WebBased Essential Neurologic Exam Video
Tutorial in Combination with a Didactic
Lecture vs. Didactic Lecture Alone: A
Randomized Trial Shelly Miller, Chuanhui
Dong, Richard Isaacson
P01.003 Neurology Residents
as Teachers: A Medical Student
Perspective Jennifer Elbaum, Stephen
Krieger, Martin Goldstein
P01.004 Neurology Residents’
Perceptions of Peer-Driven Neurology
Board Review Sessions Esteban ChengChing, Lama Chahine, MaryAnn Mays
P01.005 Potential Utility of Scenario
Based Simulations for Teaching Neurology
Residents Interpersonal/Communication
Skills and System Based Practice Dreama
Brar, Loretta Schnepel, Balena Adkins,
Scott Silliman
P01.006 Teaching Cranial Nerve
Examination Using a Virtual Patient and
the Nintendo Wiimote®: Preliminary
Evaluation Chandni Kalaria, Chen Lin,
Kyle Johnsen, David Lind, Aaron Kotranza,
Candelario Laserna, Tia Aryal, Hevil Shah,
Jerry Pruitt, Bayard Miller, Juan Cendan,
Benjamin Lok
P01.007 Review of Neurology
Education Uses of Web 2.0 Jeff Kraakevik
P01.008 Survey of Skin Preparation
Technique before Neuraxial
Procedures Christopher Grunseich, Shawn
Sumida, Ejaz Shamim
36
PD1.006 Hypertension and Its
Association with Prevalent Dementia in
the Oldest-Old Maria Corrada, Daniel
Berlau, Carrie Peltz, Claudia Kawas
P01.010 Evaluation of a Stroke
Alert Protocol Coupled with an
Education Program in the Emergency
Department Carl Hoegerl, Frederick
Goldstein, Seeniann John
P01.011 Chairmen Perspective
on Current State of Vascular and
Interventional Neurology Osama Zaidat,
Junaid Kalia, Matthew Lochen, Anthony
Furlan, Safwan Jaradeh, David Kaufman,
Henry Kaminski, Carlos Kase, Lawrence
Wechsler, Dileep Yavagal, Tudor Jovin,
Rishi Gupta, Jose Biller
P01.012 Program Directors’
Perspective on Education in Interventional
Neurology Junaid Kalia, Wendy Peltier,
David Preston, Douglas Woo, Osama
Zaidat
Clinical Neurophysiology:
Electrodiagnosis and Clinical
Peripheral Nerve Disease
P01.013 Conduction Jump
Measure on Motor Fibers To Improve
the Electrodiagnosis of Carpal Tunnel
Syndrome Philippe Lebrun-Grandié, Luc
Letenneur
P01.014 Peripheral Neuropathy in
Wegener Granulomatosis: Clinical and
Neurophysiological Features Elizabeth
Soto-Cabrera, Horacio Senties-Madrid, Iris
Gonzalez-Orizaga, Francisco GutierrezManjarrez, Bruno Estanol
P01.016 Peripheral (PCT) and Central
(CCT) Conduction Time to Quadriceps
Muscle Alessia Di Sapio, Francesca
Sperli, Simona Malucchi, Marco
Capobianco, Antonio Bertolotto, Walter
Troni
P01.017 A Prospective Study on the
Electrodiagnosis of Ulnar Neuropathy
at the Elbow (UNE) Based on Bayesian
Principles Raissa Villanueva, Paul Twydell,
Bennett Myers, Marlene Downs, David
Herrmann, Eric Logigian
P01.018 Peripheral Neuropathy
Associated to Progressive Systemic
Sclerosis: Clinical and Neurophysiological
Features Elizabeth Soto-Cabrera, Horacio
Senties-Madrid, Lydia Lopez, Francisco
Gutierrez-Manjarrez, Iris Gonzalez-Orizaga,
Jose Gien-Lopez, Bruno Estanol
P01.019 Decline in Nerve Conduction
Velocity (NCV) with Age Occurs in
Proximal Nerve Segments among
the Healthy Elderly John Engstrom,
Christopher Songster, Amy Lee, Carol
Piunti, Ari Green
P01.020 Pregabalin in Post-Traumatic
Peripheral Neuropathic Pain: Efficient
Assessment of Efficacy in a Randomized,
Double-Blind, Placebo-Controlled
Crossover Study Timothy Jenkins, Trevor
Smart, Frances Hackman, Carol Cooke,
Keith Tan, Raymond Cheung
PD1.009 Diagnostic Norms for
Subjects Aged between 50 and 89 Years
with Mild Dementia: Single or Adjusted
Cut-Off? Gilles Chopard, Geraldine
Vanholsbeeck, Sabrina Ferreira, Elloi
Magnin, Lucien Rumbach, Jean Galmiche
PD1.010 Peripheral Insulin
Predicts Rates of Brain Atrophy and
Cognitive Decline in Early Alzheimer’s
Disease Jeffrey Burns, Eric Vidoni,
Robyn Honea, Heather Anderson, Russell
Swerdlow, William Brooks
P01.028 Ocular Vestibular Evoked
Myogenic Potentials in Patients with
Migraine Eren Gozke, Nursel Erdal, Haluk
Ozkarakas
P01.040 Treatment with Bcl-220-34
after CCI Provides Protection Against
Mitochondrial and Synaptic Loss Roi Ann
Wallis, Kimberly Panizzon, Suni Allen
P01.029 Age-Dependent Pattern
of Oxygen Metabolism Response to
Continuous Visual Deprivation Andrei
Vlassenko, Melissa Rundle, Mark Mintun
P01.041 Computed Tomography
Perfusion Findings To Identify Acute
Ischemic Stroke Patients for Acute
Thrombolysis Haralabos Zacharatos,
Ameer Hassan, Mushtaq Qureshi,
Gabriela Vazquez, Robert Taylor, Mustapha
Ezzeddine, Adnan Qureshi
P01.030 Frequency and
Yield of Repeat Audio-Visual
Electroencephalography in a
Comprehensive Epilepsy Center Huijun
Wang, Rohit Marawar, Anthony Ritaccio
P01.031 Prevalence of Seizures and
Epileptiform Activity in the Acute Setting
of Cerebral Hemorrhage Jeffrey Politsky,
Igor Ugorec
Clinical Neurophysiology:
Transcranial Magnetic
Stimulation and Evoked
Potentials
P01.032 Repetitive Transcranial
Magnetic Stimulation in Children
with Attention Deficit Hyperactivity
Disorder Lazaro Gomez
P01.021 Latency Skin Sympathetic
Reflex Is Shorter Palms and Fingers
Compared to Wrist When Elicited
by Electrical Stimulus Iris GonzalezOrizaga, Elizabeth Soto-Cabrera, Horacio
Senties-Madrid, Cesar Callejas, Francisco
Gutierrez-Manjarrez, Bruno Estanol
P01.022 Simultaneous Recording of
the H Reflexes of the Flexor Carpi Radialis
and Biceps Brachii Miguel Padilla, Bruno
Estanol, Guillermo Garcia-Ramos, Horacio
Senties-Madrid
Clinical Neurophysiology: EEG/
Epilepsy
P01.023 Treatment of Hospital
Onset Seizures: A Comparison between
Two Hospitals Madeline Fields, Daniel
Labovitz, Jacqueline French
P01.024 Safety and Efficacy of
Pregabalin in Patients with Central
Post-Stroke Pain Raymond Cheung, Kevin
Murphy, Guy Bashford, Andrew Martin,
Jong Kim
P01.025 Comparison of Detection
Rates of Non-Convulsive Status
Epilepticus and Non-Convulsive Seizure
in Critically Ill Patients Using Routine EEG
and Continuous EEG in a Busy County and
a Private Hospital Shahram Izadyar, David
Friedman, Vitor Pacheco, Richard Hrachovy
P01.026 Quantitative EEG during
Nocturnal Polysomnography before
and after Treatment with Sodium
Oxybate Victor Rosenfeld, John Stern,
Dinh Ngyuen
P01.027 Source Localization of Sleep
Spindles by High Resolution EEG/MEG
Recordings Eun Hye Jeong, Jooman Han,
Songi Kim, June Sik Kim, Chun Kee Chung,
Hyang Woon Lee
Poster Session I
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P01.033 Changes in Somatosensory
Evoked Potentials to Fluctuations
in Mean Arterial Pressure during
Endoscopic Endonasal Approach to Skull
Base Surgery Parthasarthy Thirumala,
Miguel Habeych, Jeffery Balzer, Donald
Crammond
P01.034
withdrawn
P01.035 TMS-Related Metabolic
Changes in Limbic System and Default
Network in Patients with Tinnitus Andrei
Vlassenko, Lars Couture, Keith Garcia, Jay
Piccirillo, Mark Mintun
P01.036 Local Non-Synaptic
Mechanisms Underlying Very
Fast Oscillations in Rasmussen’s
Encephalitis Anita Roopun,
Venkateswaran Ramesh, Mark Baker,
Alistair Jenkins, Ming Lai, Ian Schofield,
Roger Whittaker, Roger Traub, Miles
Whittington, Mark Cunningham
Critical Care/Emergency
Neurology/Trauma I
P01.037 High Rate of Myopathy in
Aneurysmal Subarachnoid Hemorrhage
Patients Gaurav Parikh, Thomas Wolfe,
Kaiz Asif, Denise Miller-Niklasch, Safwan
Jaradeh, John Lynch, Michel Torbey
P01.038 Imaging, Interventions, and
Neurologic Outcomes in 8 ICU Patients
with Severe Hyperammonemia Prem
Kandiah, Dhruvil Pandya, Adriana Kori-Graf,
Rahul Nanchal
P01.039 Clinical, Electrophysiologic,
and Pathologic Outcomes in a Large
Animal Model of Limb Ischemia Nathan
Sumner, Gabriel Burkhardt, John Sladky,
Todd Rasmussen, Jerry Spencer, Jerry
Cowart, Lyell Jones
P01.042 A Malignant Case of
Acute Promyelocytic Leukemia with
Occlusion of Carotid Artery by Tumor
Thrombus Selena Nicholas-Bublick,
Gretchen Tietjen, John Irlam
P01.043 Mortality, Impairment,
and Disability of Patients with Acute
Traumatic Spinal Cord Injury: Does Blood
Alcohol Concentration Matter? Julio
Furlan, Michael Fehlings
P01.044 Predictors of EndotracheaI
Intubation in Patients Presenting with
Seizure Tenbit Emiru, Nauman Tariq,
Robert Taylor, Adnan Qureshi, Mustapha
Ezzeddine
P01.045 The FOUR Score Is a Predictor
of Outcome in Comatose Patients after
Cardiac Arrest Eelco Wijdicks, Jennifer
Fugate, Daniel Claassen, Alejandro
Rabinstein
P01.046 The Impact of Rebleeding
on Delayed Cerebral Ischemia (DCI)
after Aneurysmal Subarachnoid
Hemorrhage Aaron Lord, Luis Fernandez,
J. Michael Schmidt, Sachin Agarwal,
Stephan Mayer, Kiwon Lee, Jan Claassen,
E. Sander Connolly, Neeraj Badjatia
P01.047 Clinical Interest of Long
Latency Somatosensory Evoked Potentials
(N60) in Postanoxic Coma Mathieu
Bataille, Charlotte Quentin, Cedric Daubin,
Gilles-Louis Defer, Olivier Etard
P01.048 Neuron Specific Enolase as
a Predictor in Therapeutic Hypothermia
after Cardiac Arrest Jennifer Fugate,
Eelco Wijdicks, Daniel Claassen, Alejandro
Rabinstein
P01.049 Predictive Value of
Prevalent Aneurysmal Subarachnoid
Hemorrhage Grading Scales for Clinical
Outcomes Sachin Agarwal, Matthew
Vibbert, Luis Fernandez, J. Schmidt, Jan
Claassen, Stephan Mayer, Kiwon Lee,
Neeraj Badjatia
P01.050 The Effect of Motivation
on Clinical Reaction Time Assessment
in College Athletes Katherine Bohard,
James Eckner, Jeffrey Kutcher
P01.051 Gender and Racial Disparity
in Survival after Cardiac Arrest Richard
Dubinsky, Sue Lai
P01.052 Prognosis after Therapeutic
Hypothermia in Anoxic Brain Injury
Patients Based on EEG Grading
Scale Anahita Adeli, Mouhammad
Jumaa, Gena Ghearing, Frank Guyette,
Clifton Callaway, Jon Rittenberger
Cerebrovascular Disease: Stroke
Prevention
Cerebrovascular Disease:
Epidemiology I
P01.053 Transcranial Doppler with
Contrast for the Diagnosis of Vascular
Lesions in Adult Patients with Sickle Cell
Disease Abelardo Araujo, Orlando Velloso,
Ana Claudia Leite, Raquel Oliveira, Paulo
Valle Bahia
P01.064 Change in Trends in the
Occurrence of Young Stroke over the Last
Two Decades—A Study from a Tertiary
Care University Hospital, New Delhi
(India) Manmohan Mehndiratta, Rohit
Garg
P01.054 Usefulness of
Echocardiography in the Routine
Evaluation of Patients with Ischemic
Stroke/TIA Liqun Zhang, J. Harrison, Larry
Goldstein
P01.065 Prehospital Delay and
Related Factors in Patients with Acute
Ischemic Stroke or TIA: Change over
Recent 4 Years in a Community Based
Hospital Sucjoo Kim, Ji-Young Park,
Byung-Kun Kim, Ohyun Kwon, Jong-Moo
Park, JungJu Lee, Ja-Seong Koo
P01.055 Pharmacokinetics of
Extended-Release Dipyridamole Following
Administration through Gastrostomy
Tube David Greer, Leonardo Batista, David
Crandell
P01.056 Risk Profile of Subjects
Enrolled in the Randomized Evaluation of
Recurrent Stroke Comparing PFO Closure
to Established Current Standard of Care
Treatment (RESPECT) Trial over the First
Six Years of Enrollment David Thaler,
Diane Book, John Carroll, Larry Goldstein,
Helmi Lutsep, Jeffrey Saver, Richard
Smalling, David Tirschwell, Brian Van Dorn
P01.057 A Model for Delivery
of Community-Based Secondary
Prevention Care for First-Time Stroke
Survivors Kenneth Gaines, Duncan Howe,
Andrew Kurtzman, Franklin Carlisle, Alisa
Roberson, Monique Brown, Candice
Munnerlyn
P01.058 Percutaneous Closure
of Patent Foramen Ovale: Guidelines,
Selection Criteria, and Follow-Up of a
Clinical Cohort Dario Giobbe, Alessandro
Balducci, Gabriella Paglia, Paolo
Scacciatella, Mauro Giorgi, Sebastiano
Marra
P01.059 Endarterectomy for
“Hemodynamically Insignificant”
Symptomatic Carotid Stenosis Rebekah
Ahmed, John Harris, Craig Anderson,
Virginia Makeham, Michael Halmagyi
P01.060 Angioplasty with Stent
for Radiation-Induced Extra-Cranial
Stenosis Thomas Leung, Simon Yu, Yannie
Soo, Alexander Lau, Anne Chan, Lawrence
Wong
P01.061 Mechanism of Ischemic
Stroke in Takayasu Arteritis Jaechun
Hwang, Gyeong-Moon Kim, Young Bang
Oh, Chin-Sang Chung, Kwang Ho Lee, Dukkyung Kim
P01.062 Lack of Impact of Local and
National Stroke Awareness Campaigns
on TIA Referrals to a UK District General
Hospital David Collas
P01.063 A Retrospective Cohort
Study of Substance Abuse and Length
of Hospital Stay in Ischemic Stroke
Patients Lien Diep, John Kwagyan, Roger
Weir, Alice Adams, Raza Khan, Zakiya
Wynn, Sherita Chapman, Alok Dabi, S.
Fatima, Annapurni Jayam-Trouth
P01.066 Pregnancy Related Stroke
in Developing Asian Countries: Risk
Factors, Subtypes, Presentation, and
Outcome Mohammad Wasay, Shahzad
Ahmed, Kauser Mehmood, Subhash Kaul,
Bindu Menon, Mohammad Saadatnia,
Abdul Malik, Padma Gunaratne,
Manmohan Mehndiratta
P01.067 Neurofluctuations in Patients
with Subcortical Ischemic Strokes (NISS)
Study Indrani Acosta, Nusrat Harun, Hen
Hallevi, Sean Savitz
P01.068 Motor Function Impairment
among Elderly Population with History of
Stroke Afshin Divani, Gabriela Vazquez,
Kyle Brandy, Anna Barrett, Andreas Luft
P01.069 Cerebral Venous Sinus
Thrombosis in Males: Is It Uncommon
or Under-Reported? Rohit Garg, Man
Mehndiratta, Sanjay Pandey, Awadh
Pandit
P01.070 Urinary Incontinence among
Elderly Stroke Survivors Gabriela Vazquez,
Rachel Meyer, Andreas Luft, Afshin Divani
P01.071 Racial Disparities in Health
Care Costs in Stroke Patients with or
without Diabetes Majaz Moonis, Baqar
Husaini
P01.072 Investigating the Relationship
between Cholesterol Level with Increased
Risk of ICH in Different Races Bahareh
Hassanzadeh, Florence Chukwuneke,
Mohammad Moussavi, Vahid Tohidi, Ugo
Paolucci, Martin Gizzi, Jawad Kirmani
P01.073 Strokes in a Developing
Country: Does Gender Matter? Jayanthi
Arulneyam, Fahmi Al-Senani
P01.074 Disparities in Acute Stroke
Care: Role of Race and Insurance
Status Jose Romero, Helena Lau, Michael
Winter, Viken Babikian, Aleksandra Pikula,
Andrew Morrison, Thanh Nguyen, Jason
Viereck, Carlos Kase
P01.075 Stroke Subtypes in Hawaii:
Gender, Age and Ethnicity Douglas
Valenta, Cherylee Chang, Susan Asai,
Douglas Franz, Muhammad Suri
P01.076 Trends in Hospital CaseMortality Rate for Ischemic Stroke:
Does Hospital Size Matter? Manuel
Seijo-Martinez, Javier Paz-Esquete, Ramon
Ares-Rico, Angeles Bouzas Rodriguez
37
Poster Session I
P01.077 Correlation of Ischemic
Stroke and Coronary Artery Calcium
Burden: A Retrospective Analysis Paul
Lleva, Stephen Marks, Ramandeep Sahni,
Brij Singh Ahluwalia, Oceanis Vaou, Sonia
Lal, Maheep Singh
P01.089 Epidemiological and
Neurophysiological Characteristics of
Epilepsy in African American Population
with HIV Infection Mohankumar
Kurukumbi, Rajesh Gupta, Annapurni
Jayam-Trouth
P01.078 Inverse Association of
Atheromatous Aortic Arch Disease
and Atrial Fibrillation in Patients with
Ischemic Stroke and Transient Ischemic
Attack Andrés Suarez, Patricia Riccio,
Francisco Klein, Luciano Sposato
P01.090 Predictors of Refractoriness
in Patients with Post-Stroke
Epilepsy Kandan Kulandaivel, Jyoti Pillai,
Andrea Rosso, Jamie Swanson, Barbara
Jobst
P01.079 Prevalence and Risk Factors
for Stroke in Rural Communities of Middle
Belt Nigeria Emmanuel Sanya, Feyi
Adepoju, Sunday Aderibigbe, Olabode
Olaosebikan, Timothy Olarewaju
P01.080 Known Versus De Novo
Atrial Fibrillation in Patients with Acute
Ischemic Stroke and Transient Ischemic
Attack Juan Ressia Gómez, Patricia
Riccio, Francisco Klein, Agustín Jáuregui,
Marisol Ferrúa, Rafael Zamora, Luciano
Sposato
P01.081 Differences in Risk Factor
Profiles between Asymptomatic
Carotid Disease and Ischemic Stroke or
Transient Ischemic Attack of Non-Carotid
Etiology Juan Ressia Gómez, Patricia
Riccio, Francisco Klein, Luciano Sposato
P01.082 Risk Factors and
Management of Ischemic Stroke in
Korean Young Adults under 49 Years
Old Do Kyung Lee, Dae-Il Chang, Jung
Hwa Kim, Key Chung Park, Tae-Beom Ahn,
Sung Sang Yoon, Kyung Cheon Chung
P01.083 Outcomes after Spontaneous
Intracerebral Hemorrhage in South
Asians: The Race Factor Syed Abbas,
Ugo Paolucci, Mohammed Alsumrain,
Mohammad Moussavi, Martin Gizzi,
Jawad Kirmani
P01.084 Prevalence of Transthoracic
Echocardiographic Abnormalities in
Stroke Paul Eugene Lleva, Stephen Marks,
Wilbert Aronow, Raveen Deol, Kaushang
Gandhi, Brij Singh Ahluwalia
Epilepsy: Epidemiology
P01.085 Incident Epilepsy/Seizure
Disorder in US Nursing Homes by
Predisposing Conditions, 2003–
2007 Lynn Eberly, Ilo Leppik, Kenneth
Svendsen, Shuzhen Li, Susan Harms,
Judith Garrard, Beth Virnig
P01.086 A Population-Based Study of
Health-Related Quality-of-Life in Migraine
and Epilepsy Compared to Asthma and
Diabetes Nathalie Jette, Jody Pow,
Jane McChesney, Scott Patten, Jeanne
Williams, Sam Wiebe
P01.087 Admission for Status
Epilepticus over Eight Years in Tennessee:
Effect of Race and Age Amir Arain,
Pradumna Singh, Yanna Song, Van Cain,
Baqar Husaini
P01.088 Women with Epilepsy and
Folic Acid Supplementation Prior to
Pregnancy Kristi McIntosh, Autumn Klein
38
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P01.091 Analysis of 621 Death
Certificates Issued during 1998–2007
in Curitiba, Brazil, Mentioning Epilepsy
or Epileptic Seizures Renata Ducci,
Raphael Cirino, Ramon de Oliveira, Carlos
Twardowschy, Eliane Chomatas, Pedro
Kowacs
Child Neurology/Developmental
Neurobiology: Epidemiology
P01.092 Trends in Outcomes and
Hospitalization Costs among Pediatric
Spinal Cord Injury Patients in the United
States Mahta Samizadeh, Khosro Farhad,
Lubna Mehyar, Hafiz Khan, Nizar Souayah
P01.093 Trends in Outcomes and
Hospitalization Costs of Infantile Botulism
in United States Lubna Mehyar, Hafiz
Khan, Zaid Abed Al-Qudah, Shahanara
Islam, Nizar Souayah
P01.094 Idiopathic Inflammatory
Myopathies in Childhood: Analysis of 27
Cases Paulo Lorenzoni, Rosana Scola,
Claudia Kay, Lineu Werneck
P01.095 Healthcare Transitions for
Adolescents with Chronic Life-Limiting
Neurological Illnesses: Identifying
Research Priorities Lynn Straatman
P01.096 Paroxysmal Kinesigenic
Dyskinesia: The Cleveland Clinic
Experience and Literature Review Krishe
Menezes, David Rothner
P01.097 Prognostic Factors for
Outcome of Neonatal Seizures in Term
Infants Jarred Garfinkle, Michael Shevell
P01.098 Motor Stereotypies:
Normal Childhood Behavior or a
Disorder? Rebecca Gologorsky, Farhad
Sahebkar
P01.099 The Stereotypical Behavior
of Parents Whose Children Have
Stereotypies Farhad Sahebkar, Onica
Kuch, Rebecca Gologorsky
P01.100 Temporal Trends in
Presentation Time to the Emergency
Department (ED) for Pediatric Stroke
Patients: A Population-Based Study Laura
Lehman, Jane Khoury, Kathleen Alwell,
Charles Moomaw, Pooja Khatri, Brett
Kissela, Daniel Woo, Matthew Flaherty,
Opeolu Adeoye, Simona Ferioli, Joseph
Broderick
P01.101 Spectrum of Disorders Seen
at a Pediatric Movement Disorders and
Spasticity Clinic Lama Chahine, Manuel
Buitrago Blanco, Debabrata Ghosh
Aging and Dementia:
Epidemiology
P01.102 Differential Risk Factors
for Amnestic MCI and Dementia Amy
Borenstein, James Mortimer, Ding Ding,
Qian-hua Zhao, Qi-hao Guo, Douglas
Galasko, David Salmon, Ronald Petersen,
Zhen Hong
P01.103 Cortical and Subcortical
Gray Matter Volumes and Walking Speed
in Elderly Subjects: The Three-City
Study Julien Dumurgier, Fabrice Crivello,
Bernard Mazoyer, Pauline Maillard,
Béatrice Tavernier, Nathalie TzourioMazoyer, Christophe Tzourio, Alexis Elbaz
P01.104 Terminal Decline in Specific
Cognitive Domains in DementiaFree Elderly, Using Change Point
Analysis Hiroko Dodge, Chung-Chou
Chang, Mary Ganguli
P01.105 Interaction of High
Homocysteine Level and MTHFR
Polymorphism on Dementia Risk. The
3C-Dijon Study Carole Dufouil, Ophelia
Godin, Jean-Sebastien Vidal, Olivier
Rouaud, Annick Alperovitch, Christophe
Tzourio
P01.106 Gender Differences in the
Risk Profile and Male Predominance
of Silent Brain Infarction in Japanese
Elderly Subjects: The Sefuri Brain MRI
Study Takahiro Mori, Yoshikazu Miwa,
Yuki Takashima, Manabu Hashimoto,
Akira Uchino, Takefumi Yuzuriha, Toshiyuki
Sasaguri, Hiroshi Yao
P01.107 Apathy in the Very Old
and the Incidence of Dementia: The
Monzino 80-Plus Population-Based
Study Giancarlo Logroscino, Mauro
Tettamanti, Angela Recchia, Maria Teresa
Garrì, Emma Riva, Carlotta Franchi, Luca
Pasina, Alessandro Nobili, Ugo Lucca
P01.108 Association of Clinical
Dementia Rating (CDR) and Episodic
Memory (EM) Measures to Medial
Temporal Atrophy (MTA) Scores among
Different Ethnic Groups Maria Greig,
David Loewenstein, Elizabeth Potter,
Warren Barker, John Schinka, Balaibal
Ashok Raj, Yougui Wu, Daniel Varon,
Ranjan Duara
P01.109 Cognitive Impairment Is a
Major Risk Factor for the Incidence of
Disability in the Oldest-Old Daniel Berlau,
Maria Corrada, Carrie Peltz, Claudia Kawas
P01.110 Clinical Trials of Alzheimer’s
Drugs in Patients with Mild Cognitive
Impairment: Enrichment of True
Alzheimer’s Cases through Disease
Markers Giovanni Frisoni, Marco Lorenzi,
Donata Paternic≥, Cristina Scarpazza,
Elaine Irving, Olivier Blin, Susanne
Ostrowitzki
P01.111 Macro- and Micro-Structural
Brain Imaging Characteristics of Adults
Who Have Maintained Cognitive Function
Very Late in Life Caterina Rosano, Howard
Aizenstein, Alexandra Fiocco, Anne
Newman, Yan Du, Vijay Venkatraman,
Tamara Harris, Jingzhong Ding, Suzanne
Satterfield, Kristine Yaffe
Neuroepidemiology/
Health Services and
Outcomes Research: Stroke
Neuroepidemiology/Health
Services Research
P01.112 JCAHO Primary Stroke
Center Core Measures: Influence of
Concurrent Data Collection Anand
Vaishnav, Nicole Yarber, Megan Mason,
Kara Kennedy, Lisa Bellamy
P01.121 Correlations between
Stroke Severity and Different Types of
Antihyperglycemic Medication M. Ziad
Darkhabani, Bijal Mehta, Tareq Kass-Hout,
Omar Kass-Hout, Maxim Mokin, Vladan
Radovic, Marilou Ching
P01.122 Should Provision of
Angioplasty for Cerebral Vasospasm Be
a Mandatory Component for Hospitals
Treating Patients with Subarachnoid
Hemorrhage? Rakesh Khatri, Nauman
Tariq, Gabriela Vazquez, M. Fareed Suri,
Mustapha Ezzeddine, Adnan Qureshi
Neuroepidemiology/Health
Services and Outcomes
Research
P01.113 Impact of In-Patient Stroke
Rehabilitation Units on Length of Hospital
Stay: A Statewide Study Silvina Tonarelli,
Gabriela Vazquez, Mushtaq Qureshi,
Michael Tibbs, Adnan Qureshi
P01.123 Health-Related Quality of
Life across the Breadth of Neurologic
Diseases Seen in the Ambulatory
Setting Irene Katzan, Kay Bielawski,
Michael Speck, John Urchek, Eric Novak,
Nancy Obuchowski, Charles Bae, Lara Jehi,
Elizabeth Ricksecker, Chris Dopler
P01.114 Distribution of Certified
Stroke Centers in the United States Ken
Uchino, Kazuto Kobayashi
P01.124 Neurohospitalist Experience
in the UK Aisling Fitzpatrick, Peter
McColgan, Mark McCarron
P01.115 Endovascular and
Neurosurgical Treatment of Cerebral
Aneurysms among Octogenarians:
Nationwide Inpatient Sample 2002–
2006 Gustavo Rodriguez, Rakesh Khatri,
Gabriela Vazquez, Nauman Tariq, Yousef
Mohammad, Mustapha Ezzeddine, M.
Fareed Suri, Adnan Qureshi
P01.125 Neurology In-Hospital
Fall Risk Assessment: A Role for the
Physician Andrea Leep Hunderfund,
Cynthia Sweeney, LeAnn Johnson, Jeffrey
Britton
P01.116 Level of Evidence in
Current American Stroke Association
Guidelines Swaroop Pawar, M. Fareed
Suri, Kamakshi Lakshminarayan, Adnan
Qureshi, Mustapha Ezzeddine
P01.117 Endpoint for Clinical Trials
Involving Patients with Intracerebral
Hemorrhage: Modified Rankin Scale as
a Dichotomized or Ordinal Outcome Jill
Novitzke, Yuko Palesch, Renee Martin,
Adnan Qureshi, ATACH Investigators
P01.118 Transcranial Doppler
Ultrasound for Detecting Intracranial
Stenosis in Elderly Population. Results
from the Ultrasound Screening in Adults
for Intracranial Disease (USAID) Study M.
Fareed Suri, Nauman Tariq, Alexandros
Georgiadis, Mushtaq Qureshi, Gabriela
Vazquez, M. Naeem Qureshi, Adnan
Qureshi
P01.119 Anxiety Disorder among
Stroke Caregivers Is Associated with
the Presence of Depressive Symptoms
in Stroke Survivors Francisco Javier
Carod-Artal, Luciane Ferreira Coral, Daniele
Stieven Trizotto, Clarissa Menezes Moreira
P01.120 Subpar Utilization of Dental
Care among Americans with a History of
Stroke Nerses Sanossian, Nicole Gatto,
Bruce Ovbiagele
Poster Session I
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P01.126 Multiple Sclerosis and
Vitamin D Fredric Cantor, Nancy Richert,
Irene Cortese, Joan Ohayon, Fenton
Kaylan, Henry McFarland
P01.127 Survey of Outside
Physician Calls to University-Based
Neurologists Kevin Walker, L. Dewitt,
Jeffrey Wagner, Mark Bromberg, Richard
Nelson, Jennifer Majersik
P01.128 Prevalence of Neurological
Illness and Associated Mortality on
Ugandan Neurology Ward Jason Sico,
Jeffrey Bigelow, Elly Katabira, Ivan Kimuli,
Huned Patwa
P01.129 Routine Collection of Health
Status Measures in the Neurologic
Population— Is It Feasible? Irene Katzan,
Chris Dopler, Kay Bielawski, Michael
Speck, Eric Novak, Cheryl Dunphy, Charles
Bae, Lara Jehi, Nancy Obuchowski, John
Urchek
P01.130 National Institute of
Neurological Disorders and Stroke
(NINDS), National Institutes of Health
(NIH), Common Data Element (CDE)
Project: Developing General and DiseaseSpecific CDEs Stacie Trollinger, Joanne
Odenkirchen, Kristy Miller, Alexandra
Stout, Katherine McDowell, Lisa Hunegs,
Selma Kunitz
P01.131 Long-Term Community
Exposure to Drift Containing
Organophosphate Pesticides (OP)— Are
There Neurobehavioral Effects after
Three Decades? Yoram Finkelstein,
Michael Aschner, Amit Ophir, Elihu Richter
P01.132 Putting AAN-TTA Guidelines
on Botulinum Toxin into Clinical
Practice Patrick Grogan, Maria Alvarez
P01.133 Increased Use of Potentially
Inappropriate Medications in Patients
with Parkinson’s Disease Alexis Elbaz,
Henri Leleu, Jean Houssinot, Jean-Louis
Mazurie, Jean-Luc Dupupet, Marcel
Goldberg, Ellen Imbernon, Christophe
Tzourio
P01.134 Prediction Model
of Parkinson’s Disease Using
Antiparkinsonian Drug Claims Frédéric
Moisan, Jean-Luc Dupupet, Jean-Louis
Mazurie, Jean Houssinot, Marcel
Goldberg, Ellen Imbernon, Christophe
Tzourio, Alexis Elbaz
P01.135 A Pharmacoepidemiological
Evaluation of Cognitive Impairment:
Prescribing Patterns of Dementia
Drugs Raúl Arizaga, Luciano DiCesare,
Ignacio Demey, Galeno Rojas, Valeria
Baccro, Maria Barbieri, Claudia Bavec,
Jorge Campos, Luciano Codevilla, Maria
Fernández, Silvina Frontera, Vicoria
Grisolia, Diego Sarasola
P01.136 Mild Parkinsonian Signs
(MPS) Are Associated with Mild Cognitive
Impairment (MCI) but Not Predictive of
Progression to Alzheimer’s Disease (AD)
in a Door-to-Door Study of an Elderly Arab
Population Simon Israeli-Korn, Magdalena
Massarwa, Edna Schechtman, Amin
Abuful, Rosa Strugatsky, Lindsay Farrer,
Robert Friedland, Rivka Inzelberg
P01.137 Dependence Levels and Risk
of Nursing Home Placement or Death in
Patients with Alzheimer’s Disease Daniel
Murman, Mary Charlton, Robin High, Trent
McLaughlin
P01.138 Increasing Use of Disease
Modifying Drugs for MS in Canada Dalia
Rotstein, Paul O’Connor
P01.139 Tolerability, Satisfaction, and
Discontinuation of Antiepileptic Drugs
from the National Survey of Epilepsy,
Comorbidities and Health Outcomes
(EPIC) George Wan, Michael Reed, Ruth
Ottman
P01.140 Epilepsy and Mortality
in Latin America: A Systematic
Review Alejandro Escalaya, Jorge Burneo
P01.141 Epilepsy Care in Developing
World— Should the Brazilian Surgery
Program Be Replicated to Other
Countries? Francisco Arruda, Paulo
Ragazzo, Sebastião Melo-Souza
Anterior Horn: Epidemiology
P01.142 National ALS Registry:
Lessons from a Pilot Project in the State
of Georgia Sharon Usher, Kevin Ward,
Joanne Wuu, Michael Benatar
P01.143 ALS Clinical Phenotypes: A
Population-Based Study in Italy Adriano
Chio, Andrea Calvo, Letizia Mazzini, Edo
Bottacchi, Cristina Moglia, Michele Balma,
Sara Gallo, Antonio Canosa, Roberto
Mutani, Gabriele Mora
P01.144 Rate of Familial Amyotrophic
Lateral Sclerosis— A Systematic Review
and Meta-Analysis Susan Byrne, Orla
Hardiman
P01.145 Beneficial Vascular
Risk Profile Is Associated with ALS
Susceptibility Leonard van den Berg,
Nadia Sutedja, Marc Huisman, Jan Veldink
P01.146 Platform for Managing
Distributed Biological Samples with Ad
Hoc Searches from Heterogeneous Data
Sources Alexander Sherman, Mathew
Jaffa, Karen Wallace, Marianne Kearney,
Merit Cudkowicz
P01.147 KIFAP3 Has No Effect on
Survival in a Population-Based Cohort of
ALS Patients Andrea Calvo, Shiao-Lin Lai,
Gabriele Mora, Cristina Moglia, Antonio
Canosa, Gabriella Restagno, Jennifer
Schymick, Mark Cookson, Sampath
Arepalli, Andrew Singleton, Brian Traynor,
Adriano Chio
P01.148 Dysregulation of Angiogenin
in Amyotrophic Lateral Sclerosis Russell
McLaughlin, Julie Phukan, Agnieska
Slowik, David Lynch, Will McCormack,
Matthew Greenway, Simon Cronin, Jean
Saunders, Barbara Tomik, Peter Andersen,
Phil Jakeman, Orla Hardiman
P01.149 Epidemiology of Amyotrophic
Lateral Sclerosis (ALS) in the State of
Ceará, Brazil Marcio Erick Vanderlei,
William Alves, Ineusi Araúo, Francisco
Bezerra da Cunha, Maria Bitu Alencar,
Carlos Maurício Castro Costa, Francisco
Gondim
P01.150 Association of Blood Lead
with Risk of Amyotrophic Lateral Sclerosis
(ALS) Fang Fang, Lydia Kwee, Kelli Allen,
Weimin Ye, David Umbach, Mary Watson,
Jean Keller, Eugene Oddone, Dale Sandler,
Silke Schmidt, Freya Kamel
P01.151 Benign Fasciculation
Syndrome: Data from a Neuromuscular
Center Chafic Karam, Weiyi Gao, Daniel
MacGowan, Stephen Scelsa
Movement Disorders:
Parkinson's Disease:
Epidemiology and Quality of Life
P01.152 How Does Direct Care
of the Parkinson’s Disease Patient
Differ between Mid- and Late-Stage
Disease? Teresa Mangin, Karen Lyons,
Julie Carter
P01.153 Prevalence and Clinical
Correlates of Micrographia in Parkinson’s
Disease Aparna Wagle Shukla,
Song Ounprasueth, Vickie Gray, John
Schwankhaus, Walter Steve Metzer
P01.154 Real-Life Driving Outcomes
in Mild-Moderate Parkinson’s
Disease Ergun Uc, Matthew Rizzo,
Elizabeth Dastrup, Dawei Liu, Steven
Anderson, Jeffrey Dawson
P01.155 The Effect of Medicare Part
D on Parkinson’s Disease Patients Marcy
Tarrants, Terrence Shea, Michel Denarie,
Jane Castelli-Haley
P01.156 Is There an Increased Risk of
Hip Fracture in Parkinson Disease (PD)?
Analysis of the Nationwide Inpatient
Sample (NIS) Richard Dubinsky, Rajid
Bhattacharya, Sue Lai, Hilary Dubinsky
P01.157 Relationship of Brain
Organochlorine Levels with Lewy
Pathology: The Honolulu-Asia Aging
Study Web Ross, John Duda, Helen
Petrovitch, Edo Pellizzari, Qimei He, Diane
Miller, James O’Callaghan, Caroline
Tanner, Robert Abbott, Joseph Noorigian,
Lon White
P01.158 Risk Factors for Parkinson
Disease Are Different in Men and
Women: A Recursive Partitioning
Analysis Rodolfo Savica, Brandon
Grossardt, James Bower, J. Ahlskog,
Walter Rocca
P01.159 Predicting Health Status
in Parkinson’s Disease: What Matters
Most? Claire Hinnell, Catherine Hurt,
Michael Samuel, Sabine Landau, Richard
Brown
P01.160 Using Telemedicine to
Increase Access to Specialty Care
for Individuals with Movement
Disorders Lisa Deuel, E. Ray Dorsey,
Benjamin George, Jason Reminick,
Nicholas Scoglio, Anthony Joseph, Kevin
Biglan
P01.161 Effect of Handedness and
Side of Onset on Survival in Parkinson’s
Disease Renato Munhoz, Alberto Espay,
Francesca Morgante, Irene Litvan, Jie-Yuan
Li, Helio Teive, Emily Dunn, Eliza Gallin
P01.162 Incidence and Prevalence of
Parkinson's Disease in Buenos Aires City,
Argentina Diego Bauso, Juan Tartari,
Carla Stefani, Juan Rojas, Giunta Diego,
Edgardo Cristiano
P01.163 Follow-Up of Persons with
Neurologic Diseases (FOUND): Remote
Follow-Up— A Practical Approach To
Maintain Continuous Contact Caroline
Tanner, Cheryl Meng, Ira Shoulson,
Bernard Ravina, Anthony Lang, Roger
Kurlan, Kenneth Marek, David Oakes,
John Seibyl, Emily Flagg, Lisa Gauger,
Christopher Goetz, Karl Kieburtz, Diane
DiEuliis, Stanley Fahn, Robin Elliott
P01.164 High Prevalence of
Hypovitamininosis D Status in Patients
with Early Parkinson’s Disease from
the DATATOP Study Marian Evatt,
Mahlon DeLong, Peggy Auinger, Michael
McDermott, Vin Tangpricha, Parkinson’s
Study Group-PSG DATATOP Investigators
P01.165 Longitudinal Changes in
UPSIT Scores Erika Driver-Dunckley,
Joseph Hentz, Holly Shill, John Caviness,
Marwan Sabbagh, Linda Vedders, Charles
Adler
Multiple Sclerosis and Related
Diseases: Clinical Research/
Epidemiology
P01.166 Real Life Use of Natalizumab:
Results of the Austrian Nationwide
Registry Karl Vass
39
Poster Session I
P01.167 Assessing the Risk of
Malignancy in Patients with Multiple
Sclerosis Receiving Subcutaneous
Interferon beta-1a Magnhild SandbergWollheim, Gabrielle Kornmann,
Margaretha Stam Moraga, Montserrat
Miret, Enrica Alteri
P01.168 The Oregon Multiple
Sclerosis Registry (OMSR)— Preliminary
Results Stanley Cohan, Chiayi Chen,
Ruyun Jin, Tamela Stuchiner, Garry
Grunkemeier
P01.169 Rising Incidence of Multiple
Sclerosis in Females along with
Urbanization Theodora Panou, Dimitra
Kotzamani, Irene Tzanaki, Vasileios
Mastorodemos, Minas Tzagournisakis,
Gregory Chlouverakis, Cleanth Spanaki,
Andreas Plaitakis
P01.170 Acute Leukemia
in Multiple Sclerosis Patients
Treated with Mitoxantrone in the
Postmarketing Setting: The EMD Serono
Experience Ahmad AL-Sabbagh, Daryl
Dawson, Randy Bennett, Fernando
Dangond
P01.171 Cardiovascular Adverse
Events with Mitoxantrone: Results from
the Registry To Evaluate Novantrone
Effects in Worsening Multiple Sclerosis
(RENEW) Study Fernando Dangond, Daryl
Dawson, Jacquie Beagan, Daena Bock,
Peter Chang, Yuhong Yang, Randy Bennett,
Ahmad AL-Sabbagh
P01.172 Increased Risk of Multiple
Sclerosis among Women with Migraine
in the Nurses’ Health Study II Ilya Kister,
Kassandra Munger, Joseph Herbert,
Alberto Ascherio
P01.173 Individual Based Analysis of
Disease Activity in Progressive Multiple
Sclerosis Rotem Orbach, Jim Zhao,
Gilmore O’Neill, Diego Cadavid
P01.174 Sample Size Estimates for
Trials of Neuroprotection in Acute Optic
Neuritis Andrew Henderson, Daniel
Altmann, Anand Trip, Patricio Schlottmann,
David Garway-Heath, Gordon Plant, David
Miller
P01.175 Effects of Oral Fingolimod
(FTY720) on Pulmonary Function Tests
in Patients with Moderate Asthma Alan
Slade, Craig Boulton, Olivier David, Thomas
Dumortier, Robert Schmouder
P01.176 Multiple Sclerosis Is
Increasingly Becoming a Female
Disease George Kraft, Nesanet Mitiku,
Alyssa Bamer, Kara McMullen
P01.177 Diagnostic Accuracy of the
Emergency Department in the Multiple
Sclerosis Population (Data from the
Mount Sinai Resource Utilization in MS
Project [RESUMS]) Megan Alcauskas,
Stephen Krieger, Svenja Oynhausen,
Christine Hannigan, Yadira Bencosme, Fred
Lublin
P01.178 Hospital-Based Prevalence
and Incidence of Multiple Sclerosis
in Chile Violeta Diaz, Juan Antinao,
Raimundo Quezada, Jorge Barahona
40
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P01.179 Prevalence and Incidence of
Multiple Sclerosis in Campobasso (Molise
Region, Southern Italy) Paolo Bellantonio,
Gerardo Iuliano, Francesca Di Biasio,
Stefano Ruggieri
P01.180 Multiple Sclerosis: Clinical
Features and Ethnic Variation in a
Multi-Ethnic Community in Northern
Sudan Tag-Eldin Sokrab, Mohamed Nagib
Idris, Eetidal Ibrahim, Hasab-El Rasoul
Ali, Maha El Zubair, Rasha Osman, Muaz
Abdallatif
P01.181 Late-Onset Multiple
Sclerosis: A Cross-Sectional, PopulationBased Study of 1035 Consecutive
Patients Jette Frederiksen, Erica Høegh
P01.182 Emergency Medical Care of
Multiple Sclerosis Patients (Data from the
Mount Sinai Resource Utilization in MS
Project [RESUMS]) Svenja Oynhausen,
Stephen Krieger, Megan Alcauskas,
Christine Hannigan, Yadira Bencosme,
Marcus Müller, Fred Lublin
P01.183 Early Prediction of Long
-Term Evolution in Multiple Sclerosis:
Application of the Bayesian Risk Estimate
for Multiple Sclerosis (BREMS) Juan
Rojas, Liliana Patrucco, Edgardo Cristiano
P01.184 Impact of Natalizumab on
Economic and Clinical Outcomes in MS
Patients in the Real-World Setting Qian
Cai, Hiangkiat Tan, Sonalee Agarwal,
Siddhesh Kamat
P01.185 Preliminary Evaluation of
Pregnancy Outcomes from the TYSABRI®
(Natalizumab) Pregnancy Exposure
Registry Lynda Cristiano, Carmen Bozic,
Mariska Kooijmans-Coutinho
Multiple Sclerosis and Related
Diseases: Clinical Research
P01.186 Safety and Impact on Disease
Outcomes of Natalizumab in Patients
with Relapsing-Remitting MS in Clinical
Practice Helmut Butzkueven, Ludwig
Kappos, Maria Trojano, Heinz Wiendl,
Fabio Pellegrini, Shibeshih Belachew, Amy
Pace, Daniel Desgrandchamps
P01.187 Prognostic Factors for
Conversion to Clinically Definite Multiple
Sclerosis in an Italian Cohort of Subjects
with Clinically Isolated Syndromes Emilio
Portaccio, Vito Lepore, Bahia Hakiki,
Valentina Zipoli, Razzolini Lorenzo,
Giancarlo Comi, Maria Trojano, Maria Pia
Amato
P01.188 How Benign Is Benign
Multiple Sclerosis? Jorge Correale, Isabel
Peirano
P01.189 Is the Multiple Sclerosis
Severity Score at Initial Presentation to an
MS Comprehensive Care Center a Helpful
Predictor of Long-Term Outcome? Aaron
Miller, Colleen Farrell, Stephen Krieger,
Gary Cutter, Kaitlin Eng, Svetlana Zhovtis,
Michelle Fabian, Amber Salter
P01.190 Sexuality and Intimacy in
MS Patients Cécile Donze, Bruno Lenne,
Samantha Demaille, Patrick Hautecoeur
P01.191 Sub-Clinical Multiple
Sclerosis: Clinical, Neuropsychological,
and MRI Follow-Up Bahia Hakiki,
Benedetta Goretti, Emilio Portaccio,
Valentina Zipoli, Lorenzo Razzolini, Marco
Roscio, Maria Laura Stromillo, Francesca
Rossi, Maria Bartolozzi, Elisa Giunti,
Leonello Guidi, Nicola De Stefano, Angelo
Ghezzi, Maria Pia Amato
P01.192 Gender Differences in Sexual
Dysfunction of a MS Population Shalom
Haggiag, Guido Ricci, Giovanni Bolla,
Esmeralda Quartuccio, Orietta Picconi,
Maria Rosaria Fele, Claudio Gasperini,
Simonetta Galgani
P01.193 Should Primary Multiple
Sclerosis Treatment Regimen Be Changed
after a Relapse? Brian Healy, Bonnie
Glanz, James Stankiewicz, Guy Buckle,
Howard Weiner, Tanuja Chitnis
P01.194 Motor Disability in
Progressive Multiple Sclerosis Is
Independently Worsened by Relapses
before and after Progression Junger
Tang, Nuhad Abou Zeid, Nilufer Kale,
Elizabeth Atkinson, Daniel Crusan, Orhun
Kantarci
P01.195 One-Year Prospective Study
on Headache Occurrence in Multiple
Sclerosis (MS) Patients Treated with
Natalizumab Dacia Dalla Libera, Bruno
Colombo, Bucello Sebastiano, Pietro
Annovazzi, De Feo Donatella, Martinelli
Vittorio, Giancarlo Comi
P01.196 Vitamin D Insufficiency
in Patients with MS in Southeastern
Michigan and Its Relation with Age and
Race Asfa Shad, Vladimir Shvarts, Lonni
Schultz, Mirela Cerghet
P01.197 Utilization of Diagnostic
Tests and Procedures for Treated and
Untreated Patients with Multiple
Sclerosis (MS) Kavita Nair, John Corboy,
Nikita Patel, Kristijan Kahler, Richard Allen,
Robert McQueen, Vahram Ghushchyan,
Jacci Bainbridge
P01.198 Prediction of Disease
Progression in Primary Progressive
Multiple Sclerosis Liliana Patrucco, Juan
Rojas, Edgardo Cristiano
P01.199 Sudden Onset Sensorineural
Hearing Loss in Multiple Sclerosis:
Diagnosis and Prognosis Mark Hellmann,
Ronit Mosberg-Galili, Israel Steiner
P01.200 Validation of an Instrumented
Gait Measure, the iTUG, in Multiple
Sclerosis Rebecca Spain, Fay Horak,
Dennis Bourdette
P01.201 Relating Structural Brain
Damage and Functional Cortical
Reorganization in Patients with Benign
MS Antonio Giorgio, Emilio Portaccio,
Maria Laura Stromillo, Silvia Marino,
Valentina Zipoli, Gianfranco Siracusa,
Marco Battaglini, Maria Letizia Bartolozzi,
Anita Blandino, Leonello Guidi, Sandro
Sorbi, Antonio Federico, Maria Pia Amato,
Nicola De Stefano
P01.202 Assessing Baseline Health
and Functional Status of Patients with
Multiple Sclerosis: A Pilot Study Using
Novel Information Technology Deborah
Miller, Elizabeth Ricksecker, Eric Novak,
Jeffrey Cohen, Robert Fox, Jennifer
Hartman, Kathleen Schwetz, Richard
Rudick
P01.203 Vibration Sensation
Thresholds Are Associated with the
Sensory Functional System Score of
the EDSS in Multiple Sclerosis Scott
Newsome, Joseph Wang, Peter Calabresi,
Kathy Zackowski
P01.204 Impact of Medication
Adherence to Disease-Modifying Drugs
on Severe Relapse, and Direct and Indirect
Costs among Employees with Multiple
Sclerosis Amy Phillips, Jasmina Ivanova,
Rachel Bergman, Howard Birnbaum,
Michelle Stewart, Dennis Meletiche
P01.205 Health Resource Utilization
in the CLARITY Study Shehzad Ali, Stuart
Cook, Gavin Giovannoni, Giancarlo Comi,
Steven Greenberg, Alexandre Joyeux,
Kottil Rammohan, Noman Paracha, Peter
Rieckmann, Per Soelberg Sørensen, Patrick
Vermersch, Bruno Musch
Movement Disorders in Clinical
Practice
P01.206 Clinical Description of
Patients Diagnosed with Clinically
Probable Psychogenic Movement
Disorders in a Movement Disorders
Clinic Laura Jawidzik, Sue Leurgans,
Bichun Ouyang, Aikaterini Kompoliti
P01.212 Neuropsychological
Differences Between Parkinson’s
Disease Patients with Very Mild and Mild
Dementia Mariya Petrova, Margarita
Raycheva, Latchezar Traykov
P01.213 The Pupil as a Measure
of Emotion-Modulated Arousal in
Parkinson’s Disease Jenna Dietz,
Margaret Bradley, Lizabeth Jordan, Tara
Braun, Michael Okun, Dawn Bowers
P01.214 Is There the Delayed Gastric
Emptying of Untreated Patients with
Early-Stage Parkinson’s Disease? An
Analysis Using the 13C-Acetate Breath
Test Yuji Tanaka, Hiroshi Nishida, Megumi
Yamada, Akihiro Kohmura, Takeo Sakurai,
Yuichi Hayashi, Akio Kimura, Isao Hozumi,
Masahito Nagaki, Tomohiro Kato, Hisataka
Moriwaki, Takashi Inuzuka
P01.215 Toys and Gadgets:
Construct Validity of Apathy in Parkinson
Disease Beata Ferencz, Lindsey Kirsch
Darrow, Milana Bogorodskaya, Michael
Okun, Dawn Bowers
P01.216 Hallucinations in PD:
Ten-Year Prospective Longitudinal
Assessment Christopher Goetz, Bichun
Ouyang, Alice Negron, Glenn Stebbins
P01.217 Autonomic Insufficiency in
Pupillary and Cardiovascular Systems
in Parkinson Disease Samay Jain, Greg
Siegle, Stuart Steinhauer, J. Jennings,
Stephanie Studenski, J. Greenamyre
P01.207 A Brief Structured
Questionnaire To Discriminate Between
Psychogenic and Neurogenic Movement
Disorders David Glosser, Krystle Karoscik,
Tsao-Wei Liang, Daniel Kremens
P01.218 Parkinson’s Disease (PD)
Increases Risk for Mild Cognitive
Impairment (MCI) Charles Adler, Joseph
Hentz, Holly Shill, Marwan Sabbagh,
Donald Connor, Virgilio Gerald Evidente,
Erika Driver-Dunckley, Caroline Tanner,
Walter Kukull, Linda Vedders, Sandra
Jacobson, John Caviness, Thomas Beach
P01.208 Psychogenic Non-Epileptic
Spells and Movement Disorders in
Men Greg Thaera, Katherine Noe, Cynthia
Stonnington, Dona Locke, Erika DriverDunckley
P01.219 Nonmotor Symptoms
in Parkinson’s Disease with
Special Reference to Anxiety and
Depression Manmohan Mehndiratta,
Rohit Garg, Sanjay Pandey
P01.209 Are Disparities in
Parkinsonism Diagnoses Due to
Underreporting of Symptoms? Nabila
Dahodwala, Andrew Siderowf, Jason
Karlawish, John Duda, David Mandell
P01.220 Symptoms of Depression
More Than Apathy Exhibit Better Neural
Reflections of Conflict Processing in
Parkinson’s Disease (PD) Christopher
Sozda, Laura Zahodne, Dawn Bowers,
William Perlstein, Hubert Fernandez
P01.210 Quantitative Gait Changes
in Probable-RBD Patients in the Mayo
Clinic Study of Aging Eric McDade,
Bradley Boeve, Teresa Christianson, David
Knopman, Rosebud Roberts, Tanis Ferman,
Ronald Petersen
Movement Disorders:
Parkinson's Disease: Non-Motor
Symptoms
P01.211 Muted Emotional
Enhancement of Memory in Parkinson’s
Disease Lizabeth Jordan, Jenna Dietz,
Alexandra Clark, Heather McKently,
Michael Okun, Hubert Fernandez, Dawn
Bowers
Poster Session I
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P01.221 Gray Matter Changes
Associated with Early Hallucinations
in Parkinson’s Disease Javier
Pagonabarraga, Gisela Llebaria, Carles
Soriano-Mas, Berta Pascual-Sedano,
Marina López-Solà, Alexandre Gironell,
Jesús Pujol, Jaime Kulisevsky
P01.222 Predictors of Impulse
Control Disorders in MMPI-2 in Patients
Suffering from Parkinson’s Disease: A
Pilot Study Katerina Farnikova, Radko
Obereigneru, Petr Kanovsky
P01.223 Depression and Autonomic
Nerve Dysfunction in Early Parkinson’s
Disease and Essential Tremor Cheng-jie
Mao, Ju-ping Chen, Wei-dong Hu, Dongqin Chen, Chun-feng Liu
P01.224 The Addenbrooke’s Cognitive
Examination (ACE) Detects Cognitive
Impairment in Advanced Parkinson
Disease (PD) but Not in Early Parkinson
Disease Anabel Chade, María Roca,
Teresa Torralva, Ezequiel Gleichgerrcht,
Nicolás Fabbro, Gonzalo Gómez Arévalo,
Oscar Gershanik, Facundo Manes
P01.225 The Iowa Gambling Task and
Wisconsin Card Sorting Test Performance
Was Modulated by the Presence/Absence
of Apathy in Non-Depressed Parkinson’s
Disease Patients Saül Martínez-Horta,
Merce Martinez-Corral, Gisela Llebaria,
Javier Pagonabarraga, Carmen GarciaSanchez, Alexandre Gironell, Ramon
Fernandez-Bobadilla, Jaime Kulisevsky
P01.226 Depressive Symptoms
in Parkinson’s Disease May Not
Uniformly Respond to Pharmacologic
Treatment Logan Schneider, Laura
Zahodne, LaTasha Moore, Charles
Jacobson, Hubert Fernandez, Michael
Okun, Ramon Rodriguez, Irene Malaty
P01.227 Rhinorrhea: A Common
Non-Dopaminergic Feature of Parkinson
Disease Kelvin Chou, Robert Koeppe,
Nicolaas Bohnen
P01.228 The PARS Study: Evaluating
PreClinical Parkinsonian Features in
a Healthy Hyposmic Cohort Danna
Jennings, Matt Stern, Andrew Siderowf,
Ken Marek
P01.229 Dimensions of Apathy
in Parkinson Disease: Apathy Scale
Revisited Daniel Kay, Lindsey KirschDarrow, Laura Zahodne, Michael Okun,
Hubert Fernandez, Dawn Bowers
P01.230 Divergent Trajectories
of Apathy and Depression Over Two
Years in Medically-Managed, Idiopathic
Parkinson’s Disease Laura Zahodne,
Lindsey Kirsch Darrow, Hubert Fernandez,
Michael Okun, Dawn Bowers
P01.231 Ropinirole Prolonged
Release Improves Mood in Patients
with Advanced Parkinson’s Disease Not
Optimally Controlled with L-Dopa Alan
Lipschitz, Carol Rockett, Katie Rolfe
P01.232 Assessment of Sleep
Duration and Nocturnal Awakenings
in Patients with Advanced Parkinson’s
Disease Treated with Adjunctive
Ropinirole Prolonged Release Pablo
Martinez-Martin, Katie Rolfe, Alan
Lipschitz, K. Ray Chaudhuri
P01.233 Prevalence of DopamineRelated Behaviour Disorders in
Parkinsonian Patients Treated with
Continuous Subcutaneous Infusion
of Apomorphine Alexandre Eusebio,
Christine Brefel-Courbon, Caroline Moreau,
Christine Tranchant, David Devos, François
Viallet, Tatiana Witjas, Luc Defebvre, JeanPhilippe Azulay, ADDAPO Study Group
P01.234 Mood and Autonomic
Symptom Clusters in Parkinson’s
Disease Jennifer Goetz, Dawn Bowers,
Laura Zahodne, Ramon Rodriguez, Irene
Malaty, Michael Okun, Hubert Fernandez
P01.235 The Quantitative Pull Test:
A Method To Measure Parkinsonian
Postural Instability Robert McGovern,
Anne Wilson, Ashwini Rao, Paul Greene,
Guy McKhann, Pietro Mazzoni
Movement Disorders:
Parkinson's Disease:
Pathophysiology
P01.236 A Comparison of Prevalence
of Non-Motor Symptoms in Movement
Disorders Shoaib Malik, Mustafa
Siddiqui, Michael Cartwright, Ihtsham Haq
P01.246 Amiloride Accelerates
MPTP-Induced Cell Death in the
Human Dopaminergic SHSY-5Y Cells
Overexpressed with Acid-Sensitive Ion
Channel (ASIC)1a Kwok-Keung Tai, Daniel
Truong
P01.237 Parkinson Movement Tests
Performance: Feasibility and Reliability of
Video Feature Extraction for Quantization
of Standard Test Movements Xiao-ke
Gao, Kenneth Bonnet
P01.247 Role of Dynein Dysfunction in
Autophagic Stress and Neurodeneration
In Vivo and Vitro Involved in Parkinson’s
Disease Ji-jun Shi, Zeng-lin Cai, Ya-ping
Yang, Chun-feng Liu
P01.238 Neurophysiological
Correlates of Over-Inhibition in Apathetic
Parkinson’s Disease Patients Saül
Martínez-Horta, Merce Martinez-Corral,
Javier Pagonabarraga, Gisela Llebaria,
Carmen Garcia-Sanchez, Alexandre
Gironell, Jaime Kulisevsky
P01.248 Interaction of Parkinson’s
Disease and Age in PreSupplementary
Motor Area Cortical Thickness Thomas
Jubault, Jean-Francois Gagnon, Alain Ptito,
Anne Lafontaine, Sylvain Chouinard, Alan
Evans, Oury Monchi
P01.239 Who Responds Best to
Pharmacologic Treatment of Depressive
Symptoms in Parkinson’s Disease? Logan
Schneider, Laura Zahodne, Akash Patel,
Charles Jacobson, Michael Okun, Ramon
Rodriguez, Irene Malaty, Hubert Fernandez
P01.240 Effect of Rotigotine on Sleep
Quality and Control of Early Morning
Motor Function in Subjects with Idiopathic
Parkinson’s Disease Bryan Kies, K. Ray
Chaudhuri, Tim Anderson, Jennifer Fine,
Dennis Hill, Monika Rudzinska, Erwin
Surmann, John Whitesides, Babak
Boroojerdi, Claudia Trenkwalder, on Behalf
of the RECOVER Study Group
P01.241 Tracking Cognitive Change
on the MMSE and MoCA in Parkinson’s
Disease Stephanie Lessig, Steve Edland,
Jody Goldstein, Jody Corey-Bloom
P01.242 Digital Voice Analysis
in Patients with Parkinson’s Disease
(PD) Eduard Linetsky, Alex Lossos
P01.243 Binge Eating in Parkinson
Disease: Prevalence, Correlates
and the Contribution of Deep Brain
Stimulation Laura Zahodne, Frandy
Susatia, Dawn Bowers, Tiara Ong, Charles
Jacobson IV, Michael Okun, Ramon
Rodriguez, Irene Malaty, Kelly Foote,
Hubert Fernandez
P01.244 Which Nonmotor Signs
Can Best Discriminate Early Parkinson’s
Disease? A Case-Control Study Nico
Diederich, Géraldine Hipp, Vannina Pieri,
Michel Vaillant
P01.245 Mood and Neurocognitive
Contributions to a Dementia Screening
Scale in Patients with Parkinson’s
Disease Michelle Prosje, Jenna Dietz,
Barry Skoblar, Catherine Price, Russell
Bauer, Michael Okun, Hubert Fernandez,
Dawn Bowers
P01.249 Brainstem Myoinositol as a
Biomarker of Disease Severity in MSA-C:
A 3 T 1H-MRS Study Yuhei Takado,
Hironaka Igarashi, Kenshi Terajima,
Takayoshi Shimohata, Tetsutaro Ozawa,
Kouichirou Okamoto, Masatoyo Nishizawa,
Tsutomu Nakada
P01.250 The Hematopoietic Growth
Factor G-CSF Enhances Recovery in the
MPTP Mouse Model of PD Juan SanchezRamos, Vasyl Sava, Amanda Rowe, Kunyu
Li, Theresa Zesiewicz, Takashi Mori, Shijie
Song
P01.251 Ubiquitin Proteasome System
Impairment Mouse Model of Parkinson’s
Disease Xuping Li, Chao Li, Wenjie Xie,
Joseph Jankovic, Weidong Le
P01.252 Development and Evaluation
of Allosteric Modulators of Dopamine
D2 Receptors in PreClinical Rat Models:
Implications for the Treatment of
Parkinson’s Disease and Drug-Induced
Dyskinesia Dipannita Basu, Niran
Argintaru, Ritesh Daya, Spencer Heffernen,
Bailee Dyck, Ram Mishra, Rodney Johnson
P01.253 Next-Generation Sequencing
Allows for Comprehensive Detection
of Mitochondrial Variation in Brain
Tissue Stephan Zuchner, Sion Williams,
Jia Huang, Alicia Pickrell, Lloye Dillon,
Carlos Moraes, Jeffery Vance
P01.254 Detection of Polyglutamine
Protein Oligomers in Living Cells Using
Protein-Fragment Complementation
Assays Masayoshi Tada, Tom Kerppola,
Stuart Decker, Sokol Todi, Matthew
Scaglione, Maria do Carmo Costa, Henry
Paulson
P01.255 Reduced Dopamine
Transporter Density in the Ventral
Striatum of Patients with Parkinson’s
Disease and Impulse Control Disorders:
A Voxel-Wise Analysis Roberto Cilia, Ji
Hyun Ko, Sang Soo Cho, Thilo van Eimeren,
Giorgio Marotta, Giovanna Pellecchia,
Gianni Pezzoli, Angelo Antonini, Antonio
Strafella
41
Poster Session I
P01.256 Selective Metabotropic
Glutamate Receptor 5 (mGlu5) Antagonism
Reduces L-DOPA-Induced Dyskinesia in
MPTP-Lesioned Primates at the Expense
of Anti-Parkinsonian Benefit Tom
Johnston, Susan Fox, Matthew Piggott,
Jonathan Brotchie
P01.265 An Open-Label, Safety and
Immunogenicity Study of Myobloc®
(RimabotulinumtoxinB; BoNT-B) in
Patients with Cervical Dystonia—
(351) Mark Lew, Robert Chinnapongse,
Fernando Pagan, Sharon Reinhard, William
Birmingham
P01.257 Ratings of “Mental
Rigidity” Reflect Cholinergic Rather Than
Dopaminergic Denervation in Parkinson
Disease Kelvin Chou, Martijn Muller,
Robert Koeppe, Michael Kilbourn, Kirk Frey,
Roger Albin, Nicolaas Bohnen
P01.266 A Seven-Year Open-Label
Safety and Immunogenicity Study of
Myobloc® (RimabotulinumtoxinB; BoNT-B)
in Patients with Cervical Dystonia—
(401CD-NA) Robert Chinnapongse, Mark
Lew, Fernando Pagan, Sharon Reinhard,
William Birmingham
P01.258 Critical Alterations in
the Basal Ganglia Pathophysiology in
Parkinson’s Disease. A Computational
Model Approach Georgios Tsirogiannis,
Georgios Tagaris, Clementine
Karageorgiou, Konstantina Nikita
P01.259 Glycine Receptor Antibodies
in Immune-Mediated Movement
Disorders: Progressive Encephalomyelitis
with Rigidity and Myoclonus, OpsoclonusMyoclonus Syndrome, and Ocular Flutter
Syndrome Takahiro Iizuka, Yoshiaki Urano,
Saori Miyakawa, Junichi Hamada, Maria
Leite, Angela Vincent, Fumihiko Sakai,
Hideki Mochizuki
P01.260 Two Parkinson’s Disease
Patients with α-Synuclein Gene
Duplication and Rapid Cognitive
Decline Chae Won Shin, Sung Sup Park,
Beom Seok Jeon
P01.261 Evaluation of SNCA CpG
Island Methylation Level in Post-Mortem
Brain of Parkinson’s Disease and
Dementia with Lewy Bodies Lumine
Matsumoto, Atsushi Iwata, Hisatomo
Kowa, Yu Nagashima, Hiroshi Takuma,
Akira Tamaoka, Hiroshi Kurisaki, Shoji Tsuji
Movement Disorders: Dystonia I
P01.262 CD-PROBE (Cervical
Dystonia Patient Registry for Observation
of BOTOX® Efficacy) - A Multicenter,
Observational Study of Repeated
OnabotulinumtoxinA Injections in Cervical
Dystonia (CD) Patients— Preliminary
Baseline Data Joseph Jankovic, Charles
Adler, David Charles, Cynthia Comella,
Mark Stacy, Matthias Kurth, Mitchell Brin,
Lisa Misell, Lee Boo
P01.263 Why Do Cervical Dystonia
Patients Leave Academic Movement
Disorders Clinics? Chandler Gill, Neil
Manus, Michael Pelster, Jason Cook,
Wallace Title, P. Charles
P01.264 An Open-Label Safety and
Immunogenicity Study of NeuroBloc®
(MYOBLOC®; RimabotulinumtoxinB;
BoNT-B) in Patients with Cervical
Dystonia (CD) (401CD-EU) Sharon
Reinhard, Fernando Pagan, William
Birmingham, Mark Lew, Robert
Chinnapongse, Joaquim Ferreira
Integrated Neuroscience Session: Proteins, Genes,
Neurodegeneration, and the Clinical Presentations
Tuesday, April 13 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P01.267 Quantification of Cervical
Dystonia and Response to Botulinum
Toxin Using Electrical Impedance
Myography Codrin Lungu, Andrew Tarulli,
Daniel Tarsy, Phillip Mongiovi, Veronica
VanderHorst, Seward Rutkove
P01.268 Efficacy of NT 201 (Botulinum
Neurotoxin Type A Free from Complexing
Proteins) in the Treatment of Patients with
Focal Dystonia Susanne Grafe, Angelika
Hanschmann
Movement Disorders: Dystonia II
and Tardive Dyskinesia
P01.269 Immunogenicity Analysis
from a Randomized, Double-Blind
Study To Compare the Efficacy and
Safety of NeuroBloc® (Myobloc/
RimabotulinumtoxinB;BoNT-B) with
OnabotulinumtoxinA (Botox®; BoNT-A)
in Patients with Cervical Dystonia (CD)
Who Have Never Previously Received
a Botulinum Toxin Product (402CDEU) William Birmingham, Robert
Chinnapongse, Mark Lew, Fernando Pagan,
Sharon Reinhard, Joaquim Ferreira
P01.270 Safety and Efficacy of
Repeated NT 201 (Botulinum Neurotoxin
Type A Free from Complexing Proteins)
Injections of Patients with Cervical
Dystonia: A First Long-Term Safety
Analysis Susanne Grafe, Angelika
Hanschmann
P01.271 Presence of Neutralizing
Antibodies in a Patient Population with
Cervical Dystonia Prior to Clinical Study
Entry Petra Minnasch
P01.272 The Utility of Visual, Tactile,
and Mixed Tasks in the Determination
of Temporal Discrimination Thresholds
in Adult-Onset Primary Torsion
Dystonia David Bradley, Robert Whelan,
Nicola Mulrooney, Richard Walsh, Richard
Reilly, Siobhan Hutchinson, Fiona Molloy,
Michael Hutchinson
P01.273 Clinical Subtypes of
Disproportionate Anterocollis in
Parkinsonian Syndromes Gonzalo
Revuelta, Stewart Factor
P01.274 Seroconversion in Cervical
Dystonia Patients After Treatment with
Abobotulinumtoxin A Chandra Coleman,
Jean Hubble, Joseph Schwab, Jean-Luc
Beffy, Philippe Picaut, Carles Morte
P01.275 Efficacy of
AbobotulinumtoxinA for the Treatment
of Cervical Dystonia: Analysis by Patient
Subpopulation Jean Hubble, Chandra
Coleman, Joseph Schwab, Jean-Luc Beffy,
Philippe Picaut
P01.276 CD-PROBE (Cervical
Dystonia Patient Registry for
Observation of BOTOX® Efficacy) - A
Multicenter, Observational Study of
OnabotulinumtoxinA Injections in
Cervical Dystonia (CD) Patients–Interim
Patient Reported Outcome Data Joseph
Jankovic, Charles Adler, David Charles,
Cynthia Comella, Mark Stacy, Matthias
Kurth, Mitchell Brin, Lisa Misell, Lee Boo
P01.277 The Blink Reflex Recovery
Cycle Differs Between Patients with
Benign Essential Blepharospasm and
Patients with Atypical (Presumed
Psychogenic) Blepharospasm Mark
Edwards, Petra Schwingenschuh, Petra
Katschnig, James Teo, Laxmi Korlipara,
John Rothwell, Kailash Bhatia
P01.278 Asian Over Representation
Among Patients with Hemifacial Spasm
Compared to Cranial Dystonia Yuncheng
Wu, Anthony Davidson, Maosheng Huang,
Tianhong Pan, Joseph Jankovic
P01.279 Swallowing Induced
Laryngo-Pharyngeal Movement— A New
Variant of Focal PKD? Hrishikesh Kumar,
Stephanie Somers, Mandar Jog
P01.280 Curcumin Prevents the
Development of Vacuous Chewing
Movements in a Preclinical Animal
Model of Human Tardive Dyskinesia and
Proteomic Array Reveals a Possible Role
of Target Proteins in the Mechanism of
Action Christal Sookram, Mattea Tan,
Ritesh Daya, Spencer Heffernan, Bailee
Dyck, Ram Mishra
Muscle Disease/Neuromuscular
Junction: Neuromuscular
Junction Disorders
P01.281 Increasing Incidence of
Seropositive Myasthenia Gravis in British
Columbia, Canada: A 25- Year, Population
-Based Study Zahra Pakzad, Tariq Aziz,
Joel Oger
P01.282 Cardiomyopathy in
Myasthenia Gravis: The Frequency and
Characteristics Jun Tsugawa, Yoshio
Tsuboi, Hirosato Inoue, Shigeaki Suzuki,
Tatsuo Yamada
P01.283 Clinical Course of Patients
with Myasthenia Gravis in a Regional
Hospital in Hong Kong: A Retrospective
Review Sze Wai Yeung, Chi Nam Lee,
Richard Li, Sonny F. K. Hon, Man Auyeung,
Chun Ming Cheung, Tak Hong Tsoi
P01.285 Striated Muscle Antibodies:
Clinical Features and Utility in Myasthenia
Gravis Hugh McMillan, Jayashri
Srinivasan, Gyorgy Abel, Royden Jones
P01.286 MuSK-Antibody Positive
Myasthenia Gravis and Their Clinical
Features in North India Hamid Suhail,
Vivekanandhan Subbiah, Sumit Singh,
Madhuri Behari
P01.287 Muscle Specific Tyrosine
Kinase Antibody Positivity: Prevalence
and Clinical Characteristics in Western
Canada Jennifer Brealy, Tariq Aziz, Sara
Zangeneh, Joel Oger
P01.288 Novel Acetylcholinesterase
Inhibitors in Myasthenia Patients: FourYear Follow-Up Carlos Navarrete, Vera
Bril, Mireya Balart
P01.289 Benefits from SustainedRelease Pyridostigmine Bromide
in Myasthenia Gravis. Results of a
Prospective Multicenter Open-Label
Trial Jorn Sieb, Wolfgang Köhler
P01.290 Rituximab in Generalized
Myasthenia Gravis Samiullah Kundi,
Mazen Dimachkie, Mamatha Pasnoor, April
McVey, Laura Herbelin, Richard Barohn
P01.291 Response of Patients with
Refractory Myasthenia Gravis Treated
with Ritxuimab Richard Nowak, Nazlee
Zebardast, Jonathan Goldstein
P01.292 Multi-Target Treatment for
Refractory Myasthenia Gravis Claudio
Mazia, Valeria Salutto
P01.293 Trends in Outcomes and
Hospitalization Cost of Adult Patients
with Botulism in the United States Bilal
Saulat, Lubna Mehyar, Hafiz Khan, Rania
Abou Elenein, Nizar Souayah
Tuesday, April 13 | 1:00 p.m.–5:00 p.m.
Coordinators: Bradley Boeve, MD and Neill Graff-Radford, MD, FAAN
Invited Speaker Session* / 1:00 p.m.–3:00 p.m. / Reception Hall 104A–D
1:00 p.m.–1:30 p.m.
Theme 1: Frontotemporal Dementia and Parkinson’s Disease; Corticobasal Syndrome and Progressive Supranuclear Palsy and Primary Progressive
Aphasia Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD
1:30 p.m.–2:00 p.m.
Theme 2: ALS Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD
2:00 p.m.–2:30 p.m.
Theme 3: Alzheimer’s Disease Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD
2:30 pm.–3:00 p.m.
Theme 4: Lewy Body Disease, Parkinson’s Disease, and Multiple System Atrophy Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD,
FRCP, and Rosa Rademakers, PhD
Poster Session / 3:00 p.m.–3:30 p.m. / Reception Hall 104A–D
IN5-1.001 Gerstmann-SträusslerScheinker Disease Due to a Novel
Structural Mutation in the Prion Protein
Gene Claire Hinnell, Michael Coulthart,
Gerard Jansen, Neil Cashman, Julie
Lauzon, Arthur Clark, Fiona Costello,
Christopher White, Rajiv Midha, Samuel
Wiebe, Sarah Furtado
IN5-1.002 Basophilic Inclusion Body
Disease (BIBD) Is a FUSopathy David
Munoz, Manuela Neumann, Hirofumi
Kusaka, Osamu Yokota, Kenji Ishihara,
Seishi Terada, Shigetoshi Kuroda, Ian
Mackenzie
IN5-1.003 Clinical Features in
Corticobasal Syndrome Predictive
of Underlying Alpha-Synuclein
Pathology Rachel Gross, Sarah Kranick,
John Duda, John Trojanowski, Murray
Grossman
IN5-1.004 Proteomic Analysis of
Cerebrospinal Fluid in Presymptomatic
and Affected Persons Carrying Familial
Alzheimer’s Disease Mutations John
Ringman, Howard Schulman,
Christopher Becker, Ted Jones, Yuchen
Bai, Fred Immermann, Gregory Cole,
Karen Gylys, Daniel Geschwind, Jeffrey
Cummings, Hong Wan
IN5-1.005 Clinically Useful Plasma
Biomarkers in ALS Stacey Clardy, Ryan
Mitchell, Helen Stephens, Zachary
Simmons, James Connor
IN5-1.006 Different Roles of the
Proteasome and Autophagy Pathways
in the Degradation of α-Synuclein Yaping Yang, Fang Yang, Cheng-jie Mao,
Zeng-lin Cai, Jin-zhong Huang, Chunfeng Liu
IN5-1.007 Uncommon Clinical
Phenotype in Italian Patients with
FUS/TLS Mutations Nicola Ticozzi,
Cinzia Gellera, Stefano Messina, Luca
Maderna, Claudia Morelli, Barbara
Poletti, Antonia Ratti, Franco Taroni,
Robert Brown, John Landers, Vincenzo
Silani
IN5-1.008 The Plasma Communicome
in Persons at Various Levels of Genetic
Risk for Alzheimer’s Disease John
Ringman, Daniel Geschwind, Karen
Gylys, Cathy Lee, David Elashoff, Jeffrey
Cummings, Greg Cole
IN5-1.009 Common Genetic Variants
at 7p21 Show Strong Association with
Frontotemporal Lobar Degeneration
with TDP-43 Inclusions Alice ChenPlotkin, Vivianna Van Deerlin, Patrick
Sleiman, Maria Martinez-Lage, Li-San
Wang, Gerard Schellenberg, Hakon
Hakonarson, John Trojanowski, Virginia
Lee, International FTLD Collaboration
IN5-1.010 TAR DNA-Binding
Protein-43 (TDP-43) Aggregation
in Von Economo Neurons in Early
Behavioral Variant Frontotemporal
Dementia Stephanie Gaus, Druthi
Ghanta, Manu Sidhu, Bruce Miller,
Stephen DeArmond, William Seeley
Platform Session / 3:30 p.m.–5:00 p.m. / Reception Hall 104A–D
3:30 p.m.
IN5-2.001
Relation of the Alzheimer’s Disesase
Susceptibility Allele at the CR1 Locus
to Cognitive Decline and Alzheimer’s
Disease Neuropathology in Older
Persons Philip De Jager, Lori Chibnik,
Neelum Aggarwal, Joshua Shulman,
Julie Schneider, Denis Evans, David
Bennett
3:45 p.m.
IN5-2.002
A Non-Coding Penta-Nucleotide
Repeat Insertion Containing (TGGAA)
n Is Associated with Spinocerebellar
Ataxia Type 31 (SCA31) Nozomu
Sato, Takeshi Amino, Kinya Ishikawa,
Shuichi Asakawa, Taro Ishiguro, Makoto
Takahashi, Nobuyoshi Shimizu, Shoji
Tsuji, Hidehiro Mizusawa
4:00 p.m.
IN5-2.003
Proteomic Biomarker Pattern Analysis
in Cerebrospinal Fluid (CSF) from
Patients with Amyotrophic Lateral
Sclerosis (ALS) Nils von Neuhoff,
Thomas Wolf, Katja Kollewe, Peter
Bewerunge, Tonio Oumeraci, Boris
Neumann, Benedict Brors, Marc
Zapatka, Ulrich Wurster, Brigitte
Schlegelberger, Reinhard Dengler,
Susanne Petri
4:15 p.m.
IN5-2.004
CSF Biomarkers for Alzheimer’s
Disease and Frontotemporal Lobar
Degeneration William Hu, Alice
Chen-Plotkin, Steven Arnold, Murray
Grossman, Christopher Clark, Les Shaw,
Leo McCluskey, Lauren Elman, Jason
Karlawish, Howard Hurtig, Andrew
Siderowf, Holly Soares, Virginia Lee,
John Trojanowski
4:30 p.m.
IN5-2.005
Genetic and Clinical Features of
Progranulin-Associated Frontotemporal
Lobar Degeneration Alice ChenPlotkin, Patrick Sleiman, William Hu,
Maria Martinez-Lage, Robert Greene,
Shaoxu Bing, Murray Grossman, John
Trojanowski, Virginia Lee, Vivianna Van
Deerlin, International FTLD Collaboration
4:45 p.m.
IN5-2.006
TDP-43 Mutant Transgenic
Mice Develop Features of ALS
and Frontotemporal Lobar
Degeneration Iga Wegorzewska,
Shaughn Bell, Nigel Cairns, Timothy
Miller, Robert Baloh
P01.284 Differences in Clinical and
Immunological Profiles Between Early
and Late-Onset Myasthenia Gravis
in Japan Shigeaki Suzuki, Kimiaki
Utsugisawa, Yuriko Nagane, Takashi
Satoh, Masataka Kuwana, Norihiro Suzuki
*Current as of February 1, 2010
42
43
Scientific Sessions
S01 Multiple Sclerosis:
Clinical Research I
Theatre 102
Constitution Hall 106
1:45 p.m.
S01.001
Polysomnographic Investigation
of Frequency of Sleep Disorders in
Consecutive Unselected Fatigued
and Non-Fatigued Multiple Sclerosis
Patients Christian Veauthier, Helena
Radbruch, Gunnar Gäde, Carsten Pfüller,
Jan Dörr, Judith Bellmann-Strobel, Jörn
Sieb, Frauke Zipp, Paul Friedemann
1:45 p.m.
S02.001
Physical Activity and Risk of Stroke.
The Framingham Study Aleksandra
Pikula, Philip Wolf, Alexa Beiser,
Jayandra Himali, Margaret KellyHayes, Carlos Kase, Ramachandran
Vasan, Sudha Seshadri
2:00 p.m.
S01.002
Color Vision and High-Resolution OCT
Are Highly Sensitive for Detecting
Anterior Visual Pathway Abnormalities
in Multiple Sclerosis Ari Green, Jeffrey
Gelfand, Ami Cuneo, Pablo Villoslada
2:15 p.m.
S01.003
Characteristics of Walking Speed
Improvement Observed in Three WellControlled Studies of Sustained Release
Fampridine 10 mg Bid in Patients with
Multiple Sclerosis Andrew Goodman,
Ted Brown, Keith Edwards, Randall
Schapiro, Lawrence Marinucci, Ron
Cohen, Andrew Blight
2:30 p.m.
S01.004
Use of Natalizumab in Pediatric
MS Patients: A Pediatric Network
Experience E. Ann Yeh, Lauren Krupp,
Nancy Kuntz, Jayne Ness, Dorothee
Chabas-Chanezon, Tanuja Chitnis, Anita
Belman, Moses Rodriguez, Emmanuelle
Waubant, Mark Gorman, Khurram
Bashir, Network Pediatric MS Centers of
Excellence, Bianca Weinstock-Guttman
2:45 p.m.
S01.005
Measures of Early Clinical Activity
as Prognostic Factors for Long-Term
Clinical Outcomes in RelapsingRemitting Multiple Sclerosis Anthony
Traboulsee, Bernard Uitdehaag,
Ludwig Kappos, Magnhild SandbergWollheim, David Li, Peter Jongen, Cris
Constantinescu, Elisabetta Verdun, Peter
Cornelisse
3:00 p.m.
S01.006
Clinical and NeuroImaging Predictors of
Responsiveness to Immunomodulating
Therapies in a Large Single-Center
Cohort of Patients with RelapsingRemitting Multiple Sclerosis
(RRMS) Giancarlo Comi, Marzia
Romeo, Fiilippo Martinelli Boneschi,
Vittorio Martinelli, Giuseppe Liberatore,
Mariaemma Rodegher
3:15 p.m.
S01.007
Mitoxantrone Treatment in
Neuromyelitis Optica (NMO) Masaru
Matsui, Kiyoe Ohta, Keiko Tanaka,
Masayuki Tahara, Mitsuhiro Ohta,
Masami Tanaka
3:30 p.m.
S01.008
Interim Analysis of Open-Label
Extension Studies of Sustained Release
Fampridine in Patients with Multiple
Sclerosis Andrew Goodman, Ted
Brown, Keith Edwards, Randall Schapiro,
Lawrence Marinucci, Ron Cohen,
Andrew Blight, MS-F203, MS-F204, MSF203EXT, and MS-F204EXT Study
44
S02 Cerebrovascular
Disease: Stroke
Epidemiology I
2:00 p.m.
S02.002
Impact of Healthy Lifestyle Practices
on Mortality after Stroke in the
United States Amytis Towfighi, Bruce
Ovbiagele
2:15 p.m.
S02.003
Serum Levels of Soluble Receptor for
Advanced Glycation End-Products
Are Associated with Subclinical
Cerebrovascular Disease Among
Hispanics and Blacks Barry Hudson,
Yeseon Park Moon, Anastasia Kalea,
Minesh Khatri, Chensy Marquez,
Ann Marie Schmidt, Myunghee Paik,
Ralph Sacco, Charles DeCarli, Clinton
Wright, Mitchell Elkind
Tuesday, April 13 | 1:45 p.m.–3:45 p.m.
Metro Toronto Convention Centre
S03 Movement Disorders:
Epidemiology of Parkinson's
Disease
Room 718AB
1:45 p.m. Presentation of
the Movement Disorders
Research Award
Recipient:
David Eidelberg, MD
Manhasset, NY
2:15 p.m.
S03.003
Use of Non-Steroidal AntiInflammatory Drugs and Risk
of Parkinson’s Disease: A
Prospective Study and MetaAnalysis Xiang Gao, Honglei
Chen, Michael Schwarzschild,
Alberto Ascherio
2:30 p.m.
S03.004
Late-Life Hemoglobin and the
Incidence of Parkinson’s Disease:
The Honolulu-Asia Aging
Study Helen Petrovitch, Robert
Abbott, Webster Ross, Caroline
Tanner, Julie Andersen, Kamal
Masaki, Lon White
2:30 p.m.
S02.004
Disparities in Stroke Type and
Vascular Risk Factors Between Two
Hispanics Populations in Miami and
Mexico City Antonio Arauz, Jose
Romano, Juan Manuel Marquez,
Carol Artigas, Sebastian Koch,
Tatjana Rundek, Channui Dong, Diogo
Haussen, Michael Katsnelson, Clinton
Wright, Ralph Sacco
2:45 p.m.
S03.005
Parkinson’s Disease Risk
Is Increased in Discordant
Twins Exposed to Specific
Solvents Samuel Goldman,
Caroline Tanner, Cheryl Meng,
Grace Bhudhikanok, Patricia
Quinlan, Kathleen Comyns,
Monica Korell, Benjamin
Priestley, J. William Langston
2:45 p.m.
S02.005
New Ischemic Lesions on Magnetic
Resonance Imaging After
Endovascular Procedures in Patients
with Cerebrovascular Diseases:
A Systematic Review Yousef
Mohammad, Mushtaq Qureshi, Laura
Vaught, M. Fareed Suri, Marwan
Kattan, Abhijin Das, Adnan Qureshi
3:00 p.m.
S03.006
Reduced Sympathetically
Induced Heart Rate Variability
During Sleep in Parkinson’s
Disease: A Polysomnographic
Case-Control Study Nicolas
Sauvageot, Michel Vaillant, Nico
Diederich
3:00 p.m.
S02.006
Stroke-Associated Pneumonia (SAP):
Risk Factors for Its Development
and Affect on Stroke Outcome Olga
Finlayson, Moira Kapral, Ruth Hall,
Eriola Asllani, Daniel Selchen,
Gustavo Saposnik
3:15 p.m.
S02.007
Are Certified Stroke Centers
Adequately Placed To Meet
the Population Needs of United
States? Gabriela Vazquez, Silvina
Tornelli, Michael Tibbs, Jill Novitzke,
M. Fareed Suri, Adnan Qureshi
3:30 p.m.
S02.008
Immediate Effect of New Jersey
State Stroke Center Designation
Act on Quality Stroke Coverage
for New Jersey: A Model for Other
States? Jawad Kirmani, Syed Abbas,
Mohammad Moussavi, Spozhmy
Panazi, Florence Chukwuneke, Martin
Gizzi
3:15 p.m.
S03.007
What Predicts Mortality
in Parkinson’s Disease? A
Long-Term Population Based
Study Elin Forsaa, Jan Petter
Larsen, Tore Wentzel-Larsen,
Guido Alves
3:30 p.m.
S03.008
Prevalence of Parkinson Disease
in Patients and Obligate Carriers
of Gaucher Disease Joanna
Becker, Gregory Pastores,
Marissa Ferraris, Jerome Graber,
E. Kolodny, Swati Sathe
S04 Sleep Disorders
Constitution Hall 107
1:45 p.m. Presentation of the
Sleep Science Award
Recipient:
Arthur Walters, MD
Nashville, TN
2:00 p.m.
S04.002
Plasma Biomarkers of Inflammation
and Endothelial Dysfunction in Acute
Stroke Patients with and without
Sleep Apnea Alexander Kunz, Jörg
Kraus, Patrick Oschmann, Stefanie
Berger, Kerstin Retzlaff, Rainer
Dziewas
2:15 p.m.
S04.003
Relationship of Day/Night and Sleep/
Wake Patterns to Seizure Semiology
and Epilepsy Localization Marcin
Zarowski, Tobias Loddenkemper,
Martina Vendrame, Andreas
Alexopoulos, Sanjeev Kothare
2:30 p.m.
S04.004
Analysis of Subjective Sleepiness
in Patients with Multiple System
Atrophy Takayoshi Shimohata,
Hideaki Nakayama, Masahiko
Tomita, Tetsutaro Ozawa, Masatoyo
Nishizawa
2:45 p.m.
S04.005
Cardiac Autonomic Dysfunction
in Idiopathic REM Sleep Behavior
Disorder Ronald Postuma,
Paola Lanfranchi, Helene Blais,
Jean-Francois Gagnon, Jacques
Montplaisir
3:00 p.m.
S04.006
Long-Term Safety and Efficacy
of Rotigotine in Patients with
Idiopathic RLS: Five-Year Results
from a Prospective Multinational
Open-Label Follow-Up Study Birgit
Hogl, Claudia Trenkwalder, Diego
Garcia-Borreguero, Ralf Kohnen,
Werner Poewe, Karin Stiasny-Kolster,
Lars Bauer, Andreas Fichtner, Erwin
Schollmayer, Wolgang Oertel, for the
SP710 study group
3:15 p.m.
S04.007
Hypoxia Inducible Factor Pathway
Activation in Restless Legs
Syndrome Patients Stephanie
Patton, Padmavathi Ponnuru, Amanda
Snyder, Gerald Podskalny, James
Connor
3:30 p.m.
S04.008
Postmortem and Imaging
Based Analyses Reveal CNS
Hypomyelination in Restless
Legs Syndrome James Connor,
Padmavathi Ponnuru, Byeong-Yeul
Lee, Qing Yang, Gerald Podskalny,
Shoaib Alam, Richard Allen,
Christopher Earley
S05 Epilepsy: Clinical
Epilepsy
S06 Neuromuscular
Junction and Muscle
Disorders
S07 Headache I
Room 701A
Constitution Hall 105
Room 701B
1:45 p.m.
S05.001
Depiction of Seizure First
Aid Managment in Medical
Television Dramas Andrew
Moeller, Jeremy Moeller, Susan
Rahey, R. Mark Sadler
1:45 p.m.
S06.001
Muscle Pathology in Biopsy of MuSK-Ab
Positive Myasthenic Patients Shows
Mitochondrial Abnormalities Corrado
Angelini, Giovanna Cenacchi, Elisa Albertini,
Marina Fanin, Sara Martignago
1:45 p.m.
S07.001
Prevalence and Epidemiologic
Profile for Adolescent Chronic
Migraine (CM): Results of a
U.S. National Survey of Chronic
Daily Headache Richard Lipton,
Aubrey Manack, Judith Ricci,
Elsbeth Chee, Catherine Turkel,
Paul Winner
2:00 p.m.
S05.002
‘WESTCOPS’—A Scoring
System To Differentiate NonEpileptic from Epileptic Motor
Seizures Kanishk Makhija, Arun
Antony, Lina Lander, Sanjay Singh
2:15 p.m.
S05.003
Serotonin Reuptake Inhibitors
Reduce Ictal Hypoxemia in
Medically Refractory Partial
Epilepsy Lisa Bateman, ChinShang Li, Tzu-Chun Lin, Masud
Seyal
2:30 p.m.
S05.004
Autoimmune Epilepsy: A Case
Series from the EMU Matthew
Hoerth, Katherine Noe, Joseph
Sirven, Dean Wingerchuk,
Jonathan Carter, Joseph
Drazkowski
2:45 p.m.
S05.005
Catamenial Epilepsy and
Mood in Hispanic Women with
Epilepsy Adrienne Keener, Laura
Kalayjian, Kristen Fowler, Andrew
Herzog, the NIH Progesterone
Trial Study Group
3:00 p.m.
S05.006
Low Bone Mineral Density but
Normal Microarchitecture in
Premenopausal Women with
Epilepsy Alison Pack, Adi Cohen,
Robert Pelgrift, Chiyuan Zhang,
Don McMahon, Elizabeth Shane
3:15 p.m.
S05.007
Epilepsy: When To Think
Surgery! Nathalie Jette, José
Téllez Zenteno, Walter Hader,
Sophie Macrodimitris, Jorge
Burneo, Fred Andermann, Hude
Quan, Elisabeth Sherman, Lorie
Hamiwka, Amy Metcalfe, Lizbeth
Hernandez-Ronquillo, Peter
Camfield, Lionel Carmant, Elaine
Wirrell, Donald Gross, Jeptha
Davenport, Richard Huntsman,
R. Mark Sadler, Churl-Su Kwon,
Carter Snead, David Steven, Matt
Wheatley, Jean-Pierre Farmer,
Samuel Wiebe
3:30 p.m.
S05.008
Iatrogenic Pathological
Findings Related to Invasive
EEG Monitoring for Medically
Intractable Epilepsy
(MIE) Joanna Fong, William
Bingaman, Andreas Alexopoulos,
Richard Prayson
Scientific Sessions
Tuesday, April 13 | 1:45 p.m.–3:45 p.m.
2:00 p.m.
S06.002
Congenital Myasthenic Syndrome
(CMS) Caused by Mutations in Choline
Acetyltransferase (CHAT). Clinical Features,
Genetic Analysis and Expression Studies
in 11 Patients Xin-Ming Shen, Joan
Brengman, Gyula Acsadi, Thomas Crawford,
Susan Iannaccone, Emin Karaca, Chaouki
Khoury, Jean Mah, Simon Edvardson, David
Rodgers, Andrew Engel
2:15 p.m.
S06.003
Fatal Muscular Dystrophy, Congenital
Myasthenic Syndrome (CMS), and
Epidermolysis Bullosa Simplex (EBS) Due to
Plectin Deficiency Vern Juel, Lisa HobsonWebb, Edward Smith, David Stickler, Duygu
Selcen, Andrew Engel
2:30 p.m.
S06.004
Using Anthropometric Measures To
Monitor Efficacy of Pulse Intravenous
Methylprednisolone Versus Oral
Corticosteroid Therapy in the Treatment
of Juvenile Dermatomyositis Asim Haque,
Linda Ray, Veda Vedanarayanan
2:45 p.m.
S06.005
Mexiletine Trial in Non-Dystrophic
Myotonias (NDM): Feasibility of the
Interactive Voice Response (IVR)
as a Patient-Reported Outcome
Measure Yunxia Wang, Brian Bundy,
Laura Herbelin, Mazen Dimachkie, Richard
Barohn, The CINCH Study Group
3:00 p.m.
S06.006
Patient Identification of the HighestImpact Symptoms and Issues in
Facioscapulohumeral Muscular Dystrophy
(FSHD) Nicholas Johnson, Nancy Chin,
Robert Holloway, Rabi Tawil, Richard
Moxley, Christine Quinn, Barbara Vickrey,
Chad Heatwole
3:15 p.m.
S06.007
A Cooperative International
Neuromuscular Research Group (CINRG)
Study of the Relationship Between
Impairment, Activity Limitation,
Participation, and Quality of Life in Persons
with Confirmed Dystrophinopathies:
One-Year Follow-Up of Skeletal
Muscle Strength and Timed Motor
Performance Erik Henricson, Craig
McDonald, Richard Abresch, Jay Han,
Robert Leshner, Eric Hoffman, Diana
Escolar, Avital Cnaan, Fengming Hu, Angela
Zimmerman, Tina Duong, Julaine Florence,
Adrienne Arrieta, CINRG Investigators
3:30 p.m.
S06.008
Transient Expression of a Therapeutic
Dystrophin Transgene in Duchenne
Muscular Dystrophy Revealed by T Cell
Mediated Immunity Jerry Mendell,
Katherine Campbell, Louise Rodino-Klapac,
Zarife Sahenk, Christopher Shilling,
Sarah Lewis, Dawn Bowles, Steven Gray,
Chengwen Li, Gloria Galloway, Vinod Malik,
Brian Coley, Reed Clark, Juan Li, Xiao Xiao ,
Jade Samulski, Scott McPhee, R. Samulski,
Christopher Walker
2:00 p.m.
S07.002
Migraine and White Matter
Hyperintensity Volume: The
EVA MRI Cohort Tobias Kurth,
Shajahal Mohamed, Pauline
Maillard, Bernard Mazoyer,
Carole Dufouil, Christophe Tzourio
2:15 p.m.
S07.003
Hypothalamic Volume Decrease
in Hypnic Headache Dagny
Holle, Steffen Naegel, Sarah
Krebs, Charly Gaul, Elke Gizewski,
Zaza Katsarava, Mark Obermann
2:30 p.m.
S07.004
Cortical Spreading Depression
Activates Trigeminovascular
Neurons in Lamina I of the Spinal
Trigeminal Nucleus Xi Chun
Zhang, Dan Levy, Rami Burstein
2:45 p.m.
S07.005
Frequent Headaches in the
Preadolescent Pediatric
Population—A PopulationBased Study Marco Arruda,
Vincenzo Guidetti, Federica Galli,
Regina Albuquerque, Marcelo
Bigal
3:00 p.m.
S07.006
Voxel-Wise Assessment of
White and Gray Matter Damage
in Patients with Migraine and
Different Disease Phenotypes:
A Combined TBSS and VBM
Study Martina Absinta, Maria
Rocca, Bruno Colombo, Andrea
Falini, Giancarlo Comi, Massimo
Filippi
3:15 p.m.
S07.007
Depression: A Risk Factor for
Migraine Chronification: Results
from the American Migraine
Prevalence and Prevention
(AMPP) Study Sait Ashina,
Dawn Buse, Aubrey Manack,
Daniel Serrano, Morris Maizels,
Catherine Turkel, Richard Lipton
3:30 p.m.
S07.008
The Plasmatic Vascular
Endothelial Growth Factor
Level Is Decreased in Migraine
Patients Maria Toriello, Agustin
Oterino, Jesus Castillo, Ana
ALonso-Arranz, Montserrat Gago,
Julio Pascual
S08 Behavioral
Neurology: From Genetics
to Brain Function to
Behavior
S09 History of Neurology
Room 714A
Room 717AB
1:45 p.m. Presentation of the
Norman Geschwind Prize in
Behavioral Neurology
Recipient:
Keith Josephs, MD, MST, MS
Rochester, MN
2:00 p.m.
S08.002
Changes in Gray and White Matter
Perfusion During Retrieval of Spatial
Memory in the Freely Moving
Rat S. Stewart, J. Yang, T. Givard, S.
Frances, Z. Wang, J. M. Maarek, D.
Holschneider
2:15 p.m.
S08.003
Is Motor System Long-Term
Potentiation Normal in Tourette
Syndrome? Steve Wu, Kelly Isaacs,
Donald Gilbert
2:30 p.m.
S08.004
Catechol-O-Methyl Transferase
(COMT) Gene Polymorphism
Associated with Hallucinations and
Interpersonal Coldness Carmela
Tartaglia, Anna Karydas, Tricia See,
Adam Boxer, Bruce Miller, Katherine
Rankin
2:45 p.m.
S08.005
Depression Among Carriers and NonCarriers of Parkin Mutations Anil
Srivastava, Ming Tang, Elan Louis,
Helen Mejia-Santana, Ruth Ottman,
Llency Rosado, Karen Marder, Cynthia
Comella, Susan Bressman, Martha
Nance, Andrew Siderowf, Danna
Jennings, Amy Colcher, Danna
Jennings, William Scott, Cheryl
Waters, Lucien Cote, Howard Andrews,
Caroline Tanner, Susan Mickel, Stanley
Fahn, Barbara Ross, Steven Frucht,
Miguel Verbitsky, Blair Ford, Sergey
Kisselev, Roy Alcalay, Michael Rezak,
Kevin Novak, Greg Neils, Joseph
Friedman, Ronald Pfeiffer, Laura Marsh,
Bradley Hiner, Lorraine Clark, Elise
Caccappolo
3:00 p.m.
S08.006
Depression/Dysphoria and Anxiety
Are Early Symptoms in Dementia
with Lewy Bodies Carolyn Orr,
Bradley Boeve, Tanis Ferman, Glenn
Smith, Yonas Geda, J. Ahlskog, David
Knopman
3:15 p.m.
S08.007
Persistent Neuropsychiatric
Symptoms Predict Worse Cognitive
and Functional Outcome in Alzheimer’s
Disease Stephane Poulin, Bradford
Dickerson, Alzheimer’s Disease
Neuroimaging Initiative
3:30 p.m.
S08.008
Pre-Frontal Neural Dysfunction to
Emotional Stimuli: An fMRI Study of
Executive Function in Non-Demented
ALS Patients Martin Goldstein,
Michael Silverman, Dale Lange, Mark
Sivak, Ji-yeoun Yoo, Thomas Naidich
1:45 p.m. Presentation of
the Lawrence C. McHenry
Award: An Award for the
History of Neurology
Recipient:
Elan Louis, MD, MS
New York, NY
2:15 p.m.
S09.003
Unethical Person-to-Person
Transmission Experiments in
Subjects with Neurological
Vitamin Deficiency
Disorders Douglas Lanska
2:30 p.m.
S09.004
Shaking Up the Salpêtriíre: JeanMartin Charcot and Mercury
Intoxications Christopher Goetz
2:45 p.m.
S09.005
William W. Keen’s Contributions
to Treatment of Traumatic
Neuropathy Edward Fine, Raya
Wehbeh
3:00 p.m.
S09.006
The Coming of Age of Neurology:
The Conceptualization and
Organization of the First
International Neurological
Congress (1931) Elan Louis
3:15 p.m.
S09.007
Echoencephalography and the
Importance of Negative Findings
in Research Jonathan Lau
3:30 p.m.
S09.008
The NIH Yellow Berets:
Legacy of the U.S. Doctor
Draft Sandeep Khot, Buhm Soon
Park, W. T. Longstreth
S10 Multiple Sclerosis:
MRI I
Room 713AB
1:45 p.m.
S10.001
Assessment of Deep Grey Matter
Atrophy in Clinically Isolated
Syndrome (CIS) Using 7 Tesla MR
Imaging Su-Yin Lim, Ali Al-Radaideh,
Christopher Tench, Penny Gowland,
Cris Constantinescu
2:00 p.m.
S10.002
Deep Gray Matter Atrophy in a
Large Sample of Clinically Isolated
Syndrome and Early RelapsingRemitting Multiple Sclerosis
Patients Niels Bergsland, Michael
Dwyer, Dana Horakova, Ondrej
Dolezal, Eva Havrdova, Robert
Zivadinov
2:15 p.m.
S10.003
Patterns of Regional Gray
Matter Atrophy and Cognitive
Impairment in Multiple Sclerosis
Patients with Different Disease
Phenotypes Gianna Riccitelli, Maria
Rocca, Cristina Forn, Andrea Falini,
Elisabetta Pagani, Mariaemma
Rodegher, Monica Falautano, Paolo
Rossi, Giancarlo Comi, Massimo
Filippi
2:30 p.m.
S10.004
Global vs. Regional Spinal Cord
Atrophy in Multiple Sclerosis Ashish
Arora, Mohit Neema, Shahamat
Tauhid, Daniel Goldberg-Zimring,
Brian Healy, James Stankiewicz,
Christian Chavarro-Nieto, Antonia
Ceccarelli, Elisa Dell’Oglio, Charles
Guttmann, Rohit Bakshi
2:45 p.m.
S10.005
Magnetization Transfer Ratio
Imaging Is Feasible in Large
Multicenter MS Trials Douglas
Arnold, Catherine Dalton, Sridar
Narayanan, Mishkin Derakhshan,
Daniel Tozer, Kelvin Hunter, Robert
Fox, Ralf Gold, Minhua Yang,
Katherine Dawson, David Miller
3:00 p.m.
S10.006
Rapid Semi-Automatic Segmentation
of the Spinal Cord from Magnetic
Resonance Images in Multiple
Sclerosis Mohit Neema, Mark
Horsfield, Stefania Sala, Martina
Absinta, Anshika Bakshi, Maria
Sormani, Maria Rocca, Rohit Bakshi,
Massimo Filippi
3:15 p.m.
S10.007
Asymptomatic Spinal Cord Lesions
Predict Clinical Progression in
Radiologically Isolated Syndrome
(RIS) Subjects Darin T. Okuda,
Elizabeth Crabtree, Ellen Mowry,
Bruce Cree, Ari Green, Dorothee
Chabas-Chanezon, Scott Zamvil,
Emmanuelle Waubant, Douglas
Goodin, Daniel Pelletier
3:30 p.m.
S10.008
Presence of Gadolinium
Enhancement in MS Is Largely a
Phenomenon of Age Omar Khan,
Fen Bao, Megha Shah, Jai Perumal,
Aaron Boster, Stephanie Hreha, Anza
Memon, Christina Caon, Imad Zak,
Alexandros Tselis
45
Poster Session II
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
Poster Discussion Session: Epilepsy
Location: 800 Level
Moderators: Joseph Drazkowski, MD and Massimo Pandolfo, MD
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
PD2.001 Expression Analysis of
Some Candidate Genes Involved in
Neurotransmission and Neurogenesis in
Human Hippocampal Sclerosis Nerses
Bebek, Müge Sayitogu, Özkan Özdemir,
Betül Baykan, Gur Özbek, Aykut Karasu,
Altay Sencer, Ibrahim Izin, Candan Gürses,
Özden Hatirnaz, Sinem Akat, Murat Imer,
Gülcan Pulur, Ali Canbolat, Aysen Gökyigit
PD2.002 Pathogenic Mechanism
of SCN1B Mutation Affecting the β1b
Splice Variant as a Cause of Familial
Epilepsy Gustavo Patino, William
Brackenbury, Patrick Cossette, Ronald
Lafreniíre, Guy Rouleau, Lori Isom
PD2.003 Association of Interleukin1beta and Mesial Temporal Lobe Epilepsy
with Hippocampal Sclerosis Renato
Santos, Mariana Saragiotto da Silva,
Rodrigo Secolin, Clarissa Yasuda, Tonicarlo
Velasco, Américo Sakamoto, Fernando
Cendes, Íscia Lopes-Cendes, Cláudia
Maurer-Morelli
PD2.004 CNS-Related Comorbidities
in Individuals with Self-Reported Epilepsy
from the National Survey of Epilepsy,
Comorbidities and Health Outcomes
(EPIC) Ruth Ottman, Richard Lipton, Alan
Ettinger, Joyce Cramer, Michael Reed,
George Wan
PD2.005 Patterns of Epilepsy and
Associated Neurological Impairements
among Patients Attending the Pediatric
Neurology Clinic at the National Referral
Hospital, Uganda Christine MugashaGahiire, Richard Idro, Sarah Kiguli, Justus
Byarugaba
History of Neurology
P02.001 The Contributions of Two
Presidents of Israel to the Development of
Copaxone Kenneth Johnson, Pippa Loupe
P02.002 Seasonal Patterns of
Nutritional Night Blindness in the U.S.
Army during the Civil War Douglas Lanska
P02.003 A Continuum of Ideas of
Hughlings-Jackson and Wilder Penfield
about Epilepsy and Brain Function Edward
English, Robert Hogan
P02.004 Nutritional Night Blindness
and Keratomalacia Among Malnourished
Civilians during WWI Douglas Lanska
P02.005 Migraine in Dr. Faustus by
Thomas Mann Stephen Reich
P02.006 A Biology of the Mind:
Phrenology in Medicine in Antebellum
America Daniel Schneider
P02.007 Surreptitious Documentation
of Thiamin-Deficiency Disorders by Allied
POWs during WWII Douglas Lanska
P02.008 “Elementary My Dear Dr.
Allen”: The Case of Barium Toxicity and Pa
Ping Lauren Bowen, S. Subramony, Jing
Cheng, Samuel Wu, Michael Okun
P02.009 Pathogenesis and Treatment
of Infantile Beriberi in the Philippines,
1910–1912 Douglas Lanska
P02.010 The Dorsal Columns, beyond
Proprioception and Vibration Sense a
Historical Review Ingrid Park
P02.011 Pellagra Was the First
Neurodegenerative and Redox Disorder
To Be Cured: Can We Be Sure It Was
Eliminated? Adrian Williams
46
P02.012 Neurology and the Old
Testament Stephen Mathew, Jeyaraj
Pandian
P02.013 Descriptions of Parkinson’s
Disease in Ancient Indian Medical
Literature Ovallath Thazha Sujith
P02.014 Abraham Levinson
(A.L.)— His Contributions to Child
Neurology Daniel Elefant, David Rothner
P02.015 Decreased Creativity
after Stroke— Christoph Willibald
Gluck Tomislav Breitenfeld, Vesna Vargek
Solter, Darko Breitenfeld, Vida Demarin
P02.016 “Dystrophica Myotonica”
and the Legacy of Hans Steinert Shrikant
Mishra, Parampreet Singh
P02.017 Neuro-Expressionism in
Christfried Jakob Contributions from
Lake Jakob to Visceral Brain Ana Isabel
Fumagalli
P02.018 Medical and Neurological
Maladies of Sir George Everest Shrikant
Mishra, Parampreet Singh
P02.019 Charcot’s Son, Commander
Jean-Baptiste Charcot: From Neurology
to “ Pourquoi Pas?” Renato Munhoz, Helio
Teive, Jefferson Simões, Lineu Werneck
P02.020 A Brief History of
Endovascular Neurology and
Procedures Bijal Mehta, Edward Fine
P02.021 Early Contributions to the
Understanding of Frontotemporal Lobar
Degeneration from Argentina Joaquín
Barutta, John Hodges, Ezequiel
Gleichgerrcht, Teresa Torralva,
Mariangeles Pose, Agustín Ibáñez,
Facundo Manes
PD2.006 Uncinate Fasciculus
Integrity and Impaired Problem Solving
and Memory in Complex Partial
Seizures Mario Dulay, Christof Karmonik,
Amit Verma, Kimberly Raghubar, Adriana
Strutt, Michele York, Robert Grossman
PD2.007 Frequency of Thyroid
Abnormalities in Patients with Epilepsy
and Their Relationship with the Use of
Antiepileptic Drugs Iris Martínez-Juárez,
Liliana Romero-Ocampo, Erandi BravoArmenta, Ma. de los Ángeles FernándezAguilar
PD2.008 Intra-Individual Variability of
Carbamazepine and Valproic Acid Serum
Concentrations in Elderly Nursing Home
Residents Ilo Leppik, Jeannine Conway,
Melissa Strege, Angela Birnbaum
P02.035 Impact of Early Goal-Directed
Hemodynamic Optimization on Clinical
Management and Outcome After
Subarachnoid Hemorrhage: A Prospective
Controlled Study Tatsushi Mutoh, Tatsuya
Ishikawa, Taizen Nakase, Akifumi Suzuki,
Nobuyuki Yasui
PD2.009 A Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group
Study of Rufinamide Given as Adjunctive
Therapy in Patients with Refractory
Partial-Onset Seizures Victor Biton,
Gregory Krauss, Francesco Bibbiani, Allison
Mann, Carlos Perdomo, Milind Narurkar
P02.036 Extravascular Lung
Water and Pulmonary Permeability
Dynamics in Patients with Neurogenic
Pulmonary Edema after Subarachnoid
Hemorrhage Tatsushi Mutoh, Tatsuya
Ishikawa, Taizen Nakase, Akifumi Suzuki,
Nobuyuki Yasui
PD2.010 An Evaluation of the Effect
of Eslicarbazepine Acetate on Metabolic
Parameters: A Pooled Analysis of
Three Double-Blind Phase III Clinical
Studies Mark Friedman, Mark Versavel,
Jacqueline French, Luis Almeida, Elinor
Ben-Menachem, Kenneth Tripp, Christian
Elger, Patricio Soares-da-Silva
P02.037 Cell Proliferation in
Chronic Subdural Hematomas: A
Potential Mechanism of Expansion
and Recurrence J. Goodman, Shankar
Gopinath, Claudia Robertson
P02.038 Peripheral Leukocyte
Count and Matrix Metalloproteinase-2
in Cerebral Vasospasm Following
Subarachnoid Hemorrhage Sherry Chou,
MingMing Ning, Rachael Konigsberg, Eric
Loesch, Gülhan Alpargu, Steven Feske, Eng
Lo
P02.039 Vasospasm in
Aneurysmal SAH and Intracranial
Calcification Haitham Hussein, Steve
Cordina, Haralabos Zacharatos, Adnan
Qureshi, Mustapha Ezzeddine
P02.022 Epilepsy at the
Theater: Underrepresentation and
Misrepresentation of Epilepsy
in 100 Years of International
Cinematography Martina Vendrame
Critical Care/Emergency
Neurology/Trauma II
P02.023 Trends in Outcomes and
Hospitalization Costs among Spinal
Cord Injury Adult Patients in the United
States Khosro Farhad, Khan Hafiz, Abu
Nsar, Nizar Souayah
P02.024 Post-Traumatic Cerebral
Atrophy: Relationship with Diffusion
Tensor Imaging Measures of Traumatic
Axonal Injury Matthew Warner, Alvin
Chandra, Tommy Davis, Carlos Marquez
De La Plata, Jun Yi Wang, Carol Moore,
Caryn Harper, Christopher Madden, Ramon
Diaz-Arrastia
P02.025 Trends in Outcomes and
Hospitalization Costs Among Traumatic
Brain Injury in Pediatric Patients in the
United States Khosro Farhad, Hafiz Khan,
Shahanara Islam, Nizar Souayah
P02.026 Use of Diffusion-Weighted
Imaging To Assess Cytotoxic and
Interstitial Edema after Traumatic Brain
Injury Mena Milad, Nabila Choudhury,
Lifang Peng, Carol Moore, Caryn Harper,
Christopher Madden, Ramon Diaz-Arrastia
P02.027 Regional Selectivity of
Post-Traumatic Cerebral Atrophy Alvin
Chandra, Matthew Warner, Tommy Davis,
Carol Moore, Caryn Harper, Christopher
Madden, Ramon Diaz-Arrastia
P02.028 Trends in Outcomes and
Hospitalization Costs Among Traumatic
Brain Injury in Adult Patients in the United
States Nizar Souayah, Abu Nasar, Khosro
Farhad, Hussam Yacoub, Rania Abou
Elenein, Pavel Tishuk
P02.029 Can a Clinical Measure of
Reaction Time Predict a Functional SportProtective Response? Implications for
Sport Concussion Management James
Eckner, David Lipps, Hogene Kim, James
Richardson, James Ashton-Miller
P02.030 Wild Bootstrap Analysis
Detects Subject-Specific Changes in DTI
Indices after Concussion Jeffrey Bazarian,
Brian Blyth, Tong Zhu, Jianhui Zhong
P02.031 Outcome After Mild
Traumatic Brain Injury: The Role of
Gender Jeffrey Bazarian, Brian Blyth
P02.032 Traumatic Brain Injury—
”Kids in Transition” Daune MacGregor,
Alastair Hodinott, Arbelle Manicat-Emo,
Susan Stinson-Lypka, Tonya Flaming, Cindy
Bruce-Barrett
P02.033 Dual Intraventricular
Catheter Use in Severe Intraventricular
Hemorrhage Holly Hinson, Eric
Melnychuk, John Muschelli, Daniel
Hanley, Wendy Ziai
P02.034 Predictors and Impact of
Hematoma Resorption in Medically
Treated Patients with Intracerebral
Hemorrhage Nauman Tariq, Haitham
Hussein, Remy Wong, Gabriela Vazquez,
Yuko Palesch, Renee Martin, Jill Novitzke,
M. Fareed Suri, Adnan Qureshi, ATACH
Investigators
Poster Session II
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P02.040 Predictors and Outcome of
Pneumonia in Patients with Spontaneous
Intracerebral Hemorrhage Mohammad
Alsumrain, Charles Probeni, Bahareh
Hassanzadeh, Vahid Tohidi, Daniel Korya,
Mohammad Moussavi, Nicholas Melillo,
Jawad Kirmani
P02.041 Correlation of External
Cardiac Output Monitoring to
Hemodynamic Parameters and Central
Venous Pressure Readings in Critically Ill
Neurological Patients Aarti Sarwal, J.
Javier Provencio
Aging and Dementia:
Frontotemporal Dementia
Tauopathies
P02.042 Semantic Dementia
Associated with Motor Neuron Disease:
Clinicopathological Correlation Nicolas
Gaspard, Patrick Féry, Hichem Slama,
Martin Kavec, Jean-Pierre Brion, JeanChristophe Bier
P02.043 Frontotemporal Dementia
Associated with Primary Lateral Sclerosis
in the Antemortem Suvendrini Lena,
David Tang-Wai
P02.044 Divergent Network
Connectivity Changes in Behavioral
Variant FTD and Alzheimer’s
Disease Juan Zhou, Michael Greicius,
Efstathios Gennatas, Matthew Growdon,
Jung Jang, Joel Kramer, Michael Weiner,
Bruce Miller, William Seeley
P02.045 An Anatomopathological
Classification of Frontotemporal
Lobar Degeneration Jonathan Rohrer,
Tammaryn Lashley, Simon Mead, Nick
Fox, Janice Holton, Tamas Revesz, Martin
Rossor, Jason Warren
P02.046 Correlates of Alzheimer’s
Pathology in Corticobasal
Syndrome Suzee Lee, William Seeley,
Stephen Wilson, Matthew Growdon, Jung
Jang, Katherine Rankin, William Jagust,
Michael Weiner, Maria-Luisa GornoTempini, Bruce Miller, Gil Rabinovici
P02.047 Pre- and Post-Memantine
FDG-PET Imaging in Frontotemporal
Dementia Tiffany Chow, Ariel GraffGuerrero, Morris Freedman, David TangWai, Sandra Black, Bruce Pollock
P02.048 Prediction of Underlying
Alzheimer’s Disease in Corticobasal
Syndrome Rachel Gross, William Hu,
Corey McMillan, Delani Gunawardena,
Virginia Lee, John Trojanowski, Murray
Grossman
P02.049 Functional Profile of
Patients with Early Frontotemporal
Dementia and Its Relation with Executive
Functions Julieta Camino de la Llosa,
Ezequiel Gleichgerrcht, María Luz Di
Giacomo, Teresa Torralva, María Roca,
Mariangeles Pose, Facundo Manes
P02.050 Anosognosia and Behavioral
Manifestations of Dementia Leopold Liss
P02.051 Personality in Frontotemporal
Dementia Mariangeles Pose, Guido
Catagnola, Ezequiel Gleichgerrcht, Teresa
Torralva, Pablo Lopez, Fernando Torrente,
Federico Quaglia, Santiago O’Neill,
Marcelo Cetkovich, Facundo Manes
Aging and Dementia: Mild
Cognitive Impairment
P02.052 Neuropsychological
Performance in MCI at Baseline: Effect
of Apolipoprotein E ε4 Allele and Other
Candidate Genetic Variants Ana Pozueta,
Isabel Sala, Belén Sánchez Saudinós,
Ignacio Mateo, Jose Vazquez-Higuera, Eloy
Rodriguez-Rodriguez, Pascual SanchezJuan, Jon Infante, Jordi Clarimon, Alberto
Lleo, Onofre Combarros
P02.053 Self Administered
Gerocognitive Examination (SAGE) and
Mini-Mental State Examination (MMSE)
Score Changes over Time in Worried Well,
Mild Cognitive Impairment (MCI), and
Dementia Converter Patients Douglas
Scharre, Shu-Ing Chang, Maria Kataki,
Haikady Nagaraja
P02.054 Impact of Mild Cognitive
Impairment (MCI) on Patients and Their
Caregivers Trent McLaughlin, Lisa
Mucha, Gerald Crans, Enchi Liu, Michael
Grundman, Ronald Black
P02.055 Learning, Retrieval, and
Recognition Are Compromised in aMCI
and Mild AD: Are Distinct Memory
Processses Mediated by the Same
Anatomical Structures? Marcio Balthazar,
Clarissa Yasuda, Fernando Cendes, Benito
Damasceno
P02.065 Frequency of Sensory
Symptoms and Abnormal Nerve
Conduction Studies in a SCJD
Cohort Catherine Lomen-Hoerth,
Katherine Wong, Amy Kuo, Aissatou
Haman, Stephen DeArmond, Michael
Geschwind
P02.056 PreMCI and MCI:
Comparative Neuropsychological,
Clinical and Imaging Features and
Progression Rates Ranjan Duara, David
Loewenstein, Maria Greig-Custo, Elizabeth
Potter, Balaibal Raj, John Schinka, Amy
Borenstein, Sunil Saxena, Michael
Schoenberg, Warren Barker, Yougui Wu,
Jessica Banko, Huntington Potter
P02.066 Evaluation of Episodic
Memory in Illiterate and Low-Educated
Patients Catherine Belin, Didier Maillet,
Anne-Marie Ergis, Herve Le Clesiau,
Frederic Dessi, Antoine Carpentier
P02.057 Hippocampal Atrophy
Mediates the Associations between
APOE-ε4 and Amnestic MCI and
Verbal Memory James Mortimer, Amy
Borenstein, Charles DeCarli, Ding Ding,
Shugang Chu, Qian-hua Zhao, Qi-hao Guo,
Douglas Galasko, David Salmon, Ronald
Petersen, Zhen Hong
P02.058 Prevalence of Mild Cognitive
Impairment by Multiple Classifications: A
Population-Based Study Mary Ganguli,
Chung-Chou Chang, Beth Snitz, Judith
Saxton, Joni Vander Bilt
P02.059 Amnestic and NonAmnestic Mild Cognitive Impairment and
Cardiovascular Risk Factors in The 90+
Study Carrie Peltz, Maria Corrada, Daniel
Berlau, Claudia Kawas
P02.060 Dementia = (MC)2: A FourItem Screening Test for Mild Cognitive
Impairment and Dementia Vanja Douglas,
John Neuhaus, Julene Johnson, Caroline
Racine, Bruce Miller, S. Josephson
P02.061 Home-Based Activity
Changes Associated with MCI Jeffrey
Kaye, Stuart Hagler, Hiroko Dodge, Nora
Mattek, Daniel Austin, Teresa Buracchio,
Michael Pavel, Tamara Hayes
Aging and Dementia: Clinical
P02.062 Dyslipidemia in Alzheimer’s
Disease Is Associated with Blood-Brain
Barrier Impairment Gene Bowman,
Jeffery Kaye, Joseph Quinn
P02.063 Comparison of the Montreal
Cognitive Assessment (MoCA) with
the Mini-Mental State Examination in
Cognitively Impaired and Cognitively
Normal Subjects as Assessed by
Neuropsychological Testing Anne
Damian, Sandra Jacobson, Christine
Belden, Holly Shill, Marwan Sabbagh,
Linda Vedders, Joseph Hentz, John
Caviness, Charles Adler
P02.064 Anxiety as a Possible
Diagnosis Criteria for Logopenic Primary
Progressive Aphasia and Pure Progressive
Amnesia Eloi Magnin, Sabrina Ferreira,
Geraldine Vanholsbeeck, Elfriede Dariel,
Ilham Ryff, Lucien Rumbach, Pierre Vandel,
Jean Galmiche
P02.067 Alzheimer’s Disease CSF
Biomarker Levels Correlate with Baseline
Cognitive Performance and Post-Shunt
Cognitive Outcomes in Normal Pressure
Hydrocephalus Sunil Patel, Anica Law,
Edward Lee, Eric Jackson, Joanna Lopinto,
Steven Arnold, Christopher Clark, Anuj
Basil, Leslie Shaw, Sharon Xie, M. Sean
Grady, John Trojanowski, Roy Hamilton
P02.068 Obsessive Compulsive
Symptom Profile in Patients with
Behavioral Variant Frontotemporal
Dementia Guido Castagnola, Mariangeles
Pose, Teresa Torralva, Marcelo Cetkovich,
María Gonzalez Toledo, Facundo Manes
P02.069 The Boston Driving Screen—
Validation of a Clinical Tool for Assessing
Driving Problems in the Elderly Anil Nair,
Apar Gupta, Anna Hohler, Samuel Frank,
Margaret Brickley, Georgia Montouris,
Brian McGeeney, Jamie Frederick, Alan
Kurland
P02.070 Free Will, Decision-Making,
and the Frontal Lobes: Unique Legal and
Ethical Aspects in the Early Stages of
the Behavioral Variant Frontotemporal
Dementia Facundo Manes, Ezequiel
Gleichgerrcht, María Roca, Guido
Castagnola, Teresa Torralva
P02.071 Clinical Phenotype of
Dementia after Traumatic Brain Injury
(TBI) Nasreen Sayed, Ramon Diaz-Arrastia
Cerebrovascular Disease:
Clinical Aspects of
Cerebrovascular Disease
P02.072 Cervical Artery Dissection:
A Five-Year Experience of a Tertiary Care
Center Shadi Yaghi, Nancy Maalouf, Islam
Abujubara, Salah Keyrouz
P02.073 Brain Stem and Cerebellar
Strokes Are Less Cardioembolic and
Less Severe Than Hemispheric Strokes.
Prospective Data from the National Acute
Stroke Israeli Surveys (NASIS) Israel
Steiner, Michal Benderly, Isabelle KornLubetzki
P02.074 Does National Institutes
of Health Stroke Scale Score Provide
Additional Predictive Value in Good Grade
Patients with Intracerebral Hemorrhage?
Results from the Antihypertensive
Treatment of Acute Cerebral Hemorrhage
(ATACH) Study Adnan Qureshi, Yuko
Palesch, Renee Martin, Jill Novitzke,
Salvador Flores, As’ad Ehtisham, Mustapha
Ezzeddine, Joshua Goldstein, Jawad
Kirmani, Haitham Hussein, M. Fareed Suri,
Nauman Tariq, ATACH Investigators
47
Poster Session II
P02.075 Epidemiology and Outcomes
of Fever Burden Among Patients with
Acute Ischemic Stroke Michael Phipps,
Rani Desai, Charles Wira III, Dawn Bravata
P02.076 Admitted Transient Ischemic
Attack Patients Have a Lower Two-Day
Risk of Ischemic Stroke Than Predicted
by the ABCD2 Score Rajesh Gupta,
Yousef Mohammad, Vivien Lee, Shyam
Prabhakaran
P02.077 Incidence of Falling among
Elderly with History of Stroke: Health
and Retirement Study Survey 2002–
2006 Anna Barrett, Gabriela Vasquez,
Rachel Meyer, Andreas Luft, Afshin Divani
P02.078 Antecedent Chiropractic
Manipulation May Be More Frequently
Associated with Posterior Circulation
Territory Strokes Nerses Sanossian,
Jeffrey Saver, David Liebeskind, Sidney
Starkman, Doojin Kim, Latisha Ali, Bruce
Ovbiagele
P02.079 The NIH Score: Predicting
the Need for In-Patient Hospitalization
(NIH) of TIA Patients Indrani Acosta, Hen
Hallevi, Sean Savitz
P02.080 Factors Influencing Early
Cognitive Impairment After Stroke Maria
Zurru, Laura Brescacin, Claudia Alonzo,
Fabiana Ortega, Marina Romano, Silvina
Brienza, Luis Camera, Gabriel Waisman,
Edgardo Cristiano, Bruce Obviagele
P02.081 Alcohol Consumption and
Other Vascular Risk Factors Associated
with White Matter Subcortical Lesions in
Non-Demented Non-Stroke Maria Zurru,
Claudia Alonzo, Laura Brescacin, Daniela
Gil, Julieta Montecchia, Marcelo Schapira,
Luis Camera, Gabriel Waisman, Edgardo
Cristiano, Bruce Obviagele
P02.082 Clinical and Radiological
Predictors of Neurological Deterioration
in Spontaneous Cervico-Carotid
Dissections Gustavo Rodriguez, Ameer
Hassan, M. Fareed Suri, Sudeepta
Dandapat, Rehan Zahid, Yousef
Mohammad, Nauman Tariq, Gabriela
Vazquez, Ramachandra Tummala, Robert
Taylor, Adnan Qureshi
P02.083 Transcranial Doppler (TCD)
and Neurological Manifestations in
Brazilian Pediatric Patients with SCD Ana
Claudia Leite, Celia Silva, Renata Azevedo,
Patricia Moura, Raquel Oliveira, Clarisse
Lobo
P02.084 The Interval of Stenotic
Index of TCD and Middle Cerebral Artery
Stenosis Lianyuan Feng
P02.085 Frequency of Emergency
Physician and Neurologist Agreement in
the Diagnosis of TIA Carlene Kingston,
Osman Mir, George Leach, Michael Ross,
Jacquelyn Abney, Lauren Ayala, Fadi
Nahab
P02.086 Clinical and Radiological
Features of Reversible Cerebral
Vasoconstriction Syndrome Javier
Moschini, Francisco Meli, Maria
Goicochea, Macarena de la Fuente,
Sebastian Ameriso
48
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P02.087 Characterization of Ischemic
Strokes and Transient Ischemic Attacks
after Cardiovascular Procedures in a HighVolume Center Gabriela Bressán, Patricia
Riccio, Francisco Klein, Luciano Sposato
P02.088 Preparation for
Accreditation and State Designation of a
Comprehensive Stroke Center Improves
Stroke Case Volume, Evaluation, and
Treatment Response Times Bahareh
Hassanzadeh, Appaji Rayi, Madhu Gupta,
Jawad Kirmani, Martin Gizzi
P02.089 Characterization of Large
Hemispheric Infarction Seo Hyun Kim,
Hyun-Chan Jang, Do Han Kim, Ji-Yong Lee,
Sung-Soo Lee
P02.090 Vitamin D Deficiency and
Stroke Severity Peterkin Lee Kwen,
Mateen Rahman, Michael Merrill, John
Baker
P02.091 Safety, Feasibility, and
Advantages of Tapering Antihypertensive
Agents in Older Adults Preparing for
Enrollment in a Cognitive Clinical
Trial Siu-Hin Wan, Meaghan Hart, Ihab
Hajjar
P02.092 Effect of Early
Decompressive Hemicraniectomy in
Patients with Malignant Middle Cerebral
Artery Infarction Joyce Lee-Iannotti, Ryan
Armour, Rishi Gupta, Shaye Moskowitz
P02.093 Current Diagnosis and
Management of Cerebral Venous
Thrombosis in Buenos Aires,
Argentina Marcos Fernández Suárez,
María Gaitan, Javier Moschini, Sebastian
Ameriso
P02.094 A Study of Reflex and
Voluntary Cough after Acute Ischemic
Stroke Katie Ward, Kerrie Mills, Michael
Polkey, John Moxham, Lalit Kalra
P02.095 The Role of Indoleamine
2,3-Dioxygenase Activation in the
Etiology of Post-Stroke Depression Amy
Wong, Nathan Herrmann, Gayla Tennen,
Abby Li, Allison Gold, Philip Francis, Robert
Mitchell, Krista Lanctot
P02.096 Leukocyte-Platelet Complex
Formation as a Predictor of Clinical
Outcome in the Acute and Convalescent
Phases of Ischemic Stroke Maria Lukasik,
Grzegorz Dworacki, Joanna Kufel, Cezary
Watala, Bartosz Brzezicha, Wojciech
Kozubski
P02.097 Basilar Artery Occlusion
in Young Adults Julie Khoury, Dan
Capampangan, Nadine Lendzion, David
Dodick, Terri Kiernan, Timothy Ingall, Bart
Demaerschalk, Maria Aguilar
P02.098 Complications in Acute
Stroke (CAST): An Indian Multicentred
Study Jeyaraj Pandian, Arshpreet Kaur,
Rashmi Jyotsna, P. N. Sylaja, Vijaya PV,
K. V. Venkateswaralu, Sajith Sukumaran,
Kurupath Radhakrishnan, Robert Mathew,
Yashpal Singh
P02.099 Sneddon’s Syndrome Without
Antiphospholipid Antibodies: A Report of
26 Cases with Cerebral Angiography El
Mostafa El Alaoui Faris, Mounia Rahmani,
Mouna Maamar, Fatima Boutbib, My
Rachid El Hassani, Mohamed Jiddane,
Chafiq Hicham, Maria Benabdeljlil, Saadia
Aidi
P02.100 Outcomes and Predictive
Prognostic Factors in Patients with
Cerebral Venous and Dural Sinus
Thrombosis: Experience from a Tertiary
Care Hospital in India Mathew Alexander
P02.101 Antihypertensive Medication
Management in Acute Ischemic
Stroke: Evidence from Observational
Data Michael Phipps, Jason Sico, Rani
Desai, Dawn Bravata
P02.102 Ipsilateral Ptosis and
Astasia with Thalamic Infarct: A Case
Report Deepali Jain, Nader Antonios
P02.103 Prevalence and
Clinicoradiological Hallmarks of
Vertebrobasilar Dolichoectasia in Acute
Stroke Patients Ken Ikeda, Hirono Ito,
Yoshikazu Nakamura, Takehisa Hirayama,
Riya Nagata, Konosuke Iwamoto, Ryuta
Sato, Kiyoko Murata, Osamu Kano,
Kiyokazu Kawabe, Yasuo Iwasaki
P02.104 Predictors of Stroke Mortality
in a Nigerian Teaching Hospital Bertha
Ekeh
P02.105 Factors Which Influence the
Speed of Diagnosis of Cerebral Venous
Sinus Thrombosis Keith Sanders, Lisa
Johnston, Todd Ostrow
P02.106 Correlation between Two
Methods of Measuring Transcranial
Doppler Cerebral Vasomotor
Reactivity Michael Katsnelson, Jose
Romano, Iszet Campo-Bustillo, Yosdely
Echevarria, Gustavo Ortiz, Sebastian Koch
P02.107 The Effects of Uric Acid on
Severity and Early Prognosis in Ischemic
Stroke Junhyun Kim, Dae-Il Chang, Sung
Hyuk Heo, Kyung Cheon Chung, Sung Sang
Yoon, Tae-Beom Ahn, Key Chung Park
P02.108 Thalamic Infarction Causing
Astasia-Abasia, Ataxia, and Asterixis:
Clinical and Radiological Features of Two
Cases Yazan Alderazi, James Frey
P02.109 Is Pulmonary Shunting a
Risk Factor for Ischemic Stroke? Case
Series Ahmad Bayrlee, Karen Furie
P02.110 Importance of Hormonal
Medication in Young Women with
Ischemic Stroke Preeti Puntambekar,
Pratik Bhattacharya, Ramesh Madhavan,
Seemant Chaturvedi
Cerebrovascular Disease:
Hemorrhagic Stroke
P02.111 Predictors for Tracheostomy
in ICH Shadi Yaghi, Bappaditya Ray, Salah
Keyrouz
P02.112 Misdiagnosis of Cerebellar
Hemorrhage: Frequency of PseudoGastroenteritis Clinical Presentations to
the Emergency Department Seung-Han
Lee, Victoria Stanton, Richard Rothman,
Barbara Crain, Robert Wityk, David
Newman-Toker
P02.113 Factor VII for Intracerebral
Hemorrhage: A Systematic Review and
Meta-Analysis Ayman Daoud, Aninda
Acharya, Randall Edgell, Eliahu Feen,
Paisith Piriyawat, Nirav Vora, Salvador
Cruz-Flores
P02.114 An Unusual Acute
Development of Superficial
Siderosis Andrew Gomez-Vargas, Chidam
Yegappan
P02.115 Enlargement of a Distal
Part of the Optic Nerve Sheath in
Hyperacute Stage of Intracerebral
Hemorrhage Roman Herzig, David
Skoloudik, Tana Fadrna, Michal Bar,
Pavel Hradilek, Martin Roubec, Monika
Jelinkova, Daniel Sanak, Michal Kral, Jana
Chmelova, Miroslav Herman, Katerina
Langova, Petr Kanovsky
P02.116 Risk Factors and Intra
Cerebral Hemorrhage in African American
Population Rajesh Gupta, Mohankumar
Kurukumbi, Annapurni Jayam-Trouth
P02.117 Does Variance in Blood
Pressure Parameters Within 24 Hours
Predict Early Mortality in Patients with
Intracerebral Hemorrhage? Latha Stead,
Minal Jain, Neeraja Yerragondu, Anunaya
Jain, Dipti Agarwal, Balavani Palamari,
Veena Manivannan, Babak Jahromi, Wyatt
Decker
P02.118 The MCA Arrow Sign in
Subarachnoid Hemorrhage Jay Joshi,
Manisha Gupte, Sayona John, Shyam
Prabhakaran, Vivien Lee
P02.119 Does Transfer Time to
a Tertiary Care Center Play a Role in
Predicting Mortality in Intracranial
Hemorrhage? Ahmed Hassan, Ivan Rocha
Ferreria da Silva, Bichun Ouyang, Richard
Temes, Vivien Lee, Shyam Prabhakaran,
Sayona John
P02.120 Early Blood Pressure
Hemodynamics and Their Association
with Intra-Ventricular Extension of
Intracerebral Hemorrhage Minal Jain,
Anunaya Jain, Neeraja Yerragondu, Dipti
Agarwal, Veena Manivannan, Balavani
Palamari, Babak Jahromi, Wyatt Decker,
Latha Stead
P02.121 Spontaneous ICH in Chronic
Daily Alcohol Users Gayle Pletsch, Sheryl
Martin-Schild
P02.122 Systemic Blood Pressure and
Occurrence of Intracerebral Hemorrhage
in Patients with Cerebral Venous
Thrombosis Gaurav Guliani, Muna Irfan,
Haitham Hussein, M. Fareed Suri, Adnan
Qureshi
Poster Session II
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
Neural Repair and
Rehabilitation: Clinical
P02.123 Diabetic Mean Fasting
Plasma Glucose Levels and Stroke
Rehabilitation Outcome Susanna
Shepper, Rolf Martin, Mery Elashvili, Mike
Reding
P02.124 Quantifying Neural Cell
Birth in the Pediatric Spinal Cord Daniel
Becker, Yun Qu, John McDonald
P02.125 A New Marker for
Neuroinflammation in Acute Adult
Traumatic Brain Injury Pavel Tishuk,
Timothy Cunningham, Hafiz Khan, Nizar
Souayah
P02.126 Importance of Raising
Awareness about Head Injuries in
Recreational Sports Sandra Morovic,
Valentina Matijevic, Vida Demarin
P02.127 Cognitive Training and Long
-Term Follow-Up in Patients with Mild
Cognitive Impairment Veronica Villar,
Galeno Rojas, Paula Harris, Cecilia Serrano,
Carol Dillon, Monica Iturry, Leonardo
Bartoloni, Ricardo Allegri
P02.128 Sensorimotor Cortical
Changes after Botulinum Toxin Therapy
for Cervical Dystonia: A Functional MRI
Study Petr Hluštík, Robert Opavský, Pavel
Otruba, Roman Herzig, Petr Kanovský
P02.129 Effectiveness of Virtual
Reality Using Wii Gaming Technology in
STroke Rehabilitation (EVREST): Results
from a Randomized Clinical Trial Gustavo
Saposnik, Mark Bayley, Muhammad
Mamdani, Judith Hall, Kevin Thorpe,
Jackeline Willems, Donna Cheung, Bill
McIlroy, Robert Teasell, Leonardo Cohen
P02.130 Fibrocartilaginous Embolism:
Clinical Features and Outcomes Priya
Monrad, Farrah Mateen, Andrea Leep
Hunderfund, Eric Sorenson
P02.131 The Adverse Effect of
Post-Stroke Spasticity on Three-Month
Functional Outcomes Samir Belagaje,
Christopher Lindsell, Kathy Alwell, Charles
Moomaw, Kari Dunning, Dawn Kleindorfer,
Daniel Woo, Matthew Flaherty, Opeolu
Adeoye, Pooja Khatri, Joseph Broderick,
Brett Kissela
P02.132 Combat Veterans with Mild
TBI Due to Explosions Have Persisting
Neurological Deficits Robert Ruff,
Suzanne Ruff, Xiao-Feng Wang
P02.133 Frequency of Visual Field
Defects in Neuro-Rehabilitation Seema
Khurana, Iszet Campo-Bustillo, Jose
Romano
P02.134 Efficacy of NT 201 (Botulinum
Neurotoxin Type A, Free from Complexing
Proteins) in the Treatment of Patients with
Upper Limb Spasticity Petr Kanovsky,
Michael Barnes, Irena Pulte, Petra
Minnasch, Susanne Grafe
P02.135 Diagnosing Adult
Polyglucosan Body Disease: A
Case Report and Review of the
Literature Eduardo Garcia, Marybeth
Toran, Karen Dudich, Shakti Ramkissoon,
Sandro Santagata, Avraham Almozlino
P02.136 Efficacy and Safety of
Repeated NT 201 (Botulinum Neurotoxin
Type A Free from Complexing Proteins)
Treatments for up to 89 Weeks in
Upper Limb Post-Stroke Spasticity Petr
Kanovsky, Irena Pulte, Georg Comes,
Susanne Grafe
P02.137 Falls in People with Multiple
Sclerosis: Frequent and Correlated
with Balance Confidence and Disease
Severity Michelle Cameron, Dennis
Bourdette
P02.138 Scopolamine and Ketamine
Modelling of Neurocognitive Deficits:
Clinical Trials Applications Denise
Milovan, Myroslava Romach, Edward
Sellers
Multiple Sclerosis and Related
Diseases: Clinical Research/
Biomarkers
P02.139 Angiotensin II Type 1
Receptor Antibodies in Multiple
Sclerosis: A New Biomarker for Disease
Activity? Alexandra Schröder, Harald
Heidecke, De-Hyung Lee, Dominik Muller,
Johannes Stegbauer, Ralf Gold, Ralf Linker
P02.140 Immunological Factors
That Condition an Aggressive Multiple
Sclerosis Course Luisa Villar, Mercedes
Espiño, Ernesto Roldan, Maria Sadaba,
Gonzalez-Porque Pedro, Jose AlvarezCermeño
P02.141 Predictors of Response to
First-Line Disease-Modifying Therapies
in Relapsing-Remitting Multiple
Sclerosis Tamara Castillo-Trivino, Alberto
Gajofatto, Peter Bacchetti, Emmanuelle
Waubant
P02.142 Functional Bioenergetic
Measure of CD4 +-Cellular
Immunocompetence in Monoclonal
Antibody-Associated Progressive
Multifocal Leukoencephalopathy Aiden
Haghikia, Bartosz Pula, Moritz Perrech,
Sabrina Ruhrmann, Anja Potthoff, Norbert
Brockmeyer, Susan Goelz, Hans Lindå,
Tor-Bjorn Käll, Tomas Olsson, Ralf Gold,
Andrew Chan
P02.143 Lower Serum Creatinine
Levels Correlate with Blood-Brain
Barrier Dysfunction in Multiple Sclerosis
Patients Gordana Toncev, Evica Dincic,
Slavco Toncev
P02.144 The North-South MS
Prevalence Gradient in Ireland in Relation
to Vitamin D Status Roisin Lonergan,
Katie Kinsella, Patricia Fitzpatrick,
Marguerite Duggan, Sinead Jordan,
Ciaran Dunne, Richard Hagan, Jennifer
Brady, Barbara Murray, Malachi McKenna,
Michael Hutchinson, Niall Tubridy
P02.145 T-Cell Responses to
Aquaporin-4 in Neuromyelitis Optica
(NMO) Livnat Brill, Dimitrios Karussis,
Panayiota Petrou, Adi Vaknin-Dembinsky
P02.146 Frequency and Prognostic
Value of NMO-IgG Seropositivity in
Isolated Optic Neuritis Marcelo Matiello,
Andrew McKeon, Sean Pittock, Brian
Weinshenker
Multiple Sclerosis and Related
Diseases: Clinical Research/
Quality of Life
P02.158 Attitudes about PhysicianAssisted Suicide in Patients with Multiple
Sclerosis Louisa Lavy, Alyssa Bamer,
James Bowen, George Kraft
P02.147 Rituximab in Secondary
Progressive Multiple Sclerosis— OneYear Follow-Up Carolina Ionete, Biljana
Beretich, Peter Riskind
P02.159 Developing an Instrument
To Assess Caregiver Quality of Life in
Multiple Sclerosis (CAREQOL-MS) Julián
Benito-León, Jesús Rivera-Navarro, Angel
Luis Guerrero, Virginia De las Heras, José
Balseiro, Elena Rodríguez, Mireia Belló
P02.148 Clinical Markers of
Therapeutic Response and the Long-Term
Impact of Glatiramer Acetate on RelapseInduced Disability Adriana Carrá, Patricia
Onaha, Galeno Rojas, Gastón ImhoffJullier, Carlos Vrech
P02.160 Quality of Life in Multiple
Sclerosis: Exploring Transcultural
Differences Efthymia Gavala, Lampros
Samartzis, Thomas Thomaides, Julie
Webster, Helen Willis, Achilleas Aspiotis,
Yannis Zoukos
P02.149 Potential Factors Influencing
Vitamin D Metabolism in Multiple
Sclerosis Patients Jodie Burton
P02.161 Longitudinal Changes in
Depression, Fatigue, Quality of Life,
and Social Functioning in Patients with
Relapsing-Remitting Multiple Sclerosis
Receiving Subcutaneous Interferon
Beta-1a in the COGIMUS (COGnitive
Impairment in MUltiple Sclerosis)
Study Francesco Patti, Maria Amato,
Maria Trojano, S. Bastianello, Maria
Tola, Orietta Picconi, Sabina Cilia, Diego
Centonze, Claudio Gasperini, Salvatore
Cottone, Luigi Grimaldi
P02.150 Autoimmune Brainstem and
Cerebellar Encephalitis with New Auto
Antibody Emma Burbank, Michael Kruer,
Edward Kim, Grazyna Adamus, Michele
Mass
P02.151 Serum Levels of the
Phosphorylated Neurofilament Heavy
Chain Biomarker of Axonal Injury is
Reduced Five Years after Treatment by
Intravenous Methylprednisolone in the
Optic Neuritis Treatment Trial Joshua
Pasol, William Feuer, Gerry Shaw, John
Guy
P02.152 CSF Oligoclonal Bands
in Multiple Sclerosis Patients: Worse
Prognosis? Liliana Patrucco, Liliana
Patrucco, Juan Rojas, Edgardo Cristiano
P02.153 Prior Suggestive Symptoms
in Third of Patients Consulting for a
“First” Demyelinating Event Olivier Gout,
Christine Lebrun Frenay, Pierre Labauge,
Emmanuelle Le Page, Pierre Clavelou,
Sylvie Allouche
P02.154 Severe Multiple Sclerosis
Exacerbation during the Third Trimester of
Pregnancy Presenting with Tumefactive
MRI Lesions Zeenat Jaisani, David
Hojnacki, Bianca Guttman
P02.155 The Cellular Immune
Response Against Epstein-Barr Virus in
Multiple Sclerosis and Cross-Reactivity
with Brain Antigens J. Lindsey, Landon
Hatfield
P02.156 IL-23/IL-1b Ratio as a
Biomarker of Disease Activity in Multiple
Sclerosis Mathieu Vokaer, Francoise
Villee, Kaoutar El Hafsi, Patrick Stordeur
P02.157 Overlapping Molecular
Mechanisms of Protection during
Pregnancy and Disease-Modifying
Therapies in Patients with Multiple
Sclerosis Antonio Bertolotto, Nicole
Navone, Simona Malucchi, Paola
Valentino, Alessia di Sapio, Simona
Perga, Marco Capobianco, Annalisa
Pulizzi, Fabiana Marnetto, Marzia Caldano,
Francesca Gilli
P02.162 Establishing a Quality of Life
Scale Related to Relapses in Multiple
Sclerosis Antoine Baroin, Gilles Chopard,
Hassna Mokadym, Annick Lavier, Eric
Berger, Lucien Rumbach, Nathalie Rude
P02.163 Effects of Meditation on Pain
and Quality of Life in Multiple Sclerosis
and Polyneuropathy: A Controlled
Study Jinny Tavee, Mary Rensel, Sarah
Pope Planchon, Lael Stone
P02.164 Effect of Natalizumab on
Disease-Specific Quality of Life after One
Year of Natalizumab Treatment Siddhesh
Kamat, Likun Hou, Sonalee Agarwal,
Krithika Rajagopalan, Judith Stephenson
P02.165 Quality of Life in Benign
Multiple Sclerosis Line Hviid, Bonnie
Glanz, Brian Healy, David Rintell, Tanuja
Chitnis, Howard Weiner
P02.166 Improvement in HealthRelated Quality of Life in Multiple
Sclerosis Patients Receiving Natalizumab
in the United States Likun Hou, Judith
Stephenson, Krithika Rajagopalan, Sonalee
Agarwal, Siddhesh Kamat
P02.167 Comorbidity Is Associated
with Greater Decrements in Quality of Life
over Two Years in MS Ruth-Ann Marrie,
Ralph Horwitz, Gary Cutter, Tuula Tyry,
Timothy Vollmer
49
Poster Session II
Multiple Sclerosis and
Related Diseases: Clinical
Research/Quality of Life and
Neuropsychology
Multiple Sclerosis and Related
Diseases: Neuromyelitis Optica,
Multiple Sclerosis Differential
Diagnosis and Clinical Research
P02.168 Perceived Cognitive
Impairment in Multiple Sclerosis
Predicts Quality of Life Independently of
Depression Lampros Samartzis, Efthymia
Gavala, Yannis Zoukos, Julie Webster,
Helen Willis, Achilleas Aspiotis, Thomas
Thomaides
P02.178 Increased CSF Levels of
B Cells Activating Factor (BAFF) in
Neuromyelitis Optica (NMO) Adi VakninDebinsky, Livnat Brill, Oded Abramsky,
Dimitrios Karussis
P02.169 Improvement in EDSS
Corresponds with Improvement in
Quality of Life in Patients with Multiple
Sclerosis Fredrick Munschauer, Gavin
Giovannoni, Deborah Miller, Richard
Rudick, Paul O’Connor, Chris Polman, Amy
Pace, Richard Kim
P02.170 Longitudinal MRI Assessment
of Quality of Life and Disability in Early
Treated Relapsing- Remitting Multiple
Sclerosis Mikael Cohen, Christine Lebrun
Frenay, Dominique Aufauvre, Stephane
Chanalet, Christelle Filleau, William Camu,
Pierre Thomas, Gregoire Malandain, Pierre
Clavelou
P02.171 Cognitive Resilience
in Relapsing-Remitting Multiple
Sclerosis Anat Achiron, Yermi Harel, Mor
Lavie, Ely Simon, Glen Doniger
P02.172 Specific Impairments in
the Recognition of Emotional Facial
Expressions in Multiple Sclerosis
(MS) Bruno Lenne, Jean-Louis Nandrino,
Henrique Sequeira, Philippe Gallois, Patrick
Hautecoeur
P02.173 Physical Comorbidities Are
Associated with an Increased Risk of
Depression in Multiple Sclerosis RuthAnn Marrie, Gary Cutter, Tuula Tyry,
Timothy Vollmer
P02.174 Relationship between
Cognitive Performance and Neurological
Disability in Early MS Pasquale
Calabrese, Iris Katharina Penner, Mark
Freedman, Chris Polman, Gilles Edan,
Hans-Peter Hartung, David Miller, Xavier
Montalban, Frederik Barkhof, Vivian Lanius,
Rupert Sandbrink, Christoph Pohl, Brigitte
Stemper, Ludwig Kappos
P02.175 Quantifying the Effects of
Acute Relapses on Neuropsychological
Status in Multiple Sclerosis
Patients Sarah Morrow, Stephanie
Jurgensen, Dominick Paes, Christophe
Hotermans, Ralph Benedict
P02.176 Higher Cognitively
Functioning Relapsing-Remitting
Multiple Sclerosis Patients Have a
More Specific Pattern of Impairment on
Neuropsychological Testing Sandeep
Vaishnavi, John Barkenbus, C. Gualtieri
P02.177 Predicting Cognitive Decline
in Multiple Sclerosis: Implications for
Clinical Trial Design Stephen Rao, Jar-Chi
Lee, Lauren Strober, Jack Simon, Elizabeth
Fisher, Richard Rudick
50
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P02.179 Intractable Vomiting
as the Initial Presentation of
Autoimmune Aquaporin-4 Water
Channelopathy Metha Apiwattanakul,
Marcelo Matiello, Brian Weinshenker,
Claudia Lucchinetti, Andrew McKeon,
Vanda Lennon, Adam Carpenter, Sean
Pittock
P02.180 Effects of Aquaporin4
Antibody in Primary Human Astrocytes
in Culture: A Living Cell Imaging
Analysis Shuhei Nishiyama, Tatsuro
Misu, Rina Takano, Toshiyuki Takahashi,
Ichiro Nakashima, Kazuo Fujihara, Yasuto
Itoyama
P02.181 Is NMO a Paraneoplastic
Marker? Daniel Ontaneda, Welf Saupe,
Robert Fox
P02.182 Chronic Lymphocytic
Inflammation with Pontine Perivascular
Enhancement Responsive to Steroid
(CLIPPERS) Mark Keegan, Jan Debruyne,
Karl Krecke, Caterina Giannini, Jelle
van den Ameele, Veerle De Herdt,
Andrew McKeon, Robert Fealey, Brian
Weinshenker, Allen Aksamit, Elizabeth
Shuster, Bruce Krueger, Sean Pittock
P02.183 Can the Increase of T-Helper
17 Lymphocyte Percentage in Peripheral
Blood Anticipate a Relapse in Relapsing
Remitting Multiple Sclerosis? Luca
Durelli, Marinella Clerico, Simona Rolla,
Giulia Contessa, Stefania De Mercanti,
Antonio Uccelli, Mauro Zaffaroni, Paola
Cavalla, Luciano Rinaldi, Cristoforo Comi,
Roberto Cavallo, Luisa Sosso, Francesco
Novelli
P02.184 IL-27 Mediates Glatiramer
Acetate Effect on Antigen Presenting
Cells in Multiple Sclerosis Reuben
Valenzuela, Kouichi Ito, Suhayl Jalbut
P02.185 Differential Diagnosis
of Adult Leucoencephalopathies:
Validation of MR Criteria in a Series of 75
Patients Léorah Freeman, Ayman Tourbah,
Damien Galanaud, Caroline Papeix,
Benjamin Granger, Hugues Chabriat, Pierre
Labauge, Frederic Sedel
P02.186 Consistent Efficacy of
Cladribine Tablets Across Multiple
Sclerosis and Patient Characteristics,
in the Double-Blind, 96-Week CLARITY
Study Kottil Rammohan, Giancarlo Comi,
Stuart Cook, Gavin Giovannoni, Peter
Rieckmann, Per Soelberg Sørensen, Patrick
Vermersch, Peter Chang, Anthony Hamlett,
Rehan Verjee, Bruno Musch, Steven
Greenberg
P02.187 Mitochondrial Disease
Manifesting as Multiple Sclerosis:
A Report of Two Patients with Optic
Neuropathy, Brain White Matter
Abnormalities, Cerebrospinal Fluid
Oligoclonal Bands, and Novel POLG1
Variations Andoni Echaniz-Laguna, M.
Chassagne, Michel Mohr, P. Clerc-Renaud,
Christine Tranchant, Benedicte Mousson
de Camaret
Multiple Sclerosis and Related
Diseases: Neuromyelitis Optica
P02.188 Increased Serum Matrix
Metalloproteinase-9 in Neuromyelitis
Optica; Implication of Disruption of BloodBrain Barrier Takafumi Hosokawa, Hideto
Nakajima, Yoshimitsu Doi, Masakazu
Sugino, Fumiharu Kimura, Toshiaki
Hanafusa, Toshiyuki Takahashi
P02.189 Neuromyelitis Optica in
France: A Multicenter Study of 125
Patients Nicolas Collongues, Romain
Marignier, Helene Zephir, Anne Caroline
Papeix, Frederic Blanc, Cecile Ritleng,
Maia Tchikviladze, Olivier Outteryck,
Sandra Vukusic, Marie Fleury, Bertrand
Fontaine, David Brassat, Michel Clanet,
Mathieu Milh, Jean Pelletier , Bertrand
Audoin, Aurelie Ruet, Christine Lebrun
Frenay, Eric Thouvenot, William Camu,
Marc Debouverie, Alain Creange, Thibault
Moreau, Pierre Labauge, Giovanni
Castelnovo, Gilles Edan, Emmanuelle
Le Page, Gilles Defer, Bruno Barroso,
Olivier Heinzlef , Olivier Gout, Diana
Rodriguez, Sandrine Wiertlewski, David
Laplaud, Florent Borgel, Patricia Tourniaire,
Jerome Grimaud, Bruno Brochet, Patrick
Vermersch, Christian Confavreux, Jerome
De Seze
P02.190 Predictive Role of
Neuromyelitis Optica (NMO)-IgG in
Isolated Optic Neuritis and Isolated
Myelitis in the Diagnosis of NMO Carla
Tortorella, Elisabetta Di Monte, Maddalena
Ruggieri, Maria Pia Amato, Angelo Ghezzi,
Alessandra Lugaresi, Francesco Patti,
Patrizia Sola, Giovanni Bosco Zimatore,
Vita Direnzo, Pietro Iaffaldano, Mariangela
Mastrapasqua, Paolo Livrea, Maria Trojano
P02.191 Anti-Aquaporin 4 Antibodies
Increase Transiently After Rituximab
Treatment in Neuromyelitis Optica with
an Association of B Cell Activating
Factor Ichiro Nakashima, Toshiyuki
Takahashi, Bruce Cree, Chihiro Suzuki,
Kazuo Fujihara, Yasuto Itoyama, Amit BarOr
P02.192 Unconventional Spinal
Cord and Brain MRI in Neuromyelitis
Optica Jerome de Seze, Nicolas
Collongues, Jeremy Jeantroux, Francois
Rousseau, Lin Xiu, Frederic Blanc, Marie
Fleury, Jean Paul Armspach, Izzie Namer,
Stephane Kremer
P02.193 Painful Tonic Spasm in
Neuromyelitis Optica Yoshiki Takai, Ichiro
Nakashima, Tatsuro Misu, Kazuo Fujihara,
Yasuto Itoyama
P02.194 Interferon-β1b Increases Th2
Response in Neuromyelitis Optica Hideto
Nakajima, Takafumi Hosokawa, Masakazu
Sugino, Fumiharu Kimura, Toshiaki
Hanafusa, Toshiyuki Takahashi
P02.195 Chitinase Effects on Immune
Cell Responses in Multiple Sclerosis and
Neuromyelitis Optica Jorge Correale,
Marcela Fiol
P02.196 Neuropsychiatric
Presentation of Neuromyelitis Optica
Spectrum Disorders Etsuji Saji, Yasuko
Toyoshima, Kaori Yanagawa, Masatoyo
Nishizawa, Izumi Kawachi
P02.197 Comparison of Type I
Interferon Activity in Patients with
Systemic Lupus and Neuromyelitis Optica
Xuan Feng, Mounica Yanamandala, Addie
Hill, Timothy Niewold, Anthony Reder,
Adil Javed
P02.198 Tumefactive Supraspinal
Variant of Severe Neuromyelitis
Optica De-Hyung Lee, Ralf Linker, Carsten
Lukas, Imke Metz, Achim Berthele, Brueck
Wolfgang, Christine Stadelmann, Ralf
Gold, Alexandra Schroeder
P02.199 Mithocondrial DNA Signature
in Chronic Inflammatory Diseases of
the Central Nervous System Valentina
Durastanti, Filippo Menolascina, Brunella
Caronti, Francesco Marincola, Ena Wang,
Lorenzo Uccellini, Enrico Millefiorini,
Antonio Cortese, Alessandro Monaco
P02.200 Hiccup, Nausea, and
Vomiting: Neuromyelitis Optica in a
Teenage Girl Joanne Riphagen, Piet
Modderman, Aad Verrips
P02.201 Coexistence of Anti-NMO
IgG and Anti-GFAP in Neuromyelitis
Optica Ioanna Chatzi, Haralambos
Alexopoulos, Athanasia Alexoudi, Dimitrios
Tzortzis, Georgia Dokou, Panagiota
Filippakopoulou, Marinos Dalakas,
Clementine Karageorgiou
P02.202 Evaluation of Health-Related
Quality of Life, Fatigue and Depression
in Neuromyelitis Optica Jean-Baptiste
Chanson, Hélíne Zéphir, Nicolas
Collongues, Olivier Outteryck, Frédéric
Blanc, Marie Fleury, Patrick Vermersch,
Jérôme de Seze
P02.203 Early Diagnostic Biomarker
in Patients with First Neurological
Manifestation Suggestive of Multiple
Sclerosis or Neuromyelitis Optica Rita
Vadalà, Antonio Cortese, Brunella Caronti,
Mauro De Angelis, Alberto Pierallini, Enrico
Millefiorini, Elisabetta Giugni, Valentina
Durastanti
P02.204 Severe Relapse Despite
B-Cell Depletion in Neuromyelitis
Optica Claire Riley, Mark Tullman
P02.205 Fulminant Neuromyelitis
Optica Associated with Human Papilloma
Virus Vaccination Til Menge, Bruce Cree,
Andreas Saleh, Orhan Aktas, Hans-Peter
Hartung, Axel Methner, Bernd Kieseier
Poster Session II
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P02.206 Case-Report: High-Dose
Immunoablation with Autologous Stem
Cells Transplantation in Neuromyelitis
Optica Eva Krasulova, David Pohlreich,
Blanka Vackova, Marek Trneny, Manuela
Vaneckova, Zdenek Seidl, Petra Nytrova,
Helena Mareckova, Dana Horakova, Eva
Havrdova
P02.207 Antiaquaporin 4 Antibodies
Detection in Neuromyelitis Optica (NMO)
Patients Andres Villa, Pablo Mannucci,
Luciana Melamud, Orlando Garcea
Clinical Epilepsy
P02.208 Coverage of Epilepsy and
Driving in US Newspapers Srijana Zarkou,
Joseph Drazkowski, Katherine Noe,
Matthew Hoerth, Joseph Sirven
P02.209 Perceptions of Epilepsy
at Mulago Hospital in Kampala,
Uganda Jeffrey Bigelow
P02.210 Treatment Continuation
Patterns, Resource Use, and Costs Among
Patients with Epilepsy in a Medicaid
Population Jamie Forlenza, Stephen
Johnston, Laurie Costa, Greg Lenhart, Emily
Durden, Steve Ascher, Augusto Grinspan
P02.211 The Epilepsy Treatment
Gap in the Ecuadorian Amazon Patricio
Espinosa, Aaron Berkowitz, Nicole Falcone,
Denise Dvorquez, Kathleen Principe,
William Principe, Melissa Murphy,
Christopher Shanahan, Ann Kao, Dominic
Fee, Karin Swartz, Blanca Vasquez, Sydney
Cash
P02.212 Assessing the Value of a
Medical Home for Children and Youth with
Epilepsy in Medically Underserved and
Rural Populations Paul Levisohn, Deborah
McGruder
P02.213 A Study on the Change of
Quality of Life in People with Epilepsy
after Two-Year Follow-Up Zhen Hong,
Dehao Zhao, Peimin Yu, Guoxing Zhu
P02.214 Do Mood Instability
Symptoms in Epilepsy Represent Formal
Bipolar Disorder? Connie Lau, Alan
Ettinger, Sandra Hamberger, Kristina
Fanning, Michael Reed
P02.215 Health Anxiety and Somatic
Vigilance in Epilepsy and Non-Epileptic
Behavioral Spells Danielle Koby, Cindy
Nelson, Max Trenerry, Gregory Worrell
P02.216 Oro-Dental and Maxillofacial
Trauma in Epilepsy: Our Experience at a
Tertiary Hospital in Lagos Francis Ojini,
Richard Adewole, Mustapha Danesi
P02.217 Spinal Cord Compression: A
Potential Risk in Individuals with Mental
Retardation and Epilepsy Sonia Lal,
Raveen Deol, Venkat Ramani
P02.218 Rapid Screening for Anxiety
and Major Depressive Disorders and
Suicidal Risk in an Outpatient Neurology
Clinic Andres Kanner, Erica Sanchez,
Hilary Kanner
P02.219 Cognitive Function
Assessment in Patients with Epilepsy
Using Community Screening Interview
for Dementia Taofiki Sunmonu, Olubunmi
Ogunrin, Morenikeji Komolafe, Adesola
Ogunniyi
P02.220 Fatigue in People with
Epilepsy. The Validation of the Fatigue
Symptom Inventory, the Fatigue
Assessment Instrument, and the
Fatigue Severity Scale in Patients with
Epilepsy Jose Tellez Zenteno, Lizbeth
Hernandez-Ronquillo, Moien-Afshari
Farzad, Britz Jan, Knox Katherine
P02.221 MERRF: Clinical Features,
Muscle Biopsy, and Molecular
Genetics Paulo Lorenzoni, Rosana Scola,
Claudia Kay, Raquel Arndt, Carlos Silvado,
Lineu Werneck
P02.222 Frequency and Correlates of
Perceived Stigma in a Nigerian Epilepsy
Population Michael Fawale, Mayowa
Owolabi, Adesola Ogunniyi
P02.223 Early Seizures after
Discharge from a Seizure Monitoring
Unit Sunil Goli, Suzanne Miller, Edward
Faught
P02.224 Effect of Pregnancy on
Seizure Frequency in Women with
Epilepsy Angela La Neve, Marzia
Plantamura, Giovanni Boero, Teresa
Francavilla, Giuseppe Pontrelli, Paolo
Lamberti, Giancarlo Logroscino
P02.225 Inadequate Vitamin D Levels
in Pediatric Patients with Epilepsy Leon
Weinstock, Raya Wehbeh, Barbara Teter,
Bianca Weinstock-Guttman
P02.226 Recurrent Status Epilepticus
as the Primary Neurological Manifestation
of Cerebral Autosomal Dominant
Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL): A Case
Report Catherine Ikard, James Schmidley,
Naim Haddad
P02.227 Mycophenolate Mofetil
Responsive Anti-Glutamic Acid
Decarboxylase Antibody Associated
Limbic Encephalitis Shiv Saidha, Sinead
Murphy, Aoife Ronayne, Peter McCarthy,
Michael Hennessy, Timothy Counihan
Anterior Horn: Clinical Studies
P02.228 Computerized Dynamic
Posturography (CDP) Identifies an
Early Subclinical Balance Disorder in
Amyotrophic Lateral Sclerosis (ALS)
Patients Not Diagnosed by Clinical
Balance Assessment Mohammed Sanjak,
Mark Hirsch, Kimberly Lang, Kerry Duffy,
Amber Ward, Jordan Lyerly, Jaime Shue,
Priscilla Russo, Urvi Desai, Elena Bravver,
Benjamin Brooks
P02.229 Detecting Disordered Sleep in
Patients with ALS: Results of a 10-Minute
Targeted Sleep Questionnaire Hans
Katzberg, Adam Seligman, Nancy Yuan,
Charles Cho, Jonathan Katz, Robert Miller,
Yuen So
P02.230 Validation of a Shorter ALSSpecific Quality of Life Instrument: The
ALSSQOL-R Zachary Simmons, Stephanie
Felgoise, Jamie Rodriguez, Susan Walsh,
Barbara Bremer, Helen Stephens
P02.241 Baseline and Longitudinal
Perspectives on Motor Cortex Grey
and White Matter in ALS Kevin Yang,
Christopher Hanstock, Myrlene Gee,
Sanjay Kalra
P02.231 Prospective Study of
Depression, ALS-Related Symptoms, and
Research Enrollment Nazem Atassi, Merit
Cudkowicz
P02.242 Slow Saccades in BulbarOnset Amyotrophic Lateral Sclerosis
(ALS) Colette Donaghy, Ralph Pinnock,
Raeburn Forbes, Chris Cardwell, Orla
Hardiman, Victor Patterson, R. McGivern, J.
Gibson
P02.232 Utility of Forced Expiratory
Volume in Six Seconds for Assessment
of Respiratory Function in Patients with
Amyotrophic Lateral Sclerosis Margaret
Walker, Susan Gronka, Sharon Usher,
Nazem Atassi, Joanne Wuu, Mary Lou
Watson, Jeremy Shefner, Merit Cudkowicz,
Michael Benatar
P02.233 Plasma Levels of
Neurofilament Heavy Subunit (NF-H) Are
Increased in ALS Patients; Correlation
with Site of Onset and Survival in Patients
at Two Centers in Evaluation of Plasma
NF-H as a Potential ALS Biomarker Kevin
Boylan, Jonathan Glass, Cui Yang, Julia
Crook, Michael Heckman, Kelly Crystal,
Meraida Polak, Gerry Shaw
P02.234 Effects of Noninvasive
Ventilation on Sleep Outcomes in Patients
with Amyotrophic Lateral Sclerosis Hans
Katzberg, Adam Seligman, Nancy Yuan,
Charles Cho, Jonathan Katz, Robert Miller,
Yuen So
P02.235 Muscle Ultrasound Quantifies
Reduction of Muscle Thickness over Time
in ALS Patients Christopher Lee, Amanda
Peltier, Peter Donofrio
P02.236 Using Eye Movements
to Distinguish Amyotrophic Lateral
Sclerosis (ALS) from Its Variants and
Mimics Colette Donaghy, Matthew
Thurtell, Erik Pioro, R. Leigh
P02.237 The Prevalence and Effect of
Diabetes on the Course of Amyotrophic
Lateral Sclerosis Zaid Al-Qudah, Lubna
Mehyar, Natalia Krivitskaya, Khan Hafiz,
Shahanara Islam, Nazsa Baker, Nizar
Souayah
P02.238 Evidence for a Decreased
Activity of the Resting State Motor
Network in Patients with ALS Massimo
Filippi, Martina Absinta, Federica
Agosta, Maria Rocca, Paola Valsasina,
Stefania Sala, Nilo Riva, Alessandro
Prelle, Domenico Caputo, Michele Perini,
Raffaella Fazio, Giancarlo Comi
P02.239 Cerebrospinal Fluid and
Serum Neurofilament Light Chain
Levels in ALS Patients Isabella
Simone, Maddalena Ruggieri, Rosanna
Tortelli, Eustachio D’Errico, Antonio Leo,
Mariangela Mastrapasqua, Rosaria Leante,
Rosa Capozzo, Paolo Livrea, Giancarlo
Logroscino
P02.240 15-30 Hz Intermuscular
Coherence: A Novel Biomarker of
Upper Motor Neurone Dysfunction in
Amyotrophic Lateral Sclerosis Karen
Fisher, Mark Baker, Boubker Zaaimi,
Stephan Jaiser, Tim Williams, Stuart Baker
P02.243 Assessment of CSF
Biomarkers in a Pilot Study of Memantine
in ALS Todd Levine, Robert Bowser,
Nicole Hank, David Saperstein
P02.244 Nutritional Prognostic
Factors in Amyotrophic Lateral
Sclerosis Johannes Dorst, Albert Ludolph,
Corinna Hendrich, Peter Kuehnlein, AnneDorte Sperfeld
P02.245 Shoulder Pain in ALS Doreen
Ho, Robin Ruthazer, James Russell
P02.246 Oral Secretion Scale
(OSS) Score in Amyotrophic Lateral
Sclerosis (ALS) Patients Is Associated
with Tolerance of Noninvasive Positive
Pressure Ventilation (NPPV), Need
for Hospice or Transition to Tracheal
Positive Pressure Ventilation (TPPV)
and Survival Pamela Cazzolli, Benjamin
Brooks, Joseph Lewarski, Douglas McKim,
Robert Chatburn
Muscle Disease/Neuromuscular
Junction: Mitochondrial
Disorders: Clinical
P02.247 Maternally Inherited LimbGirdle Myopathy with Neck Extensor and
Cardiopulmonary Involvement Resulting
from a Mitochondrial tRNA Leu3302 Point
Mutation Annabel Wang, Mariella Simon,
Douglas Wallace, Tahseen Mozaffar
P02.248 A Novel Mitochondrial
tRNAIle Mutation Uniquely Affecting the
Variable Loop in a Patient with Chronic
Progressive External Ophthalmoplegia
(CPEO) Andres Berardo, Jorida çoku,
Bulent Kurt, Salvatore Di Mauro, Michio
Hirano
P02.249 Clinical and Molecular
Characterization of the MERRF Mutation
A8344G in a Family without CNS
Involvement Veronica Crugnola, Lorenzo
Peverelli, Andreina Bordoni, Patrizia
Ciscato, Diego Spagnoli, Nereo Bresolin,
Giacomo Comi, Maurizio Moggio, Monica
Sciacco
P02.250 Diverse Clinical Presentations
in Adults with Carnitine Deficiency Yitao
Ma, Douglas Laske, Daniel Brown, Jin Luo
P02.251 Mitoshondrial Myopathy,
a Rare or a Common Human Disease?
Based on Nationwide MELAS Cohort
Study Yasutoshi Koga, Shu-ichi Yastuga,
Nataliya Povalko, Toyojiro Mastuishi
P02.252 Cardiofaciocutaneous
Syndrome Due to BRAF Mutation Causes
CoQ10 Myopathy Paul Golumbek, Alan
Pestronk, Robert Heuckeroth
51
Poster Session II
P02.253 Relapsing Encephalopathy
Associated with Coenzyme Q10
Deficiency R. Brian Sommerville, Anne
Cross, Alan Pestronk
P02.254 A Prospective Randomized
Double-Blind and Placebo-Controlled
Phase II Trial— Effect of CoQ 10
on Statin-Induced Mitochondrial
Dysfunction Naganand Sripathi, Kavita
Grover, Lester Kobylak, Mei Lu, Lonni
Schultz, Christine Geauvreau, Georgirene
Vladutiu
P02.255 Acquired and Environmental
Mitochondrial Toxicity in Patients with
Adult-Onset Chronic Progressive External
Ophthalmoplegia Gerald Pfeffer, Sandra
Sirrs, Michelle Mezei
P02.256 “Incidental” Mitochondrial
Myopathy Veronica Crugnola, Valeria
Lucchini, Dario Ronchi, Maria Grazia
D’Angelo, Andreina Bordoni, Gigliola
Fagiolari, Lorenzo Peverelli, Stefano Jann,
Nereo Bresolin, Giacomo Comi, Maurizio
Moggio, Monica Sciacco
Muscle Disease/Neuromuscular
Junction: Myopathy: Clinical
Studies
P02.257 Genetic Markers for CK
Outliers in Army Recruits; Relationship
to Exertional Rhabdomyolysis? Kimbra
Kenney, Rodney Gonzalez, Carmen
Contreras-Sesvold, Andre Blokhin,
Nyamkhishig Sambuughin, Patricia
Deuster, Laurie Hoover, Sheila Muldoon,
William Campbell
P02.258 Clinicopathological Features
of Patients with Dermatomyositis with
Subcutaneous Edema Akihiro Sugai,
Tetsuya Takahashi, Takayoshi Shimohata,
Masatoyo Nishizawa
P02.259 Autoimmune Myopathy
without Inflammation (AMWI); Clinical
and Laboratory Features Nizar Chahin
P02.260 Sporadic Inclusion
Body Myositis: Evaluation of 116
Cases Matthew Wicklund, William
Arnold, John Kissel
P02.261 Amyloid Myopathy: A
Diagnostic Dilemma Isaac Annan,
Kymberly Gyure, Ludwig Gutmann
P02.262 Electromyography in Dropped
Head Syndrome Following Remote
Radiation Shahram Gharibshahi, William
Arnold, Bakri Elsheikh, John Kissel
P02.263 Prevalence and Risk Factors
of Muscular Complications among
Patients Using Statins Khalid El-Salem,
Bashar Ababneh, Ahmed Malkawi, Yousef
Khader, Ali Alrefai
P02.264 Myopathy Developed during
Clevudine Therapy Myung-Goo Ji, Nam
Hee Kim
P02.265 Acetazolamide-Induced
Recurrent Paralysis Yessar Hussain,
Deborah Bradshaw
52
Tuesday, April 13 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P02.266 Characterization of
Electrophysiological Findings in 55
Patients with Biopsy-Proven Critical
Illness Myopathy Andrew Godbey,
Muhammad Al-Lozi
P02.267 Psychometric Evaluation
of the Short Form 36 and Individualized
Neuromuscular Quality of Life (INQoL)
Questionnaire Domains in Patients with
Muscle Disease and Myasthenia Gravis
(MG) Reza Sadjadi, Michael Rose
Ethics, Pain, and Palliative Care
P02.268 Ethical and Social Challenges
in Healthcare for Adolescents and Young
Adults with Cerebral Palsy Danae
Lariviere-Bastien, Eric Racine
P02.269 Experience and Attitudes of
Healthcare Professionals Regarding Ethics
Issues and End-of-Life Decision Making in
Patients Suffering from Chronic Disorders
of Consciousness Catherine Rodrigue, Eric
Racine, Richard Riopelle, James Bernat
P02.270 Hope and Patient Expectation
in Deep Brain Stimulation (DBS):
Healthcare Provider Perspectives and
Approaches Emily Bell, Bruce Maxwell,
Mary Pat McAndrews, Eric Racine
P02.271 Euthanasia in Patients
Suffering from Dementia: PatientOriented Ethical Approach Patrick Cras,
Willem Van Ijperen, Ellen Peeters
P02.272 Quantitative Assessment
of the Pain Disability in Individuals
with Nervous System Disorders Due to
Polytrauma, According to the AMA Guides
to Evaluation of Permanent Impairment
Fifth Edition Armando Miciano
P02.273 Worsening of Fibromyalgia
Symptoms Following Abrupt
Discontinuation of Milnacipran: Results
from a Randomized, Double-Blind,
Placebo-Controlled Trial Philippe Saxe,
Lesley Arnold, R. Michael Gendreau, Allan
Spera, Judy Gendreau, Yong Wang
P02.274 The Efficacy and Tolerability
of Milnacipran 100 mg/day Monotherapy
for the Management of Fibromyalgia:
A Randomized, Double-Blind, PlaceboControlled Trial Lesley Arnold, R. Michael
Gendreau, Allan Spera, Judy Gendreau,
Yong Wang
P02.275 A Randomized, Double-Blind,
Placebo-Controlled, Multicenter, Phase
2 Trial of Intradermal Onabotulinumtoxin
A Injections in the Treatment of Post
Herpetic Neuralgia (PHN) Michael
Tuchman, Patrick Kesslak, Wayne Lam,
Rozalina Dimitrova, Amanda Vandenburgh,
Mitchell Brin, Susan Abu-Shakra
P02.276 Efficacy and Safety of LongTerm Lidocaine Trigger Point Injections in
Patients with Chronic Musculoskeletal
Pain Mihaela Hangan, Neetu Dhadwal,
Frances Dyro, Jin Li
P02.277 Ethical Challenges
Encountered in an Experimental Research
Protocol for Rabies Encephalitis Aarti
Sarwal, Joshua Botdorf, David Fleming
P02.278 Palliative Care in
Neurological Catastrophes: Guidelines for
System-Specific Supportive Care Amy
Sullivan, Keith Swetz
P02.279 The Enigma of a Chronic
Pain Syndrome-A High Level of
Diagnostic Suspicion, Vigilance, and
Close Follow-Up Sometimes Results in an
Alternative Diagnosis (Acute Intermittent
Porphyria) Jay Rosenberg, Andrew
Blumenfeld
Sleep Disorders: Restless Legs
Syndrome Treatment
P02.280 A Randomized, Crossover
Polysomnography Study of Gabapentin
Enacarbil in Subjects with Moderate-toSevere Primary Restless Legs Syndrome
and Associated Sleep Disturbance John
Hudson, Markus Schmidt, Richard Bogan,
John Winkelman, Sarah DeRossett,
Christina Hill-Zabala
P02.281 An Open-Label, 52-Week
Extension Study to Assess the Long-Term
Tolerability and Efficacy of Gabapentin
Enacarbil in Subjects with Moderateto-Severe Primary Restless Legs
Syndrome Aaron Ellenbogen, Stephen
Thein, David Winslow, Philip Becker, Jerry
Tolson, Heather Conklin, Marie-Liesse
Lassauzet, Dan Chen
P02.282 Population Pharmacokinetics
and Pharmacodynamics of Gabapentin
after Administration of Gabapentin
Enacarbil in Subjects with Primary
Restless Legs Syndrome Ritu Lal,
Juthamas Sukbuntherng, Kenneth Cundy
P02.283 Gabapentin Enacarbil
Improves RLS Symptoms and Subjective
Measures of Sleep in Subjects with
Primary Restless Legs Syndrome with
and without Severe Sleep Disturbance:
Secondary Analyses from Two
Studies Richard Bogan, Aaron Ellenbogen,
Philip Becker, Eric Ball, William Ondo,
Clete Kushida, Nicola Williams, Christine
Caivano
P02.284 Gabapentin Enacarbil
Relieves the Pain Associated with
Restless Legs Syndrome Ronald Ziman,
Daniel Lee, A. Thomas Perkins, J. Steven
Poceta, Arthur Walters, Ronald Barrett
P02.285 An Examination of Mood,
Quality of Life, and Function in Subjects
with Primary Restless Legs Syndrome
(RLS) Treated with Gabapentin Enacarbil
Compared with Placebo Ronald Ziman,
Daniel Lee, A. Thomas Perkins, J. Steven
Poceta, Arthur Walters, Ronald Barrett
P02.286 Evaluating Maintenance of
Improvements in Sleep and Quality of Life
in Subjects with Restless Legs Syndrome
Treated with Gabapentin Enacarbil for
up to 36 Weeks Richard Bogan, Michel
Cramer Bornemann, Clete Kushida, Ronald
Barrett
P02.287 An Evaluation of Gabapentin
Enacarbil and Restless Legs Syndrome
Symptom Augmentation in Subjects
Treated for 12 Weeks: Secondary
Analyses from Two Studies Aaron
Ellenbogen, Richard Bogan, Eric Ball,
William Ondo, Clete Kushida, Nicola
Williams, Christine Caivano
P02.288 Augmentation during
Treatment with Ropinirole in Restless
Legs Syndrome. Results From a
Prospective, Multicentric Study Over
66 Weeks Diego Garcia-Borreguero,
Birgit Högl, Luigi Ferini-Strambi, John
Winkelman, Christina Hill-Zabala, Richard
Allen
Sleep Disorders: Restless
Legs Syndrome Pathology and
Pathophysiology
P02.289 Neuroanatomical Aspect
of the Diencephalospinal Dopaminergic
Pathway in the Non-Human Primate:
Potential Implications for Restless Legs
Syndrome Quentin Barraud, Incarnation
Aubert, Ibrahim Obeid, Francois Tison,
Erwan Bezard, Ghorayeb Imad
P02.290 Proteomic Analysis of the
Cerebrospinal Fluid of Patients with
Restless Legs Syndrome Stephanie
Patton, Thomas Clardy, Yong-Won Cho,
Richard Allen, Christopher Earley, James
Connor
P02.291 A New Locus for Familial
Restless Legs Syndrome on Chromosome
21 in a Large Utah Kindred Jacinda
Sampson, Lisa Baird, Brith Otterud, Mark
Leppert
Guidelines, Government
Relations, and Getting Paid
A thriving neurology practice needs a blueprint for success.
Your Academy helps you use the latest research, technology,
and tools to enhance your practice and provide the best
possible care to your patients.
Get expert advice and share experiences:
• Discuss evaluation and management (E/M) coding with
colleagues
• Speak with guidelines authors
• Network with peers who have participated in Academy
advocacy programs
• Learn how to use quality and performance measures
Free to all Annual Meeting attendees.
Monday, April 12, 3:00 p.m.–5:00 p.m. | InterContinental Toronto Centre, Ballroom B
Learn more at
www.aan.com/view/bce
Scientific Sessions
S11 Multiple Sclerosis:
Clinical Trials I
Theatre 102
Constitution Hall 106
4:00 p.m.
S11.001
Optimal Design and Analysis
of Phase I/II Clinical Trials
in Multiple Sclerosis with
Gadolinium Enhancing Lesions as
the Endpoint Brian Healy, David
Ikle, Gary Cutter
4:00 p.m.
S12.001
Safety of Full Dose Intravenous
rt-PA Followed by Intra-Arterial
Therapy for Acute Cerebral
Infarction Raul Nogueira, Shihab
Masrur, Leonardo Batista, Reza
Hakimelahi, Albert Yoo, Lee
Schwamm
4:15 p.m.
S11.002
Twice Weekly Versus Daily
Glatiramer Acetate: Results of
a Randomized, Rater-Blinded
Prospective Clinical Trial Clinical
and MRI Study in RelapsingRemitting MS Christina Caon,
Jai Perumal, Alexandros Tselis,
Wendy Ching, Fen Bao, Zahid
Latif, Imad Zak, Omar Khan
4:30 p.m.
S11.003
A Randomized, Controlled
Trial of Neuroprotection with
Lamotrigine in Secondary
Progressive Multiple
Sclerosis Raju Kapoor, Julian
Furby, Thomas Hayton, Kenneth
Smith, Daniel Altmann, Robert
Brenner, Jeremy Chataway,
Richard Hughes, David Miller
4:45 p.m.
S11.004
Oral Fingolimod (FTY720) vs
Placebo in Relapsing-Remitting
Multiple Sclerosis: 24-Month
Clinical Efficacy Results
from a Randomized, DoubleBlind, Placebo-Controlled,
Multicenter Phase III Study
(FREEDOMS) Ludwig Kappos,
Paul O’Connor, Chris Polman,
Reinhard Hohlfeld, Ernst-Wilhelm
Radue, Peter Calabresi, Krzysztof
Selmaj, Catherine Agoropoulou,
Malgorzata Leyk, Lixin ZhangAuberson, on Behalf of the
FREEDOMS Study Group
5:00 p.m.
S11.005
Oral Fingolimod (FTY720)
Reduces Inflammatory Activity
vs Placebo in RelapsingRemitting Multiple Sclerosis:
24-Month MRI Results from
a Randomized, DoubleBlind, Placebo-Controlled,
Multicenter Phase III Study
(FREEDOMS) Ernst-Wilhelm
Radue, Paul O’Connor, Chris
Polman, Reinhard Hohlfeld, Peter
Calabresi, Krzysztof Selmaj,
Catherine Agoropoulou, Lixin
Zhang-Auberson, Malgorzata
Leyk, Ludwig Kappos, on Behalf
of the FREEDOMS Study Group
54
S12 Cerebrovascular
Disease: Acute Stroke
Therapy
4:15 p.m.
S12.002
Risk of Thrombolysis in Older
Patients: Analysis of a Large
Database Afshin Mohammadi,
Salvador Cruz-Flores, Randall
Edgell, Nirav Vora, Amer
Alshekhlee
4:30 p.m.
S12.003
Gaze Paralysis in the Baseline
NIH Stroke Scale (NIHSS) Exam
Is an Independent Predictor of
Hemorrhagic Complications
After Ischemic Stroke Sherman
Chen, Enrique Leira, Patricia
Davis, James Torner, Jason Day,
Harold Adams
4:45 p.m.
S12.004
Increasing IV rt-PA Use Using
Modern Eligibility Criteria. The
Simplified Management of
Acute Stroke Using Revised
Treatment (SMART) Criteria
Study: Feasibility, Safety, and
Efficacy David Tong, Nobl
Barazangi, Jack Rose, Shirley
Chen, Jeff Thomas, Daniel
McDermitt, Ann Bedenk, Jackie
Phan
5:00 p.m.
S12.005
Effect of Admission Blood
Glucose on tPA -Induced
Arterial Recanalization in Acute
Ischemic Stroke: A MultiCenter Transcranial Doppler
Study Joseph Sebastian, Carol
Derksen, Mohammad Ibrahim,
Georgios Tsivgoulis, Andrei
Alexandrov, Vijay Sharma, Ken
Uchino, Andrew Demchuk,
Ashfaq Shuaib, Maher Saqqur
Tuesday, April 13 | 4:00 p.m.–5:15 p.m.
Metro Toronto Convention Centre
S13 Movement Disorders:
Huntington's Disease:
Pathophysiology and Clinical
Assessment
Room 718AB
4:00 p.m. Presentation
of the Jon Stolk Award in
Movement Disorders for
Young Investigators
Recipient:
E. Ray Dorsey, MD
Rochester, NY
4:15 p.m.
S13.002
Using the Mattis Dementia
Rating Scale (DRS) To Track
Cognitive Change in Huntington’s
Disease (HD) Jody Corey-Bloom,
Steven Edland, Jody Goldstein,
Guerry Peavy, Mark Jacobson,
Stephanie Lessig
4:30 p.m.
S13.003
A New Factor To Reduce Levels
of Aggregates Formed by
Mutant Huntingtin, Ataxin-3
and SOD1: The Cytosolic
Aminopeptidase PSA Raphael
Hourez, Alfred Goldberg
4:45 p.m.
S13.004
GH Response to Arginine Test
Differentiates Two Subgroups
of Huntington’s Disease
Patients Elena Salvatore, Carlo
Rinaldi, Tecla Tucci, Luigi Di
Maio, Carolina Di Somma, Silvia
Savastano, Gaetano Lombardi,
Alessandro Filla, Annamaria
Colao, Giuseppe De Michele
5:00 p.m.
S13.005
Identification and Validation
of an Abnormal Metabolic
Network Associated with
Phenoconversion of Preclinical
Huntington’s Disease Chengke
Tang, Andrew Feigin, Matthew
Bussa, Yilong Ma, Shichun Peng,
Mark Guttman, Jane Paulsen,
Vijay Dhawan, David Eidelberg
S14 Aging and Dementia:
Epidemiology
S15 Epilepsy: Clinical
Neurophysiology and
Imaging
S16 Anterior Horn: Clinical
Studies
Constitution Hall 107
Room 701A
Constitution Hall 105
4:00 p.m.
S14.001
Diabetes Mellitus and Its
Treatments Predict Incident Mild
Cognitive Impairment: The Mayo
Clinic Study of Aging Rosebud
Roberts, Yonas Geda, David
Knopman, Ruth Cha, V. Pankratz,
Bradley Boeve, Robert Ivnik,
Ronald Petersen, Walter Rocca
4:00 p.m.
S15.001
Spontaneous Seizures Recorded
Intraoperatively on Hippocampal
Electrocorticography
(IH-ECoG) and Hippocampal
Pathology Aashit Shah, Darren
Fuerst, Ian Zitron, Marie Atkinson,
William Kupsky, Sandeep Mittal
4:00 p.m.
S16.001
Lithium Carbonate in ALS: A
Treatment Failure Adriano Chio,
Gabriele Mora, Massimo Corbo,
Claudia Caponnetto, Jessica
Mandrioli, Fabrizio Salvi, Gianni
Sorar∙, Letizia Mazzini, Vincenzo
Silani, Maria Rosaria Tola, Fabio
Giannini, Mario Sabatelli, Maria
Monsurr≥, Giuseppe Borghero,
Isabella Simone , Michele Perini,
Francesco Patti, Norina Marcello,
Vladimiro Pietrini, Fabrizio Pisani,
Elisabetta Pupillo, Andrea Calvo,
Cristina Moglia, Giancarlo
Logroscino, Ettore Beghi
4:15 p.m.
S14.002
Incident Dementia in Mild
Cognitive Impairment Varies
According to Cognitive
Domains David Knopman,
Rosebud Roberts, Walter Rocca,
Vernon Pankratz, Ruth Cha,
Ronald Petersen
4:30 p.m.
S14.003
Physical Activity Over the Life
Course and Its Association with
Cognitive Impairment in Old
Age Laura Middleton, Deborah
Barnes, Li-Yung Lui, Kristine Yaffe
4:45 p.m.
S14.004
Mediterranean Diet (MeDi) and
Subclinical Cerebrovascular
Disease Adam Brickman, Jose
Luchsinger, Truman Brown,
Charlie DeCarli, Yaakov Stern,
Yian Gu, Nikolaos Scarmeas
5:00 p.m.
S14.005
Higher Incidence of Amnestic
Than Non-Amnestic Mild
Cognitive Impairment: The Mayo
Clinic Study of Aging Rosebud
Roberts, Yonas Geda, David
Knopman, Bradley Boeve, Ruth
Cha, V. Pankratz, Robert Ivnik,
Walter Rocca, Ronald Petersen
4:15 p.m.
S15.002
Gray Voxel-Based Morphometry
(VBM) and Clinical Findings
of Three Patterns of Drug
Response in Mesial Temporal
Lobe Epilepsy (MTLE) Elizabeth
Bilevicius, Clarissa Yasuda,
Mariana Silva, Carlos Guerreiro,
Iscia Lopes-Cendes, Fernando
Cendes
4:30 p.m.
S15.003
Correlation of MRI Involvement
with Clinical and EEG Data in
Sturge-Weber Syndrome Georg
Evers, András Fogarasi, Cecilia
Mellado, Ingrid Tuxhorn, Péter
Halász, Péter Barsi, György
Rásonyi, Csilla Gyimesi,
Zsuzsanna Siegler, József
Janszky, Rita Jakus, Dean Sarco,
Richard Burgess, Mustafa Sahin,
Friedrich G. Woermann , Tobias
Loddenkemper
4:45 p.m.
S15.004
SPECT Perfusion Patterns in
Temporal Lobe Epilepsy—
Correlation with Ictal EEG, MRI,
and Surgical Outcome Sita
Sattaluri, Pushpalatha Sudhakar,
Manas Panigrahi, Sundaram
Challa
5:00 p.m.
S15.005
Left Temporal PET
Hypometabolism Predicts fMRI
Language Laterality William
Gaillard, Elizabeth Duke, Edythe
Wiggs, Andrey Finegersh,
Clarissa Liew, Irene Dustin,
Sabina Miranda, Susumu Sato,
William Theodore
Scientific Sessions
Tuesday, April 13 | 4:00 p.m.–5:15 p.m.
4:15 p.m.
S16.002
Phase II Controlled Trial of
Lithium Carbonate in Patients
with Amyotrophic Lateral
Sclerosis Robert Miller, Dallas
Forshew, Jonathan Katz, Dan
Moore, Mark Spitalny, Michael
Valan, Richard Barohn, Mark
Bromberg, Kimberly Goslin,
Michael Graves, Leo McCluskey,
April McVey, Tahseen Mozaffar,
Alan Pestronk, Mark Ross, Ericka
Simpson
4:30 p.m.
S16.003
Cognitive Impairment Is a
Negative Prognostic Indicator
in ALS: A Population -Based
Study Marwa Elamin, Julie
Phukan, Susan Byrne, Norah
Jordan, Nail Pender, Orla
Hardiman
4:45 p.m.
S16.004
Examination of SOD1 Protein
Levels in the CSF of ALS
Patients Seung-Joo Chun,
Matthew Jaffa, Leah Winer,
Merit Cudkowicz, Timothy Miller
5:00 p.m.
S16.005
Cerebrospinal Fluid Biomarkers
Panel in Amyotrophic Lateral
Sclerosis James Connor, Ryan
Mitchell, Zachary Simmons
S17 Critical Care, Trauma,
and Inpatient Neurology
Room 701B
4:00 p.m. Presentation of
the Founders Award
Recipient:
Farrah Mateen, MD
Baltimore, MD
4:15 p.m.
S17.002
The Effect of Concussion on
Clinically Measured Reaction
Time in NCAA Division I
Collegiate Athletes: A Pilot
Study James Eckner, Jeffrey
Kutcher, James Richardson
4:30 p.m.
S17.003
Effect of Serum Glucose
Concentrations during
Acute Hospitalization on
Hematoma Expansion,
Perihematomal Edema, and
Three-Month Outcome among
Patients with Intracerebral
Hemorrhage. Results from the
Antihypertensive Treatment
of Acute Cerebral Hemorrhage
(ATACH) Study Adnan Qureshi,
Yuko Palesch, Renee Martin, Jill
Novitzke, Salvador Flores, Asad
Ehtisham, Mustapha Ezzeddine,
Joshua Goldstein, Jawad
Kirmani, Haitham Hussein, M.
Fareed Suri, Nauman Tariq, Yaun
Liu, ATACH Investigators
4:45 p.m.
S17.004
Neurohospitalists Reduce
Length of Stay for Acute
Ischemic Stroke Patients Steven
Dawson, Kevin Barret, Carol
Raper, William Freeman
5:00 p.m.
S17.005
Validation of CT Classification
Scale for Clinical Trials of
Traumatic Brain Injury Victoria
Pan, Caryn Harper, Carol Moore,
Christopher Madden, Ramon
Diaz-Arrastia
S18 Interventional Neurology
S19 Movement Disorders:
Dystonia
S20 Neurologic Education
Room 714A
Room 717AB
Room 713AB
4:00 p.m.
S18.001
Intracranial Angioplasty
and/or Stent Placement in
Octogenarians Is Associated
with a Threefold Greater Risk
of Periprocedural Stroke or
Death Robert Taylor, Nauman
Tariq, M. Fareed Suri, Farhan
Siddiq, Gabriela Vazquez,
Ramachandra Tummala, Joan
Wojak, John Chaloupka, Adnan
Qureshi
4:00 p.m.
S19.001
Botulinum Toxin Injections
Reduce Excessive Cortical
Plasticity in Patients with
Cervical Dystonia Maja Kojovic,
Antonio Caronni, Matteo
Bologna, Kailash Bhatia, John
Rothwell, Mark Edwards
4:00 p.m.
S20.001
Assessing Core Competencies
in Clinical Neurophysiology: A
Vignette-Based Tool Devon
Rubin, Eric Sorenson,
Joseph Drazkowski, Barbara
Westmoreland
4:15 p.m.
S18.002
Safety of Elective Coiling of
Cerebral Aneurysms Equal or
Less Than 7mm: A Multicenter
Analysis Osama Zaidat,
Junaid Kalia, Leonardo Batista,
Sabareesh Natarajan, Mahmoud
Rayes, Vahid Etezadi, Johynny
Pryor, Raul Nogueira, Elad Levy,
Andrew Xavier, Rishi Gupta, Italo
Linfante, Thanh Nguyen, Sandra
Narayanan, Albert Schuette,
Randall Edgell
4:30 p.m.
S18.003
A Review of Periprocedural
Stroke and Death Rates in
18,205 Patients Undergoing
Carotid Angioplasty and Stent
Placement Alberto Maud,
Silvina Tonarelli, Gabriela
Vazquez, M. Fareed Suri, Adnan
Qureshi
4:45 p.m.
S18.004
Natural History of Asymptomatic
Restenosis Following
Endovascular Treatment of
Symptomatic Intracranial
Stenosis. A Multicenter
Study Haitham Hussein,
Nauman Tariq, Stanley Kim,
Ameer Hassan, M. Fareed Suri,
Ramachandra Tummala, Robert
Taylor, Mohammad Abdelmoula,
Adnan Qureshi
4:15 p.m.
S19.002
De Novo and Recurrent
Mutations in ATP1A3 Are
Common in Rapid-Onset
Dystonia-Parkinsonism Allison
Brashear, Debbie Hill, Beverly
Snively, Kathleen Sweadner,
Laurie Ozelius
4:30 p.m.
S19.003
Are the Yips a Form of Golfer’s
Cramp or Focal, Task-Specific
Dystonia Charles Adler, Debra
Crews, Kanav Kahol, Marco
Santello, Brie Noble, John
Caviness
4:45 p.m.
S19.004
Subthalamic Nucleus (STN)
Deep Brain Stimulation (DBS)
in Patients with Primary Cranial
Cervical Dystonia Jill Ostrem,
Jamie Grace, Graham Glass,
Caroline Racine, Monica Volz,
Susan Heath, Philip Starr
5:00 p.m.
S19.005
New Triggers in Rapid-Onset
Dystonia-Parkinsonism
(RDP) Allison Brashear, Debbie
Hill, Beverly Snively, Kathleen
Sweadner, Laurie Ozelius
4:15 p.m.
S20.002
Effects on Knowledge Retention
Produced by Repeated Testing
with Standardized Patients in
Neurological Education Douglas
Larsen, Amy Lawson, Andrew
Butler, Henry Roediger III
4:30 p.m.
S20.003
The Standardized Patient
Outcomes Trial (SPOT)
in Neurology: Assessing
the Effectiveness of the
Standardized Patient Session
at Teaching the Cranial Nerve
Exam Andrew Lin, Yoon Kang,
Juliet Aizer, Joseph Safdieh
4:45 p.m.
S20.004
Is Team-Based Learning
Effective in Undergraduate
Neurology Education? Kevin Tan,
Nagaendran Kandiah, Nigel Tan
5:00 p.m.
S20.005
Evaluating Medical Student
Professionalism in a Neurology
Clinic From the Patient
Perspective Larry Davis, Molly
King
5:00 p.m.
S18.005
Comparison between
Thrombolytic Bridging Therapy
and Primary Endovascular
Treatment in Acute Ischemic
Stroke: A Multicenter
Study Jefferson Miley, Gabriela
Vazquez, Muhammad Zeeshan
Memon, Haitham Hussein, M.
Fareed Suri, Gustavo Rodriguez,
Ramachandra Tummala, Robert
Taylor, Adnan Qureshi
55
Wednesday, April 14 Highlights
Poster Discussion Session
Exhibits
7:30 a.m.–12:00 p.m.
(Author stand by poster from 7:30 a.m.–9:00 a.m.)
11:30 a.m. 5:00 p.m.
3:00 p.m.–7:30 p.m.
(Author stand by poster from 6:00 p.m.–7:30 p.m.)
MTCC, Exhibit Hall DE
Ten posters in six neurologic topics have been selected for discussion.
Posters will be grouped in a separate area where topic experts will
facilitate questions and answers with attendees and poster authors
during the 90-minute author standby time.
Contemporary Clinical Issues and Case Studies
Plenary Session
9:00 a.m.–12:00 p.m.
MTCC, Exhibit Hall FG
Moderator: Carlayne E. Jackson, MD, FAAN,
Member, Science Committee
This session highlights issues most critical to
practicing neurologists, including abstracts
related to new therapeutic developments, clinical
applications of basic and translational research,
and innovative technical developments. In addition
to the Contemporary Clinical Issues discussion, a case study format
addresses topics of interest.
David B. Clifford, MD, FAAN
Washington University School of Medicine/Saint Louis, MO
Discussant: Kenneth L. Tyler, MD, FAAN/Denver, CO
David W. Dodick, MD
Mayo Clinic-Phoenix/Phoenix, AZ
Discussant: Anne Louise Oaklander, MD, PhD, FAAN/Lincoln, MA
Hans-Christoph Diener, MD, PhD, FAHA, FAAN
University Duisburg-Essen/Essen Germany
Discussant: Robert G. Hart, MD/San Antonio, TX
In addition to the Contemporary Clinical Issues discussion, a case study
format will be presented by the following presenters:
Title: “Sports Concussion”
Jeffrey S. Kutcher, MD
University of Michigan Hospital/Ann Arbor, MI
Title: “Spinal Muscular Atrophy: A Story of Rags to Riches”
John T. Kissel, MD, FAAN
Ohio State University/Columbus, OH
Topic: CDC and H1N1
James J. Sejvar, MD
Centers for Disease Control and Prevention/Decatur, GA
Complimentary Luncheon: 12:00 p.m.–2:00 p.m.
See the latest in pharmaceutical products, medical equipment,
publications, and products to assist with practice management,
teaching methods, and research activities.
American Academy of Neurology and American
Academy of Neurology Foundation Awards
Luncheon
12:00 p.m.–1:30 p.m.
MTCC, Exhibit Hall B
Join AAN leaders as they honor the recipients of the 2010 AAN
Awards. From enterprising high school students to world-renowned
researchers, this program recognizes some of the top accomplishments
in neuroscience research. Past keynote speakers on the importance
of neurologic diseases include Tedy Bruschi, NFL player and stroke
survivor; Dame Julie Andrews, Academy Award-winning actress
and supporter for Huntington’s Chorea and the Hereditary Disease
Foundation; Cuba Gooding, Jr., actor and supporter for MS research;
Leeza Gibbons, television and radio journalist and advocate for people
with Alzheimer’s disease; the famed concert pianist and conductor
Maestro Leon Fleischer, who continues to play the piano despite
dystonia; Mayo Clinic researcher Anthony Windebank, MD; and
advocate for Parkinson’s disease research Michael J. Fox. Tickets
are available for $50. Buy a ticket and show your support for award
recipients. Student and Junior members of the AAN may attend this
event at no cost by requesting a ticket.
Reserve a Department Table and Be Recognized
Bring your department together and gain exposure for your team at the
Awards Luncheon by reserving a department table. Give your residents and
fellows the chance to sit together with department faculty and chairs in a
place of honor among the top minds in the neurology/neuroscience academic
community. To reserve a department table, download the reservation form at
www.aan.com/am. If you have questions about reserving a department table,
contact Sarah Glover at rsvpevents@aan.com.
NEW! Platform Session Times
2:00 p.m.–4:00 p.m.
4:15 p.m.–5:30 p.m.
New time slots this year allow registrants to attend the Highlights in
the Field program of their choice.
Current Practice Issues in Neurology: Health
Care Reform
5:30 p.m.–7:00 p.m.
With health care reform in the news and on everyone’s mind, this free
event will explain how reform initiatives impact neurologists and their
patients.
56
Poster Session III
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
Anterior Horn: Imaging
Poster Discussion Session: Anterior Horn: Therapeutics
Location: 800 Level
Moderator: Bryan Traynor, MD
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
PD3.001 Power Wheelchair
Utilization Benchmarks for Patients with
Amyotrophic Lateral Sclerosis: Selection,
Timing, Satisfaction, and Cost Amber
Ward, Mohammed Sanjak, Kerry Duffy,
Nicole Williams, Mindy Nichols, Elena
Bravver, Benjamin Brooks
PD3.002 Repetitive Rhythmic Exercise
(RRE) Mediated by Supported Treadmill
Ambulation Training (STAT) Pilot Trial:
RRE-STAT Is Feasible, Safe, Tolerable
with 21-34 Percent Positive Treatment
Effect Size over Eight Weeks and
Improves on Treadmill and Over Ground
Gait in Amyotrophic Lateral Sclerosis
(ALS) Patients Sanjak Mohammed, Kerry
Duffy, Amber Ward, Jordan Lyerly, Priscilla
Russo, Jaime Shue, Urvi Desai, Elena
Bravver, Benjamin Brooks
Infections/AIDS/Prion Disease
P03.001 Neuropathological Studies of
Patients with Non-Herpetic Acute Limbic
Encephalitis Koichi Okamoto, Fukio Fujita,
Yuichi Tashiro, Masamitsu Takatama
P03.002 Surveillance for Progressive
Multifocal Leukoencephalopathy: Possible
Approaches James Sejvar, Avindra Nath,
Eugene Major
P03.003 The Prevalence of Human
Polyomavirus DNA in Cerebrospinal Fluid
of Patients with Varied Neurological
Diseases Yung-Yee Chang, Cheng-Hui
Peng, Min-Yu Lan, Yin-Fa Chen, Jia-Shou
Liu
P03.004 Clinical Manifestations in
Two Spanish Families with CreutzfeldtJakob Disease Margarita Pondal, Teodoro
Del Ser, Felix Bermejo-Pareja, Alberto
Rabano
P03.005 Pruritus in CreutzfeldtJakob Disease Joab Chapman, Oren
Cohen, Hedok Lee, Zeev Nitzan, Hanna
Rosenmann, Shmuel Appel, Isak Prohovnik
P03.006 How To Interpret a Blood
Contaminated Traumatic Spinal
Tap? Farzad Afshari, Alexander Rajput
P03.007 A Simple Method To
Reduce Infection of Ventriculoperitoneal
Shunts Vikas Gupta, Tausif Rehman, Atiq
Rehman, Hasaan Bashir
P03.008 Therapeutic Challenge of
Neurotuberculosis: An Observational
Case Study Abhijit Chaudhuri
58
PD3.003 Systemic Transplantation
of C-Kit+ Cells Exerts a Therapeutic
Effect in a Model of Amyotrophic Lateral
Sclerosis Stefania Corti, Monica Nizzardo,
Martina Nardini, Chiara Donadoni, Sabrina
Salani, Chiara Simone, Marianna Falcone,
Nicoletta Mezzina, Francesca Gianni,
Giulietta Riboldi, Nereo Bresolin, Giacomo
Comi
PD3.004 A Decrease in Body
Mass Index Is Associated with Faster
Progression of Motor Symptoms and
Shorter Survival in ALS Ali Jawaid,
Santosh Murthy, Andrew Wilson, Salah
Qureshi, Moath Amro, Michael Wheaton,
Ericka Simpson, Yadollah Harati, Adriana
Strutt, Michele York, Paul Schulz
PD3.005 NonInvasive Ventilation in
Admitted Amyotrophic Lateral Sclerosis
Patients with Acute Respiratory
Failure Virginia Pujol Lereis, Gisella
Gargiulo Monachelli, Gabriel Rodriguez,
Martin Sivori, Andres Villa, Raul Rey
PD3.006 Riluzole and Antioxidants:
Effects in a Preclinical Model
System Utilizing Homocysteine,
a Known Modulator of Sporadic
Amyotrophic Lateral Sclerosis (ALS)
Pathogenesis Richelle Hemendinger,
Edward Armstrong III, Benjamin Brooks
PD3.009 Elevated Urinary
Coproporphyrin III (CoproIII) Identifies
Clinically Significant Mercury (Hg) and
Arsenic (As) Intoxication in Unselected
Motor Neuron Disease (MND)
Patients Zhifang Li, Elena Bravver,
Benjamin Brooks
PD3.007 Update on ALSUntangled;
a Global Scientific Effort To Investigate
Alternative and Off-Label Treatment
Options for Patients with ALS Richard
Bedlack
PD3.010 The Effect of Riluzole on
Cellular Injury in ALS: Insights from
a Multi-Modal Non-Conventional
MRI Study Stephanie Hreha, Megan
Mackinzie, Megha Shah, Fen Bao, Ronald
Bailey, Michael McCaffrey, Agnes Acsadi,
Richard Lewis, Omar Khan
PD3.008 Oligomers That Redirect
AMPA Splicing To Reduce Excitotoxicity
as Potential Therapeutics for ALS Terry
Heiman-Patterson, Nicole Lykens, Jyotti
Reddi, Christina Ferrer, Jeffrey Deitch,
Melanie Tallent, Gordon Lutz
P03.017 Trends in Outcomes and
Hospitalization Costs Among Patients
with Tetanus in the United States Mahta
Samizadeh, Khosro Farhad, Hafiz Khan, Abu
Nasar, Nizar Souayah
P03.010 Tuberculosis, an Uncommon
Cause of Cerebral Venous Thrombosis
in Children Abderrahim Bougteba, Assia
Basir
Aging and Dementia: Imaging:
Other
P03.011 Bartonella Cat
Scratch Disease Presenting as
Neuroretinitis and Headache without
Lymphadenopathy Joanna Gan, Alan
Mandell, James Otis, Michael Perloff
P03.012 Meningoencephalitis
Caused by Rickettsia Conori Abderrahim
Bougteba, Assia Basir
P03.013 The Role of
Dexamethasone in Cryptococcus gattii
Meningitis Madeleine Sharp, Kristine
Chapman
P03.014 Neurocysticercosis: A Not
so Rare Parasitic Infection in Geneva,
Switzerland Verónica Castillo, Pierre R.
Burkhard
P03.015 Admission Surveillance
Cultures for Methicillin-Resistant
Staphylococcus Aureus (MRSA) and
Vancomycin-Resistant Enterococci (VRE)
in a Neurocritical Care Unit Wendy Ziai,
Paras Minhas, Alex Shangraw
P03.016 Cladophialophora
bantiana Cerebral Abscesses in an
Immunocompetent Host Laura Mason
P03.028 Brain Cortex Thinning
in Motor and Extra-Motor Areas in
Amyotrophic Lateral Sclerosis Domenico
Mezzapesa, Carla Tortorella, Franca
Dicuonzo, Aristide Carella, Maria De Caro,
Maria Barulli, Rosanna Tortelli, Francesco
Federico, Paolo Livrea, Isabella Simone
P03.029 Clinical Features and Natural
History in ALS Patients with Upper Motor
Neuron Abnormalities on Conventional
Brain MRI Genevieve Matte, Erik Pioro
P03.030 Fibre Tractography of the
Corticospinal Tract in Recent Onset
Motor Neuron Disease: A Longitudinal
Study Maaike van der Graaff, Matthan
Caan, Caroline Sage, Erik Akkerman,
Cristina Lavini, Charles Majoie, Aart
Nederveen, Aeilko Zwinderman, Frans Vos,
Stefan Sunaert, Frans Brugman, Leonard
Van den Berg, Maarten de Rijk, Pieter Van
Doorn, Marianne De Visser
P03.031 Proton MRS of Thalamus
and Basal Ganglia in Amyotrophic Lateral
Sclerosis Khema Sharma, Varan Govind,
Sulaiman Sheriff, Andrew Maudsley
P03.032 DTI and MRS of the Cervical
Spinal Cord in ALS Michael Benatar,
Govind Nair, Nader Metwalli, Sharon
Usher, Xiaoping Hu, John Carew
P03.009 Development of CNS
Complications After Initiation of
Antituberculosis Treatment Maria
Alejandra Gonzalez Duarte, Jesus Higuera
Calleja, Guillermo García-Ramos
P03.018 Brain MRI in Sporadic
Jakob-Creutzfeldt Disease Is Often
Misread Michael Geschwind, Chiara
Kuryan, Tatiana Cattaruzza, Paolo Vitali,
Stephen DeArmond, Katherine Wong
P03.019 Distinct Patterns of
Cerebral Blood Flow in Frontotemporal
Lobar Degeneration and Alzheimer’s
Disease William Hu, Ze Wang, John
Detre, Virginia Lee, John Trojanowski,
Murray Grossman
P03.020 The Value of FDG-PET
Imaging in the Diagnosis of Atypical/
Unclear Dementias: A Retrospective
Memory Clinic Study Robert Laforce,
James P. Buteau, Nancy Paquet, Louis
Verret, Michíle Houde, Rémi W. Bouchard
P03.021 Hippocampal Gray
Matter Volume Declines at a Faster
Rate in Cognitively Normal APOE e4
Carriers Leslie Baxter, Seban Liu, Kewei
Chen, Richard Caselli
P03.022 Mapping Amygdalar
Structural Differences in Alzheimer’s
Patients with 3T MRI Marina Boccardi,
Enrica Cavedo, Alberto Beltramello, Carlo
Caltagirone, Paul Thompson, Giovanni
Frisoni
P03.023 Mapping Cortical Thickness
in Autosomal Dominant Alzheimer’s
Disease Carriers Liana Apostolova,
Kristy Hwang, Luis Medina, Amity Green,
Rebecca Dutton, Jeffrey Lai, Daniel
Geschwind, Jeffrey Cummings, Paul
Thompson, John Ringman
P03.024 Survey of Protocols for
Manual Hippocampal Volumetry:
Preparatory Steps for an EADC-ADNI
Harmonized Protocol Giovanni Frisoni,
Marina Boccardi, Rossana Ganzola, Simon
Duchesne, Nicolas Robitaille, Alberto
Redolfi, George Bartzokis Bartzokis, John
Csernansky, Mony de Leon, Ronald Killiany,
Stéfane Lehéricy, Nikolai Malykhin,
Johannes Pantel, Jens Pruessner, Hilkka
Soininen, Clifford Jack
P03.025 Predictive Value of an
Index of Cholinergic Damage (ICD) for
Cognitive Performance in Alzheimer
Disease Christopher Ahuja, Fuqiang Gao,
Sandra Black
P03.026 Hypothalamic Atrophy
and Decline in Physical Activity Are
Associated with Bone Loss in a Study
of Non-Demented Aging and Early
Alzheimer’s Disease Natalia Loskutova,
Robyn Honea, Eric Vidoni, Jeffrey Burns
P03.027 Seriation of Cortical Atrophy
in the Degenerative Dementias John
Listerud, David Libon, Peachie Moore,
Murray Grossman
Poster Session III
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P03.033 The Utilization of 3 Tesla
Neuroimaging as a Biomarker for
Cognitive Impairment in Amyotrophic
Lateral Sclerosis Peter Bede, Colin
Doherty, Arun Bokde, Michael Ewers,
Harald Hampel, Orla Hardiman
P03.034 Nuclear Magnetic Resonance
(NMR)-Based Metabolomic Analysis of
Cerebrospinal Fluid (CSF) in Amyotrophic
Lateral Sclerosis (ALS) Patients Helene
Blasco, Philippe Corcia, Ségolíne Veau,
Patrick Vourc’h, David Devos, Caroline
Moreau, Julien Praline, Lydie NadalDesbarats, Christian R. Andres
P03.035 Assessing Motor Neuron
Loss in the ALS Rat with Electrical
Impedance Myography Seward Rutkove,
Lucy Wang, Jia Li
P03.036 Clinical and MRI Predictors
of Long-Term Evolution in Amyotrophic
Lateral Sclerosis: A 3.4-Year FollowUp Study Federica Agosta, Elisabetta
Pagani, Melissa Petrolini, Maria Sormani,
Domenico Caputo, Michele Perini,
Alessandro Prelle, Fabrizio Salvi, Massimo
Filippi
P03.037 Degeneration of the Mid
Cingulate Cortex in Amyotrophic Lateral
Sclerosis Detected In Vivo with MR
Spectroscopy Namratha Sudharshan,
Chris Hanstock, Benjamin Hui, Timothy
Pyra, Wendy Jonhston, Sanjay Kalra
P03.038 Upper Motor Neuron and
Extramotor White Matter Involvement
in Phenotypes of Recent Onset Motor
Neuron Disease; a Longitudinal Diffusion
Tensor Study Using Voxel-Based
Analyses Caroline Sage, Maaike van der
Graaff, Matthan Caan, Ronald Peeters,
Wim Van Hecke, Erik Akkerman, Cristina
Lavini, Charles Majoie, Leonard Van den
Berg, Frans Brugman, Marianne De Visser,
Wim Robberecht, Stefan Sunaert
Muscle Disease/Neuromuscular
Junction: Muscular Dystrophies
P03.039 Outcome Measures
Validation Study for Mesoangioblasts
Transplantation in Children Affected by
Duchenne Muscular Dystrophy Serena
Bonfiglio, Alberto Lerario, Andrea
Tettamanti, Sarah Marktel, Sara
Napolitano, Stefano Previtali, Marina
Scarlato, Maria Grazia Natali Sora, Nereo
Bresolin, Giancarlo Comi, Roberto Gatti,
Fabio Ciceri, Giulio Cossu, Yvan Torrente
P03.040 The Six-Minute Walk Test
in Duchenne Muscular Dystrophy:
Longitudinal Observations Craig
McDonald, Erik Henricson, Richard
Abresch, Jay Han, Alina Nicorici, Erica
Goude, Gary Elfring, Allen Reha, Samit
Hirawat, Langdon Miller
P03.041 Pulmonary Function
Characteristics of Boys with Duchenne
and Becker Muscular Dystrophy by Age
Groups and Steroid Use: One-Year Data
from the CINRG Longitudinal Study
Project R. Abresch, Craig McDonald, Jay
Han, Robert Leshner, Diana Escolar, Avital
Cnaan, Eric Hoffman, Adrienne Arrieta,
Tina Duong, Fenming Hu, Julaine Florence,
CINRG Investigators
P03.042 Functional Motor
Performance Characteristics of Boys
with Duchenne Muscular Dystrophy by
Age Groups and Steroid Use: One-Year
Data from the CINRG Longitudinal Study
Project Craig McDonald, Erik Henricson,
Richard Abresch, Jay Han, Robert Leshner,
Diana Escolar, Eric Hoffman, Avital Cnaan,
Addrienne Arrietta, Fenming Hu, Angela
Zimmerman, Tina Duong, Julaine Florence,
CINRG Investigators
P03.043 Risk Factors for Fractures
in the Muscular Dystrophy Surveillance,
Tracking, and Research Network
Cohort Lisa Miller, Kathy James,
Katherine Mathews, Shree Pandya, Susan
Apkon, Chris Cunniff
P03.044 Preclinical Safety of AVI4658, a Phosphorodiamidate Morpholino
Oligomer (PMO) Being Developed To
Skip Exon 51 in Duchenne Muscular
Dystrophy Peter Sazani, Stephen
Shrewsbury
P03.045 Should All Patients
with FSHD Be Screened for Retinal
Telangiectasias? Constantine Farmakidis,
Mina Chung, Rabi Tawil
P03.046 Muscle Imaging
in Oculopharyngeal Muscular
Dystrophy Celedonio Marquez, Carmen
Paradas, Montse Olive, Juan Bautista,
Jose Manuel Morales, Antonio Cano,
Fernando Castellanos, Laura Gonzalez,
Ricard Rojas, Raul Garcia
P03.047 Are Brain White Matter
Changes and Muscle Involvement Related
in DM1? Elena Pegoraro, Vincenzo Romeo,
Marina Fanin, Renzo Manara, Mario
Ermani, Chiara Ferrati, Corrado Angelini
P03.048 Brain Morphometry and
Psychological Evaluation in Myotonic
Dystrophy Type 1 (DM1) Helena
Mendonça, Clarissa Yasuda, Marcondes
França Júnior, Fabiano Reis, Veronica
Zanardi, Carlos Guerreiro, Fernando
Cendes, Anamarli Nucci
Cerebrovascular Disease:
Genetics/Clinical Aspects of
Cerebrovascular Disease
P03.049 The Correlation between
GPIa C807T SNPs and Young Ischemic
Stroke in Shanghai Chinese of Han
Population Dongya Huang, Jingang Zhang
P03.050 Using Latent Semantic
Analysis To Measure the Association
of KCNN4 and ACTA2 Genes and
Ischemic Stroke Ramin Zand, Vida Abedi,
Mohammed Yeasin
P03.051 A Novel Heteroplasmic
Cytochrome b Mutation in the
Mitochondrial DNA Is Associated
with MELAS (Mitochondrial
Encephalomyopathy, Lactic Acidosis, and
Stroke-Like Episodes) Lauren Hyams,
Genevieve Langley, Lauren Mylacraine,
John Shoffner
P03.052 Genome-Wide Association
Studies of MRI-Defined Brain Infarcts:
Meta-Analysis from the CHARGE
Consortium Stephanie Debette, Josh
Bis, Myriam Fornage, Helena Schmidt,
M. Ikram, Sigurdur Sigurdsson, Gerardo
Heiss, Maksim Struchalin, Albert Smith,
Aad van der Lugt, Charles DeCarli, Thomas
Lumley, David Knopman, Christian Enzinger,
Gudny Eiriksdottir, Peter Koudstaal, Anita
DeStefano, Bruce Psaty, Carole Dufouil,
Diane Catellier, Franz Fazekas, Thor
Aspelund, Yurii Aulchenko, Alexa Beiser,
Jerome Rotter, Christophe Tzourio, Dean
Shibata, Maria Tscherner, Tamara Harris,
Fernando Rivadeneira , Larry Atwood,
Kenneth Rice, Rebecca Gottesman, Mark
van Buchem, Andre Uitterlinden, Margaret
Kelly-Hayes, Mary Cushman, Yicheng Zhu,
Eric Boerwinkle, Vilmundur Gudnason,
Albert Hofman, Jose Romero, Oscar Lopez,
Cornelia van Duijn, Rhoda Au, Susan
Heckbert, Philip Wolf, Thomas Mosley,
Sudha Seshadri, Monique Breteler,
Reinhold Schmidt, Lenore Launer, Will
Longstreth, Jr
P03.054 Utility of Measuring Distal
Motor Function in the NIHSS: Correlation
with Motor Arm Function Kathryn
Kirchoff, Stephanie Shaftman, Victor Zach,
David Tanne, Barbara Tilley, Mark Gorman,
Steven Levine
P03.055 Brain Arteriovenous
Malformations: Outcome after
Interventional Versus Conservative
Management. Prospective Study of 302
Patients Carlos Cantú, Alberto Mimenza,
Marco Zenteno, Juan Sánchez, Guillermo
García
P03.056 Non-Convulsive Status
Epilepticus after Acute Ischemic
Stroke Andrés Rodríguez, Darío Scocco,
Analía Calle, Agustín Jáureui, Patricia
Riccio, Alfredo Thomson, Francisco Klein,
Luciano Sposato
P03.057 Young Women’s Stroke
Etiology Differs from Young Men: An
Analysis of 511 Patients Emily Nakagawa,
Michael Hoffmann
P03.058 Short-Term Stroke Outcomes
in the Oldest Old: A Buenos Aires Heath
System Study Claudia Alonzo, Laura
Brescacin, Maria Zurrú, Marina Romano,
Silvina Brienza, Fabiana Ortega, Luis
Camera, Gabriel Waisman, Edgardo
Cristiano, Bruce Obviagele
Cerebrovascular Disease: Stroke
Imaging
P03.059 The No Smoking Sign: Insular
Infarction Hebah Hefzy, Rachel Wulf
Silver, Brian Silver
P03.060 Whole-Brain CT Perfusion
(CTP) Using a Novel Volume Helical
Shuttle (VHS) Technique on a
Conventional 64-Slice CT Scanner:
Utility in Routine Stroke Evaluation Nobl
Barazangi, Albert Lu, Jack Rose, Shirley
Chen, Derk Purcell, Amy Huang, Jerry
Barakos, David Tong
P03.061 Frequency and
Characterization of MR Diffusion Lesions
in Acute Spontaneous Intracerebral
Hemorrhage Jonathan Kleinman, Nancy
Fischbein, Alisa Gean, Ryan Snider,
Michael Mlynash, Rashmi Narayana, Irina
Eyngorn, Chitra Venkatasubramanian,
Jean-Marc Olivot, Gregory Albers,
Christine Wijman
P03.062 Detecting Infarcted Tissue
with Perfusion-Based Measures on
MRI Richard Leigh, Argye Hillis, Peter
Barker
P03.063 Diagnostic and Prognostic
Value of Magnetic Resonance
Imaging in Spinal Dural Arteriovenous
Fistula RajaNandini Muralidharan,
Andrea Saladino, Giuseppe Lanzino, John
Atkinson, Alejandro Rabinstein
P03.053 Evidence for a Heritable
Contribution to Death from Ischemic
Stroke Jennifer Majersik, Lisa CannonAlbright
59
Poster Session III
P03.064 Imaging More with Less:
Whole Brain 64-Slice Stroke CT Imaging
Using Currently Available Volume Shuttle
(VS) and Novel Volume Helical Shuttle
(VHS) Brain Perfusion Does Not Increase
Radiation Exposure Jack Rose, Qui Luong,
Nobl Barazangi, Derk Purcell, Amy Huang,
Shirley Chen, Jerome Barakos, David Tong,
Kirk Moon
P03.065 How Accurate Is 3D
Rotational Angiography in Evaluating
Intracranial Stenosis in Patients with
Stroke? Qi Li, Jialun Li, Fajin Lv, Tianyou
Luo, Peng Xie
P03.066 3D CT Angiography for
Detection of Intracranial Aneurysms:
Comparison with 3D Rotational
Angiography Qi Li, Jialun Li, Fajin Lv, Peng
Xie
P03.067 Computational Fluid
Dynamics of Retrograde Leptomeningeal
Collateral Flow in Acute Ischemic
Stroke: Unique Insight on Essential
Hemodynamics David Liebeskind, Fabien
Scalzo, Yiemeng Hoi, Qing Hao, Xiao Hu,
David Steinman
P03.068 Volume of Infarction on
Diffusion Weighted Imaging Predicts Poor
Neurologic Outcome in Children Following
an Acute Ischemic Stroke Nassim
Zecavati, Rani Singh, Jennifer Pettiford,
Cara Olsen, Nadja Kadom
P03.069 A Combined Power M-Mode
and Spectrogram TCD Microemboli
Signal Criteria for Improving Emboli
Detection and Reliability Youngbin Choi,
Maher Saqqur, Albert Jin, Eileen Stewart,
Caroline Stephenson, Mohamed Ibrahim,
Jean-Martin Boulanger, Shelagh Coutts,
Andrew Demchuk, Talip Asil
P03.070 Microbleed Detection in
Traumatic Brain Injury by 7T MRI Kathryn
Hammond-Rosenbluth, Janine Lupo, Esther
Yuh, Adam Kincaid, Hana Lee, Duan Xu,
Srivathsa Veeraraghavan, Geoffrey Manley,
Sarah Nelson, Pratik Mukherjee
P03.071 Yield of Diagnostic Tests
in Evaluating Syncopal Episodes in the
Emergency Room Shafiuddin Ahmed,
David Marks
P03.072 Is Admission and
Diagnostic Testing Needed To Evaluate
Syncope? Shafiuddin Ahmed, David
Marks
P03.073 An Unusual Case of Bilateral
Carotid Artery Webs and Stroke May
Kim, Matthew Tenser, Latisha Ali, Satoshi
Tateshima, Jeffrey Saver
P03.074 Comparison of NASCET and
ECST Ratio with Absolute Methods of
Measurement for Grading Carotid Artery
Stenosis with Noninvasive Imaging
Modalities Chiara Zavanone, Sandrine
Deltour, Emma Ragone, Aurelie Drier,
Sophie Crozier, Fabien Koskas, Yves
Samson
60
P03.075 Transcranial Doppler
Ultrasonography (TDU) Is Useful in
Guiding Treatment of Cerebral Vasospasm
in Aneurysmal Subarachnoid Hemorrhage
(SAH) Fabienne Perren, Bawarjan Schatlo,
Marc Kotowski, Philippe Bijlenga, Vitor
Pereira-Mendes, Yvan Gasche, Karl
Schaller
P03.076 MRI Diffusion-Weighted
Imaging for Predicting Poor Outcome
Following Cardiac Arrest David Greer,
Patricia Scripko, James Bartscher, Erica
Camargo, John Sims, Aneesh Singhal,
Karen Furie
P03.077 Distal Hyperintense Vessels
in Acute Ischemic Stroke Beyond Three
Hours Dileep Yavagal, Diogo Haussen
P03.078 Hyperglycemia and
Perfusion in Acute MCA Occlusion David
Liebeskind, Radoslav Raychev, Qing Hao,
Xiao Hu, Monica Sapo, Farzad Buxey,
Jeffry Alger, Jeffrey Saver, UCLA Stroke
Investigators
P03.079 Variability in Determining
Acute Stroke Lesion Volumes from ADC
Maps Richard Leigh, Argye Hillis, Peter
Barker
P03.080 Use of Transcranial Doppler
for the Detection of Severe Carotid
Stenosis Sanjeev Sivakumar, Deepak
Arjundas, Sivakumar Rajappa
P03.081 Dual Energy CT Scan and
Pathological Analysis of Ex-Vivo Carotid
Plaque Venkata Dandamudi, Christine
Thomas, Ibrahim Bechwati, Claudia
Fitzgerald, Kinan Hreib
P03.082 Prevalence of Asymptomatic
Intracranial Stenosis in US Elderly
Population: Results from the Ultrasound
Screening in Adults for Intracranial
Disease (USAID) Study M. Fareed Suri,
Nauman Tariq, Alexandros Georgiadis,
Mushtaq Qureshi, Gabriela Vazquez, M.
Naeem Qureshi, Adnan Qureshi
P03.083 MRI (DWI, T2, Flair
Sequences) Findings of an Acute Ischemic
Stroke in a 61-Year-Old Patient Taken at
Least 30 Minutes Before Symptom Onset:
A Case Report Remia Paduga, Gary
Gronseth
P03.084 Carotid Intima Media
Thickness Does Not Correlate with
Coronary Artery Atherosclerosis in
Pakistani Population Ismail Khatri, Faika
Usman, Syed Mumtaz Shah, Waqas
Ahmed, Ayesha Vohra, Ali Alam
P03.085 CT Perfusion Imaging in
Spectacular Shrinking Deficit Vivien Lee,
Sayona John, Yousef Mohammad, Shyam
Prabhakaran
P03.086 Transcranial Doppler FollowUp after Intracranial Stenting Jose
Romano, Dileep Yavagal, Frank Cabrera,
Yosdely Echevarria, Sebastian Koch
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P03.087 Association of Interleukin
1b and Volume of Acute Ischemic Infarct
on Magnetic Resonance Imaging Minal
Jain, Anunaya Jain, Neeraja Yerragondu,
Dipti Agarwal, Balavani Palamari, Veena
Manivannan, Babak Jahromi, Wyatt
Decker, Latha Stead
P03.088 Abnormal White Matter
Structure Is Present in Regions of Vascular
Steal Phenomenon in Patients with
Arterial Steno-Occlusive Disease John
Conklin, Jorn Fierstra, Adrian Crawley, Jay
Han, Julien Poublanc, Daniel Mandell,
Frank Silver, Tymianksi Michael, Joseph
Fisher, David Mikulis
P03.089 The Predictive Value of Early
Regional Changes of Cerebral Blood
Flow for Ischemic Tissue Damage in an
Embolic Rat Stroke Model Maureen
Walberer, Heiko Backes, Maria Dennin,
Bernd Neumaier, Heike Endepols, Mathias
Hoehn, Gereon Fink, Rudolf Graf, Michael
Schroeter
Child Neurology/Developmental
Neurobiology: Imaging
P03.090 Metabolic and Diffusion
Abnormalities of the Thalamus and
Their Cognitive Correlates in Unilateral
Sturge-Weber Syndrome Balint Alkonyi,
Harry Chugani, Michael Behen, Stacey
Halverson, Emily Helder, Malek Makki,
Csaba Juhasz
P03.091 Are “Screening” MRIs for
Asymptomatic NF-1 Patients Necessary
or Cost Effective? Sahithya Wintrich,
Manikum Moodley, Erika Schneider, Paul
Ruggieri, Jack Lake, David Rothner
P03.092 Cerebrovascular Reactivity
in Children with Hematological Disorders
Including Sickle Cell Disease Nomazulu
Dlamini, Suzan Williams, Melanie Kirby,
Ivanna Yau, Daune Macgregor, Gabrielle
deVeber, William Logan
P03.093 Headaches (HA) in
Children and Adolescents (C/A) with
Neurofibromatosis Type 1 (NF-I) D.
Elefant, A. Rothner
P03.094 Childhood Stroke in Saudi
Arabia: Etiology, Course and Recurrence
Rates Mohammed Aldosari, Mohammad
Al-Muhaizea, Aood Almuslamani, Aziza
Chedrawi, Hesham Al-Dhalaan
P03.095 Familial Pediatric Cavernous
Malformation in a New Mexican CohortClinical, Radiological, and Pathologic
Correlate Vikas Gupta, Leslie Morrison,
Howard Yonas, Rafael Medina-Flores
Epilepsy: Imaging
P03.096 White Matter Reorganization
in a Rat Model of Temporal Lobe Epilepsy
Observed Using Enhanced MRI Mansi
Parekh, William Triplett, Paul Carney,
Thomas Mareci
P03.097 MRI Structural Analysis of
the Hippocampus in Families with Mesial
Temporal Lobe Epilepsy Marcia Morita,
Luiz Betting, Clarissa Yasuda, Claudia
Maurer-Morelli, Iscia Lopes-Cendes,
Fernando Cendes
P03.098 DTI Voxel-Based Analysis
of Patients with Idiopathic Generalized
Epilepsy Luiz Betting, Marcia Morita,
Clarissa Yasuda, Li Li, Iscia Lopes-Cendes,
Marilisa Guerreiro, Carlos Guerreiro,
Fernando Cendes
P03.108 Are Periventricular Lesions
Specific for Multiple Sclerosis? Gianna
Casini, Mary Yurashevich, Rohini Vanga,
Subasini Dash, Suhayl Dhib-Jalbut, Brian
Gerhardstein, Matilde Inglese, Win Toe,
Konstantin Balashov
P03.099 Voxel Based Morphometry
Reveals Association Between Gray
Matter Loss and Dysfunctional Odor
Identification in MTLE Patients Maria
Natalicio, Clarissa Yasuda, Maria Da Silva,
Fernando Cendes
P03.109 A Five-Year Serial
Longitudinal Study of Deep Gray
Matter Atrophy in Patients with
Multiple Sclerosis Niels Bergsland,
Dana Horakova, Michael Dwyer, Deepa
Ramasamy, Eva Havrdova, Zdenek Seidl,
Ondrej Dolezal, Sara Hussein, Ellen Carl,
Manuela Vaneckova, Robert Zivadinov
P03.100 fMRI Validation of
Novel MEG Expressive Language
Tasks Elizabeth Donner, Frank Wang,
Marion Malone, Elizabeth Pang
P03.101 Receptive Language
Localization with Magnetic Source
Imaging in Correlation with Electrical
Cortical Stimulation Wenbo Zhang, Gail
Risse, Joel Landsteiner, Brian Owens,
Laura Petersen, Mary Dunn, Frank Ritter,
Michael Frost, Jason Doescher, Patricia
Penovich, Robert Doss, El-Hadi Mouderres,
Deanna Dickens
P03.102 Relationship between
MEG Spike Sources and fMRI Language
Patterns in Children with Epilepsy Omer
Bar-Yosef, Hiroshi Otsubo, Chaung
Sylvester, Drew Morris, William Logan,
Elizabeth Donner
P03.103 Conflicting
Neuropsychological and Amytal
Test Results: Outcomes in Temporal
Lobectomies Christina Cheung, Brent
Hayman-Abello, Rick McLachlan, David
Steven, Jorge Burneo
P03.104 Surgical Failure in
Refractory MTLE Is Associated with
Progression of Atrophy in Contralateral
Hippocampus Clarissa Yasuda, Jarbas
Neto, Amanda Pereira, Marcia Morita,
Alberto Costa, Tânia Cardoso, Helder
Tedeschi, Evandro Oliveira, Marilisa
Guerreiro, Carlos Guerreiro, Fernando
Cendes
P03.105 Alterations of Intracerebral
GABA Levels by Titration with
Levetiracetam in Patients with Focal
Epilepsies Thilo Hammen, Marc Doelken,
Angelika Mennecke, Arndt Doerfler,
Hermann Stefan
Multiple Sclerosis and Related
Diseases: MRI Diverse
P03.106 Corpus Callosum “Silent”
Atrophy in Relapsing-Remitting Multiple
Sclerosis Patients: A Seven-Year
Prospective Study Fernando Figueira,
Gustavo Figueira
P03.107 Functional and MRI
Studies of Corpus Callosum (CC) in
Relapsing-Remitting Multiple Sclerosis
(RRMS) Bruno Lenne, Jean-Louis
Nandrino, Henrique Sequeira, Philippe
Gallois, Patrick Hautecoeur
Poster Session III
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P03.110 Brain Atrophy Predicts the
Conversion From a Clinically Isolated
Syndrome to Multiple Sclerosis Daniel
Goldberg-Zimring, Christian ChavarroNieto, Brian Healy, Anat Achiron, Simon
Warfield, Mohit Neema, Ashish Arora,
Rohit Bakshi
P03.111 A 3T MRI Investigation of
the Topography of Whole Spinal Cord
Atrophy in Multiple Sclerosis Joshua
Klein, Ashish Arora, Mohit Neema,
Brian Healy, Shahamat Tauhid, Daniel
Goldberg-Zimring, Christian ChavarroNieto, James Stankiewicz, Adam Cohen,
Antonia Ceccarelli, Elisa Dell’Oglio, Charles
Guttmann, Rohit Bakshi
P03.112 Whole Brain and
Tract-Specific Diffusion Tensor and
Magnetization Transfer Imaging
Values Correlate with Quantified Brain
Atrophy Daniel Harrison, John Ratchford,
Sheena Farrell, Peter Calabresi, Daniel
Reich
P03.113 The Relationship Between
Spinal Cord Atrophy, Brain Atrophy, and
Disability in Multiple Sclerosis Adam
Cohen, Mohit Neema, Ashish Arora, Elisa
Dell’Oglio, Ralph Benedict, Shahamat
Tauhid, Daniel Goldberg-Zimring, Christian
Chavarro-Nieto, Antonia Ceccarelli,
Joshua Klein, James Stankiewicz, Charles
Guttmann, Rohit Bakshi
P03.114 Benefits of Alemtuzumab
Are Evident Even in Relapsing-Remitting
Multiple Sclerosis Patients Who
Experience Autoimmune Adverse
Events Vesna Brinar, N. A. on Behalf of
the CAMMS223 Study Group
P03.115 Natalizumab and Risk of
Melanoma: A Prospective Follow-Up
of Patients Treated by Natalizumab for
Multiple Sclerosis Emeline Castela,
Christine Lebrun Frenay, Muriel Laffon,
Fanny Rocher, Thierry Passeron
Multiple Sclerosis and Related
Diseases: MRI/Technique and
PET
P03.116 Measurement of Yearly
Change in RRMS Brain Volume Using 3T
MRI Scans Stuart Cook, Leo Wolansky,
Jojy Cheriyan, Diego Cadavid
P03.117 Quantitative MRI Reveals
Abnormality of Fornix and Cingulum
in MS Stephanie Syc, John Ratchford,
Sheena Farrell, Jonathan Grynspan, Peter
Calabresi, Daniel Reich
P03.118 Low Contrast Visual
Stimuli Yield Differential Volumes of
Functional MRI Activation in Affected
and Unaffected Eyes Following Recovery
from Optic Neuritis Robert Bermel,
Jeffrey Cohen, Lael Stone, Blessy Mathew,
Michael Phillips, Mark Lowe
P03.119 Cerebral White and Grey
Matter MRI Segmentation with Lesion InPainting in Multiple Sclerosis Jonathan
Jackson, Declan Chard, Elisa Dell’Oglio,
Brian Healy, Mohit Neema, Rohit Bakshi,
David Miller, Claudia Wheeler-Kingshott
P03.120 3 Tesla Imaging of the
Brain in Multiple Sclerosis Patients
with Nystagmus—A New Diagnostic
Tool Parameswaran Iyer, Andrew Fagan,
Aliz Takacs, James Meaney, Niall Colgan,
Stephen Meredith, Kathleen Curran, Janice
Redmond
P03.121 Imaging CNS Myelin by PET
in Multiple Sclerosis Using the Thioflafin
Derivative [11C]-PIB Bruno Stankoff, Leorah
Bosqué-Freeman, Maris-Stephane Aigrot,
Frederic Dolle, Catherine Lubetzki, Bernard
Zalc, Michel Bottlaender
P03.122 Cerebral Activation
Patterns Associated with Increased
Working Memory Load in Multiple
Sclerosis Lindsay Barker, Bonnie Glanz,
Elisabeth Moes, Bradford Dickerson,
Charles Guttmann, Guy Buckle
P03.123 Assessment of Neuronal
Pathology in the Cerebral Grey Matter of
Patients with MS: Added Value of PET
with [11C]-Flumazenil Léorah Freeman,
Claire Leroy, Damien Galanaud, Rana
Assouad, Ayman Tourbah, Caroline
Papeix, Claude Comtat, Catherine Lubetzki,
Jacques Delforge, Michel Bottlaender,
Bruno Stankoff
P03.124 Focal Cerebral Increases
of α-[11C]Methyl-L-Tryptophan Uptake
Suggest Activation of the Kynurenine
Pathway in Multiple Sclerosis: A PET
Study Balint Alkonyi, James Garbern,
Diane Chugani, Otto Muzik, Pulak
Chakraborty, Csaba Juhasz
P03.125 24-Month Efficacy and
Safety Outcomes From the TRANSFORMS
Extension Study of Oral Fingolimod
(FTY720) in Patients with RelapsingRemitting Multiple Sclerosis Bhupendra
Khatri, Frederik Barkhof, Giancarlo Comi,
Hans-Peter Hartung, Ludwig Kappos,
Xavier Montalban, Jean Pelletier, Tracy
Stites, Stacy Wu, Frederick Holdbrook,
Jeffrey Cohen, on Behalf of the
TRANSFORMS Study Group
Multiple Sclerosis and Related
Diseases: MRI/Technique
P03.126 Chronic Cerebrospinal
Venous Insufficiency and Iron Deposition
on Susceptibility-Weighted Imaging in
Patients with Multiple Sclerosis Michael
Dwyer, Paolo Zamboni, Mark Haacke, Erica
Menegatti, Bianca Weinstock-Guttman,
Claudiu Schirda, Anna Malagoni, David
Hojnacki, Cheryl Kennedy, Ellen Carl, Niels
Bergsland, Sara Hussein, Mari HeininenBrown, Ilaria Bartolomei, Fabrizio Salvi,
Robert Zivadinov
P03.127 Triple Stimulation in Patients
with Clinical Isolated Syndromes:
Sensitivity To Detect Clinically Silent
Lesions in Comparison to Transcranial
Magnetic Stimulation and Visual/
Somatosensory Evoked Potentials Ulrich
Hofstadt-van Oy, Christoph Klawe, Dirk
Hagenburger, Michael Strotzer, Stefan
Lieser, Patrick Oschmann
P03.128 Hypoperfusion of Brain
Parenchyma Is Strongly Associated with
the Severity of Chronic Cerebrospinal
Venous Insufficiency in Patients with
Multiple Sclerosis Paolo Zamboni, Eric
Menegatti, Bianca Weinstock-Guttman,
Michael Dwyer, Claudiu Schirda, Anna
Maria Malagoni, David Hojnacki, Cheryl
Kennedy, Ellen Carl, Niels Bergsland,
Christopher Magnano, Ilaria Bartolomei,
Fabrizio Salvi, Robert Zivadinov
P03.129 A Comparison of MS and
Ischemic Lesions as Visualized Using 7
Tesla T2* Phase Imaging Ian Donaldson,
Emma Tallantyre, Jennifer Dixon, Samuel
Wharton, Penny Gowland, Peter Morris,
Nikos Evangelou
P03.130 Impaired Motor Performance
in MS Is Associated with Increased GABA
Level in Sensorimotor Cortex Pallab
Bhattacharyya, Michael Phillips, Lael
Stone, Mark Lowe
P03.131 The Need for Standardization
of Lesion Activity Analysis Categorization
in the Multiple Sclerosis Clinical
Trials David Wack, Michael Dwyer, Niels
Bergsland, Robert Zivadinov
P03.132 Assessing Brain Tissue
Damage in Subjects with Radiologically
Isolated Syndrome Francesca Rossi,
Maria Laura Stromillo, Bahia Hakiki,
Marco Battaglini, Antonio Giorgio, Emilio
Portaccio, Gian Michele Malentacchi,
Maria Letizia Bartolozzi, Antonio Federico,
Sandro Sorbi, Maria Pia Amato, Nicola De
Stefano
P03.133 Cine Cerebrospinal Fluid
Imaging in Multiple Sclerosis. A CaseControl Study Christopher Magnano,
Claudiu Schirda, Bianca WeinstockGuttman, David Hojnacki, Niels Bergsland,
Cheryl Kennedy, Justine Reuther, Christina
Brooks, Michael Dwyer, Robert Zivadinov
P03.134 DTI Correlates of Cognitive
Dysfunction in Patients with Benign
MS and with Clinically Isolated
Syndrome Matilde Inglese, Gunja Parikh,
Maxim Bester, James Babb, Joseph
Herbert, Robert Grossman, Mariana Lazar
P03.135 Detecting Multiple Sclerosis
Cortical Lesions Post-Mortem Using
3, and 7 Tesla Magnetic Resonance
Imaging Bing Yao, Peter van Geldern,
Christina Chen, Vasiliki Ikonomidou,
Hellmut Merkle, Marshall Davis, Fredric
Cantor, Jeff Duyn, Henry McFarland,
Francesca Bagnato
Multiple Sclerosis and Related
Diseases: Clinical Research
Sleep and Genetics
P03.136 Multiple Sclerosis (MS)
Patients, with and without Restless Legs
Syndrome (RLS), Have Frequent Sleep
Disturbances on Polysomnographic
Studies Joelle Proulx-Therrien, Steven
Brass, Pierre Duquette
P03.137 Quality of Life in Multiple
Sclerosis Patients Is Associated
with Poor Sleep as Assessed by
Polysomnography Daria Trojan, Marta
Kaminska, Amit Bar-Or, Deborah Da Costa,
Andrea Benedetti, Yves Lapierre, Douglas
Arnold, Ann Robinson, Deborah Weiss,
Kevin Schwartzman, Adriana Venturini, R.
John Kimoff
P03.138 Clinical Pathway for the
Differential Diagnosis of Daytime
Sleepiness in MS Using Self-Administered
Scales Stefan Braune
P03.139 Gene Expression Profiling of
Post-Mortem Multiple Sclerosis Derived
Normal Appearing White Matter and
Active Lesion Tissue Ka Ka Ting, Simon
Hawke
P03.140 HLA Allele Interactions
Associated with Multiple Sclerosis
Activity, Severity, and Progression Maria
Liguori, Brian Healy, Dong Tran, Bonnie
Glanz, Cara Wolfish, Samia Khoury, Howard
Weiner, Philip De Jager, Charles Guttmann
P03.141 Familial Multiple
Sclerosis, Does Consanguinity Has
a Role? Mohammed Al Jumah,
Suliman Kojan, Ibrahim AlAbdulkaream,
Mohammed Al Blawi
P03.142 NQO1 Inborn Gene
Polymorphism and Susceprtibility in
Multiple Sclerosis Athanasia Alexoudi,
Ioanna Chatzi, Sofia Zachaki, Christiana
Stavropoulou, Asimina Athanasouli,
Thomas Tsolis, Constantina Sambani,
Clementine Karageorgiou
Behavioral Neurology: Imaging,
Genetics, and Other
P03.143 XYY Syndrome: A Possible
Model for Autism Spectrum Disorder
(ASD) David Roeltgen, Judith Ross
61
Poster Session III
P03.144 Polymorphism in Progranulin
Gene Associated with Structural
Differences in Brains of Normal
Controls Carmela Tartaglia, Victor Laluz,
Marc Sollberger, Rosa Rademakers, Anna
Karydas, Matt Baker, Tricia See, Kate
Rankin, Bruce Miller
P03.145 Presenilin 1 S170P
Mutation with a Limbic Encephalitis Like
Presentation Tobias Langheinrich, Charles
Romanowski, Stephen Wharton, Marios
Hadjivassiliou
P03.146 Clinical Correlations of
Asymmetric Temporal and Parietal
Lobe Glucose Hypometabolism Daniel
Claassen, Ioana Stoian, Keith Josephs,
Patrick Peller
P03.147 Glucose Metabolism in
Progressive Non-Fluent Aphasia Patients
with Versus without Parkinsonism Jee
Hoon Roh, Sang Won Seo, Kim Geon Ha,
Duk L. Na
P03.148 Shape Analysis of the
Neostriatum in Frontotemporal Lobar
Degeneration, Alzheimer’s Disease,
and Healthy Controls— Regional and
Functionally Significant Atrophy Jeffrey
Looi, Mark Walterfang, Martin Styner, Leif
Svensson, Olof Lindberg, Per Ostberg, Eva
Orndahl, Dennis Velakoulis, Rajeev Kumar,
Lars-Olof Wahlund
Movement Disorders:
Neuroimaging
P03.157 Olfactory Tract and
Substantia Nigra Diffusion Tensor Imaging
and Olfactory Function Testing in De
Novo Parkinson’s Disease Tyler Rolheiser,
Heather Fulton, Kim Good, Ron Leslie,
John Fisk, Roger McKelvey, Kerri Schoffer,
Naeem Khan, Harry Robertson
P03.158 Clinical and DAT Imaging
Characteristics of Parkinson’s Disease
Patients According to Their Smell Test
Result Andre Felicio, Clecio GodeiroJunior, Ming Shih, Vanderci Borges, Sonia
Silva, Rodrigo Bressan, Luiz Andrade,
Henrique Ferraz
P03.159 Volumetric MRI as an
Image Biomarker for the Early Diagnosis
of Parkinson’s Disease Mya Schiess,
Timothy Ellmore, Richard Castriotta, Diane
Bick, Marie-Francoise Doursout, Erin
Stimming, Roger Bick
P03.149 Spatial Localization of
Densely Ischemic Regions Associated
with Motor Extinction in Acute
Stroke Mikolaj Pawlak, Jennifer HeidlerGary, Edward Herskovits, Argye Hillis
P03.160 Volumetric Imaging Markers
of Early Dementia in Older Patients with
Parkinson’s Disease Richard Camicioli,
Jennifer Sabino, Myrlene Gee, Chris
Hanstock, Derek Emery, Wayne Martin
P03.150 Investigating the Relation
Between Basal Ganglia Volume and
Intelligence Penny MacDonald, Sherif
Karama, Hooman Ganjavi, Alan Evans
P03.161 Functional MRI in De Novo
Patients with Parkinson’s Disease during
a Self-Paced Simple Motor Task Claudio
Lucetti, Filippo Baldacci, Carlo Tessa,
Paolo Del Dotto, Chiara Logi, Caterina
Berti, Stefano Diciotti, Lorenzo Paoli,
Paolo Cecchi, Andrea Ginestroni, Mario
Mascalchi, Ubaldo Bonuccelli
P03.151 Léger de Main: The Thalamus
and the Automatic Limb Darrell Newman,
David Burkholder, Richard Elias
P03.152 Primal Neuroanthropology—
The Study of Archetypal Postures,
Movements, and Behavior in Sports and
Related Activity That Connect Us to Our
Evolution, Infancy, Neurodegeneration,
and Primordial Selves Kenneth Gross
Behavioral Neurology: Other
P03.153 Filial Catamenial
Phantosmia Alan Hirsch, Jhanvi Menon,
Jhoette Dumlao
P03.154 Surgical Resection of
Hypothalamic Hamartomas for Severe
Behavioral Symptoms Eric Hastriter, John
Kerrigan, Harold Rekate, Yu-tze Ng
P03.155 Early Exposure to Anti
Convulsants and the Development of
Autism in Epilepsy Samiah Al-Zaidy,
Hayley Wood, Wendy Roberts, Shelly
Weiss
62
P03.156 Visuo-Motor Deficits
and Damage to White Matter Tracts
in a Posterior Cortical Atrophy
Patient Raffaella Migliaccio, Federica
Agosta, Monica Toba, Fabian Corlier,
Leonardo Cruz De Souza, Stephane
Lehericy, Marie Sarazin, Dalila Samri,
Bruno Dubois, Massimo Filippi, Paolo
Bartolomeo
P03.162 A Novel Set Shifting fMRI
Task Identifies Differences in Brain
Activation in Parkinson’s Disease and
Healthy Controls Michele York, Christof
Karmonik, Phillip Burton, Doug Richards,
Ekta Kakkar, Robert Grossman, Joseph
Jankovic
P03.163 The Topographical
Distribution of White Matter Damage
in Parkinson’s Disease and Progressive
Supranuclear Palsy Sebastiano
Galantucci, Federica Agosta, Igor Petrovic,
Vladana Spica, Milica Jecmenica, Giulia
Longoni, Vladimir Kostic, Massimo Filippi
P03.164 The In-Vivo Topographical
Distribution of Brain Tissue Loss
Associated with Depression in Parkinson’s
Disease: A Voxel-Based Morphometry
Study Vladimir Kostic, Federica Agosta,
Igor Petrovic, Sebastiano Galantucci,
Vladana Spica, Milica Jecmenica,
Massimo Filippi
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P03.165 Pattern of Global and
Regional Brain Volume in Progressive
Supranuclear Palsy Identified by MRI
Using “Freesurfer” Post Processing
Software Rita Vadala, Giuseppe Bomboi,
Alberto Pierallini, Elisabetta Giugni
P03.166 Comparison of Clinical
Features and [18F]FP-CIT PET Findings
between Drug-Induced Parkinsonism
with and without Underlying Parkinson’s
Disease Youngshin Yoon, Jae Seung Kim,
Kyung A. Kim, Chong Sik Lee
P03.167 Aging Effects of [18F]FP-CIT
PET Measures in the Striatum of Drug
Naïve, De Novo PD Patients: Comparison
with Normal Subjects Chong Lee, Chang
You, Kyung Kim, Jae Kim
P03.168 Baroreflex Sensitivity
and Power Spectral Analysis during
Autonomic Testing in Different
Extrapyramidal Syndromes Heinz
Reichmann, Daniela Berg, Ludger Schoels,
Tjalf Ziemssen
P03.169 Bulbar Function Is Correlated
with Neuroimaging Outcomes in
Parkinson’s Disease Catherine Gallagher,
Sterling Johnson, Moo Chung, Benjamin
Brooks, James Abbs, Selami Dogan,
Barbara Bendlin, Robert Nickles, W. Brown
P03.170 Symptomatic Correlation
of [18F]FP-CIT PET Measures in PD
Patients Chang You, Chong Lee
Movement Disorders: Ataxia and
Cerebellar Disease
P03.171 Identifying Drugs for the
Treatment of Spinocerebellar Ataxia Type
2 (SCA2) Daniel Scoles, Lance Pflieger,
Stefan Pulst
P03.172
WITHDRAWN
P03.173 Effects of Erythropoietin
Single Dose Treatment in Patients
with Friedreich Ataxia Sylvia Boesch,
Wolfgang Nachbauer, Sascha Hering,
Markus Seifert, Hannes Steinkellner,
Markus Reindl, Brigitte Sturm, Guenther
Weiss, Barbara Scheiber-Mojdehkar,
Werner Poewe
P03.174 The Emerging Role of
Spinocerebellar Ataxia 17 in a Canadian
Movement Disorders Clinic Katie
Wiltshire, Sarah Furtado, Scott Kraft, Jillian
Parboosingh, Oksana Suchowersky
P03.175 Case Report: Human
Immunodeficiency Virus Type 2 (HIV 2) and
Ataxia Raam Sambandam, Zhigao Huang
P03.176 Retrospective Analysis
of the Use of Varenicline (Chantix®) in
Ataxia Israt Jahan, Abinaya Chari, Clifton
Gooch, Kelly Sullivan, Laurie Dempsey,
Juan Sanchez-Ramos, Theresa Zesiewicz
P03.177 Case Report: Bilateral
Ballism Following Postinfectious
Meningoencephalitis with Demyelinating
Polyneuropathy, Ophthalmoplegia, Bulbar
Dysfunction, Areflexia, and Negative
Anti-GQ1B Antibody Riley Bove, Ruchira
Jha, Daniel Weisholtz, Tommy Thomas,
Richard Woolf, Galen Henderson
P03.178 A Case of Subacute
Encephalopathy, Ataxia, and Myoclonus
Due to Amantadine Toxicity in Chronic
Renal Insufficiency Angela Hardwick,
Michael Devereaux, Benjamin Walter
P03.179 SCA-17 Presenting with
an Unusually Mild Phenotype Sarah
Wahlster, Phyllis Grable-Esposito, Herminia
Rosas, Jeremy Schmahmann, Richard
Myers, Gillis Tammy, Jayalakshmi Mysore,
Marcy McDonald, Diane Lucente, Jang-Ho
Cha
P03.180 Efficacy and Safety of
Idebenone in a Six-Month US Phase III
Clinical Study of Idebenone in Children
with Friedreich’s Ataxia David Lynch,
Susan Perlman, William Andrews, Thomas
Meier
Movement Disorders:
Parkinson's Disease: Genetics
P03.181 Parkin and Pink1 Promote
DRP1-Mediated Mitochondrial Fusion
in Cellular Models Maria Damiano, Lori
Buhlman, Giulia Bertolin, Rosa Ferrando
Miguel, Amandine Roux, Alexis Brice, Olga
Corti
P03.182 Neuropathological and
Biochemical Report of a Patient with a
Parkin Mutation Hugh Kearney, Helene
Plun-Favreau, John Hardy, Francesca Brett,
Tim Lynch
P03.183 LRRK2 G2019S Mutation
in an Argentinean Cohort of Patients
with Parkinson’s Disease Emilia Gatto,
Daniela Converso, José Martí-Massó, Coro
Paisán Ruiz, Gabriel Persi, Jose Etcheverry,
Virginia Parisi, Fernando Leiguarda, María
Carreras, Juan Poderoso
P03.189 Olfactory Loss in LRRK2
Related Parkinsonism Laura SilveiraMoriyama, Renato Munhoz, Margarete
Carvalho, Salmo Raskin, Ekaterina
Rogaeva, Tais Moriyama, Patricia Aguiar,
Rodrigo Bressan, Andre Felicio, Orlando
Barsottini, Luis Augusto Andrade, Hsin
Chien, Vicenzo Bonifati, Egberto Barbosa,
Helio Teive , Andrew Lees
P03.200 Lafora Disease: An
Experience of 10 Years in the National
Institute of Neurology and Neurosurgery,
Mexico Liliana Romero-Ocampo, Erandi
Bravo-Armenta, Steven Vargas, Luis
Ruano-Calderon, Francisca FernandezValverde, Adriana Morales-Ochoa, Ma.
Elisa Alonso-Vilatela, Rosalba VegaOrozco, Iris Martínez-Juárez
P03.190 Mitochondrial Impairment
in Manifesting LRRK2-G2019S
Carriers Oliver Bandmann, Krisztina
Johansen, Jan Aasly, Heather Mortiboys
P03.201 Investigation of
Bromodomain-Containing Protein 2
(BRD2) Gene Mutations in Photosensitive
Epilepsy Betul Baykal, Ebru Nur VanliYavuz, Ozkan Ozdemir, Suzin Catal, Nerses
Bebek, Ugur Ozbek
P03.191 Olfactory Dysfunction
Associated with LRRK2 G2019S
Mutations Kaili Stanley, Vicki Shanker,
Deborah Raymond, Paul Soto, Richard
Lipton, Susan Bressman, Rachel SaundersPullman
P03.192 Parkinsonism and Progressive
External Ophthalmoplegia with Multiple
Mitochondrial DNA Deletions: Report of
Two New Cases Brandon Barton, Sandra
Jackson, Nico Diederich
P03.193 New Mutations Identified in
the SYNE1 Gene in ARCA-1 Patients Anne
Noreau, Pierre Provencher, Cynthia
Bourassa, Patrick Dion, Nicolas Dupre,
Alexis Brice, Guy Rouleau
P03.194 Systematic Integration
of GWAS Data into Ongoing MetaAnalyses of Parkinson’s Disease Genetic
Association Studies Christina Lill,
Johannes Roehr, Sachin Bagade, BritMaren Schjeide, Matthew McQueen, Lars
Bertram
Epilepsy: Basic Science,
Genetics, and Epidemiology
P03.184 PINK1 Mediates the
Stress-Induced Degradation of
Parkin Aleksandar Rakovic, Anne
Grunewald, Alfredo Ramirez, Slobodanka
Orolicki, Katja Lohmann, Christine Klein
P03.195 Microglia Contribute
to Synaptic Stripping During
Epileptogenesis: Animal and Human
Evidence Martina Vendrame, Delia Talos,
Frances Jensen
P03.185 Mutations in the LRRK2
(G2019S) and the Glucocerebrosidase
Genes Can Influence the Clinical Course
and Pre Morbid Behavior of Patients with
Parkinson’s Disease Tanya Gurevich, Anat
Mirelman, Avner Thaler, Shiran Levy, Elissa
Ash, Avi Orr-Urtreger, Nir Giladi
P03.196 Ca2+ Channel Promiscuity
of Small Conductance Ca2+-Activated K+
channels (SK) in Hippocampal Pyramidal
Neurons Felix Benninger, Shmuel Chen,
Yoel Yaari
P03.186 Genetic Risk Factors for
Cognitive Impairment in the DATATOP
Cohort Karen Marder, Lorraine Clark,
Michael McDermott, Ergun Uc, PSG
DATATOP Investigators
P03.187 Functional Polymorphisms
of Human Dopamine Pathway Genes
COMT, DBH and MAOB: A Pilot SNP Study
of Single Gene Locus and Gene-Gene
Interaction in Parkinson Disease Tao Xie,
Allan Levey, Yilang Tang, Joseph Cubells,
Wenzhen Duan
P03.188 Progression of Motor
Features in Elderly LRRK2 G2019S NonManifesting Carriers Marta San Luciano,
Richard Lipton, Cuiling Wang, Laurie
Ozelius, Mindy Katz, Susan Bressman, Amy
Sanders, Rachel Saunders-Pullman
Poster Session III
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P03.197 Differential Cellular
Distribution of Acetyl CoA Synthetases in
the Rat Brain: Implications for Ketogenic
Diet Mediated Neuroprotection Aryan
Namboodiri, John Moffet, Prasanth
Ariannur, Peethambaran Arun, Chikkathur
Madhavarao, Batool Kirmani
P03.198 Using SCN1A Gene Mutation
Screening in Clinical Practice Marina
Gonsales, Paula Preto, Marilisa Guerreiro,
Iscia Lopes-Cendes
P03.199 Familial Cortical Myoclonic
Tremor with Epilepsy (FCMTE): Mapping
the Third Gene to 5p in a Large French
Family: FCMTE 3 Eloi Magnin, Christel
Depienne, Delphine Bouteiller, Giovanni
Stevanin, Cécile Saint-Martin, Marie
Vidailhet, Emmanuelle Apartis, Eric
LeGuern, Pierre Labauge, Lucien Rumbach
P03.202 Decreasing Presentations
of Seizures to Emergency Departments
in a Large Australian Population Dennis
Cordato, Peter Thomas, Ghia Darshan,
Taneja Sanjeev, John Worthington, Alan
McDougall, Suzanne Hodgkinson, Hanna
Ibrahim, Neil Griffith, Cecilia CappelenSmith, Roy Beran
P03.203 Characteristics and Outcome
of Post-Hypoxic Status Epilepticus Neena
Jamwal, Imran Ali, Siddharth Sehgal,
Shekhar Raj, L. Greenfield
P03.204 Risk Factors for the
Development of Prolonged Status
Epilepticus Francisco Gutierrez Manjarrez,
Iris Gonzalez Orizaga, Elizabeth Soto
Cabrera, Horacio Senties Madrid,
Guillermo Garcia Ramos, Hector Barragan
Campos, Bruno Estanol Vidal
Peripheral Nerve: Inherited
Neuropathies: Clinical and
Genetic Insights
P03.205 Clinical Neurophysiologic
and Genetic Presentation in Patients
with Axonal Charcot-Marie-Tooth
Disease Jelena Nikodinovic, Vedrana
Milic Rasic, Slobodanka Todorovic,
Vidosava Rakocevic Stojanovic, Jelena
Mladenovic
P03.206 Increased Activity of
Mutant TRPV4 Channels Is a Commom
Feature in Both Scapuloperoneal Spinal
Muscular Atrophy and Hereditary Motor
and Sensory Neuropathy Type IIC Faisal
Fecto, Yong Shi, Han-Xiang Deng, Jianhua
Yan, Haujie Yau, Marco Martina, Teepu
Siddique
P03.207 Development of the Pediatric
Charcot-Marie-Tooth Disease Quality of
Life Instrument (pCMT-QOL): An Outcome
Measure for Clinical Trials Sindhu
Ramchandren, Joshua Burns, Michael Shy
P03.208 Development and Validation
of the Charcot-Marie-Tooth Disease
Pediatric (CMTPed) Scale Joshua Burns,
Rosemary Shy, Tim Estilow, Gyula Acsadi,
Allan Glanzman, Robert Ouvrier, Francesco
Muntoni, Mary Reilly, Michael Shy, Richard
Finkel
P03.209 Axonal Deformities in a
Mouse Model of Hereditary Neuropathy
with Liability to Pressure Palsies
(HNPP) Mario Saporta, Istvan Katona,
Yunhong Bai, Michael Shy, Jun Li
P03.210 Novel Mutation in
First Codon of Connexin 32 Causing
CMT-X Dreama Brar, Sat Dev Batish,
Michael Pulley
P03.211 Ethambutol Toxicity
Exacerbating the Phenotype of
CMT2A2 Ekokobe Fonkem, Elaine Binkley,
Monica Skordil, John Kissel, Victoria
Lawson
P03.212 Phenotypic Characteristics
of Hereditary Motor and Sensory
Neuropathy Type VI (HMSN VI) Hye Yang,
Kee Duk Park, Kyoung-Gyu Choi, Byung-Ok
Choi
P03.213 Phenotypical Features of
14 Moroccan Families with Autosomal
Recessive Charcot-Marie-Tooth Disease
Associated with Mutations in the GDAP1
Gene Nazha Birouk, Ahmed Bouhouche,
Halima Belaïdi, Hamid Azzeddine, Odile
Dubourg, Ali Benomar, Thierry Maisonobe,
Mohamed Yahyaoui, Eric Le Guern, Reda
Ouazzani
P03.214 Distribution of CharcotMarie-Tooth Disease Subtypes and
Frequency of Positive Genetic Testing
Results Carly Siskind, Stephanie Sottile,
Shawna Feely, Lindsey Miller, Michael Shy
Neurogenetics and Gene
Therapy
P03.215 Allele-Specific Expression
Changes in SNCA and GAK in Parkinson
Disease Brain Tissue Nathan Pankratz,
William Nichols, Xiaoling Xuei, Diane
Kissell, Michael Pauciulo, Salvatore Spina,
Yunlong Liu, Mingxiang Teng, Bernardino
Ghetti, Howard Edenberg, Tatiana Foroud
P03.216 Impact of Mutations in
Parkin on Mitochondrial Function and
Morphology Anne Grünewald, Lisa
Voges, Aleksandar Rakovic, Meike
Kasten, Norman Kock, Anthony Schapira,
Slobodanka Orolicki, Christine Klein
P03.217 Spinocerebellar Ataxia Type
31 (SCA31) Is a Common Late-Onset
Purely Cerebellar Ataxia Kinya Ishikawa,
Yusuke Niimi, Nozomu Sato, Takeshi
Amino, Hitomi Matsuo, Taro Ishiguro,
Makoto Takahashi, Masato Obayashi,
Hidehiro Mizusawa
P03.218 Cytochrome Oxidase Gene
Variations and Their Potential Functional
Consequences Russell Swerdlow, Jane
Lu, Mariana Rodova, Isaac Onyango, E.
Lezi, Raquel Esteves
P03.219 Variation Databases for
Neurodegenerative Disorders Shoji Tsuji,
Makiko Yoshida, Yuji Takahashi, Asako
Koike, Yoko Fukuda, Jun Goto
P03.220 Changes in MicroRNA
Expression Profile in Mesial Temporal
Sclerosis Danyella Dogini, Tiago Pereira,
Cristiane Rocha, Clarissa Yassuda, Helder
Tedeschi, Evandro de Oliveira, Claudia
Maurer-Morelli, Fernando Cendes, Iscia
Lopes-Cendes
P03.221 Spinal Cord Atrophy
Correlates with Clinical Disability in
Friedreich Ataxia Marcondes Franca, Jr,
Felipe Bergo, Anelyssa D’Abreu, Luciana
Bonadia, Marilza Silva, Iscia LopesCendes, Fernando Cendes
P03.222 Hematopoietic Stem
Cell Transplantation for Adult-Onset
Krabbe Disease: First Report in the
Literature Madeleine Sharp, Corree Laule,
Sandra Sirrs
P03.223 Altered GABA Receptor
Expression and Function in Fragile X
Knockout Mice Daniel Adusei, Laura
Pacey, David Hampson
P03.224 Isolated Hexosaminidase B
Deficiency in a Family with Late Onset
Spinocerebellar Degeneration Dina
Amrom, Frederick Andermann, Serge
Melançon, Eva Andermann
P03.225 Superior Cerebellar Peduncle
Atrophy in Friedreich’s Ataxia Correlates
with Disease Symptoms Hamed Akhlaghi,
Louise Corben, Johnson Bradshaw, Nellie
Georgiou-Karistianis, Martin Delatycki,
Gary Egan, Elsdon Storey
P03.226 Neuroprotective Potential of
DJ-1 in Neurodegenerative Diseases Nirit
Lev, Daniel Offen, Eldad Melamed
P03.227 Protein Analysis in Cells
with Oxidative Phosphorylation
Deficiency Celia Tengan, Andresa
Rodrigues, Katia Oliveira, Beatriz Kiyomoto
P03.228 Phenotypes of 117
Korean Patients with Mitochondrial
Disorders Eun Hye Jeong, Ji Soo Shin,
Eun Kyung Park, Su Jin Hwang, Sun Young
Cho, Ki Wha Chung, Byung-Ok Choi
P03.229 Maternally Inherited Spastic
Paraplegia Due to a Mitochondrial DNA
Mutation Christophe Verny, Adriana
Prundean, Naïg Gueguen, Valérie
Desquiret, Frederic Dubas, Arnaud
Chevrollier, Patrizia Amati-Bonneau,
Dominique Bonneau, Pascal Reynier,
Vincent Procaccio
P03.230 Electrophysiological Evidence
of Subclinical Multi-System Involvement
in Pure OPA1 Autosomal Dominant Optic
Atrophy Mark Baker, Karen Fisher, Roger
Whittaker, Stuart Baker, Patrick Yu-WaiMan, Patrick Chinnery
P03.231 The “Ear of the Lynx” MRI
Sign in Spastic Paraparesis with SPG 11
Mutations Belen Pascual, Mario Riverol,
Joseph Masdeu
P03.232 Regional Brain Energy Deficit
in a Preclinical Model of Huntington
Disease: Presymptomatic Compensatory
Mechanisms Fanny Mochel, Brandon
Durant, Raphael Schiffmann, Alexandra
Durr
P03.233 Phenotype-Genotype
Correlation of Four Novel Senataxin
Gene Mutations in Hungarian
Patients Zsuzsanna Pal, Klara Pentelenyi,
Anikó Gal, Viktoria Remenyi, Arndt Rolfs,
Maria Molnar
63
Poster Session III
P03.234 Genetic Epidemiological and
Clinicopathological Study of Familial and
Sporadic Amyotrophic Lateral Sclerosis
with FUS Mutations in the Japanese
Population Yuji Takahashi, Jun Goto,
Masahiko Watanabe, Shuji Kishida, Yuichi
Maruki, Shigeo Murayama, Shoji Tsuji
P03.235 Application of a MicroarrayBased Whole Mitochondrial DNA
Sequence Analysis for Molecular
Diagnosis of Mitochondrial
Diseases Hiroyuki Ishiura, Yuji Takahashi,
Shinobu Fukumura, Yoshiko Nomura,
Ritsuko Hanajima, Yasuo Terao, Akihiro
Yugeta, Jun Shimizu, Jun Goto, Shoji Tsuji
P03.236 TIMM8A 3`UTR Mutations
in Subjects with Deafness and Dystonia
May Affect TIMM8A Expression Russell
Swerdlow, Joseph Fontes, Mariana
Rodova
P03.237 The Phenotype of CADASIL
in a Family with Hemozygous and
Heterozygous Same R1231C Notch3
Mutation Saeed Bohlega, Najeeb Qadi,
Mohammad Alhamed, Brian Meyer
P03.238 Genetic Testing of Oxidative
Phosphorylation Diseases: Comparison
of Next Generation Sequencing with
Capillary Sequencing Approaches John
Shoffner, Genevieve Langley, Lauren
Mylacraine, Lauren Hyams
P03.239 Lithium Reduces Cell Death
in an In Vitro Model of Machado-Joseph
Disease Camila Lopes, Tiago Pereira,
Rovilson Gilioli, Iscia Lopes-Cendes
P03.240 Vitamin D Receptor Gene
Confers Genetic Risks for Parkinson
Disease Guney Bademci, Jeffery Vance,
Todd Edwards, Amber Burt, Stephan
Zuchner, William Scott, Eden Martin,
Liyong Wang
P03.241 The PhenX Toolkit: Providing
Standard Measures of Neurological
Traits for Genome-Wide Association
Studies Jeffery Vance, Lindsay Farrer,
Maiese Deborah, Wayne Huggins, Erin
Ramos, Tracey Grant, Carol Hamilton
Aging and Dementia: Genetics
P03.242 PICALM and ApoE
Polymorphisms in Italian Patients with
Alzheimer’s Disease Benedetta Nacmias,
Silvia Bagnoli, Irene Piaceri, Andrea Tedde,
Valentina Bessi, Laura Bracco, Biancamaria
Guarnieri, Sandro Sorbi
P03.243 First Report of
Frontotemporal Dementia-Like Phenotype
in an Argentine Family with Presenilin-1
M146V Alzheimer’s Disease with
Pick Bodies Ricardo Allegri, Leonardo
Bartoloni, Cecilia Serrano, Galeno Rojas,
Miguel Riudavets, Gustavo Sevlever,
Analia Taratuto, Peter St George-Hyslop
P03.244 Histone Deacetylases
Suppress CGG Repeat Induced
Neurodegeneration in Drosophila Model
of FXTAS Peter Todd, J. Taylor, Henry
Paulson
64
P03.245 Apolipoprotein E
Polymorphism and Age of Onset for
Alzheimer’s Disease in a Quadriethnic
Sample Oh Dae Kwon, Aisha Khaleeq,
Hye Guk Ryu
P03.246 CALHM1 P86L Polymorphism
Is Associated with Late-Onset Alzheimer’s
Disease under a Recessive Model Merce
Boada Rovira, Carmen Antunez Almagro,
Jesus Lopez-Arrieta, Jose Jorge Galan,
Francisco Moron, Isabel Hernandez Ruiz,
Juan Marin, Pablo Martinez-Lage, Jose
Carrasco, Luis Real, Antonio GonzalezPerez, Lluis Tarraga Mestre, Agustin Ruiz
P03.247 Genetic Variability in
Cholesteryl Ester Transfer Protein
(CETP) Is Independently Associated with
Protection from Incident Dementia Amy
Sanders, Cuiling Wang, Mindy Katz, Carol
Derby, Nir Barzilai, Laurie Ozelius, Richard
Lipton
P03.248 Incidence of a Positive Family
History in Genetic Prion Disease: Data
from a Large Cohort Julie Thai, Tricia See,
David Johnson, Amy Kuo, Katherine Wong,
Stephen DeArmond, Jill Goldman, Bruce
Miller, Michael Geschwind
P03.249 KIBRA: A Candidate Gene for
Alzheimer’s Disease with Implications for
Memory Jeremy Burgess, Otto Pedraza,
Meron Hirpa, Thuy Nguyen, Ma Li, Zou
Fanggeng, Steven Younkin, Julia Crook,
Vernon Pankratz, Ronald Petersen, Neill
Graff-Radford, Nilufer Ertekin-Taner
Aging and Dementia:
Therapeutics
P03.250 Dimebon (Latrepirdine) Does
Not Enhance Cognition by Actions on
Acetylcholinesterase or NMDA Receptor
Modulation Marco Giorgetti, Sebastián
Bernales, Iván Alfaro, Christophe Drieu La
Rochelle, Thomas Cremers, C. Anthony
Altar, Robert Wronski, Andrew Protter
P03.251 Safety and Tolerability
of a Once-Daily, Extended-Release
Memantine Formulation (28 mg) in
Patients with Moderate to Severe
Alzheimer’s Disease: Results of a 52Week Open-Label Trial Barnett Meyers,
Min Lin, Stephen Graham
P03.252 Predictors of Adherence
among Alzheimer’s Disease Patients
Receiving Oral Therapy: Results of a
Retrospective Database Analysis Bijan
Borah, Patricia Sacco, Victoria Zarotsky
P03.253 Effectiveness of Memantine
in Patients with Moderate to Severe
Alzheimer’s Disease as Measured by the
Caregiver Perceived Burden Questionnaire
(CPBQ) Teresa Wilcox, Wen-Hung Chen,
Sean O’Quinn, Juliana Setyawan, Judith
Saxton, M. Haim Erder
P03.254 Donepezil’s Effect on
Cognition in Severe Alzheimer’s
Disease: A Pooled Data Analysis Jeffrey
Cummings, Joan Mackell, Sharon
Richardson
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P03.255 Evaluating Cognitive Effects
of Oral Rivastigmine Using Subscales
and Items of the ADAS-Cog in Patients
with Mild to Moderate Parkinson’s
Disease Dementia Frederick Schmitt, Dag
Aarsland, Kolbjorn Brønnick, Jason Olin,
Xiangyi Meng
P03.256 Effects of Rivastigmine
Transdermal Patch on Cognitive Ability in
Patients with Mild to Moderately Severe
Alzheimer’s Disease George Grossberg,
Frederick Schmitt, Jason Olin, Xiangyi
Meng
P03.257 Effects of Oral Rivastigmine
on Specific Cognitive Abilities in
Patients with Mild to Moderately
Severe Alzheimer’s Disease: A Pooled
Analysis Martin Farlow, Jeffrey
Cummings, Jason Olin, Xiangyi Meng
P03.258 Benefits of ExtendedRelease Memantine (28 mg, Once Daily)
on Caregiver Distress: Results of a
Multinational, Double-Blind, PlaceboControlled Trial in Moderate to Severe
Alzheimer’s Disease George Grossberg,
Facundo Manes, Ricardo Allegri, Luis
Miguel Gutierrez Robledo, Sergio Gloger,
Lei Xie, Xinwei Daniel Jia, James Perhach,
Michael Tocco, Stephen Graham
P03.259 Dimebon (Latrepirdine)
Promotes Neurite Outgrowth and
Prevents Loss of Mitochondrial
Membrane Potential in Cultured
Hippocampal Neurons Sebastián
Bernales, Iván Alfaro, Andrew Protter
P03.260 Dimebon (Latrepirdine)
Is Well-Tolerated in Patients with
Alzheimer’s Disease Receiving
Memantine or Memantine Plus
Donepezil Anton Porsteinsson, Bryan
Selby, Fong Wang, Pierre Tariot
P03.261 The Effects of Cholinesterase
Inhibitors of Developing Dementia
from Mild Cognitive Impairment Pablo
Martinez-Lage, Isabel Hernandez Ruiz,
Montserrat Alegret Llorens, Sergi Valero
Ventura, James Becker, Oscar Lopez, Lluis
Tarraga Mestre, Merce Boada Rovira
Child Neurology/Developmental
Neurobiology: Genetics/
Therapeutics
P03.262 Recognition and Therapy of
Tetrahydrobiopterin Deficiency (BH4) in
Childhood Dystonia, a Spectrum of Dopa
Responsive Disorders Bennett Lavenstein,
Uta Kozecki-Lichter, Kenneth Rosenbaum
P03.263 Partial Trisomy 2p13.3-P16.3:
Report of a Patient with Developmental
Delay and Polymicrogyria, and Review of
the Literature; a Shared Locus for Bilateral
Perisylvian Polymicrogyria Narrowed
to 2p16.1-P16.3 Dina Amrom, Bernard
Dan, Nicolas Deconinck, Daniel Brasseur,
Catherine Christophe, Bruno Pichon,
Christopher Walsh, Eva Andermann
P03.264 A Novel Congenital Disorder
of Glycosylation Caused by Deficiency in
ALG11 (ALG11-CDG) Luc Regal, Wendy
Vleugels, Valerie Race, François Foulquier,
Linda De Meirleir, Katrien Jansen, Jaak
Jaeken, Gert Matthijs
P03.265 L-Dopa Therapy in Angelman
Syndrome of Childhood Bennett
Lavenstein, Andrea Gropman
P03.266 Pyruvate Therapy on Leigh
Syndrome Due to a Novel Mutation in
PDH E1a Gene Nataliya Povalko, Toyojiro
Matsuishi, Etsuo Naito, Masashi Tanaka,
Yasutoshi Koga
P03.267 Lacosamide as
Add-On Therapy in Pediatric
Epilepsy: Retrospective Clinical
Experience Michael Chez
P03.268 Idebenone as a Potential
Therapy for Ataxia with Oculomotor
Apraxia Type I— Results of a OneYear N-of-1 Trial Grace Yoon, Robyn
Westmacott, Brenda Banwell
P03.269 Treatment of Pediatric
Status Migrainosus: Can We Prevent
the “Bounce Back”? Genevieve Legault,
Harley Eisman, Michael Shevell
P03.270 Mapping of Loci for
Autistic Spectrum Disorder on
Chromosomes 7q31.31-31.33 and
9q21.33-q22.2 Mohammed Aldosari,
Latifa Al-Sharif, Dania Khalil, Jameela
Shinwari, Ahood Almuslamani, Nada Al
Tassan, Michael Nester
Poster Session III
Wednesday, April 14 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P03.276 Effect of Healthy
Subjects’ Age on Systemic Exposure to
Armodafinil Mona Darwish, Mary Kirby,
Edward Hellriegel, Ronghua Yang, Philmore
Robertson, Jr
P03.277 Outcomes of Sodium Oxybate
Therapy for Narcolepsy in an Out Patient
Sleep Clinic Population Jo Anne Turner,
Richard Bogan
P03.278 Narcolepsy Risk in Relation
to Alcohol and Caffeinated Beverage
Consumption Among Genetically
Susceptible Individuals: A PopulationBased Case-Control Study Thanh Ton,
Nathaniel Watson, W. T. Longstreth
P03.279 Daytime Sleepiness Is
Associated with Reduced Baroreflex
Sensitivity in OSAS and Not in
Narcolepsy Daniela Grimaldi, Alessandro
Silvani, Giorgio Barletta, Christian
Franceschini, Stefano Vandi, Giuseppe
Plazzi, Pasquale Montagna, Pietro Cortelli
P03.280 A Multicenter, Randomized,
Double-Blind, Placebo-Controlled fMRI
Study of the Effect of Armodafinil on
Prefrontal Cortical Activation in Patients
with Residual Excessive Sleepiness
Associated with CPAP-Treated
OSA Gregory Rippon, Douglas Greve,
Stephen Duntley, Linda Larson-Prior,
Andrew Krystal, Bruce Fischl, Stephen
Thein, Ronghua Yang, Jeffrey Dayno, Clete
Kushida, Robert Thomas
P03.281 Myotonic Dystrophy and
Sleep-Disordered Breathing: Emergence
of Severe Central Sleep Apnea After
Initiation of Non Invasive Positive Airway
Pressure Raam Sambandam, John
Decerce
P03.282 Respiratory-Related
Rhythmic Movements of Sleep
(RRMS) Divya Gupta, Irving Smith,
Sushanth Bhat
Sleep Disorders: Neurological
Issues and Disorders in Sleep
P03.283 Circadian Rhythm of Core
Body Temperature in an Animal Model
of Chronic Epilepsy Sachin Talathi, Junli
Zhou, William Ditto, Paul Carney
P03.284 Use of Sleep Medications
Prior to Presentation to Sleep Clinic in
Patients with Epilepsy and Insomnia: A
Retrospective Study Mausumi Khaund,
Alcibiades Rodriguez
P03.290 Sleep-Related Falling Out
of Bed in Parkinson’s Disease Douglas
Wallace, Henry Moore-Quiroga, Fatta
Nahab, Salim Dib, Cenk Sengun, Carlos
Singer, Alberto Ramos
P03.285 Sleep Disorders in Children
with Attention-Deficit/Hyperactivity
Disorder (ADHD) Recorded Over Night by
Video-Polysomnography Rosalia SilvestriHobson, Antonella Gagliano, Irene Arico’,
Tiziana Calarese, Rosaria Condurso
P03.291 Sleep Abnormalities in
the Pallido-Ponto-Nigral Degeneration
Kindred Andrew Spector, Zbigniew
Wszolek, Brittany Dugger, Ryan Uitti,
Paul Fredrickson, Joseph Kaplan, Bradley
Boeve, Dennis Dickson, Audrey Strongosky,
Siong-Chi Lin
P03.286 Potential Mechanisms
Underlying Spatial Learning and Memory
Impairment Following Sleep Deprivation
in Early Development Rama Maganti, Do
Young Kim, Heather Milligan, Julianne
Wilke, Tom Bautista, Jong Rho
P03.287 Shifting Demographics in
REM Sleep Behavior Disorder: Sex Ratio,
Antidepressants, and Autoimmunity YoEl Ju, Linda Larson-Prior, Stephen Duntley
P03.288 Self- Perceived Personality
Changes in Healthy Adults Reporting
Dream Enactment Behavior Scott Findley,
Dona Locke, Charlene Snyder, Richard
Caselli
P03.289 Sleep Disturbance, Dreams,
Mood, and Impulsive-Compulsive
Behaviours in Parkinson’s Disease Sean
O’Sullivan, Clare Loane, Andrew Lawrence,
Andrew Evans, Paola Piccini, Andrew Lees
P03.292 Improvement in Multiple
Symptoms of Fibromyalgia with Sodium
Oxybate Treatment: Results from a
US Phase III Randomized, Controlled
Trial Todd Swick, Victor Rosenfeld, Sarah
Alvarez-Horine, Y. Grace Wang, Diane
Guinta, I. Jon Russell
P03.293 Sodium Oxybate Reduces
Pain and Improves Function and PGIC
in Fibromyalgia: Results from an
International, Randomized, Double-Blind,
Placebo-Controlled, Phase III Trial Todd
Swick, Michael Spaeth, Ernest Choy, Sarah
Alvarez-Horine, Y. Grace Wang, Beverly
Benson, Robert Bennett
P03.271 Psychiatric Comorbidity and
Management in Patients with Tuberous
Sclerosis Complex Thomas Chung, Cheryl
Fiser, Daniel Nelson, David Franz, Darcy
Krueger
Sleep Disorders: General Sleep,
Narcolepsy, and Sleep Related
Breathing Disorders
P03.272 Serotonergic Modulation
of Eye Movements in Sleep Assessed
by Automated Detection Mark
Boulos, Karthikeyan Umapathy, Peyman
Shokrollahi, Kristiina McConville, Tess
Sudenis, Dana Jewell, Sridhar Krishnan,
Brian Murray
P03.273 Slow Eye Movements
in Light Sleep on the Maintenance
of Wakefulness Test as a Marker of
Sleepiness Mark Boulos, Karthikeyan
Umapathy, Peyman Shokrollahi, Kristiina
McConville, Tess Sudenis, Dana Jewell,
Sridhar Krishnan, Brian Murray
P03.274 Race-Ethnic Variation of
Sleep Symptoms in an Urban MultiEthnic Cohort: The Northern Manhattan
Study Alberto Ramos, Chuanhui Dong,
Sandino Cespedes, William Wohlgemuth,
Bernadette Boden-Albala, Mitchell Elkind,
Clinton Wright, Ralph Sacco, Tatjana
Rundek
P03.275 Epworth Sleepiness Scale
(ESS) and SleepMed Insomnia Index
(SMI) as Outcome Measures in Treated
Narcolepsy Jo Anne Turner, Richard
Bogan
65
Integrated Neuroscience Session: Emerging Treatments in
Neuromuscular Disease
Integrated Neuroscience Session: Multiple Sclerosis Imaging
Wednesday, April 14 | 2:00 p.m.–6:00 p.m.
Wednesday, April 14 | 2:00 p.m.–6:00 p.m.
Coordinators: Daniel Reich, MD, PhD and Nancy Sicotte, MD, FAAN
Coordinators: Nicholas Maragakis, MD and Charles Thornton, MD, FAAN
Platform Sessions / 2:00 p.m.–3:30 p.m. / Constitution Hall 105
Platform Session / 2:00 p.m.–3:15 p.m. / Reception Hall 104A–D
2:00 p.m.
IN6-1.001
Preliminary Results with AVI-4658
of Dystrophin Expression, Safety
and Pharmacokinetics from the First
Systemic Administration Study in Boys
with Duchenne Muscular Dystrophy
(DMD), with a Phosphorodiamidate
Morpholino Oligomer (PMO) to Skip
Exon 51 Francesco Muntoni, Kate
Bushby, Sebahattin Cirak, Michela
Guglieri, Shirley Leow, Stephen
Shrewsbury
2:15 p.m.
IN6-1.002
A Phase I/IIa Systemic Study on
Antisense Oligonucleotide Compound
PRO051 in Patients with Duchenne
Muscular Dystrophy Nathalie
Goemans, Mar Tulinius, Gunnar Buyse,
Sjef de Kimpe, Judith van Deutekom
2:30 p.m.
IN6-1.003
Clinical Trial Testing Lithium Carbonate
and Riluzole in Patients with ALS
Terminates Early for Futility Swati
Aggarwal, Lorne Zinman, David
Schoenfeld, Robin Conwit, Jeremy
Shefner, Merit Cudkowicz
2:45 p.m.
IN6-1.004
ACE-031 Significantly Increases Lean
Body Mass and Muscle Volume in
Healthy Postmenopausal Volunteers
Following a Single Subcutaneous
Dose Niels Borgstein, Yijun Yang,
Carolyn Condon, Dawn Wilson, Eric
Haltom, Jennifer Lackey, Jasbir Seehra,
Mathew Sherman
3:00 p.m.
IN6-1.005
Adult Murine Derived Mesoangioblasts
Successfully Recovered Dysferlin
Expression in a Murine Model of
Dysferlinopathy Jordi Díaz-Manera,
Thierry Touvier, Rossana Tonlorenzi,
Laura Perani, Arianna Dellavalle,
Graziella Messina, Patrizia Pessina,
Eduard Gallardo, Isabel Illa, Yvan
Torrente, Giulio Cossu
IN6-2.004 Pulsed Electromagnetic
Fields To Reduce Diabetic Neuropathic
Pain and Stimulate Neuronal Repair: A
Randomized Controlled Trial Michael
Weintraub, David Herrmann, A. Smith,
Misha Backonja, Steven Cole
IN6-2.006 Initial Efficacy and Safety
Evaluation in Cynomolgus Monkeys
of AVI-5038, a Peptide Conjugated
Phosphorodiamidate Morpholino
Oligomer (PPMO) Being Developed to
Skip Exon 50 in Duchenne Muscular
Dystrophy Peter Sazani, Stephen
Shrewsbury
2:00 p.m.
IN7-1.001
Correlation of Retinal Nerve Fiber
Layer Thickness in Optical Coherence
Tomography with Visual Cortex MR
Spectroscopy and Brain Atrophy in
Multiple Sclerosis Caspar Pfueller,
Alexander Brandt, Jens Wuerfel, Florian
Schubert, Bernadeta Walaszek, Helmar
Waiczies, Markus Bock, Frauke Zipp,
Friedemann Paul, Bernd Ittermann
2:15 p.m.
IN7-1.002
The Role of CD 4 T-Cells and Epitope
Specific CD8 T-Cells in the Formation
of T1 Hypointense Lesions in a Murine
Model of MS Istvan Pirko, Jeremiah
McDole, Yi Chen, Anne Lohrey, Scott
Dunn, Aaron Johnson
2:30 p.m.
IN7-1.003
Quantitative Venous Vasculature
Assessment on SusceptibilityWeighted Imaging Reflects Presence
of Severe Chronic Venous Insufficiency
in the Brain Parenchyma of Multiple
Sclerosis Patients. A Case-Control
Study Guy Poloni, Paolo Zamboni, Mark
Haacke, Stefano Bastianello, Michael
Dwyer, Niels Bergsland, Claudiu
Schirda, David Wack, Christopher
Magnano, Bianca Weinstock-Guttman,
Fabrizio Salvi, David Hojnacki, Robert
Zivadinov
2:45 p.m.
IN7-1.004
7 Tesla MR Imaging Marker
Distinguishes Between MS and
Ischemic Brain Lesions Emma
Tallantyre, Jennifer Dixon, Ian
Donaldson, Paul Morgan, Peter Morris,
Nikos Evangelou
3:15 p.m.
IN7-1.006
Contribution of Cortical Lesion Types
to Cortical Thinning in MS: A Combined
3T-7T MRI Study>
3:00 p.m.
IN7-1.005
Cortical Thickness in MS as Long
-Term Predictor of Physical Impairment:
Results From a Longitudinal and
Observational Large Study Mehul
Sampat, Christopher Nguyen, Darin
Okuda, Roland Henry, Daniel Pelletier
Poster Session / 3:15 p.m.–4:30 p.m. / Reception Hall 104A–D
IN6-2.001 Single, High Doses
of Epoetin alfa Increase Frataxin
in Patients with Friedreich’s
Ataxia Francesco Sacca, Raffaele Piro,
Giuseppe De Michele, Fabio Acquaviva,
Antonella Antenora, Guido Carlomagno,
Sergio Cocozza, Alessandra Denaro,
Anna Guacci, Angela Marsili, Gaetano
Perrotta, Giorgia Puorro, Antonio
Cittadini, Alessandro Filla
IN6-2.002 Intrathecal Delivery of
Autologous Mesenchymal Stem Cells
in Patients with Amyotrophic Lateral
Sclerosis Clementine Karageorgiou,
Ioanna Chatzi, Athanasia Alexoudi,
Andreas Papasavvas, Georgios
Gortzolidis, Elissaios Karageorgiou,
Eleni Papageorgiou, Georgios Tagaris,
Aikaterini Stavropoulou-Gioka
IN6-2.003 Prolonged Administration
of High- Dose Ascorbic Acid Impairs
Rat Sciatic Nerve Functional Recovery
After Crush Injury Itzik Wirguin, Marina
Bersudsky
IN6-2.005 Tafamidis (Fx-1006A):
A First-In-Class Disease-Modifying
Therapy for Transthyretin Type Familial
Amyloid Polyneuropathy Teresa
Coelho, Luis Maia, Ana Martins da
Silva, Marcia Waddington Cruz, Violane
Plante-Bordeneuve, Pierre Lozeron,
Ole Suhr, Josep Campistol, Isabel
Conceicao, Hartmut Schmidt, Pedro
Trigo, Jeff Packman, Donna Grogan
Invited Speaker Session* / 4:30 p.m.–5:00 p.m. / Reception Hall 104A–D
4:30 p.m.–5:00 p.m.
Gene Therapy for Muscular Dystrophy: Progress and Lessons Learned Jerry Mendell, MD
Platform Session / 5:00 p.m.-6:00 p.m. / Reception Hall 104A–D
5:00 PM
IN6-3.001
Complete Rescue of SMA Mouse
Model by Systemic Delivery of scAAV9
Mediating SMN Replacement Chiara
Valori, Ke Ning., Matthew Wyles,
Mimoun Azzouz
*Current as of February 1, 2010
66
5:20 PM
IN6-3.002
Antisense Therapeutics for the
Treatment of Neurodegenerative
Disorders: Preclinical Studies Richard
Smith, Robert Fey, Richard Geary,
Robert Boyd, Scott Henry, John Grundy,
Daniel Norris, Ed Wancewicz, Holly
Kordasiewcz, Don Cleveland
5:40 PM
IN6-3.003
Pharmacokinetics of IV Immunoglobulin
and Outcome in Guillain-Barré
Syndrome Krista Kuitwaard, Jenny de
Gelder, Anne Tio-Gillen, Wim Hop, Teun
van Gelder, Albert van Toorenenbergen,
Pieter van Doorn, Bart Jacobs
IN6-2.007 Proof-of-Concept for a
Novel Small Molecule Hsp90 Inhibitor
for Spinal and Bulbar Muscular Atrophy
(SBMA) Allan Rubenstein, Udai
Pandey, Zahara Jaffer, Ruihong Chen,
Sophia Barluenga, Nicolas Winssinger,
J. Taylor
Poster Session / 3:30 p.m.–4:30 p.m. / Constitution Hall 105
IN7-2.001 Ganglion Cell Layer
Volume by Spectralis Optical
Coherence Tomography (OCT) in
Multiple Sclerosis Emma Davies,
Lauren Talman, Dina Jacobs, James
Wilson, Clyde Markowitz, Steven
Galetta, Elliot Frohman, Peter Calabresi,
Laura Balcer
IN7-2.004 Relation between
Thalamic Atrophy and Long-Term
Disability Progression in Multiple
Sclerosis: An Eight-Year Follow-Up
Study Maria Rocca, Sarlota Mesaros,
Elisabetta Pagani, Maria Pia Sormani,
Giancarlo Comi, Vittorio Martinelli,
Massilmo Filippi
IN7-2.002 Cortical Microglial
Activation Is Associated with
Disability in Secondary Progressive
Multiple Sclerosis: An In Vivo Imaging
Study Marios Politis, Paolo Giannetti,
Paul Su, Federico Turkheimer, Shiva
Keihaninejad, Kit Wu, Adam Waldman,
Richard Reynolds, Richard Nicholas,
Paola Piccini
IN7-2.005 Long-Term Evolution
of Chronic Black Holes in T1Weighted MRIs of Multiple Sclerosis
Patients Raghavan Gopalakrishnan,
Jar-Chi Lee, Richard Rudick, Elizabeth
Fisher
IN7-2.003 3T MRI Frequency of MS
Cortical Lesions and Their Relationship
with Cognitive Performance Andrea
Mike, Bonnie Glanz, Peter Hildenbrand,
Dominik Meier, Khalima Bolden, Elisa
Dell’Oglio, Brian Healy, Maria Liguori,
Rohit Bakshi, Charles Guttmann
IN7-2.006 Objective Quantification
of Cerebrospinal Fluid (CSF) Flow
Rate in Cerebral Aqueduct in Patients
with Multiple Sclerosis Claudiu
Schirda, Paolo Zamboni, Christopher
Magnano, Eric Lindzen, David Wack,
Bianca Weinstock-Guttman, Deepa
Ramasamy, Ellen Carl, David Hojnacki,
Cheryl Kennedy, Michael Dwyer, Niels
Bergsland, Jennifer Cox, Fabrizion Salvi,
Robert Zivadinov
IN7-2.007 Increased Conspicuity of
Cervical Spinal Cord Lesions in Multiple
Sclerosis on Multiple-Echo Recalled
Gradient Echo (MERGE) Images at
3T Iordanis Evangelou, Nancy Richert,
Steven Jacobson, Bibiana Bielekova,
Daniel Reich
IN7-2.008 Relaxometry—A New
MR Marker of Neurodegeneration in
Multiple Sclerosis? Jan Krasensky,
Manuela Vaneckova, Eva Havrdova,
Andrea Burgetova, Dana Horakova,
Zdenek Seidl
IN7-2.009 Magnetic Resonance
Disease Severity Scale (MRDSS) for
Patients with Multiple Sclerosis: A
Longitudinal Study Mohit Neema,
Jennifer Moodie, Brian Healy, Guy
Buckle, Susan Gauthier, Bonnie Glanz,
Tanuja Chitnis, Samia Khoury, Charles
Guttmann, Howard Weiner, Rohit Bakshi
IN7-2.010 Identifying the Start of
Multiple Sclerosis Inflammation: A
Serial DTI Study Daniel Ontaneda, Ken
Sakaie, Jian Lin, Xiaofeng Wang, Mark
Lowe, Michael Phillips, Robert Fox
Invited Speaker Session* / 4:30 p.m.–6:00 p.m. / Constitution Hall 105
4:30 p.m.–4:50 p.m.
Microvascular Changes Associated with MS Lesion Formation William Rooney, PhD
4:50 p.m.–5:10 p.m.
Whole-Brain Relaxometry and Myelin Water Imaging: Techniques and Applications to MS and Other Neurological Disorders Sean Deoni, PhD
5:10 p.m.–5:30 p.m.
Typical Presentations of Sinovenous Stenosis and Thrombosis: Lessons From Neuroradiologic Evaluation Ari Blitz, MD
5:30 p.m.–5:50 p.m.
Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: A Paradigm Shift in the Physiology of Cerebral Venous Return Paolo Zamboni, MD
5:50 p.m.–6:00 p.m.
Panel Discussion
*Current as of February 1, 2010
67
Scientific Sessions
S21 Multiple Sclerosis:
Clinical Trials II
S23 Movement Disorders:
Parkinson's Disease / NonMotor Symptoms
S24 Aging and Dementia:
Imaging
S25 Epilepsy: Antiepileptic
Drug Therapy
Scientific Sessions
Wednesday, April 14 | 2:00 p.m.–4:00 p.m.
S26 Peripheral Nerve:
Clinical Advances in
Peripheral Neuropathy
S27 Infections
S28 Neuro-ophthalmology/
Neuro-otology
Theatre 102
Constitution Hall 106
Room 718AB
Constitution Hall 107
Room 716A
Room 701B
Room 701A
Room 714B
2:00 p.m.
S21.001
Oral Teriflunomide or Placebo Added to
Glatiramer Acetate for Six Months in
Patients with Relapsing Multiple Sclerosis:
Safety and Efficacy Results Mark
Freedman, Jerry Wolinsky, Gérald Frangin,
Christian Confavreux, Giancarlo Comi,
William Byrnes, Ludwig Kappos, Tomas
Olsson, Aaron Miller, Paul O’Connor
2:00 p.m.
S22.001
Levels of Matrix
Metalloproteinase-9 (MMP9) Are Associated with
Inflammation and Severity in
Acute Ischemic Stroke Lauren
Nentwich, Fabricio Lima, Gisele
Silva, Leonardo Batista, Matthew
Maas, Shahmir Kamalian, Alona
Muzikansky, Ken Arai, Sophia
Hartdegen, Steven Feske, Ron
Walls, Eng Lo, Karen Furie
2:00 p.m.
S23.001
Depression and Anxiety
Phenotypes in Parkinson’s
Disease Richard Brown, David
Burn, John Hindle, Catherine Hurt,
Sabine Landau, Mike Samuel, Ken
Wilson
2:00 p.m.
S24.001
Histopathological Validation of
Amyloid Imaging with Florbetapir
F 18 (18F-AV-45) PET in an Ongoing
Phase III Prospective Clinical Study
of Subjects at the End of Life Adam
Fleisher, Julie Schneider, Thomas
Beach, Barry Bedell, Simone
Zehntner, Jose Gamez, Franco
Sicuro, Meenaskshi Patel, Marwan
Sabbagh, Christopher Clark, Michael
Krautkramer, Michael Pontecorvo,
Abhinay Joshi, Mark Mintun,
Matthew Flitter , Franz Hefti, Daniel
Skovronsky
2:00 p.m.
S25.001
Investigating the Role of Interleukin1Beta in Temporal Lobe Epilepsy in the
Pilocarpine Rat Model Using RNA
Interference Vinicius Pascoal, Rafael
Marchesini, Tiago Pereira, Rovilson
Gilioli, Jaqueline Malheiros, Roberson
Polli, Hilde Buzzá, Alberto Tannús,
Luciene Covolan, Ésper Cavalheiro,
Fernando Cendes, Iscia Lopes-Cendes
2:00 p.m.
S26.001
Randomized Controlled Trial of
Immunoglobulin Intravenous
10% (NewGam, Octapharma
AG) in CIDP (POINT Trial) David
Cornblath, Richard Hughes,
Marinos Dalakas, Norman Latov,
Pieter Van Doorn, Hans Hartung,
Stefan Haag, Stefan Wietek
2:00 p.m.
S27.001
Herpes Simplex Virus (HSV)
Infections in Cancer Patients:
The Memorial Sloan Kettering
Cancer Center (MSKCC)
Experience Jerome Graber, Lisa
DeAngelis
2:00 p.m.
S28.001
Large Genomic Deletions in
CACNA1A Causing Episodic Ataxia
Type 2 Ji-Jun Wan, Hafsa Mamsa,
Janine Johnston, Elizabeth Spriggs,
Harvey Singer, David Zee, Alhamza AlBayati, Robert Baloh, Joanna Jen
2:15 p.m.
S25.002
Polymorphisms in Drug-Transporter
Genes Are Significantly Associated
with Response to Antiepileptic
Drugs in Mesial Temporal Lobe
Epilepsy Mariana Silva, Elisabeth
Bilevicius, Renato Santos, Rodrigo
Secolin, Claudia Maurer-Morelli,
Fernando Cendes, Iscia Lopes-Cendes
2:15 p.m.
S26.002
Heterogeneity of Polyneuropathy
Associated with Anti-MAG
Antibodies Laurent Magy,
Raphaél Kaboré, Christiane
Caudie, Gaël Gallouedec,
Jean-Michel Vallat
2:15 p.m.
S27.002
Evaluation of Rabies Virus
Infection of Adult Mouse
Dorsal Root Ganglia Neurons:
Role of Oxidative Stress Alan
Jackson, Wafa Kammouni, Elena
Zherebitskaya, Paul Fernyhough
2:15 p.m.
S28.002
Retinal Nerve Fiber Layer (RNFL)
Thickness by Optical Coherence
Tomography (OCT) in Multiple
Sclerosis (MS): Relation to Visual
Function Using Current vs. HighResolution Technologies Jennifer
Graves, Lauren Talman, Amy Conger,
Stephanie Syc, Dina Jacobs, Clyde
Markowitz, Yang Dai, Gui-shuang
Ying, Steven Galetta, Elliot Frohman,
Peter Calabresi, Laura Balcer
2:15 p.m.
S21.002
Double-Blind, Placebo-Controlled,
Randomized Phase II Serial MRI, Safety
and Tolerability Study of Two Doses of
CDP323 in Subjects with Relapsing Forms
of Multiple Sclerosis over 24 Weeks Chris
Polman, James Bowen, Frederik Barkhof,
David Bates, Daniel Wynn, Evert Sanders,
Christian Wolf, Tony Morris, Petra Duda,
Birgit Weinkauf, Frances Lynn, Barbara
Bennett
2:30 p.m.
S21.003
Recombinant T Cell Receptor Ligand (RTL)
for the Treatment of Multiple Sclerosis:
Report of a Phase I Clinical Trial Vijayshree
Yadav, Dennis Bourdette, James Bowen,
Sharon Lynch, David Mattson, Jana
Preiningerova, Clive Rose, Richard Stead,
Adolph Ferro, Andrew Goldstein, Gregory
Burrows, Halina Offner, Arthur Vandenbark
2:45 p.m.
S21.004
A Multi-Center Randomized Clinical Trial
of Donepezil to Treat Memory Impairment
in Multiple Sclerosis Lauren Krupp,
Christopher Christodoulou, Patricia Melville,
William Scherl, Ling-Yu Pai, Ralph Benedict,
Andrew Goodman, Syed Rizvi, Steven
Schwid, Bianca Weinstock-Guttman, Holly
Westervelt, Heather Wishart
3:00 p.m.
S21.005
Atorvastatin Reduces the Risk of New
Brain MRI Lesions in Patients with
Clinically Isolated Syndrome (CIS)
Compared to Placebo Emmanuelle
Waubant, Daniel Pelletier, Michele Mass,
Jeffrey Cohen, Mariko Kita, Anne Cross,
Amit Bar-Or, Timothy Vollmer, Michael
Racke, Olaf Stuve, Steven Schwid,
Andrew Goodman, Norman Kachuck, Jana
Preiningerova, Bianca Weinstock-Guttman
, Peter Calabresi, Aaron Miller, Masoud
Mokhtarani, David Iklé, Stacey Murphy,
Linna Ding, Ellen Rosenberg, ITN020AI
Study Management Team, Collin Spencer,
Scott Zamvil
3:15 p.m.
S21.006
Pilot Phase I/II Clinical Trial with
Autologous Mesenchymal Stem Cells
in Patients with Multiple Sclerosis and
Amyotrophic Lateral Sclerosis Dimitrios
Karussis, Clementine Karageorgiou, Basan
Gowda-Kurkalli, Adi Vaknin-Dembinsky,
John Gomori, Ibrahim Kassis, Panayiota
Petrou, Jeff Bulte, Shimon Slavin
3:30 p.m.
S21.007
Omega-3 Fatty Acids as an Adjunct
Therapy for Depression in Multiple
Sclerosis: A Randomized, Double-Blind,
Placebo-Controlled Pilot Trial Lynne
Shinto, Gail Marracci, Lauren Stuber, Dennis
Bourdette
3:45 p.m.
S21.008
Analysis of Clinical and Radiological
Disease Activity-Free Status in Patients
with Relapsing Remitting Multiple
Sclerosis (RRMS) Treated with Cladribine
Tablets, in the Double-Blind, 96-Week
CLARITY Study Gavin Giovannoni,
Giancarlo Comi, Stuart Cook, Kottil
Rammohan, Peter Rieckmann, Per Soelberg
Sørensen, Patrick Vermersch, Peter Chang,
Anthony Hamlett, Rehan Verjee, Bruno
Musch, Steven Greenberg
68
S22 Cerebrovascular
Disease I
Wednesday, April 14 | 2:00 p.m.–4:00 p.m.
Metro Toronto Convention Centre
2:15 p.m.
S22.002
Spinal Cord Infarcts: LongTerm Outcome and Prognostic
Predictors Carrie Robertson,
Alejandro Rabinstein
2:30 p.m.
S22.003
Risk Factors for Readmission
after Hospitalized Stroke Yu-wei
Chen, Mei-Chiun Tseng, HueyJuan Lin
2:45 p.m.
S22.004
The NIHSS-Mapped Rankin
Score: A Novel Index of
Pretreatment Disability and
Treatment-Induced Improvement
in Disability in Acute Stroke
Trials Jeffrey Saver, Sidney
Starkman
3:00 p.m.
S22.005
The Very Long-Term Risk and
Prognosis of Post-Stroke
Epilepsy in Patients with a
Previous Young Stroke FrankErik de Leeuw, Loes Jacobs,
Noortje Maaijwee, Renate Arntz,
Henny Schoonderwaldt, Lucille
Dorresteijn
3:15 p.m.
S22.006
Cognitive Dysfunction in
Children and Adolescents with
Sickle Cell Disease without
Evidence of Stroke: Preliminary
Results Ana Claudia Leite,
Janete Silva, Heber Maia Filho,
Ursula Thome, Patricia Moura,
Clarisse Lobo
3:30 p.m.
S22.007
Increase in Circulating
Endothelial Progenitor Cells by
Statin Therapy in Patients with
Acute Ischemic Stroke Qiang
Dong, Ya Lin Chen
3:45 p.m.
S22.008
The Impact of Diabetes on the
Extent of Pial Collaterals in
Ischemic Stroke Patients Marc
Lazzaro, Michael Chen,
Gregory Christoforidis, Shyam
Prabhakaran, Yousef Mohammad
2:15 p.m.
S23.002
Imaging Gambling Severity in
Patients with Parkinson’s Disease:
Evidence of Fronto-Striatal
Disconnection Roberto Cilia, Sang
Soo Cho, Thilo van Eimeren, Giorgio
Marotta, Chiara Siri, Ji Hyun Ko,
Giovanna Pellecchia, Gianni Pezzoli,
Angelo Antonini, Antonio Strafella
2:30 p.m.
S23.003
Fatigue in Parkinson’s Disease
Is Associated with Reduced
Brain Serotonin and Dopamine
Innervation Nicola Pavese, Vinod
Metta, Subrata Bose, K. Chaudhuri,
David Brooks
2:45 p.m.
S23.004
A Multi-Center, PlaceboControlled, Double-Blind Trial To
Examine the Safety and Efficacy
of Pimavanserin in the Treatment
of Psychosis in Parkinson’s
Disease Joseph Friedman, Bernard
Ravina, Roger Mills, Hilde Williams,
Daun Bahr, Perry Peters, Francois
Tison, David Burn
3:00 p.m.
S23.005
Severity of REM Atonia Loss in
Idiopathic REM Sleep Behavior
Disorder Predicts Parkinson
Disease Ronald Postuma, JeanFrancois Gagnon, Sylvie Rompre,
Jacques Montplaisir
3:15 p.m.
S23.006
Effect of Rotigotine on Non-Motor
Symptoms in Subjects with
Idiopathic Parkinson’s Disease K.
Ray Chaudhuri, Monika Rudzinska,
Bryan Kies, Jennifer Fine, Dennis
Hill, Tim Anderson, Edwin Surmann,
John Whitesides, Babak Boroojerdi,
Claudia Trenkwalder, on Behalf of
the RECOVER Study Group
3:30 p.m.
S23.007
Clinical Validation of Diagnostic
Procedures for Parkinson’s Disease
Dementia (PD-D) Brandon Barton,
David Grabli, Bryan Bernard,
Virginie Czernecki, Jennifer
Goldman, Glenn Stebbins, Bruno
Dubois, Christopher Goetz
3:45 p.m.
S23.008
Can Motor Features of Parkinson’s
Disease Be Used To Predict
Occurrence of Non-Motor
Symptoms of the Disease? Renato
Munhoz, Helio Teive, Hariklia
Eleftherohorinou, Lachlan Coin,
Andrew Lees, Lineu Werneck, Laura
Silveira-Moriyama
2:15 p.m.
S24.002
Effect of Minimal Atrophy of the
Hippocampus (HPC) and Entorhinal
Cortex (ERC) on Memory and
Functional Ability Daniel Varon,
Elizabeth Potter, Miriam Rodriguez,
David Loewenstein, Warren Barker,
Balaibal Ashok Raj, John Schinka,
Maria Greig, Yougui Wu, Ranjan
Duara
2:30 p.m.
S24.003
Distinct Clinical and Metabolic
Deficits in Alzheimer’s Disease
and Posterior Cortical Atrophy
Are Not Related to Amyloid
Distribution Michael Rosenbloom,
Adi Alkalay, Neha Agarwal, Suzanne
Baker, James O’Neill, Mustafa
Janabi, Irene Yen, Matthew Growdon,
Jung Jang, Cindee Madison, Bruce
Miller, William Jagust, Gil Rabinovici
2:45 p.m.
S24.004
Mapping Cortical Atrophy in
Parkinson’s Disease Patients
with Cognitive Impairment and
Dementia Kristy Hwang, Mona
Beyer, Amity Green, Paul Thompson,
Carmen Janvin, Jan Larsen, Jeffrey
Cummings, Dag Aarsland, Liana
Apostolova
3:00 p.m.
S24.005
The Impact of Atrophy to Mechanical
Structure Measurements in
Brain Kaspar-Josche Streitberger,
Dagmar Krefting, Ingolf Sack, Jürgen
Braun, Friedemann Paul
3:15 p.m.
S24.006
MRI Predictors of Cognitive
Change in a Diverse and
Carefully Characterized Elderly
Population Owen Carmichael, Dan
Mungas, Laurel Beckett, Danielle
Harvey, Sarah Farias, Bruce Reed,
John Olichney, Joshua Miller, Charles
DeCarli
3:30 p.m.
S24.007
Degenerative Dementia as the
Failure of a Large-Scale Distributed
Network John Listerud, David Libon,
Peachie Moore, Murray Grossman
3:45 p.m.
S24.008
Abnormal Modular Organization
of Structural Cortical Network in
Alzheimer’s Disease Zhang Chen,
Yong He, Gaolang Gong, Rosa-neto
Pedro, Lingzhong Fan, Alan Evans
2:30 p.m.
S25.003
Comparing Bioequivalence of Generic
Antiepilepsy Drugs (AEDs) Gregory
Krauss, Barbara Davit, Brian Caffo,
Yi-Ting Chang, Craig Hendrix, Anitha
Palamakula
2:30 p.m.
S26.003
Motor Neuropathies and
Serum IgM Binding to NS6S
Heparin Disaccharide or GM1
Ganglioside Alan Pestronk,
Miguel Chuquilin Arista, Rati
Choksi
2:45 p.m.
S25.004
Neurologist-Patient Dialogue about
Mood/Behavior and Adverse Effects
of Antiepileptic Drugs: Results of a
Phase II Communication Study John
Stern, Patricia Penovich, Gregory
Holmes, Corey Eagan, Meaghan
Onofrey, Eileen Kois, David Labiner,
Frank Gilliam
2:45 p.m.
S26.004
Reliability and Validity of In-Vivo
Corneal Confocal Microscopy
as a Novel Small-Fiber Test for
Diabetic Polyneuropathy Bruce
Perkins, Paul Hertz, Andrej
Orszag, Eduardo Ng, Patti Nwe,
Vera Bril
3:00 p.m.
S25.005
Retigabine 600, 900, or 1200 mg/
Day Provides Effective Adjunctive
Therapy in Adults with Refractory
Epilepsy with Baseline Total
Partial-Seizure Frequency of ≤8 or
>8 Seizures Per 28 Days Jacqueline
French, Bassel Abou-Khalil, Martin
Brodie, Susan Hall, Kevin Nanry
3:00 p.m.
S26.005
Clinical Utility of LDI Compared
with QTT for Small Fibre
Neuropathy Vera Bril, Eduardo
Ng, Patti Nwe, MyLan Ngo, Rita
Leung, Slavcho Todorochko,
Andrej Orzag, Bruce Perkins
3:15 p.m.
S25.006
Safety, Tolerability, Efficacy
and? Dosing of Rufinamide in
Pediatric Epilepsy: A Single Center
Experience Vasu Gooty, Tobias
Loddenkemper, Martina Vendrame,
Masanori Takeoka, Ann Bergin,
Yaman Eksioglu, Frank Duffy,
Alexander Rotenberg, Annapurna
Poduri, Mark Libenson, Blaise
Bourgeois, Sanjeev Kothare
3:30 p.m.
S25.007
Effects of Breastfeeding in
Children of Women on Antiepileptic
Drugs Kimford Meador, Gus Baker,
Nancy Browning, Jill Clayton-Smith,
Deborah Coombs-Cantrell, Morris
Cohen, Laura Kalayjian, Andres
Kanner, Joyce Liporace, Page Pennell,
Michael Privitera, David Loring
3:45 p.m.
S25.008
HLA B*1502 as a Genetic Marker
for Carbamazepine Induced Stevens
Johnson Syndrome Sivakumar
Rajappa, Srinivasan Venkatesan
3:15 p.m.
S26.006
Upper and Lower Limb Aδ
Fiber Conduction Velocities by
Contact Heat Evoked Potential
Stimulation (CHEPS) Benn
Smith, Mark Ross
3:30 p.m.
S26.007
Declines in Compound Motor
Action Potential Amplitudes
(CMAPs) in Peripheral Nerve
Conduction Studies (NCS)
Associated with Age May Be
Related to Inflammation and
Glucose Metabolism Ari Green,
Christopher Songster, Amy Lee,
Carol Piunti, John Engstrom
3:45 p.m.
S26.008
The Effect of Lifestyle
Intervention on Nerve
Regeneration in Metabolic
Syndrome A. Smith, Robin
Marcus, Colin Arsenault, Charles
Latner, Michael Porzio, Haimei
Wang, Sheldon Smith, Arwen
Fuller, J. Singleton
2:30 p.m.
S27.003
Neurologic Complications
Associated with 2009 Pandemic
Influenza A (H1N1) Virus
Infection, 2009–2010 James
Sejvar
2:45 p.m.
S27.004
Preliminary Evidence for
Selective Orbitofrontal
Dysfunction in Patients with
HIV Infection Evan Wong,
Ami Tsuchida, Marie-Josee
Brouillette, Richard Lalonde,
Lesley Fellows
3:00 p.m.
S27.005
The Neuradapt Study:
Volumetric and Metabolic
Changes in Basal Ganglia
of Patients with HIVAssociated Neurocognitive
Disorders Matteo Vassallo,
Alexandra Harvey-Langton,
Christine Lebrun-Frenay,
Stephane Chanalet, Gregoire
Malandain, Jacques Durant,
Christian Pradier, Philippe Robert,
Jacqueline Cottalorda, Michel
Ticchioni, Pierre Dellamonica
3:15 p.m.
S27.006
A Comparison of Rating
Scales and an Evaluation
of Progression of HIVAssociated Neurocognitive
Disorder Nishiena Gandhi,
Richard Moxley IV, Jason
Creighton, Heidi VornbrockRossa, Richard Skolasky, Ola
Selnes, Justin McArthur, Ned
Sacktor
3:30 p.m.
S27.007
Insulin Receptor as a Biomarker
for HAND in a Cohort of HIVInfected Women Valerie Wojna,
Yamil Gerena, Richard Skolasky,
Raul Mayo, Avindra Nath
3:45 p.m.
S27.008
Clinico-Pathologic Study of
Prion Disease Mimics Numthip
Chitravas, Richard Jung, R. Leigh,
Diane Kofskey, Mark Cohen
2:30 p.m.
S28.003
Weight Gain and Recurrence in
Idiopathic Intracranial Hypertension:
An Expanded Case-Control
Study Melissa Ko, Sally Chang,
Maysa Ridha, Tabassum Ali, Luis
Mejico, Nicholas Volpe, Steven
Galetta, Laura Balcer, Grant Liu
2:45 p.m.
S28.004
Non-Mydriatic Fundus Photography
in the Diagnosis of Acute
Neuro-Ophthalmic Disease in the
Emergency Department (ED) Beau
Bruce, Cedric Lamirel, David Wright,
Antoinette Ward, Nancy Newman,
Valerie Biousse
3:00 p.m.
S28.005
Optical Coherence Tomography
(OCT) Measurements and Visual
Function Tests in a Secondary
Progressive MS Trial of the
Compound Dirucotide Kristin Galetta,
Lauren Talman, Kim Cello, Tony Verco,
Sally Jones, Peter Calabresi, Steven
Galetta, Jack Werner, John Keltner,
Laura Balcer, Clyde Markowitz
3:15 p.m.
S28.006
Photophobia: Is the Central Visual
System Necessary? Sarah Dolgonos,
Craig Evinger
3:30 p.m.
S28.007
Contribution of Structural and
Functional Visual Outcomes to
Work Capacity and Employment
Status in Multiple Sclerosis David
Sackel, Lauren Talman, Dina Jacobs,
Amy Conger, James Wilson, Clyde
Markowitz, Peter Calabresi, Elliot
Frohman, Steven Galetta, Ralph
Benedict, Sarah Morrow, Laura Balcer
3:45 p.m.
S28.008
Increased Resting State Activity
of the Visual Cortex in Patients
with Leber Hereditary Optic
Neuropathy Maria Rocca, Paola
Valsasina, Stefania Bianchi-Marzoli,
Melissa Petrolini, Jacopo Milesi,
Andrea Falini, Giancarlo Comi,
Massimo Filippi
S29 Neuroepidemiology
Room 713AB
2:00 p.m. Presentation of
the Bruce S. Schoenberg
International Award in
Neuroepidemiology
Recipient:
Judith Kwasa, MD
Kisumu, Kenya
2:30 p.m.
S29.003
The Frequency, Outcome, and
Causes of Post-Operative
Cognitive Decline in Older
People Emma Jones, David
Green, Katja Kossakowski,
Nathan Gauge, Eirini Katsaiti,
Jennifer Stevens, Clive Ballard
2:45 p.m.
S29.004
Does Baseline Self-Efficacy
for Managing Parkinson’s
Disease Predict Outcomes? Lisa
Shulman, Ann Gruber-Baldini,
Karen Anderson, Paul Fishman,
Brad Robottom, William Weiner,
Stephen Reich
3:00 p.m.
S29.005
Restless Legs Syndrome (RLS)
Diagnosis in an Integrated
Health Delivery System, and
Concordance with Four RLS
Criteria Questions Stephen Van
Den Eeden, Kathleen Albers,
Julie Davidson, Rita Popat,
Amethyst Leimpeter, Caroline
Tanner, Michael Irizarry, Charles
Quesenberry, Lorene Nelson
3:15 p.m.
S29.006
Quality Indicators for Multiple
Sclerosis Eric Cheng, Carolyn
Crandall, Barbara Giesser, Jodie
Haselkorn, Chris Bever, Paul
Shekelle, Ron Hays, Barbara
Vickrey
3:30 p.m.
S29.007
A Multi-Center Study Assessing
the Impact of Seizures in
Mortality After Ischemic
Stroke Jorge Burneo, Jiming
Fang, Gustavo Saposnik
3:45 p.m.
S29.008
First Stroke, Acute Symptomatic
Seizures, and Early Mortality: A
Prospective Cohort Study. The
EPISTROKE Group (*) Ettore
Beghi, Roberto D’Alessandro,
Laureta Delaj, Flavia Mattana
S30 Multiple Sclerosis:
Genetics and Human
Immunopathogenesis
Room 717AB
2:00 p.m.
S30.001
Alzheimer’s Disease Risk Alleles in
PCDH11X and SORL1 Are Associated
with the Rate of Cognitive
Decline in Subjects with Multiple
Sclerosis Zongqi Xia, Lori Chibnik,
Joshua Shulman, Cristin Aubin, Dong
Tran, Bonnie Glanz, Charles Guttmann,
Samia Khoury, Tanuja Chitnis, Howard
Weiner, Philip De Jager
2:15 p.m.
S30.002
IL12A, MPHOSPH9/CDK2AP1, and
RGS1 Are Novel Multiple Sclerosis
Susceptibility Loci International
MS Genetics Consortium (IMSGC),
Federica Esposito, Nikolaos
Patsopoulos, Barbara Stranger, Filippo
Martinelli Boneschi, Giancarlo Comi,
David Hafler, Paul de Bakker, Philip
De Jager
2:30 p.m.
S30.003
The MSGene Database—Systematic
Meta-Analyses and Field Synopsis
of Genetic Association Studies in
Multiple Sclerosis Christina Lill,
Matthew McQueen, Johannes Roehr,
Brit-Maren Schjeide, Ute Zauft,
Sachin Bagade, Frauke Zipp, Lars
Bertram
2:45 p.m.
S30.004
mRNA-Expression Patterns of
Intracellular TRADD, FADD, cFlip,
TRAF2 and Caspase 8 in RelapsingRemitting Multiple Sclerosis Regina
Budde, Tobias Thomas, Martin
Berghoff
3:00 p.m.
S30.005
Influence of Glial Factors on B Cell
Biology: Implication in Multiple
Sclerosis Pathogenesis Nathalie
Lebeurrier, Ichiro Nakashima, Aja
Rieger, Philippe Saikali, Antonia
Kobert, Jack Antel, Yasuto Itoyama,
Amit Bar-Or
3:15 p.m.
S30.006
The Effect of Neutralizing Antibody
Testing on Treatment Patterns
Versus Usual Care in Interferon
Treated Multiple Sclerosis
Patients Barbara Green, Edward Fox,
Andrew Goodman, Clyde Markowitz,
Ronald Murray
3:30 p.m.
S30.007
New Genetic Factors in MS: TRAPS
and TNFRSF1A R92Q Mutation
in Argentina Marcelo Kauffman,
Dolores Gonzalez Moron, Orlando
Garcea, Andres Villa
3:45 p.m.
S30.008
A Link Between Autoimmunity and
Neurodegeneration in Multiple
Sclerosis Sangmin Lee, Lijing Xu,
Yoojin Shin, Lidia Gardner, Anastasia
Hertzes, Michele Roberts, F.
Curtis Dohan, Cedric Raine, Ramin
Homayouni, Michael Levin
69
Poster Session IV
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
Poster Discussion Session: Movement Disorders: Parkinson's Disease: Treatment
Behavioral Neurology: Memory
Location: 800 Level
Moderators: TBD
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
PD4.001 A Randomized, Double-Blind,
Placebo-Controlled Cross-Over Trial of
the Adenosine 2a Antagonist SYN115 in
Parkinson Disease Kevin Black, Meghan
Campbell, Wesley Dickerson, Mary Creech,
Jonathan Koller, St. Clare Chung, Stephen
Bandak
PD4.002 The Natural Progression of
Clinical Symptoms in Parkinson’s Disease
May Not Be Faster in the Earlier Stages:
Results from the ADAGIO Delayed-Start
Study Olivier Rascol
PD4.003 Overnight Conversion From
Immediate-Release to Extended-Release
Pramipexole for Adjunctive Treatment of
Advanced Parkinson’s Disease Anthony
Schapira, Paolo Barone, Robert Hauser,
Youshikuni Mizuno, Werner Poewe,
Olivier Rascol, Michael Busse, Laurence
Salin, Mandy Sohr, in the Name of the
Pramipexole ER Studies Group
Headache and Facial Pain
P04.001 Reversible Hypohidrosis
with Topiramate Therapy for Chronic
Migraine Shira Markowitz, Matthew
Robbins, Clair Cascella, Huma Sheikh,
Brian Grosberg
P04.002 Headache and Neurological
Deficits with Cerebrospinal Fluid
Lymphocytosis (HaNDL): Could It Be an
Autoimmune Disease? Gülsen AkmanDemir, Erdem Tüzün, Dilaver Kaya, Burçak
Vural, Elif Ugurel, Sema Içöz, Mefküre
Eraksoy, Angela Vincent, Mustafa Ertas,
Murat Kürtüncü
P04.003 Application of the Kano
Methodology for Evaluating Migraine
Treatment Expectations Among
Neurologists in Spain. The MIGREXX
Study Jorge Matias-Guiu, Gonzalo Nocea,
Teresa Caloto
P04.004 High Migraine Frequency
May Be Associated with Increased
Interictal Platelet Activation in Episodic
Migraine Jill Jesurum, Cindy Fuller, Sylvia
Lucas, Natalia Murinova, Lisa Hales, Elisa
McGee
P04.005 Response of SUNCT
(Short-Lasting Unilateral Neuralgiform
Headaches with Conjunctival Injection
and Tearing), SUNA (Short-Lasting
Unilateral Neuralgiform Headaches
with Autonomic Symptoms) and Primary
Stabbing Headaches to Occipital Nerve
Stimulation (ONS) Juana Marin, Peter
Goadsby
P04.006 Lifetime Anxiety Symptoms
in Migrainous Vertigo Gulden Akdal,
Birgul Balci, Aysegül Ozer, Elif Onur
70
PD4.004 Efficacy of the Adenosine
A 2A Receptor Antagonist BIIB014 in
Parkinson’s Disease (PD) Patients with
Motor Fluctuations Spyridon (Spyros)
Papapetropoulos, Rupam Borgohain, Mark
Kellett, Nir Giladi, Davorka Tomic, Alex
Coppell, John Barnard, Ying Zhu, Gilmore
O’Neill
PD4.005 Safety and Tolerability Profile
of the Adenosine A 2A Receptor Antagonist
BIIB014 as an Adjunct Treatment in
Parkinson’s Disease (PD) Patients with
Motor Fluctuations Spyridon (Spyros)
Papapetropoulos, Rupam Borgohain, Mark
Kellett, Nir Giladi, Davorka Tomic, Alex
Coppell, John Barnard, Ying Zhu, Gilmore
O’Neill
PD4.006 Initial Diagnosis and
Treatment Patterns in Parkinson’s
Disease Maureen Lage, Marcy Tarrants,
Jane Castelli-Haley
PD4.007 Long-Term Study on
Clinical Benefits and Quality of Life of
Intraduodenal Levodopa in Routine Care
for a Cohort of Treatment-Naïve Patients
with Advanced Parkinson’s Disease S.
Pälhagen, N. Dizdar, T. Hauge, B.
Holmberg, R. Jansson, J. Linder, H. Widner,
A. Johansson
PD4.008 Synthesis and Evaluation
of Novel Compounds for the Treatment
of Parkinson’s Disease Niran Argintaru,
Dipannita Basu, Bailee Dyck, Ram Mishra,
Rodney Johnson
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
PD4.009 Controlled Study of
Intermittent Theta-Burst Transcranial
Magnetic Stimulation for the Treatment
of Parkinson’s Disease David Benninger,
Brian Berman, Elise Houdayer, Natassja
Pal, Dave Luckenbaugh, Logan Schneider,
Sabina Miranda, Mark Hallett
PD4.010 Effect of Safinamide on
Levodopa-Induced Dyskinesia in Patients
with Parkinson’s Disease Mohit Bhatt,
Dana Chirileanu, Chandrashekhar
Meshram, Paolo Stanzione, Emma Forrest,
Valentina Lucini, on Behalf of the Study 016
Investigators
P04.030 Double Dissociation
of Semantic and Episodic Memory
Impairment in Temporal Variant
Frontotemporal Dementia and Alzheimer’s
Disease Kimiko Domoto-Reilly, Lucille
Pellerin, Alyson Negreira, Michael
Brickhouse, Daisy Sapolsky, Bradford
Dickerson
P04.031 False Recognition of
Unfamiliar Faces in Frontotemporal
Dementia Steven Rapcsak, Emily
Edmonds, Maya Henry, G. Hishaw, Bryan
Woodruff
P04.032 Loss of Future Oriented
Behavior in a Patient with Behavioral
Variant Frontotemporal Dementia Jee
Hoon Roh, Mee kyung Seo, Ji Hye Yoon,
Duk L. Na
P04.033 MRI Features Mimicking
Limbic Encephalitis and CJD in
Hashimoto’s Encephalopathy Without
Paraneoplastic Antibodies Asa Cordle,
Matthew Ostrander, Daniel Kaufer
P04.034 Profiles of Performance in
Verbal Serial List Learning in Alzheimer’s
Disease and Semantic Dementia Ashley
Boller, Brianna Morgan, David Libon,
Murray Grossman
P04.007 Evaluation of Efficacy and
Safety of MAP0004 in Reversing Central
Sensitization and Treating Migraine in
Established Allodynic Patients Stewart
Tepper, Shashidhar Kori, Scott Borland,
Min Wang, Bin Hu, Stephen Silberstein
P04.008 The Timing of Gastric Stasis
in an Acute Migraine and Its Impact on
Treatment Shashidhar Kori, Sheena
Aurora
P04.009 Occipital Neuralgia
as an Isolated Symptom of Bone
Metastasis Caused by Hepatocellular
Carcinoma Myung-Goo Ji, Nam Hee Kim
P04.014 Spinal Subdural Collection
in the Setting of a Spontaneous
Cerebrospinal Fluid Leak Vera Fridman
P04.022 Atypical Presentation of
Cerebellar Mutism in an Adult Tina Lin,
May Kim
P04.015 The Headache UnderResponse to Treatment (HURT) Index:
An Instrument Developed by the “Lifting
the Burden” Campaign To Improve
Management of Headache, Especially
in Primary Care Dawn Buse, Timothy
Steiner, Daniel Serrano, Michael Reed,
Richard Lipton
P04.023 Effect of Education on
Severity of Language Dysfunction After
Stroke Marlis Gonzalez-Fernandez,
Cameron Davis, John Molitoris, Argye
Hillis
P04.016 Scleral Buckle as a Unique
Cause of Facial Pain Babak Movassaghi,
David Watson
P04.010 Posttraumatic and
Postsurgical Nummular Headache Brian
Grosberg, Jelena Pavlovic, Matthew
Robbins, Uri Napchan, Seymour Solomon,
Richard Lipton
P04.017 Determinants of MigraineRelated Disability Richard Lipton, Andrew
Blumenfeld, Jack Ishak, Sepideh Varon,
Ariane Kawata, Aubrey Manack, Dawn
Buse, Peter Goadsby
P04.011 Clinical Phenotypes and
Morphological Changes of the Circle of
Willis in Migraineurs Ken Ikeda, Hirono
Ito, Konosuke Iwamoto, Kiyoko Murata, Yuji
Kawase, Osamu Kano, Kiyokazu Kawabe,
Hiroaki Iguchi, Yasuo Iwasaki
P04.018 Magnetic Resonance
Perfusion Imaging in Hemiplegic
Migraine Sirinan Tazen, C. Haynes
Ralsten, Margaret Jaynes, David Watson
P04.012 Syncopal Migraine: Migraine
as a Cause of Syncope David Curfman,
Michael Chilungu, Robert Daroff, Amer
Alshekhlee, Gisela Chelimsky, Thomas
Chelimsky
P04.013 Putative Clinical, Mechanical
and Local Paracrine Mechanisms
of Pituitary Adenoma-Attributed
Headache Christoph Schankin, Markus
Krumbholz, Anna Kristin Reifferscheid,
Jennifer Linn, Walter Rachinger, Petra
Sostak, Thomas Arzberger, Andreas
Straube
P04.019 Migrainous Vertigo
Presenting in the Perimenopause Jan
Brandes, Susan Roberson, Mark Bennett,
David Haynes
Behavioral Neurology: Language
and Praxis
P04.020 Spatial Vision, Intellectual
Loss, and Neuroimaging Variables as
Predictors of Constructional Apraxia
in Patients with Cerebrovascular
Disease Daniel Capruso, Patrick Pullicino,
Kerry Hamsher
P04.021 Spatially Adherent
Graphemic Perseveration Waldo
Guerrero, Kenneth Heilman, Abhay Kumar,
Anuali Khaku
P04.024 Narrative Discourse in
Parkinson Disease Sharon Ash, Rachel
Goldmann Gross, Brianna Morgan,
Ashley Boller, Andrew Siderowf, Murray
Grossman
P04.025 You Don’t Say: A New Variant
of PPA? Kirk Daffner, Scott McGinnis,
Daisy Sapolsky, Bradford Dickerson
P04.026 Quantifier Comprehension
in Corticobasal Syndrome and
Frontotemporal Degeneration Brianna
Morgan, Rachel Goldmann Gross, Corey
McMillan, Ashley Boller, Murray Grossman
P04.027 Extrapyramidal Signs in
Primary Progressive Aphasia Sarah
Kremen, Mario Mendez, Po-Heng Tsai,
Edmond Teng
P04.028 Impaired Decision-Making
Strategies for Pronoun Resolution in
Behavioral-Variant Frontotemporal
Dementia (bvFTD) Megan Reilly, Corey
McMillan, Robin Clark, Murray Grossman
P04.029 Language Circuits
Investigated with Semantic Decision/
Tone Decision fMRI Task and Independent
Component Analysis (ICA) Kwang Ki
Kim, Prasanna Karunanayaka, Michael
Privitera, Christi Banks, Scott Holland, Jerzy
Szaflarski
P04.035 Patterns of Memory Deficit
Modify the Rate of Conversion to
Dementia in a Large Sample of Patients
with Mild Cognitive Impairment Pablo
Martinez-Lage, Isabel Hernandez, Merce
Boada Rovira, Montserrat Alegret, Ana
Espinosa, Georgina Vinyes, Ana Mauleon,
Asuncion Lafuente, Maitee Rosende,
Susana Ruiz, James Becker, Lluis Tarraga
P04.036 Graphabulation, a New Form
of Confabulation J. Hoon Roh, Duk L. Na
P04.037 Vitamin D, Fall Frequency,
and Cognitive Function in Free-Living
Elders Amie Peterson, Nora Mattek,
Aaron Clemons, Gene Bowman, Teresa
Buracchio, Jeffrey Kaye, Joseph Quinn
P04.038 Prospective Evaluation of
32 Patients with Symptoms of Transient
Global Amnesia (TGA) in a Community
Hospital of Argentina Maria Fernandez,
Juan Rojas, Angel Golimstok, Edgardo
Cristiano
P04.039 Hyposmia, Central
Cholinergic Integrity, and Cognitive
Impairment in Parkinson Disease Without
Dementia Nicolaas Bohnen, Martijn
Muller, Vikas Kotagal, Robert Koeppe,
Michael Kilbourn, Roger Albin, Kirk Frey
P04.040 Dissociation Between Two
Routes to Action in Gesture Imitation Eric
Roy, Timour Al-Khindi, Mark Gravely, Loch
MacDonald, Sandra Black, Tom Schweizer
Behavioral Neurology: Executive
and Motor Functions
P04.041 Gait Disorders, an
Interesting Marker of Frontotemporal
Dementia Gilles Allali, Bruno Dubois,
Frederic Assal, Elise Lallart, Leonardo de
Souza, Maxime Bertoux, Cedric Annweiler,
Francois Herrmann, Richard Levy, Olivier
Beauchet
P04.042 Validation of a Simple
Bedside Antisaccade Task in
Neurodegenerative Dementia Joanna
Hellmuth, Alisa Matlin, Mary Widmeyer,
Ashley Berhel, Aria Jafari, Joel Kramer,
Bruce Miller, Adam Boxer
P04.043 Reckless Driving Associated
with Dopamine Agonist Use: A Case
Series Alida Griffith, Pinky Agarwal,
Marilyn Borromeo-Westner
P04.044 Right Inferior Frontal Gyrus Is
Necessary for Interference Suppression,
but Not Error Correction, in the Eriksen
Flanker Task Maiya Geddes, Ami
Tsuchida, Mandana Modirrousta, Adam
Aron, Lesley Fellows
P04.045 Executive Functions and
Cognition in Amyotrophic Lateral
Sclerosis Natalia Sierra, Alberto
Dubrovsky, Ana Gamba, Teresa Torralva,
María Roca, Facundo Manes
P04.046 Insight of Involuntary
Movements in Early Huntington’s Disease:
A Simple Explanation Damian Justo,
Perrine Charles, Valerie Hahn-Barma,
Lionel Naccache, Sophie Tezenas Du
Montcel, Celine Jauffret, Cecilia Marelli,
Marcela Gargiulo, Alexandra Durr
P04.047 Relationship Between
Cognition and Spatiotemporal Gait
Parameters in Parkinson Disease without
Dementia Nicolaas Bohnen, Martijn
Muller, Kirk Frey, Roger Albin
P04.048 Quantification of Increased
Mirror Overflow in ADHD: Laterality and
Gender Effects Stewart Mostofsky, Priya
Xavier, Lindsey MacNeil, Kelly Isaacs,
Amanda Lewis, Martha Denckla, Donald
Gilbert
P04.049 Excessive Hoarding in
Parkinson’s Disease Sean O’Sullivan,
Atbin Djamshidian, Andrew Evans, Clare
Loane, Andrew Lees, Andrew Lawrence
P04.050 Neuropsychological Profile of
Adult Patients with Duchenne Muscular
Dystrophy Natalia Sierra, Lilia Mesa,
Alberto Dubrovsky, Pablo Sojo, Teresa
Torralva, María Roca, Fernando Chloaca,
Laura Pirra, Facundo Manes
Anterior Horn: Spinal Muscular
Atrophy
P04.051 Trends in Outcomes and
Hospitalization Costs among Patients with
Warding’s Hoffman Disease in the United
States Khan Hafiz, Lubna Mehyar, Bilal
Saulat, Shahanara Islam, Nizar Souayah
Poster Session IV
P04.052 The Role of Ulnar Compound
Muscle Action Potential (U-CMAP)
as a Surrogate Outcome Measure in
Ambulatory Adults with Spinal Muscular
Atrophy (AA-SMA) Bakri Elsheikh,
Kathryn Swoboda, Charles Scott, Wendy
King, Elizabeth Bollman, Kristin Krosschell,
Bernard LaSalle, Stephen Kolb, John Kissel
P04.053 Beta-Lactam Antibiotics
Offer Neuroprotection in a Spinal
Muscular Atrophy Mouse Model by
Multiple Mechanisms Monica Nizzardo,
Martina Nardini, Dario Ronchi, Sabrina
Salani, Chiara Simone, Marianna Falcone,
Chiara Donadoni, Nicoletta Mezzina,
Francesca Gianni, Nereo Bresolin, Giacomo
Comi, Stefania Corti
P04.054 Salbutamol Increases
SMN mRNA in Spinal Muscular Atrophy
Patients (SMA): Relevance for Clinical
Trial Design Francesco Tiziano, Rosa
Lomastro, Anna Pinto, Sonia Messina,
Adele D’Amico, Stefania Fiori, Carla
Angelozzi, Marika Pane, Eugenio Mercuri,
Enrico Bertini, Giovanni Neri, Christina
Brahe
P04.055 Further Progress in Defining
UBE-1 Mutations and Downstream
Effects Underlying X-Linked Lethal
Infantile SMA (XL-SMA) Lisa Baumbach,
Mary Ellen Ahearn, Juliane Ramser, Kemal
Yariz, Thomas Prior, Zafar Nawaz, Antonio
Barrientos, Alfons Meindl
P04.056 Hand Held Dynamometry
and Fixed Maximal Voluntary Isometric
Contraction Strength Testing in
Ambulatory Adults with Spinal Muscular
Atrophy Wendy King, Bakri Elsheikh,
Chuck Scott, Bernard LaSalle, Kristin
Krochell, John Kissel
P04.057 Biomarker Study for Spinal
Muscular Atrophy: Study Design and
Preliminary Results Richard Finkel,
Thomas Crawford, Kathryn Swoboda,
Petra Kaufmann, Margaret Bell, Rebecca
Li, Felicia Trachtenberg, Thomas Plasterer,
Peter Juhasz, Xiaohong Li, Karen Chen,
Rory Olson, Jenny Shu, Sergey Paushkin,
Dione Kobayashi, Cynthia Joyce, Suzanne
Forrest
P04.058 Videofluorography in
Spinal and Bulbar Muscular Atrophy
(SBMA) Haruhiko Banno, Masahisa
Katsuno, Keisuke Suzuki, Seiya Tanaka,
Motoshi Kawashima, Noriaki Suga,
Atsushi Hashizume, Yasushi Fujimoto, Gen
Sobue
P04.059 Reliability of the Six-Minute
Walk Test in Ambulatory Patients with
Spinal Muscular Atrophy W. Arnold, Bakri
Elsheikh, Kathryn Swoboda, Charles Scott,
Wendy King, Elizabeth Bollman, Bernard
LaSalle, Kristin Krosschell, John Kissel
P04.060 Fatigue Related
Spatiotemporal Gait Changes During the
Six-Minute Walk Test in Spinal Muscular
Atrophy (SMA) Jacqueline Montes, Sally
Dunaway, Megan Montgomery, Douglas
Sproule, Petra Kaufmann, Darryl De Vivo,
Ashwini Rao
Anterior Horn: Genetics
P04.061 A Novel BSCL2/Seipin
Variant Associated with Atypical Silver
Syndrome Mimicking ALS Jennifer
Michaels, Thomas Winder
P04.062 Studies of Sequence
Changes of the Dynactin p150 Gene In
Vitro Marianne Stockmann, Marie MeyerOhlendorf, Corinna Hendrich, Tobias
Böckers, Albert Ludolph, Stefan Liebau
P04.063 FUS Mutations in a
Large Series of Sporadic and Familial
ALS Cristina Moglia, Andrea Calvo, ShiaoLin Lai, Yevgeniya Abramzon, Jennifer
Schymick, Rita Guerreiro, Dietrich Stephan,
Travis Dunckley, Roberto Mutani, Gabriele
Mora, Sara Gallo, Fabio Giannini, Stefania
Battistini, Fabrizio Salvi, Ilaria Bartolomei
, Cecilia Carlesi, Gabriele Siciliano,
Jessica Mandrioli, Patrizia Sola, Claudia
Caponnetto, Giovanni Mancardi, Kalliopi
Marinou, Maura Brunetti, Amelia Conte,
Mario Sabatelli, Francesca Valentino,
Vincenzo La Bella, Gioacchino Tedeschi,
Maria Rosaria Monsurr≥, Gabriella
Restagno , Brian J. Traynor, Adriano Chio
P04.064 Fronto-Temporal Dementia
in 3 ALS Families with TARDBP Missense
Mutation Andrea Calvo, Cristina Moglia,
Michele Balma, Gabriella Restagno, Irene
Ossola, Maura Brunetti, Anna Montuschi,
Anna Cistaro, Anna Picca, Bryan Traynor,
Jennifer Schymick, Roberto Mutani,
Giovanna Marrosu, Maria Murru, Giuseppe
Borghero , Adriano Chio
P04.065 The Mutational Spectrum of
Adult Onset Dominant-Inherited Familial
Amyotrophic Lateral Sclerosis in Chinese
Population on Taiwan Yi-Chung Lee, BingWen Soong, Ching-Piao Tsai
Peripheral Nerve: Progress in
Amyloid Neuropathies
P04.066 Initial Findings from the
Transthyretin Amyloidosis Outcomes
Survey (THAOS)—A Global Web-Based
Registry Violane Plante-Bordeneuve,
Teresa Coelho, Bo-Goran Ericzon, Rodney
Falk, Sh√-ichi Ikeda, Mat Mauer, Ole Suhr,
Pedro Trigo, Donna Grogan
P04.067 Skin Denervation in Amyloid
Neuropathy with a Hot-Spot Mutation of
Transthyretin (Ala97Ser) in Taiwan SungTsang Hsieh, Ming-Jen Lee, Chi-Chao
Chao
P04.068 Outcome Measures for
Transthyretin Type Familial Amyloid
Polyneuropathy Teresa Coehlo, Ingemar
Merkies, Aaron Vinik, Etta Vinik, Jason
Chan, Jeff Packman, Donna Grogan
P04.069 Post-Liver Transplant
ATTR Val30Met Patients: CNS Clinical
Phenotype Luis Maia, Sara Cavaco,
Manuel Pires, Joel Freitas, Daniel Dias,
Helena Miranda, Rui Magalhães, Manuel
Correia, Teresa Coelho
71
Poster Session IV
P04.070 Transthyretin Familial
Amyloid Polyneuropathy: Does a
Mitochondrial Polymorphism Entirely
Explain the Parent-of-Origin Difference in
Penetrance? Violaine Plante-Bordeneuve,
Malin Olsson, Urban Hellman, Ole Suhr,
Catherine Bonaiti-Pellié, Bernard Bonaiti
Aging and Dementia: Amyloid
and Gray Matter Imaging
P04.071 Patterns of Amyloid
Deposition in Individual Patients with Mild
Cognitive Impairment: An 11C-PIB PET
Study Najlaa Ahmad Nazri, Sofia Sofia
Rodriguez Martinez De Llano, Aren Okello,
Paul Edison, Jaana Koivunen, Noora
Scheinin, Juha Rinne, David Brooks, Nicola
Pavese
P04.072 Cortical Thickness Change
in Alzheimer’s Disease Over Six Months:
Data from ADNI James Paskavitz, Yong
He, Kristina Deduck, Barry Bedell, Alan
Evans, Alex Zijdenbos
P04.073 Can We Use Pons as a
Reference Region for the Analysis of [11C]
PIB PET? Paul Edison, Rainer Hinz, Anil
Ramalackansingh, John Thomas, Federico
Turkheimer, David Brooks
P04.074 Florbetaben β-Amyloid
Brain PET— Correlation with Cognition
Parameters in Alzheimer Disease Osama
Sabri, Julia Luthardt, Marianne Patt,
Eva Hammerstein, Kristin Hartwig,
Georg Becker, Andreas Schildan, Ulrich
Hegerl, Beate Rohde, Cornelia Reininger,
Hermann-Josef Gertz, Henryk Barthel
P04.075 Voxel-Based Longitudinal
Changes of Gray Matter Density in
Incipient Alzheimer’s Disease Marco
Lorenzi, Giovanni Frisoni
P04.076 In Cognitively Healthy and
Mildly Impaired Individuals Florbetapir F
18 PET Measures of Amyloid Deposition
Correlate with the Degree of Functional
Impairment Assessed Six Months Later P. Murali Doraiswamy, R. Edward Coleman,
Jeffrey Petrella, Forrest Sheldon, Michael
Pontecorvo, Franz Hefti, Alan Carpenter,
Daniel Skovronsky, Christopher Clark
P04.077 FDG-PET Pattern in Patients
with White Matter Changes with and
without Dementia: Differentiation from
Alzheimer Disease Belen Pascual, Elena
Prieto, Josep Marti-Climent, Javier Arbizu,
Joseph Masdeu
P04.078 Hippocampal Activation
during Episodic Memory Processing in
Healthy Adult Apolipoprotein E ε4 Carriers
Is Significantly Influenced by Age Lisa
Nichols, Joseph Masdeu, Venkata Mattay,
Philip Kohn, Fabio Sambataro, Matthew
Emery, Bhaskar Kolachana, J. Shane
Kippenhan, Daniel Weinberger, Karen
Berman
P04.079 The Changes of Cortical Gray
Matter in Alzheimer’s Disease According
to Clinical Dementia Rating: Voxel- Based
Morphometric Study Young Chul Youn,
Jae won Jang
72
P04.080 Progression of Prodromal
AD Associated with Amyloid Deposition
Using PIB PET Imaging Shizuo Hatashita,
Hidetomo Yamasaki
Aging and Dementia: Other
P04.081 Immunosignature of
Alzheimer’s Disease Lucas Restrepo,
Phillip Stafford, Mitch Magee, Stephen
Johnston
P04.082 Capgras Syndrome
and the Cognitive Neuroscience of
Attachment Anthony Jack, Rochelle
Hudson, Georges Naasan, Regina Cesaro,
Zimbul Albo, Alan Lerner
P04.083 Diagnostic Serendipity
in Evaluating Normal-Pressure
Hydrocephalus Aleksandra Stark, Daniel
Kaufer, Elizabeth Joran
P04.084 Verbal Memory Decline
in Alzheimer’s Disease Is Associated
with an Impairment of Frontal Executive
Control Novraj Dhanjal, Jane Warren,
Richard Wise
P04.085 Evidence That Cognitive
Activities During Adulthood Modify
the Reserve-Building Effects of
Education Bruce Reed, Dan Mungas,
Maritza Dowling, Joshua Sonnen, Sarah
Tomaszewski Farias, Milton Strauss, Eddie
Billingslea, David Bennett
P04.086 The Cognitive Reserve
Reflected in Sex Differences Is Not
Altered by APOE Genotype Leslie Baxter,
Kara Dassel, Amylou Dueck, Richard
Caselli
P04.087 Micronutrients and
Neuropsychologic Function in Patients
with Mild Cognitive Impairment and
Alzheimer’s Disease Gereon Nelles,
Wilhelm Stahl, Ludger Pientka, Maria
Polidori, Helen Griffith
P04.088 Development of a Caregiver
Burden Assessment in Alzheimer’s
Disease Diane Ito, Jonathan Stokes,
Elizabeth Piault-Louis, Josephine LiMcLeod
P04.089 Assessing Differences
in CoMorbidities, Utilization, and
Expenditures for Alzheimer’s Medicare
Beneficiaries Compared to the NonAlzheimer’s Medicare Population Kara
Suter, Amanda Forys, Susanne Machacz,
Joel Bobula, Trent McLaughlin
P04.090 Clinically Confirmed
Normal Pressure Hydrocephalus Usually
Has Alzheimer’s Disease Pathology
at Autopsy Danielle Cabral, Thomas
Beach, Linda Vedders, Lucia Sue, Sandra
Jacobson, Kent Myers, Marwan Sabbagh
P04.091 Intranasal Insulin Modulates
Hippocampal Activation According to
APOE-ε4 Genotype in Early Alzheimer’s
Disease George Thomas, William Brooks,
Cary Savage, Jeffrey Burns
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
Cerebrovascular Disease: Other
P04.105 Are Stroke Prevention
Measures Better Utilized in Primary
Stroke Centers? Kumar Rajamani, Scott
Millis, Flicia Mada, Leeza Salowich-Palm,
Sabrina Hinton, Panayiotis Mitsias,
Diane Vaphiadis, Sam Watson, Seemant
Chaturvedi
P04.093 Diagnostic Value of
Presenting Symptoms and Physical
Signs in Spinal Dural Arteriovenous
Fistula RajaNandini Muralidharan,
Andrea Saladino, Giuseppe Lanzino, John
Atkinson, Alejandro Rabinstein
P04.106 Free-Floating Thrombus of
the Carotid Artery Detected on Carotid
Ultrasound in Patients with Cerebral
Infarcts: A 10-Year Study Sheila
Srinivasan, Hoe Chin Chua, Boon Choon
Teo, Ziqun Phua, Johnny Eng
P04.094 The Northern Manhattan
Study Global Vascular Risk Score
Is Associated with Cognitive
Performance Jessica Loring, Chuanhui
Dong, Norbelina Disla, Tatjana Rundek,
Mitchell Elkind, Ralph Sacco, Yaakov Stern,
Clinton Wright
P04.107 Sex Differences in Acute
Ischemic Stroke in the Young Adult
Population Johanna Morton, Esteban
Cheng-Ching, Irene Katzan
P04.092 Age-Related Changes in
Processing Syntactically Ambiguous
Sentences: Evidence from fMRI Delani
Gunawardena, Corey McMillan, Vanessa
Troiani, Murray Grossman
P04.095 Augmented Treatment
Efficacy - A Repeated Measures Analysis
of NINDS rt-PA Study Wuwei Feng,
Gabriela Vasquez, Muhammad Suri,
Kamakshi Lakshminarayan, Qureshi
Qureshi
P04.096 Increased Expression of the
Endocannabinoid Receptor 1 in Acute
Human Stroke Marcello Naccarato, Paola
Caruso, Nelly Redolfi, Veronica Macchi,
Andrea Porzionato, Raffaele De Caro,
Giorgio Stanta, Gilberto Pizzolato
P04.097 Ischemic Lesion Pattern Was
Different According to Antithrombotic
Treatment Status in Acute Cardioembolic
Stroke Hyo-Jin Kim, Hye-Jin Kim, Ju-Hun
Lee, Kang-Yeol Park, Kyung-Hee Cho,
A-Hyun Cho, Sang-Won Ha, Kyung-Bok
Lee, Jee-Hyun Kwon, Dong-Eog Kim, JaeKwan Cha, Hahn-Young Kim, Dong-Wha
Kang, Jong S Kim, Sun U. Kwon
P04.098 Comparison of 10 mg and
5 mg Warfarin Loading Regimen as the
Initiation of Anticoagulation for Acute
Ischemic Stroke Patients Jun-Sang
Sunwoo, Yong-Seok Lee, Hyung-Min Kwon
P04.099
Withdrawn
P04.100 Cephalocervical Aneurysms
Associated with Fibromuscular
Dysplasia Sol Cavanagh, Patricio
Brand, Martin Nogués, Javier Moschini,
Sebastian Ameriso
P04.101 Awareness of Stroke by
Nigerians at High Risk Kolawole Wahab,
Bode Kayode, Omotosho Musa
P04.102 Modafinil in Post Stroke
Fatigue Iftekhar Ahmed, Natasha Ahmed,
Ann Sly
P04.103 The Clinical Features of LateOnset Poststroke Seizures Shiho Okuda,
Shin Takano, Masao Ueno, Youji Tomota,
Hirotoshi Hamaguchi, Fumio Kanda
P04.104 Cocaine Strokes: Are
Large Vessel Atherosclerosis and Small
Vessel Disease More Prevalent Than
Vasospasm? Sharief Taraman, Pratik
Bhattacharya, Seemant Chaturvedi,
Ramesh Madhavan
P04.108 Stroke Registry Definitions
Lack Consensus Across the US Karen
Albright, Sheryl Martin-Schild, M. Sline, H.
Bockholt, Sean Savitz
P04.109 Factors Predictive of
Length of Stay in Acute Ischemic Stroke
Patients Devon Conway, Nishant
Ranawat
P04.110 Incidence of Stroke and
Stroke-Related Mortality on Ugandan
Neurology Ward Jason Sico, Jeffrey
Bigelow, Ivan Kimuli, Elly Katabira, Huned
Patwa
P04.111 Barriers to Thrombolysis
in Acute Ischiemic Stroke Sapna Erat
Sreedharan, William Jeffries, Janakan
Ravindran
P04.112 Concomitant Anterior
Circulation Infarction and Age Correlate
with Clinical Outcome in Posterior
Circulation Strokes Jacob Kitchener,
Austin Hake, Nirav Vora, Randall Edgell,
Salvador Cruz-Flores, Paisith Piriyawat,
Eliahu Feen, Aninda Acharya, John
Chibnall, Tagann Chaisam, Sushant Kale,
Saengduan Mayotarn, Ayman Daoud, Eve
Holzemer, Janet Severine
P04.113 Currently Used Stroke
Registry Definitions Have Poor Inter Rater
Reliability When Compared with ACC
Guidelines Karen Albright, H. Bockholt,
Sheryl Martin-Schild, M. Sline, Sean Savitz
P04.114 Ischemic Stroke Due to
Paradoxical Embolisms in the Hereditary
Hemorrhagic Telangiectasia Disease:
New Evidence for Repeated Screening
and Early Treatment of Pulmonary
Arteriovenous Malformations (PAVM).
Study of Two Cases and a Literature
Review Espartaco Ribeiro, Julien Cogez,
Emmanuel Babin, Fausto Viader, Gilles
Defer
P04.115 Aspirin Failure in
Noncardioembolic Ischemic Stroke:
A Retrospective Cohort Study on
Its Incidence, Choice of Antiplatelet
Treatment, and Clinical Outcome Alan
Tse, Raymond Cheung
Poster Session IV
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P04.116 Heart Rate Variability
Changes Occur with MCA Stroke, Related
to the Extent of Insular Ischemia Karen
Orjuela, Xiao Hu, Qing Hao, Nils Borgstrom,
Jeffry Alger, Noriko Salamon, Pablo
Villablanca, Latisha Ali, Bruce Ovbiagele,
Doojin Kim, Sidney Starkman, Jeffrey
Saver, David Liebeskind
P04.117 TGF beta 1 and Acute
Ischemic Stroke: The Protective Effect for
Stroke Occurrence Suroto Setijorumekso,
Sutedjo Widjojo, Suratno Sastrosukarno,
Agus Soedomo, O. S. Hartanto, Risono
Risono, Diah Mirawati
P04.118 A Systems Approach to
Stroke Care: The University Hospitals
Cleveland Experience Cathy Sila, Leigh
McCartney, Nancy Tinsley, Erin Supan,
Robert Tarr, Warren Selman, Anthony
Furlan
P04.119 Acute Anticoagulation
with Intravenous Un-Fractionated
Heparin Reduces Early Recurrences in
Cardio Embolic Stroke Spyros Zafeiris,
Mastorodemos Vasileios, Mavrides
Mihalis, Tzagournisakis Minas, Spilioti
Marhta, Plaitakis Andreas
Movement Disorders: Essential
Tremor
P04.120 Subclinical Tremor in Normal
Controls with vs. without a Family History
of Essential Tremor: Data from the United
States and Turkey Elan Louis, Okan Dogu,
Ruth Ottman
P04.121 Increased Number of
Heterotopic Purkinje Cells in Essential
Tremor Sheng-Han Kuo, Cordelia EricksonDavis, Arthur Gillman, Phyllis Faust, Jean
Paul Vonsattel, Elan Louis
P04.122 Holmes’ Tremor: Etiology and
Outcome—A Case Series of 37 Patients
from the Mayo Clinic Kathrin Czarnecki,
Joseph Matsumoto
P04.123 Embarrassment in Essential
Tremor: Discrepancies Between Patients
and Neurologist-Experts Rebecca Traub,
Elan Louis
P04.124 Specificity of Purkinje Cell
Loss in Essential Tremor Ali Rajput,
Christopher Robinson, Michele Rajput,
Alex Rajput
P04.125 Depressive Symptoms in
Essential Tremor Patients Roberto Prado,
Lis Ferreira, Ana Gabriela Prado, Vivian
Andrade
P04.126 Validity and Reliability of
Computerized Tremor Spirography as
Outcome Measure for Clinical Trials in
Essential Tremor Dietrich Haubenberger,
Daniel Kalowitz, Fatta Nahab, Camilo Toro,
Dominic Ippolito, Loretta Wittevrongel,
Mark Hallett
Movement Disorders:
Parkinson's Disease: Treatment
P04.127 Long-Term Safety and
Efficacy of Pramipexole Extended-Release
in Early Parkinson’s Disease Robert
Hauser, Paolo Barone, Youshikuni Mizuno,
Werner Poewe, Olivier Rascol, Anthony
Schapira, Jaana Harjula, Mandy Sohr,
Laurence Salin, in the Name of the
Pramipexole ER Studies Group
P04.128 Long-Term Efficacy and
Safety of Pramipexole Extended-Release
in Advanced Parkinson’s Disease: An
Open-Label Trial Anthony Schapira, Paolo
Barone, Robert Hauser, Youshikuni Mizuno,
Olivier Rascol, Michael Busse, Laurence
Salin, Mandy Sohr, Werner Poewe, in the
Name of the Pramipexole ER Studies Group
P04.129 Comparison of IPX066, a
Novel Extended-Release Oral CarbidopaLevodopa Formulation, to ImmediateRelease Carbidopa-Levodopa in Patients
with Advanced Parkinson’s Disease
(PD) Ann Hsu, Leonard Verhagen Metman,
Aaron Ellenbogen, Martin O’Connell, Nishit
Modi, Sherron Kell, Suneel Gupta
P04.130 Carbidopa/Levodopa
Pharmacy Errors in Parkinson’s
Disease Nasim Khadem, Melissa
Nirenberg
P04.131 Long-Term Treatment of
Advanced Parkinson’s Disease with
Rotigotine Peter LeWitt, Babak Boroojerdi,
Werner Poewe, on Behalf of the SP516 and
SP715 Study Groups
P04.132 Three-Year Efficacy and
Safety Data for Ropinirole Prolonged
Release in Patients with Early Parkinson’s
Disease Mark Lew, Katie Rolfe, Kenneth
Shulman
P04.133 Open-Label Extension Trial
Assessing the Effects of Long-Term
Treatment with Rotigotine in Subjects
with Early-Stage, Idiopathic Parkinson’s
Disease: Results from up to Seven
Years Ray Watts, Babak Boroojerdi,
Joseph Jankovic, on Behalf of the SP702
Study Group
P04.134
3,4-Dihydroxyphenylacetaldehyde
Research Supports Rasagiline
Neuroprotection Found in ADAGIO
Study William Burke, Michael Panneton,
Vijay Kumar, James Galvin
P04.135 A Five Year Prospective
Assessment of Advanced Parkinson’s
Disease Patients Treated with
Subcutaneous Apomorphine Infusion
or Subthalamic Nucleus Deep Brain
Stimulation Angelo Antonini, Ioannis
Isaias, Roberto Cilia, Andrea Landi, Claudio
Mariani, Francesca Natuzzi, Francesco
Vergani, Erik Sganzerla, Roberto Piolti,
Carlo Ferrarese, Gianni Pezzoli
P04.136 Adverse Events and
Patient Satisfaction Associated with
Dopamine Agonist and Levodopa Use
for RLS Richard Allen, Eric Ball, Ranjani
Manjunath, Rachel Higbie, Mechele Lee,
Michael Calloway, Paul Nisbet, William
Ondo
P04.137 Parkinson’s Disease
and Idiopathic Restless Leg
Syndrome Elizabeth Dragan, William
Ondo
P04.138 Quantitative
Assessment of Acute L-Dopa Effects
on Parkinsonian Dysphagia with
Videofluoroscopy Francois Viallet,
Martine Baudo, Bernard Teston, Dominique
Gayraud, Marie-Noelle Sert
P04.139 Repetitive Transcranial
Magnetic Stimulation (rTMS) for the
Treatment of Apathy in Parkinson’s
Disease: Results from a Double-Blind,
Sham-Controlled, Randomized, Controlled
Trial Hubert Fernandez, Dawn Bowers,
William Triggs, William Perlstein, Chris
Hass, Laura Zahodne, Michael Okun,
Ramon Rodriguez, Irene Malaty, Samuel
Wu
P04.140 Improvements in Awake
Time Spent “On” Throughout the Day
in Patients with Advanced Parkinson’s
Disease Treated with Adjunctive
Ropinirole Prolonged Release James
Cooper, Katie Rolfe, Alan Lipschitz, K. Ray
Chaudhuri
P04.141 Utilizing Intensive-Amplitude
Specific Therapeutic Approaches as
an Effective Strategy for Improving
Functional Mobility in Patients Diagnosed
with Parkinson’s Disease Roxanne Julius,
Mike Sandmann, Jawad Bajwa, Penny
Tatman, Amy Fehrer
P04.142 Parkinson Movement Tests
Performance: Effects of Acute Medication
Challenge on Quantitative Measures in
Standard Movement Tests Xiao-ke Gao,
Kenneth Bonnet
P04.143 Can Large Amplitude
Exercise (ThinkBIG) and Nintendo Wii®
Game Exercise Offer Parkinson Disease
Neuroprotection? Maria Alvarez, Patrick
Grogan, Melinda Rodriguez
P04.144 Parkinson’s Disease Patients:
“Owls” or “ Larks” Aleksandar Videnovic,
Charleston Noble, Richard Ginnetti,
Angelica Marconi, Teresa Kuhta, Tanya
Simuni, Cindy Zadikoff, Phyllis Zee
P04.145 Differential Response
of Speed, Amplitude, and Rhythm to
Dopaminergic Medications in Parkinson’s
Disease Alberto Espay, Dustin Heldman,
Robert Chen, Sang-jin Kim, Jennifer
Vaughan, Emily Dunn, Andrew Duker,
Joseph Giuffrida
P04.146 Higher Proportion of
Responders on the Clinical Global
Impression – Improvement Scale with
Ropinirole Prolonged Release Compared
with Ropinirole Immediate Release in
Patients with Advanced Parkinson’s
Disease Kenneth Shulman, Katie Rolfe,
Fabrizio Stocchi
P04.147 Improvements in Nocturnal
Symptoms with Ropinirole Prolonged
Release in Patients with Advanced
Parkinson’s Disease and with Significant
Nocturnal Symptoms Not Optimally
Controlled with L-Dopa K. Ray Chaudhuri,
James Cooper, Katie Rolfe, Alan Lipschitz,
Pablo Martinez-Martin
Movement Disorders:
Parkinson's Disease: Surgical
Treatment
P04.148 Visuo-Motor Function
in Patients with Parkinson’s Disease
Does Not Improve with Subthalamic
Stimulation Simon Israeli-Korn, Shraga
Hocherman, Sharon Hassin, Oren Cohen,
Edna Schechtman, Rivka Inzelberg
P04.149 The National Deep Brain
Stimulation Brain Tissue Network (DBSBTN): Preliminary Results Vinata VedamMai, Nolie Krock, Michael Ullman, William
Shain, Karen Smith, Anthony Yachnis,
Dennis Steindler, Brent Reynolds, Fernando
Pagan, Stacy Merritt, Jill Marjama-Lyons,
Penelope Hogarth, Andrew Resnick,
Michael Okun
P04.150 Brain Micro-Structural
Features of Parkinsonian Signs in Very Old
Persons: A Diffusion Tensor Imaging Study
of the Health Aging and Body Composition
(Health ABC) Cohort Caterina Rosano,
Howard Aizenstein, Vijay Venkatraman,
David Bennett, Christopher Taylor, Kristine
Yaffe, Tamara Harris, Stephen Kritchevsky,
Anne Newman
P04.151 Cortico-Striatal Activity
Patterns During a Finger-Movement fMRI
Task in Parkinson’s Disease Patients On
and Off Medication Kristina Martinu,
Clotilde Degroot, Antonio Strafella, Oury
Monchi
P04.152 Deep Brain Stimulation
Effects on Cardiovagal Responses in
Patients with Parkinson’s Disease JyhGong Hou, Laura Jui-Chen Wu, Eugene Lai
P04.153 ADC Value of Substantia
Nigra in Idiopathic Parkinson’s Disease
with Unilateral Motor Symptom KyungWook Kang, Byeong-Chae Kim, Tai-Seung
Nam, Joon Tae Kim, Seong-Min Choi,
Seung Han Lee, Man-Seok Park, Myeong
Kyu Kim, Ki Hyun Cho
P04.154 Pallidal Stimulation in
Advanced Parkinson’s Patients with
Contraindications for Subthalamic
Stimulation Tiphaine Rouaud, Thibaut
Dondaine, Sophie Drapier, Claire
Haegelen, François Lallement, Julie Péron,
Sylvie Raoul, Paul Sauleau, Marc Verin
73
Poster Session IV
P04.155 Recognition Mismatch of
Non-Motor Symptoms in DBS Candidates
Among Parkinson Patients and Caregivers
May Be Scale Driven Nelson Hwynn,
Ihtsham Haq, Irene Malaty, Andrew
Resnick, Yunfeng Dai, Michael Okun,
Danica Carew, Kelly Foote, Samuel Wu,
Atchar Sudhyadhom, Ramon Rodriguez,
Charles Jacobson IV, Hubert Fernandez
P04.156 Lesion Rather Than
Stimulation: Laterality of Microlesion
Impacts Postoperative Verbal Fluency
Decline in Subthalamic Deep Brain
Stimulation Surgery Lars Wojtecki, Lars
Timmermann, Ute Habel, Christiane Reck,
Volker Sturm, Frank Schneider, Alfons
Schnitzler
P04.157 Pediatric Deep Brain
Stimulation at Cook Children’s Medical
Center: 22 Consecutive Cases Warren
Marks, John Honeycutt, Fernando Acosta,
Jr, Mary Ann Reed
Movement Disorders: Atypical
Parkinsonism and Wilson's
Disease
P04.158 The Unified Multiple System
Atrophy Rating Scale (UMSARS) Is Also
Suitable To Reveal the Progression
of Chinese Multiple System Atrophy
Patients Jun Xu, Yong Chen, Xuexu Zhao
P04.159 Autopsy-Proven Progressive
Supranuclear Palsy Presenting as
Behavioral Variant Frontotemporal
Dementia Anhar Hassan, Joseph Parisi,
Keith Josephs
P04.160 A Novel Mutation of CP
Genes Inhibits Its Secretion and Causes
Aceruloplasminemia Hisatomo Kowa,
Ayumi Hida, Atushi Iwata, Shin Kwak, Jun
Shimizu, Shoji Tsuji
P04.161 Concordance for Wilson’s
Disease Phenotype Among Siblings Anna
Czlonkowska, Grzegorz Chabik, Stanislaw
Wolanin, Grazyna Gromadzka
P04.162 Treatment of Multiple
System Atrophy Using Intravenous
Immunoglobulins: A Preliminary
Report Peter Novak, Paula Ravin,
Bernadette White, Arlene Williams, Vera
Novak
P04.163 The Determinants
of Disability in Corticobasal
Syndrome Sandra Ruby, Bradley
Robottom, Jason Hawley, Karen Anderson,
Julie Medalie, Paul Fishman, Stephen
Reich, William Weiner, Lisa Shulman
P04.164 Jaw-Opening Oromandibular
Dystonia Secondary to Wilson’s
Disease—A Preliminary Report of Five
Cases after Use of Botulinum Toxin Type
A Renato Munhoz, Helio Teive, Leandro
Kuppel, Nilson Becker, Paulo Muller, Lineu
Werneck
74
P04.165 Methyltetrahydrofolate
Reductase Gene Polymorphism: A
Novel Genetic Factor That Modifies
Phenotypic Effects of Copper Toxicity in
Wilson’s Disease Anna Czlonkowska,
G. Gromadzka, Magdalena Rudnicka,
Grzegorz Chabik
Movement Disorders:
Parkinson's Disease:
Neurochemistry
P04.166 Aminopyridines Correct
Presymptomatic Neuronal Dysfunction
and Improve Late Behavioral and
Cellular Phenotype in a Mouse Model
of Spinocerebellar Ataxia Type 1
(SCA1) Raphael Hourez, Laurent Servais,
David Gall, Massimo Pandolfo, Serge
Schiffmann
P04.167 Zona Incerta Lesions Affect
Striatal Neurochemistry and Behavioural
Asymmetry in 6OHDA-Lesioned
Rats Georgia Davies, Rick Koch, Andrew
Haack, Cindy Moore, Charles Meshul, Ruth
Walker
P04.168 Distinct Roles of GABAergic
Interneurons in the Regulation of Striatal
Output Pathways Alexandra Nelson, Aryn
Gittis, Anatol Kreitzer
P04.169 Reduced Expression of
Catecholamine Regulated Protein (CRP40)
in Pre Clinical Animal Models and Human
Striatum Post-Mortem Samples Obtained
from Subjects with Parkinson’s Disease
(PD) Ram Mishra, Bailee Dyck, Venu Nair,
Joseph Gabriele, Zdenek Pristupa, Mattea
Tan, Nancy Thomas
P04.170 Post-Mortem Neurochemical
Evidence for Decreased Putamen
Aldehyde Dehydrogenase in Parkinson
Disease David Goldstein, Patricia Sullivan,
Courtney Holmes, Irwin Kopin, Margaret
Basile, Deborah Mash
P04.171 SEP-228791, a Novel
Dopamine and Norepinephrine Re-Uptake
Inhibitor, Has Anti-Parkinsonian Actions,
without Eliciting Dyskinesia, in the MPTPLesioned Primate Model of Parkinson’s
Disease Tom Johnston, Susan Fox,
Jianguo Ma, Liming Shao, Una Campbell,
Jonathan Brotchie
P04.172 Neurodegenerative Markers
in CSF in Patients Suffering from
Parkinson’s Disease Hana Prikrylová
Vranová, Martin Nevrlý, Jan Mareš, David
Stejskal, Petr Kanovský
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P04.175 A Novel Computerized
Word-Naming Test Shows That CrossedHemisphere Processing Speed Is Slowed
in Multiple Sclerosis Patients Joshua
Bacon, Tamar Bacon, Ilya Kister, Joseph
Herbert
P04.176 Cognitive and Psychosocial
Evaluation of Patients with “Benign
Multiple Sclerosis” Ana-Luiza Sayao,
Anna-Marie Bueno, Virginia Devonshire,
Helen Tremlett
P04.177 Ten-Year Trends by
Patient-Report Metrics in Multiple
Sclerosis Functional and Psychosocial
Limitations Barbara Teter, Cornelia
Mihai, Brian Apatoff, Patricia Coyle, Alfred
Frontera, Andrew Goodman, Malcolm
Gottesman, Joseph Herbert, Richard
Holub, Burk Jubelt, Lauren Krupp, Michael
Lenihan, Fred Lublin, Aaron Miller, Fredrick
Munschauer, Paulette Niewczyk, Allan
Perel, David Snyder, Mark Tullman, Robert
Zivadinov, Bianca Weinstock-Guttman
P04.178 Depression and Fatigue
in Clinically Definite Multiple Sclerosis
(CDMS, McDonald Criteria)— Results
from the Oregon Multiple Sclerosis
Registry (OMSR) Stanley Cohan, Chiayi
Chen, Ruyun Jin, Adam Bodie, Tamela
Stuchiner, Garry Grunkemeier
P04.179 Multiple Sclerosis: EDSS and
Disease Duration: Effects on Cognition
in a Community Based Study Myassar
Zarif, Mark Gudesblatt, Barbara Bumstead,
Max Gutman, Lori Fafard, Laura Graffitti,
Carol Seidel, Lourdes Cruz, Joan Bohuslaw,
Serina Fahie, Chris Burke, Jocelyn Caputo,
Susan Riley, Ely Simon, Glen Doniger
P04.180 Cognitive Impairment
in Patients with Clinically Isolated
Syndrome: A Reappraisal After Eight
Years Rana Assouad, Anne Claire Viret,
Caroline Bensa, Antoine Gueguen, Pierre
Lecanuet, Antoine Moulignier, Bruno
Stankoff, Clotilde Arnaud, Olivier Gout
P04.181 Group Psychotherapy in
Patients with Multiple Sclerosis: A SixMonth Study in Groups with Different
Disability Scores Sara Collorone,
Simona Pontecorvo, Stefano Pascucci,
Massimiliano Prencipe, Ada Francia
Multiple Sclerosis and Related
Diseases: Clinical Research /
Neuropsychology
P04.182 Longitudinal Changes on
Self-Report of Cognitive Symptoms on
the Perceived Deficits Questionnaire
in MS: Correlations with Changes
in Neuropsychologic Tests and
Depression Jesus Lovera, Jorge Melara,
Elliot Frohman, Theodore Brown, Daniel
Bandari, Katherine Wild, Ruth Whitham,
Dennis Bourdette
P04.173 Apathy in Multiple Sclerosis
and Its Association with Depression,
Fatigue, and Cognitive Impairment Regina
Berkovich, Bryan Spann
Multiple Sclerosis and Related
Diseases: Clinical Research and
Pathology
P04.174 Episodic Memory in a Cohort
of 395 Multiple Sclerosis Patients Hélíne
Brissart, Elodie Morele, Marc Debouverie
P04.183 Estimating the Probability
of Employment Status Transitions and
Exploration of Influential Factors Amber
Salter, Rachel Moreau, Tuula Tyry, RuthAnn Marrie, Timothy Vollmer, Gary Cutter
P04.184 Hand Function, Mobility, and
Employment Status in the NARCOMS
Registry Rachel Moreau, Amber Salter,
Tuula Tyry, Ruth-Ann Marrie, Timothy
Vollmer, Gary Cutter
P04.185 Ipsilateral Motor Cortex
Activity in RRMS: Compensation or
Not? Nancy Sicotte, Kyle Kern, Joseph
Sarcona, Michael Montag, Barbara Giesser
P04.186 Pregnancy Outcomes from
the AVONEX® (Interferon beta-1a)
Pregnancy Exposure Registry Pamela
Foulds, Sandra Richman, Gabrielle Glick,
Timna Onigman
P04.187 An Assessment of
Bone Health Lifestyle Factors in MS
Patients Nancy Hammond, Nicholas
Levine, Sharon Lynch
P04.188 Lack of Congruence in the
Ratings of Patients’ Health Status by
Patients with Multiple Sclerosis and Their
Physicians Marcelo Kremenchutzky, Len
Walt
P04.189 Impact of Treatment
Adherence on Clinical and Economic
Outcomes among Multiple Sclerosis
Patients Receiving Disease-Modifying
Therapies Hiangkiat Tan, Qian Cai,
Sonalee Agarwal, Siddhesh Kamat
P04.190 Headache in Multiple
Sclerosis. Clinical and Therapeutical
Correlations Chiara Monaldini, Jay
Guido Capone, Maria Luisa Caniatti,
Ilaria Casetta, Susanna Guttmann, Enrico
Granieri, Maria Rosaria Tola
P04.191 Spectrum of Clinical
Symptoms in Early MS with Pathologically
Confirmed Cortical Demyelination Reem
Bunyan, Brendan Kelley, Richard
Ransohoff, Kristine Thomsen, Bernd
Scheithauer, Joseph Parisi, Caterina
Giannini, Linda Linbo, S. Roemer, Claudia
Lucchinetti
P04.192 Increasing Macroscopic
Pathological Damage in Multiple Sclerosis
(MS) Is Associated with More Severe
Disease Milestones Richard Nicholas,
Bishan Radotra, Federico Roncaroli,
Richard Reynolds
Multiple Sclerosis and Related
Diseases: Drug Mechanisms I
P04.193 Changes in Circulating
Tregs Parallel Reductions in Activated
T Cells during Daclizumab Treatment
of MS James Sheridan, Ying Zhang,
Katherine Riester, Gilmore O’Neill, Valdimir
Vexler, Jacob Elkins
P04.194 Hypereosinophilia with
Natalizumab Fanny Rocher, Muriel Laffon,
Mickael Cohen, Christine Lebrun Frenay
P04.195 In MS Patients, When
Should MxA mRNA Be Measured after
Interferon-beta Injections? Regina Lam,
Joel Oger
Poster Session IV
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P04.196 Differential Effects of a
Selective Sphingosine 1-Phosphate
Receptor 1 (S1P1) Modulator (CS-0777)
on Circulating Lymphocyte Subsets in
Multiple Sclerosis Patients Hamim Zahir,
James Moberly, Daniel Ford, Kenneth
Truitt, Amit Bar-Or, Timothy Vollmer
P04.207 Pharmacokinetics of Oral
BG-12 Alone Compared with BG-12 and
Interferon β-1a or Glatiramer Acetate
Administered Together, Studied in Healthy
Volunteers James Woodworth, Zhenming
Zhao, Scott Stecher, Liyu Yang, Katherine
Dawson
P04.197 Interferon Beta-1a
Modulation of B Cells: Implications for
Relapsing Multiple Sclerosis Hui Huang,
Sumandeep Sumandeep, Kouichi Ito,
Suhayl Dhib-Jalbut
P04.208 Laquinimod In Vitro HighThroughput Gene Analysis Reveals
Orchestrated Th2 Shift in RelapsingRemitting Multiple Sclerosis Michael
Gurevich, Rotem Orbach, Tamir Tuller,
Anna Feldman, Anat Achiron
P04.198 Effects of Glatiramer Acetate
on Proliferation and Differentiation of
OLN-93 Cells and Its Interaction with
FGF2 Alvaro Barrera-Ocampo, Martin
Berghoff, Mario Giraldo Velásquez
P04.199 Unusual Development
of Progressive Multifocal
Leukoencephalopathy with High JC
Virus Titer in a Patient with Multiple
Sclerosis after Two Years of Natalizumab
Therapy Tjalf Ziemssen, Henning
Bagelmann, Jochen Machetanz
P04.200 In Vitro Whole Blood
Monitoring of Biological Response to
Type I Interferon Therapy in Multiple
Sclerosis Mathieu Vokaer, Francoise
Villee, Kaoutar El Hafsi, Patrick Stordeur
P04.201 Intravenous Immunoglobulin
(IVIG) in Treatment of Central Pontine
and Extrapontine Myelinolysis Shahram
Izadyar, Shumaila Sultan, Joseph Kass,
Corey Goldsmith
P04.202 An IL-2 Paradox; Blocking
CD25 on T Cells Induces IL-2-Driven
Activation of CD56bright NK Cells Jayne
Martin, Neha Jakhete, Xiang Wang,
Bibiana Bielekova
P04.203 P2X7 Purinergic Receptor
on Monocytes of Patients with Multiple
Sclerosis: Effects of Glatiramer Acetate
Immune Modulation Carlo Avolio,
Mariantonietta Caragnano, Paola
Tortorella, Anna Lia, Roberta Grasso,
Maddalena Ruggieri, Paolo Livrea, Luigi
Specchio, Maria Trojano
P04.204 Treatment Effects of IFNB-1b
on Cognitive Performance in Patients
with a First Event Suggestive of MS Iris
Katharina Penner, Pasquale Calabrese,
Mark Freedman, Chris Polman, Gilles
Edan, Hans Hartung, David Miller, Xavier
Montalban, Frederik Barkhof, Vivian Lanius,
Rupert Sandbrink, Christoph Pohl, Brigitte
Stemper, Ludwig Kappos
P04.205 CD161/CCR6 (IL-17
Associated) Expression in Relapsing MS:
Effect of Glatiramer Acetate on Immune
Regulation Lloyd Kasper, Alan Bergeron,
John Delong, Kathleen Smith, Kathleen
Ryan, Jacqueline Channon
P04.206 Systematic Assessment of
JC Virus in Multiple Sclerosis Patients
Treated with Natalizumab Iuliana Slesari,
Olivier Heinzlef, Jean-Dominique Poveda
P04.209 Omega-3 Fatty Acids
Treatment in Relapsing-Remitting
Multiple Sclerosis Kjell-Morten Myhr,
Sjur Reinertsen, Antonie Beiske, Harald
Hovdal, Rune Midgard, Frøydis Dalene, Jan
Schepel, Grete Kleveland, Halfdan Kierulf,
Randi Eikeland, Alla Bru, Olaf Henriksen,
Terje Kristensen, Astrid Edland, Ingrid
Bjørnä, Søren Bakke, Tom Pedersen, Finn
Lilleäs, Bärd Bjørnarä, Inge Christoffer
Olsen, Rita Nilsen, Kristian Bjerve
P04.210 Duration Following Severe
Attacks of CNS Demyelinating Disease
to Plasma Exchange Initiation: How Long
Is Too Long? Setty Magana, Stephen
Weigand, Kristine Thomsen, Jayawant
Mandrekar, Claudia Lucchinetti, Mark
Keegan
P04.211 Safety and Efficacy of
Autologous T-Cell Immunotherapy
(Tovaxin) in Patients with Active
Relapsing-Remitting Multiple
Sclerosis Dawn McGuire, Edward Fox,
Clyde Markowitz, Stanley Cohan, Daniel
Wynn, Donna Rill, Mary Riser, Shannon
Inman
P04.212 Synergistic Mechanisms of
Fumarate Treatment in CNS Autommunity:
Augmenting Axon Protective Effects in
Combination Therapies Christiane Reick,
Gisa Ellrichmann, De-Hyung Lee, Ralf Gold,
Ralf Linker
P04.213 Alemtuzumab Reduces
Disease Progression in RRMS: Long-Term
Results of the CAMMS223 Trial Omar
Khan, N. A. on Behalf of the CAMMS223
Study Group
P04.214 Prediction and
Characterization of CD56bright NK Cell
Expansion during Daclizumab Treatment
for Multiple Sclerosis James Sheridan,
Ying Zhang, Katherine Riester, Gilmore
O’Neill, Meina Tang, Jacob Elkins
P04.215 Multiple Sclerosis and Other
CNS Demyelination after Treatment
with Tumor Necrosis Factor alpha
Blockers George Hutton, Mirla Avila, Pilar
Guillermo Prieto, Jose Avila, Victor Rivera
P04.216 Copolymer-1 Shows
Neuroprotective Effects Via Peripheral
Immunomodulation Rather Than Direct
Actions on Neurons Sven Meuth,
Alexander Herrmann, Kerstin Göbel, Nico
Melzer, Ole Simon, Stefan Bittner, Heinz
Wiendl
P04.217 Cellular and Humoral
Influenza Vaccine-Specific Immune
Responses in Patients with Multiple
Sclerosis Treated with FTY720 or
Interferon-beta Matthias Mehling,
Stefanie Fritz, Patricia Hilbert, Raija
Lindberg, Jens Kuhle, Ludwig Kappos,
Christoph Hess
P04.227 Validation of a Novel
Computerized Performance-Based
Functional Assessment for HIV Associated
Neurocognitive Disorders Liana
Rosenthal, Richard Skolasky, Richard
Moxley IV, Heidi Vornbrock Roosa, Ola
Selnes, Amy Eschman, Justin McArthur,
Ned Sacktor
P04.218 Production of Neurotrophic
Factors in MS Patients Treated with
Disease Modifying Therapies Yang MaoDraayer, Julia Knight, John Soltys, Hillel
Panitch
P04.228 Clinical and Cognitive
Associations with Midsagittal
Corpus Callosum Area in HIV Infected
Patients Rola Khedraki, Mehul Sampat,
Jared Price, Daniel McCaffrey, Daniel
Branson, Bradford Navia, David Tate
P04.219 Effects of Cladribine Tablets
on Circulating Lymphocyte Subset
Reconstitution in the 96-Week CLARITY
Study in Relapsing-Remitting Multiple
Sclerosis (RRMS) Per Soelberg Sørensen,
Peter Rieckmann, Giancarlo Comi, Stuart
Cook, Gavin Giovannoni, Kottil Rammohan,
Patrick Vermersch, Daena Bock, Anthony
Hamlett, Téa Fevr, Bruno Musch, Steven
Greenberg
P04.220 Plasmacytoid Denditic
Cells (pDC) in Multiple Sclerosis: IFN-β
Treatment Inhibits pDC Secretion of
Chemokines Specific for CCR5-Positive
Th1 Cells Latt Aung, Suhayl Dhib-Jalbut,
Konstantin Balashov
P04.221 Decreased Chemokine
Directed Migration of Effector Memory T
Cells in Fingolimod-Treated Patients Trina
Johnson, Amit Bar-Or, Jack Antel
P04.222 The Activation of Microglia
and Macrophages Is Attenuated by
Laquinimod Janet Wang, Claudia Silva,
Scott Sloka, V. Wee Yong
P04.223 Glatiramer Acetate-Reactive
T Lymphocytes Regulate Oligodendrocyte
Progenitor Cell Number In Vitro Yueting
Zhang, Farzaneh Jalili, Nadia Oumara,
Andleeb Zameer, Gregory Cosentino, Liat
Hayardeny, Jack Antel, Amit Bar-Or, Gareth
John
AIDS
P04.224 Predictors of Ventricular
Volume in HIV Disease James Becker,
Bruce Cohen, Eileen Martin, Eric Miller,
Joanne Mullen, Ann Ragin, Ned Sacktor,
Ola Selnes, Owen Carmichael
P04.225 Dual Infection with HIV and
HCV Has Worse Effects on Cognition Than
Infection with HIV Alone Inna Kleyman,
Jennifer Manly, Jason Lazar, Mardge
Cohen, Elizabeth Golub, Chenglong Liu,
Leigh Pearce, Victor Valcour, Kathryn
Anastos, Howard Crystal
P04.226 Utility of HIV-Associated
Neuropathy Screening Tools in Western
Kenya: Pilot Testing Deanna Cettomai,
Judith Kwasa, Caroline Kendi, Gretchen
Birbeck, Richard Price, Elizabeth Bukusi,
Craig Cohen, Ana-Claire Meyer
P04.229 Treatment of Mice with HIV
Encephalitis with a Novel Interferon-alpha
Blocker William Tyor, Cari Fritz-French,
Rajeth Koneru, Ligia Padilla, Hee Young
Hwang, Leonard Maroun, Jennifer Ward,
Markus Dettenhofer
P04.230 Matrix Metalloproteinase-1
Protects Against HIV-1 Tat-Induced
Neurotoxicity by Cleavage-Dependent
and Cleavage-Independent
Mechanisms Jeffrey Rumbaugh,
Muznabanu Bachani, Avindra Nath
P04.231 Atrophy in the Medial
Temporal Lobes of HIV Patients Is
Correlated to ADC Stage Nosheen
Jawaid Rafique, Henrietta Afari, Daniel
McCaffrey, Jared Price, Daniel Branson,
Bradford Navia, David Tate
P04.232 Gray Matter Volume Loss
in HIV Associated Dementia Matthias
Maschke, Michael Kueper, Kasja Rabe,
Stefan Esser, Elke Gizewski, Ingo Husstedt,
Mark Obermann
P04.233 Mechanisms of Neurotoxicity
Induced by Morphine in the HIV-1
Transgenic Rat Walter Royal III, Sanjit
Roy, Huifen Li, Odell Jones, Joseph Bryant
Infections/AIDS
P04.234 Utility of a Diagnostic Tool
for HIV-Associated Cognitive Impairment
in Western Kenya: Pilot Testing Judith
Kwasa, Deanna Cettomai, Edwin Lwanya,
Dennis Osiemo, Patrick Oyaro, Gretchen
Birbeck, Richard Price, Elizabeth Bukusi,
Craig Cohen, Ana-Claire Meyer
P04.235 Pattern of
Neuropsychological Performance Among
HIV-Positive Patients in Kenya Judith
Kwasa, Edwin Lwanya, Deanna Cettomai,
Dennis Osiemo, Patrick Oyaro, Gretchen
Birbeck, Richard Price, Elizabeth Bukusi,
Craig Cohen, Ana-Claire Meyer
P04.236 Prevalence of Seizures in
HIV Patients Measured in the Outpatient
Setting Kristi Nord, Stuart Tomko,
Deborah Forst, Liliana Robles, David
Friedman, Joseph Kass
P04.237 CNS Immune Reconstitution
Inflammatory Syndrome (IRIS) in an
HIV-Infected Patient with a Stable
CD4 Cell Count and Undetectable Viral
Load Michele Mass
75
Poster Session IV
P04.238 Prevalence of HTLV-1 Among
Selected Cases of Progressive Spastic
Non-Compressive Myelopathy in North
Eastern Nigeria Abdullahi Ibrahim, Yakub
Nyandaiti
P04.252 Psychogenic Non-Epileptic
Seizures in Postural Orthostatic
Tachycardia Syndrome Katherine Noe,
Joseph Drazkowski, Joseph Sirven, Brent
Goodman
P04.263 Menstrual Exacerbation in
Irritable Bowel Syndrome, Fibromyalgia,
and Interstitial Cystitis Thomas
Chelimsky, Shruti Madan, Umit Ulas,
Gisela Chelimsky, Kevin McNeeley
P04.239 Progression of Nerve
Conduction and EMG Abnormalities in
Acute West Nile Virus Infection Logan
McDaneld, Edward Kim, Jau-Shin Lou
Autonomic Disorders: Testing
Methods and Treatments
P04.253 Low Iron Storage and Anemia
in Adolescents with Postural Tachycardia
Syndrome (POTS) Imad Jarjour, Laila
Jarjour
P04.264 Prospective Elderly
Human Blood-CNS Biodistribution and
Neurocognitive Studies of a Quaternary
Amine Antimuscarinic Agent for
Overactive Bladder (OAB): The SMART
Trial Michael Oefelein, Gary Kay, David
Staskin, Howard Goldman
P04.254 What Is the Optimal Duration
of a Tilt Table Test? Iyavut Thaipisuttikul,
Aninda Acharya, Laurence Kinsella
Neuro-Ophthalmology/NeuroOtology
P04.240 Factors Governing Herpes
Simplex Virus Type 1 (HSV-1) Infection
of Brain Tissues in Organotypic
Cultures Israel Steiner, Meytal Cohen,
Efrat Braun, Amos Panet
P04.241 Encephalitis Associated with
Pandemic H1N1-2009: Case Report and
Review Adam Edwards, Kathleen Currey
P04.242 Novel H1N1
Encephalomyelitis Kristen Smith, Ryan
Smith, Alessandro Serra, Bashar Katirji
Autonomic Disorders:
Comorbidities and Clinical
Connections
P04.243 High Cervical Cord Injury with
Posterior Reversible Leukoencephalopathy
Syndrome: Case Report Yessar Hussain,
Terrence Li, Ma Jiaxin
P04.244 Focal Hyperhidrosis Due to
Irritative Effect of Nerve Root and Spinal
Cord Mass Lesions Robert Fealey, J.
D. Bartleson, Eduardo Benarroch, Paola
Sandroni
P04.245 Underlying Autonomic
Dysfunction in Cough Syncope William
Cheshire
P04.246 Comorbid Health Conditions
in Women with Syncope Umit Ulas,
Thomas Chelimsky, Giesla Chelimsky,
Kevin McNeely, Alshekhlee Amer
P04.247 Can Sex Hormone
Dysregulation Cause Autonomic
Storm? Umit Ulas, Baha Arafah, Kevin
McNeeley, Di Zhang, Gisela Chelimsky,
Thomas Chelimsky
P04.248 The Identification and
Characterization of Autonomic
Dysfunction in Migraineurs with and
without Auras Mark Stillman, Fetnat
Fouad-Terazi, Lan Zhou, Stewart Tepper,
Neil Cherian
P04.249 Orthostatic and NonOrthostatic Headache in Postural
Tachycardia Syndrome (POTS) Ramesh
Khurana, Lindsay Eisenberg
P04.250 Menstrual Symptom
Alteration in Orthostatic Intolerance,
Syncope, and Migraine Thomas
Chelimsky, Devraj Sukul, Umit Ulas, Shruti
Madan, Di Zhang, Kevin McNeeley, Gisela
Chelimsky
P04.251 Pregnancy in Postural
Tachycardia Syndrome: Clinical Course
and Maternal and Fetal Outcomes Hasti
Poya, Glenna Bett, Svetlana Blitshteyn
76
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P04.255 Cardiac
Metaiodobenzylguanidine (cMIBG)
Scintigraphy Is a Useful Tool To Access
Subclinical Autonomic Involvement
in Peripheral Neuropathies Osvaldo
Nascimento, Marco Antonio Leite, Marcos
Freitas, Wilson Marques Junior, Camila
Pupe
P04.256 Catecholaminergic
Denervation in the Brain and Heart in
Parkinson Disease: Associations with
Non-Motor Manifestations David
Goldstein
P04.257 A Modification to the
Quantitative Direct and Indirect Axon
Reflex Sudomotor Test (QDIRT) Enhances
Test Utility Ben Illigens, Christopher
Gibbons, Roy Freeman
P04.258 Treatment Induced
Diabetic Neuropathy—An Acute
Reversible Painful Autonomic
Neuropathy Christopher Gibbons, Roy
Freeman
P04.259 Contamination of the
Norepinephrine Pro-Drug Droxidopa by
Dihydroxyphenylacetaldehyde Courtney
Holmes, David Goldstein
P04.260 Pleasant Olfactory
Stimulation Enhances Cardiovagal
Modulation in Mild Traumatic Brain
Injury Patients Max Hilz, Harald Marthol,
Tim Schroeder, Anja Roámeiál, Thomas
Hummel, Steven Flanagan, Philip De
Fina, Stefan Schwab, Christoph Lang, Eva
Heuberger, Theresa Rameder
P04.261 Hematopoietic Cell
Transplantation for AdolescentOnset Cerebral X-Linked
Adrenoleukodystrophy Takashi
Matsukawa, Tomotaka Yamamoto, Keiki
Kumano, Tsuyoshi Takahashi, Sachiko Seo,
Yuji Takahashi, Jun Goto, Mineo Kurokawa,
Shoji Tsuji
Autonomic Disorders: Bowel and
Bladder Disorders
P04.262 Prevalence of Somatic and
Autonomic Small Fiber Neuropathy in
a Cohort of Patients with Inflammatory
Bowel Disease (IBD) Liana Melo Coelho,
Gisele Oliveira, Allyne Mayane Costa,
Patricia Aquino, Lucia Libanez Campelo
Braga, Marcellus Henrique Ponte de Souza,
Francisco Rola, José Correia, Francisco de
Assis Gondim
P04.265 Self-Complementary AAV
Induces Rapid and Highly Efficient
Allotopic Expression of the Human ND4
Complex I Subunit in the Mouse Visual
System Rajeshwari Koilkonda, Tsung-Han
Chou, Vittorio Porciatti, William Hauswirth,
John Guy
P04.266 Idiopathic Intracranial
Hypertension at a Canadian Tertiary Care
Centre Mary-Magdalene Dodd, Vivek
Patel, Carlos Torres, David Zackon, Miguel
Bussiere
P04.267 Neuroretinitis with Bartonella
Henselae and EBV Co-Infection:
Direct Infection or Immunomodulated
Reaction? Hossein Ansari, Paola Pergami,
Kathryn Moffett, Michael McAllister
P04.268 Obstructive Sleep Apnea
(OSA) in Idiopathic Intracranial
Hypertension (IIH): A Prospective
Study Matthew Thurtell, Beau Bruce,
David Rye, Nancy Newman, Valerie
Biousse
P04.269 Neuro-Ophthalmological
Implications of CADASIL Federighi
Pamela, Alessandra Rufa, Maria Dotti,
Elena Pretegiani, Francesca Rosini, Silvia
Bianchi, Antonio Federico
P04.270 Short Term Adaptation of
Visual Search Strategies in Simulated
Hemianopia Sara Simpson, Mathias
Abegg, Jason Barton
P04.271 Region-Specific Patters of
White Matter Diffusivity Changes in
Leber’s Hereditary Optic Neuropathy:
A Tract-Based Spatial Statistics
Study Jacopo Milesi, Maria Rocca,
Stefania Bianchi-Marzoli, Melissa Petrolini,
Lisa Melzi, Andrea Falini, Giancarlo Comi,
Massimo Filippi
P04.272 Retinal Nerve Fibre Layer
Thickness and Brain Volume in Acute
Optic Neuritis Klaus Kallenbach, Birgit
Sander, Michael Larsen, Henrik Larsson,
Jette Frederiksen
P04.273 Anemia-Dependent Transient
Cortical Visual Loss Heralding Acute
Myelogenous Leukemia in a Woman with
Basilar Stenosis Marc Dinkin, Jacqueline
Winterkorn
P04.274 Optical Coherence
Tomography as Measure of the Effects
of Glatiramer Acetate on Axonal Loss
in Patients with Acute Optic Neuritis
(AON) Mark Kupersmith, Peter Calabresi,
Gary Cutter, Robert Sergott, Ron Neumann
P04.286 The m.3244G>A Mutation in
mtDNA Is Another Cause of Progressive
External Ophthalmoplegia Evangelia
Sotiriou, Jorida Coku, Kurenai Tanji,
Hua-bin Huang, Michio Hirano, Salvatore
DiMauro
P04.275 Is Down Slower Than
Up? Vertical Saccades in Progressive
Supranuclear Palsy (PSP) Athena
Chen, David Riley, Anand Joshi, Ke Liao,
Alessandro Serra, R. Leigh
P04.287 Saccadic Abnormalities in
Ocular Myasthenia Reflect Morphological
Differences between Neuromuscular
Junctions of Extraocular Muscle-Fiber
Types Alessandro Serra, Richard Jung,
Numthip Chitravas, Henry Kaminski, R.
Leigh
P04.276 The Usefulness of Bedside
Neuro-Otological Examination in
Differentiating Central and Peripheral
Causes of Isolated Vertigo in Emergency
Room Ji-Young Park, Byung-Kun Kim,
Sucjoo Kim, Jaseong Koo, Ohyun Kwon,
Jong-Moo Park, Jung Ju Lee
P04.277 Vestibular Evoked Neurogenic
Potentials Using Air-Conducted
Sound: The Discovery of a New Scalp
Recorded Potential (N6) That Probably
Originates from the Midbrain Eleftherios
Papathanasiou, Athena Lemesiou, Stavros
Hadjiloizou, Panayiota Myrianthopoulou,
Marios Pantzaris, Savvas Papacostas
Poster Session IV
Wednesday, April 14 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P04.288 Prevalence of Clinical NeuroOphthalmic Abnormalities in an ALS
Cohort Heather Moss, Steven Galetta,
Laura Balcer, Lauren Talman, Murray
Grossman, Lauren Elman, Leo McCluskey,
Grant Liu
P04.289 Ocular Myositis in Crohn’s
Disease with MRI Imaging Mimicking
Thyroid Ophthalmopathy Shan Chen,
Mohammad Fouladvand
P04.290 Saccade Related Gamma
Oscillations Recorded from the Human
Basal Ganglia and Thalamus Originate
from Ocular Muscles Arun Sundaram,
James Sharpe, Robert Chen, William
Hutchison
Medical Student Essay Award
Recipients
P04.291 Immunological Aspects
of Cell Transplantation in Parkinson’s
Disease Amanda Rowlands
P04.292 Utility of Quantitative
Sensory Testing and Neuropathy
Screening Tools in Identifying HIVAssociated Peripheral Neuropathy in
Western Kenya: a Pilot Testing Deanna
Cettomai
P04.293 Elementary My Dear Dr.
Allen: the Care of Barium Toxicity and Pa
Ping Lauren Bowen
P04.294 Neurogenetics: Parent of
Origin Effects in Autistic Copy Number
Variation, a Possible Mechanism for
Autism Pathogenesis Benjamin Kwan
P04.278 Vestibular Dysfuctions in
Migrainous Vertigo Evaluated by Rotatory
Chair Ji-yun Park, Tae-Kyeong Lee, Sun-Ah
Park, Ki-Bum Sung, Jong-Ho Park
P04.279 Horizontal Conjugate
Gaze Deviation in the Acute Vestibular
Syndrome Jorge Kattah, John Pula, David
Newman-Toker
P04.280 Bilateral Synergistic
Convergence with Horizontal Gaze
Palsy and Scoliosis. Is the Mechanism
Supranuclear? Berker Bakbak, Joanna
Jen, Tulay Kansu
P04.281 The Video Head Impulse
Test: Diagnostic Accuracy in Peripheral
Vestibulopathy Konrad Weber, Hamish
MacDougall, Leigh McGarvie, G. Halmagyi,
Ian Curthoys
P04.282 Acute Encephalopathy,
Multiple Ocular Motor Deficits and
Bilateral Ptosis Following Embolization of
Branches of the External Carotid Artery
Feeding a Carotid Body Tumor Ahmed
El-Dokla, Amar Swarnkar, Philip Cherian,
Luis Mejico
P04.283 Prosaccade and Antisaccade
Performances in Spinocerebellar Ataxia
Type 2 and Other Genetic Ataxias Pamela
Federighi, Francesca Rosini, Giacomo
Veneri, Elena Pretegiani, Maria Dotti,
Antonio Federico, Alessandra Rufa
P04.284 Cerebral Hemispheric Eye
Movement Disorders Are Different in
Parkin-Linked and Idiopathic Parkinson’s
Disease Wolfgang Heide, Bjorn Machner,
Andreas Sprenger, Philipp Baumbach,
Peter Pramstaller, Christine Klein, Christoph
Helmchen
P04.285 Recurrence of Symptoms
after Successful Carotid Cavernous
Fistula Endovascular Treatment Aimee
Szewka, Gioconda Mojica, Janet Rucker,
Thomas Mizen, Victor Aletich, Demetrius
Lopes, Susan Ksiaszek
The NEW 2010 Exhibit Hall:
For Your Professional—and Personal—Interests.
Visit the 2010 AAN Annual Meeting Exhibit Hall to discover and watch live presentations on the latest products
and services designed to help you excel in your profession and provide the best care for neurology patients.
Then visit the Exhibit Hall’s new MarketPlace where non-neurology related companies and organizations will
showcase exciting offerings of personal interest.
Monday, April 12 / 5:00 p.m.–7:00 p.m.
Tuesday, April 13–Wednesday, 14 / 11:30 a.m.–5:00 p.m. / special luncheon 12:00 p.m.–2:00 p.m.
Thursday, April 15 / 11:30 a.m.–4:00 p.m. / special luncheon 12:00 p.m.–2:00 p.m.
Visit www.aan.com/view/exhibit for more information.
77
Scientific Sessions
S31 Multiple Sclerosis:
Biomarkers
S33 Current and Future
Treatment of Parkinson's
Disease
S34 Aging and Dementia:
Recognition and Treatment
Theatre 102
Constitution Hall 106
Room 718AB
Constitution Hall 107
4:15 p.m.
S31.001
Evaluation of New
Immunological Targets in
Neuromyelitis Optica JeanBaptiste Chanson, Ilaria Paolini,
Nicolas Collongues, MariaClaudia Alcaro, Frédéric Blanc,
Francesca Barbetti, Marie Fleury,
Elisa Peroni, Paolo Rovero,
Gabrielle Rudolf, Francesco Lolli,
Elisabeth Trifilieff, Anna-Maria
Papini, Jérôme de Seze
4:15 p.m.
S32.001
Blood-Brain-Barrier Permeability
Derangements in Posterior
Circulation Ischemia: Frequency,
Clinical Correlates, and
Relation to Hemorrhagic
Transformation Meng Lee,
Jeffrey Saver, Jeffry Alger,
Qing Hao, Sidney Starkman,
Latisha Ali, Doojin Kim, Bruce
Ovbiagele, Paul Vespa, Michael
Froehler, Matthew Tenser, Noriko
Salamon, J. Pablo Villablanca,
Reza Jahan, Gary Duckwiler
, Satoshi Tateshima, Nestor
Gonzalez, Fernando Vinuela,
David Liebeskind
4:15 p.m.
S33.001
Plasma and Brain Levels
of PYM50028 (Cogane™)
Associated with
Neurorestorative Efficacy in
Rodent and Primate Models
of Parkinson’s Disease:
Translation to Once Daily
Dosing in Humans Susan Fox,
Tom Johnston, James Koprich,
Philippe Huot, Caroline Ward,
Nick Meyers, Patrick Howson,
Jonathan Brotchie
4:15 p.m.
S34.001
Safety and Tolerability of
Extended-Release Memantine
(Once Daily, 28 mg) in Patients
with Moderate to Severe
Alzheimer’s Disease: An OpenLabel Extension Study Gustavo
Alva, George Grossberg, Facundo
Manes, Ricardo Allegri, Luis
Miguel Guttierez Robledo, Sergio
Gloger, Lei Xie, Xinwei Daniel Jia,
James Perhach, Stephen Graham
4:30 p.m.
S31.002
Effects of Natalizumab
Treatment on the Presence
of JC Virus DNA in Blood or
Urine in Multiple Sclerosis
Patients Richard Rudick, Paul
O’Connor, Chris Polman, Andrew
Goodman, Soma Ray, Stephanie
Jurgensen, Susan Goelz, Fiona
Forrestal, Leonid Gorelik, Alfred
Sandrock
4:45 p.m.
S31.003
Evaluation of the Incidence of
Anti-JCV Antibodies in a Cohort
of Natalizumab-Treated MS
Patients Leonid Gorelik, Sarah
Bixler, Michaela Lerner, Ewa
Wilson, Anne Cheung, Ling Ling
Chen, Melissa Berman, Mary
Crossman, Ken Simon, Brian
Schlain, Susan Goelz, Meena
Subramanyam
5:00 p.m.
S31.004
Anti-GAGA4 IgM Antibodies
(gMS[®Dx Test) Differentiate
Newly Diagnosed Relapsing
-Remitting Multiple Sclerosis
Patients From Other
Inflammatory Demyelinating
Disease Patients Within One
Year from Diagnosis Jennifer
Yarden, Hollie Schmidt, Jette
Frederiksen, Hayrettin Tumani,
Johannes Brettschneider, Sana
Abdul, Sven Jarius, Brigitte
Wildemann, Diego Franciotta,
Larissa Spector, Ella Fire, Nir
Dotan
5:15 p.m.
S31.005
MS Immunopattern
Heterogeneity Persists in Active
Lesions throughout Duration
of Disease: Relation to Plaque
Type and Clinical Course Claudia
Lucchinetti, Josa Frischer, Joseph
Parisi, Stephen Weigand, Kristine
Thomsen, Wolfgang Brueck, Hans
Lassmann, Jayawant Mandrekar
78
S32 Cerebrovascular
Disease: Stroke Imaging
Wednesday, April 14 | 4:15 p.m.–5:30 p.m.
Metro Toronto Convention Centre
4:30 p.m.
S32.002
HIV-Vasculopathy and VZVVasculitis as Cause of Stroke
in HIV-Infected Patients Jose
Gutierrez, Sebastian Koch, Jose
Romano, Michael Katsnelson,
Roberto Sanchez, Gustavo Ortiz
4:45 p.m.
S32.003
Loss of Consciousness at
the Onset of Subarachnoid
Hemorrhage Is Highly Predictive
of Aneurysmal Rupture Stefan
Dupont, Eelco Wijdicks, Alejandro
Rabinstein
5:00 p.m.
S32.004
Extra- or Intra-Cranial
Dissection Involving Multiple
Arteries: A Distinct Clinical and
Angiographic Syndrome? Marc
Lazzaro, Ameer Hassan, Rehan
Zahid, Sudeepta Dandapat,
Gabriela Vazquez, Gustavo
Rodriguez, Mustafa Ezzedine,
M. Fareed Suri, Ramachandra
Tummula, Robert Taylor, Adnan
Qureshi, Yousef Mohammad
5:15 p.m.
S32.005
Block-Design Versus EventRelated fMRI for Language
Evaluation in Post-Stroke
Aphasia Jane Allendorfer,
Christi Banks, Jennifer Vannest,
Angel Ball, Stephen Page, Brett
Kissela, Kenneth Eaton, Scott
Holland, Jerzy Szaflarski
4:30 p.m.
S33.002
ADX10059 a Negative Allosteric
Modulator of the Metabotropic
Glutamate 5 Receptor (mGlur5)
Effectively Controls Chorea
and Dystonia in a Primate
Model of Levodopa Induced
Dyskinesia Charlotte Keywood,
Erwan Bezard, Francoise Girard,
Vincent Mutel
4:45 p.m.
S33.003
24-Hour Symptom Control
with Ropinirole Prolonged
Release in Patients with
Advanced Parkinson’s Disease
Not Optimally Controlled with
L-Dopa Fabrizio Stocchi, Katie
Rolfe, James Cooper, Alan
Lipschitz
5:00 p.m.
S33.004
UWA-0121, a Novel Dopamine
and Serotonin Re-Uptake
Inhibitor, Increases Quality
and Duration of L-DOPA AntiParkinsonian Actions in the
MPTP-Lesioned Primate Model
of Parkinson’s Disease Philippe
Huot, Tom Johnston, M. Gabriela
Reyes, Katie Lewis, Susan Fox,
Matthew Piggott, Jonathan
Brotchie
5:15 p.m.
S33.005
Perfusion MRI in
Parkinson Disease Reveals
Pharmacodynamics of the
Adenosine A2a Antagonist
SYN115 Kevin Black, Jonathan
Koller, Meghan Campbell,
Stephen Bandak
4:30 p.m.
S34.002
A Randomized, Double-Blind,
Controlled Study of the Efficacy
of Quinacrine in the Treatment
of Sporadic CJD Michael
Geschwind, Amy Kuo, Benjamin
Raudabaugh, Aissatou Haman,
Gillian Devereux, David Johnson,
Charles Torres-Chae, Julie
Thai, Katherine Wong, Stanley
Prusiner, John Neuhaus, Stephen
DeArmond, Bruce Miller
4:45 p.m.
S34.003
Vitamin D Deficiency and
Cognitive Impairment in
Older Women: A Multicentric
Cross- Sectional Study Cédric
Annweiler, Gilles Allali, AnneMarie Schott, Didier Le Gall,
François Herrmann, Olivier
Beauchet
5:00 p.m.
S34.004
An Evaluation of the Prodromal
Alzheimer’s Disease Diagnostic
Criteria within the ADNI Cohort
Study Howard Feldman, Jian
Han, Stephen Kaplita, Robert
Berman, Vlad Coric, Bongin Yoo,
Thomas Kelleher, Leah Burns,
Charles Albright, Pablo Lapuerta
5:15 p.m.
S34.005
Neuropsychological Outcomes
Following 18-Months of
Uninterrupted Intravenous
Immunoglobulin (IVIg) Treatment
in Patients with Alzheimer’s
Disease (AD) Diamanto
Tsakanikas, Norman Relkin
S35 Headache II
Room 716A
4:15 p.m. Presentation of
the Harold Wolff-John
Graham: An Award for
Headache/Facial Pain
Research
Recipient:
Ana Recober, MD
Iowa City, IA
4:30 p.m.
S35.002
Evaluation of Safety and Efficacy
of MAP0004 in Treating Acute
Menstrual Migraine Curt
Schreiber, Shashidhar Kori, Sylvia
Lucas, Scott Borland, Min Wang,
Bin Hu, Jan Brandes
4:45 p.m.
S35.003
OnabotulinumtoxinA Treatment
Improves Health-Related Quality
of Life and Reduces the Impact
of Chronic Migraine: 56-Week
Results from the PREEMPT
Clinical Program Richard Lipton,
Sepideh Varon, Peter Goadsby,
Ronald DeGryse, Catherine Turkel
5:00 p.m.
S35.004
Efficacy of Telcagepant in
Subgroups: Pooled Analysis of
Data from Phase III Studies Tony
Ho, Kathryn Connor, Andrew Ho,
James Kost, Xiaoyin Fan, David
Dodick, Stephen Silberstein,
Christopher Lines, Christopher
Assaid
5:15 p.m.
S35.005
OnabotulinumtoxinA for
Treatment of Chronic Migraine:
56-Week Analysis of the
PREEMPT Chronic Migraine
Subgroup with Baseline
Acute Headache Medication
Overuse Stephen Silberstein,
Joel Saper, Michael Stein,
Ronald DeGryse, Catherine Turkel
Scientific Sessions
Wednesday, April 14 | 4:15 p.m.–5:30 p.m.
S36 Anterior Horn: Spinal
Muscular Atrophy
S37 Neurologic
Manifestations: Imaging and
Therapeutics
Room 701B
Room 701A
4:15 p.m.
S36.001
Maximum Ulnar Compound
Motor Action Potential (CMAP)
Is Related to Motor Function in
Children with Spinal Muscular
Atrophy: Report from the SMA
CARNI-VAL Clinical Trial Aga
Lewelt, Kristin Krosschell, Charles
Scott, John Kissel, Thomas
Crawford, Gyula Acsadi, Guy
D’Anjou, Bakri Elsheik, Sandra
Reyna, Bernie Lasalle, Mary
Schroth, Louise Simard, Jo Anne
Maczulski, Kathryn Swoboda
4:15 p.m.
S37.001
The Effects of High Dose
Interferon-β1a on Plasma
Endothelial Microparticles:
Correlation with MRI
Parameters Mary LoweryNordberg, Erin Eaton, J.
Alexander, Eduardo GonzalezToledo, Meghan Harris, Kathrine
Chalamidas, Jeanie McGee,
Alireza Minagar
4:30 p.m.
S36.002
SMN Transcript Quantification
as a Surrogate Outcome
Measure in Spinal Muscular
Atrophy (SMA) Clinical
Trials: Towards a Validated
International Standard Operating
Procedure (SOP) Louise Simard,
F. Danilo Tiziano, Rosa Lomastro,
Elzbieta Slominski, Giovanni Neri,
Christina Brahe
4:45 p.m.
S36.003
Segmental Thigh Muscle
Volumes Estimated by Magnetic
Resonance Imaging (MRI)
Remain Stable over a Six-Month
Interval in Spinal Muscular
Atrophy (SMA): An Effective
Early Biomarker? Megan
Montgomery, Mark Punyanitya,
Wei Shen, Stephen Dashnaw,
Jacqueline Montes, Sally
Dunaway, Petra Kaufmann, Darryl
De Vivo, Douglas Sproule
5:00 p.m.
S36.004
Dominantly Inherited Spinal
Muscular Atrophy with Lower
Limb Predominance Showing
Linkage to 14q32 Matthew
Harms, Peggy Allred, Robert
Gardner, Jose Americo
Fernandes-Filho, Julaine
Florence, Alan Pestronk,
Muhammad Al-Lozi, Robert Baloh
5:15 p.m.
S36.005
Investigating the Cellular Site
of Action of Survival Motor
Neuron Protein Gyu Hwan Park,
Yuka Maeno-Hikichi, Tomoyuki
Awano, Katelyn Nelson, Lynn
Landmesser, Umrao Monani
4:30 p.m.
S37.002
Characterizing Cerebrovascular
Disease in Idiopathic
Hypereosinophilic Syndrome:
A Systematic Review Kathryn
Kirchoff, Sarah Cherian, Steven
Levine
4:45 p.m.
S37.003
Cognitive Functions and Cerebral
Volume in Neuromyelitis
Optica Frederic Blanc, Barbara
Jung, Vincent Noblet, Nadine
Longato, Catherine Kleitz,
Nadjette Cremel, François
Rousseau, Stephane Kremer,
Jean-Paul Armspach, Jerome
de Seze
5:00 p.m.
S37.004
Presentations and Clinical
Associations of Posterior
Reversible Encephalopathy
Syndrome Jennifer Fugate,
Daniel Claassen, Osman Kozak,
Harry Cloft, David Kallmes,
Alejandro Rabinstein
5:15 p.m.
S37.005
Neuroimaging Markers of
Accelerated Brain Aging in
Middle Aged Patients with
Type-1 Diabetes (T1D) Howard
Aizenstein, Vijay Venkatraman,
Trevor Orchard, Anne Newman,
Peter Gianaros, Elsa Strotmeyer,
Christopher Ryan, Tamara
Harris, Kristine Yaffe, Stephen
Kritchevsky, Caterina Rosano
S38 Neurogenetics: Basic
Science and Therapeutics
Room 714B
4:15 p.m. Presentation of
the S. Weir Mitchell Award
Recipient:
Peter Todd, MD, PhD
Ann Arbor, MI
4:30 p.m.
S38.002
Gentamicin Treatment of
Duchenne Muscular Dystrophy
Reinforces the Potential
for Mutation Suppression
Therapy Vinod Malik, Louise
Rodino-Klapac, Laurence
Viollet, Cheryl Wall, Wendy
King, Roula Al-Dahhak, Sarah
Lewis, Christopher Shilling,
Janaiah Kota, John Hayes, John
Mahan, Katherine Campbell,
Brenda Banwell, Majed Dasouki,
Victoria Watts , Kumaraswamy
Sivakumar, Ricardo Bien-Willner,
Kevin Flanigan, Zarife Sahenk,
Richard Barohn, Christopher
Walker, Jerry Mendell
4:45 p.m.
S38.003
Modification of Adenoassociated
Virus (AAV) To Deliver DNA to
Mitochondria Hong Yu, John
Guy
5:00 p.m.
S38.004
PGC-1alpha Is Involved in the
Pathogenesis of the Blunted
Antioxidant Response in
Friedreich’s Ataxia and Is
a Potential Therapeutic
Target Massimo Pandolfo, Mario
Manto, Daniele Marmolino
5:15 p.m.
S38.005
New Rodent Model
for Hereditary Spastic
Paraplegia Odelia Ghodsizadeh,
Mackenzie Schumer, Lesley
Fisher, Michele Basso, Robert
Hammer, Yaz Kisanuki
S39 Neuro-oncology:
Paraneoplastic Disorders
S40 Multiple Sclerosis:
Epidemiology
Room 713AB
Room 717AB
4:15 p.m.
S39.001
Paraneoplastic Neurological
Syndromes from the
Euronetwork Database. A
European Study from 20
Centres Bruno Giometto,
Wolfgang Grisold, Roberta
Vitaliani, Guido Bertolini, PNS
Euronetwork
4:15 p.m.
S40.001
Variations in the Gender Ratio
of Multiple Sclerosis Linked to
Converging Smoking Trends
in Men and Women Natalia
Palacios, Alvaro Alonso, Henrik
Bronnum-Hansen, Alberto
Ascherio
4:30 p.m.
S39.002
Paraneoplastic Dysautonomia:
55 Cases from the PNS
Euronetwork Database Roberta
Vitaliani, Guido Bertolini, Bruno
Giometto, PNS Euronetwork
4:45 p.m.
S39.003
Autoantibodies to the GABAB
Receptor Associate with Limbic
Encephalitis and Seizures,
and Alter GABAB Receptor
Function Eric Lancaster, Meizan
Lai, Ethan Hughes, Xiaoyu Peng,
Stephen Moss, Rita BaliceGordon, Josep Dalmau
5:00 p.m.
S39.004
Anti-NMDA Receptor Patient
Antibodies Potentiate NMDA
Receptor Currents in Cultured
Hippocampal Neurons Leo
Wang, Xiaoping Jiang, Amanda
Taylor, Alan Pestronk, Krista
Moulder
5:15 p.m.
S39.005
Death of Purkinje, Granule,
and Molecular Layer Neurons
Following Uptake of Anti-Hu
Antibodies in Organotypic
Rat Cerebellar Cultures John
Greenlee, Susan Clawson,
Kenneth Hill, Noel Carlson
4:30 p.m.
S40.002
Increase of Relapse Rate in
Patients with Multiple Sclerosis
after In-Vitro Fertilization Is
Related to the Use of LHRH
Agonists: A Multicenter
Retrospective Study in
France Laure Michel, Yohann
Foucher, Jerome De Seze, Sandra
Vukusic, Christian Confavreux,
David Brassat, Pierre Clavelou,
Jean Christophe Ouallet, Bruno
Brochet, Jean Pelletier, Pierre
Labauge, Christine Lebrun Frenay,
Fabienne Lefrere, Marylíne Jacq,
Sandrine Wiertlewsk , David
Laplaud
4:45 p.m.
S40.003
Breastfeeding Is Not Related
with the Risk of Post Partum
Relapses in Women with
Multiple Sclerosis Emilio
Portaccio, Angelo Ghezzi, Bahia
Hakiki, Valentina Zipoli, Lorenzo
Razzolini, Vittorio Martinelli, Lucia
Moiola, Francesco Patti, Loredana
La Mantia, Gianluigi Mancardi,
Claudio Solaro, Maria Rosaria
Tola, Carlo Pozzilli, Laura De
Giglio, Rocco Totaro , Alessandra
Lugaresi, Valeria Di Tommaso,
Damiano Paolicelli, Maria
Giovanna Marrosu, Giancarlo
Comi, Maria Trojano, Maria Pia
Amato
5:00 p.m.
S40.004
The Curious Case of Vitamin D,
Pregnancy, Breastfeeding, and
Postpartum Multiple Sclerosis
Relapses Annette Langer-Gould,
Rohit Gupta, Stephen Van Den
Eeden, Ronald Horst, Lorene
Nelson, Bruce Hollis
5:15 p.m.
S40.005
Subcutaneous Interferon beta1a Treatment and Pregnancy
Outcomes in Patients with
Multiple Sclerosis Magnhild
Sandberg-Wollheim, Enrica
Alteri, Margaretha Stam Moraga,
Gabrielle Kornmann
79
Thursday, April 15 Highlights
Frontiers in Clinical Neuroscience Plenary
Session
publications, and products to assist with practice management,
teaching methods, and research activities.
9:00 a.m.–11:00 a.m.
NEW! Platform Session Times
7:30 a.m.–12:00 p.m.
(Author stand by poster from 7:30 a.m.–9:00 a.m.)
MTCC, Exhibit Hall FG
1:15 p.m.–2:30 p.m.
2:45 p.m.–3:45 p.m.
3:00 p.m.–7:30 p.m.
(Author stand by poster from 6:00 p.m.–7:30 p.m.)
This session focuses on translational research related to clinical issues
of importance. Four physician-scientists outline their recent research
findings, along with the clinical implications.
Moderator: Stefan M. Pulst, MD, FAAN
Chair, Science Committee and Scientific
Program Subcommittee
”Reflections on Memory: What Neurosurgical
Patients Have Taught Us”
Brenda Milner, PhD
Montreal Neurological Institute,
Montreal, QC, Canada
”Clinical Spectrum and Cellular Mechanisms of
Autoimmunity to NMDA and Other Synaptic
Receptors”
Josep O. Dalmau, MD, PhD
University of Pennsylvania, Philadelphia, PA
”Stroke and Alzheimer’s Disease: Fellow Travelers
or Partners in Crime?”
Vladimir Hachinski, MD, DSc, FAAN
London Health Center, London, ON, Canada
”Neurologists Listening to Neurons: Intracortically
Based Brain-Computer Interfaces”
Leigh R. Hochberg, MD, PhD
Massachusetts General Hospital and Brigham and
Women’s Hospital; Harvard Medical School; Brown
University; Providence VA Medical Center, Boston, MA
Exhibits
11:30 a.m.–4:00 p.m.
Complimentary Luncheon
12:00 p.m.–2:00 p.m.
MTCC, Exhibit Hall DE
See the latest in pharmaceutical products, medical equipment,
80
Thursday, April 15 Highlights
NEW! AAN Awards Plenary Session
4:00 p.m.–6:00 p.m.
MTCC, Exhibit Hall FG
Moderator: Brenda Banwell, MD,
Member, Science Committee
The Awards Plenary Session highlights some of
the best and brightest in the field today, featuring
presentations by the recipients of four top 2010
awards. Sure to become a staple of future Annual
Meetings, three of the lectures will become
perennials: The Potamkin Prize for Research in Pick’s, Alzheimer’s,
and Related Diseases, the Sheila Essey Award—An Award for ALS
Research, and the John Dystel Prize for Multiple Sclerosis Research,
with the fourth lecture in rotation. In 2010 the rotating lecture will
feature a presentation from the recipient of the Dreifuss-Penry
Epilepsy Award.
Sheila Essey Award–An Award for ALS
Research
Presented by the American Academy of Neurology and the ALS
Association and supported through the philanthropy of the Essey Family
Fund and the ALS Association.
Recipient: Clive Svendsen, PhD/ Madison, WI
Poster Discussion Session
Ten posters in six neurologic topics have been selected for discussion.
Posters will be grouped in a separate area where topic experts will
facilitate questions and answers with attendees and poster authors
during the 90-minute author standby time.
NEW! Highlights in the Field
These new sessions bring you all you need to know for your
subspecialty or area of special interest. Get overviews in subspecialty
topics from the past year featuring scientific and educational abstracts,
journal articles, subspecialty society updates, tips, resources, and
more. Look for highlights from the following AAN Sections:
xx Autonomic Nervous System/Neuroendocrinology/Pain and
Palliative Care Wednesday, April 14 12:00 p.m. to 1:30 p.m.
xx Behavioral Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Child Neurology/Women’s Issues in Neurology
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Clinical Neurophysiology
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Critical Care and Emergency Neurology/Endovascular and
Interventional Neurology/Stroke and Vascular Neurology
Thursday, April 15 11:15 a.m. to 12:45 p.m.
xx Epilepsy Monday, April 12 12:00 p.m. to 1:30 p.m.
xx Ethics Thursday, April 15 11:15 a.m. to 12:45 p.m.
Dreifuss-Penry Epilepsy Award
Sponsored by the American Academy of Neurology and endowed
by members of the AAN Epilepsy Section; Abbott Laboratories,
Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.;
GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Neurologics;
Pfizer Inc; Shire US, Inc; and UCB Pharma.
Recipient: Martin Gallagher, MD, PhD/ Nashville, TN
Potamkin Prize for Research in Pick’s,
Alzheimer’s, and Related Diseases
Sponsored by the American Academy of Neurology, the AAN
Foundation, and funded through the philanthropy of the Potamkin
Family.
Recipients: Bruce L. Miller, MD/ San Francisco, CA
Lennart Mucke, MD/ San Francisco, CA
The following sections will conduct their regular business meetings as
follows:
xx A.B. Baker Section of Neurologic Educators Monday, April 12
12:00 p.m. to 1:00 p.m.
xx Headache & Facial Pain Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx History Section Tuesday, April 13 1:00 p.m. to 2:00 p.m.
xx Multiple Sclerosis Monday, April 12 4:00 p.m. to 5:30 p.m.
xx Neurohospitalist Tuesday, April 13 12:00 pm.m-1:30 p.m.
2010 Corporate Roundtable Members*
The AAN Foundation thanks its 2010 Corporate Roundtable Members for their demonstrated vision, commitment, and strong support of
neurologic research.
$40,000
Allergan, Inc.
Eli Lilly and Company
Forest Laboratories, Inc.
Genentech, Inc./Roche
Teva Neuroscience, Inc.
John Dystel Prize for Multiple Sclerosis Research
Presented by the American Academy of Neurology and the National
Multiple Sclerosis Society and made possible through a special
contribution from the John Dystel Multiple Sclerosis Research Fund at
the National Multiple Sclerosis Society.
Recipient: David Hafler, MD, MSc/ New Haven, CT
xx General Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Geriatric Neurology Wednesday, April 14 12:15 p.m. to 1:30 p.m.
xx Government Service Neurologists
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Movement Disorders Wednesday, April 14 12:00 p.m. to 1:30 p.m.
xx Multiple Sclerosis Thursday, April 15 11:15 p.m. to 12:15 p.m.
xx Neural Repair and Rehabilitation/Spine
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Neuroepidemiology Thursday, April 15 11:15 a.m.to 12:45 p.m.
xx Neurogenetics Wednesday, April 14, 12:00 p.m. to 1:30 p.m.
xx Neuroimaging Thursday, April 15 11:15 a.m. to 12:45 p.m.
xx Neuro-infectious Disease
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Neuromuscular Thursday, April 15 11:15 a.m. to 12:45 p.m.
xx Neuro-oncology Thursday, April 15 11:15 a.m. to 12:45 p.m.
xx Neuro-ophthalmology/Neuro-otology
Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Sleep Medicine Tuesday, April 13 12:00 p.m. to 1:30 p.m.
xx Sports Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m.
Information is subject to change.
*Current as of February 8, 2010
$30,000
Pfizer Inc
Sepracor Inc.
UCB Inc.
$20,000
Acorda Therapeutics, Inc.
Bayer Healthcare Pharmaceuticals, Inc.
Biogen Idec
Boehringer Ingelheim Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc.
Genzyme Corporation
Medivation, Inc.
Merz Pharmaceuticals Inc.
Novartis Pharmaceuticals Corporation
PhotoThera, Inc.
Questcor Pharmaceuticals, Inc.
Upsher-Smith Laboratories, Inc.
81
Poster Session V
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
Poster Discussion Session: Multiple Sclerosis and Related Diseases: Drug Mechanisms
Location: 800 Level
Moderator: Michael Racke, MD
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
PD5.001 Effect of Immunomodulatory
Agents (IMAs) on Cortical Inflammatory
Lesions (CLs) in Patients with RelapsingRemitting Multiple Sclerosis (RRMS):
A 2-Year Longitudinal Comparison
Study Paolo Gallo, Valentina Bernardi,
Francesca Rinaldi, Alice Favaretto, Irene
Mattisi, Paola Perini, Luciano Rinaldi,
Massimiliano Calabrese
PD5.002 Induction of Immune
Tolerance in Multiple Sclerosis Patients
by Epicutaneous Immunization with
Myelin Peptides Agata Walczak, Maciej
Jurynczyk, Krzysztof Selmaj
PD5.003 Glatiramer Acetate
Immunomodulates Pro-Inflammatory B
Cell Function in Central Nervous System
Autoimmune Disease Deetje Hertzenberg,
Martina Betz, Klaus Lehmann-Horn, Scott
Zamvil, Patrice Lalive D’Epinay, Bernhard
Hemmer, Martin Weber
Behavioral Neurology: Emotion
and Insight
P05.001 The Contribution of
Neuropsychiatric Symptoms to the Cost of
Frontotemporal, Alzheimer, and Vascular
Dementia Care Galeno Rojas, Leonardo
Bartoloni, Cecilia Serrano, Carol Dillon,
Ricardo Allegri
P05.002 Subgenual Cingulate Gyrus
Deep Brain Stimulation for Refractory
Major Depressive Disorder: PET
Findings Sakina Rizvi, Jakub Konarski,
Sidney Kennedy, Peter Giacobbe, Helen
Mayberg, Andres Lozano
P05.003 Psychiatric Comorbidities
Are Frequent in Patients with Migraine,
Epilepsy, and Multiple Sclerosis Andres
Kanner, Alan Ettinger, Bichun Ouyang,
Hilary Kanner, Sandra Hamberger, Connie
Lau
P05.004 The Effectiveness of the One
-Item Interview “Are You Depressed?” in
Multiple Sclerosis and Hereditary Spastic
Paraplegia Katrin Gross-Paju, Liina Vahter,
Mark Braschinsky, Sulev Haldre, Tiina
Talvik
P05.005 Structural Brain Differences
Associated with Personality Dimitrios
Kapogiannis, Angelina Sutin, Paul Costa,
Susan Resnick
P05.006 Laughter Induction in the NIH
OCD DBS Cohort: A Potential Predictor
of Therapeutic Response? Ihtsham
Haq, Kelly Foote, Samuel Wu, Atchar
Sudhyadhom, Wayne Goodman, Nicola
Ricciutti, Dawn Bowers, Charles Jacobson,
Herbert Ward, Michael Okun
82
PD5.004 Laquinimod Induces UpRegulation of BDNF in Serum of Patients
with Relapsing-Remitting Multiple
Sclerosis Jan Thöne, Silvia Seubert,
Rebecca Conrad, Giancarlo Comi, Stefan
Wiese, Liat Hayardeny, Ralf Gold, Ralf
Linker
PD5.006 Prolonged Reduction
in Circulating Lymphocytes After
Discontinuation of FTY720 (Fingolimod):
Possible Relationship to Duration of
Therapy Mark Keezer, Yves Lapierre, Igor
Shames, David Haegert, Amit Bar-Or, Jack
Antel
PD5.005 Detection and Quantification
of IFNB-1b-Induced NAbs Using Various
Assays and Laboratories Hans Hartung,
Bernd Kieseier, Douglas Goodin, Barry
Arnason, Giancarlo Comi, Stuart Cook,
Massimo Filippi, Douglas Jeffery, Ludwig
Kappos, Paul O’Connor, Timon Bogumil,
Volker Knappertz, Christoph Pohl, Rupert
Sandbrink, Brigitte Stemper , Stephan Lehr,
Joachim Reischl
PD5.007 Interferon-beta Decreases
Energetic Activity in CD4+-Lymphocytes:
A Possible Mechanism of Action? Aiden
Haghikia, Derek Pappas, Bartosz Pula,
Sabrina Ruhrmann, Elahe Taherzadeh-Fard,
Denis Akad, Larissa Arning, Susan Goelz,
Ralf Gold, Sergio Baranzini, Andrew Chan
P05.007 Traumatic Brain Injuries and
Psychogenic Nonepileptic Seizures W.
Curt LaFrance, Jr., Marie DeLuca
P05.008 Tizanidine Improves Geriatric
Depression Scale Scores in Stroke and
Brain Injury Survivors with Spastic
Hemiparesis: Post-Hoc Analysis from
a Randomized, Double-Blind, PlaceboControlled Trial Stuart Yablon, David
Simpson, Jean-Michel Gracies, Richard
Barbano, Allison Brashear
P05.009 Receptive Aprosodia and
the Acquired Loss of Empathy Following
Acute Stroke Shaan Khurshid, Argye Hillis
P05.010 Metacognitive Sensitivity
to Neuropsychological Impairment
in Frontotemporal Degeneration and
Alzheimer’s Disease Lauren Massimo,
David Libon, Brianna Morgan, Ashley
Boller, Peachie Moore, Murray Grossman
Behavioral Neurology: Attention
and Visual Functions
P05.011 Line Bisection and “ Where”
Perceptual-Attentional Spatial Bias: Aged
Men Go Right Peii Chen, Kelly Goedert,
Elizabeth Murray, Karen Kelly, Shpresa
Ahmeti, Anna Barrett
P05.012 Posterior Cortical Atrophy
and Cholinesterase Inhibitors: Do They
Help? Paul McMonagle
P05.013 Superior Temporal Sulcus and
Detection of Rare Events Petra Haitova,
Milan Brazdil, Radek Marecek, Michal
Mikl, Petr Krupa, Ivan Rektor
PD5.009 Vitamin D Metabolites Are
Linked to Clinical and MRI Outcomes
in Multiple Sclerosis Patients Bianca
Weinstock-Guttman, Robert Zivadinov, Jun
Qu, Eunjin Bang, David Hojnacki, Frederick
Munschauer, Niels Bergsland, Sarah
Hussein, Laura Willis, Marya Cherneva,
Murali Ramanathan
PD5.010 Early Effects of Natalizumab
on the Cognitive Functioning, Fatigue
and Quality of Life of African American
Patients with Multiple Sclerosis Judith
Stephenson, Likun Hou, Sonalee Agarwal,
Siddhesh Kamat, Krithika Rajagopalan
P05.014 Drug-Induced Changes in
Performance on the Divided Attention
Task in Subjects with a History of
Recreational Drug Use Naama LevyCooperman, Boris Danilov, Myroslava
Romach, Edward Sellers
P05.015 A Descriptive Study on
Constructional Apraxia in Multiple
Sclerosis Manuela de Stefano, Raffaella
Migliaccio, Daniela Buonanno, Gioacchino
Tedeschi, Ugo Nocentini, Patrizia Montella
Movement Disorders:
Huntington's Disease
P05.021 Effect of Tetrabenazine
(TBZ) on Motor Function in Patients
with Huntington Disease (HD) Joseph
Ferrara, Giovanni Mostile, Christine Hunter,
Octavian Adam, Joseph Jankovic
P05.016 The Clinical Presentation and
Functional Neuroimaging Characteristics
of Posterior Cortical Atrophy Po-Heng
Tsai, Mario Mendez
P05.022 Huntington Disease
Prevalence in a Cohort from Argentina:
Analysis of Normal CAG Repeats in
Huntingtin Gene Among HD Patients and
Control Individuals Virginia Parisi, Gabriel
Persi, Viviana Varela, Jose Etcheverry,
Fernando Leiguarda, Daniela Converso,
Emilia Gatto
P05.017 Late-Life Attention Deficit
Hyperactivity Disorder (ADHD): A
Neglected Condition in a Memory
Clinic Ezequiel Gleichgerrcht, Teresa
Torralva, Alicia Lischinsky, María Roca,
Facundo Manes
P05.023 Interaction of Normal and
Mutant CAG Repeat Sizes and Age at
Onset in a Huntington Disease Cohort
from Argentina Emilia Gatto, Gabriel
Persi, Virginia Parisi, Jose Etcheverry,
Fernando Leiguarda, Viviana Varela
P05.018 Disorders of Higher Cognitive
Visual Functions in Pure Alexia Jagan
Pillai, Steven Sparr
P05.024 Clinical Correlates
of Eye Movements in Huntington
Disease Cameron Jeter, Ashley Hood,
Alicia Palao, Saumil Patel, Joseph
Jankovic, Anne Sereno
P05.019 The Iowa Gambling Tasks and
Its Relation with Fluid Intelligence María
Roca, Teresa Torralva, Ezequiel
Gleichgerrcht, John Duncan, Facundo
Manes
P05.020 Armodafinil and Modafinil
Counteract the Attentional Dysfunction
Associated with Sleep Deprivation:
Implications for Treating Parkinson’s
Dementia and Dementia with Lewy
Bodies Gregory Rippon, Keith Wesnes
P05.027 OFF Test for Patients
Treated with Globus Pallidus Internus
Deep Brain Stimulation for Huntington’s
Disease Victoria Gonzalez-Martinez,
Laura Cif, Brigitte Biolsi, Ana Maria Moura,
Hassan El Fertit, Philippe Coubes
P05.036 Long-Term Follow-Up
of Immune Thrombocytopenia after
Treatment of Multiple Sclerosis
Patients with Alemtuzumab in
CAMMS223 Edward Fox, N. A. on Behalf
of the CAMMS223 Study Group
P05.028 Upper Face Chorea in
Huntington Disease Robert Fekete,
Joseph Jankovic
P05.037 Network Analysis of
Transcriptional Regulation in Response
to Interferon-β-1a Multiple Sclerosis
Treatment Suggests a Molecular Basis for
Adverse Effects Michael Hecker, Robert
Goertsches, Christian Fatum, Dirk Koczan,
Hans-Juergen Thiesen, Reinhard Guthke,
Uwe Zettl
P05.029 Impact of Caffeine Intake on
Huntington’s Disease (HD) Course Cécile
Duru, Clémence Simonin, Florence Richard,
Pascale Hincker, Julia Salleron, Perrine
Charles, Katia Youssov, Sylvie Burnouf,
Jean-Philippe Azulay, Christophe Verny,
Christine Tranchant, Cyril Goizet, Luc
Defebvre, Bernard Sablonniíre, Monique
Romon , Luc Buée, Philippe Amouyel,
Olivier Godefroy, Alexandra Dürr, AnneCatherine Bachoud-lévi, David Blum, Pierre
Krystkowiak
P05.030 Increases of 8-Hydroxy-2Deoxyguanosine Plasma Levels in Patients
with Huntington’s Disease Isaac Túnez,
Inmaculada Tasset, Eduardo Agüera,
Francisco Sánchez, Ricardo FernandezBolanos, Fernando Sánchez-Lopez
PD5.008 Effect of Intramuscular
Interferon beta-1a on Gray Matter
Atrophy in Relapsing-Remitting Multiple
Sclerosis Kunio Nakamura, Richard
Rudick, Jar-Chi Lee, Pamela Foulds,
Elizabeth Fisher
P05.025 Impact of Placebo Treatment
in Huntington’s Disease Esther Cubo,
Miguel González, Inés Del Puerto, Olga
Fernández Arconada, Justo Garcia de
Yebenes
P05.026 Evaluation of mGluR5 in Early
Parkinson and Huntington Disease Using
18
F-FPEB PET Imaging Danna Jennings,
Kenneth Marek, David Russell, Jeff
Batis, Andre Koren, Olivier Barret, Gilles
Tamagnan, John Seibyl
Poster Session V
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P05.031 Rate of Change in Early
Huntington’s Disease Patients Without
Antipsychotics Christina Meyer, Bernhard
Landwehrmeyer, Casten Schwenke, Adam
Doble, Michael Orth, Albert Ludolph
Multiple Sclerosis and Related
Diseases: Drug Mechanisms II
P05.032 Pharmacokinetics of Oral
Teriflunomide, a Novel Oral DiseaseModifying Agent Under Investigation
for the Treatment of Multiple
Sclerosis Tharin Limsakun, Francoise
Menguy-Vacheron
P05.033 Teriflunomide Treatment
Reduces Infiltration of Macrophages,
T Cells and B Cells, and Increases
Survival of Oligodendrocytes in
the Spinal Cord of the Dark Agouti
Rat Model of Experimental Allergic
Encephalomyelitis Margaret Petty, Lan
Lee, Xioayou Ying, Michelle Taurino, Julian
Oliver, Kathleen McMonagle-Strucko,
Cecilia Marta
P05.034 25-OH Vitamin D3 Reduces
Interferon Gamma and Interleukin-17
Release from CD4 + T-Cells Edward Knapp,
Christopher Eckstein, Peter Calabresi
P05.035 Continuous DownRegulation of VLA-4 and Accumulation
of Natalizumab at the VLA-4 Receptor:
Potential Molecular Basis of Enhanced
Treatment Efficacy and Occurrence of
Opportunistic Infections Jörg Kraus,
Katrin Oppermann, Peter Wipfler, Georg
Pilz, Andrea Harrer, Shahrzad Afazel,
Elisabeth Haschke-Becher, Alexander
Kunz, Stefan Golaszewski, Wolfgang
Staffen, Gunther Ladurner
P05.038 Oral Fingolimod (FTY720) in
Relapsing-Remitting Multiple Sclerosis:
Baseline Patient Demographics and
Disease Characteristics from a Two-Year
Phase III Trial (FREEDOMS II) Peter
Calabresi, Douglas Goodin, Douglas
Jeffery, Fred Lublin, Kottil Rammohan,
Anthony Reder, Timothy Vollmer, Tracy
Stites, Bingbing Li, Rebecca Gottschalk,
Manoj Malhotra, on Behalf of the
FREEDOMS II Study Group
P05.039 Serum from Interferonβ-1b Treated MS Patients Induced In
Vitro Stabilization of the Blood-Brain
Barrier Marcus Mueller, Achim Frese,
Isabelle Nassenstein, Maike Hoppen,
Martin Marziniak, E. Bernd Ringelstein,
Kwang Kim, Wolf Schaebitz, Jörg Kraus
P05.040 Pharmacological Changes
Induced by Administration of PEGylated
IFNb -1a in Healthy Volunteers Larisa
Miller, Michaela Lerner, Mary Crossman,
Stacy Hitchman, Gudarz Davar, Meena
Subramanyam
P05.041 Persistence of Neutralizing
Antibodies Against Interferon Beta in
Multiple Sclerosis Patients Switching
to Natalizumab Malin Lundkvist, Ajith
Sominanda, Jan Hillert, Anna FogdellHahn
P05.042 Sustained Positive Effects
of Alemtuzumab on Diverse Neurological
Functions in Relapsing-Remitting Multiple
Sclerosis Patients Edward Fox, N. A. on
Behalf of the CAMMS223 Study Group
P05.043 Plasma Exchanges in
Severe and Acute Inflammatory
Demyelinating Attacks of the Central
Nervous System Sandrine Brunot, Sandra
Vukusic, Agnís Fromont, Grégory Couvreur,
Christiane Mousson, Maurice Giroud,
Christian Confavreux, Thibault Moreau
P05.044 Vitamin D and Cognitive
Impairment in Multiple Sclerosis
(MS) Sarah Morrow, Murali Ramanathan,
Ralph Benedict, Jun Qu, Xiaotao Duan,
Barbara Teter, David Hojnacki, Robert
Zivadinov, Bianca Weinstock-Guttman
P05.045 Effects of Pro-Inflammatory
Cytokines on Cannabinoid CB1 and CB2
Receptors in Immune Cells of Normal
Subjects and Patients with Multiple
Sclerosis Lucie Jean-Gilles, Angela Fahey,
Manjit Braitch, Laura Edwards, R. Adrian
Robins, Louise Showe, M. Liaque Latif,
Steve Alexander, Victoria Chapman, Dave
Kendall, Cris Constantinescu
P05.046 Morphea in a Multiple
Sclerosis Patient Treated with
Natalizumab Katayoun Alikhani, Marcelo
Kremenchutzky
P05.047 The Kinetics of CSF
Lymphocyte Recovery after Cessation
of Natalizumab in Patients with Multiple
Sclerosis Adil Javed, Howard Rossman,
Anthony Reder
P05.048 Expanded Laboratory
Surveillance for PML in a Large Cohort
of Patients on Natalizumab for Multiple
Sclerosis Lilyana Amezcua, Regina
Berkovich, Margaret Burnett, Jose
Aparicio, Norman Kachuck
P05.049 Glatiramer Acetate
Reduces Th17 Inflammation and
Induces Regulatory T-Cells in the CNS
of Mice with Relapsing-Remitting and
Chronic Experimental Autoimmune
Encephalomyelitis Rina Aharoni, Raya
Eilam, Ariel Stock, Anya Vainshtein, Elias
Shezen, Ruth Arnon
P05.050 Amelanotic Lentigo Maligna
Melanoma Associated with Long-Term
Natalizumab Treatment for Multiple
Sclerosis Jonathan Carter, Suzanne
Connolly
P05.051 Rapid Onset of Natalizumab
Effect Regardless of Baseline Disease
Activity in Multiple Sclerosis Ludwig
Kappos, Richard Rudick, Chris Polman, Paul
O’Connor, Patrick Vermersch, Heinz Wiendl,
Amy Pace, Daniel Desgrandchamps,
Christophe Hotermans
P05.052 BAF312, a Selective S1P1/
S1P5 Receptor Modulator, Effectively
Reduces Absolute Lymphocyte Counts
in Human Volunteers and Demonstrates
the Relevance of S1P1 in Mediating a
Transient Heart Rate Reduction Erik
Wallström, Peter Gergely, Barbara
Nuesslein-Hildesheim, Frédéric Zécri, Nigel
Cooke, Christian Bruns, Olivier Luttringer,
Tobias Sing, Andrea Groenewegen,
Mitchell Rosenberg, Marc Saltzman
P05.053 The Immunoregulatory
Properties of Laquinimod on Human B
Cells Shahar Nussbaum, Ayelet Snir, Liat
Hayardeny, Doron Melamed, Ariel Miller,
Elias Toubi
P05.054 IFNB-1b Therapy Reduces
vs. Glatiramer Acetate the Evolution of
Permanent T1 Hypointensities (“Black
Holes”) on Brain MRI in Treatment-Naïve
RRMS Patients Massimo Filippi, Mara
Rocca, Fabiano Camesasca, Stuart Cook,
Giancarlo Comi, Douglas Goodin, Paul
O’Connor, Douglas Jeffery, Hans-Peter
Hartung, Barry Arnason, Ludwig Kappos,
Jerry Wolinsky, Volker Knappertz,
Christoph Pohl, Karola Beckmann ,
Catherine Brown, Douglas Arnold, Gary
Cutter, Rupert Sandbrink, Timon Bogumil
P05.055 Course of Multiple Sclerosis
Associated Fatigue during Treatment
with Glatiramer Acetate Maren Nowack,
Dagmar Rinas, Volker Limmroth, Barbara
Tettenborn, Norman Putzki
P05.056 Time Dependent Ex Vivo
RNA Expression Analysis of Monocytes
Derived from Glatiramer Acetate Treated
Multiple Sclerosis Patients Robert
Goertsches, Michael Hecker, Madhan
Thamilarasan, Dirk Koczan, Hans-Juergen
Thiesen, Uwe Zettl
P05.057 The Influence of Plasma
Exchange Treatment on Cellular Immunity
in Multiple Sclerosis Relapses Refractory
to Steroid Therapy Mariusz Stasiolek,
Alexandra Schroeder, Chris Meyer, De
Hyung Lee, Ralf Gold, Ralf Linker
P05.058 Oral Administration of the
Small Molecule Lipoic Acid Leads to
Elevation in cAMP Levels in Multiple
Sclerosis Sonemany Salinthone,
Vijayshree Yadav, Dennis Bourdette, Daniel
Carr
P05.059 Association of Th1/
Th2-Related Chemokine Receptors in
Peripheral T Cells with Disease Activity
and Immunomodulatory Treatment in
Patients with Multiple Sclerosis and
Neuromyelitis Optica Yuko Shimizu, Kohei
Ota, Sachiko Kubo, Masaki Kobayashi,
Shinichiro Uchiyama
P05.060 Low-Contrast Letter Acuity
Detects Visual Function Improvement
in Phase III Relapsing MS Trials of
Natalizumab Laura Balcer, Steven Galetta,
Chris Polman, Richard Rudick, Fredrick
Munschauer, Eric Eggenberger, Peter
Calabresi, Annie Zhang, Richard Kim
P05.061 Long -Term Treatment
of Multiple Sclerosis with Glatiramer
Acetate: Natural History of the Subtypes
of Anti-Glatiramer Acetate Antibodies
and Their Correlation with Clinical
Efficacy Talma Brenner, Dvora Teitelbaum,
Camille Sicsic, Dimitrios Karussis
P05.062 A Treatment for LipoatrophyInduced Injection with Subcutaneous
Glatiramer Acetate Christine Lebrun
Frenay, Lydiane Mondot, Marc Bertagna,
Pierre Thomas, Mikael Cohen
Multiple Sclerosis and Related
Diseases: Ocular Coherence
Tomography
P05.063 Ocular Coherence
Tomography in a Three-Year-Old with
Neuromyelitis Optica Christopher
Eckstein, Stephanie Syc, Christina Warner,
Peter Calabresi
P05.064 Retinal Nerve Fibre Layer
Thickness Is Associated with Cognitive
Performance in Youth with Multiple
Sclerosis Constantina Lafoyiannis,
Christine Till, Mary Desrocher, R. Buncic,
Brenda Banwell
P05.065 Optical Coherence
Tomography as a Clinical Trial Outcome
Measure: Implications of Treating
On-Study Relapses with Intravenous
Methylprednisolone Robert Bermel, Peter
Imrey, Jeffrey Cohen
83
Poster Session V
P05.066 Improving Optical Coherence
Tomography Sensitivity and Specificity in
Multiple Sclerosis by Analysis of Retinal
Nerve Fiber Layer Shape Alexander
Brandt, Markus Bock, Sebastian Bischoff,
Sebastian Mansow-Model, Friedemann
Paul
P05.067 Maximizing the Reliability
of Serial Stratus OCT Testing in Multiple
Sclerosis Patients Mark Morrow
P05.068 Retinal Nerve Fiber Layer
Thickness Correlates with Gray and White
Matter Volume in MS John Ratchford,
Sheena Farrell, Navid Shiee, Christina
Warner, Stephanie Syc, Scott Newsome,
Daniel Harrison, Elliot Frohman, Laura
Balcer, Dzung Pham, Daniel Reich, Peter
Calabresi
P05.069 Visual Function in
Neuromyelitis Optica: From Retina to
Optic Tracts Jerome de Seze, Marie
Bouyon, Jeremy Jeantroux, Nicolas
Collongues, Frederic Blanc, Marie
Fleury, Laurent Ballonzoli, Claude Speeg,
Stephane Kremer
P05.070 Trend Towards Lowering
of Multiple Sclerosis Severity Scores
Among More Recent Enrollees Into
the New York State Multiple Sclerosis
Consortium Joseph Herbert, Eric Chamot,
Joshua Bacon, Brian Apatoff, Karen Blitz,
Patricia Coyle, Andrew Goodman, Malcolm
Gottesman, Keith Edwards, Alfred Frontera,
Richard Holub, Burk Jubelt, Mustafa
Khan, Lauren Krupp, Michael Lenihan ,
Fred Lublin, Cornelia Mihai, Aaron Miller,
Frederick Munschauer, Allan Perel, David
Snyder, Barbara Teter, Mark Tullman,
Bianca Weinstock-Guttman, Robert
Zivadinov, Ilya Kister
P05.071 Comparability of Randomized
Controlled Versus Observational Studies:
Findings from the Toronto Observational
Study of Natalizumab in Multiple
Sclerosis Kristen Krysko, Paul O’Connor
P05.072 Demographic and Clinical
Characteristics of Patients Treated with
Natalizumab in Post-Marketing Setting.
A Prospective Multicenter Observational
Study of 1000 Patients Laure Dagrassa,
Patrick Vermersch, Jerome De seze, Bruno
Brochet, Lucien Rumbach, Christine Lebrun,
Marc Debouverie, David Laplaud, Philippe
Cabre, Christian Confavreux, Jean Pelletier,
Gilles Defer, William Camu, Ayman
Tourbah, Pierre Labauge , Pierre Clavelou,
Olivier Casez, Patrick Hautecoeur, Caroline
Papeix, Gilles Edan, Didier Ferriby, Roland
Liblau, Michel Clanet, David Brassat
Multiple Sclerosis and Related
Diseases: Human Basic
Research
P05.073 Circulating Perforin+CD8+
and T-Bet+CD8+ Lymphocytes in
Relapsing Remitting, Secondary
Progressive and Primary Progressive
Multiple Sclerosis Patients Giovanni
Frisullo, Viviana Nociti, Raffaele Iorio,
Domenico Plantone, Agata Katia Patanella,
Pietro Tonali, Anna Paola Batocchi
84
P05.074 Response of Human
Oligodendrocyte Progenitors to Growth
Factors and Axon Signals Qiao Ling
Cui, Gabriella Fragoso, Veronique Miron,
Guillermina Almazan, Jack Antel
P05.075 Mesenchymal Stem Cell
Therapy as a Control of Pro-Inflammatory
Th1 and Th17 Responses in Multiple
Sclerosis Peter Darlington, Marie-Noelle
Boivin, Christel Renoux, Jeffrey Cohen, Luis
Solchaga, Amit Bar-Or
P05.076 Intrathecal Anti-MOG
Antibody Production Is Elevated in
Multiple Sclerosis Eric Klawiter, Laura
Piccio, Jeri-Anne Lyons, Kevin O’Connor,
Anne Cross
P05.077 Bio Assays for
the Investigation of Sub Lethal
Neurobiological Injury in Multiple
Sclerosis Gregoire Morisse, Sandeep
Vanamala, Isabel Rambaldi, Sathyanath
Rajasekharan, Amit Bar-Or
P05.078 IL-11 Producing Cells Are a
New T-Cell Subset That Promotes Th17Differentiation in Patients with Clinically
Isolated Syndrome Suggestive of Multiple
Sclerosis Xin Zhang, Yazhong Tao,
Jianping Jin, Yunan Tang, Silva MarkovicPlese
P05.079 Immune-Mediate Changes
to the Astrocyte Cytoskeleton as Seen in
Multiple Sclerosis Peter Darlington, Jack
Antel, Amit Bar-Or
Aging and Dementia: Risk
Factors
P05.080 Cerebral Atrophy Is
Correlated with White Matter
Hyperintensity, but Not with Brain
Microbleeds Yusuke Yakushiji, Megumi
Hara, Yusuke Nanri, Makoto Eriguchi,
Tomoyuki Noguchi, Masashi Nishihara,
Masanori Nishiyama, Hideo Hara
P05.081 Cerebrovascular Risk Factors
Influence Age-Related Memory Decline
in APOE E4 Carriers Richard Caselli,
Amylou Dueck, Dona Locke, Marwan
Sabbagh, Geoffrey Ahern, Steven Rapcsak,
Leslie Baxter, Roy Yaari, Bryan Woodruff,
Charlene Snyder, Scott Findley, Eric
Reiman
P05.082 Hemodynamic Correlates
of Vascular Risk Factors in Patients with
Alzheimer’s Disease Takashi Yamazaki,
Daiki Takano, Ken Nagata
P05.083 Cerebrovascular Reactivity
in Patients with Alzheimer’s Disease:
Correlation with Cognition and White
Matter Lesions Yong Soo Shim, A-Hyun
Cho, Dong Suk Shim, Dong-Won Yang
P05.084 Association of Vascular
Risk Factors and White Matter
Hyperintensities with Regional
Cerebral Atrophy in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI)
Cohort Lindsay Horton, Kyle Womack,
Ramon Diaz-Arrastia
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P05.085 Clinical Correlating Factors
and Cognitive Function in CommunityDwelling Healthy Subjects with Cerebral
Microbleeds (MBs) Yuki Takashima,
Takahiro Mori, Manabu Hashimoto, Akira
Uchino, Takefumi Yuzuriha, Hiroshi Yao
P05.086 Language and Behavior
Domains Enhance the Value of the Clinical
Dementia Rating Scale David Knopman,
Sandra Weintraub, V. Pankratz
P05.087 NCAT: A Visual-Based
Cognitive Assessment Tool for
Use in a Multiracial Multilingual
Population Nagaendran Kandiah, Lynn
Wiryasaputra, Esther Chua
P05.088 Utility of an Abbreviated
Version of the Executive and Social
Cognition Battery in the Detection of
Executive Deficits in Early Behavioral
Variant Frontotemporal Dementia
Patients Ezequiel Gleichgerrcht, Teresa
Torralva, María Roca, Facundo Manes
P05.089 Cardiorespiratory Fitness Is
Associated with Brain Atrophy in Early
Alzheimer Disease Robyn Honea, Eric
Vidoni, Heather Anderson, William Brooks,
Russell Swerdlow, Jeffrey Burns
Aging and Dementia: Lewy Body
Disorders
P05.090 Does REM Sleep Behavior
Disorder Improve the Diagnostic Accuracy
of Dementia with Lewy Bodies? Validation
with an Autopsy Sample Tanis Ferman,
Bradley Boeve, Ryan Uitti, Zbigniew
Wszolek, Jay Van Gerpen, Neill GraffRadford, V. Shane Pankratz, Ronald
Petersen, David Knopman, Joseph Parisi,
Dennis Dickson, Glenn Smith
P05.091 Probable REM Sleep Behavior
Disorder Is Associated with Decreased
Olfaction in Cognitively Normal Subjects:
The Mayo Clinic Study of Aging Brendon
Boot, Bradley Boeve, Rosebud Roberts,
Yonas Geda, David Knopman, Eric
Tangalos, Glenn Smith, Robert Ivnik,
Vernon Pankratz, Teresa Christianson,
Michael Silber, Tanis Ferman, Ronald
Petersen
P05.092 Validation of the Mayo
Fluctuations Scale in an Autopsy
Confirmed Sample of DLB, AD and Normal
Controls Winnie Pao, Tanis Ferman,
Bradley Boeve, Glenn Smith, Dennis
Dickson, Joseph Paris, Ryan Uitti, Jay Van
Gerpen, Zbigniew Wszolek, Neill GraffRadford, David Knopman, Ronald Petersen
P05.093 Risk of One Year Decline
in Functional Activities in Dementia
with Lewy Bodies and Alzheimer
Disease Dawn Gill, Thomas Koepsell,
Rebecca Hubbard, Walter Kukull
P05.094 The Evaluation of Alzheimer’s
Disease (AD) and Lewy Body Disease
(LBD) Using Clinical and Semiquantitative
MRI Measures Miriam Rodriguez,
Elizabeth Potter, Qian Shen, Warren Barker,
Maria Grieg-Custo, Joscelyn Agron, David
Loewenstein, Ranjan Duara
P05.095 Visual Hallucinations,
Visuospatial Dysfunction and Brain
SPECT Perfusion in Dementia with
Lewy Bodies Michael Misch, Elizabeth
Hollingdrake, Sandra Black, Mario Masellis
P05.096 Screening for REM Sleep
Behavior Disorder in the CommunityDwelling Elderly: Validation of the Mayo
Sleep Questionnaire in the Mayo Clinic
Study of Aging Bradley Boeve, Jennifer
Molano, Tanis Ferman, Glenn Smith, Kevin
Bieniek, Maja Tippmann-Peikert, David
Knopman, V. Shane Pankratz, Yonas Geda,
Rosebud Roberts, Eric Tangalos, Michael
Silber, Ronald Petersen
P05.097 Sensitivity of the
Clock Drawing Test in Parkinson’s
Disease Patients with Mild Cognitive
Impairment Evelyne Matteau, Martine
Simard, Melanie Langlois, Nicolas Dupre
P05.098 Excessive Daytime
Somnolence Is Objectively Demonstrated
in Early Dementia with Lewy Bodies but
Is Not a Feature of Early Alzheimer’s
Disease Bradley Boeve, Tanis Ferman,
Michael Silber, Siong-Chi Lin, Glenn Smith,
Ryan Uitti, Jay Van Gerpen, Zbigniew
Wszolek, Neill Graff-Radford, David
Knopman, Ronald Petersen
P05.099 Probable REM Sleep Behavior
Disorder in Cognitively Normal Elderly
Subjects and Risk of Cognitive Impairment
and/or Parkinsonism: The Mayo Clinic
Study of Aging Brendon Boot, Bradley
Boeve, Teresa Christianson, Rosebud
Roberts, Yonas Geda, David Knopman, Eric
Tangalos, Robert Ivnik, Vernon Pankratz,
Michael Silber, Tanis Ferman, Ronald
Petersen
Aging and Dementia: Basic
Science
P05.100 Phytic Acid as a
Potential Therapy for Alzheimer’s
Disease Thimmappa Anekonda, Teri
Wadsworth, Randy Woltjer, Christopher
Harris, Babett Petriko, Joseph Quinn
P05.101 Alzheimer’s Impairs
Responses to Speed Changes in
Simulated Self-Movement: A Visual
Motion Evoked Potentials Study Roberto
Fernandez, Charles Duffy
P05.102 Differential Activation
of Tumor Necrosis Factor Receptors
Distinguishes Between Brains From
Alzheimer’s Disease and Non-Demented
Patients Xin Cheng, Libang Yang, Ping He,
Rena Li, Yong Shen
P05.103 Aging-Related DownRegulation of Dynein Causes
Accumulation of α-Synuclein Zeng-lin
Cai, Ji-jun Shi, Ya-ping Yang, Wei-dong Hu,
Chun-feng Liu
P05.104 Production and
Characterization of High Affinity Rabbit
Monoclonal Antibodies to Amyloid β
40 (Aβ40) and Amyloid β 42 (Aβ42)
Peptides Pankaj Mehta, Marc Barshatzky,
Anna Potempska, Bruce Patrick, Sangita
Mehta, David Miller
Poster Session V
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P05.105 Prolonged Disease Duration
Is Associated with Lower Neuritic
Amyloid Plaque Burden in Alzheimer’s
Disease Gregory Jicha, Peter Nelson,
Erin Abner, Marta Mendiondo, Frederick
Schmitt, William Markesbery, Richard
Kryscio
P05.106 Intracerebroventricular
Injection of Tumor Necrosis Factor-α
Monoclonal Antibody (Infliximab)
Reduces Cerebral Amyloid Plaques and
Neurofibrillary Tangles Rapidly in Aged
APP/PS1 Double Transgenic Mice Jun Xu,
Jianquan Shi, Wei Shen, Yingdong Zhang,
Jun Chen, Haiqing Zhu, Qiaoquan Zhang,
Yao Chen, Lingling Zhong, Yong Chen,
Yinwei Zhu
P05.107 Dimensions of AD
Neuropathology: Differential
Relationships with Age and ApoE Dan
Mungas, Rochelle Tractenberg, Paul Crane,
Julie Schneider, David Bennett
P05.116 Peripheral Nerve
Inflammation and Muscle Denervation in
mSOD1 Transgenic Mice: Which Comes
First? Osamu Kano, David Beers, Jenny
Henkel, Weihua Zhao, Bing Liao, Stanley
Appel
P05.117 Purification of Motor Neurons
Derived from Embryonic Stem Cells
Cultures Stephanie Milazi, Andrea Price,
Benjamin Brooks, Jean-Luc Mougeot
P05.118 Treatment with a Soluble
Activin Receptor Type IlB Attenuates
Loss of Lean Tissue and Grip Strength in
SODG93A Mice Niels Borgstein, Jennifer
Lachey, Vicki Wong, Jeffrey Ucran, Jas
Seehra
Muscle Disease/Neuromuscular
Junction: Myopathy: Basic
Science
P05.108 Splicing Isoforms of SORCS1
and APP Processing Shinya Tokuhiro,
Peter St George-Hyslop, Ekaterina Rogaeva
P05.119 Killing Two Birds with One
Botox Dose: The Anti-Inflammatory
Effects of C. botulinum Toxin Type
A Andrew Gomez-Vargas, Dinesh
Kumbhare
P05.109 Deficits in Covert Orienting of
Visual Attention in Alzheimer’s Disease:
Relationship to HMPAO SPECT Measures
of Cortical Hypoperfusion Brandon
Vasquez, Brian Buck, Sandra Black,
Farrell Leibovitch, Nancy Lobaugh, Curtis
Caldwell, Marlene Behrmann
P05.120 Expression of Heat Shock
Proteins in Skeletal Muscle From
Idiopathic Inflammatory Myopathy
and Duchenne Muscular Dystrophy
Patients Jan De Bleecker, Kim Creus,
Jean-Jacques Martin, Joachim Weis, Boel
De Paepe
Anterior Horn: Basic Science
P05.121 The Dysferlin
Interactome Bilal Azakir, Sabrina Di Fulvio,
Christian Therrien, Michael Sinnreich
P05.110 Alteration of snRNAs in
Amyotrophic Lateral Sclerosis Tomohiko
Ishihara, Atsushi Shiga, Akiyoshi Kakita,
Akio Yokoseki, Masatoyo Nishizawa,
Hitoshi Takahashi, Osamu Onodera
P05.111 CD4 +CD25 + Regulatory
T-Cells Suppress Microglial Activation in a
Mouse Model of ALS Weihua Zhao, David
Beers, Jenny Henkel, Bing Liao, Stanley
Appel
P05.112 Growth Inhibitory Factor
Inhibits the Progression of Amyotrophic
Lateral Sclerosis Model Mice Kazunori
Hashimoto, Yuichi Hayashi, Takashi
Inuzuka, Isao Hozumi
P05.113 Familial ALS-Linked Mutant
SOD1 Impairs a Network of RNA-Binding
Proteins That Regulate VEGF and Other
Cell Survival Factors Liang Lu, Lei Zheng,
Shin Oh, Peter King
P05.114 Oxidative Stress as Target
for Neuroprotection in Experimental
Models of Amyotrophic Lateral
Sclerosis (ALS) Aikaterini Nanou, Adrian
Higginbottom, Chiara Valori, Matthew
Wyles, Ke Ning, Pamela Shaw, Mimoun
Azzouz
P05.115 Effects of Cholesterol
β-D-Glucoside (CβG) on Respiration
and Reactive Oxygen Species
(ROS) Generation in Rat Brain
Mitochondria Alexander Panov, Jeremy
Presson, Nataliya Kubalik, Benjamin
Brooks, Christopher Shaw
P05.122 Increased Transcript of
the Non-Coding β-Site of Amyloid-β
Precursor Protein Cleaving Enzyme
(BACE1-Antisense) and BACE1-mRNA in
Sporadic Inclusion Body Myositis (s-IBM)
Muscle Fibers and in an IBM Model Anna
Nogalska, W. King Engel, Valerie Askanas
P05.123 Experimentally Induced
Endoplasmic Reticulum Stress (ERS)
Decreases VMA21 and Impairs the
Autophagosomal-Lysosomal-System
(A-L-S) in Cultured Human Muscle Fibers
(CHMFs): Relevance to Sporadic Inclusion
Body Myositis (s-IBM) Anna Nogalska,
Carla D’Agostino, W. King Engel, Valerie
Askanas
P05.124 Altered Pre-mRNA
Processing Is a Common Feature of
Muscle Cells in Senescence and Myotonic
Dystrophy Type 2 (DM2) Giovanni Meola,
Manuela Malatesta, Federica Perdoni,
Rosanna Cardani, Enrico Bugiardini, Marzia
Giagnacovo, Carlo Pellicciari
P05.125 Treatment of CoQ10
Deficiency Fibroblasts with Ubiquinone
Analogs and Vitamin C: Time Dependent
Effect on Bioenergetic and Oxidative
Stress Status Luis López, Catarina Quinzii
Hirano, Estela Area, Ali Naini, Shamina
Rahaman, Markus Schuelke, Leonardo
Salviati, Salvatore Di Mauro, Michio Hirano
P05.126 ROS Production, Oxidative
Stress, and Cell Death Correlate with the
Level of CoQ10 in Fibroblast Models of
CoQ10 Deficiency Catarina Quinzii, Luis
Lopez, Robert Gilkerson, Beatriz Dorado,
Jorida Coku, Ali Naini, Clotilde LagierTourenne, Meriem Tazir, Markus Sckuelke,
Rosalba Carrozzo, Filippo Santorelli,
Shamina Rahman, Leonardo Salviati,
Michel Koenig, Salvatore Di Mauro ,
Michio Hirano
P05.127 Clinical and Laboratory
Features in a Family with an ANT1
(SLC25A4) Gene Mutation: Effects on
Monomeric OXPHOS Enzyme Assembly
and Supercomplex Formation Lauren
Hyams, Genevieve Langley, Lauren
Mylacraine, John Shoffner
P05.128 SURF1 Mutation: Effects on
Supercomplex Formation and Monomeric
Enzyme Assembly Lauren Mylacraine,
Genevieve Langley, Lauren Hyams, John
Shoffner
P05.129 Complex V (ATP Synthase)
Mutations: Diverse Effects on
Supercomplex Formation and Oxidative
Phosphorylation Function Lauren
Mylacraine, Genevieve Langley, Lauren
Hyams, John Shoffner
P05.130 Effects of a Novel Complex
III (Cytochrome b Subunit) Mutation on
Supercomplex Formation in a Patient
with Mitochondrial Myopathy Genevieve
Langley, Lauren Mylacraine, Lauren Hyams,
John Shoffner
P05.131 Quantitative Oxidative
Phosphorylation Enzyme Subunit Western
Blot: Role of Testing in a Multifaceted
Approach for Diagnosis of Mitochondrial
Disease Genevieve Langley, Lauren
Mylacraine, Lauren Hyams, John Shoffner
Child Neurology/Developmental
Neurobiology: Basic Science/
Neuroimmunology
P05.132 Neuronal Voltage-Gated
Potassium Channel Autoimmunity in
Children Radhika Dhamija, Deborah
Renaud, Sean Pittock, Andrew McKeon,
Elaine Wirrell, Nancy Kuntz, Vanda Lennon
P05.133 Reduced GLE1 Protein
Levels Cause Axonal Growth Defects
in Zebrafish Motor Neurons Adil
Seytanoglu, Chiara Valori, Tennore
Ramesh, Basil Sharrack, Mimoun Azzouz
P05.134 Autoimmune Limbic
Encephalitis in a Paediatric
Patient Blathnaid Mc Coy, Tomoyuki
Akiyama, Elysa Widjaja, Cristina Go
P05.135 Transient Mutism in Para
Infectious Encephalopathy Johan
Berghuis, Aad Verrips
P05.136 Severe Central and Peripheral
Neuro-Lupus: Role of CSF B Cells and
Chemokines Brajesh Agrawal, Jane
Taylor, Hossam AbdelSalam, Zeng Wang,
Gurpreet Mandar, Michael Pranzatelli
P05.137 Increased Susceptibility of
the Glut-1 Knockout Mouse to Postnatal
Hypoxia Michael Rotstein, Paivi Ullner,
Hong Yang, Vadim Ten, Darryl De Vivo
P05.138 Menstrual Migraine in
Adolescents Ashley Nemes, A. David
Rothner
P05.139 Do Children Learn New
Motor Skills Differently From Adults? Toni
Pearson, Christine Kim, John Krakauer,
Pietro Mazzoni
Neural Repair and
Rehabilitation: Basic Science,
Therapeutics, and Outcomes
Measures
P05.140 Lithium Promotes Survival
and Proliferation of Transplanted NestinExpressing Cells Isolated From Neonatal
Blood In Vitro and Vivo Tsutomu Iseda,
Masayuki Hashimoto, Dongming Sun,
Yasuhiro Maeda, Wise Young
P05.141 Effect of Mesenchymal
Stem Cell-Derived Neural Progenitors
on Demyelination and Immune Cell
Infiltration in Mice with Experimental
Autoimmune Encephalomyelitis Sadia
Sahabi, Qijiang Yan, Violaine Harris, Xin-he
Liu, Tamara Vyshkina, Saud Sadiq
P05.142 Postconcussion Syndrome
after Blast Injuries in OEF and OIF
Veterans Mario Mendez, Deidre O’Neill,
Eliot Licht, Dominique Peppers
P05.143 HIF-1α-Mediated
Neuroprotection on MPP+-Induced
Apoptosis in SH-SY5Y Cells Tianhong
Pan, Yuncheng Wu, Wenjie Xie, Weidong
Le, Joseph Jankovic
P05.144 Efficacy of Dietary Agmatine
Sulfate in Herniated Lumbar DiscAssociated Radiculopathy. A Randomized,
Double-Blind, Placebo-Controlled
Study Gad Gilad, Ory Keynan, Yigal
Mirovsky, Samuel Dekel, Varda Gilad
P05.145 Is Confrontation Testing
Adequate To Detect Visual Field
Defects? Iszet Bustillo, Seema Khurana,
Jose Romano
P05.146 Arbaclofen Placarbil Is
Efficacious and Safe in a Study of the
Treatment of Spasticity Due to Spinal
Cord Injury F. Jacob Huff, Patricia Nance,
Alberto Martinez-Arizala, Ziyad Ayyoub,
Dan Chen, Sheryl Baldwin, Amy Bian,
David Stamler
Cerebrovascular Disease: Basic
Science
P05.147 High Triglyceride in
Leukoaraiosis-Free Small Vessel Occlusive
Stroke Yu-Ri Jeong, Jong-Moo Park,
Byung-Kun Kim, Jaseong Koo, JungJu Lee,
Ohyun Kwon
P05.148 The Role of Akt/Protein
Kinase B and P38-alpha in Retinal
Ischemic Post-Conditioning Ajay Sampat,
John Dreixler, Afzhal Shaikh, Marcus
Marcet, Steven Roth
85
Poster Session V
P05.149 Are Levels of the
Neuromodulator Adenosine Depressed
During Hyperoxia? Tobias Kulik, German
Echeverry, Richard Winn
P05.150 Increased TGF-β Signaling
Underlies the Pathogenesis of Cerebral
Autosomal Recessive Arteriopathy
with Subcortical Infarcts and
Leukoencephalopathy (CARASIL) Hiroaki
Nozaki, Atushi Shiga, Hirotoshi Kawata,
Kunimasa Arima, Kenju Hara, Toshio
Fukutake, Akio Yokoseki, Akihide Koyama,
Toshiaki Takahashi, Mari Ikeda, Akira
Tanaka, Imaharu Nakano, Shu-ichi Ikeda,
Tadashi Yamamoto, Takeshi Ikeuchi ,
Masatoyo Nishizawa, Shoji Tsuji, Osamu
Onodera
P05.151 Serum Levels of Chemokine
CCL2 in Patients with Intracerebral
Hemorrhage Jacek Losy, Jaroslaw
Zaremba, Alicja Kalinowska
P05.152 Tissue Plasminogen Activator
Gene Expression in Ischemic Stroke Glen
Jickling, Bradley Ander, Xinhua Zhan, Paul
Lapchak, Frank Sharp
P05.153 Circulating Levels of ProInflammatory Cytokines After Acute
Ischemic Stroke as Markers of Stroke
Severity Neeraja Yerragondu, Minal Jain,
Anunaya Jain, Dipti Agarwal, Balavani
Palamari, Veena Manivannan, Babak
Jahromi, Wyatt Decker, Latha Stead
P05.154 Serum Il-6 as a Marker of
Functional Outcome after Acute Ischemic
Stroke Anunaya Jain, Minal Jain, Neeraja
Yerragondu, Dipti Agarwal, Balavani
Palamari, Veena Manivannan, Babak
Jahromi, Wyatt Decker, Latha Stead
Cerebrovascular Disease: Acute
Stroke Therapy
P05.155 Intravenous Fibrinolysis
3 to 4.5 Hours After Acute Ischemic
Stroke Onset: A Single Institution
Experience Yazan Alderazi, Julian Yang,
Mohamed Teleb, Jason Chang, Alwala
Awad, James Frey, Lucas Restrepo
P05.156 Successful Intra-Arterial
Altepase (IA t-PA) Intervention in Two
Pediatric Patients Matthew Smith,
Paola Pergami, Margaret Jaynes, Jeffrey
Carpenter, Ansaar Rai
P05.157 Using IV TPA To Treat 106
Patients with or without IA Interventions
in 104 Weeks, the Outcome and Mortality
Analysis at Discharge David Wang, Arun
Talkad, Maureen Mathews, Jan Jahnel,
Judi Beck, Clayton McNeil, Bradley
Gleason, Huaguan Zheng
P05.158 Selection of Antiplatelet at
Discharge after Aspirin and Clopidogrel
Loading for Acute Ischemic Stroke Gayle
Pletsch, Lester Leung, Joe Tarsia, Karen
Albright, Sheryl Martin-Schild
P05.159 Outcomes Differences by
Mechanism in Stroke Treated with IV tPA:
An Unrecognized Pattern? Julian Yang,
Yazan Alderazi, Jason Chang, Mohamed
Teleb, Gunjan Parikh, Al Wala Awad,
James Frey, Lucas Restrepo
86
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P05.160 Evaluation of Optimal Blood
Pressure Level in Acute Lacunar Stroke
Patients Using Ambulatory Blood Pressure
Monitoring Yasumasa Yamamoto,
Tomoyuki Ohara
P05.170 Dravet Syndrome and Deep
Brain Stimulation: Seizure Control After
10 Years of Treatment Danielle Andrade,
Clement Hamani, Andres Lozano, Richard
Wennberg
P05.161 Acute Ischemic Stroke
Caused by an Acute Internal Carotid
Artery Occlusion: Factors Predicting
Better Clinical Outcome in Patients
Undergoing Emergent Carotid
Endarterectomy Roman Herzig, David
Skoloudik, Michal Kral, Daniel Sanak,
Martin Roubec, Ondrej Skoda, Petr
Bachleda, Petr Utikal, Petr Havranek,
Toman Hrbac, Milan Fucik, Jana
Zapletalova, Tomas Veverka, Andrea
Bartkova, Jan Mares, Petr Hlustik, Michal
Bar, Petr Kanovsky
P05.171 A Clinical Trial of Adjunct
Carvedilol-CR as a P-Glycoprotein
(P-Gp) Inhibitor for Medically Intractible
Epilepsy Derek Chong, Emily Cohen, Frank
Gilliam
P05.162 A Pivotal Study Evaluating
the Ischemic Stroke System (ISS*) for
Treatment of Acute Ischemic Stroke up
to 24 Hours from Stroke Onset Thomas
Devlin
P05.163 Oxygen Use for Suspected
Acute Ischemic Stroke in Pre-Hospital and
Emergency Department Settings Yu-Feng
Chan, Lynne Richardson, Maya Katz, Ari
Moskowitz, Aneesh Singhal, Kevin Chason,
Tavis Allison, Daniel Lakoff, Annie Yang,
Steven Levine
P05.164 Erythropoietin May Have
Neuroprotective Role in Ischemic
Stroke Patients with Advanced
Renal Disease Vahid Tohidi, Bahareh
Hassanzadeh, Mohammad Moussavi,
Charles Porbeni, Spozhmy Panazi, Martin
Gizzi, Jawad Kirmani
Epilepsy: Refractory Epilepsy
Therapy
P05.165 Outcome of Surgery for
Temporal Lobe Epilepsy Evaluated with
Non-Invasive Protocol Sita Sattaluri,
Manas Panigrahi, Pushpalatha Sudhakar,
Sundaram Challa, Sailaja Sarva,
Shanmukhi Somayajula
P05.166 Survival Analyses between
Surgical and Clinical Treatments for
Refractory MTLE: A Prospective Study
with Five Years of Follow-Up Clarissa
Yasuda, Marcia Morita, TΓnia Cardoso,
Alberto Costa, Carlos Guerreiro, Marilisa
Guerreiro, Helder Tedeschi, Evandro
Oliveira, Fernando Cendes
P05.167 Preference-Based Quality of
Life Measures for Neocortical Epilepsy
Surgery Health Outcomes Jitesh Kar,
Frank Gilliam, Nita Limdi, Meredith Kilgore,
Robert Knowlton
P05.168 Timing of Surgical Resection
of Cavernous Malformation and Seizure
Outcome Steve Chung, Kris Smith
P05.169 Seizure Response to
Vagus Nerve Stimulation: Three-Year
Follow-Up and Effects of Syndromic
Classification Thaddeus Walczak, Edward
Walczak, James White, Jeanne Beattie,
Lizbeth DePadua, Ilo Leppik
P05.172 Lacosamide in Refractory
Status Epilepticus: A Report of Four
Patients Luis Mayor- Romero, Mohamad
Koubeissi
P05.173 Biopsy-Proven Rasmussen’s
Encephalitis: Seizure Suppression
and Partial Reversal of Deficits
with Antiepileptic Medications and
Tacrolimus Carmel Armon, Sivakumar
Natanasabapathy, Dennis Oh, Luis Moral,
Barbara Greco, William House
P05.174 The Approach of the Harvard
Epilepsy Botanical Program to the Study
of Herbal Therapies for Epilepsy Dana
Ekstein, H. White, James Stables, Steven
Schachter
Epilepsy Therapy: Antiepileptic
Drugs
P05.175 Retention Rate MetaAnalysis and Computational Modeling
Results of Second Generation
Antiepileptic Drugs in Epilepsy Patients
with Partial Onset Seizures Gregory
Holmes, Joyce Cramer, Josemir Sander,
Nancy Zhang, D. Russell Wada, Frank
Wiegand
P05.176 Clinical Experience with
Generic Levetiracetam in a Tertiary Care
Epilepsy Clinic Siresha Chaluvadi, Larry
Tran, Corey Goldsmith, David Friedman
P05.177 Rapid Titration of
Lacosamide with Simultaneous Reduction
in Concomitant AEDs Is Well-Tolerated
and Effective in Reducing Seizures in
Patients with Drug-Resistant PartialOnset Epilepsy Alison Griffiths, Gregory
Krauss, Ashela Bean, Stephanie Swords,
Amanda Cole
P05.178 A Multicenter, Open-Label
Trial To Assess the Safety and Tolerability
of a Single Intravenous Loading Dose
of Lacosamide Followed by Oral
Maintenance as Adjunctive Therapy in
Subjects with Partial-Onset Seizures: An
Interim Report Nathan Fountain, Gregory
Krauss, Jouko Isojarvi, Deanne Dilley,
Pamela Doty, G. David Rudd
P05.179 Long-Term Efficacy of
Lacosamide for Partial-Onset Seizures:
An Interim Evaluation of Completer
Cohorts Exposed to Lacosamide for up
to 36 Months Elinor Ben-Menachem,
Jacqueline French, Jouko Isojarvi, David
Hebert, Pamela Doty
P05.180 Outcome of Infants with
Prenatal Exposure to Lacosamide During
the Clinical Development Program Jouko
Isojarvi, Christina Williams, Pamela Doty
P05.181 Long-Term Safety and
Tolerability of Lacosamide for PartialOnset Seizures: An Interim Evaluation
of Patients Exposed to Lacosamide
in Double-Blind and Open-Label
Trials William Rosenfeld, Felix Rosenow,
Jouko Isojarvi, David Hebert, Pamela Doty
P05.192 Retigabine 600, 900, or 1200
mg/Day as Adjunctive Therapy in Adult
Patients with Refractory Epilepsy with
Partial-Onset Seizures Robert Leroy,
Jacqueline French, Antonio Gil-Nagel,
Susan Hall, Kevan VanLandingham
P05.182 Pharmacokinetic Evaluation
of Intravenous Lacosamide as Short-Term
Replacement for Oral Lacosamide in
Partial-Onset Seizures Willi Cawello,
Gregory Krauss, Melissa Brock, Andrea
Eggert-Formella
P05.193 Long-Term Maintenance of
Efficacy with Retigabine 600-1200 mg/
Day in Adult Patients with Refractory
Epilepsy: Extension Study of RESTORE
1 Robert Leroy, William Rosenfeld, Susan
Hall, Kevan VanLandingham, Narinder
Lotay
P05.183 Effect of Carisbamate, a
Novel Antiepileptic Drug, on Cognition
in Three Placebo-Controlled, Healthy
Volunteer, Multiple-Dose Studies H.
Robert Brashear, Gerald Novak, Frank
Wiegand, Kimford Meador
P05.194 Long-Term Maintenance of
Efficacy with Retigabine 600-1200 mg/
day in Adult Patients with Refractory
Epilepsy: Extension Study of RESTORE
2 Holger Lerche, Robert Leroy, Susan Hall,
Kevan VanLandingham, Narinder Lotay
P05.184 A Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group
Study of Rufinamide Given as Adjunctive
Therapy in Patients with Refractory
Partial-Onset Seizures Victor Biton
P05.195 Work Loss and Associated
Costs in U.S. Employees with Epilepsy
Receiving Multiple Antiepileptic
Drugs Jamie Forlenza, Emily Durden,
Stephen Johnston, Steve Ascher, George
Wan
P05.185 An Investigation of the
Effects of Eslicarbazepine Acetate on
Hyponatremia: A Pooled Analysis of
Three Double-Blind Phase III Clinical
Studies Mark Versavel, Elinor BenMenachem, Kenneth Tripp, Christian Elger,
Luis Almeida, Patricio Soares-da-Silva
P05.186 Lacosamide Efficacy in
Partial-Onset Seizures with and without
Secondary Generalization: A Pooled
Analysis of Three Phase II/III Trials Jouko
Isojarvi, Felix Rosenow, R. E. Faught, David
Hebert, Pamela Doty
P05.187 Improvement in PatientReported Outcomes Seen in Patients
Responding to Lacosamide: Pooled
QOLIE-31, SSQ and PGIC Data From 3
Phase II/III Clinical Trials Joyce Cramer,
Christine De La Loge, Simon Borghs, Knut
Mueller, Andrea Eggert-Formella, Pamela
Doty
P05.188 Lacosamide Add-On
Treatment: Results of Open Label 6
Months Follow-Up Hermann Stefan, Frank
Kerling, Bernhard Steinhoff
P05.189 Efficacy of Retigabine 6001200mg/day in Patients with Refractory
Epilepsy with Partial-Onset Seizure:
Integrated Analysis of Three Randomized
Studies Roger Porter, Jacqueline French,
Martin Brodie, Kevan VanLandingham,
Kevin Nanry, Susan Hall
P05.190 Retigabine Provides Effective
Adjunctive Therapy in Adults with
Refractory Epilepsy with Partial-Onset
Seizures, Irrespective of Gender, Race,
and Age Elza Targas Yacubian, Bassel
Abou-Khalil, Christian Elger, Sue Hall,
Kevan VanLandingham
P05.191 The Effects of Retigabine on
the Pharmacokinetics of Concomitantly
Administered Antiepileptic Drugs Debra
Tompson, Kevan VanLandingham
Poster Session V
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P05.204 UCB Antiepileptic Drug
Pregnancy Registry Cynthia Harden,
Shilpa Alekar, Ilo Leppik, Georgia
Montouris, Angela Scheuerle
Epilepsy: Clinical
Neurophysiology
P05.205 Electroclinical Features and
Results of Intracranial Recordings in
Atypical Cases of Mesial Temporal Lobe
Epilepsy (mTLE): “A Pseudo-Extratemporal
Epilepsy”? Kanjana Unnwongse, Imad
Najm, William Bingaman, Andreas
Alexopoulos
P05.206 Computer Modeling of the
Cause and Treatment of Epilepsy in the
Dentate Gyrus Thomas Cronin, Faysal
Altahawi, Bradley Gill, Manu Raam
P05.207 A Video-EEG Analysis Study
of Dialeptic Seizures: In 100 Patients with
Generalized and Focal Epilepsies Betul
Baykal, Ebru Altindag, Berend Feddersen,
Sevda Ozel, Nazmi Arslan, Soheyl
Noachtar
P05.196 The Effects of Antiepileptic
Drugs in Oral Health Cecilia Aragon,
Jorge Burneo, Andrea Cornacchio
P05.208 Unilateral Opercular
Lesion and Eating-Induced Epileptic
Spasms Siresha Chaluvadi, Doris Kung,
David Friedman, Michael Newmark
P05.197 Epilepsy in Pregnancy in a
Minority Population Adel Olshansky,
Alhamza Al-Bayati, Alice Stek, Larisa
Yedigarova, Laura Kalayjian
P05.209 Ictal Lip-Smacking
in Temporal Lobe Epilepsy Has
a Stereotyped Electrographic
Signature Amy Wasterlain, Josef Parvizi
P05.198 Carbamazepine
Co Administration with an Oral
Contraceptive: Effects on Steroid
Pharmacokinetics, Bleeding, and
Ovulation Anne Davis, Carolyn Westhoff,
Frank Stanczyk
P05.210 Helpless Romantics: Ictal
Kissing (IK) as a Release Phenomenon
in Non-Dominant Temporal Lobe
Epilepsy Razi Rashid, Katherine Eder,
Michael Macken, Stephan Schuele
P05.199 Levetiracetam in the
Treatment of Idiopathic Generalized
Epilepsies: A Long-Term Observational
Study Ioannis Tsiropoulos, Katerina
Tsatsou, Nozomi Akanuma, Michail
Koutroumanidis
P05.200 Levetiracetam Induced
Thrombocytopenia Kinshuk Sahaya,
Munish Goyal, Aarti Sarwal, Niranjan
Singh
P05.201 An Investigation of the Effect
of Eslicarbazepine Acetate on Cardiac
Repolarization: A Pooled Analysis of
Over-Read Electrocardiograms From
Three Double-Blind Phase III Clinical
Studies Mark Versavel, Kenneth Tripp,
Luis Almeida, Patricio Soares-da-Silva
P05.202 Effect of Eslicarbazepine
Acetate on the SteadyState Pharmacokinetics and
Pharmacodynamics of Warfarin in Healthy
Subjects Jacqueline Zummo, Manuel
Vaz-da-Silva, Luis Almeida, Amilcar Falcao,
Mark Versavel, Eva Soares, Joana Maia,
Teresa Nunes, Patricio Soares-da-Silva
P05.203 Pregabalin vs Placebo for the
Treatment of Partial Onset Seizures in
Patients Taking Concomitant Antiepileptic
Drugs: An Analysis of Combined Clinical
Trials Torbjörn Tomson, Suzanne Giordano,
Mary Almas
P05.211 Utility of Interictal Heart Rate
Variability in Lateralizing Epileptogenic
Foci Shan Chen, Michale Rosenberg,
Eli Neiman, Kavitha Velicheti, Taly Agha,
Joseph Drazkowski, Brent Goodman
P05.212 Periictal Heart Rate Changes
in Patients with Localization-Related
Epilepsy Eun Hye Jeong, Won Sup Kim,
Kyoung-Gyu Choi, Kee-Duk Park, Hyang
Woon Lee
P05.213 A Descriptive Analysis of
Prognostic Indicators in Patients with
Non-Convulsive Status Epilepticus in a
Tertiary Hospital Population Chantelle
Hrazdil, Raed Alroughani, Manouchehr
Javidan
P05.214 Aphasic Status Epilepticus:
Electroclinical Correlation Eric Ericson,
Michael Macken, Stephan Schuele
Child Neurology/Developmental
Neurobiology: Clinical
Neurophysiology/Epilepsy
P05.215 Electroclinical Correlates of
Postictal Psychosis in a Child Manpreet
Kaur, Rohit Marawar, Karen Powers,
Anthony Ritaccio
P05.216 Status Epilepticus, Both
Convulsive and Non-Convulsive, in the
Elderly: A Tertiary-Care Hospital-Based
Study in South India Jagarlapudi Murthy,
Devdutt Deshmukh, Amrit Saxena, Gautam
Tripathy
P05.217 Maturational Changes of
SSVEPs Elicited by Intermittent Photic
Stimulation Ala Birca, Lionel Carmant,
Anne Lortie, Phetsamone Vannasing,
Hannelore Sauerwein, Manon Robert,
Louise Lemay, Dominique Piper, Valentina
Donici, Maryse Lassonde
P05.228 A Randomized, PlaceboControlled Trial of Gabapentin
Enacarbil in Subjects with Neuropathic
Pain Associated with Post-Herpetic
Neuralgia Richard Rauck, R. Norman
Harden, Theresa Jimenez, Carrie McClung,
Ole Graff
P05.218 Infantile Spasms:
Retrospective Review of Epilepsy
Outcome Patricia Krief, Tanya Sweeney,
Robin Smith, Joseph Maytal
P05.229 Onset of Treatment Response
to NGX-4010, a High-Concentration
Capsaicin Patch, in Patients with
Postherpetic Neuralgia Gordon Irving,
Miroslav Backonja, Richard Rauck, Jeffrey
Tobias, Geertrui Vanhove
P05.219 Association Between
Clinical, Morphological, and Biochemical
Findings and Central and Peripheral
Nerve Conduction in Late Infantile
Metachromatic Leukodystrophy C. i Dali,
M. Dunoe, N. Barton, R. Mensah, J. Griffin,
C. Krarup
P05.220 Intraoperative MEP and
SEP Monitoring in Spinal Surgery for
Predicting Postoperative Minor Motor
Deficits Bo-mi Kim, Eun Mi Lee, Joong
Koo Kang
P05.221 “Simple Febrile Seizures Plus
(SFS+)”: It Is Okay To Have More Than One
Seizure Within a 24 Hour Period Marie
Grill, Yu-tze Ng
P05.222 Clinical Features of Children
with Refractory Epilepsy and MRI Evident
Versus MRI Occult Malformations of
Cortical Development Rohit Das, Dana
Marafie, Annapurna Poduri
Peripheral Nerve: Noninvasive
Measures, and Neuropathic Pain
P05.223 In-Vivo Confocal Microscopy
of Meissner Corpuscles as a Measure of
Early HIV Neuropathy David Herrmann,
Michael McDermott, Michele Ferguson,
Christi Alessi-Fox, Giovanni Schifitto
P05.224 Sweat Gland Duct Density
with Optical Coherence Tomography in
Peripheral Neuropathy Mayank Mathur,
Krystle Karoscik, Thomas Leist, Eduardo De
Sousa
P05.225 A Quantitative Device To
Test Touch Sensitivity on the Finger
Pad William Kennedy, Gwen Crabb,
James Hodges, Mona Selim, Thaddeus
Brink, Donald Simone
P05.226 Peripheral Nerve Function
in HIV-Infection: Electrophysiological
and Quantitative Sensory Test Results
in the CHARTER Study Muhammad
Al-Lozi, Ronald Ellis, Florin Vaida,
Chelsea FitzSimons, Ann Collier, J. Allen
McCutchan, Justin McArthur, Susan
Morgello, David Simpson, Christina Marra,
Benjamin Gelman, David Clifford, Scott
Letendre, Igor Grant
P05.227 Pathophysiology of Painful
Neuropathy: Correlations of Contact Heat
Evoked Potential with Skin Innervation
and Features of Neuropathic Pain ChiChao Chao, Ming-Tsung Tseng, Sung-Tsang
Hsieh
P05.230 The Neuromuscular Spectrum
of Herpes Zoster Infection in the Upper
Limb Edward Tay, Bashar Katirji, Amer
Alshekhlee, Marek Buczek, Saef Ahmad
P05.231 Epidermal Nerve Fiber
Density as a Potential Marker for Central
Pain Syndromes Devanshi Gupta, John
Harney
P05.232 Multi-Microcramps
(MMC) Syndrome: A New Pathogenic
Concept of Subtle Lower Motor
Neuron (LMN) Lability Causing Very
Disturbing, Continuing Muscle Pains,
Sometimes Gratifyingly Treatable–But
Often Misinterpreted as Mysterious
“Fibromyalgia” or “Psychogenic” W. King
Engel
Neurologic Manifestations of
Systemic Disease I
P05.233 Renal Cell Carcinoma
Presenting with Sensory Ataxia Due
to Acute Inflammatory Demyelinating
Polyneuropathy Arnaldo Da Silva,
Radoslav Raychev, Jeffrey Frank, Scott
Eggener, Kourosh Rezania
P05.234 Sacral Polyradiculitis Due
to HSV2 (Elsberg Syndrome): A Report
of Two Cases Bernadette Schoneburg,
Steven Lewis
P05.235 The Occurrence of Central
Nervous System Demyelination in
Diabetes Lubna Mehyar, Natalia
Krivitskaya, Hafiz Khan, Shahanara Islam,
Abu Nasar, Huey-Jen Lee, Hussam Yacoub,
Nizar Souayah
P05.236 A Case of Mistaken Identity:
Anti-NMDA Receptor Encephalitis in a
Young Woman JingTian Wang, Jay Desai,
May Kim
P05.237 Thiamine Deficiency
Presenting with Encephalopathy and
Optic Neuropathy after Chemoradiation
for Tongue Cancer Rimas Lukas, Juan
Piantino, Jeffrey Nichols, Ezra Cohen,
Daniel Haraf, Kourosh Rezania
P05.238 Evaluation of Central Effects
of Diabetes Mellitus by Multimodal
Evoked Potentials and Brain Magnetic
Imaging Tests Mohammed EL-Sherif,
Sabry Elmogy, Seyam Salem, Mohamed
Elkhateeb, Maha Belal, Saleh Attia
87
Poster Session V
P05.239 Silent Brain Infarctions
in Diabetes Mellitus Patients: The
Multimodal Evoked Potential Tests
Sensitivity and Specificity Mohammed
EL-Sherif, Mohamed Elkhateeb, Nabil
Awad Alla, Saleh Attia
P05.240 Neuro Psychiatric
Manifestations of Systemic Lupus
Erythematosus: A Monocentric
Retrospective Study of 96
Patients Nathalie Philippi, Etienne
Dahan, Vincent Poindron, Stéphane Vinzio,
Benjamin Cretin, Laurent Balonzoli, AnneSophie Korganow, Andoni Echaniz-Laguna,
Valerie Wolf, Bruno Moulin, Jean-Louis
Dietemann, Pierre Vidailhet, Christine
Tranchant, Emmanuel Andres, Michel
Fischbach, Dan Lipsker, Thierry Martin,
Jean-Louis Pasquali, Jean Sibilia, Jerome
De Seze
P05.241 Lower Extemity Amyotrophic
Diplegia (LAD): Prevalence and Pattern
of Weakness Iryna Muzyka, Mazen
Dimachkie, Richard Barohn, Jonathan
Katz, Carlayne Jackson, Yunxia Wang,
April McVey, Mamatha Pasnoor, Tahsen
Mozaffar, Arthur Dick, Jeffrey Rosenfeld
P05.242 Light Sensitivity Due to
Erythropoietic Protoporphyria Responds
to Oral Prednisone Paul Golumbek, Soe
Mar
P05.243 ANCA-Negative
Wegener’s Granulomatosis Presenting
as a Cavernous Sinus Syndrome Lisa
Costelloe, Orla Tuohy, Paul Brennan,
Francesca Brett, Michael Farrell, Joan
Moroney
P05.244 Treatment of Adult Spasticity
with Myobloc® (RimabotulinumtoxinB;
BoNT-B) in Clinical Practice: A Multicenter
Retrospective Chart Review Robert
Chinnapongse, Meg Corliss
P05.245 Serotonin Syndrome After
Administration of Milnacipran for
Fibromyalgia Roula Ainchaybah, Hussam
Yacoub, Nizar Souayah
P05.246 Effect of Apocynin, a NADPH
Oxidase Inhibitor, on Cerebral Miocroglia
in Sabra Rat Model of Hypertension Bella
Gross, Olga Azrilin, Hector Cohen, Shifra
Sela, Eilam Palzur
P05.247 Neurological Manifestations
of Behçet Disease: Epidemiology, Clinical
Characteristics, and Management in a
Series of Hospitalized Patients Ignacio
Casanova, Manuel Bartolome, Maria
Jose Catalan, Teresa Lapeña, Rocio
García-Cobos, Daniella Di capua, Arturo
Sampedro, Cesar García, Jesus PortaEtessam
P05.248 MELAS Syndrome Presenting
as Pure Word Deafness and Wernicke’s
Aphasia Georges Naasan, Michael
DeGeorgia
P05.249 Selective Cerebellar
Degeneration Following Carbon Monoxide
Poisoning: A Case Report Hui-Jun Yang,
Jin-Hwan Cho, Beom-Seok Jeon
88
P05.250 A Case of Low -Dose Oral
Methotrexate-Induced Reversible
Neurotoxicity Bandhu Paudyal, Ryan
Viets, Maryna Skliut
P05.251 Association between
Stroke Severity and the Intensity of
Periodontitis Joanna Slowik, Marcin
Wnuk, Kinga Grzech, Anna Jurczak, Maria
Chomyszyn-Gajewska, Agnieszka Slowik
P05.252 Autoimmune MuSK-Positive
Myasthenia Gravis in Two Sisters Stanley
Iyadurai, Muhammad Al-Lozi
P05.253 P-ANCA-Related
Neurological Syndromes: Two Cases with
Atypical Presentation Masaki Kobayashi,
Yuko Shimizu, Masahiro Iguchi, Yuri Inose,
Shinichiro Uchiyama
P05.254 Atypical Case of Posterior
Reversible Encephalopathy Syndrome in
an HIV-Seropositive Patient Hebah Hefzy,
Sasha Zivkovic, Walter Bartynski
P05.255 Facial Onset Sensorimotor
Neuronopathy: A Case Series Dobrin
Dobrev, Richard Barohn, Saud Khan, April
McVey, Laura Herbelin, Mazen Dimachkie
P05.256 Intracerebral Hemorrhage,
CNS Vasculitis, and Sjogren’s Syndrome
in a 57-Year-Old Female: A Case
Report Marvin Sih, Nadera Sweiss,
Kourosh Rezania
P05.257 Supplement-Associated
Hyperammonia after c(K)achetic Episode
(SHAKE) Syndrome Michael Perloff, Emily
Welsh, Jan Kucera
P05.258 A Case of Reversible
Brainstem Hypertensive
Encephalopathy Orla Tuohy, Lisa
Costelloe, Albi Chalissery, Joan Moroney
P05.259 Atypical Presentation of
Posterior Reversible Leukoencephalopathy
in a Sickle Cell Patient Anjana Nair,
Fernando Testai
P05.260 Acute Combined
Degeneration Associated with
B12 Deficiency and Nitrous Oxide
Anesthesia Ales Hlubocky, Troy
Wiedenbeck, Jonathan McKinnon, Amy
Almaraz, Jonathan Carter, Virgilio Gerald
Evidente
P05.261 Churg Strauss Syndrome
Associated with Asymmetric Neuropathy
and Multiple Effusions Bernadette
Calabek, Peter Hitzenberger, Otto Berger,
Hermann Moser, Ludwig Erlacher, Sonja
Brandstätter, Wolfgang Grisold
Interventional Neurology
P05.262 Intrasinus Thrombolysis
of Deep Cerebral Sinus Thrombosis
Resulting in Reversible Thalamic
Infarcts Nidhi Sood, Arun Talkad
P05.263 Is Thrombolysis a Safe
Option in Patients with an Unruptured
Aneurysms? Remy Wong, Nauman Tariq,
Robert Taylor, M. Fareed Suri, Mustapha
Ezzeddine, Adnan Qureshi
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
Metro Toronto Convention Centre / Room 808
P05.264 Prominent Loss of
Clinical Benefit Among Patients with
Acute Ischemic Stroke Treated with
Endovascular Treatment After Six Hours
of Symptom Onset Jefferson Miley,
Gabriela Vazquez, Muhammad Zeeshan
Memon, Haitham Hussein, Mushtaq
Qureshi, M. Fareed Suri, Robert Taylor,
Ramachandra Tummala, Adnan Qureshi
P05.274 Low Risk of Intracranial
and Systemic Hemorrhages in Patients
Treated with Dual Antiplatelets Beyond
One-Month after Neurovascular
Angioplasty and Stent Placement Ameer
Hassan, Gabriela Vazquez, Amy Puchta,
Gustavo Rodriguez, M. Fareed Suri,
Ramachandra Tummala, Robert Taylor,
Adnan Qureshi
P05.265 Acute Stroke Interventions
Based on the Radiographic Time
Window for Those Who Present
Beyond the Current Therapeutic
Time Window Adham Kamel, Tara
Ramachangran, Ravi Patel, Amar
Swrankar, Juliuse-Gene Latorre, Yahia Lodi
P05.275 Long Term Clinical- Outcome
of Patients Undergoing Intracranial
Stent in the Setting of Acute Ischemic
Stroke Ambooj Tiwari, Amit Kansara,
Paritosh Pandey, Seemant Chaturvedi,
Andrew Xavier
P05.266 Use of Intravenous Heparin
Prior to CEA in Acute Internal Carotid
Ischemic Syndrome: A Preliminary
Demonstration of Safety and Possible
Efficacy Wei Liu, Chakorn Chansakul,
Murray Flaster
P05.267 Anesthesia Patterns for
Endovascular Therapy in Acute Ischemic
Stroke Junaid Kalia, DaiWai Olson, Rishi
Gupta, Alex Abou-Chebl, Osama Zaidat,
David McDonagh
P05.268 Intravenous Thrombolysis
with rt-PA Even within the First-Three
Hours Is Not Effective for Large Artery
Stroke Rajiv Padmanabhan, Kevin Kane,
Marc Fisher, Majaz Moonis
P05.269 Role of Vertebral Dominance
Pattern in Ischemic Stroke Subtype Ugo
Paolucci, Mohammad Moussavi, Spozhmy
Panazi, Martin Gizzi, Jawad Kirmani
P05.270 Reversible Arterial
Vasoconstriction in Sturge Weber
Syndrome Presenting with
Postcoital Headache and Transient
Hemiplegia Matthew Grantz, Elaine
Skalabrin, Michael Wilder, L. DeWitt,
Benjamin Lewis, Jennifer Majersik, Juliann
Allred, Amer Malik, Pegah Afra
P05.271 Evaluating Rates of
Recanalization and Outcomes in Patients
Receiving Full Dose of IV tPA Followed
by IA Thrombolytics Versus Followed by
Mechanical Intervention Ugo Paolucci,
Mohammad Moussavi, Spozhmy Panazi,
Martin Gizzi, Jawad Kirmani
P05.272 Risk of Contrast Induced
Nephropathy in Patients Undergoing
Endovascular Treatment of Acute
Ischemic Stroke Ashish Nanda, Sonal
Mehta, Daniel Hsu
P05.273 Long-Term Clinical and
Angiographic Outcomes in Patients with
Spontaneous Cervico-Cranial Dissections
Treated with Stent Placement Ameer
Hassan, Gustavo Rodriguez, Nauman Tariq,
Gabriela Vazquez, M. Fareed Suri, Adnan
Qureshi
P05.276 Patients with Arteriovenous
Malformations of the Brain Demonstrate
Impaired Cognitive Status at the Time of
Diagnosis Leo Galvin, Niall Pender, John
Thornton, Paul Brennan, Joan Moroney
P05.277 Effect of Hypertension
on Hematoma Volume in an
Experimental Model of Intracerebral
Hemorrhage Afshin Divani, Blake
Siljander, Vance Fredrickson, Ming Lin,
Laina Bretzke, Ryan Chamberlain
P05.278 Diagnosing Ischemic
and Hemorrhagic Complication Post
Neuro Intervention Using a Conebeam
CT: A Sensitivity and Specificity
Analysis Junaid Kalia, Michael Abraham,
Kaiz Asif, Osama Zaidat
P05.279 Intravascular Ultrasound
(IVUS) Guided Angioplasty of a Carotid
Dissection in a Patient with Fibromuscular
Dysplasia Esteban Cheng-Ching,
Muhammad Hussain, Heather Gornik, Rishi
Gupta
Thursday, April 15 | 7:30 a.m.–12:00 p.m.
First Authors Stand by Poster from 7:30 a.m.–9:00 a.m.
P05.285 Giant Cell Arteritis
Diagnosed by a Cerebellar Infarction: A
Case Report Chiara Zavanone, Sandrine
Deltour, David Saadoun, Frederique
Charlotte, Sophie Crozier, Antoine Chevrel,
Yves Samson
P05.286 Acute Stroke Intervention
Using Penumbra Device Intervention
Versus Multi-Device Intervention: Effect
on Clinical Efficacy and Recanalization
Time Junaid Kalia, Aamir Badruddin, John
Lynch, Brian-Fred Fitzsimmons, Osama
Zaidat
Neuroscience Research Prize
Recipients
P05.287 High Glucose Levels Alter
Morphine Signaling Systems: A Novel
Pathway for Sugar Addiction Jan Gong
P05.288 Relationship Between
Cellular Dopamine and Morphine
Concentrations Suggests Supplemental
Treatment for Parkinson’s Disease
Addiction Anauva Kalra-Lall
Poster Session V
Neural Repair/Rehabilitation:
Imaging
P05.290 Evidence of Regional
Cortical Atrophy in Patients with
Cerebrotendinous Xanthomatosis Silvia
Guerrera, Maria Laura Stromillo, Andrea
Mignarri, Marco Battaglini, Placido
Bramanti, Silvia Marino, Carol Di Perri,
Antonio Federico, Maria Teresa Dotti,
Nicola De Stefano
Neurologic Manifestations of
Systemic Disease: Other
P05.291 Effect of Hyperglycemia
after the Correction of Glucose Level
or Decreased Body Temperature on the
Prognosis of Patients with Hypoglycemic
Coma Tetsuhiko Ikeda, Tetsuya Takahashi,
Masato Kanazawa, Masatoyo Nishizawa,
Takayoshi Shimohata
P05.289 Calcium Signaling and
Glutamate Receptor Trafficking in the
Retina Theresa Tharakan
RED: 10AM Run/Walk Ad
Useage: To be placed in the Abstract Listing
Specs: 8.25” x 5.5625” (full bleed +.125”): B+W
P05.280 Evaluating Rate of
Recanalization and Outcomes in Patients
Receiving Full Dose of IV tPA Bridged
to IA Therapy Compared to IA Therapy
Alone Jawad Kirmani, Ugo Paolucci,
Mohammad Moussavi, Spozhmy Panezai,
Martin Gizzi
P05.281 Immediate Technical
Outcome of Elective Symptomatic
Carotid Stenting with Embolic Protective
Devices Performed by Interventional
Neurologists Kaiz Asif, Junaid Kalia,
Khaled Asi, Ayman Gheith, John Lynch,
Brian-Fred Fitzsimmons, Osama Zaidat
P05.282 Obesity and Intracranial
Stent Thrombosis David Rose, Sebastian
Koch, Yolanda Reyes-Iglesias, Dileep
Yavagal
P05.283 Exploratory Analysis of Time
Delays in Administrating Endovascular
Therapy for Acute Ischemic Stroke Amit
Kansara, Ambooj Tiwari, Sandra
Narayanan, Andrew Xavier
P05.284 Manometery-Guided
Endovascular Management of Dural Sinus
Stenosis Via Balloon Angioplasty and
Stenting Junaid Kalia, John Lynch, BrianFred Fitzsimmons, Bernd Remler, Osama
Zaidat
Raise funds for
brain research.
One step at a time.
Get moving to support new fellowships.
Register for the 2010 Run/Walk for
Brain Research on page 113, then
set up your pledge sponsorships at
www.aan.com/view/runwalk.
89
Integrated Neuroscience Session: Deep Brain Stimulation:
Where Are We and Where Do We Go From Here?
Thursday, April 15 | 12:00 p.m.–4:00 p.m.
Coordinators: Andres Lozano, MD and Jerrold Vitek, MD, PhD
Invited Speaker Session* / 12:00 p.m.–1:30 p.m. / Reception Hall 104A–D
12:00 p.m.–12:25 p.m. How Does Deep Brain Stimulation Work Jerrold Vitek, MD, PhD
12:25 p.m.–12:45 p.m. GPi Versus STN Deep Brain Stimulation for Parkinson’s Disease TBD
12:45 pm.–1:05 p.m.
Deep Brain Stimulation for Dystonia Marie Vidhailet, MD
1:05 p.m.–1:30 p.m.
Emerging Indications for Deep Brain Stimulation Andres Lozano, MD
Poster Session / 1:30 p.m.–2:30 p.m. / Reception Hall 104A–D
IN8-1.001 Ethics of Control in DBS:
Consent and Control Centered in
Patients’ Values Paul Ford, Cynthia
Kubu
IN8-1.002 Deep Brain Stimulation
with Individualized Gamma Frequencies
of the Human Subthalamic Nucleus
Is as Effective as High Frequency
Stimulation for Parkinson’s
Disease Eric Tsang, Clement Hamani,
Elena Moro, Filomena Mazzella, Utpal
Saha, Andres Lozano, Mojgan Hodaie,
Rosalind Chuang, Shen-Yang Lim,
Thomas Steeves, Bogdan Neagu,
Robert Chen
IN8-1.003 Steady or Not Following
Thalamic Deep Brain Stimulation for
Essential Tremor Nelson Hwynn, Chris
Hass, Pamela Zeilman, Janet Romrell,
Yunfeng Dai, Samuel Wu, Kelly Foote,
S. Subramony, Oyama Genko, Frances
Velez-Lago, Hubert Fernandez, Ramon
Rodriguez, Irene Malaty, Michael Okun
IN8-1.004 Unilateral STN DBS
Improves Sleep in Parkinson’s
Disease Amy Amara, Harrison Walker,
Stephanie Guthrie, Gary Cutter, David
Standaert, Ray Watts
IN8-1.005 Comparing Microelectrode
Recording Versus Imaging Targeting
During Pallidal Deep Brain Stimulation
for Parkinson’s Disease Kristine
Ziemba, Virgilio Gerald Evidente, Mark
Lyons
IN8-1.008 Apathy After STN DBS:
Are Patients with Impulse Control
Disorders at Risk? Tatiana Witjas,
Alexandre Eusebio, Marie Delfini, Jean
Regis, Jean Claude Peragut, Jean
Philippe Azulay
IN8-1.006 Automated Optimization
of Deep Brain Stimulation Settings
Across Multiple Parkinson’s Disease
Motor Symptoms Joseph Giuffrida, Jay
Alberts, Jerrold Vitek, Thomas Mera
IN8-1.009 An Open-Label,
Exploratory Study of the Efficacy and
Safety of Repetitive Transcranial
Magnetic Coil Stimulation (rTMS) in
Aphasia in Alzheimer’s Disease Gayatri
Devi, Elizabeth Shin, Linda Heier,
Henning Voss, James Halper, Sandlin
Lowe, Vanessa Lo
IN8-1.007 Adjuvant Medication
Reduces Post-DBS Impulsivity:
A Saccade Study in Parkinson
Disease Ashley Hood, Mya Schiess,
Anne Sereno
IN8-1.010 Deep Brain Stimulation
Can Suppress Pathological
Synchronization in Parkinsonian
Patients Alexandre Eusebio, Wesley
Thevathasan, Louise Doyle Gaynor, Alek
Pogosyan, Ed Bye, Thomas Foltynie,
Luvic Zrinzo, Keyoumars Ashkan, Tipu
Aziz, Peter Brown
Platform Session / 2:30 p.m.-4:00 p.m. / Reception Hall 104A–D
2:30 p.m.
IN8-2.001
Anatomical Location of Deep Brain
Stimulation Electrodes in Chronic
Cluster Headache Denys Fontaine,
Michel Lanteri-Minet, Yves Lazorthes,
Gilles Geraud, Nelly Fabre, Patrick
Mertens, Malou Navez, Serge Blond,
Christian Lucas, Francois Dubois, Lemlih
Ouchchane, Jean-Jacques Lemaire
2:45 p.m.
IN8-2.002
Benefits and Risks of Deep Brain
Stimulation for People with
Parkionson’s Disease (PD SURG
Collaborative Group) Keith Wheatley,
Adrian Williams, Natalie Ives, Caroline
Rick, Smitaa Patel
3:00 p.m.
IN8-2.003
Unilateral Pedunculopontine
Nucleus Deep Brain Stimulation in
Progressive Supranuclear Palsy: A Pilot
Study Mark Simpson, Andres Lozano,
Yu-Yan Poon, Clement Hamani, Cindy
Zadikoff, Jonathan Dostrovsky, William
Hutchison, Elena Moro
3:15 p.m.
IN8-2.004
Responsive Brain Stimulation for
Treatment of Medically Intractable
Mesial Temporal Epilepsy in Adults:
Results of a Subset Analysis from the
RNS™ System Pivotal Investigation in
Epilepsy Vicenta Salanova, Martha
Morrell
3:30 p.m.
IN8-2.005
Does Subthalamic DBS Directly
Impact Levodopa-Induced
Dyskinesias? Joseph Rudolph, Sabrina
Ahmmad, Ronald Alterman, Michele
Tagliati
3:45 p.m.
IN8-2.006
Effects of Deep Brain Stimulation at
Individually Established Frequencies on
the Motor Signs of Parkinson’s Disease
and Essential Tremor Patients Bogdan
Neagu, Eric Tsang, Utpal Saha, Sang
Kim, Filomena Mazzella, Clement
Hamani, Elena Moro, Mojgan Hodaie,
Andres Lozano, Robert Chen
*Current as of February 1, 2010
91
Scientific Sessions
S41 Multiple Sclerosis:
Clinical Immunology
S42 Cerebrovascular
Disease: Stroke
Prevention
S43 Movement Disorders:
Essential Tremor and
Ataxia
S44 Aging and Dementia:
Cellular Anatomy and
Exercise Physiology
S45 Child Neurology:
Developmental
Neurobiology
Scientific Sessions
Thursday, April 15 | 1:15 p.m.–2:30 p.m.
S46 Peripheral Nerve:
Molecular Mechanisms
of Peripheral Neuropathy
S47 Neurologic
Manifestations: Clinical
Neurophysiology and
Epidemiology
S48 Autonomic Disorders:
Frontiers of Autonomic
Neurology
S49 Cerebrovascular
Disease: Hemorrhagic
Stroke
S50 Multiple Sclerosis:
EAE/Animal Models
Theatre 102
Constitution Hall 106
Room 718AB
Constitution Hall 107
Room 701B
Constitution Hall 105
Room 713AB
Room 717AB
Room 714A
Room 701A
1:15 p.m.
S41.001
TLR9 Processing in
Multiple Sclerosis: A New
Immunomodulatory Effect of
Interferon-beta Konstantin
Balashov, Suhayl Dhib-Jalbut,
Latt Latt Aung
1:15 p.m.
S42.001
De Novo Atrial Fibrillation After
Carotid Endarterectomy Andrés
Suarez, Andrés Rodríguez, Matias
Altounian, Mauro Andreoli,
Gabriela Bressán, Juan Ressia
Gómez, Agustín Jáuregui, Patricia
Riccio, Luciano Sposato
1:15 p.m.
S43.001
Replication of the LINGO1 Gene
Association with Essential
Tremor in a North American
Population Lorraine Clark, Naeun
Park, Sergey Kisselev, Joseph
Lee, Elan Louis
1:15 p.m.
S44.001
Frontoinsular von Economo
Neuron and Forked Cell
Degeneration in Behavioral
Variant Frontotemporal
Dementia Eun-Joo Kim, Manu
Sidhu, Stephanie Gaus, Marcelo
Macedo, Eric Huang, Bruce
Miller, Stephen DeArmond,
William Seeley
1:15 p.m.
S45.001
Effect of Timing of
Glucocorticoid Administration
on Cerebellar Growth in Preterm
Newborns Emily Tam, Vann
Chau, Colin Studholme, Kenneth
Poskitt, A. James Barkovich,
Donna Ferriero, Steven Miller
1:15 p.m.
S46.001
Oral Curcumin Treatment
Partially Mitigates the
Phenotype of the R98C Knock-In
Mouse Model of CMT1B Agnes
Patzko, Istvan Katona, Mario
Saporta, Agnes Jani-Acsadi,
Michael Shy
1:15 p.m.
S47.001
NMDA Receptor Autoimmunity
in the Absence of Malignancy:
A Case Series Ged O’ Connor,
Sajid Farid, Iqbal Mudassir,
Colin Doherty, Daniel Healy, Orla
Hardiman
1:15 p.m.
S48.001
Up-Regulation of
Catecholaminergic Innervation to
Sweat Glands in Early Diabetic
Neuropathy Ningshan Wang,
Christopher Gibbons, Christopher
Brown, Roy Freeman
1:15 p.m.
S50.001
Reduction of Microglia Activity
in a Model of Multiple Sclerosis
by Dipyridamole V. Wee Yong,
Scott Sloka, Hollie Mowbray,
Janet Wang, Brooke Verhaeghe,
Yan Fan, Luanne Metz
1:30 p.m.
S45.002
Location of Early Brain Lesions
Impacts Integration of Cognitive
and Emotional Information Tal
Shany-Ur, Amichai Brezner,
Katherine Rankin, Simone
Shamay-Tsoory
1:30 p.m.
S46.002
Spontaneous Demyelinating
Autoimmune Neuropathy
in ICAM-1 Deficient NOD
Mice Gerd Meyer zu Horste,
Houda El-Haddad, Anne
Mausberg, Stefan Martin, HansPeter Hartung, Bernd Kieseier
1:30 p.m.
S47.002
Central and Peripheral
Demyelination as a Side
Effect of Infliximab: A Case
Series Kenkichi Nozaki, Marc
Judson
1:30 p.m.
S48.002
Familial Dysautonomia: A
Genetic Disease with Afferent
Baroreflex Failure Lucy NorcliffeKaufmann, Felicia Axelrod,
Horacio Kaufmann
1:15 p.m.
S49.001
Female Gender Is an
Independent Predictor
of Poor Outcome After
Spontaneous Intra Cerebral
Hemorrhage Neeraja
Yerragondu, Minal Jain, Anunaya
Jain, Veena Manivannan, Dipti
Agarwal, Balavani Palamari,
Babak Jahromi, Wyatt Decker,
Latha Stead
1:45 p.m.
S47.003
Sjögren’s Syndrome Associated
Polyneuropathy: Clinical and
Immunological Profiles Pantelis
Pavlakis, Haralampos
Alexopoulos, Michael Kosmidis,
Eleftherios Stamboulis,
Athanasios Tzioufas, Haralampos
Moutsopoulos, Marinos Dalakas
1:45 p.m.
S48.003
Hypovitaminosis D (HVD) in
Postural Tachycardia Syndrome
(POTS) in Adolescents Imad
Jarjour, Laila Jarjour
1:30 p.m.
S41.002
Th17 Cells Enter Inflamed CNS
Parenchyma Independently of
VLA-4 Blockade Rothhammer
Veit, Franziska Petermann, Malte
Claussen, Bernhard Hemmer,
Thomas Korn
1:45 p.m.
S41.003
Neuroprotective Activity of
Methylthioadenosine for the
Treatment of Multiple Sclerosis
and Other Neurological
Diseases Pablo Villoslada,
Alessandra di Penta, Martin
Kerschensteiner, Hannah
Pellkofer, Carlos Matute, María
Victoria Sánchez-Gómez, María
Domercq, Miroslav Gottlieb,
Valentin Ceña, Iciar Lopez, Jordi
Aberch, Albert Giralt, Jack Parent,
Helen Zang, Alan Chu , Jordi
Serra, Beatriz Moreno
2:00 p.m.
S41.004
Novel Neuroprotective
Outcomes of Vitamin D
in Models of Multiple
Sclerosis Scott Sloka, Claudia
Silva, Janet Wang, Yan Fan,
Luanne Metz, Peter Stys, Wee
Yong
2:15 p.m.
S41.005
Effect of Laquinimod on
Monocyte Subsets Tal Birnberg,
Steffen Jung
1:30 p.m.
S42.002
Does Aspirin Failure Increase
the Chances of Recurrent Stroke
and/or Death Among Patients
with Ischemic Stroke: A Pooled
Analysis of Two Prospective
Trials Steve Cordina, Gabriela
Vazquez, M. Fareed Suri,
Kamakshi Lakhsminarayan,
Harold Adams, Jr, Adnan Qureshi
1:45 p.m.
S42.003
Cerebral Ischemic and
Hemorrhagic Events in Patients
with Atrial Fibrillation on
Warfarin: A Prospective MultiCentre Study Maurizio Paciaroni,
Giancarlo Agnelli, Walter
Ageno, Valeria Caso, Francesco
Corea, Alessia Lanari, Andrea
Alberti, Paolo Previdi, Marta
Fedele, Giorgia Manina, Cristina
Vedovati, Michele Venti, Antonia
Billeci, Maurizio Batta, Giorgio
Silvestrelli
2:00 p.m.
S42.004
Factors Associated with
Dimensions of Poor Sleep in
a Stroke and TIA Cohort: The
Stroke Warning Information
and Faster Treatment (SWIFT)
Study Bernadette Boden-Albala,
Laura Evensen, Joshua Stillman,
Joshua Willey, Margaret Doyle,
Myunghee Paik
2:15 p.m.
S42.005
Headache as a Risk Factor
for Neurovascular Events
in Pediatric Brain Tumor
Patients Sarah Kranick, Cynthia
Campen, Scott Kasner, Sudha
Kessler, Rebecca Ichord, Daniel
Licht, Sabrina Smith, Lauren
Beslow, Michael Fisher
92
Thursday, April 15 | 1:15 p.m.–2:30 p.m.
Metro Toronto Convention Centre
1:30 p.m.
S43.002
Faster Rate of Cognitive Decline
in Essential Tremor Patients
Than Controls: A PopulationBased Prospective Study Elan
Louis, Julian Benito-Leon, Saturio
Vega-Quiroga, Felix BermejoPareja
1:45 p.m.
S43.003
Depolarization Block of Purkinje
Neurons in a Mouse Model of
Spinocerebellar Ataxia Type
3 Vikram Shakkottai, James
Dell’Orco, Henry Paulson
2:00 p.m.
S43.004
“Hairy Baskets” Associated
with Degenerative Purkinje
Cell Changes: A New
Pathological Finding in Essential
Tremor Cordelia Erickson-Davis,
Phyllis Faust, Jean Paul Vonsattel,
Elan Louis
2:15 p.m.
S43.005
Effects of Erythropoietin on
Endothelial Progenitor Cells,
Frataxin Levels, and Oxidative
Metabolism in the Skeletal
Muscle of Friedreich Ataxia
Patients Wolfgang Nachbauer,
Julia Wanschitz, Markus Reindl,
Barbara Scheiber-Mojdehkar,
Werner Poewe, Sylvia Boesch
1:30 p.m.
S44.002
Quantitative Analysis of the
Neuroanatomic Distribution and
Progression of Cerebral Amyloid
Angiopathy Across the Cognitive
Continuum Nicolas Badre,
William Markesbery, Gregory
Jicha
1:45 p.m.
S44.003
Declines of Metabotropic
Glutamate Receptor in Patients
with Early AD: In Vivo Evidence
of a Novel Biomarker for
Hippocampal Dysfunction Pedro
Rosa Neto, Jared Rowley,
Dorothee Shoemaker,
Betteke Van Noort, Ludymila
Kandratavicius, Luciano Minuzzi,
Serge Gauthier
2:00 p.m.
S44.004
Physical Exercise, Cognitive
Activity, Caloric Intake, and Mild
Cognitive Impairment: The Mayo
Clinic Study of Aging Yonas
Geda, Rosebud Roberts, David
Knopman, Teresa Christianson,
Vernon Pankratz, Bradley Boeve,
Robert Ivnik, Eric Tangalos,
Walter Rocca, Ronald Petersen
2:15 p.m.
S44.005
Cardiorespiratory Fitness
Change and Dementia
Progression in Early Alzheimer’s
Disease Eric Vidoni, Robyn
Honea, Heather Anderson,
Jeffrey Burns
1:45 p.m.
S45.003
PTEN Depletion Rescues
the á-Actin Deficit in Axonal
Growth Cones in Motoneurons
from a Mouse Model of Spinal
Muscular Atrophy Ke Ning,
Carsten Drepper, Azza Ismail,
Chiara Valori, Matthew Wyles,
Adrian Higginbottom, Thomas
Herrmann, Pamela Shaw, Basil
Sharrack, Michael Sendtner,
Mimoun Azzouz
2:00 p.m.
S45.004
Arcuate Fasciculus FiberTracking Identification and
Speech Development in Patients
with Congenital Bilateral
Perisylvian Malformations Anita
Dias Saporta, Ajay Kumar,
Rajkumar Govindan, Senthil
Sundaram, Harry Chugani
2:15 p.m.
S45.005
Glial Fibrillary Acidic Protein
(GFAP) Mutations, Age of Onset
and Clinical Presentation in
Alexander Disease Morgan
Prust, Albee Messing, Tom
Hartka, Alex Sokohl, Raphael
Schiffmann, Heather GordishDressman, Rafael Gorospe,
Adeline Vanderver
1:45 p.m.
S46.003
Unfolded Protein Response (UPR)
Activation in a Mouse Model
of Early-Onset CMT 1B Mario
Saporta, Yunhong Bai, Brian Shy,
Agnes Patzko, Maria Pennuto,
Cherie Southwood, Alexander
Gow, Cinzia Ferri, Maria Feltri,
Michelle Crowther, Daniel
Kirschner, Lawrence Wrabetz,
Michael Shy
2:00 p.m.
S46.004
Distinct Pathogenic Processes
between Fig4-Deficient Sensory
and Motor Neurons Istvan
Katona, Xuebao Zhang, Yunhong
Bai, Michael Shy, Quing Yan,
Jun Li
2:15 p.m.
S46.005
NT-3 Gene Therapy Improves
Compound Muscle Action
Potential (CMAP) and Function in
Mouse Model for Charcot-MarieTooth (CMT) Neuropathy Zarife
Sahenk, Gloria Galloway, Chris
Edwards, Jerry Mendell, Kelly
Clark
2:00 p.m.
S47.004
Cross-Sectional Survey of
Neurologic Dysfunction and
Headaches in North American
Patients with Behcet’s
Disease Ilya Kister, Maria
Filopoulos, Monalyn De Los
Reyes Labitigan, Sara Crystal,
Matthew Robbins, Joseph
Herbert, Yusuf Yazici
2:15 p.m.
S47.005
Long Term Cognitive and
Neurological Outcomes
Following Successful Cardiac
Defibrillation for Out-of-Hospital
Cardiac Arrest: A PopulationBased Study Farrah Mateen,
Keith Josephs, Max Trenerry,
M. Donna Felmlee Devine, Amy
Weaver, Roger White
2:00 p.m.
S48.004
Improved Orthostatic Responses
in Fabry Patients After Enzyme
Replacement Therapy Max Hilz,
Harald Marthol, Stefan Schwab,
Edwin Kolodny, Miroslaw Brys,
Brigitte Stemper
2:15 p.m.
S48.005
Autoimmune Autonomic
Ganglionopathy: A Reversible
Cortical Dementia Christopher
Gibbons, Justin Centi, Roy
Freeman
1:30 p.m.
S49.002
Predictors of Hemorrhage
Volume in Hypertensive
Intracerebral
Hemorrhage Mohammad
Wasay, Ammar Masud, Adnan
Yousuf, Darshan Lal, Safia Awan
1:45 p.m.
S49.003
The Impact of Weekend
Admission on In-Hospital
Mortality in Intracerebral
Hemorrhage Jay Joshi, Manisha
Gupte, Bichun Ouyang, Sayona
John, Shyam Prabhakaran, Vivien
Lee
2:00 p.m.
S49.004
Troponin I Levels Are
Associated with In-Hospital
Mortality in Subarachnoid
Hemorrhage Manisha Gupte,
Jay Joshi, Sayona John, Shyam
Prabhakaran, Vivien Lee
2:15 p.m.
S49.005
Elevated Troponin Is Predictive
of Disability but Not Mortality
in the Acute Intracerebral
Hemorrhage Nina Tsakadze,
Pedro Hernandez-Frau, Karen
Wilson, Reza Behrouz
1:30 p.m.
S50.002
Protective Effect of
TLR7-Deficiency in
Experimental Autoimmune
Encephalomyelitis Patrice Lalive,
Mahdia Benkoucha, Marie-Laure
Santiago-Raber
1:45 p.m.
S50.003
Age-Associated Susceptibility
to Central Nervous System
Autoimmune Disease Is
Associated with Cerebral
MHCII Expression by CD19+
B Cells, CD8+DC and Gr-1
Monocytes Petra Cravens,
Bernd Kieseier, Martin Weber,
Christiane Knobbe, Rehana
Hussain, Li-hong Ben, Oliver
Neuhaus, Carsten Korth, HansPeter Hartung, Michael Racke,
Jan Cohen Tervaert, Scott Zamvil,
Olaf Stuve
2:00 p.m.
S50.004
Pharmacological PrP-Silencing
Accelerates CNS Autoimmune
Disease Via TCR Signaling Sima
Zein, Wei Hu, Stefan Nessler,
Bernhard Hemmer, Todd Eagar,
Lawrence Kane, S. Rutger
Leliveld, Anne Gocke, Amy LovettRacke, Li Hong Ben, Rehana
Hussain, Jeffrey Elliot, Krishna
Puttaparthi, Petra Cravens,
Benjamin Petsch , Katherine
Deming, Lothar Stitz, Michael
Racke, Carsten Korth, Olaf Stuve
2:15 p.m.
S50.005
Molecular Imaging in
Experimental Autoimmune
Encephalomyelitis Dorothea
Buck, Annette Foerschler,
Thomas Korn, Stefan Nessler,
Patrick Vollmar, Hortenzia Jacobi,
Sybille Reder, Constantin Lapa,
Christine Stadelmann, Alexander
Drzezga, Claus Zimmer, Bernhard
Hemmer
93
Scientific Sessions
S51 Multiple Sclerosis:
Clinical Research II
Theatre 102
2:45 p.m.
S51.001
Multiple Sclerosis: Quality of
Life and Perceived DeficitRelationship to Cognition in a
Community-Based Study Mark
Gudesblatt, Myassar Zarif,
Barbara Bumstead, Max Gutman,
Lori Fafard, Laura Graffitti, Carol
Seidel, Lourdes Cruz, Serina
Fahie, Joan Bohuslaw, Chris
Burke, Jocelyn Caputo, Susan
Riley, Ely Simon, Glen Doniger
3:00 p.m.
S51.002
Multiple Sclerosis: Fatigue
and Depression: Effects on
Cognition in a CommunityBased Study Mark Gudesblatt,
Myassar Zarif, Barbara Bumstead,
Max Gutman, Lori Fafard,
Laura Graffitti, Carol Seidel,
Lourdes Cruz, Serina Fahie, Joan
Bohuslaw, Chris Burke, Jocelyn
Caputo, Susan Riley, Ely Simon,
Glen Doniger
3:15 p.m.
S51.003
CSF Identification of Novel
Initiating Targets and Putative
Prognostic Markers of Multiple
Sclerosis in Pediatric-Onset
CNS Demyelination Ajit
Singh Dhaunchak, Brenda
Banwell, Douglas Arnold, Dessa
Sadovnick, Christopher Becker,
Howard Schulman, David
Colman, Amit Bar-Or
3:30 p.m.
S51.004
The Self IgG Repertoire
Directed Against CNS Antigens
Discriminates NMO From MS
and Healthy Subjects Hélíne
Zéphir, Didier Lefranc, Nicolas
Collongues, Frédéric Blanc,
Patricia Dussart, Sylvain
Dubucquoi, Marie Fleury,
F. Viallet, Alain Créange,
Jean-François Pélissier, Lionel
Prin, Jérôme de Síze, Patrick
Vermersch
94
S52 Cerebrovascular
Disease II
Constitution Hall 106
2:45 p.m. Presentation of
Michael S. Pessin Stroke
Leadership Award
Recipient:
Shelagh Coutts, MD
Calgary, AB, Canada
3:00 p.m.
S52.002
Optimal Timing of
Anticoagulation after
Central Nervous System
Hemorrhage in Patients with
High Thromboembolic Risk:
A Systematic Review of the
Literature Julio Furlan, Gregory
Hawryluk, James Austin, Jang
Lee, Cian O’Kelly, Michael
Fehlings
3:15 p.m.
S52.003
The Possible Risk of Intra
Operative Hypothermia for
Strokes Complicating Cardiac
Surgery Isabelle Korn-Lubetzki,
Israel Steiner, Avraham Oren,
Rachel Tauber, Bettina Steiner
Birmanns, Daniel Bitran
3:30 p.m.
S52.004
Stroke in Patients with a Left
Ventricular Assist Device: One
Institution’s Experience Crystal
Tung, Natalie Hoffman,
Tudor Jovin, Robert Kormos,
Mouhammad Jumaa
Thursday, April 15 | 2:45 p.m.–3:45 p.m.
Metro Toronto Convention Centre
S53 Movement Disorders:
Parkinson's Disease and
Atypical Parkinsonism
S54 Aging and Dementia:
Genetics
S55 Clinical
Neurophysiology: Intraoperative
Neurophysiologic Monitoring;
Evoked Potentials
Scientific Sessions
Thursday, April 15 | 2:45 p.m.–3:45 p.m.
S56 Anterior Horn: Basic
Science
S57 Neural Repair and
Neurorehabilitation
S58 Behavioral
Neurology: Language,
Action, and Memory
S59 Ethics
S60 Multiple Sclerosis:
MRI II
Room 718AB
Constitution Hall 107
Room 701B
Constitution Hall 105
Room 713AB
Room 717AB
Room 714A
Room 701A
2:45 p.m.
S53.001
Autosomal Dominant Late-Onset
Parkinsonism with Dementia—
Association with a Novel PD
Gene Norbert Brüggemann,
Wiebe Külper, Johann Hagenah,
Vera Tadic, Holger Tönnies, Peter
Bauer, Olaf Riess, Arnd Rolfs,
Reiner Siebert, Peter Vieregge,
Katja Lohmann, Christine Klein
2:45 p.m.
S54.001
Enhancing Power for Gene
Discovery in Alzheimer’s
Disease: Intermediate
Phenotypes and Functional
Validation in Drosophila Joshua
Shulman, Cristin Aubin, Dong
Tran, Patricia Kramer, Mel Feany,
David Bennett, Philip De Jager
2:45 p.m.
S55.001
Intraoperative Neurophysiologic
Monitoring in the Endovascular
and Surgical Treatment of
Pediatric Arteriovenous
Malformations Viet Nguyen,
Sungho Cho, Steven Chang, Gary
Steinberg, Michael Marks, Huy
Do, Jaime Lopez
2:45 p.m.
S56.001
Cytoplasmic C-Terminus TDP-43
Aggregate Leads to Increased
Phosphorylation of Full-Length
TDP-43 in Culture Cell Yuko
Ariizumi, Tomohiko Ishihara,
Mariko Yokoo, Atsushi Shiga,
Akio Yokoseki, Osamu Onodera,
Masatoyo Nishizawa
2:45 p.m.
S57.001
Serial Investigation of Neuronal
Reorganisation in Acute
Stroke Patients Using fMRI
Techniques Lalit Kalra, Fernando
Zelaya, Steve Williams
2:45 p.m.
S58.001
Sounds of Silence: Pauses
in the Speech of Progressive
Non-Fluent Aphasics Sharon
Ash, David Adamowicz, Corey
McMillan, Murray Grossman
3:00 p.m.
S54.002
Telomere Shortening Is a
Biomarker for Biological
Aging Min Kang, Nicole Schupf,
Joseph Lee, Lawrence Honig
3:00 p.m.
S55.002
Interhemispheric Inhibition and
Facilitation in Patients with
Callosal Infarction Jie-Yuan Li,
Ping-Hong Lai, Robert Chen
3:15 p.m.
S55.003
Multimodal Visual, Motor
and Somatosensory Evoked
Potentials (EP) as Markers and
Predictors of the Disease Course
in Patients with Early Relapsing
Remitting Multiple Sclerosis
(RRMS)—A Prospective Three
Year Study Regina Schlager,
Marcus D’souza, Leticia Grize,
Christian Schindler, Ludwig
Kappos, Peter Fuhr
3:00 p.m.
S58.002
Factors Associated with Impulse
Control Disorders in Parkinson’s
Disease: A Case-Control Study
of 564 Subjects Valerie Voon,
Juergen Koester, Anthony Lang,
Marc Potenza, Andrew Siderowf,
Jacquie Whetteckey, Daniel
Weintraub, Glen Wunderlich,
Mark Stacy
2:45 p.m.
S60.001
Corpus Callosum Area and
Thalamic Volume as Predictors
of Cognitive Impairment in
Children and Adolescents with
MS Christine Till, Berengere
Broche, Rezwan Ghassemi, Sridar
Narayanan, Louis Collins, John
Sled, Douglas Arnold, Brenda
Banwell
3:15 p.m.
S54.003
Estrogen Receptor Alpha Gene
Variants Are Associated with
Alzheimer’s Disease in the
Spanish Population Mercí Boada
Rovira, Carmen Antunez Almagro,
Jesús López-Arrieta, Antonio
Caruz, Concha Moreno-Rey,
Reposo Ramírez-Lorca, Francisco
Jesús Morón, Isabel Hernández
Ruiz, Ana Mauleon, Maitée
Rosende-Roca, Pablo MartínezLage, Juan Marin, Lluís Tárraga,
Montserrat Alegret, José Rafael
Pedrajas, Nuria Urda, José Luis
Royo, Maria Eugenia Saez, Javier
Gayan, Antonio González-Pérez,
Luis Miguel Real, Agustín Ruiz,
Jose Jorge Galán
3:00 p.m.
S56.002
Microglial Transformation From
a Motoneuron Protective to a
Toxic Phenotype in a Mouse
Model of ALS Bing Liao, Weihua
Zhao, David R. Beers, Jenny S.
Henkel, Stanley Appel
3:00 p.m.
S57.002
Combining Visual Rehabilitation
and Noninvasive Brain
Stimulation To Enhance Function
in Patients with Hemianopia Ela
Plow, Souzana Obretenova,
Mark Halko, Patricia Schulz, Lais
Oliveira, Nurhan Torun, Mary Lou
Jackson, Alvaro Pascual-Leone,
Lotfi Merabet
2:45 p.m.
S59.001
Significant Pain Relief
in Treatment Resistant
Neuropathic Pain. Results
from the First Multicenter,
Randomized Trial with
Intravenous Immunoglobulin
(IGD 001 Trial, Eudract 2007007007-32) Stefano Jann, Maria
Fruguglietti, Ada Francia, Roberto
Sterzi
3:15 p.m.
S56.003
Prion-Like Propagation of
SOD1 Misfolding In Vitro Neil
Cashman, Leslie Grad, Anat
Yanai, William Guest, Megan
O’Neill, Edward Pokrishevsky,
Masoud Yousefi, Steven Plotkin
3:15 p.m.
S57.003
Integrity of Intra- and InterHemispheric Motor Fibers
Predicts Recovery Potential in
Chronic Stroke Patients Robert
Lindenberg, Lin Zhu, Gottfried
Schlaug
3:30 p.m.
S56.004
CD4+ T-Cells Induce
Alternatively Activated
(M2) Microglia in the ALS
Mouse Jenny Henkel, David
Beers, Weihua Zhao, Bing Liao,
Stanley Appel
3:30 p.m.
S57.004
Measuring Regional Cerebral
Blood Flow Changes Induced
by Non Invasive BrainStimulation Xin Zheng, David
Alsop, Robert Lindenberg,
Gottfried Schlaug
3:15 p.m.
S58.003
Accuracy-Certainty Memory
Profiles Enhance Discrimination
among Alzheimer’s Disease,
Mild Cognitive Impairment, and
Normal Elderly Controls Daniel
Kaufer, Feng Liu, Elizabeth Snitz,
James Becker, Judith Saxton,
Steven DeKosky, Oscar Lopez
3:00 p.m.
S53.002
Early Clinical Features
Differentiate Cerebellar Variant
of Multiple System Atrophy
and Sporadic Ataxia Alexandra
Lloyd-Smith, Michael Schulzer,
Sian Spacey
3:15 p.m.
S53.003
Freezing of Gait in Parkinson
Disease Is Associated with
Reduced Dopaminergic
Innervation of the Dorsal
Caudate Nucleus Roger Albin,
Martijn Muller, Robert Koeppe,
Michael Kilbourn, Kirk Frey,
Nicolaas Bohnen
3:30 p.m.
S53.004
White Matter Lesions
Augment Motor Impairments
of Nigrostriatal Dopaminergic
Denervation in Parkinson
Disease Roger Albin, Martijn
Muller, Christopher Bogan,
Robert Koeppe, Michael Kilbourn,
Kirk Frey, Nicolaas Bohnen
3:30 p.m.
S54.004
Olfactory Receptor Cluster
Copy Number Is Associated
with Age at Onset of Alzheimer
Disease Yanchun Li, Chad Shaw,
Kinga Szigeti
3:30 p.m.
S55.004
Microvascular Decompression
for Hemifacial Spasm: Evaluating
the Prognostic Value of Intra
Operative Lateral Spread
Response Monitoring and
Clinical Characteristics in 293
Patients Aalap Shah, Tara
Nikonow, Miguel Habeych,
Parthasarthy Thirumala, Yue-Fang
Chang, Michael Horowitz
3:30 p.m.
S58.004
Hypoperfusion in the Left Inferior
Parietal Lobule Correlates
with Severity of Apraxia in
Corticobasal Syndrome Mario
Masellis, Wendy Galpern, Philip
Francis, Isabelle Guimont, Farrell
Leibovitch, Anthony Lang, Sandra
Black
3:00 p.m.
S59.002
Evaluation of Neurogenic
Intermittent Claudication in
Lumbar Spinal Stenosis John
Markman, Maria Frazer, Ross
Hanson, Nicole Murray
3:15 p.m.
S59.003
Functional Connectivity
in Patients with Chronic
Neuropathic Pain Meredith
Barad, Justin Brown, Elena
Sherman, Neil Chaterjee, Sean
Mackey
3:30 p.m.
S59.004
Functional Polymorphisms of
Catechol-O-Methyl Transferase
(COMT) and Dopamine BetaHydroxylase (DBH) and Chronic
Pain in the Elderly Richard
Lipton, Lucas McCarthy, Mindy
Katz, Laurie Ozelius
3:00 p.m.
S60.002
Subregional Hippocampal
Atrophy Is Linked to Depressive
Symptoms in Multiple
Sclerosis Stefan Gold, Kyle Kern,
Mary-Frances O’Connor, Michael
Montag, Aileen Kim, Ye Yoo,
Barbara Giesser, Nancy Sicotte
3:15 p.m.
S60.003
Definition of Regional
Distribution of Gray Matter Loss
in MS Patients with Fatigue:
A Voxel-Based Morphometry
Study Gianna Riccitelli, Maria
Rocca, Cristina Forn, Bruno
Colombo, Giancarlo Comi,
Massimo Filippi
3:30 p.m.
S60.004
Magnetic Resonance Evidence
of the Involvement of the
Striatal-Thalamic-Frontal Cortex
System in Determining Fatigue in
Multiple Sclerosis Paolo Gallo,
Francesca Rinaldi, Paola Grossi,
Alice Favaretto, Massimiliano
Calabrese
95
Poster Session VI
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
Cerebrovascular Disease: Acute Stroke Therapy
Location: 800 Level
Moderators: Pooja Khatri, MD and Walter Koroshetz, MD, FAAN
Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions
and answers with attendees and poster authors during the 90-minute author standby time.
Thursday, April 15, 2010
3:00 p.m.–7:30 p.m.
PD6.001 The Impact of NIH Stroke
Scale on Functional Outcome Varies by
the Hemisphere of Involvement in Major
Ischemic Stroke Leonardo Batista, Fabricio
Lima, Raul Nogueira, Ramon Gonzalez,
Walter Koroshetz, William Dillon, Wade
Smith, Karen Furie, Michael Lev, Albert Yoo
PD6.002 Early Recurrence of Cerebral
Ischemia in Patients with Symptomatic
Carotid Artery Stenosis Henning
Mast, Jay Mohr, Claudia Elste, Andreas
Hartmann, Christian Stapf
Cerebrovascular Disease:
Epidemiology II
P06.001 Acute Kidney Injury Is
Associated with Hospital Mortality
after Acute Ischemic Stroke, but Not
Intracerebral Hemorrhage Minesh Khatri,
Derk Adams, Kyra Becker, Christine Logar,
W. T. Longstreth, David Tirschwell
P06.002 Depressive Symptoms and
Incidence of First Stroke: Does Stroke
Risk Decline after Depressive Symptoms
Resolve? M. Maria Glymour
P06.003 Incidence of Cerebral Venous
Thrombosis in United States: 2002–2006.
A National Analysis Yousef Mohammad,
M. Fareed Suri, Gabriela Vazquez, Tariq
Nauman, Marwan Kattan, Gaurav Guliani,
Adnan Qureshi
P06.004 Endocarditis Is a Common
Stroke Mechanism in Hemodialysis
Patients Mesha Gay Brown, Mark Weiner,
Sidney Kobrin, Scott Kasner, Steven Messe
PD6.003 Safety and Feasibility of
Intravenous Autologous Bone Marrow
Derived Stem Cell Therapy for Patients
with Acute Ischaemic Stroke: An OpenLabel, Phase I Trial Kameshwar Prasad,
Rohit Bhatia, Sujata Mohanty, MV Padma
Srivastava, Ajay Garg, Achal Srivastava,
Vinay Goyal, Manjari Tripathi, Amit Kumar,
Arti Vij, NK Misra, C. S. Bal
PD6.004 Utilization of Helicopter
Transport for Patients with Suspected
Acute Ischemic Stroke Mark MacKenzie,
Craig Domke, Thomas Jeerakathil
PD6.005 The Safety of Clopidogrel
Loading in the Treatment of Acute
Ischemic Stroke and Transient Ischemic
Attacks Lester Leung, Joe Tarsia, Gayle
Pletsch, Karen Albright, Sheryl MartinSchild
P06.008 Load of Myocardial Infarction
and Risk of Brain Infarction: The AGESReykjavik Study Jean-Sebastien Vidal,
Sigurdur Sigurdsson, Thor Aspelund,
Tamara Harris, Vilmundur Gudnason,
Andrew Arai, Lenore Launer
P06.009 The Northern Manhattan
Study Global Vascular Risk Score Is
Associated with Leukoaraiosis Clinton
Wright, Chuanhui Dong, Joanna Guzman,
Mitchell Elkind, Tatjana Rundek, Charles
DeCarli, Ralph Sacco
P06.010 Newly Diagnosed Diabetes
Portends a Poor Outcome for Acute
Stroke Patients Regardless of the
Subtype Mohammad Moussavi, Bahareh
Hassanzadeh, Madhu Gupta, Florence
Chukwuneke, Mohammad Alsumrian,
Charles Porbeni, Martin Gizzi, Jawad
Kirmani
P06.011 Chocolate Consumption and
Risk of Stroke Sarah Sahib, Joel Ray,
Gustavo Saposnik
P06.005 Low Rates of Blood Pressure
Goal Achievement among Minorities
with Stroke and Coronary Artery
Disease Are Not Due to Less Aggressive
Treatment Nerses Sanossian, Sharmineh
Shams, Adrian Burgos, Gene Sung
P06.012 Seasonal Variation of Stroke
in Relation to Influenza Infection S.
Kohake, J. Khoury, C. J. Moomaw,
K. Alwell, BM Kissela, D. Woo, M. L.
Flaherty, O. Adeoye, P. Khatri, S. Ferioli, D.
Kleindorfer
P06.006 Physical Activity and
Functional Outcome from Stroke Pamela
Rist, I-Min Lee, Tobias Kurth
P06.013 Trends in Outcome and
Hospitalization Cost Among Adult
Patients with Acute Ischemic Stroke in
the United States Hafiz Khan, Hussam
Yacoub, Khosro Farhad, Lubna Mehyar,
Shahanara Islam, Bilal Saulat, Rania Abou
Elenein, Nizar Souayah
P06.007 Should ICH Outcome
Prediction Models Be Modified in African
Americans? Pratik Bhattacharya, Wazim
Mohamed, Lakshmi Shankar, Denise
Rhoney, Seemant Chaturvedi, Ramesh
Madhavan
PD6.006 Are You Ever Too Old for
Thrombolysis? Intravenous Recombinant
Tissue Plasminogen Activator in Patients
Age 80 and Older Shirley Chen, Nobl
Barazangi, Jack Rose, Ann Bedenk, Jackie
Phan, David Tong
PD6.007 Use of Perfusion CT to Guide
Stroke Thrombolysis Between Three and
Six Hours Is Safe and Effective Laszlo
Sztriha, Jozef Jarosz, Lalit Kalra, Dulka
Manawadu
PD6.008 Stroke Mimics Treated
with IVTPA: A Retrospective
Analysis Mohamed Teleb, Julian Yang,
Jason Chang, Yazan Alderazi, Alwala
Awad, Gunjan Parikh, Lucas Restrepo,
James Frey
P06.014 Accuracy of the New ICD-9
Code for “Drip-and-Ship” Thrombolytic
Treatment in Patients with Acute Ischemic
Stroke Silvina Tonarelli, Michael Tibbs,
M. Naeem Qureshi, Gustavo Rodriguez,
Kamakshi Lakshminarayan, Adnan Qureshi,
Gabriela Vazquez
P06.015 Racial and Geographic
Differences in Fish Consumption: The
REasons for Geographic and Racial
Differences in Stroke (REGARDS)
Study Fadi Nahab, Anh Le, Suzanne Judd,
Michael Frankel, Jamy Ard, P. Newby,
Virginia Howard
P06.016 Stroke-Associated
Pneumonia (SAP): Do Academic and
Community Hospitals Have Similar
Incident Risk and Outcomes? Olga
Finlayson, Moira Kapral, Ruth Hall, Eriola
Asllani, Daniel Selchen, Gustavo Saposnik
P06.017 Prevalence of Thyroid
Abnormalities and Associations with
Cerebrovascular Disease in a Nationwide
Survey May Kim, Nerses Sanossian
P06.018 Pronounced Association
of Elevated Serum Homocysteine with
Stroke in Subgroups of Individuals: A
Nationwide Study Amytis Towfighi, Bruce
Ovbiagele
P06.019 Impact of Microalbuminuria
on Incident Stroke Risk: A MetaAnalysis Meng Lee, Shen-Chih Chang,
Jeffrey Saver, Kuo-Hsuan Chang, HungWei Liao, Bruce Ovbiagele
P06.020 Incidence of First Stroke in a
Total Population Study Agust Hilmarsson,
Olafur Kjartansson, Elias Olafsson
PD6.009 Thrombolysis for Acute
Ischaemic Stroke in Patients Over 80
Years of Age: A Perspective from Clinical
Practice Laszlo Sztriha, Dulka Manawadu,
Jozef Jarosz, Lalit Kalra
PD6.010 Borderline Elevation of
International Normalized Ratio and Use
of Intravenous Recombinant Tissue
Plasminogen Activator Harsh Aggarwal,
Ameer Hassan, Gustavo Rodriguez, M.
Fareed Suri, Kamakshi Lakshminarayan,
Robert Taylor, Mustapha Ezzeddine, Adnan
Qureshi
Muscle Disease/Neuromuscular
Junction: Inherited Myopathy
P06.021 Distal Myopathies: A
Retrospective Study of 28 Cases Jerome
Franques, Emmanuelle Campana-Salort,
Shahram Attarian, Annie Verschueren,
Bruno Eymard, Carla Fernandez, Andre
Maues De Paula, Dominique FigarellaBranger, Nicolas Levy, Pascale Richard,
Nicole Monnier, Carina WallgrenPettersson, Bjarne Udd, Jean-Francois
Pellissier, Jean Pouget
P06.022 Progressive Dysphagia
in Limb Girdle Muscular Dystrophy
Type 2B: An Extension of the Clinical
Phenotype Richard Walsh, Fiona Hill,
Francesca Brett, Richard Charlton, Rita
Barresi, Dominick McCabe
P06.023 Oculopharyngodistal
Myopathy Is a Distinct Entity— Clinical
and Genetic Characterization of 40
Turkish OPDM Patients Hacer Durmus,
Steve Laval, Feza Deymeer, Yesim Parman,
Esen Kiyan, Munevver Gokyigit, Cumhur
Ertekin, Straub Volker, Ibrahim Ercan, Kate
Busby, Hanns Lochmüller, Piraye Piraye
Serdaroglu-Oflazer
P06.026 Non-GNE Related
Quadriceps Sparing Myopathy: A Case
Report Shrikant Mishra, Doris Cardenas,
Aldobrando Broccolini, Yadira Ayoub,
Chai Saechao, Daniel No, Daniel Darvish,
Parampreet Singh
P06.027 Scoliosis Surgery (ScSu) in
Respiratorily-Compromised Congenital
Neuromuscular Patients Can Fatally
Worsen Ventilatory Function or Engender
Nocturnal BiPAP Dependency, as
Evidenced in Four Children with FocalLoss-of-Cross-Striations (FLCS) Shalini
Mahajan, W. King Engel
P06.028 Sparing of Myofiber
Membranes in Infantile Pompe’s Disease:
Dissociated Excitation-Contraction
Coupling Ludwig Gutmann, Margaret
Jaynes, Kymberly Gyure, Christopher
Nance, Laurie Gutmann
P06.038 The Pathological
Characterization of Peripheral Neuropathy
in Copper Deficiency Sean Taylor, Neeraj
Kumar, James Dyck
P06.051 Timed Vibration Predicts
Progression to Symptomatic Neuropathy
in Diabetic Subjects J. Singleton, Collin
Arsenault, A. Smith
P06.039 Statin Toxicity for Sensory
Neurons In Vitro: Mechanism of Action
Distinct from Cholesterol Synthesis Beth
Murinson, Zachary Sender
Peripheral Nerve: Acute Immune
Neuropathies
P06.040 Sensori-Motor CMT “ Like”
Neuropathy with Ataxia Ophtalmoplegia
and Dysarthria in Moroccan Patient with
Homozygote POLG Mutation Mohammed
Abdoh Rafai, Fatima Zahra Boulaajaj,
Bouchra El Moutawakil, Ilham Slassi
P06.041 SCA3 Presenting as an
Isolated Axonal Polyneuropathy Tracey
Graves, Roberto Guiloff
Peripheral Nerve: Diabetic
Neuropathy
P06.029 Clinical Methodology
and Outcome of Enzyme Replacement
Therapy in a Series of Late-Onset GSDII
Patients Corrado Angelini, Claudio
Semplicini, Chiara Ferrati, Paola Tonin,
Massimiliano Filosto, Elena Pegoraro
P06.042 Impaired Neurovascular
Repair in Subjects with Diabetes
Following Intracutaneous Axotomy Gigi
Ebenezer, Ryan O’Donnell, Peter Hauer,
Nicholas Cimino, Justin McArthur, Michael
Polydefkis
P06.030 Analysis of Cardiac
Involvement in Children and Adults
with Pompe Disease from the Pompe
Registry Edward Cupler, Barry Byrne,
Laura Case, Angela Genge, Priya Kishnani,
Ying Zhang, Suyash Prasad
P06.043 MNSI, Electrophysiologic and
Epidermal Nerve Fiber Density Findings
in Cryptogenic Sensory Polyneuropathy
Compared to Diabetic Polyneuropathy
and Normal Controls Mamatha Pasnoor,
Yuvraj Nijjar, Laura Herbelin, Douglas
Wright, Janelle Ryals, Mazen Dimachkie,
Richard Barohn
P06.031 Enzyme Replacement
Therapy in Five Adults with Late-Onset
Pompe Disease Carly Oboudiyat, Gregory
Pastores, Marrisa Ferraris, Swati Sathe
Peripheral Nerve: Nutritional,
Metabolic, and Small Fiber
Neuropathy
P06.044 Is Clinically Diagnosed
Diabetic Peripheral Neuropathy
Predominantly Metabolic or Vascular
in Origin? Mayowa Owolabi, Aarinola
Ipadeola, Jokotade Adeleye
P06.032 Characterization of NonLength-Dependent Small Fiber Sensory
Neuropathy Sara Khan, Lan Zhou
P06.045 Electrodiagnostic Features
of CIDP in Diabetes Mellitus Hiroyuki
Nodera, Russell Chin, Jennifer Langsdorf,
Bridget Carey, Norman Latov
P06.033 Natural History of Idiopathic
Small and Large Fiber Polyneuropathy: A
Retrospective Study Rami Assi, Victoria
Lawson, John Kissel
P06.046 Type 2 Diabetes Mellitus
Exacerbates Neuropathy in Patients with
CMT1a Sourabh Arora, Steven Baker
P06.034 Sensory Neuropathy in
Patients with Cryoglobulin Negative
Hepatitis-C Infection Min-Suk Yoon, Mark
Obermann, Christina Dockweiler, Roland
Assert, Ali Canbay, Sebastian Haag, Guido
Gerken, Hans-Christopher Diener, Zaza
Katsarava
P06.024 Dominant Cardiomyopathy
and Very Distal Myopathy with
Rod, Myofibrillar and AVSF
Myopathology Stanley Iyadurai, Conrad
Weihl, Alan Pestronk
P06.035 Alcohol-Related Peripheral
Neuropathy Is Not Caused by Nutritional
Deficiency Michelle Mellion, VanAnh
Nguyen, Ming Tong, Princess Mark, Jack
Wands, Jame Gilchrist, Suzanne de la
Monte
P06.025 Hereditary Myopathy with
Early Respiratory Failure (HMERF)—A
Uniform Clinical Phenotype with Several
Possible Genotypes Lars Edstrom, Bengt
Isberg, Fengqing Xiang, Kathe Dahlbom,
Thomas Sejersen, Bjarne Udd
P06.036 Peripheral and Central
Large Fiber Dysfunction in Idiopathic
Hyperhomocysteinemia Ramin Ansari,
Favio Bumanlag, Ruma Mukerjee, J.
Robert Chang, Tania Giovannetti, Bassel E.
Sawaya, Jin Jun Luo
P06.037 Lower Extremity Weakness
and Dysesthesias Associated with Zinc
Deficiency Stanley Iyadurai, Taylor Bear,
Glenn Lopate
96
Poster Session VI
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P06.047 Epidemiology of Peripheral
Neuropathy (PN) in a Tertiary
Neuromuscular Disease Clinic in
Northeast Brazil Francisco de Assis
Gondim, Paulo Marcelo Sales, Francisco
Basilio, Gisele Oliveira, Carlos Augusto
Teixeira, Carlos Castro Costa
P06.048 Multi-Factorial Analysis
of Risk Factors for the Development of
Peripheral Neuropathy Kartik Sivaraaman,
Hussain Wajid, Jin Luo
P06.049 Dizziness and Loss of Balance
in Diabetics: The Relative Contribution
of Vestibular vs. Somatosensory
Dysfunction; Implications for Therapeutic
Intervention Mary Walch, Charles
Maitland, Winston Ortiz
P06.050 Effects of Brief Supervised
Exercise Program on Diabetic
Neuropathy Mamatha Pasnoor, Patricia
Kluding, Rupali Rupali, Benjamin Tseng,
Laura Herbelin, Kevin Farmer, Stephen
Jernigan, Douglas Wright
P06.052 Acute Motor Axonal
Neuropathy Presenting with Ventral
Horn and Proximal Root Involvement:
A Case Report and Review of the
Literature Mahmoud Rayes, Sindhu
Ramchandren, Sulaiman Mohammad,
Alexandros Tselis, Richard Lewis
P06.053 Guillain-Barre Syndrome
after Influenza Vaccination in the United
States. A Report from the CDC/FDA
Vaccine Adverse Event Reporting System.
(1990–2009) Hussam Yacoub, Hafiz Khan,
Shahanara Islam, Nizar Souayah
P06.054 Cerebrospinal Fluid
Oligoclonal IgM Bands in Guillain-Barré
Syndrome Diana Ferraro, Anna Maria
Simone, Maria Grazia Venneri, Jessica
Mandrioli, Roberta Bedin, Giuliana Galassi,
Maria Chiara Malaguti, Paolo Frigio
Nichelli, Patrizia Sola
P06.055 Guillain-Barre Syndrome
after Hepatitis Vaccination in the United
States. A Report from the CDC/FDA
Vaccine Adverse Event Reporting System.
(1990–2009) Hussam Yacoub, Hafiz
Khan, Shahanara Islam, Khosro Farhad,
Peter Michas-Martin, Bilal Saulat, Rania
Aboualenein, Nizar Souayah
P06.056 Guillain-Barre Syndrome
after GARDASIL Vaccination in the United
States. A Report from the CDC/FDA
Vaccine Adverse Event Reporting System.
(2006–2009) Peter Michas-Martin,
Hafiz Kahn, Shahanara Islam, Rania Abou
Elenein, Khosro Farhad, Bilal Saulat, Nizar
Souayah
P06.057 Acute Motor Conduction
Block Neuropathy (AMCBN): Review of
11Cases Julien Gallard, Shahram Attarian,
Francoise Bouhour, Stephane Mathis,
Emilien Delmont, Yon Andoni Echaniz
Laguna, Karine Viala, Jean Pouget
P06.058 Anti-Ganglioside Antibodies
in Guillain-Barré Syndrome Patient Sera
Activate Small GTPase RhoA Gang
Zhang, Sowmia Manoharan, Kazim Sheikh
P06.059 Preciding Infections, the
Spectrum of Morbidity and Outcome of
Guillain-Barré Syndrome in the Intensive
Care Unit David Dolezil, Pavel Adam
P06.060 Case of Recurrent
Guillain-Barré Syndrome with Three
Episodes David Dolezil, Libor Svoboda,
Tomaš Peisker, Eva Medová, Pavel Adam,
Radim Mazanec
Peripheral Nerve: Chronic
Relapsing Neuropathies
P06.061 Rituximab in
Polyneuropathies with Anti-MAG
Antibodies: Efficacy, Tolerance, and
Predictive Factors of Response to
Treatment Claude Desnuelle, Pierre-Yves
Jeandel, Charles Benaïm, Jean Gabriel
Fuzibet, Emilien Delmont
P06.062 Cauda Equina Hypertrophy
with Abundant Onion Bulb Formation
Presenting as a Lower Motor Neuron
Syndrome Erin O’Ferrall, Daniel Gendron,
Marie-Christine Guiot, Michael Sinnreich
P06.063 Chronic Inflammatory
Demyelinating Polyneuropathy Disease
Activity Status (CDAS): Recommendations
for Clinical Research Standards Kenneth
Gorson, Ivo Van Schaik, Ingemar Merkies,
Richard Lewis, Richard Barohn, Carol Koski,
David Cornblath, Richard Hughes, Angelika
Hahn
P06.064 A Randomized Controlled
Trial Comparing Two Different
IV Immunoglobulins in CIDP (CICStudy) Krista Kuitwaard, Leonard van den
Berg, Marinus Vermeulen, Esther Brusse,
Elisabeth Cats, Anneke van der Kooi,
Nicolette Notermans, W.-Ludo van der Pol,
Ivo van Schaik, Sonja van Nes, Wim Hop,
Pieter van Doorn
P06.065 “Real World” Use of IVIg in
CIDP: Assessment of Utilization Across
the Scope of Practice Jonathan Katz,
David Saperstein, Tahseen Mozaffar,
Michelle Greer
P06.066 Proteonomic Analysis
of Amyloid-Like IgM Neuropathy in
Waldenstrom’s Macroglobulinemia Juan
Figueroa, P. James B. Dyck, Ahmet Dogan,
Christopher Klein
P06.067 Increased Frequency of
HLA-DRB1*15 in Patients with Multifocal
Motor Neuropathy Leonard Van den Berg,
Nadia Sutedja, Elisabeth Cats, Sanne
Piepers, Ludo Van der Pol
P06.068 Autonomic Dysfunction in
Chronic Inflammatory Demyelinating
Polyradiculoneuropathy Juan Figueroa, P.
James B. Dyck, Phillip Low
P06.069 Non-Myeloblative
Autologous Hematopoietic Stem Cell
Transplantation for Chronic Inflammatory
Demyelinating Neuropathy (CIDP)
Treatment Amilton Barreira, Wilson
Junior, Jean Ramos, Doralina Brum, AnaBeatriz Stracieri, Maria-Carolina Oliveira,
Daniela Moraes, Dannielle Godoi, Júlio
Voltarelli
P06.070 Interest of Intensive
Intravenous Immunoglobulins (IVIG)
Regimen in CIDP Partially IVIg
Responders Pierre Lozeron, Marie
Théaudin-Saliou, Catherine Lacroix, David
Adams
97
Poster Session VI
Peripheral Nerve: Focal and
Multifocal Neuropathies
P06.071 Clinical Characteristics
and Potential Therapeutic Implications
of Inflammatory Pseudotumor of
Nerve Michelle Mauermann, Bernd
Scheithauer, Robert Spinner, Kimberly
Amrami, David Kline, Robert Tiel, Peter
Dyck, Christopher Nance, JaNean
Engelstad, P. James B. Dyck
P06.072 Inflammatory Post-Surgical
Neuropathy Nathan Staff, JaNean
Engelstad, Peter Dyck, P. James B. Dyck
P06.073 Anterior Interosseous Nerve
Syndrome Following Procedures Thomas
Brennan, Edward Cupler
P06.074 Phrenic Nerve Pacemaker for
Isolated Diaphragmatic Palsy in Neuralgic
Amyotrophy Xinrong Lu, Ghazala Hayat,
Diana Balsalobre, Peter Ward, Kenneth
Smith
P06.075 Phrenic Neuropathies:
A Clinical and Electrodiagnostic
Study Simon Podnar
P06.076 The Timing and Distribution
of Triggers among 268 Bouts of Neuralgic
Amyotrophy Mark Ferrante
P06.077 “Hold Your Arms High”
Traction Lesions of the Brachial Plexus in
Bodyflying Walter Haupt, Amande Pauls,
Norbert Galldiks
P06.078 High-Dose Intravenous
Steroids in Definite or Suspected ImmuneMediated Neuropathies Eduardo NobileOrazio, Francesca Gallia, Fabrizia Terenghi
P06.079 Predictors of Positive Nerve
Biopsies in Presumed Vasculitis Christina
Fournier, Stephanie Scala, Jayashri
Srinivasan
P06.080 Hereditary Neuropathy with
Pressure Palsies: Analysis of 24 De Novo
Unrelated Cases Christopher Scheiner,
Anthony Amato, Matthew Wicklund
Neuroepidemiology/Health
Services and Outcomes
Research: Peripheral Nervous
System
P06.081 Disparities in the Diagnosis
of Duchenne and Becker Muscular
Dystrophy: Data from the MDSTARnet,
1999–2007 Christopher Cunniff, Jennifer
Andrews, Emma Ciafaloni, Deborah Fox,
Caleb Holtzer, Zhenqiang Lu, Lisa Miller,
John Meaney
P06.082 Respiratory Care Trends
for Duchenne and Becker Muscular
Dystrophies (DBMD): Data From the MD
STARnet, 2001–2007 Daniel Mandel,
Daniel Sheehan, Shree Pandya, Christina
Westfield, Deborah Fox, Sarah Nabukera,
Katherine Mathews, Christopher Cunniff,
Carolyn Constantin, David Birnkrant
P06.083 Clinical and
Electrophysiological Features in 58
Chilean Children with Guillain-Barré
Syndrome Claudia Castiglioni, Alejandra
Diaz, Maria Beytia, Lorena Pizarro, Eliana
Rodillo
98
P06.084 Impact of Botulinum Toxin
Type A (BoNTA) on Health Utility in
Patients Receiving Treatment for
Approved Therapeutic Indications: Interim
Analysis of a Large Ongoing Phase IV
Prospective Observational Cohort Study
(MDs on BOTOX® Utility-Mobility) in
Canada Theodore Wein, Mandar Jog,
Richard Beauchamp, Robert Miller, Meetu
Bhogal, Susan Simonyi
P06.085 Evaluation of Quality of Life
in Korean Charcot-Marie-Tooth Disease
Patients Hye Yang, Jisoo Shin, Byung-Ok
Choi
P06.086 Caregiving Parents of
Children with Neuromuscular Conditions:
Experiences of Stress and Personal
Growth Susan Cadell, Lynn Straatman
P06.087 Baseline Characteristics of
Patients Receiving Botulinum Toxin Type
A for Approved Therapeutic Indications
in a Large Ongoing Phase IV Prospective
Observational Cohort Study (MDs
on BOTOX® UTILITY— MOBILITY) in
Canada Theodore Wein, Mandar Jog,
Richard Beauchamp, Robert Miller, Meetu
Bhogal, Susan Simonyi
P06.088 Edge Motion Technology
To Detect Abnormalities of Gait and
Balance William Bauer, John Tsotsos,
Evgueni Simine, Steven Benedict, Brendan
Bauer, Daniel Lynch, Frank Bunn
P06.089 Dual-Task Related Gait
Changes and Risk of Falls: A Systematic
Review Olivier Beauchet, Cédric
Annweiler, Gilles Allali, Frederic Assal,
François Herrmann
Neuro-oncology: Primary and
Metastatic Tumors
P06.090 Incidence of Central
Nervous System Tumors in Two Different
Populations from Argentina Ignacio
Casas-Parera, Mario Melcom, Manuel
Fernández Pardal, Mariana Báez, Alejandra
Báez, Juan Martín Cardozo Oliver, Erica
Rojas Bilbao, Carlos Rugilo, Inés Tamer,
Mario Halfon, Liliana Giménez, Cecilia
Sánchez Retamal, Inés Aparisi, Verónica
Baró, Mariel Bonaldo , René Boudot,
Carlos Cabrera, Laura Clement, Mariano
Díaz Java, Gustavo Di Rienzo, Marcelo
Fellner, Fabiana Gandolfi, Cristina Giménez,
Emilio Girardet, Aurora Grassi, Susana
Ibáñez, Patricio Labal, Lorena Maraviglia,
Carlos Lozano, Oscar Moreno , Mónica
Moro, Graciela Oyarzo, Liliana Pérez, Ana
Prieto, Eugenia Romero, Gastón Ruston,
Hugo Solaligue, Pedro Villavicencio, Vivian
Colombo, María Esther Domínguez, Laura
Escur, Juan Gutiérrez, Silvia Hid, Pedro
Ordoqui, Fernando Rodríguez Forgués ,
Néstor Torres
P06.091 Pattern of Pediatric
Brain Tumors in Province of
Egypt, a Multidisciplinary Team
Experience Hassan Salama, Hatem Badr,
Mohammed Mansour, Ashraf Ezzeldeen,
Hosam Maaty
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P06.092 Hemangiopericytoma
Affecting the Central Nervous
System Christian Grommes, Maame
Dankwah, Phillip Gutin, Mark Bilsky, Jason
Huse, Thomas Kaley, Marc Rosenblum,
Lauren Abrey, Antonio Omuro
P06.093 Esthesioneuroblastoma:
Clinical and Survival Analysis at a Single
Institution in Argentina Macarena de la
Fuente, Ricardo Marengo, Martin Nogues,
Blanca Diez, Naomi Arakaki, Alejandro
Muggeri
P06.094 Glioblastoma Multiforme,
Adenoid-Type with Melanocytic
Differentiation Erica Rojas-Bilbao, Juan
Cardozo-Oliver, Ignacio Casas-Parera
P06.095 Brain Metastases from
Melanoma: Implications for Future
Studies Samuel Goldlust, Andrew
Lassman, Lindsay Jacks, Lisa DeAngelis,
Edward Avila
P06.096 A Retrospective Study of
Central Nervous System Metastases
in Esophageal Cancer Shivani Patel,
Jennifer Serventi, Nimish Mohile
P06.097 Incidence of Cerebral
Metastasis: A Population-Based Study in
an Island Community Agust Hilmarsson,
Olafur Kjartansson, Helgi Isaksson,
Aron Bjornsson, Jon Hrafnkelsson, Elias
Olafsson
P06.098 Upfront Association of
Carboplatin and Pemetrexed in Patients
with Brain Metastasis of a Non Small
Cell Lung Cancer Olivier Bailon, Kader
Chouahnia, Alexandre Augier, Iríne Coman,
Catherine Belin, Sophie Bouvier, Laurent
Zelek, Jean-François Morere, Antoine
Carpentier
P06.099 Bevacizumab as Treatment
for Brain Metastasis of Lung Cancer Rima
El-Abassi, Ivo Tremont-Lukats
Neuro-oncology: Neurologic
Complications of Cancer
P06.100 Leptomeningeal
Plasmacytosis as an Early Manifestation
of Waldenstrom’s Macroglobulinemia—A
Case Report Brian Scott, Vishal Patel,
Matthew Tilem, Rabinowitz Arthur
P06.101 Richter’s Syndrome of the
Spinal Cord Tracey Graves, Graham
Collins, Christian Hatton, Allyson Parry
P06.102 Cranial Nerve Neuropathy as
Initial Presentation of Recurrent Multiple
Myeloma Rima El-Abassi, Ivo TremontLukats
P06.103 A Unique Case of
Hyperviscosity Syndrome in a Patient with
Chronic Lymphocytic Leukemia Treated
with Rituximab Fazeel Siddiqui, Brajesh
Agrawal, Harirama Acharya, Rodger Elble
P06.104 Acute Obstructive
Hydrocephallus in Griscelli
Syndrome Logan McDaneld, Thomas Koch
P06.105 A Case of Intracranial Plasma
Cell Granuloma Presenting as a Mass
Lesion Preeti Puntambekar, Sunitha
Santhakumar, Sandeep Mittal, William
Kupsky, Alexandros Tselis
P06.106 Subdural Hematoma in
Cancer Patients Samuel Singer, Jordan
Reichman, Babak Navi, Alan Segal, Lisa
DeAngelis
P06.107 Orofacial Dyskinesia:
A Possible Paraneoplasic
Disoder? Ruxandra Costa, Stephen
Gancher, Jennifer Lycette, Vanda Lennon
P06.108 Previous Biopsy History
and Histopathological Outcome Affect
Cognition and Quality of Life Following
Breast Biopsy Bruno Giordani, Janet
Osuch, Christina Cusumano, Stephanie
Smith, Pam Haan, Ravi Khattree, Laura
Symonds, Wei Xue, Adrian Blow, Michael
Boivin
P06.109 Coagulation State and
Carotid Profile Assessment as a
Cerebrovascular Complication in Central
Nervous System Tumor Tiara Aninditha,
Mursyid Bustami, Teguh Ranakusuma
P06.110 Gemcitabine-Induced
Myopathy Elena Pentsova, Anli Liu, Adilia
Hormigo, Xi Chen
Neurologic Manifestations of
Systemic Disease II
P06.111 Voltage Gated Potassium
Channel Antibody Negative
Neuromyotonia and Optic Neuritis
Associated with Hodgkin Lymphoma:
Paraneoplastic Neuromyotonia
Plus Andrew Solomon, Michael Kruer,
Crystal Fo, Alexander Landfield, Barry
Oken, Dennis Bourdette
P06.112 A Case of Mistaken Identity:
Anti-NMDA Receptor Encephalitis in a
Young Woman JingTian Wang, Jay Desai,
May Kim
P06.113 Steroid Responsive
Encephalopathy Associated with
Vestibular Symptoms and Sleep
Disorders: Clinical, PSG, MSLT, ENG, CSF,
and Brain MRI Correlates Bibhutibhushan
Mishra, Leah Gaedeke, Richard Amdur,
Leslie Williams, James Bicksel, Bernhard
Samuel
P06.114 Brain and Spinal Cord
Infarction Secondary to Giant Cell
Arteritis (GCA) after Intrathecal
Ziconotide Melissa Cortez, L. DeWitt,
Mark Bromberg
P06.115 Rare Neurological
Complications Associated with
Intravenous Immunoglobulin
Infusion Obinna Moneme, Andrew Slivka,
William Arnold, Bakri Elsheikh
P06.116 Striational Antibodies in a
Paraneoplastic Context: A Case-Control
Study Andrew McKeon, Sean Pittock,
Vanda Lennon
Poster Session VI
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P06.117 Cerebrotendinous
Xanthomatosis: Clinical Manifestations in
Long-Term Follow-Up Aad Verrips, Tijmen
Balvers
P06.130 Hypoglycemic
Encephalopathy with Normal Brain
MRI Munish Goyal, Gyanendra Kumar,
Niranjan Singh
P06.118 Cognitive Impairment
in Moderate Chronic Kidney Disease
Compared with Hemodialysis Patients: A
Pilot Study Anne Murray, Ali Kolste, Sarah
Pederson, David Zaun
Multiple Sclerosis and Related
Diseases: Clinical Trials
P06.119 Summary of Cardiac Safety
from a Randomized, Placebo-Controlled,
Trial of Dextromethorphan/Quinidine
(STAR) for Treatment of Pseudobulbar
Affect Randall Kaye, Craig Pratt
P06.120 Cognitive Dysfunctions in
Primary Sjögren Syndrome Frederic Blanc,
Nadine Longato, Catherine Kleitz, Barbara
Jung, Laure Di Bitonto, Nadjette Cremel,
Christelle Sordet, Marie Fleury, Jean
Sibilia, Jerome de Seze
P06.121 Auto Immune Encephalitis:
Clinical, Radiological and Immunological
Data Jérôme Aupy, Nicolas Collongues,
Benjamin Cretin, Frederic Blanc, MarieCéline Fleury, Patrice Bourgin, Edouard
Hirsh, Jérôme De Seze
P06.122 Peripheral and Central
Nervous System (PNS and CNS)
Involvement in the Primary Carnitine
Deficiency of Adult Jin Luo, Yitao Ma,
Douglas Laske, Daniel Brown
P06.123 Celiac Disease Presenting
as a Disabling Myopathy Without
Gastrointestinal Symptoms Charlene
Hoffman Snyder, Mark Ross
P06.124 Idiopathic Intracranial
Hypertension Treatment Trial Michael
Wall, Mark Kupersmith, James Corbett,
Karl Kieburtz, Michael McDermott,
Deborah Friedman, Steven Feldon, John
Keltner
P06.125 Auto-Immune Encephalitis
and Striatal Hypermetabolism Frederique
Fluchere, Alexandre Eusebio, Emmanuelle
Bernit, Elsa Kaphan, Eric Guedj, JeanPhilippe Azulay
P06.126 Hashimoto’s Encephalopathy
and Idiopathic Thrombocytopenic
Purpura Rohit Marawar, Huijun Wang,
Barbara Changizi
P06.127 Mononeuritis Multiplex
as Result of Acute Hepatitis B-Related
Vasculitis Mihaela Hangan, Jin Li
P06.128 Safety and Tolerability
of Dextromethorphan/Quinidine for
Pseudobulbar Affect in a 12-Week,
Open-Label Extension Study Erik Pioro,
Benjamin Brooks, Jeffrey Cummings,
Randolph Schiffer, Daniel Wynn, Adrian
Hepner, Randall Kaye, on Behalf of the
STAR Trial Investigators
P06.129 Proton Magnetic
Resonance Spectroscopy (1)H-MRS as
a Tool in Neuroimmunological Disease
Monitoring Simona Pontecorvo, Emanuele
Tinelli, Manuela Morreale, Maria
esmeralda Quartuccio, Massimiliano
Prencipe, Ada Francia
P06.131 Efficacy and Safety of
Weekly Intramuscular Interferon Beta-1a
in Patients More Than 50 Years of
Age Christian Lampl, Regine Buffels,
Wolfgang Mair, Xiaojun You, Volker
Limmroth
P06.132 Nocebo Responses in
Disease-Modifying and Symptomatic
Treatment Trials for Multiple Sclerosis: A
Systematic Review Dimos Mitsikostas,
Dimitrios Papadopoulos
P06.133 Natalizumab Is Effective in
RRMS Patients Who Do Not Respond
to Sequential Therapy with Interferon
beta and Glatiramer Acetate: Result
of a Switching Study Anza Memon,
Christina Caon, Jai Perumal, Aaron Boster,
Alexandros Tselis, Stephanie Hreha, Fen
Bao, Omar Khan
P06.138 Short-Term
Immunosuppression with Mitoxantrone
Followed by Long-Term Glatiramer
Acetate vs Glatiramer Acetate Alone:
Results at 60 Months in Patients with
Relapsing Multiple Sclerosis Timothy
Vollmer, Amit Bar-Or, Denise Campagnolo,
Hillel Panitch, Douglas Arnold
P06.139 Surgical Procedures for
Medically Intractable Multiple Sclerosis
Associated Trigeminal Neuralgia Karen
Truitt, Mark Keegan, James Watson, John
Atkinson
P06.140 Frequency of Mitoxantrone
Related Heart Involvement in Patients
Affected by Multiple Sclerosis Giovanni
Savettieri, Paolo Aridon, Marco D’Amelio,
Maria Antonietta Mazzola, Sabrina
Realmuto, Leila Zummo, Giuseppe Salemi,
Paolo Ragonese
P06.141 Immunogenicity of PEGylated
Interferon Beta-1a: Data from Preclinical
and Phase I Clinical Studies Darren Baker,
Michaela Lerner, Meena Subramanyam,
Gudarz Davar, Susan Goelz, Miranda van
Beers, Huub Schellekens
P06.134 Phase II Double-Blind
Controlled Clinical Trial with T-Cell
Vaccination in Multiple Sclerosis Rivka
Abulafia-Lapid, Massimo Filippi, Panayiota
Petrou, Adi Vaknin-Dembinsky, Michal
Mor, Oded Abramsky, Henry Atlan,
Dimitrios Karussis
P06.142 Evaluation of Natalizumab
for the Relief of Multiple Sclerosis
Associated Fatigue: The ENER-G
Study Jeffrey Wilken, Robert Kane,
Cynthia Sullivan, Mark Gudesblatt, Sylvia
Lucas, Robert Fallis, Amy Pace, Richard
Kim
P06.135 Cancer Risk among Patients
with Multiple Sclerosis During the
Treatment Era: The CARIMS Study
Update Christine Lebrun Frenay, Marc
Debouverie, David Brassat, Patrick
Vermersch, Gilles Defer, Jerome De Seze,
Pierre Clavelou, Olivier Heinzlef, Lucien
Rumbach, Sandrine Wiertlevski, Patricia
Tourniaire, Frederic Berthier
P06.143 Immunotherapy After
Discontinuation of Natalizumab in
Relapsing Multiple Sclerosis Neeta Garg,
Kevin Kane
P06.136 Response to Treatment with
Sustained Release Fampridine in Patients
with Multiple Sclerosis Is Independent
of Baseline Patient Characteristics
and Concomitant Immunomodulator
Therapy Theodore Brown, Randall
Schapiro, Keith Edwards, Andrew
Goodman, Lawrence Marinucci, Ron
Cohen, Andrew Blight, on Behalf of the
MS-F202, MS-F203, and MS-F204 Study
Groups
P06.137 Oral Fingolimod (FTY720)
Treatment Improves the Performance
of Daily Activities Compared with
Intramuscular Interferon β-1a: PatientReported Indices for Multiple Sclerosis
(PRIMUS)-Activities Results from a
Phase III Study (TRANSFORMS) Jeffrey
Cohen, Frederik Barkhof, Giancarlo Comi,
Hans-Peter Hartung, Ludwig Kappos,
Bhupendra Khatri, Xavier Montalban, Jean
Pelletier, Tracy Stites, Stacy Wu, James
Jin, Benjamin Eckert, on Behalf of the
TRANSFORMS Study Group
P06.144 Combined Transcranial and
Extracranial Venous Doppler Evaluation
(CTEVD Study). Description of the Design
and Interim Results of an Epidemiological
Study of the Prevalence of Chronic
Cerebrospinal Venous Insufficiency in MS
and Related Diseases Robert Zivadinov,
Karen Marr, Murali Ramanathan, Paolo
Zamboni, Ralph Benedict, Gary Cutter,
Cheryl Kennedy, Makki Elfadil, David
Hojnacki, Frederick Munschauer, Justine
Reuther, Christina Brooks, Kristin Hunt,
Michelle Andrews, Bianca WeinstockGuttman
P06.145 Adherence to DiseaseModifying Therapies in Patients with
Relapsing Multiple Sclerosis: Two-Year
Interim Results of the Global Adherence
Project Estefania Arroyo, Cecilia Grau,
Juan Parra, Olga Sanchez Solino
P06.146 Utilization and Safety of
Intramuscular Interferon Beta-1a in the
Postmarketing Setting Pamela Foulds,
Sandra Richman, Susan Friend
P06.147 Effects of Glucosamine
Sulfate on Multiple Sclerosis Progression:
A Randomized, Placebo-Controlled
Trial Vahid Shaygannejad, Fereshteh
Ashtari, Mohsen Janghorbani
P06.148 Objective and Subjective
Efficacy of Natalizumab on Disability
and Fatigue in Relapsing Remitting
(RR) and Relapsing Progressive (RP)
Multiple Sclerosis (MS) over a Two Year
Period Ioannis Doumos, Vassiliki Kotsi,
Elissaios Karageorgiou, Dimitrios Tzortzis,
Moira Tzitzika, Panagiota Karanasou,
Christos Giannoulis, Helen Papageorgiou,
Sofia Tsiara, Clementine Karageorgiou
P06.149 Baseline Characteristics
of Patients in the DEFINE Trial: A
Randomized, Multicenter, Double-Blind,
Placebo-Controlled, Randomized, Phase
III Study of BG-12 in Relapsing-Remitting
Multiple Sclerosis Ralf Gold, Douglas
Arnold, Ludwig Kappos, Amit Bar-Or, Gavin
Giovannoni, Krzysztof Selmaj, Minhua
Yang, Katherine Dawson
P06.150 ReaLiNat Study: A European
Multicenter Study Investigating
Benefits and Risks of Natalizumab in
Real Life Joerg Kraus, Bruno Brochet,
Uwe Zettl, Thomas Berger, Sebastian
Humpert, Martin Marziniak, Wolfgang
Kristoferitsch, Peter Schnabl, Franz
Aichner, Hayrettin Tumani, Marcus Müller,
Peter Wipfler, Julian Zimmermann, Irina
Sapunova-Mayer, Hamid Assar , Joerg
Weber, Helmut Rauschka, Lydia Bernhardt,
Cristina Vouga, Gabriele Gillwaldt, Gunther
Ladurner
P06.151 Discontinuing DiseaseModifying Therapy in Progressive
Multiple Sclerosis— Can We Stop What
We Have Started? Roisin Lonergan,
Katie Kinsella, Marguerite Duggan,
Sinead Jordan, David Bradley, Michael
Hutchinson, Niall Tubridy
P06.152 Comparison of Adherence
and Persistence Associated with FirstLine Disease-Modifying Therapies Among
Patients with Multiple Sclerosis Rachel
Halpern, Sonalee Agarwal, Leigh Borton,
Tomislav Babic
P06.153 Factors Related to Adherence
in Spanish Patients with MS: Two Year
Results of the GAP Study Juan Parra,
Cecilia Grau, Estefania Arroyo, Olga
Sanchez Solino
P06.154 Baseline Characteristics
of a Subpopulation of Indian Patients
Enrolled in Two Phase Three Trials for Oral
BG-12 in Relapsing-Remitting Multiple
Sclerosis Madhuri Behari, Meena
Kanikannan, Pahari Ghosh, Ralf Gold,
Robert Fox, Douglas Arnold, David Miller,
Minhua Yang, Katherine Dawson
P06.155 Clinical Efficacy of
Natalizumab and Immunological Effects
in Progressive MS Patients with High
Degrees of Disability Dimitrios Karussis,
Oded Ambramsky, Panayiota Petrou, Tamir
Ben Hur, Adi Vaknin-Dembinsky
P06.156 Real-World Assessment of
Adherence and Persistence to SecondLine Disease-Modifying Therapies Among
Multiple Sclerosis Patients Rachel
Halpern, Sonalee Agarwal, Leigh Borton,
Tomislav Babic
99
Poster Session VI
P06.157 GERONIMUS Study:
Progression Rates to Multiple Sclerosis
According to McDonald and Poser
Criteria in Patients with Clinically Isolated
Syndrome. On Behalf of the GERONIMUS
Study Group Roberto D’Alessandro
P06.158 Baseline Characteristics
of Patients Enrolled in a Randomized,
Multicenter, Placebo-Controlled and Active
Comparator Trial Evaluating Efficacy and
Safety of BG-12 in Relapsing-Remitting
Multiple Sclerosis: The CONFIRM
Trial Robert Fox, David Miller, Ted Phillips,
Mariko Kita, Michael Hutchinson, Eva
Havrdova, Minhua Yang, Katherine Dawson
P06.159 Efficacy of Short Courses
of Parenteral Cladribine in Patients with
Aggressive Multiple Sclerosis Elizabeth
Hartman, Rebecca Romero, Dusan Stefoski,
Roumen Balabanov, Adil Javed
P06.160 High Dose Cyclophosphamide
Treatment in Marburg Variant of Multiple
Sclerosis (MS): A Case Report Kenkichi
Nozaki, Nada Abou Fayssal
P06.161 Impact of Intramuscular
Interferon Beta-1a on Multiple Sclerosis
Disease Severity: Analysis of Patients from
the MSCRG and ASSURANCE Studies
Using the Multiple Sclerosis Severity
Scale Joseph Herbert, Bianca WeinstockGuttman, Pamela Foulds, Xiaojun You
P06.162 Characteristics of Switching
From Interferon beta to Glatiramer Acetate
in Non- Respondent- Relapsing Remitting
Multiple Sclerosis Celia Oreja-Guevara,
Pedro Bermejo-Velasco, Ambrosio Miralles,
Exuperio Diez-Tejedor
P06.163 Four Cases of Co-Morbid
Multiple Sclerosis and Psoriasis: Sustained
Remission of Both Conditions While on
Natalizumab Regina Berkovich
P06.164 Exploring Alemtuzumab’s
Long Term Efficacy and Safety:
Design of the CARE-MS Extension
Study Christopher LaGanke, N. A. on
Behalf of the CAMMS Study Groups
P06.165 Efficacy of Natalizumab in
a French Cohort of Multiple Sclerosis
Patients Olivier Outteryck, Jean-Claude
Ongagna, Hélíne Zéphir, M.-C. Fleury,
Arnaud Lacour, Frédéric Blanc, Patrick
Vermersch, Jérome de Síze
P06.166 Central Demyelination
Complicating the Use of Anti-TNFα in the
Treatment of Inflammatory Bowel Disease
(IBD): A Retrospective Study Carolina
Ionete, Valentine Ebuh, Anupam Singh,
Kevin Kane, Jane Lavallee, Peter Riskind,
John Zawacki
P06.167 Improvement in PatientReported Fatigue and Cognitive
Function over Time with Natalizumab
Treatment Judith Stephenson, Sonalee
Agarwal, Likun Hou, Siddhesh Kamat,
Krithika Rajagopalan
P06.168 Motherhood and
Natalizumab—Effects of Natalizumab
Therapy on Pregnancy Outcome and
Disease Activity during Pregnancy Kerstin
Hellwig, Aiden Haghikia, Ralf Gold
100
P06.169 Dosing of Rituximab in
Demyelinating Disease: How Much Is
Enough? Benjamin Greenberg, Donna
Graves, Jason Silversteen, Gina Remington,
Elliot Frohman
P06.170 Oral Fingolimod (FTY720)
Reduces the Rate of Relapses That Require
Steroid Intervention or Hospitalization
Compared with Intramuscular
Interferon β-1a: Results from a Phase
III Study (TRANSFORMS) in Multiple
Sclerosis Bhupendra Khatri, Frederik
Barkhof, Giancarlo Comi, Hans-Peter
Hartung, Ludwig Kappos, Xavier Montalban,
Jean Pelletier, Tracy Stites, Stacy Wu,
Benjamin Eckert, Jeffrey Cohen, on Behalf
of the TRANSFORMS Study Group
Multiple Sclerosis and Related
Diseases: Clinical Trials and
Clinical Research
P06.171 Oral Fingolimod (FTY720) vs
Placebo in Relapsing-Remitting Multiple
Sclerosis: 24-Month Safety and Tolerability
Results from a Randomized, Double-Blind,
Placebo-Controlled, Multicenter Phase
III Study (FREEDOMS) Paul O’Connor,
Chris Polman, Reinhard Hohlfeld, ErnstWilhelm Radue, Peter Calabresi, Krzysztof
Selmaj, Lixin Zhang-Auberson, Catherine
Agoropoulou, Malgorzata Leyk, Ludwig
Kappos, on Behalf of the FREEDOMS Study
Group
P06.172 Leukocyte Dynamics
Following Alemtuzumab Treatment of
Relapsing-Remitting Multiple Sclerosis in
a Phase II Study (CAMMS223) Alasdair
Coles, N. A. on Behalf of the CAMMS223
Study Group
P06.173 Efficacy and Safety of
Natalizumab in the STRATA Study Chris
Polman, Andrew Goodman, Ludwig Kappos,
Fred Lublin, Paul O’Connor, Richard Rudick,
Stephanie Jurgensen, Dominick Paes, Fiona
Forrestal, Christophe Hotermans
P06.174 Simvastatin Treatment
Favours the Long-Term Outcome of
Patients with ON Anna Tsakiri, Benedikte
Wanscher, Jette Frederiksen
P06.175 Efficacy of Natalizumab After
Insufficient Response to Other DiseaseModifying Therapies for the Treatment
of Relapsing- Remitting Multiple
Sclerosis Norman Putzki
P06.176 Natalizumab Treatment
for Multiple Sclerosis in Clinical
Practice Dinah Thyerlei, Lynda Hillman,
Valerie Woolvett, Dora Krasucki, Annette
Wundes
P06.177 Use of Glatiramer Acetate
During Pregnancy: Offering Women a
Choice Aaron Miller, Jennifer Reardon
P06.178 Immunological Response
to Glatiramer Acetate in MS Patients
after Different Pretreatments—The
CopImmunoNet Study Nina Kleiner, Tjalf
Ziemssen
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P06.179 Development and
First Evaluation of the New Patient
Management and Documentation System
MSDS 3D for Patients with Multiple
Sclerosis Tjalf Ziemssen, Fabian Kratzsch,
Marco Eulitz, Raimar Kempcke, Nina Kleiner
P06.190 Diffusion Tensor Imaging
Reveals Differences in Normal Appearing
Corpus Callosum in Childhood Onset
Multiple Sclerosis and Monophasic
Demyelinating Events Jan-Mendelt
Tillema, Istvan Pirko
P06.180 Intellectual Enrichment
Lessens the Negative Impact of Brain
Atrophy on Cognition in Multiple
Sclerosis James Sumowski, Glenn Wylie,
Nancy Chiaravalloti, John DeLuca
P06.191 White Holes and Their Impact
on Physical Disability in Patients with
Multiple Sclerosis Francesca Bagnato,
Vasiliki Ikonomidou, Peter van Gelderen,
Sungyoung Auh, Marco Riva, Fernanda
Tovar-Moll, Nancy Richert, Joan Ohayon,
Fredric Cantor, Jeffrey Duyn, Henry
McFarland
P06.181 Multiple Sclerosis (MS) and
Pregnancy: A Comparison Study Dessa
Sadovnick, Magdalena Dybalski, Colleen
Guimond, Irene Yee, Pierre Duquette
Multiple Sclerosis and Related
Diseases: Clinical Immunology
P06.182 Inflammatory Cytokines and
Chemokines in the Cerebrospinal Fluid
of Multiple Sclerosis Patients Following
Administration of Natalizumab Aaron
Kithcart, Amy Lovett-Racke, Olaf Stüve,
Nancy Monsoon, Caroline Whitacre,
Michael Racke
P06.183 PI3Kγ: A Sex-Specific and
Novel Therapeutic Target in the Treatment
of CNS Autoimmune Injury NaTosha
Gatson, Hong Ji, Christian Rommel,
Caroline Whitacre
P06.184 Anti-Inflammatory and
Pro-Metabolic Effects of BG-12 in Glial
Cells Douglas Feinstein, Paul Polak, Lucia
Lisa, Cinzia Dello Russo, Shao Xia Lin,
Anthony Sharp
Multiple Sclerosis and Related
Diseases: Disease Prediction and
Diagnosis
P06.185 On Prediction Power
of MRI for Future Development of
Relapsing Remitting Form of Multiple
Sclerosis Manuela Vaneckova, Jan
Krasensky, Eva Havrdova, Dana Horakova,
Zdenek Seidl
P06.186 Relapsing Tumefactive
Lesions Are Associated with a
More Aggressive Course of Multiple
Sclerosis Sibyl Wray, Adil Javed, Bruce
Hughes
P06.187 Diffusion Tensor Imaging as a
Clinical Trial Outcome Metric: Sample Size
Estimates Robert Fox, Ken Sakaie, Jian
Lin, Thomas Cronin, Mark Lowe, Michael
Phillips, Xiao-feng Wang
P06.188 Memory Impairment in MS
Correlates to Hemodynamic Response
in Event-Related fMRI of Episodic
Memory Lael Stone, Katherine Koenig,
Blessy Mathew, Stephen Rao, Robert
Bermel, Micheal Phillips, Mark Lowe
P06.189 Early MS Activity on
Subtraction MRI Predicts Lesion Accrual
and Atrophy over Five Years Maria Liguori,
Dominik Meier, Peter Hildenbrand, Brian
Healy, Bastian Moraal, Rohit Bakshi, Tanuja
Chitnis, Frederik Barkhof, Charles Guttmann
P06.192 MRI-Only Conversion
to MS Following a Clinically Isolated
Syndrome Declan Chard, Catherine Dalton,
Josephine Swanton, Leonora Fisniku,
Katherine Miszkiel, Alan Thompson, Gordon
Plant, David Miller
P06.193 Post-Natalizumab Rebound: A
CNS Immune Reconstitution Inflammatory
Syndrome (CIRIS) Jai Perumal, Christina
Caon, Stephanie Hreha, Fen Bao, Megha
Shah, Zahid Latif, Imad Zak, Alexandros
Tselis, Omar Khan
P06.194 Diagnosing Multiple Sclerosis
from Conventional MR Images Using
Pattern Recognition Techniques Martin
Weygandt, Hackmack Kerstin, Caspar
Pfüller, Judith Bellmann-Strobel,
Friedemann Paul, Frauke Zipp, John-Dylan
Haynes
Multiple Sclerosis and Related
Diseases: Multiple Sclerosis
Differential Diagnosis
P06.195 Multiple Sclerosis and
Systemic Sarcoidosis: A Double
Diagnosis Aimee Szewka, Monica
McAndrews, Michael Ko, Dusan Stefoski,
Roumen Balabanov
P06.196 Cerbral Amyloid Angiitis:
Two Unique Case Presentations Rohit
Marawar, Kelly Donnelly, Earl Zimmerman,
Jiang Qian, Michael Gruenthal
P06.197 An Unusual Case of a Rapidly
Progressive Leucoencephalopathy Arjune
Sen, Prem Ranji, Ute Pohl, Abhijit Chaudhuri
P06.198 Development of
Neurosarcoidosis During Exposure to AntiTNF-Alpha Medications for Rheumatoid
Arthritis: Case Report Daniel Harrison,
Carlos Pardo-Villamizar, Justin McArthur
P06.199 Solitary Focal Demyelinating
Lesion as a Cause of Progressive
Myelopathy William Schmalstieg, Mark
Keegan, Brian Weinshenker
P06.200 Multiple Sclerosis in
a Patient with Duchenne Muscular
Dystrophy Adrienne Salomon, Negar
Sodeifi, Babak Movassaghi, David Libell
P06.201 Atypical Symptoms to ’Flag’
Non-Demyelinating Disease in Patients
with Suspected MS Siobhan Kelly, Elijah
Chaila, Niall Tubridy, Michael Hutchinson
Poster Session VI
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
First Authors Stand by Poster from 6:00 p.m.–7:30 p.m.
P06.202 Association of Parkinsonian
Syndrome with Multiple Sclerosis: A
Report of 27 Cases Valerie Jaillon-Riviere,
Karine Droulon, Jerome De Seze, Christine
Lebrun, Jean Pelletier, Patrick Vermersch,
Giovanni Castelnovo, Patrick Hautecoeur,
Olivier Heinzlef, Lucien Rumbach, Gilles
Defer
P06.203 Long-Term Intrathecal
Baclofen Therapy in Ambulatory Multiple
Sclerosis Patients James Stark, Armistead
Williams, Saud Sadiq
P06.204 Therapeutic Considerations
and Outcome of Steroid Refractory
Neurosarcoidosis: Five-Year Single Centre
Experience Sandipan Pati, Yazan Alderazi,
Roberto Bomprezzi, Aman Deep, Timothy
Vollmer
Multiple Sclerosis and Related
Diseases: EAE/Drugs
P06.205 Ingested (Oral) Somatostatin
(SST) Inhibits Acute EAE Staley Brod,
Zachary Hood
P06.206 Possible Neuroprotection
and Th17 Modulation by a Red Wine
Component, Resveratrol, in a Mouse
Model for Multiple Sclerosis, Theiler’s
Virus Infection Fumitaka Sato, John
Rose, Noel Carlson, Alireza Minagar, Ikuo
Tsunoda
P06.207 Detailed Analysis of CD52
Expression and Cellular Depletion/
Repopulation after Alemtuzumab
Treatment in HuCD52 Transgenic
Mice Michael Turner, Michael LaMorte,
Matthew Gale, Jacqueline Shields,
Johanne Kaplan, Bruce Roberts, William
Siders
P06.208 Axonal Protection Effect of
Laquinimod Appears Partially Independent
of Its Inhibitory Effect on Inflammation
and Demyelination in Experimental
Autoimmune Encephalomyelitis Christiane
Wegner, Christine Stadelmann, Emanuel
Raymond, Bracha Timan, Liat Hayardeny,
Wolfgang Brück
P06.209 Protection from CD8+ T
Cell-Mediated Experimental Autoimmune
Encephalomyelitis by CD28 Superagonistor Glatiramer Acetate-Stimulated CD4 + T
Cells Shin-Young Na, Niklas Beyersdorf,
Rainer Apfel, Thomas Kerkau, Thomas
Hünig
P06.210 Intrathecal Methotrexate
Reduces Astrogliosis in a Murine Model
of Experimental Demyelination Adam
Nassery, Xinhe Liu, Jesse Greenberg, Andre
Mueller, Saud Sadiq
P06.211 Effects of Acamprosate
(Acamp) in Experimental Autoimmune
Encephalomyelitis (EAE) Zohara Sternberg,
Raymond Sobel, Bing Zhu, Fredrick
Munschauer
P06.212 Oral Treatment with Purified
Polysaccharide A (PSA) of Human
Commensal Bacteroides fragilis Protects
Against Experimental CNS Demyelinating
Disease Javier Ochoa-Repáraz, Yan Wang,
Daniel Miecarz, Sakhina Begum-Haque,
Dennis Kasper, Lloyd Kasper
P06.222 Mouse Loci Influencing
Inflammatory Demyelinating Disease:
Shared Synteny Between Tmevd2/Eae3
and the MS Locus on Chr 1 Identified by
Admixture Mapping Chase Petersen,
Karren Spach, Elizabeth Blankenhorn,
William Hickey, Cory Teuscher
P06.213 Therapeutic Effects of Oral
Fingolimod (FTY720) in an Animal Model
of the Progressive Disability of Multiple
Sclerosis Andrew Pachner, Priyanka Apte,
Jennifer Brady, Libin Li
P06.223 Sustained Release Fampridine
Improves Walking Speed Across a Wide
Range of Baseline Deficits: Pooled Data
from Three Placebo-Controlled Studies
in Patients with Multiple Sclerosis Keith
Edwards, Theodore Brown, Randall
Schapiro, Andrew Goodman, Lawrence
Marinucci, Ron Cohen, Andrew Blight, on
Behalf of the MS-F202, MS-F203, and MSF204 Study Groups
P06.214 Effects of Glatiramer Acetate
on T Cells in the Mouse Model Xin Ding,
Rainer Apfel, Thomas Kerkau, Thomas
Hünig, Niklas Beyersdorf
Multiple Sclerosis and Related
Diseases: EAE/Drugs and
Disease Mechanisms and
Imaging and Genetics
P06.215 Beneficial Effect of
IgG Glycans Hydrolysis by EndoS
in Experimental Autoimmune
Encephalitis Mahdia Benkhoucha, MarieLaure Santiago-Raber, Martin Weber,
Mattias Collins, Patrice Lalive
P06.216 Alteration of Osteopontin
Cytokine Expression in Experimental
Autoimmune Encephalomyelitis by
Glatiramer Acetate Sakhina BegumHaque, Marc Christy, Eli Kasper, Islam
Fayed, Javier Ochoa-Reparaz, Daniel
Mielcarz, Jacqueline Smith, Azizul Haque,
Lloyd Kasper
P06.217 Lipoic Acid Confers
Neuroprotection in Experimental
Autoimmune Optic Neuritis Priya
Chaudhary, Gail Marracci, Xiaolin Yu,
Danielle Galipeau, Dennis Bourdette
P06.218 A Cyclophilin D Inhibitor
(Debio 025) Protects Axons in Experimental
Autoimmune Encephlomyelitis: A New
Therapeutic Target for Neuroprotecion in
Multiple Sclerosis Dennis Bourdette, Gail
Marracci, Priya Chaudhary, Jean-Maurice
Dumont, Grégoire Vuagniaux, Michael Forte
P06.219 Dietary Supplementation
with N-3 Polyunsaturated Fatty Acids
Restores Normal Emotional Behaviors
in Autoimmune-Prone BAFF Transgenic
Mice Rosalia Crupi, Linda Sparz, Edoardo
Spina, Fortunato Battaglia
P06.220 BAF312, a Potent and
Selective S1P1/5 Receptor Modulator
Reverses Ongoing Chronic EAE in
Mice Barbara Nuesslein-Hildesheim,
Frédéric Zécri, Christian Bruns, Nigel Cooke,
Timothy Seabrook, Paul Smith
P06.221 In Vivo Characterization
of the Therapeutic Effect of Glatiramer
Acetate in Experimental Autoimmune
Encephalomyelitis by Magnetic Resonance
Imaging (MRI) Rina Aharoni, Inbal Biton,
Ruth Arnon
P06.224 Does Benign Form of
Neuromyelitis Optica Exist? Nicolas
Collongues, Philippe Cabre, Romain
Marignier, Helene Zephir, Anne Caroline
Papeix, Bertrand Audoin, Christine
Lebrun Frenay, Bertrand Fontaine, Patrick
Vermersch, Christian Confavreux, Jerome
De Seze
Multiple Sclerosis and Related
Diseases: EAE Disease
Mechanisms
P06.225 Identifying Factors That
Determine Disease Susceptibility in
C57BL/6 Mice for Adoptive Transfer
of Experimental Autoimmune
Encephalomyelitis Tresa Zacharias, LiHong Ben, Petra Cravens, Sima Zein, Todd
Eagar, Rehana Hussain, Stefan Nessler,
Scott Zamvil, Olaf Stuve
P06.226 Central Motor Conduction
Failure Examined with the Triple
Stimulation Technique Correlates with
Pyramidal Tract Dysfunction and Disability
in Patients with Multiple Sclerosis Ulrich
Hofstadt-van Oy, Christoph Klawe, Dirk
Hagenburger, Reinhard Reuá, Patrick
Oschmann
P06.227 CMV Infection Modulates
the Disease Course of TMEV Induced
Demyelinating Disease in SJL/J
Mice Istvan Pirko, Rhonda Cardin, Yi Chen,
Anne Lohrey, Robert Zivadinov, Aaron
Johnson
P06.228 Cytochrome C Deficiency
Ameliorates Neurodegeneration in Animal
Models of Amyotrophic Lateral Sclerosis
and Multiple Sclerosis Andrew Chan,
Ulrich Schweizer, Bartosz Pula, Sabrina
Ruhrmann, Ralf Gold, Michael Sendtner,
Stefan Wiese, Aiden Haghikia
P06.229 Serum Phosphorylated
Neurofilament Heavy Chain Is a Marker
of Axonal Loss in Experimental Optic
Neuritis Tania Arguello, Gerry Shaw,
Vittorio Porciatti, Rajeshwari Koilkonda,
John Guy
P06.230 Mercury Increases
Th17 Polarization and Exacerbates
Experimental Autoimmune
Encephalomyelitis: Dependence on Matrix
Metalloproteinase-9 Scott Sloka, Claudia
Silva, Janet Wang, Yan Fan, Tiona Todoruk,
Luanne Metz, Wee Yong
P06.231 Etiology of Exaggerated Axon
Loss in MAGKO Mice with EAE: Activated
Microglia Laying in Wait? Melina Jones,
Thien Nguyen, John Griffin, Peter Calabresi
P06.232 Specific Regulation of CD4 T
Cells During Autoimmune Demyelination
by microRNA Marcin Mycko, Agnieszka
Machlanska, Maria Cichalewska,
Magdalena Marasiewicz, Bozena
Szymanska, Hanna Cwiklinska, Krzysztof
Selmaj
P06.233 Estrogen Dependent
Attenuation of EAE in a Transgenic Mouse
Expressing the RNA Regulator, HuR, in
Astrocytes Crystal Wheeler, Burt Nabors,
Scott Barnum, Xianzhen Hu, Trenton
Schoeb, Peter King
P06.234 Therapeutic Effects of
Lipoic Acid in Experimental Autoimmune
Encephalomyelitis Depend on Expression
of the Prostaglandin Receptor EP2 Gail
Marracci, Priya Chaudhary, Brooke Morris,
Sonemany Salinthone, Daniel Carr, Dennis
Bourdette
Aging and Dementia: Imaging
Connectivity
P06.235 Relationship between
Microstructural Degeneration of
the Corpus Callosum, White Matter
Hyperintensities, and Executive Function
in Cognitively Intact Elderly Lisa Silbert,
Louie Perkins, Jeffrey Kaye
P06.236 Aging and Gender Effects
on the Cortical Anatomical Network
Efficiency Gaolang Gong, Pedro RosaNeto, Felix Carbonell, John Chen, Yong He,
Alan Evans
P06.237 Distinct White Matter
Tract Changes in Frontotemporal
Dementia Associated with FTLD and
Alzheimer’s Disease Pathology or CSF
Biomarkers William Hu, Hui Zhang, Corey
McMillan, Virginia Lee, John Trojanowski,
Murray Grossman
P06.238 Structural Correlates of
Memory Performance with Diffusion
Tensor Imaging Efrat Sasson, Glen Doniger,
Ofer Pasternak, Ely Simon, Yaniv Assaf
P06.239 The Effect of Memantine
on the Activity of the Resting Working
Memory Network in Alzheimer’s
Disease D. Paternico’, M. Lorenzi, A.
Beltramello, E. Canu, G. Zoccatelli,
M. Cotelli, F. B. Pizzini, D. Costardi, F.
Alessandrini, S. Rosini, G. B. Frisoni
P06.240 Age Effect on Functional
Connectivity David Jones, Prashanthi
Vemuri, Mary Machulda, Kirk Welker,
Bradley Boeve, David Knopman, Ronald
Petersen, Clifford Jack
P06.241 White Matter Integrity
Accounts for Reaction Time in Older
Adults Geoffrey Kerchner, Caroline Racine,
Sandra Hale, Victor Laluz, Reva Wilheim,
Stephen Hauser, Bruce Miller, Joel Kramer
101
Poster Session VI
P06.242 Early and Late Onset
Alzheimer’s Disease Patients Have Distinct
Patterns of White Matter Damage Elisa
Canu, Federica Agosta, Michela Pievani,
Giovanni Frisoni, Massimo Filippi
P06.243 Evidence for Brain White
Matter Damage and Atrophy with Aging:
A Diffusion Tensor MRI Tractography
Study Federica Agosta, Stefania Sala,
Elisabetta Pagani, Domenico Caputo,
Massimo Filippi
P06.244 Regional Relation of Gray
Matter Atrophy with Corpus Callosum
Alteration in Normal, MCI, and AD Dong
Young Lee, Evan Fletcher, Oliver Martinez,
Natalia Zozulya, Jane Kim, Jeannie Tran,
Michael Buonocore, Owen Carmichael,
Charles DeCarli
Headache and Facial Pain
P06.245 Telcagepant Does Not
Reduce Exercise Tolerance in Patients
with Exercise- Induced Myocardial
Ischemia Andrew Ho, Bernard Chaitman,
Martin Behm, Janice Rowe, John Palcza,
Tine Laethem, Ingeborg Heirman, Deborah
Panebianco, Valentin Moiseev, Sergey
Martsevich, Almena Free, Tony Ho, Neville
Bittar, Steven Chrysant, Zhanna Kobalava
, Jeffrey Chodakewitz, M. Gail Murphy,
Rebecca Blanchard
P06.246 Cutaneous Allodynia as a
Prognostic Factor in the Treatment of
Migraine with Botulinum Toxin Paul
Mathew, Fred Cutrer, Ivan Garza
P06.247 Does Gender Affect Efficacy
and Tolerability of SumaRT/Nap During
the Early Intervention Treatment of
Migraine? Shelly Lener, Jill Palchinsky,
Nathalie Richard, April Thompson
P06.248 Headache Prophylaxis Using
Combination Therapy—A Statistical
Modeling Study Bibhutibhushan Mishra,
Leah Gaedeke, Richard Amdur, Bernhard
Samuel
P06.249 Experience with Botulinum
Toxin Type A in the Treatment of Medically
Intractable Pediatric Chronic Daily
Headache Kamran Ahmed, Kimberly Oas,
Kenneth Mack, Ivan Garza
P06.250 OnabotulinumtoxinA for
Treatment of Chronic Migraine: Analysis
of the 56-Week PREEMPT 1 Trial Sheena
Aurora, Ninan Mathew, Stephen Forner,
Dennis Riff, Xiaofang Lei, Catherine Turkel
P06.251 OnabotulinumtoxinA for
Treatment of Chronic Migraine: Analysis
of the 56-Week PREEMPT 2 Trial David
Dodick, Marek Gawel, Reto Agosti, Tamara
Ann Miller, Xiaofang Lei, Catherine Turkel
P06.252 Intracranial Hypotension
Mimicking Focal Spinal Amyotrophy Enrico
Ferrante, Dante Facchetti, Ines Arpino,
Alberto Citterio, Roberto Sterzi
P06.253 OnabotulinumtoxinA for
Chronic Migraine: PREEMPT Trials
Establish a Safe and Effective Dose and
Injection Paradigm Andrew Blumenfeld,
Stephen Silberstein, David Dodick, Sheena
Aurora, Catherine Turkel, William Binder
102
P06.254 Antialgic Effect of Low
Intensity Laser in the Treatment of
Cervicogenic Headaches Jose Speciali,
Renata Pizzo, Fabiola Dach, Rosane Lizarelli
P06.255 Acute Medication Use
Patterns in Episodic Migraine: Results
of the American Migraine Prevalence
and Prevention Study (AMPP) Richard
Lipton, Dawn Buse, Daniel Serrano, Wendy
Golden, Ya-Ting Chen, Marcelo Bigal
P06.268 Reversible Cerebral
Vasoconstriction (RCVS) in Children and
Adolescents (C/A): Its Role in Thunderclap
Headaches Shalaka Indulkar, Catalina
Cleves, S. Pinar Karakas, Sumit Parikh, A.
David Rothner
P06.269 Osmophobia Is
Increased in Menstrually Associated
Migraine Christine Matarese, F. Michael
Cutrer
P06.256 Spreading Depression: The
Effects of Antiepileptic Drugs Used in
Migraine Prophylaxis Joao Baptista De
Moraes
P06.270 Cardiac Autonomic
Dysfunctions in Migraine Attack Dong-jin
Shin, Sung-Hyouk Kim, Wook-Jin Chung,
Seung-Won Seol
P06.257 Is Telcagepant Effective
in Migraineurs Who Previously Used
Opioids? Andrew Ho, James Kost, Carl
Dahlof, Stephen Silberstein, Samar Froman,
Heather Leibensperger, Christopher Lines,
Tony Ho
P06.258 Fungal Sinusitis: A Surgically
Treatable Cause of Chronic Daily
Headache Pedro Kowacs, Renato Iachinski,
Gustavo Nogueira, Ana Amélia Torres
P06.259 Efficacy of Enalapril in
Migraine Prophylaxis: Does It Work
Through Endothelial Dysfunction
Recovery? Seyed Ali Sonbolestan,
Kiyan Heshmat, Shaghayegh Javanmard,
Mohammad Saadatnia
P06.260 Intravenous Valproate Sodium
Aborts Migraine Headaches Rapidly Radi
Shahien, Abdalla Bowirrat, Saad Abu Saleh
P06.261 Acute Anti-Migraine
Efficacy and Tolerability of Zelrix™, a
Novel Iontophoretic Transdermal Patch of
Sumatriptan Mark Pierce, Angel Angelov
P06.262 Bilateral Masseter and
Temporalis Hypertrophy: Case Report
and Review of Literature Pinky Agarwal,
Marilyn Borromeo-Wesner, Alida Griffith
P06.263 Pulse IV Steroid and IV
Valproate Combination Therapy for
Sustained Relief of Chronic, Treatment
Refractory Headaches in Patients with
Psychiatric Disorders Hasan Askari,
Muhammad Zaidi
P06.264 Regression of Chronic
Migraine and High Frequency Episodic
Migraine to Low Frequency Migraine
through Surgery Deborah Reed, Bahman
Guyuron
P06.265 Spontaneous Retinal
Venous Pulsations as a Window to CSF
Pressures—Are They Reliable? Paul
McMonagle
P06.266 A Case of Multiple Cranial
Neuropathies from Perineural Spread of a
Non-Melanoma Skin Cancer Ryan Walsh,
David Capobianco
P06.267 Serial Polysomnography in
Hypnic Headache Shows No Association
with REM Sleep Mark Obermann, Dagny
Holle, Thomas Wessendorf, Sebastian
Zaremba, Charly Gaul, Hans-Christoph
Diener, Zaza Katsarava
Friday, April 16 Highlights
Thursday, April 15 | 3:00 p.m.–7:30 p.m.
Metro Toronto Convention Centre / Room 808
P06.281 Natural History of Post
-Traumatic Headache: Prevalence, Impact,
and Clinical Characteristics Sylvia
Lucas, Jeanne Hoffman, Sureyya Dikmen,
Kathleen Bell
Future of Neuroscience Conference: Frontiers in Neuroimaging:
Coming Soon to a Scanner Near You
P06.282 An Analysis of Practice
Guidelines on Headache Published by
American Academy of Neurology Arun
Antony, Najib Murr
This interactive day-long program focuses on neuroimaging, and will feature poster sessions, platform presentations, a series of case vignettes,
and several invited speakers discussing new developments in the field. The presenters will combine high-level science with practical clinical
application. Registration is required to attend this session, in addition to Annual Meeting registration fee.
P06.283 New Daily Persistent
Headaches (NDPH)—Follow Up and
Outcome in Children and Adolescents
(C/A) Sahithya Wintrich, David Rothner
9:00 a.m.–9:20 a.m.
Brief History of Neuroimaging in Neurology
9:00 a.m.–5:00 p.m., Room 718A
Walter Koroshetz, MD
P06.271 A Tale of Two Systems:
Cardiac Cephalalgia vs. Neurologic
Cardiodynia Paul Mathew, Christopher
Boes, Ivan Garza
P06.284 Body Mass Index (BMI) and
Migraine in the Korean Population Min
Kyung Chu, Kyung Mi Oh, Byung-Gun Kim,
Jae-Myun Chung, Kwang Soo Lee, Richard
Lipton
9:20 a.m.–9:55 a.m.
Imaging White Matter Connections: A
Transforming MRI Technology
P06.272 Onset and Potential
Initiating Factors in New Daily-Persistent
Headache Matthew Robbins, Brian
Grosberg, Uri Napchan, Sara Crystal,
Richard Lipton
P06.285 Temporomandibular
Disorders, Headache Status and
Headache Frequency: A Population-Based
Study Jose Speciali, Daniela Gonçalves,
Cinara Camparis, Marcelo Bigal
9:55 a.m.–10:30 a.m.
High Field Strength Structural MRI: What
Becomes Visible With Increasing Teslas
P06.273 Relationship between
Headache Frequency and MigraineRelated Disability in the International
Burden of Migraine Study (IBMS) Wilcox
Teresa, Andrew Blumenfeld, Sepideh Varon,
Krista Payne, Aubrey Manack, Dawn Buse,
Peter Goadsby, Richard Lipton
P06.286 Sex Hormone Receptor
Gene Polymorphisms and Migraine:
A Systematic Review and MetaAnalysis Markus Schuerks, Pamela Rist,
Tobias Kurth
P06.274 The Effect of Serum Glucose
Level on Cerebrovascular Reactivity to CO2
in Women with Migraine without Aura:
Transcranial Doppler Study Using Breath
Holding Method Jeong-Ho Park, Sun-Ah
Park, Tae-Kyeong Lee, Ki-Bum Sung
P06.275 Impact of Nutritional Factors
on the Prevalence of Headache or
Migraine Catherine Buettner
P06.276 Rates and Predictors of
Remission from Chronic Migraine (CM)
to Episodic Migraine (EM): Results from
the American Migraine Prevalence and
Prevention (AMPP) Study Aubrey Manack,
Dawn Buse, Daniel Serrano, Catherine
Turkel, Richard Lipton
P06.277 Prevalence of Chronic Daily
Headaches as a Function of Parental
Headache Status—Results from the
“Attention Brazil Project” Marco Arruda,
Vincenzo Guidetti, Federica Galli, Regina
Albuquerque, Marcelo Bigal
P06.278 PTSD, Drug Abuse, and
Migraine: New Findings from the National
Comorbidity Survey Replication (NCS-R) B.
Peterlin, Andrea Rosso, Fred Sheftell, David
Libon, Jana Mossey, Kathleen Merikangas
P06.279 Cutaneous Allodynia—A
Predictor of Migraine Chronification: A
Longitudinal Population-Based Study Sait
Ashina, Dawn Buse, Marcelo Bigal, Daniel
Serrano, Michael Reed, Richard Lipton
P06.280 Results from an International
Observational Study of Pregnancy
Outcomes Following Exposure to
Sumatriptan, Naratriptan, or the Fixed
Dose Tablet Sumatriptan and Naproxen
Sodium (SumaRT/Nap) Frederick Derosier,
Marianne Cunnington
P06.287 Relationship between
Migraine Status and Functional Outcome
from Stroke Pamela Rist, Julie Buring,
Tobias Kurth
P06.288 Acute Treatment of Migraine
in Patients with Cardiovascular Disease
or Risk Factors Wendy Golden, Marcelo
Bigal, Junhua Yu, Henry Hu, Diana Brixner,
Richard Lipton, Joanne LaFleur
P06.289 5-HTTLPR Polymorphism
in the Serotonin Transporter Gene and
Migraine: A Systematic Review and MetaAnalysis Markus Schuerks, Pamela Rist,
Tobias Kurth
P06.290 Caffeine Intake in
Adolescents Upon First Visit to Headache
Specialty Center Chad Whyte, A. Rothner
P06.291 Association between
Socioeconomic Status and Migraine with
and without Aura Anke Winter, Julie
Buring, Tobias Kurth
P06.292 Field Testing Chronic Migraine
Criteria in the Population: Results of the
German Headache Consortium (GHC)
Study Zaza Katsarava, Aubrey Manack,
Min-Suk Yoon, Mark Obermann, Dagny
Holle, Peter Dommes, Catherine Turkel,
Richard Lipton, Hans-Christoph Diener
P06.293 Triptan Use as a Function of
Cardiovascular Risk. A Population-Based
Study Marcelo Bigal, Wendy Golden,
Dawn Buse, Ya-Ting Chen, Richard Lipton
P06.294 Prenatal Tabagism and
Alcohol Intake Are Associated with
Chronic Daily Headache at Childhood. A
Population-Based Study Marco Arruda,
Vincenzo Guidetti, Federica Galli, Regina
Albuquerque, Marcelo Bigal
Jeremy Schmahmann, MD, FAAN
Jeff Duyn, PhD
10:30 a.m.–11:05 a.m.
Imaging Brain Networks: Merging Structural
and Functional MRI
Michael Greicius, MD, MPH
11:05 a.m.–11:25 a.m.
Break and Posters
11:25 a.m.–12:00 p.m.
Quantitative Imaging as a Marker
of Diagnosis and Progression of
Neurodegenerative Diseases
Bradford Dickerson, MD
12:00 p.m.
SC01.001
Functional Networks in Chronic Migraine:
A Resting State Functional Connectivity
MRI Study Todd Schwedt, Soe Mar,
Tracy Nolan, Tammie Benzinger, Bradley
Schlaggar, Linda Larson-Prior
12:15 p.m.
SC01.002
Adenosine A2A Receptor Availability in
Parkinson’s Disease Patients with and
without Levodopa Induced Dyskinesias
Studied with [11C] SCH442416 PET Anil
Ramlackhansingh, Subrata Bose, Imtiaz
Ahmed, Federico Turkheimer, Nicola Pavese,
David Brooks
1:30 p.m.–2:05 p.m.
Functional Imaging of Targets in Psychiatric
Disease
Helen Mayberg, MD
2:05 p.m.–2:40 p.m.
Quantitative Perfusion Imaging in Acute
Stroke: Treatment Decisions Based on
Imaging
Ting-Yim Lee, PhD, FCCPM
2:40 p.m.
SC01.003
21.1-Tesla Magnetic Resonance Microscopy
(MRM) in Neurodegeneration Katherine
Schweitzer, Parastou Foroutan, Dennis
Dickson, Uwe Klose, Daniela Berg, Daniel
Broderick, Zbigniew Wszolek, Samuel Grant
2:55 p.m.
SC01.004
Hippocampal Neuropil Atrophy Visualized
in Mild Alzheimer’s Disease Using 7-Tesla
MRI Geoffrey Kerchner, Christopher Hess,
Kathryn Hammond-Rosenbluth, Duan Xu,
Douglas Kelley, Daniel Vigneron, Sarah
Nelson, Bruce Miller
3:10 p.m.–3:30 p.m.
Break and Posters
3:30 p.m.–4:05 p.m.
MRI Focused Ultrasound: Turning Deep
Brain Structures On and Off
Ferenc Jolesz, MD
4:05 p.m.–4:40 p.m.
The New PET: Imaging Molecular Targets in
Neurological Disease
Peter Herscovitch, MD
4:40 p.m.–5:00 p.m.
Questions and Answers
Poster Presentations
Presentation Times: 11:05 a.m.–11:25 a.m., 3:10 p.m.–3:30 p.m.
SC02.001 Correlation of directional
diffusivity with Neurological Status in
Leukodystrophies Soe Mar, Tammie
Benzinger
SC02.002 Serotonergic Terminals are
Differentially Affected in Parkinson’s
Disease: An in vivo 11C-DASB PET
study Marios Politis, Kit Wu, Clare Loane,
Lorenzo Kiferle, Sophie Molloy, David
Brooks, Paola Piccini
SC02.003 Reliable Detection of Specific
Spatial Patterns of Cortical Thinning in
Subtypes of Primary Progressive Aphasia:
A Quantitative MRI-Based Imaging
Biomarker Bradford Dickerson, Daisy
Sapolsky, Alyson Negreira, Michael
Brickhouse, Derin Cobia, Emily Rogalski,
Sandra Weintraub, M. Mesulam
SC02.004 Quantification of Age-Related
Shape Changes in the Cerebral Cortex Using
Fractal Dimension Richard King, Kristen
Kennedy, Karen Rodrigue, Denise Park
SC02.005 Using Multi-Modal Imaging
to Tease Apart Atypical Dementia
Cases Howard Chertkow, Jim Nikelski,
Gabriel Leger, Leah Litwin, Victor
Whitehead, Alan Evans
SC02.007 Primary Outcome Analysis
of the Multicentre Phase II Trial of
18F-Flutemetamol, a Pittsburgh Compound
B Derivative for In Vivo Beta Amyloid
Imaging Rik Vandenberghe, Koen Van
Laere, Adrian Ivanoiu, Eric Salmon,
Eric Triau, Gunhild Waldemar, Steen
Hasselbalch, Ian Law, Allen Andersen, A.
Korner, L. Minthon, Chris Buckley, Lennart
Thurfjell, David Brooks
SC02.008 Resting State Functional
Connectivity is Disrupted after Traumatic
Axonal Injury (TAI) Tianshi Wu, Shuvro De,
An Nguyen, Carlos Marquez de la Plata,
Carol Moore, Caryn Harper, Christopher
Madden, Ramon Diaz-Arrastia
SC02.009 Abnormal Interictal Resting State
Activity in Episodic Migraine Till Sprenger,
Christian Seifert, Michael Valet, Kathrin
Staehle, Thomas Toelle, Annette Foerschler,
Claus Zimmer, Peter Goadsby
SC02.010 Network-Level Structural
Covariance in the Developing Brain Brandon
Zielinski, Efstathios Gennatas, Juan Zhou,
William Seeley
SC02.006 Functional MRI Suggests Iron
Deposition in Pain Regulatory Nuclei
in Episodic Migraine and Chronic Daily
Headache Stewart Tepper, Kechung Liu,
Stephen Jones, Micheal Phillips, Mark
Stillman, Mary Horvat, Mark Lowe
Richard King, MD, PhD
12:30 p.m.–1:30 p.m.
Luncheon
New! Clinical Trials Session
12:00 p.m.–1:30 p.m., MTCC Theatre 102
This midday seminar covers important clinical topics identified from other society meetings that affect patient care. The latest updates within
several clinical trials conducted over the course of the last year will be presented with a question and answer period following. The session will
cover several scientific topics.
Scientific Program Highlights Plenary Session
5:15 p.m.–6:15 p.m., MTCC, Theatre 102
Moderator: Stefan M. Pulst, MD, FAAN, Chair, Science Committee and Scientific Program Subcommittee
This plenary reviews the most critical new research from more than 2,000 studies presented throughout the 2010 Scientific
Program. Education Programs will end at 5:00 p.m. Friday, allowing time for meeting participants to attend this session.
103
Integrated Neuroscience Session: Ischemic Stroke,
Interventional, and Endovascular Therapies/Large Vessel Disease
Integrated Neuroscience Session:
Molecular Markers and Targets in Neuro-oncology
Friday, April 16 | 8:00 a.m.–12:00 p.m.
Friday, April 16 | 1:00 p.m.–5:00 p.m.
Coordinators: Seemant Chaturvedi, MD, FAAN and Pierre Fayad, MD
Coordinators: Tracy Batchelor, MD, MPH and Josep Dalmau, MD, PhD
Invited Speaker Session* / 8:00 a.m–9:30 a.m. / Reception Hall 104A–D
Platform Session / 1:00 p.m–2:30 p.m. / Reception Hall 104A–D
8:00 a.m.–8:20 a.m.
Acute Occlusive Large Vessel Disease Raul Nogueira, MD
8:20 a.m.–8:40 a.m.
Extracranial Large Vessel Disease and Carotid Revascularization Adnan Qureshi, MD, FAAN
8:40 a.m.–9:00 a.m.
Non-Atherosclerotic Large Vessel Vasculopathy Cheryl Bushnell, MD, MHS
9:00 a.m.–9:20 a.m.
Intracranial Atherosclerotic Large Vessel Disease Edward Feldmann, MD
9:20 a.m.–9:30 a.m.
Questions and Answers
1:00 p.m.
IN10-1.001
Radiation Sensitivity of Neural and
Progenitor Stem Cells Nizar Souayah,
Lubna Mehyar, Nazsa Baker, Steve
Levison
Poster Session / 9:30 a.m.–10:30 a.m. / Reception Hall 104A–D
IN9-1.001 Occurrence of Subacute
Recanalization and Collateral
Formation in Patients with Cerebral
Venous Thrombosis. A Serial
Venographic Study Abeer Farraq,
Muna Irfan, Gaurav Guliani, Yousef
Mohammad, Jay Joshi, Robert Taylor,
M. Fareed Suri, Adnan Qureshi
IN9-1.002 Trends in Clinical Outcome,
Recanalisation and Reocclusion
with Different Stroke Subtypes: A
Multi-Center Transcranial Doppler
Study Joseph Sebastian, Georgios
Tsivgoulis, Andrei Alexandrov, Vijay
Sharma, Khurshid Khan, Mohammed
Ibrahim, Ken Uchino, Ashfaq Shuaib,
Andrew Demchuk, Maher Saqqur
IN9-1.003 Intra-Arterial Thrombolytic
Infusion after Six Hours of Symptom
Onset in Patients with Anterior
Circulation Ischemic Stroke: A Matched
Case Control Study Mushtaq Qureshi,
Jefferson Miley, Gabriela Vazquez,
Muhammad Zeeshan Memon, Haitham
Hussein, M. Fareed Suri, Ramachandra
Tummala, Robert Taylor, Harold Adams,
Adnan Qureshi
IN9-1.004 Safety and Feasibility of
Intracranial Stenting for Acute Ischemic
Stroke Beyond Eight Hours of Symptom
Onset Ambooj Tiwari, Natasha Purai,
Amit Kansara, Andrew Xavier
IN9-1.005 How Frequently Are
Ischemic Stroke Patients Eligible for
Decompressive Hemicraniectomy? A
Population-Based Study Richard Curry,
Ope Adeoye, Brett Kissela, Kathleen
Alwell, Charles Moomaw, Matthew
Flaherty, Pooja Khatri, Daniel Woo,
Simona Ferioli, Joseph Broderick, Dawn
Kleindorfer
IN9-1.006 A National Study
Comparing Carotid Artery
Stent Placement with Carotid
Endarterectomy in Octogenarians and
Non-Octogenarian Population Rakesh
Khatri, Gabriela Vazquez, M. Fareed
Suri, Yousef Mohammad, Kamakshi
Lakhsminarayan, Adnan Qureshi
IN9-1.007 Endovascular
Management of Symptomatic
Extracranial Stenosis and Associated
Secondary Tandem Stenosis Fazeel
Siddiqui, Gabriela Vazquez, Ameer
Hassan, Nauman Tariq, M. Fareed Suri,
Robert Taylor, Adnan Qureshi
IN9-1.009 Stenting and
Angioplasty in Small, Distal
Cerebral Arteries for Symptomatic
Intracranial Atherosclerosis Using
Wingspan Junaid Kalia, Kaiz Asif, John
Lynch, Brian-Fred Fitzsimmons, Osama
Zaidat
IN9-1.008 Factors Associated
with Neurological Complications
Following Intracranial Angioplasty and/
or Stent Placement. A Multicentric
Study Nauman Tariq, Ameer Hassan,
Gabriela Vazquez, Haitham Hussein,
M. Fareed Suri, Alexandros Georgiadis,
Ramachandra Tummala, Robert Taylor,
Adnan Qureshi
IN9-1.010 Impact of Endovascular
Treatment for Cerebral Vasospasm
on Subarachnoid Hemorrhage Patient
Outcomes in a Comprehensive Stroke
Program Alberto Maud, Rakesh Khatri,
Haralabos Zacharatos, Muhammad
Zeeshan Memon, Ather Taqui, Mushtaq
Qureshi, Gabriela Vazquez, M. Fareed
Suri, Ramachandra Tummala, Robert
Taylor, Mustapha Ezzeddine, Adnan
Qureshi
1:15 p.m.
IN10-1.002
Role of Perfusion MR Imaging in
Differentiating Between TumorProgression and Pseudo-Progression
in Recurrent Glioblastoma
Multiforme Christel HeidemansHazelaar, Bas Van der Kallen, Antoinette
Verbeek, Charles Vecht
1:30 p.m.
IN10-1.003
Sunitinib as an Antitumor Substance
in Human Meningioma Cells Christian
Mawrin, Nadine Andrae, Elmar Kirches
2:00 p.m.
IN10-1.005
Retrospective Review of Symptomatic
Intracranial Hemorrhage (ICH)
in Cancer Patients Treated with
Bevacizumab; the Memorial SloanKettering (MSK) Experience Mustafa
Khasraw, Samuel Goldlust, Andrew
Lassman, Lisa DeAngelis
2:15 p.m.
IN10-1.006
[18F]FACBC and [18F]FLT PET Imaging
for Glioblastomas (GBM) Christian
Grommes, Timothy Akhurst, Ronald
Blasberg, Bradley Beattie, Mikhail
Doubrovin, Jenna Monaster, Andrew
Lassman
IN10-2.002A Dramatic and
Prolonged Response to Meningeal
Gliomatosis Jeremy Rudnick, Rebecca
Naor, Franklin Moser, Surasak
Phuphanich
IN10-2.004Multi-Parametric Imaging
and Immunohistochemistry Studies
of the Effects of YC-1 on Rat C6
Glioma Josée Bergeron, Antonio
Aliaga, Barry Bedell
IN10-2.006Late Relapse in
Primary Central Nervous System
Lymphoma Lakshmi Nayak, Marc
Ladanyi, Cyrus Hedvat, Lauren Abrey,
Lisa DeAngelis
IN10-2.003Lacosamide in Brain Tumor
Patients Lizbeth Robles-Irizarry, Kathy
Lupica, Glen Stevens
IN10-2.005Post-Therapy NonHemorrhagic T1 Hyperintensity on MRI
in PCNSL Patients and Its Prognostic
Implication Vineet Punia, Sasan Karimi,
Antonio Omuro
IN10-2.007Neurological Outcome of
Childhood Brain Tumor Survivors Sari
Pietilä, Anne Mäkipernaa, Hanna Lenko,
Anna-Maija Koivisto, Raija Korpela
1:45 p.m.
IN10-1.004
Efficacy of Bevacizumab Following
Tyrosine Kinase Inhibitors Targeting
Vascular Endothelial Growth Factor
Receptor (VEGF-R) for Recurrent
Glioblastoma (GBM) Samuel Goldlust,
Robert Cavaliere, Antonio Omuro,
Lisa DeAngelis, Lauren Abrey, Herbert
Newton, Meier Hsu, Andrew Lassman
Poster Session / 2:30 p.m–3:30 p.m. / Reception Hall 104A–D
IN10-2.001Primary Central Nervous
System EBV-Associated Lymphomatoid
Granulomatosis: A Comprehensive
Study of Three Cases Pamela New,
Hidehero Takei, Chung-Che Chang,
Youli Zu
Invited Speaker Session* / 3:30 p.m–5:00 p.m. / Reception Hall 104A–D
3:30 p.m.–3:55 p.m.
MGMT in the Management of Gliomas Warren Mason, MD
3:55 p.m.–4:15 p.m.
Tumorigenic Glioma Stem Cells Santosh Kesari, MD, PhD
4:15 p.m.–4:35 p.m.
Angiogenesis-Targeting Therapy for Malignant Gliomas Patrick Wen, MD, FAAN
4:35 p.m.–5:00 p.m.
Targeted Therapies in Glioblastoma Alfred Yung, MD, FAAN
Platform Session / 10:30 a.m.–12:00 p.m. / Reception Hall 104A–D
10:30 a.m.
IN9-2.001
Ultra-Early Recanalization and Re
Occlusion in Patients with Acute
Ischemic Stroke: A Multimodal
Serial Angiographic Study Mushtaq
Qureshi, Alberto Maud, M. Fareed Suri,
Ramachandra Tummala, Robert Taylor,
Mustapha Ezzeddine, Adnan Qureshi
10:45 a.m.
IN9-2.002
Building Radiological Support
for Intra-Arterial Delivery by
Gaining Efficiency—The BRIDGE
Study Andrew Barreto, Sminil
Mahajan, Shuichi Suzuki, Kathy
Masters, Vivek Misra, Indrani Acosta,
Sean Savitz, Roc Chen, Nicole Gonzales,
Anitha Abraham, Terrell Evans, Clarence
Johnson, Nusrat Harun, Digvijaya
Navalkele, James Grotta
11:00 a.m.
IN9-2.003
Hospital and Operator Characteristics
Associated with Optimal
Outcomes Following Carotid Artery
Stenting Seemant Chaturvedi, William
Gray, Jon Matsumura, Patrick Verta,
Lei Peng
11:15 a.m.
IN9-2.004
Evolving Technique in Vertebral Artery
Origin Stenting Randall Edgell, Rishi
Gupta, Linfante Italo, Andrew Xavier,
Alex Abou-Chebl, Raul Nogueira,
Siddhartha Varma, Junaid Kalia, Vahid
Etezadi, Osama Zaidat, Research
Consortium Society of Vascular and
Interventional Neurology
11:30 a.m.
IN9-2.005
Transcranial Laser Therapy for Acute
Ischemic Stroke: A Pooled Analysis of
NEST-1 and NEST-2 Andrew Stemer,
Branko Huisa, Justin Zivin
11:45 a.m.
IN9-2.006
Acute Intra-Carotid Delivery of
Mesenchymal Stem Cells in Middle
Cerebral Artery Occlusion Dileep
Yavagal, Tienlong Pham, Baowan Lin,
Sushrut Dharmadhikari, Philip Garza,
Ian McNiece, Joshua Hare, Miguel
Perez-Pinzo
*Current as of February 1, 2010
104
*Current as of February 1, 2010
105
2010 Virtual Annual Meeting
Products ordered on this order form will be mailed during the Annual Meeting.
2010 Syllabi on CD
Enjoy quick and convenient access to
complete syllabi from more than 175
education programs.
2010 Webcast-on-Demand
Receive online access to the slides, audio, and
video of more than 130 hours of education
programs and presentations on the latest
science, including all six plenary sessions.
Owning both the Webcast-on-Demand
and the Syllabi on CD provides a quick and
convenient method to stay up-to-date on AAN
education programming.
2010 Practice CD
Convenient access to 15 AAN Regional
Conference and Annual Meeting practice
related syllabi conveniently located on a
single disk.
Attending the 2010 Annual Meeting?
xx Order your copy of the Syllabi on CD,
online access to Webcast-on-Demand, the
MP3 On-Demand, and practice CD on the
registration order form on page 113
under box C.
xx Pick up your products at the Annual
Meeting. If you do not pick up your CD at the
meeting, there will be an additional $15.00
shipping and handling charge.
Not Attending the 2010 Annual Meeting?
If you are unable to attend the Annual
Meeting, order your copy of the Syllabi on CD,
online access to Webcast-on-Demand, MP3
DVD, and Practice CD and take advantage of
the special pre-meeting pricing. Simply fill out
and fax the completed order form located on
this page to (651) 361-4800. Products ordered
on this form will be mailed during or after the
Annual Meeting.
SPECIAL RATE ON SYLLABI
ON CD FOR AAN JUNIOR MEMBERS
Purchase the 2010 Annual Meeting Syllabi
on CD at a discounted pre-meeting rate of
$49. This rate is only available to AAN Junior
members (one copy per Junior member).
Note: the discounted rate is available until
March 10, 2010. Orders received after
March 10, 2010, will be charged the
member meeting price.
2010 Virtual Annual Meeting Order Form
Special Reduced Pricing
Before March 10
After March 10
Quantity_
Total
$49
$99
$149
$299
$299
$299
_______ _______ _______ ��������
��������
��������
$99
$149
$199
$599
$599
$599
_______ _______ _______ ��������
��������
��������
Syllabi oN CD
Junior and Non-Neurologist Member (limit 1)
Member Neurologist
Nonmember
WEBCAST-ON-DEMAND
Junior and Non-Neurologist Member (limit 1)
Member Neurologist
Nonmember
Virtual Annual Meeting Two-Pack (Syllabi on CD and Webcast on-Demand)
Junior and Non-Neurologist Member (limit 1)
Member Neurologist
Nonmember
$129
$199
$299
$849
$849
$849
_______ _______ _______ ��������
��������
��������
$39
$49
$59
$99
$99
$99
_______ _______ _______ ��������
��������
��������
MP3 On-Demand and DVD (available after AAN Annual Meeting)
Junior and Non-Neurologist Member
$99
$299
Member Neurologist
$149
$299
Nonmember
$199
$299
_______ _______ _______ ��������
��������
��������
Practice CD
Junior and Non-Neurologist Member
Member Neurologist
Nonmember
Virtual Annual Meeting Three-Pack (Webcast, syllabi, and mp3)
Junior and Non-Neurologist Member
Member Neurologist
Nonmember
$199
$299
$499
US Shipping:
$39.00 – $75.00������������������������������������������������������� $7.95
$75.01 – $120.00���������������������������������������������������� $9.95
$120.01 – $250.00������������������������������������������������ $12.95
$250.01 – $500.00������������������������������������������������ $14.95
For orders over $500 and international orders call
AAN Member Services (see below).
$1,099
$1,099
$1,099
Please send:
Grand Total Shipping (see left)
Total amount due _______ _______ _______ ��������
��������
��������
$
$
$
Price includes applicable sales tax
For questions, contact AAN Member Services at memberservices@aan.com,
(800) 879-1960, or (651) 695-2717 (International).
Junior and Non-Neurologist Member
Member Neurologist Nonmember
Name ������������������������������������
Address (for shipping)�������������������������
����������������������������������������
Payment (must accompany form):
Check (US funds only, do not send cash)
Make Payable to American Academy
of Neurology
VISA Master Card
American Express
Address line 2 ������������������������������
Credit card number
����������������������������������������
����������������������������������������
City/State ���������������������������������
Expiration Date ___ /___
ZIP/Postal code �����������������������������
Print name���������������������������������
Signature����������������������������������
Country�����������������������������������
Phone������������������������������������
Mail or fax completed order form to:
American Academy of Neurology / 1080 Montreal Avenue / St. Paul, MN 55116 / Fax: (651) 361-4800
Did You Know?
Still available: 2009 Syllabi on CD, printed syllabi, Webcast-on-Demand, audio
CDs, and MP3 downloads are still available from the 2009 Annual Meeting. Visit
the AAN Store™ at www.aan.com/store for more information.
107
General Information
Cme/Accreditation
Unlabeled Use Disclosure
Internet Center
Cell Phones
Accreditation
The AAN requires all Annual Meeting presenters to disclose if a
product is not labeled for the use being discussed or if the product
is still investigational. Unlabeled use disclosures will be included in
individual program materials.
The AAN strives to offer the latest in technological products and
services designed to make communicating between the office,
colleagues, or family easier while attending the 62nd Annual Meeting.
The Internet Center provides attendees with computer workstations,
printers, and Internet access. Check email, enter course or session
notes, or search the AAN website. Enhancements to the Internet
Message Center allow faster access to messages and the ability to
search for other attendees by name, company, or networking topics
of interest.
The AAN requests that attendees turn cellular phones and pagers to
vibrate mode upon entering all Annual Meeting programs. Contact your
service provider directly to inquire if service is available and/or the
applicable rates.
Wireless Connection
Sponsored by Neurology®
The Metro Toronto Convention Centre is a nonsmoking facility. For
the health and comfort of everyone, smoking is prohibited at Annual
Meeting functions, which include all education and scientific activities
and social functions.
Business Center
Press Room
Metro Toronto Convention Centre has a business center that offers
administrative and office services, including copy machines, faxes, and
shipping services. The business center is located in the North Building
on the Third Floor.
Only authorized media may use the Press Room at the Annual Meeting.
Journalists must check in at the Press Room and provide proper
credentials. For more information, contact Angela Babb at
ababb@aan.com or (651) 695-2789.
First Aid Station
Volunteer Opportunities
A First Aid station is located in the North Building on the second
floor of the Metro Toronto Convention Centre. The station is staffed
by licensed medical professionals and fully equipped with supplies,
including automatic external defibrillators (AED). The station is
operational throughout the duration of the Annual Meeting.
Education and Scientific Program Monitors
The AAN is accredited by the Accreditation Council for Continuing
Medical Education (ACCME) to sponsor continuing medical education
(CME) for physicians.
CME: American Medical Association
Physician’s Recognition Award™
The AAN designates select Annual Meeting activities for a specific
number of AMA PRA Category 1 Credit™ hours towards the American
Medical Association Physician’s Recognition Award. (See individual
program description for specific number of credits per program.)
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
CME: Education Program
AMA PRA Category 1 Credits are awarded for courses, seminars,
workshops, morning reports, neuro flashes, neurology skills pavilions,
luncheons, and kick-off programs. (See individual program description
for specific number of credits per program). Confirmation of CME
credits earned at the 2010 Annual Meeting will be available to
attendees approximately four to six weeks after the Annual Meeting.
Disclaimers/Disclosures
Education/Scientific Disclaimer
The primary purpose of the Annual Meeting is to offer education and
scientific programs to attendees. Information presented—as well as
publications, technologies, products, and/or services discussed—is
intended to inform attendees about the knowledge, techniques,
and experience of physicians willing to share that information
with colleagues.
A diversity of opinions exists in the medical field and the views of
Annual Meeting physician participants do not represent those of the
AAN or constitute endorsement by the AAN. The AAN disclaims
any and all liability for all claims that may result from the use of
information, publications, products, and/or services discussed at the
Annual Meeting.
Disclosure of Commercial Relationships
According to AAN and ACCME policies, Annual Meeting presenters
must disclose any significant financial or other relationship with
industry. All presenters must sign an AAN Letter of Agreement stating
explicitly they understand and will adhere to AAN and ACCME policies
that require full disclosure of commercial relationships, unlabeled
use of products, and identification of data sources. Full disclosure of
presenters’ commercial relationships will be included in individual
program materials. This policy is intended to provide attendees
with information about faculty commercial relationships in order for
attendees to evaluate material discussed during an education activity.
108
General Information
Education Grants
Some Annual Meeting education and scientific programs are
supported in part by education grants from the AAN’s industry
supporters. Support acknowledgment statements are included in
individual program descriptions and materials. Although industry
support is received, all programs are developed and implemented
solely by the AAN Education Committee and its Annual Meeting
Subcommittee, the Science Committee and its Scientific Program
Subcommittee, and AAN staff. Industry supporters must sign an
AAN Letter of Agreement stating they will not influence the faculty
or directors and agreeing to no direct control or input. The AAN uses
grant funds to support and enhance existing, as well as new,
education programs.
Services
Child Care Information
A variety of child care options is available in Toronto, Ontario. Check
with the concierge at your hotel on or before your arrival to make
your arrangements.
Shuttle Services
Complimentary shuttle bus service will be provided between
designated official AAN hotels (see below) and the convention centre.
Schedules will be available at the Metro Toronto Convention Centre
and will also be posted in each hotel lobby that has shuttle service.
Route 1
xx Sheraton Centre Toronto Hotel
xx Hilton Toronto (will use Sheraton stop)
Route 2
xx The Fairmont Royal York
xx The Strathcona Hotel (will use Fairmont stop)
Route 3
xx Radisson Admiral Hotel-Toronto Harbourfront
xx The Westin Harbour Castle
Route 4
xx Hyatt Regency Toronto
Route 5
xx Toronto Marriott Downtown Eaton Centre Hotel
xx Delta Chelsea Hotel
xx Courtyard by Marriott Downtown Toronto
Wireless Internet hotspots will be available at the Metro Toronto
Convention Centre.
Guidelines
Photography and Recording of Programs
The AAN strictly prohibits all unauthorized photography (flash, digital,
or otherwise), audio and/or videotaping during the Annual Meeting.
Equipment will be confiscated.
Consent to Use of Photographic Images
Registration and attendance at, or participation in, AAN/AAN
Professional Association meetings and other related activities
constitutes attendee’s authorization to AAN’s use and distribution
(both now and in the future) of the attendee’s image or voice in
photographs, video recordings, electronic reproductions, and audio
recordings of the events and activities.
Language
The official language of the Annual Meeting is English. No
simultaneous translation is available.
No Smoking
Monitors are needed for all education program offerings and scientific
platform sessions to distribute and collect evaluation materials and
assist directors, faculty, session co-chairs, and staff as required.
The AAN will waive all monitors’ Annual Meeting registration and
education program fees as well as grant CME credit for the monitored
program. Space is available on a first-come, first-served basis. For an
application form or more information, contact Kyle Krause at
kkrause@aan.com or (651) 695-2733.
EMG Skills Workshop Volunteers
Volunteers are needed to participate in the EMG Clinical Skills
Workshops on Sunday, April 11, and Monday, April 12. Volunteers
are also needed to participate in the Neurophysiologic Intraoperative
Monitoring Skills Workshop on Wednesday, April 14.
Skills workshop subjects will receive a waived meeting registration
and workshop fee as well as payment of $40 per noninvasive session
and $60 per invasive session. Space is available on a first-come,
first-served basis. For more information, contact Elizabeth Busch at
ebusch@aan.com or (651) 332-8685.
Weather/Attire
The climate in Toronto in early spring is generally cool and damp.
In April, temperatures usually range from 42 degrees to 70 degrees
Fahrenheit. It can be quite wet, so a waterproof coat and umbrella are
a good idea, as are layered clothing and a good jacket.
The AAN promotes business casual attire for the duration of the
Annual Meeting. Consider bringing a light jacket or sweater to Annual
Meeting activities since meeting room temperatures and personal
comfort levels vary.
109
Registration
Online Registration
Enjoy the convenience and efficiency of registering online at
www.aan.com/abstractreg.
Early Registration Deadline: March 10, 2010
Register early to avoid increased general registration and Education
Program fees. Any registrations received after March 10, 2010, will
be charged higher rates. On-site registration opens at 8:00 a.m. on
Saturday, April 10, 2010, at the Metro Toronto Convention Centre.
Underserved Countries
If you are from one of the following countries, you are entitled to
receive your general registration fee waived and access to lower cost
hotels. In addition, you also qualify for two free education programs. To
register online, enter an Invitation Code of “unmbr” if you are an AAN
member or “unnon” if you are not an AAN member.
US and Canadian registrants who submit their registration form
before March 10, 2010, will receive Annual Meeting name badges and
Education Program tickets by mail. Those who register after March 10,
2010, will pick up their badges and tickets on-site. Badges and tickets
will be reprinted once at no cost. There will be a $100 administrative
fee for each reprint thereafter.
The countries are: Afghanistan, Bangladesh, Benin, Bolivia, Burkina
Faso, Burundi, Cambodia, Cameroon, Central African Rep., Chad,
Comoros, Congo Dem. Rep., Congo Rep., Cote d’lvoire, Eritrea, Ethiopia,
Gambia, Ghana, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras,
Kenya, Korea Dem. Rep. North, Kyrgyz Rep., Lao PDR, Liberia,
Madagascar, Malawi, Mali, Mauritania, Mozambique, Myanmar,
Nepal, Nicaragua, Niger, Rwanda, Sao Tome and Principe, Senegal,
Sierre Leone, Somalia, Sudan, Tajikistan, Tanzania, Togo, Uganda,
Uzbekistan, Vietnam, Yemen Rep., Zambia, and Zimbabwe.
Fees
Scientific Program Presenters
General Registration Fee
The general registration fee is mandatory for all registrants and is
determined by AAN member type.
AAN Member Types Include:
Medical Student/PhD Candidate Members: Medical Students and
PhD candidates who are members of the AAN are not required to
pay the general registration fee and pay non-neurologist rates for
Education Programs.
Junior Members: Non-neurologist rates are for Junior (resident, fellow,
post-doctoral graduate) members of the AAN. Physicians in training
who are not Junior members must pay nonmember rates.
Business Administrator, Research Scientist, Non-Neurologist Clinician
Members: These members pay non-neurologist member rates.
Fellow, Active, Associate, Honorary, and Senior Members: AAN
members must pay their current year’s dues to register at neurologist
member rates. Honorary and Senior members are not required to pay
the general registration fee.
Many programs and events are FREE with
your badge. See page 110 for details.
Special Membership Considerations
Nonmembers: Become an AAN member and receive significant
discounts on Annual Meeting registration and Education Program fees.
For an AAN membership application, contact AAN Member Services
at (800) 879-1960 or (651) 695-2717.
Medical Student/PhD Candidate nonmembers: To be eligible for the
student rate as a nonmember, a student ID card or a letter from a
professor must be submitted. The general Annual Meeting registration
fee will be waived but nonmember rates must be paid for all Education
Programs. For an AAN membership application, contact AAN Member
Services at (800) 879-1960 or (651) 695-2717 (international).
110
Registration
All platform and poster presenters must submit a registration form and
pay the applicable registration fee. Note that fees after March 10 are
significantly higher. Registration by March 10, 2010, is encouraged.
Education Programs
There is a fee for each selected offering within the Education Program.
Enrollment is limited. Registration by March 10, 2010, is encouraged.
Virtual Annual Meeting
2010 Virtual Annual Meeting Three-Pack—$299 Member Pre-Meeting
Price ($1,099 List Price) Save $800 on the 2010 Webcasts-On-Demand
and on DVD, 2010 Syllabi on CD, and 2010 MP3-On-Demand and on
DVD.
2010 Webcasts-On-Demand and on DVD—Enjoy online access or disk
archive of the slides, audio, and video of more than 130 hours of the
latest science and education programs and presentations, including
all six plenary sessions. (Purchase separately for $149 Member PreMeeting Price vs. $599 List Price.)
2010 Syllabi on CD—Quick and convenient access to complete syllabi
from more than 175 education programs. (Purchase separately for $99
Member Pre-Meeting Price vs. $299 List Price.)
2010 MP3-On-Demand and on DVD—Audio files on today’s most
significant scientific topics can be downloaded to your MP3 player or
listened to on your disk player or computer. (Purchase separately for
$149 Member Pre-Meeting Price vs. $299 List Price.)
2010 Virtual Annual Meeting Two-Pack—$199 Member
Pre-Meeting Price ($849 List Price) Save $650 on the
Webcasts-On-Demand and on DVD, plus the 2010 Syllabi on CD.
2010 Practice CD—$49 Member Pre-Meeting Price ($99 List Price)
Enhance your practice and improve your bottom line with these
15 AAN Regional Conference and Annual Meeting practicerelated programs.
Celebration for Research; Neurobowl®, Neuro
Film Festival, Main Stage, Neuro Hop, and more!
Each registered meeting attendee will receive one free ticket to these
celebration events. Guest tickets are $50 each. See page 24.
American Academy of Neurology and
American Academy of Neurology Foundation
Awards Luncheon
Join the leaders of the AAN, the Science Committee, and the Lecture
Awards Subcommittee in honoring recipients of the 2010 Scientific
Awards Program on April 14, 2010. A limited number of seats are
available for $50. Junior and Medical Student members may attend
this event at no cost, but must obtain a ticket through registration.
Group Registration Deadline: February 26, 2010
Group registrations are those in which 10 or more individuals’ fees are
paid for with one check or credit card. No administrative fee is charged
to register a group as long as housing is secured through the AAN’s
official housing company, Convention Management Resources (CMR).
Groups that have not secured housing through CMR can still register as
a group; however, a $1,000 administrative fee will be charged. Contact
CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 9792283 (international) to receive special registration instructions. See
page 114 for housing information.
Changes to Syllabi Process—
Download in Advance
Obtaining your Education Program syllabi is quicker and
easier than ever. All registered attendees will be able
to download the full syllabi for their selected programs,
starting in late March. All registered attendees will
receive an email notification once syllabi are available.
Printed syllabi will not be available. Printed slides
will be available in program rooms.
Cancelled or Closed Programs
Education programs may be canceled or closed due to capacity or
insufficient enrollment. If any selections are canceled or closed and
payment was made by credit card, the amount charged will include
only the available programs. If paid by check, a full refund will be
issued for affected programs. Allow four to six weeks after the Annual
Meeting for processing refunds.
Cancellations/Refunds of Registration
Until March 10, 2010
Refund less $50 administrative fee
March 11–April 2, 2010
Refund less $100 administrative fee
After April 2, 2010
No refund
xx All cancellations must be submitted in writing to
aanreg@cmrus.com or fax to (415) 979-2260.
xx No-shows will not receive a refund.
xx Name substitutions are not permitted.
xx No refunds will be processed for amounts of $20 or less.
xx Programs are subject to cancellation if enrollment is insufficient. In
the event of cancellation, registration for the cancelled course will be
fully refunded.
xx The AAN is not responsible for airfare, hotel, or other costs incurred
by participants in the event of program or registration cancellation.
Special Needs Deadline: March 10
The Metro Toronto Convention Centre and the AAN are in compliance
with the Americans with Disabilities Act or Human Rights Code and
strive to accommodate all visitors. Information booths, designated
parking, and assisted listening devices are available. If you require
special accommodation to attend the Annual Meeting, contact
Sarah Glover no later than March 10, 2010, at sglover@aan.com
or (651) 695-2804.
Note: Kosher meals can be provided at any breakfast, lunch, or dinner
seminar and should be arranged no later than March 10, 2010, by
contacting Sarah Glover at sglover@aan.com or (651) 695-2804. There is
a $25 surcharge per meal. On-site requests cannot be accommodated.
Exhibits Only
To view the exhibits without registering for the Annual Meeting, a
single-day pass is available at on-site registration for $100 per day.
Changes in Education Programs
Select education programs carefully. An administrative fee of $20 will
be charged for each program change or cancellation. To assure correct
mailing of your name badge and tickets, changes must be submitted
in writing and received no later than March 10, 2010. After that date,
changes must be made on-site and will be charged an administrative
fee of $30 for each program change or cancellation.
111
What’s Free with Your Badge?
The AAN Annual Meeting provides tremendous value to all registered attendees, with free access to a variety of programs and events included in
your economical registration fee.
Events of Interest to All Attendees
Scientific Platform and Poster Sessions
60 Scientific Platform Sessions and 6 poster sessions throughout
the meeting
Plenary Sessions
xx Presidential Plenary Session
xx Hot Topics Plenary Session
xx Frontiers in Clinical Neuroscience Plenary Session
xx Contemporary Clinical Issues and Case Studies Plenary Session
xx Awards Plenary Session
xx Scientific Program Highlights Plenary Session
Integrated Neuroscience Sessions
xx Emerging Concepts in Genetics
xx Pediatric Demyelinating Disorders
xx Current Concepts in Cognitive Neuroscience: Implications for
Neurological Disease
xx Emerging Treatments in Neuromuscular Disease
xx Global Neurology: Toxins and Infections
xx Proteins, Genes, Neurodegeneration, and the Clinical Presentations
xx Multiple Sclerosis Imaging
xx Deep Brain Stimulation: Where Are We and Where Do We Go
From Here?
xx Ischemic Stroke, Interventional, and Endovascular Therapies/Large
Vessel Disease
xx Molecular Markers and Targets in Neuro-oncology
Highlights in the Field
Enjoy subspecialty highlights and networking with colleagues at
meetings held throughout the meeting.
Celebration for Research: Neurobowl®, Main Stage, Neuro
Film Festival, and Neuro Hop
Sunday, April 11
Exhibit Hall and Complimentary Luncheons
xx Opening Reception: Monday, April 12, 5:00 p.m.–7:00 p.m.
xx Hall Hours: Tuesday–Wednesday, 11:30 a.m.–5:00 p.m.; Thursday,
11:30 a.m.–4:00 p.m.
xx Complimentary Luncheons: Tuesday–Thursday, 12:00 p.m.–2:00 p.m.
112
Of Interest to Practicing Neurologists
xx BRAINS Colloquium: Critical Thinking for Critical Issues
xx Patient Safety Colloquium: Diagnostic Errors in Neurology
xx Practice Colloquium: Dialogue with the Insurer Medical Directors: A
Conversation You Don’t Have Every Day
xx Education Colloquium: International Education
xx Web Wonders: The Must-Have Technologies for
Neurologists in 2010
xx Best Care Expo: Guidelines, Government Relations,
and Getting Paid
xx ABPN MOC Informational Session
xx Ethics Colloquium
xx Corporate Therapeutic Updates
xx Controversial Issues in Practice Session: Health Care Reform
Of Interest to Neurology Advocates
xx Best Care Expo: Guidelines, Government Relations, and Getting Paid
xx Palatucci Advocacy Action Planning Roundtable
Of Interest to Students, Residents, and Fellows
Medical and graduate students and PhD candidates who present a
student ID card or are AAN members receive free admission to the
Annual Meeting.
xx ABPN Resident Informational Session
xx SIGN Meeting and Reception
xx Consortium of Neurology Residents and Fellows Meeting
xx Basic Science Resident Curriculum
xx Residents and Fellows Career Forum and Reception
xx Resident/Medical Student Rush Line
Check in at the Information Booth each morning for tickets to available
courses for that day. Two tickets will be held for each course, available
on a first-come, first-served basis.
Of Interest to International Attendees
xx International Attendee Summit
xx Integrated Neuroscience Session: Global Neurology: Toxins
and Infections
xx Education Colloquium: International Education
xx International Component Posters at the Residents and Fellows
Career Forum and Reception
xx Members of underserved countries are entitled to receive
their general registration fee waived and qualify for free Rush
Line programs.
How to Register
The deadline for early registration is March 10, 2010. After this date, you must
register on-site. Register quickly and easily at www.aan.com/abstractreg
Step 1: Personal Information
Box D: Additional Activities (optional): Register for special
events, including:
Remove the mailing label on the back of this book and affix it to the
Personal Information box on the registration form. If the information
on the label is incorrect, make corrections on the label or in the
space provided.
xx Celebration for Research
xx AAN/AAN Foundation Awards Luncheon
xx Run/Walk for Brain Research
xx Buy a Brain Fundraiser
Note: It is important that this information be current. A confirmation
letter will be emailed or faxed. Name badge, tickets, and CME
transcripts will be mailed to the address provided.
Step 2: Education Program
Step 5: Payment
Shade the boxes corresponding to the Education Program type you
wish to register and enter the program number on the line.
Indicate method of payment. Full payment in US funds must
accompany your registration form. Include credit card information or
enclose a check made payable to the American Academy of Neurology.
Note: Government credit cards are not accepted for advance
registration, as they cannot be processed without the actual credit
card. Government credit cards may be used on-site.
Deadline: March 10
Registrations will be processed according to the date of receipt.
Registrations received after March 10, 2010, will be processed at a
higher rate. On-site registration opens Saturday, April 10, 2010, at 8:00
a.m. at the Metro Toronto Convention Centre.
Box C: Virtual Annual Meeting (optional): Select a Syllabi on
CD, Webcast-on-Demand, and/or Practice CD. Price includes applicable
sales tax. If you do not pick up your CD at the AAN Store during the
Annual Meeting, there will be an additional $15 shipping and
handling charge.
Questions:
US/Canada
International
Email
(800) 676-4226
(415) 979-2283
aanreg@cmrus.com
Education Program Fee Schedule
Use this table to calculate the fees for the number of registered programs. Tally the number of each type of program. Multiply the amount by the fee for your
membership type. Transfer the total amount to Box B on the registration form.
Note: Do not use this schedule for on-site registration. Neurologist member and nonmember fees increase $20.00 per program on-site.
Program Type:
AC/PC (Half-Day Course) AS (After-Dinner Seminar) BS (Breakfast Seminar) CS (Case Studies Program) DS (Dinner Seminar) EP* (Directors Conference) FC (Full-Day Course) KP (Kick-Off Program) LS (Luncheon Seminar) MR (Morning Report) NF (Neuro Flash) NP (Neurology Skills Pavilion) PW (PM Skills Workshop) SC** (Science Conference) SW (Skills Workshop) TP (Therapy Program) Junior and
Non-Neurologist Member:
Member Neurologist:
x $45 = x $75 = x $70 = x $80 = x $110 = x $125 = x $90 = x $55 = x $70 = x $80 = x $110 = x $180 = x $180 = x $100 = x $350 = x $20 = Nonmember:
(Honorary, Senior, Fellow, Active, Associate)
(Junior, Research Scientist, Non-neurologist
Clinician, Business Administrators, Students)
x $110 = x $110 = x $95 = x $115 = x $160 = x $255 = x $210 = x $85 = x $95 = x $105 = x $160 = x $235 = x $235 = x $155 = x $460 = x $45 = x $140 = x $150 = x $125 = x $155 = x $185 = x $385 = x $265 = x $110 = x $125 = x $135 = x $185 = x $315 = x $315 = x $210 = x $615 = x $60 = *If you are attending the Clerkship and Program Directors’ Conference (1EP.001) only and no other Annual Meeting events, the cost increases $50.
** If you are attending the Future of Neuroscience Conference (7SC.001) only, and no other Annual Meeting events, the cost increases $70 ($170 on-site) and includes Thursday
and Friday Scientific events. Medical students and PhD candidates may attend at no charge but MUST register and receive a ticket.
114
Primary Focus of Practice
City/State/Country
Fax
Member Neurologist (Active, Associate, Fellow)
$240
$355 Member Neurologist (Senior, Honorary)
$0
$0 $545
$775 Nonmember BOX C: Virtual Annual Meeting
Syllabi CD
There is a fee for each selected Education Program. Calculate the total
in the Education Program Fee Schedule on page 112 and enter in Box B
in the Fees section. To register for a program, shade the box and enter
the complete number of the program on the line.
Saturday, April 10, 2010
1EP. 1AC. 2BS. 2AC. 2FC. 2DS. 2NP. Junior and Non-Neurologist Member
$39
$99 Member Neurologist
$49
$99 Nonmember
$59
$99 MP3 ON-DEMAND and DVD (available after AAN Annual Meeting)
3AS. 3MR. 3NF. $849 $849 $849 $199
$299
$499
$1,099 $1,099 $1,099 BOX D: Additional Opportunities (check all that apply)
Wednesday, April 14, 2010
Celebration for Research Guest Tickets (one free ticket per registrant)
5CS. 5SW. Thursday, April 15, 2010
6TP. 6CS. $50 ea. Run/Walk for Brain Research $25 ea. AAN and AAN Foundation Awards Luncheon (Junior Members and Students free upon request)
$50 ea. Support Research, Buy a Brain $5 ea. TOTAL Friday, April 16, 2010
Registrations received after March 10, 2010, will be processed at higher rates
7SC. 7PC. 7PW. 7TP. 7NP. 7NF. Saturday, April 17, 2010
4. Exhibitors
I would like to receive hard copy mailings, invitations, and emails from exhibitors.
5. Payment
Check/Money Order Payment must accompany registration. Make check payable
to American Academy of Neurology (US funds only). A $25 charge will apply to
checks returned for insufficient funds.
8AC. Questions:
$129
$199
$299
Junior and Non-Neurologist Member
$99
$299 Member Neurologist
$149
$299 Nonmember
$199
$299 Virtual Annual Meeting Three-Pack (Webcast, Syllabi, and MP3)
Junior and Non-Neurologist Member
Member Neurologist
Nonmember
4PC. 4NP. 6BS. 6PC. Junior and Non-Neurologist Member (limit 1)
$99
$599 Member Neurologist
$149
$599 Nonmember
$199
$599 Virtual Annual Meeting Two-Pack (Syllabi on CD and Webcast ON-DEMAND)
2SW. 2LS. 2PC. Tuesday, April 13, 2010
5BS. 5PC. $299 $299 $299 Junior and Non-Neurologist Member (limit 1)
Member Neurologist
Nonmember
Practice CD
3SW. 3PC. 3DS. 4BS. 4LS. $49
$99
$149
1KP. 1NP. Monday, April 12, 2010
3BS. 3AC. 3FC. Junior and Non-Neurologist Member (limit 1)
Member Neurologist
Nonmember
Webcast ON-DEMAND
1FC. 1PC. Sunday, April 11, 2010
Register:
$0 Calculated in program fee schedule on page 112 2. Education Program
8BS. After March 10
$0
BOX B: Education Program Fees
Email
7BS. 7AC. 7FC. Before March 10
Student Junior and Non-Neurologist Member $90
$120 (Junior, Business Administrator, Non-Neurologist Clinician, Research Scientist)
ZIP/Postal Code
Telephone
Total Program Fees
(Enter in Box B on Registration Form): BOX A: General Registration Fee
Address
Registrant’s mailing and email addresses will be used for AANgenerated hard copy mailings and emails related to the Annual
Meeting. Check the box if you would also like to receive hard copy
mailings, invitations, and emails from third-party exhibitors.
Box B: Education Program Fees: Calculate the total fees using the
Education Program Fee Schedule.
One form per registrant
Name (last, first, middle) and degree (MD, DO, PhD, RN)
Indicate your Primary Focus of Practice: Aging/Dementia, Behavioral Neurology,
Cerebrovascular Disease, Chronic Pain, CNS Infectious Disease, Critical Care,
EEG, EMG, Epilepsy, General Neurology, Headache, Interventional Neurology,
Movement Disorders, Neuro-oncology, Neuro-ophthalmology, Neuropharmacology,
Neurorehabilitation, Sleep Disorders, or currently not in practice.
Box A: General Registration Fee: Select the appropriate fee. All
attendees and Scientific Program presenters are required to pay this
fee. See page 108 for fee inclusion details.
3. Fees
1. Personal Information
AAN ID Number
Step 4: Exhibitors
Step 3: Fees
AAN 62ND Annual Meeting Registration Form / Deadline: March 10, 2010
VISA Master Card Online: www.aan.com/abstractreg / Fax: (415) 979-2260
Mail: A AN Registration / CMR
33 New Montgomery, Suite 1100
San Francisco, CA 94105
Card number: Expiration date: aanreg@cmrus.com
(800) 676-4226 US/Canada
(415) 979-2283 International
Signature
American Express Diner’s Club
/ No government credit cards.
I authorize the AAN to charge my credit card the amount determined by the AAN as
registration fees.
Fed ID# 41-0726167AAN
115
Hotel Reservations
Save on Hotel Reservations
Take advantage of the AAN’s special hotel rates to make your
trip more affordable. Annual Meeting hotel accommodations are
processed by Convention Management Resources (CMR).
AAN Online Hotel Reservations
www.aan.com/abstractreg
The AAN makes it easy and convenient to book your hotel rooms for
the 62nd Annual Meeting. Booking online allows you to:
xx Take advantage of the AAN’s special hotel rates
xx View room descriptions, photos, and availability
xx Access maps of hotel proximity to Annual Meeting locations
Mail, Fax, or Telephone Reservations
All correspondence, questions, and inquiries should be directed to
CMR at:
Mail:
AAN Housing c/o CMR
33 New Montgomery, Suite 1100
San Francisco, CA 94105
email: aanhousing@cmrus.com
Fax:
Credit card reservations only
(415) 979-2260
Phone:
Credit card reservations only
US/Canada (800) 676-4226
International (415) 979-2283
Hours:
Monday–Friday
6:00 a.m.–6:00 p.m. (PST)
Deposits
xx All hotels require a credit card guarantee or a check deposit of $300
(US dollars) per room and $500 (US dollars) per suite. Deposits will
be credited towards your first night’s room and tax.
xx No hotel reservation will be processed without a credit card
guarantee or a deposit.
xx Deposits are refundable up to seven days prior to arrival, after which
there will be no refunds.
xx Credit cards will be charged for one night’s room and tax if you fail
to arrive on the confirmed date of arrival or if you fail to cancel your
reservation at least seven days prior to arrival.
Hotel Reservations Form
Confirmations, Changes, and Cancellations
xx You will receive your hotel confirmation from CMR. This is the only
confirmation you will receive.
xx Contact CMR if your housing confirmation is not received within one
week of mailing.
xx Please check your arrival and departure dates carefully.
xx After March 10, 2010, you may still submit your hotel form to CMR.
After this date, however, rooms are subject to availability.
Note: Some hotels may charge a penalty for changes made to your
departure date after you have checked in.
Group Accommodations
Reservation Deadline: March 10, 2010 / Meeting Dates: April 10–April 17, 2010
1. Confirmation to:
Please type or print clearly. One form per registrant. Confirmations
sent by mail, fax, or email.
Nonsmoking room
Company name
6. Occupants:
List all occupants, giving primary occupant first:
Mailing address
Additional Tax/Assessments
Fax
Booking your room through the official AAN housing company assures
you are getting a room at the hotel that best fits your needs. You
are also helping the AAN maintain consistent and competitive and
registration fees. The reason is simple. When a city is selected as the
site for the AAN Annual Meeting, contracts are signed with several
hotels reserving a specific number of rooms to be available for meeting
attendees. If these rooms are not sold, the AAN is liable financially.
Penalties incurred affect the overall costs of the Annual Meeting
and what the AAN charges for registration, exhibit space, and
other services.
Smoking room
Note: Special requests are forwarded to the hotels for their
consideration and are subject to availability.
Blocks of 10 or more sleeping rooms are considered a group. Fax your
written request to (415) 979-2260 or email to aanhousing@cmrus.com
and you will be contacted by an AAN Housing Consultant.
Why Book a Hotel Room Through the AAN?
Special Needs: Name (last, first, middle)
City/State/Zip
xx Rates do not include the 13.00% hotel tax.
xx An $8 per night assessment fee is included to offset the expense of
the meeting.
NOTE: All hotel rates are listed in Canadian dollars and the amount
due at the time of check out from your hotel will be based on current
exchange rates.
5. Special Requests:
1. Country
2. 3. Telephone
4. 7. Payment:
Email
International attendees indicate country/city code: 2. Hotel Preference:
Please indicate your choice (list ten hotels).
Hotel rooms assigned on a first-come, first-served basis.
1. All AAN hotel reservations must be guaranteed with a credit card or
check deposit of $300 per room, $500 per suite. No hotel reservations
will be processed without a guarantee. Cancellation deadline is seven
days prior to arrival date. Late cancellations subject to forfeit of room
deposit or one night’s room plus tax charge.
Check enclosed; Check no. Payable to: Convention Management Resources
2. 7. 3. 8. 4. 9. 5. 10. VISA American Express Diner’s Club
Card number: Expiration date: Cardholder’s name: 6. 3. Accommodations:
Master Card Signature: To register online visit www.aan.com/abstractreg
Single: 1 person, 1 bed
Double: 2 people, 1 bed
Double/Double: 2 people, 2 beds
Triple: 3 people, 2 beds
Quad: 4 people, 2 beds
Suite: 1 bedroom
Suite: 2 bedrooms
By mail:
AAN Housing/CMR
33 New Montgomery, Suite 1100
San Francisco, CA 94105
Note: Suites are available on a limited basis. All persons requesting a
suite will be contacted by an AAN Housing Consultant.
By email:
4. Arrivals and Departures:
By phone: Credit card reservations only
Day and date of arrival: aanhousing@cmrus.com
Day and date of departure: US/Canada (800) 676-4226
International (415) 979-2283
Note: Some hotels may charge a penalty for departure date changes
after check-in.
By fax: Credit card reservations only
(415) 979-2260
Hours:
Monday–Friday
6:00 a.m.–6:00 p.m. (PST)
Note: Rates are listed in Canadian dollars. The amount you pay when
you check out will be based on the current exchange rates.
116
117
Travel Information
Opportunities for Students, Residents, and Fellows
Save on Travel Arrangements
Direct Through Airlines
Book your travel now to Toronto, ON, Canada and take advantage
of special airline discounts available to meeting attendees and
their companions.
Airport
You may also contact your preferred airline directly and receive a 2- to
10-percent discount off regularly published fares. You must reference
the AAN Annual Meeting and provide the appropriate airline discount
codes listed below.
Toronto is served by the Toronto Pearson International Airport, located
approximately 16 miles from the downtown area, and the Toronto City
Centre Airport, located 8 minutes from downtown via ferry.
Airline Discount Codes Phone Number Website
United 586LT
(800) 521-4041
www.united.com
American 9940AC
(800) 433-1790
www.aa.com
Reservations and Discounts
Delta
NM483
(800) 328-1111
www.delta.com
Porter
NEURO10
(888) 619-8622
www.flyporter.com
Carlson Wagonlit Travel
Carlson Wagonlit Travel is the official travel agency for the Annual
Meeting. For discounted airline tickets to the Annual Meeting and all of
your pre- or post-meeting vacation plans including tours, event tickets,
car rental, and more, contact Carlson Wagonlit Travel at:
(City Centre Airport)
Discounts are subject to availability—book well in advance. Normal
mileage and status upgrades apply for all airline programs. A service
fee may be charged for reservations made via phone.
Travel Updates
Phone: (866) 978-1071
Email: aanparticipants@carlsonwagonlit.com
Hours:Monday–Friday, 7:30 a.m.–5:00 p.m. CST
Closed weekends and holidays
A $52 international per ticket service charge will be assessed.
For travel information updates, visit the AAN Annual Meeting website
at www.aan.com/am.
A valid passport is required for travel between the United States
and Canada.
The AAN Alliance offers a variety of tours
during the AAN’s 62nd Annual Meeting
in Toronto. Tours are open to all Annual
Meeting attendees, their families, and
guests. Tours are sponsored by the AAN
Alliance and operated by the JPdL Destination
Management tour company.
Tour Registration
Reservations for all tours are available
by advance registration only and must be
received by Thursday, March 18, 2010, by 5:00
p.m. EST, to guarantee space.
To register, download the registration form at
www.aan.com/go/about/alliance
Submit printed form:
xx By Fax to the AAN Tour Bureau at
(416) 221-6372 (Visa, American Express &
Master Card only)
xx By Mail to AAN Tour Bureau, c/o JPdL
Toronto, 2 Berkeley Street, Suite 500,
Toronto, ON, Canada, M5A 4J5 (Money
Order in Canadian Funds only), Visa,
American Express & Master Card
When registering, keep the following in mind:
xx Credit card, check, and money order
payments will be accepted until March 18,
2010. Registrations will be accepted based
on availability.
xx Advance registration is required.
xx Prepaid tickets will be held in your name at
the convention center’s Registration Desk.
xx JPdL Destination Management tour
company reserves the right to cancel tours
when the minimum number of registrants
is not met; pre-registered registrants will
receive a full refund.
xx All tour buses depart from and return to
the Metro Toronto Convention Centre
North. Please arrive 15 minutes prior to
departure.
xx A jacket and comfortable walking shoes are
recommended for all tours.
xx On-site registration will be subject to a
$10.00 handling fee.
Medical and graduate students and PhD candidates who present a
student ID card or are AAN members receive free admission to the
Annual Meeting. See page 112 for registration rates for residents
and fellows.
Basic Science Resident Curriculum
A multi-year basic science curriculum, launched at the 2007 Annual
Meeting, will help neurology residents prepare for Part I of the
Neurology Boards, and the RITE ™.
See page 23 for more details.
Celebration for Research: Neurobowl®, Main Stage, Neuro
Film Festival, and Neuro Hop
Sunday, April 11/ 6:30 p.m.–11:00 p.m.
See page 24 for details.
Consortium of Neurology Residents and Fellows Meeting
Monday, April 12 / 5:00 p.m.–6:00 p.m.
AAN Alliance Tours
Tours Available in
the Toronto Area
To help build careers in neurology, the AAN 62nd Annual Meeting
offers a variety of opportunities to students, residents, and fellows.
Annual Meeting registration for students, residents, and fellows
includes scientific platform and poster sessions, Plenary Sessions,
Colloquia, Awards Luncheon, Celebration for Research, and Exhibits.
Medical students and residents also receive a reduced rate for
Education Programs.
Tour Information
Sunday, April 11
2:00 p.m.-5:00 p.m.
Discover Toronto City Tour
Monday, April 12
9:00 a.m.-5:00 p.m.
Niagara: The Wonder of It All
Tuesday, April 13
12:00 p.m.-5:00 p.m.
Historic Architectural City Tour with Visits to
Bata Shoe Museum and Casa Loma
Wednesday, April 14
1:00 p.m.-5:00 p.m.
Two Unique Museums: Royal Ontario Museum
and the Gardiner Museum of Ceramic Art
Come and learn about the consortium, meet officers, and participate in
discussions on a variety of topics related to residents and fellows.
Residents and Fellows Career Forum and Reception
Monday, April 12 / 6:30 p.m.–9:00 p.m.
Learn how to search for a fellowship, how program directors select
fellows, and how a fellowship could benefit your career. Find out how
to start a career in academics/research and private practice.
Socialize with other residents and fellows as well as representatives
from various neurology programs and learn about potential positions
from headhunters. Advertisers in Dendrite™ Careers in Neurology will
also be on hand to discuss job opportunities.
Programs that feature an international element will have the
opportunity to showcase their programs.
Free and open to all meeting registrants. See page 28 for more
information.
American Board of Psychiatry and Neurology Resident
Informational Session
Monday, April 12 / 4:00 p.m.–5:00 p.m.
Meet members of the American Board of Psychiatry and Neurology
(ABPN). The panel will discuss all aspects of the neurology boards
and what is expected from candidates. Free and open to all
meeting registrants.
SIGN Meeting and Reception
Monday, April 12 / 5:00 p.m.–6:30 p.m.
Student and faculty representatives from existing Student Interest
Groups in Neurology (SIGN) chapters and those interested in starting
chapters will gather for presentations and discussions. This is free and
open to all medical students.
American Academy of Neurology and American Academy of
Neurology Foundation Awards Luncheon
Wednesday, April 14 / 12:00 p.m.–1:30 p.m.
MTCC, Exhibit Hall B
Join AAN leaders as they honor the recipients of the 2010 AAN
Awards. From enterprising high school students to world renowned
researchers, this program recognizes some of the top accomplishments
in neuroscience research. See page 54 for more information.
Resident/Medical Student Rush Line
Check in at the Information Booth each morning for tickets to available courses for that day. Two tickets will be held for each course, available
on a first-come, first-served basis. Eligible participants are limited to one free course per day, two free courses for the week unless there are
unclaimed rush tickets ten minutes prior to a course starting. The program is available for half-day and full-day courses, case-study, kick-off,
Neuro Flash, Neurology Skills Pavilion, Morning Report, and therapy programs. Seminars, workshops, and luncheons are not included. No CME
will be provided.
Thursday, April 15
1:00 p.m.-5:00 p.m.
Truly Canadian!
Opportunities to Save Money:
Visit www.aan.com/go/about/alliance for more
details.
Discount on Virtual Annual Meeting products if ordered before Annual Meeting (see page 104).
Education and Scientific Program Monitors, Skills Workshop Volunteers (see page 107)
AAN Staff Contact
Donna Honeyman
dhoneyman@aan.com
phone: (651) 695-2713
fax: (651) 361-4813
Note: All tour fees are Canadian currency.
118
119
Educational Programs and Scientific Sessions by Topic
Aging/Dementia/Degenerative Disease
1KP.001
Assessment of Rapidly Progressive Dementias
and Related Neurologic Conditions...............................................................7
2DS.001 Mild Cognitive Impairment: Implications for Clinicians...............................8
3MR.001 Morning Report: Behavioral Neurology........................................................8
3PC.003 Non-Alzheimer’s Dementia............................................................................9
3AS.001 Improving Accuracy of Dementia Diagnosis:
Case Studies with Both Imaging and Neuropathology................................9
PD1
Aging and Dementia: Risk Factors Poster Discussion Session................ 34
P01
Poster Session I............................................................................................ 34
Presidential Plenary Session....................................................................... 31
IN5
Proteins, Genes, Neurodegeneration, and the Clinical
Presentations Integrated Neuroscience Session.......................................41
P02
Poster Session II........................................................................................... 44
S14
Aging and Dementia: Epidemiology............................................................ 52
5BS.001 Anosognosia and Anosodiaphoria in Stroke and Dementia......................10
P03
Poster Session III.......................................................................................... 56
Geriatric Neurology Highlights in the Field................................................ 79
S24
Aging and Dementia:Imaging...................................................................... 66
P04
Poster Session IV......................................................................................... 68
S34
Aging and Dementia: Recognition and Treatment.................................... 76
5CS.001 Case Studies: Dementia...............................................................................11
6BS.001 Differential Diagnosis of Dementia: Linking Clinical
Syndromes to Pathology...............................................................................11
P05
Poster Session V........................................................................................... 80
S44
Aging and Dementia: Cellular Anatomy and Exercise Physiology........... 90
S54
Aging and Dementia: Genetics................................................................... 92
P06
Poster Session VI......................................................................................... 94
7BS.001 Diagnosing Spells in Older Adults...............................................................12
7FC.002 Dementia Update..........................................................................................13
8BS.001 Vascular Cognitive Impairment and Dementia:
Current Status and Future............................................................................13
Cerebrovascular Disease/Interventional Neurology
1KP.004
2FC.006
3AC.004
3LS.001
3PC.004
3DS.002
3NF.001
3AS.002
P01
4LS.001
S02
4PC.003
P02
S12
S18
4NP.001
P03
S22
5PC.005
P04
S32
P05
S42
120
Surviving Stroke Call: A Guide for Non-Vascular Neurologists..................7
Cerebrovascular Disease................................................................................7
Update on Endovascular Treatment of Cerebrovascular Diseases.............8
Primary and Comprehensive Stroke Centers:
The Future of Stroke Care..............................................................................9
Stroke Prevention in 2010..............................................................................9
Stroke in Children and Neonates...................................................................9
Acute Stroke Management............................................................................9
Stroke Rehabilitation for Spatial Neglect:
Win-Win Treatment Science..........................................................................9
Poster Session I............................................................................................ 34
Telemedicine Increases Options for Successful
Stroke Treatment: Nuts and Bolts...............................................................10
Cerebrovascular Disease: Stroke Epidemiology I...................................... 42
Localization in Clinical Neurology................................................................10
Poster Session II........................................................................................... 44
Cerebrovascular Disease: Acute Stroke Therapy...................................... 52
Interventional Neurology............................................................................. 53
Neurology Skills Pavilion: Acute Stroke Alert............................................10
Hot Topics Plenary Session......................................................................... 32
Poster Session III.......................................................................................... 56
Contemporary Clinical Issues and Course Studies Plenary Session....... 54
Cerebrovascular Disease I........................................................................... 66
Perioperative Stroke: A Practical Approach to Risk Stratification
and Modification During the Preoperative Evaluation...............................11
Poster Session IV......................................................................................... 68
Cerebrovascular Disease: Stroke Imaging................................................. 76
Frontiers in Clinical Neuroscience Plenary Session.................................. 78
Poster Session V........................................................................................... 80
Critical Care and Emergency Neurology/Endovascular
and Interventional/Stroke and Vascular Neurology Highlights
in the Field..................................................................................................... 79
Cerebrovascular Disease: Stroke Prevention............................................ 90
S49
S52
PD6
P06
6TP.003
7BS.004
IN9
7FC.001
7PC.004
8BS.005
8AC.002
Cerebrovascular Disease: Hemorrhagic Stroke......................................... 91
Cerebrovascular Disease II.......................................................................... 92
Cerebrovascular Disease: Acute Stroke Therapy
Poster Discussion Session........................................................................... 94
Poster Session VI......................................................................................... 94
Therapy Program: Stroke..............................................................................12
Unruptured Intracranial Aneurysms and Intracranial Vascular
Malformations: What a Practicing Neurologist Needs to Know..............12
Ischemic Stroke, Interventional, and Endovascular Therapies / Large
Vessel Disease Integrated Neuroscience Session................................. 102
Genetics in Neurology..................................................................................13
Stroke In Young Adults.................................................................................13
Clinical Trials Session................................................................................ 101
Advances in the Care of Brain Injury After Resuscitation
from Cardiac Arrest.......................................................................................13
Women’s Issues In Cerebrovascular Diseases...........................................13
Child Neurology/Developmental Neurobiology
1KP.003
2AC.006
IN2
3BS.003
3AC.001
3DS.002
3AS.004
P01
P03
5PC.002
P05
S45
7AC.006
7PC.004
7PC.006
7NF.001
Movement Disorder Emergencies: Adults and Children..............................7
Advanced Topics in Pediatric Neurology I:
Neurodegenerative Diseases.........................................................................7
Pediatric Demyelinating Disorders Integrated
Neuroscience Session................................................................................. 26
Blink and You Live: Coma Prognosis in Child Neurology..............................8
Advanced Topics in Pediatric Neurology II: Neuro-oncology......................8
Stroke in Children and Neonates...................................................................9
EEG In Children: Developmental Maturation, Variants, Epilepsy
Syndromes, and Identification of Surgical Candidates................................9
Poster Session I............................................................................................ 34
Child Neurology / Woman’s Issues Highlights in the Field....................... 79
Presidential Plenary Session....................................................................... 31
Poster Session III.......................................................................................... 56
Diagnosis and Management of Movement Disorders in Children............11
Poster Session V........................................................................................... 80
Child Neurology: Developmental Neurobiology........................................ 90
Child Neurology I...........................................................................................13
Stroke In Young Adults.................................................................................13
Child Neurology II..........................................................................................13
Neuro Flash: Child Neurology.......................................................................13
Cognitive Neurology/Neurologic Disorders Presenting with Psychiatric
Symptoms/Behavioral Neurology
2BS.001
2AC.001
3BS.001
3MR.001
IN4
3AC.003
4BS.001
S08
4PC.003
5BS.001
P03
5PC.001
P04
P05
6PC.001
S58
7PC.001
8BS.001
Attention Deficit Hyperactivity Disorder Across the Lifespan....................7
Structure Function Correlations in Behavioral Neurology...........................7
Can I Drive? Can I Fly?.....................................................................................8
Morning Report: Behavioral Neurology........................................................8
Current Concepts in Cognitive Neuroscience: Implications for
Neurological Diseases Integrated Neuroscience Session....................... 30
Traumatic Brain Injury.....................................................................................8
The Neurology of Social Behavior.................................................................9
Behavioral Neurology Highlights in the Field............................................ 79
Behavioral Neurology: From Genetics to Brain
Function to Behavior.................................................................................... 43
Localization in Clinical Neurology................................................................10
Anosognosia and Anosodiaphoria in Stroke and Dementia......................10
Poster Session III.......................................................................................... 56
Primer of Cognitive Neurology.....................................................................11
Poster Session IV......................................................................................... 68
Poster Session V........................................................................................... 80
Frontiers in Clinical Neuroscience Plenary Session.................................. 78
Psychiatry for the Neurologist.....................................................................12
Behavioral Neurology: Language, Action, and Memory........................... 93
Behavioral Neurology: Contemporary Topics: Vision................................13
Vascular Cognitive Impairment and Dementia:
Current Status and Future............................................................................13
Critical Care/Emergency Neurology/Trauma
1KP.003
Movement Disorder Emergencies: Adults and Children..............................7
Educational Programs and Scientific Sessions by Topic
3PC.002
P01
P02
S17
5PC.003
6BS.002
6PC.002
7FC.004
7PC.002
8BS.005
Traumatic Spinal Cord Injury..........................................................................9
Poster Session I............................................................................................ 34
Poster Session II........................................................................................... 44
Critical Care, Trauma, and Inpatient Neurology........................................ 53
Emergency Neurology...................................................................................11
Critical Care Epilepsy/EEG...........................................................................11
Critical Care and Emergency Neurology/Endovascular
and Interventional/Stroke and Vascular Neurology Highlights
in the Field..................................................................................................... 79
Neurologic Consultations in the ICU...........................................................12
Neurologic Intensive Care............................................................................13
Emergency Room Neuro-ophthalmology....................................................13
Advances in the Care of Brain Injury After Resuscitation
from Cardiac Arrest.......................................................................................13
Demyelinating Disorders/Multiple Sclerosis and Related Diseases
1KP.007
2AC.003
IN2
Multiple Sclerosis (Quint)Essentials..............................................................7
Update on Multiple Sclerosis I: Basic Science.............................................7
Pediatric Demyelinating Disorders Integrated
Neuroscience Session................................................................................. 26
2PC.003 Update on Multiple Sclerosis II: Clinical.......................................................8
3MR.003 Morning Report: Multiple Sclerosis..............................................................8
3PC.001 Diagnostic Dilemmas in Multiple Sclerosis..................................................9
3NF.003 Neuro Flash: Multiple Sclerosis.....................................................................9
P01
Poster Session I............................................................................................ 34
S01
Multiple Sclerosis: Clinical Research I....................................................... 42
S10
Multiple Sclerosis: MRI I............................................................................. 43
P02
Poster Session II........................................................................................... 44
S11
Multiple Sclerosis: Clinical Trials I.............................................................. 52
P03
Poster Session III.......................................................................................... 56
S21
Multiple Sclerosis: Clinical Trials II............................................................. 66
S30
Multiple Sclerosis: Genetics and Human Immunopathogenesis............. 67
IN7
Multiple Sclerosis Imaging Integrated Neuroscience Session................ 65
P04
Poster Session IV......................................................................................... 68
S31
Multiple Sclerosis: Biomarkers................................................................... 76
S40
Multiple Sclerosis: Epidemiology............................................................... 77
5CS.004 Case Studies: Multiple Sclerosis.................................................................11
6BS.003 Criteria for Stopping and Starting Multiple Sclerosis Therapy.................11
PD5
Multiple Sclerosis and Related Diseases:
Drug Mechanisms Poster Discussion Session........................................... 80
P05
Poster Session V........................................................................................... 80
Multiple Sclerosis Highlights in the Field.................................................. 79
S41
Multiple Sclerosis: Clinical Immunology.................................................... 90
S50
Multiple Sclerosis: EAE/Animal Models.................................................... 91
S51
Multiple Sclerosis: Clinical Research II...................................................... 92
S60
Multiple Sclerosis: MRI II............................................................................ 93
P06
Poster Session VI......................................................................................... 94
6TP.002 Therapy Program: Multiple Sclerosis..........................................................12
7AC.003 Clinical Issues in Multiple Sclerosis............................................................13
7PC.003 MRI and Multiple Sclerosis..........................................................................13
8AC.003 Neuromyelitis Optica: Scientific and Clinical Update................................13
Epilepsy/Clinical Neurophysiology (EEG)
1KP.006
2PC.001
3FC.003
3AS.004
4BS.005
P01
S05
PD2
P02
S15
Intractable Epilepsy: What to Do When Nothing Works............................7
How to Analyze Spells by Video-EEG............................................................8
Clinical Epilepsy...............................................................................................8
Epilepsy Highlights in the Field................................................................... 79
EEG In Children: Developmental Maturation, Variants, Epilepsy
Syndromes, and Identification of Surgical Candidates................................9
Recognition and Management of the Many Types
of Status Epilepticus.......................................................................................9
Poster Session I............................................................................................ 34
Clinical Neurophysiology Highlights in the Field....................................... 79
Epilepsy: Clinical Epilepsy........................................................................... 42
Epilepsy Poster Discussion Session........................................................... 44
Poster Session II........................................................................................... 44
Epilepsy: Clinical Neurophysiology and Imaging....................................... 52
P03
5SW.001
S25
6BS.002
P05
S55
6TP.001
7FC.005
7NF.002
Hot Topics Plenary Session......................................................................... 32
Poster Session III.......................................................................................... 56
Neurophysiologic Intraoperative Monitoring.............................................11
Epilepsy: Antiepileptic Drug Therapy......................................................... 66
Critical Care Epilepsy/EEG...........................................................................11
Poster Session V........................................................................................... 80
Clinical Neurophysiology: Intraoperative
Neurophysiologic Monitoring; Evoked Potentials..................................... 92
Therapy Program: Epilepsy...........................................................................12
Clinical EEG....................................................................................................13
Neuro Flash: Epilepsy....................................................................................13
Ethics/Professionalism
4BS.003
4EC.001
4PC.004
P02
5BS.004
S59
Advanced Palliative Care and Symptom Management of ALS,
Alzheimer’s Disease, or Parkinson’s Disease...............................................9
Ethics Colloquium..........................................................................................10
Practical Legal Issues for Neurologists.......................................................10
Poster Session II........................................................................................... 44
Case Studies: Clinical Ethics, Professionalism, and
Evidence-based Care of Patients with Severe Life-limiting
Neurologic Disease.......................................................................................10
Ethics Highlights in the Field....................................................................... 79
Ethics............................................................................................................. 93
General Neurology/Neurology of Systemic Disease
2BS.003
2FC.002
2FC.005
3BS.001
3FC.002
3AS.003
4BS.006
4PC.003
5PC.003
S37
P05
S47
6PC.001
6PC.004
P06
7BS.003
7FC.003
8AC.001
Global Health Challenges: Neurology in Developing Countries..................7
Neurology Update I.........................................................................................7
Continuum Test Your Knowledge: A Multiple-Choice
Question Review.............................................................................................7
Can I Drive? Can I Fly?.....................................................................................8
Therapy in Neurology......................................................................................8
Clinical Pearls in Bedside Neurology.............................................................9
Bone Disease for the Practicing Neurologist................................................9
General Neurology Highlights in the Field................................................. 79
Localization in Clinical Neurology................................................................10
Emergency Neurology...................................................................................11
Neurologic Manifestations: Imaging and Therapeutics........................... 77
Poster Session V........................................................................................... 80
Neurologic Manifestations: Clinical Neurophysiology
and Epidemiology......................................................................................... 91
Psychiatry for the Neurologist.....................................................................12
Women’s Neurologic Issues in Pregnancy..................................................12
Poster Session VI......................................................................................... 94
Neurologic Complications of Nutritional Deficiencies...............................12
Neurology Update II......................................................................................13
Neurologic Complications of Medical Disease..........................................13
Headache
2BS.006
Peripheral Nerve Blocks and Other Interventional
Procedures for Headache and Facial Pain ...................................................7
3MR.002 Morning Report: Chronic Migraine: Basis and Tools
for Management..............................................................................................8
3FC.004 Headaches in Adults.......................................................................................8
S07
Headache I.................................................................................................... 43
Contemporary Clinical Issues and Case Studies Plenary Session........... 54
P04
Poster Session IV......................................................................................... 68
S35
Headache II................................................................................................... 76
P06
Poster Session VI......................................................................................... 94
7TP.003 Therapy Program: Headache........................................................................13
8AC.004 Hot Topics in Headaches and Related Disorders.......................................13
History of Neurology
S09
P02
5BS.002
5PC.004
History of Neurology.................................................................................... 43
Poster Session II........................................................................................... 44
Archival Neurologic Films.............................................................................10
History of Neurology: Landmark Case Studies
of Neurological Giants..................................................................................11
121
Educational Programs and Scientific Sessions by Topic
Imaging
2AC.003
2FC.004
3AC.002
4PC.001
6CS.004
7SC.001
7PC.003
Update on Multiple Sclerosis I: Basic Science.............................................7
Update in Neuroimaging: Essentials and Beyond–Part I............................7
Update in Neuroimaging: Essentials and Beyond–Part II...........................8
Spine Neuroimaging: Clinical-Radiologic Correlation................................10
Neuroimaging Highlights in the Field......................................................... 79
Case Studies: Neuroimaging........................................................................12
Future of Neuroscience Conference: Frontiers in
Neuroimaging: Coming Soon to a Scanner Near You................................13
MRI and Multiple Sclerosis..........................................................................13
Infectious Disease/AIDS/Prion Disease
2BS.003
IN3
3FC.005
4BS.004
P03
S27
P04
8BS.004
Global Health Challenges: Neurology in Developing Countries..................7
Global Neurology: Toxins and Infections Integrated
Neuroscience Session................................................................................. 29
Infections of the Nervous System.................................................................8
Approach to Acute CNS Infections................................................................9
Neuro-infectious Disease Highlights in the Field...................................... 79
Poster Session III.......................................................................................... 56
Contemporary Clinical Issues and Case Studies Plenary Session........... 54
Infections...................................................................................................... 67
Poster Session IV......................................................................................... 68
Neurologic Complications of Immunosuppressive
and Immunomodulatory Therapy.................................................................13
Movement Disorders
1KP.003
2FC.001
2DS.002
3DS.001
4BS.002
Movement Disorder Emergencies: Adults and Children..............................7
Movement Disorders......................................................................................7
The Dystonias: Diagnosis, Treatment, and Update on Causes...................8
Top 10 Pitfalls in the Diagnosis of Parkinson’s Disease...............................9
Introduction to the Evaluation and Therapy of Restless Legs Syndrome
and Periodic Limb Movements in Sleep........................................................9
P01
Poster Session I............................................................................................ 34
S03
Movement Disorders: Epidemiology of Parkinson’s Disease................... 42
S13
Movement Disorders: Huntington’s Disease: Pathophysiology
and Clinical Assessment.............................................................................. 52
S19
Movement Disorders: Dystonia.................................................................. 53
5BS.005 Hyperkinetic Movement Disorders: Diagnosis and Treatment.................10
P03
Poster Session III.......................................................................................... 56
Movement Disorders Highlights in the Field............................................. 79
S23
Movement Disorders: Parkinson’s Disease / Non-Motor Symptoms..... 66
5PC.002 Diagnosis and Management of Movement Disorders in Children............11
PD4
Movement Disorders: Parkinson’s Disease: Treatment
Poster Discussion Session........................................................................... 68
P04
Poster Session IV......................................................................................... 68
S33
Current and Future Treatment of Parkinson’s Disease............................. 76
5CS.003 Case Studies: Unusual Movement Disorders.............................................11
P05
Poster Session V........................................................................................... 80
IN8
Deep Brain Stimulation: Where Are We and Where Do
We Go From Here Integrated Neuroscience Session............................... 89
S43
Movement Disorders: Essential Tremor and Ataxia................................. 90
S53
Movement Disorders: Parkinson’s Disease and
Atypical Parkinsonism................................................................................. 92
7BS.006 Update on Ataxias.........................................................................................12
7AC.001 Deep Brain Stimulation Management.........................................................13
7AC.002 Botulinum Toxins: Practical Issues and Clinical Uses
for Neurologists.............................................................................................13
7FC.001 Genetics in Neurology..................................................................................13
7PW.001 Clinical Usefulness of Botulinum Toxin and
Treatment of Dystonia..................................................................................13
7TP.002 Therapy Program: Movement Disorders.....................................................13
8BS.003 Balance and Gait Disorders..........................................................................13
8AC.006 Parkinson’s Disease and Movement Disorders Update.............................13
122
Neuroepidemiology/Health Services Research
P01
Poster Session I............................................................................................ 34
S29
Neuroepidemiology...................................................................................... 67
Neuroepidemiology Highlights in the Field................................................ 79
P06
Poster Session VI......................................................................................... 94
Neurogenetics/Gene Therapy
1KP.009
IN1
2AC.003
2PC.002
3NF.002
3AS.006
P03
S38
7FC.001
Biological Rhythms and Neurologic Disease................................................7
Emerging Concepts in Genetics Integrated Neuroscience Session........ 25
Update on Multiple Sclerosis I: Basic Science.............................................7
Genetic Testing in Clinical Neurology...........................................................8
Neuro Flash: Neurogenetics...........................................................................9
Diagnosis and Management of Leukodystrophies.......................................9
Hot Topics Plenary Session......................................................................... 32
Poster Session III.......................................................................................... 56
Neurogenetics Highlights in the Field........................................................ 79
Neurogenetics: Basic Science and Therapeutics...................................... 77
Genetics in Neurology..................................................................................13
Neurometabolic Disorders/Neurotoxicology/Neuroendocrinology
1KP.009
2DS.005
3DS.004
4PC.005
6CS.003
7FC.001
Biological Rhythms and Neurologic Disease................................................7
Important Drug Interactions for Neurologists and Psychiatrists................8
Mitochondrial Disorders in Neurology..........................................................9
Neurotoxicology............................................................................................10
Case Studies: Adult Metabolic Disorders...................................................12
Genetics in Neurology..................................................................................13
Neuromuscular Disease/Clinical Neurophysiology (EMG)/Anterior Horn/
Autonomic Disorders/Peripheral Nerve
1KP.002
2BS.002
2AC.005
2SW.001
2NP.001
3FC.006
3SW.001
P01
S06
4PC.002
4PC.003
P02
S16
PD3
P03
IN6
S26
P04
S36
5CS.002
6BS.005
P05
S46
S48
S55
S56
P06
Diagnosis and Management of Motor Neuron Disease: ALS.....................7
Update on Myotonias.....................................................................................7
Neuromuscular Junction Disorders...............................................................7
EMG Skills Workshop: Basic..........................................................................7
Neurology Skills Pavilion: Neuromuscular Bedside Rounds........................8
Peripheral Neuropathy....................................................................................8
Advanced Techniques in EMG and Neuromuscular Disease......................8
Poster Session I............................................................................................ 34
Neuromuscular Junction and Muscle Disorders....................................... 43
Evaluation and Management of Autonomic Disorders..............................10
Localization in Clinical Neurology................................................................10
Poster Session II........................................................................................... 44
Anterior Horn: Clinical Studies.................................................................... 53
Anterior Horn: Therapeutics Poster Discussion Session.......................... 56
Poster Session III.......................................................................................... 56
Autonomic/Neuroendocrinology/Pain and Palliative
Care Highlights in the Field......................................................................... 79
Contemporary Clinical Issues and Case Studies Plenary Sessions......... 54
Emerging Treatments in Neuromuscular Disease
Integrated Neuroscience Session.............................................................. 64
Peripheral Nerve: Clinical Advances in Peripheral Neuropathy.............. 67
Poster Session IV......................................................................................... 68
Anterior Horn: Spinal Muscular Atrophy.................................................... 77
Case Studies: Unusual Diagnostic and Management
of Cases in Neuromuscular Disease............................................................11
Small Fiber Neuropathies: Somatic, Autonomic,
or a Mixture of Both......................................................................................11
Neuromuscular Highlights in the Field....................................................... 79
Poster Session V........................................................................................... 80
Peripheral Nerve: Molecular Mechanisms
of Peripheral Neuropathy............................................................................ 91
Autonomic Disorders: Frontiers of Autonomic Neurology........................ 91
Clinical Neurophysiology: Intraoperative Neurophysiologic
Monitoring; Evoked Potentials.................................................................... 92
Anterior Horn: Basic Science...................................................................... 93
Poster Session VI......................................................................................... 94
Educational Programs and Scientific Sessions by Topic
7BS.002
7AC.005
7PC.005
7TP.001
8BS.002
8AC.005
Rapid Quantitation in EMG: Learning Accurate and
Efficient Motor Unit Potential Analysis.......................................................12
Clinical EMG I................................................................................................13
Clinical Trials Session................................................................................ 101
Clinical EMG II...............................................................................................13
Therapy Program: Neuromuscular Disease................................................13
Autoimmune Testing in Neuropathy: Indications
for the Practicing Clinician............................................................................13
Clinical Approach to Muscle Disease..........................................................13
Neuro-oncology
S39
6PC.003
P06
7BS.005
7AC.004
IN10
Neuro-oncology: Paraneoplastic Disorders............................................... 77
Frontiers in Clinical Neuroscience Plenary Session.................................. 78
Neuro-oncology Highlights in the Field...................................................... 79
Neuro-oncology Update I: Primary Brain Tumors.......................................12
Poster Session VI......................................................................................... 94
Case Studies in Neuro-oncology.................................................................12
Neuro-oncology Update II: Systemic Cancer..............................................13
Molecular Markers and Targets in Neuro-oncology
Integrated Neuroscience Session............................................................ 103
Neuro-ophthalmology/Neuro-otology
1KP.008
2BS.004
3FC.007
3DS.003
3NF.004
5BS.003
S28
P04
6BS.004
6CS.001
7PC.002
7NP.001
8AC.007
Top 10 Neuro-ophthalmic Diagnoses You Can’t Afford to Miss.................7
Canalith Repositioning for Benign Paroxysmal Positional Vertigo.............7
Neuro-ophthalmology.....................................................................................8
Common and Important Ophthalmoscopic Findings....................................9
Neuro Flash: Neuro-Ophthalmology..............................................................9
Neuro-ophthelmology/Neuro-otology Highlights in the Field................. 79
Eye Movement Disorders: A Systematic Approach
to the Evaluation of Diplopia........................................................................10
Neuro-ophthalmology/ Neuro-otology....................................................... 67
Poster Session IV......................................................................................... 68
Nystagmus: An Organized Approach..........................................................11
Now You See It, Now You Know It; (Nearly)
Pathognomonic Signs in Neuro-ophthalmology Findings..........................12
Emergency Room Neuro-ophthalmology....................................................13
Neurology Skills Pavilion: Neuro-ophthalmology
and Neurovestibular Exam Lab....................................................................13
Neuro-otology...............................................................................................13
Neural Repair/Rehabilitation
2DS.006
3AC.003
3PC.002
3AS.002
3AS.005
P02
P05
S57
Implications of Combat-Related Traumatic Brain Injury..............................8
Traumatic Brain Injury.....................................................................................8
Traumatic Spinal Cord Injury..........................................................................9
Stroke Rehabilitation for Spatial Neglect:
Win-Win Treatment Science..........................................................................9
Brain Computer Interfaces: Frontiers in
Neurology and Neuroscience.........................................................................9
Neural Repair/Spine Highlights in the Field............................................... 79
Poster Session II........................................................................................... 44
Contemporary Clinical Issues and Case Studies Plenary Session........... 54
Poster Session V........................................................................................... 80
Neural Repair and Neurorehabilitation...................................................... 93
Pain
3FC.001
4BS.003
6PC.005
Challenging Pain Patients...............................................................................8
Advanced Palliative Care and Symptom Management of
ALS, Alzheimer’s Disease, or Parkinson’s Disease......................................9
Autonomic/Neuroendocinology/Pain and Palliative
Care Highlights in the Field......................................................................... 79
Common Spine Disorders.............................................................................12
Practice Management
1FC.001 The Practice of Neurology: Issues in Coding and Reimbursement.............7
1EC.001 BRAINS Colloquium........................................................................................7
1NP.001 Neurology Skills Pavilion: Health Information
Technology for Neurology: The Electronic Frontier......................................7
1KP.005 Starting Your Career: The Early Years...........................................................7
2EC.001 Patient Safety Colloquium: Diagnostic Errors in Neurology........................7
2AC.002 Making Sure Your Electronic Health Record System is a Success.............7
2LS.001 E/M: Minimize Mistakes, Maximize Reimbursement..................................7
2LS.002 Bulletproof Your Practice: What You Need to Know About
Compliance and Regulatory Issues to Stay Ahead of the Curve................7
2EC.002 Practice Colloquium: Are You Ready? Meeting Practice
Challenges Posed by Performance, Payers, & Policy...................................8
2PC.006 Bedside Evidence-Based Medicine: How to Deconstruct
Articles in Order to Take Care of Patients.....................................................8
2DS.003 Practice Survival for Neurologists: Business
Strategies for Success....................................................................................8
3LS.001 Primary and Comprehensive Stroke Centers:
The Future of Stroke Care..............................................................................9
4LS.001 Telemedicine Increases Options for Successful Stroke
Treatment: Nuts and Bolts...........................................................................10
Research/Education
1AC.001
1EP.001
1PC.001
2BS.005
2AC.004
2PC.004
3BS.002
3EC.001
P01
4EC.002
S20
Resident Basic Science I: Neuropathology...................................................7
Clerkship and Program Directors Conference..............................................7
Resident Basic Science II: Clinical Application
of Neuropathology..........................................................................................7
Clinical Grant Writing.....................................................................................7
Clinical Research Methods I..........................................................................7
Clinical Research Methods II.........................................................................8
Career Development for Clinician Educators................................................8
Education Colloquium: International Education...........................................8
Poster Session I............................................................................................ 34
NIH Sponsored Clinical Trials in Neurology: What’s Going On?
How to Participate? How Can We Do Better?............................................10
Neurologic Education................................................................................... 53
Sleep Disorders
2FC.003
2DS.004
4BS.002
S04
P02
P03
6CS.002
Neurology of Sleep..........................................................................................7
The Interface of Sleep and Neurologic Disorders........................................8
Introduction to the Evaluation and Therapy of Restless
Legs Syndrome and Periodic Limb Movements in Sleep.............................9
Sleep Medicine Highlights in the Field....................................................... 79
Sleep Disorders............................................................................................ 42
Poster Session II........................................................................................... 44
Poster Session III.......................................................................................... 56
Case Studies: Sleep Medicine.....................................................................12
Spinal Cord/Nerve Root Disorders
2PC.005
2DS.006
3PC.002
3AS.005
4PC.001
6PC.005
Myelopathies...................................................................................................8
Implications of Combat-Related Traumatic Brain Injury..............................8
Traumatic Spinal Cord Injury..........................................................................9
Brain Computer Interfaces: Frontiers in
Neurology and Neuroscience.........................................................................9
Neural Repair/Spine Highlights in the Field............................................... 79
Spine Neuroimaging: Clinical-Radiologic Correlation................................10
Common Spine Disorders.............................................................................12
Women’s Issues
4BS.006
6PC.004
8AC.002
Bone Disease for the Practicing Neurologist................................................9
Child Neurology/Women’s Issues Highlights in the Field........................ 79
Women’s Neurologic Issues in Pregnancy..................................................12
Women’s Issues In Cerebrovascular Diseases...........................................13
123
Exhibitor Listing
Exhibit Hours: Monday, April 12, 5:00 p.m.–7:00 p.m. / Tuesday, April 13, 11:30 a.m.–5:00 p.m.
Wednesday, April 14, 11:30 a.m.–5:00 p.m. / Thursday, April 15, 11:30 a.m.–4:00 p.m.
Lundbeck Inc. (formerly Ovation
Pharmaceuticals)
(847) 282-1000
The AAN would like to acknowledge the following exhibitors’ participation in the 62nd Annual Meeting:
Accera
(303) 999-3700
Biogen Idec, Inc.
(617) 914-7074
Acorda Therapeutics
(914) 347-4300
BioMed Central Ltd
+44 203 192 2000
Admar Neurodiagnostic
Instruments
1-800-331-3957
Bioness, Inc.
(800) 211-9136
Allergan, Inc.
(714) 246-4500
Boehringer Ingelheim
Pharmaceuticals, Inc.
(203) 798-9988
Alzheimer’s Association
(312) 335-5897
Borm Bruckmeier Publishing
(310) 414-8300
AMBU, Inc.
(800) 262-8462
Boston Scientific Neurovascular
(510) 440-7701
American Association
of Neuromuscular &
Electrodiagnostic Medicine
Foundation
(507) 288-0100
Bozeman Deaconess Hospital
(406) 599-0674
American Association
of Neuromuscular and
Electrodiagnostic Medicine
(507) 288-0100
Cambridge University Press
(212) 924-3900
Canadian Epilepsy Alliance
(604) 807-8683
American Board of Psychiatry &
Neurology
(847) 229-6500
Canadian League Against
Epilepsy
(519) 433-4073
American Parkinson Disease
Association
(718) 981-8001
CareFusion (formerly Cardinal
Health)
(608) 273-5000
APBD Research Foundation
(212) 290-2546
CleveMed
(216) 791-6720
Athena Diagnostics, Inc.
(800) 394-4493
Clinical Neurology News
(973) 290-8200
Aurora Health Care
(800) 307-7497
Clinical Neurology and
Neurophysiology Symposium
2011
+9722 652-0574
Austrian Society of Neurology
+43-512-8091-19
Baxter
(847) 940-2000
Bayer HealthCare
Pharmaceuticals
(973) 305-5000
Baylor Health Care System
(972) 860-8505
Benign Essential Blepharospasm
Research Foundation, Inc.
(409) 832-0788
124
Cadwell Laboratories, Inc.
(509) 735-6481
Cure PSP - Society for
Progressive Supranuclear Palsy
(PSP), Inc.
(410) 785-7004
Genzyme Therapeutics
(617) 252-7500
Cyberonics, Inc.
(800) 332-1375
Grass Technologies, An AstroMed, Inc. Subsidary
(401) 828-4000
Demos Medical Publishing
(212) 683-0072
DigiTrace SleepMed
(803) 779-5454
Duchenne Connect/Parent
Project Muscular Dystrophy
(404) 778-0553
Dystonia Medical Research
Foundation
(312) 755-0198
Electrical Geodesics, Inc.
(541) 687-7962
Electro-Cap International, Inc.
(937) 456-6099
Elekta, Inc.
(770) 670-2592
EMD Serono, Inc.
(781) 681-2329
EMD Serono, Inc.
(781) 681-2477
Endo Pharmaceuticals Inc.
(610) 459-7273
Equinox Health Solutions Inc
(213) 712-7402
European Federation of
Neurological Societies (EFNS)
+39-055-4362-098
European Neurological Society
+41-61-686-7711
CNS Vital Signs
(888) 750-6941
Fold Rx Pharmaceuticals, Inc.
(617) 252-5500
Community Health Systems
(800) 367-6813
Forest Pharmaceuticals, Inc.
(212) 224-6698
Compumedics USA, LTD.
(704) 749-3200
GBS/CIDP Foundation
International
(610) 667-0131
Congressionally Directed Medical
Research Programs (CDMRP)
(301) 619-7071
Genzyme Corporation
(617) 252-7549
Glycominds Inc.
(650) 269-3420
HCA Physician Recruitment
(866) 889-0203
Health and Science Opinion
Research
(760) 598-3770
Health Match BC
(604) 736-5920
Heidelberg Engineering
(800) 931-2230
HRA Research
(973) 240-1200
IgG America, Inc.
(877) 674-9700
In-Step Mobility Products, Inc.
(847) 676-1275
International Essential Tremor
Foundation (IETF)
(913) 341-3880
Ipsen
(650) 624-4900
Jari Electrode Supply
(408) 847-1895
Kadlec Health System
(509) 942-2115
Karger Publishers
(860) 675-7834
Kronus, Inc.
(208) 377-4800
La Lettre Du Neurologue
33-1-466-76283
Lilly USA, LLC
(317) 276-2000
Lions Club International
(630) 571-5466
Lippincott Williams & Wilkins Wolters Kluwer Health
(215) 521-8300
Magnolia Regional Health Center
(662) 293-7683
Magstim
(905) 582-1139
Magventure A/S Denmark
+45 4-499-8444
MAP Pharmaceuticals, Inc.
(650) 386-3100
McKesson
(206) 441-2400
Natus Medical Incorporated
(650) 802-0400
NeuroBrain Diagnostic
(954) 985-5633
NeurogesX, Inc.
(650) 358-3300
Neurology Reviews
(973) 206-3434
NeuroMetrix, Inc.
(781) 890-9989
Nexstim, Inc.
(608) 852-5785
Medivation
(415) 543-3470
Nextgen Healthcare Information
Systems, Inc.
(215) 657-7010
MedLink Corporation
(619) 640-4660
Nihon Kohden America, Inc.
(800) 325-0283
Medtronic, Inc.
(763) 514-4000
Novartis Pharmaceuticals
Corporation
(862) 778-8300
Merck & Co, Inc.
(267) 305-5000
Merz Pharmaceuticals, LLC
(336) 856-2003
Minnesota Epilepsy Group, P.A.
(651) 241-5285
Multigon Industries, Inc.
(914) 376-5200
Multiple Sclerosis Association of
America
(856) 488-4500
National Headache Foundation
(312) 274-2650
National Institute of Neurological
Disorders and Stroke (NINDS)
(301) 496-5751
National Multiple Sclerosis
Society
(212) 476-0457
NationalRad
(877) SDI-NMSI
National Spasmodic Dysphonia
Association
(800) 795-6732
National Spasmodic Torticollis
Association
(714) 378-9837
Nature Publishing Group
(212) 726-9200
Origin Biomed Inc.
(902) 404-3908
Oxford University Press
(212) 726-6000
Pamlab, LLC
(985) 893-4097
Parkinson’s Disease Foundation,
Inc.
(212) 923-4700
Pfizer Inc
(212) 773-2323
Practical Neurology
(484) 581-1834
PracticeLink.com - The Online
Physician Job Bank
1 (800) 776-8383
Professional Risk Management
Services, Inc.
(703) 907-3800
Questcor Pharmaceuticals
(510) 400-0700
Restless Legs Syndrome
Foundation, Inc.
(507) 287-6465
Rochester Electro-Medical, Inc.
(813) 963-2933
Sage Publications
(805) 410-7239
Santhera Pharmaceuticals (USA),
Inc.
(617) 886-5161
Saunders/Mosby-Elsevier, Inc.
(215) 239-3490
Science Trax LLC
(800) 620-1179
Screen, Inc
(206) 517-5087
Sepracor, Inc.
(508) 481-6700
Spinal Muscular Atrophy
Foundation
(646) 253-7100
Society for Vascular &
Interventional Neurology
(414) 389-8613
Walgreens-Option Care
(847) 964-8186
WE MOVE (Worldwide Education
and Awareness for Movement
Disorders)
(212) 875-8312
Wiley-Blackwell
(781) 388-8361
World Association of Sleep
Medicine (WASM)
(514) 874-1998
World Parkinson Congress
(646) 388-7650
WR Medical Electronics Co.
(651) 430-1200
Zogenix
(858) 436-3377
Solstice Neurosciences, Inc.
(267) 620-8044
Springer
(212) 460-1500
St. Vincent Healthcare
(406) 237-4003
Talecris Biotherapeutics Inc.
(919) 316-6300
TEVA Neuroscience, Inc.
(816) 718-1624
The Churkendoose Project - The
Handle Institute
(704) 755-0200
The Electrode Store
(360) 829-0400
The Movement Disorder Society
(414) 276-2145
Tourette Syndrome Association
(718) 224-2999
Transgenomic, Inc.
(402) 452-5400
UCB, Inc.
(800) 477-7877
United Council for Neurologic
Subspecialties (UCNS)
(651) 332-8681
UpToDate
(800) 998-6374
US Bioservices Specialty
Pharmacy
(888) 518-7246
Current as of 2/10/2010
125
62ND Annual Meeting Committee Members and Staff
Annual Meeting Committees
Meeting Management Committee
Stanley Fahn, MD, FAAN, Chair
Neil A. Busis, MD, FAAN
Terrence L. Cascino, MD, FAAN
Cynthia L. Comella, MD, FAAN
John Corboy, MD, FAAN
Robert C. Griggs, MD, FAAN
Jonathan P. Hosey, MD, FAAN
Carlayne E. Jackson, MD, FAAN
Ralph F. Józefowicz, MD, FAAN
Robert T. Leshner, MD, FAAN
John C. Morris, MD, FAAN
Sandra F. Olson, MD, FAAN
Stefan M. Pulst, MD, FAAN
Steven P. Ringel, MD, FAAN
Stephen M. Sergay, MB BCh, FAAN
Bruce Sigsbee, MD, FAAN
Austin J. Sumner, MD, FAAN
Thomas R. Swift, MD, FAAN
Patrick Toalson
Scientific Program Subcommittee
Cynthia L. Comella, MD, FAAN, Chair
Imran I. Ali, MD, FAAN
Peter R. Bergethon, MD
Allison Brashear, MD, FAAN
John W. Engstrom, MD, FAAN
Charles C. Flippen, II, MD, FAAN
Frederick G. Flynn, DO, FAAN
Daniel B. Hier, MD, MBA, FAAN
Jonathan P. Hosey, MD, FAAN
Steven L. Lewis, MD, FAAN
Jennifer R. Molano, MD
John C. Morgan, MD, PhD
Mark L. Moster, MD, FAAN
Joseph E. Safdieh, MD
Pradeep K. Sahota, MD, FAAN
Joseph I. Sirven, MD, FAAN
A. Gordon Smith, MD
Barney J. Stern, MD, FAAN
Laura J. Balcer, MD, MSCE
Robert H. Baloh, MD, PhD
Eric Cheng, MD
William P. Cheshire, Jr., MD, FAAN
F. Michael Cutrer, MD, FAAN
Janis Daly, MS, PhD
Charles S. DeCarli, MD, FAAN
Bradford Dickerson, MD
Edward J. Dropcho, MD
Patricia A. Evans, MD, FAAP, FAAN
Gloria Galloway, MD, FAAN
Claude Hemphill, III, MD, FAAN
Vern C. Juel, MD
Brett M. Kissela, MD, FAAN
Peter J. Koehler, MD, PhD, FAAN
Sookyong Koh, MD, PhD
Steven L. Lewis, MD, FAAN
Nicholas J. Maragakis, MD
Alireza Minagar, MD, FAAN
Avindra Nath, MBBS, FAAN
Raul G. Nogueira, MD
Louis J. Ptacek, MD, FAAN
Joseph I. Sirven, MD, FAAN
Olaf Stuve, MD, PhD
Bradley V. Vaughn, MD, FAAN
Emmanuelle Waubant, MD
Theresa A. Zesiewicz, MD, FAAN
Annual Meeting Subcommittee
Abstract Reviewers
Education Committee
Cynthia L. Comella, MD, FAAN, Chair
Thomas D. Bird, MD, FAAN
Richard D. Brower, MD, FAAN
Seemant Chaturvedi, MD, FAAN
John B. Chawluk, MD, FAAN
Bruce A. C. Cree, MD, PhD
Neill R. Graff-Radford, MD, FAAN
Carlayne E. Jackson, MD, FAAN
David W. Loring, PhD
Jonathan W. Mink, MD, PhD, FAAN
Todd D. Rozen, MD, FAAN
Science Committee
Stefan M. Pulst, MD, FAAN, Chair
Brenda Banwell, MD
David Q. Beversdorf, MD
Merit E. Cudkowicz, MD, MSC
Neill R. Graff-Radford, MD, FAAN
126
Carlayne E. Jackson, MD, FAAN
Karen C. Johnston, MD, MSC
Samia J. Khoury, MD
Richard D. King, MD, PhD
Mark F. Mehler, MD
Jose G. Merino, MD, MPhil
Massimo Pandolfo, MD
Walter A. Rocca, MD, MPH
Raymond P. Roos, MD, FAAN
Natalia Sana Rost, MD
Nina F. Schor, MD, PhD
Jeffery M. Vance, MD, PhD
Walter J. Koroshetz, MD, FAAN
Steve Alexander, MD
Imran Ali, MD, FAAN
Muhammad Al-Lozi, MD
Anthony Amato, MD
Liana Apostolova, MD
Sheena Aurora, MD
Alon Avidan, MD, MPH
Rohit Bakshi, MD, FAAN
Amit Bar-Or, MD, FRCPC
Richard Bedlack, MD, PhD
Jeffrey Bennett, MD, PhD
James Bernat, MD, FAAN
Bibiana Bielekova, MD
Christopher Boes, MD
Aaron Boster, MD
Andrea Bozoki, MD
Richard Brower, MD, FAAN
Robert Brown, MD, FAAN
Jeffrey Burns, MD
Rami Burstein, PhD
Paul Carney, MD
Jose Cavazos, MD, PhD, FAAN
Kevin Chapman, MD
Thomas Chelimsky, MD, FAAN
Peter Chin, MD
Tanuja Chitnis, MD
Michael Chopp, PhD
Emma Ciafaloni, MD, FAAN
Jeffrey Cohen, MD
Steven Cramer, MD
Kirk Daffner, MD
Nabila Dahodwala, MD
Josep Dalmau, MD, PhD
Philip De Jager, MD, PhD
Mahlon DeLong, MD
Elliot Dimberg, MD
Michael Dowling, MD, PhD
Eric Eggenberger, DO, FAAN
Mitchell Elkind, MD, MS, FAAN
Stewart Factor, DO, FAAN
Camilo Fadul, MD, FAAN
Elizabeth Finger, MD
Marc Fisher, MD, FAAN
Nathan Fountain, MD
Edward Fox, MD, PhD
Robert Fox, MD, FAAN
Michael Frankel, MD
Giovanni Frisoni, MD
William Gaillard, MD
Charlene Gamaldo, MD
Christopher Goetz, MD, FAAN
Ralf Gold, MD
Myla Goldman, MD
Errol Gordon, MD
Philip Gorelick, MD, FAAN
Benjamin Greenberg, MD
Rishi Gupta, MD
May Han, MD
Judith Heidebrink, MD
Kenneth Heilman, MD, FAAN
Bernhard Hemmer, MD
Victor Henderson, MD, FAAN
Andrew Hershey, MD, PhD
Lawrence Hirsch, MD, FAAN
Fuki Hisama, MD
Ahmet Hoke, MD, PhD
James Howard, MD, FAAN
Aatif Husain, MD
Costantino Iadecola, MD
Matilde Inglese, MD, PhD
Kurt Jaeckle, MD, FAAN
Cheryl Jay, MD
Barbara Jobst, MD
Karen Johnston, MD, MSC
S. Claiborne Johnston, MD, PhD
Keith Josephs, MD
Tudor Jovin, MD
Brian Kaspar, PhD
Roger E. Kelley, Jr. MD, FAAN
Omar Khan, MD, PhD
Ramesh Khurana, MD, FAAN
Chelsea Kidwell, MD
Bernd Kieseier, MD
Richard King, MD, PhD
Revere Kinkel, MD, FAAN
Mariko Kita, MD
Christine Klein, MD
Dawn Kleindorfer, MD
Annette Langer-Gould, MD
James Leverenz, MD
Richard Lewis, MD, FAAN
Jun Li, MD, PhD
Italo Linfante, MD
Richard Lipton, MD, FAAN
Eng Lo, MD
Catherine Lomen-Hoerth, MD, PhD
Elan Louis, MD, MS, FAAN
Sylvia Lucas, MD, PhD
David Lynch, MD, PhD
Eugene Major, PhD
Ruth-Ann Marrie, MD
Katherine Mathews, MD
Stephan Mayer, MD
Micheline McCarthy, MD, PhD, FAAN
Louise McCullough, MD, PhD
Matthew Meriggioli, MD
Brett Meyer, MD
Timothy Miller, MD, PhD
Margherita Milone, MD
Nancy Minshew, MD, FAAN
Thomas Montine, MD, PhD
Lauren Moo, MD
Anil Nair, MD
Robert Naismith, MD
David Newman-Toker, MD, PhD
Thanh Nguyen, MD
Martin Niethammer, MD, PhD
Katherine Noe, MD, PhD
Marc Nuwer, MD, PhD, FAAN
Anne Louise Oaklander, MD, PhD, FAAN
Michael Okun, MD
Bruce Ovbiagele, MD
Andrew Pachner, MD
Soojin Park, MD
Henry Paulson, MD, PhD, FAAN
Steven Pavlakis, MD, FAAN
Victoria Pelak, MD
Daniel Pelletier, MD
Brian Popko, PhD
Svetlana Pundik, MD
Joseph Quinn, MD
Jeffrey Raizer, MD
Amy Rauchway, DO
Daniel Reich, MD, PhD
Caterina Rosano, MD, MPH
Heidi Roth, MD
Julie Rowin, MD
Walter Royal, MD
Devon Rubin, MD, FAAN
Robert Ruff, MD, PhD, FAAN
Seward Rutkove, MD
Marwan Sabbagh, MD, FAAN
Joseph Safdieh, MD
Juan Sanchez-Ramos, MD, PhD
Paola Sandroni, MD, PhD, FAAN
Jeffrey Saver, MD, FAAN
Sean Savitz, MD
Ernestina Saxton, MD, PhD
Nikolaos Scarmeas, MD
Julie Schneider, MD, MS
Lori Schuh, MD, FAAN
Robert Schwendimann, MD, FAAN
Kathleen Shannon, MD
Anthony Shapira, MD
Nancy Sicotte, MD, FAAN
Cathy Sila, MD, FAAN
Lisa Silbert, MD
John Sims, MD
J. Robinson Singleton, MD
B. Joy Snider, MD, PhD
Evan Snyder MD, PhD
Mark Stacy, MD, FAAN
John Stern, MD, FAAN
Gretchen Tietjen, MD
Ann Tilton, MD, FAAN
David Tirschwell, MD
Bryan Traynor, MD
Ryan Uitti, MD, FAAN
Angela Vincent, MBBS, MSc
Cheryl Waters, MD, FAAN
Nathaniel Watson, MD
Martina Wiedau-Pazos, MD
Heinz Wiendl, MD
Dean Wingerchuk, MD, FAAN
Elaine Wirrell, MD
George Wittenberg, MD, PhD
Gil Wolfe, MD, FAAN
David Wolk, MD
Michael Wong, MD, PhD
Daniel Woo, MD
Gregory Worrell, MD
Thoru Yamada, MD
George York, MD, FAAN
Scott Zamvil, MD, PhD
Lorne Zinman, MD
Robert Zivadinov, MD
Stephan Zuchner, MD
Susan Dunlop
Annual Meeting Staff
Naomi Reeves
Catherine M. Rydell, CAE
Director, Development
Alberta Zais
Director, Corporate Relations
Cheryl Alementi
Senior Administrator, Education
Elizabeth Busch
Administrator, Grants
Bridget Farley
Manager, Exhibits and Corporate Relations
Sarah Glover
Senior Specialist, Conference Management
Julie Grengs
Senior Specialist, Research, Education, and
Development
Andy Halverson
Promotions Project Manager, Center for Research,
Education, and Development
Kevin Heinz
Senior Manager, Education and Science
Terry Heinz
Administrator, Grants and Research
Erin Jackson
Program Manager, Scientific Programs
Kyle Krause
Administrator, Scientific Programs
Valerie Mendoza
Manager, Conference Management
Amy Nostdahl
Program Manager, Education Programs
Tina Novack
Executive Assistant, Executive Administration
Lucy Persaud
Program Manager, Education
Nancy Poechmann
Program Manager, Education
Julie Ratzloff
Senior Manager, Conference Management
Administrator, Programming and Logistics
Chief Executive Officer
AAN, AAN Professional Association, AAN
Foundation, and AAN Enterprises, Inc.
Kristine Retka
Christine E. Phelps
Senior Administrator, Exhibits & Affiliate Meetings
Deputy Executive Director
AAN and AAN Foundation
Kris Fridgen
Senior Director, Center for Research, Education,
and Development
Susan Rodmyre
Administrator, Corporate Relations
Franziska Schwarz
Lori Strachota
Program Manager, Conference Management
Wendy Vokaty
Senior Specialist, Center for Research, Education,
and Development
Director, Education
127
Offices and Hours of Operations
AAN Alliance Booth and Registration
MTCC North Building (Level 200)
Lost and Found (Registration)
MTCC South Building (Level 600)
Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:30 a.m.–4:00 p.m.
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m.
Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m.
AAN Research Area
MTCC South Building (Level 600)
Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
AAN Meeting Information
MTCC South Building (Level 600) and North Building (Level 200)
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m.
Monday, April 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–8:00 p.m.
Tuesday, April 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m.
Wednesday, April 14–Friday, April 16 . . . . . . . . . . . 6:00 a.m.–7:30 p.m.
Saturday, April 17 (North Building Level 200 only) . . . . . . 6:00 a.m.–1:00 p.m.
Academy Central
MTCC South Building (Level 600)
Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Materials Distribution
MTCC South Building (Level 600)
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m.
Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m.
Materials Distribution
MTCC North Building (Level 200)
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m.
BrainPAC Booth
MTCC South Building (Level 600)
Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Exhibitor Registration
MTCC South Building (Level 600)
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m.
Sunday, April 11–Wednesday, April 14 . . . . . . . . . . 6:30 a.m.–6:30 p.m.
Thursday, April 15 . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–12:00 p.m.
Housing Desk
MTCC South Building (Level 600)
Saturday, April 11–Thursday, April 15 . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Friday, April 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–2:00 p.m.
Internet and Message Center
MTCC South Building (Level 600)
Saturday, April 10–Sunday, April 11 . . . . . . . . . . . . 6:30 a.m.–6:30 p.m.
Monday, April 12–Friday, April 16 . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Internet and Message Center
MTCC North Building (Level 200)
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–1:00 p.m.
2010 Annual Meeting Supporters
Current as of 2/8/10
ThankYou
Lost and Found (Registration)
MTCC North Building (Level 200)
Acorda Therapeutics, Inc.
Forest Laboratories, Inc.
Pfizer Inc/Medivation, Inc.
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m.
4/11 Newspaper Belly Band
4/12 Door Drop Insert Marketing
Meeting Administration Office
MTCC South Building (Level 600)
4/12 Door Drop Marketing
Genzmye Corporation
Corporate Therapeutic Update
4/12 Door Drop Insert Marketing
4/13 Door Drop Insert Marketing
Exhibit Guide
Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Banner Marketing
Exhibit Guide
PSAV Presentation Services
Membership
MTCC South Building (Level 600)
Corporate Therapeutic Update
Residents Scholarship Fund
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m.
Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m.
Exhibit Guide
Glycominds Inc.
Allergan, Inc.
4/12 Door Drop Insert Marketing
Groff Trust
4/13 Door Drop Insert Marketing
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m.
Corporate Therapeutic Update
Ipsen Pharma
Neurology Community Information
TBD
Exhibit Guide
4/12 Door Drop Insert Marketing
Exhibit Hall Presentation Stage
Exhibit Guide
Press Room
MTCC South Building (Room 803AB)
Resident/Medical Student Scholarship
Fund
Kronus
Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10:00 a.m.–6:00 p.m.
Monday, April 12–Thursday, April 15 . . . . . . . . . . . . 7:00 a.m.–7:00 p.m.
Residents Scholarship Fund
Lundbeck Inc.
Membership
MTCC North Building (Level 200)
Registration
MTCC South Building (Level 600)
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m.
Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m.
Registration
MTCC North Building (Level 200)
American Board of Psychiatry and
Neurology (ABPN)
Exhibit Guide
Bayer Healthcare Pharmaceuticals, Inc.
7AC.003 Clinical Issues in MS
Eli Lilly and Company
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m.
2BS.001 ADHD Across the Lifespan
Speaker Ready Room
MTCC North Building (Room 205AB)
Residents Scholarship Fund
Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m.
Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m.
Monday, April 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–8:00 p.m.
Tuesday, April 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m.
Wednesday, April 14–Friday, April 16 . . . . . . . . . . . 6:00 a.m.–7:30 p.m.
Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–1:00 p.m.
Celebration for Research Gold Sponsor
Exhibit Guide
EMD Serono, Inc.
EMD Serono, Inc./Pfizer Inc
4/12 Door Drop Insert Marketing
Banner Marketing
Carpet Marketing
Exhibit Hall Opening Reception
Banner Marketing
Exhibit Guide
2BS.006 Peripheral Nerve Block
Exhibit Guide
4/12 Door Drop Insert Marketing
Banner Marketing
Medtronic, Inc.
7AC.001 Deep Brain Stimulation
Management
Celebration for Research – Neuro Film
Festival
Questcor Pharmaceuticals, Inc.
Residents Scholarship Fund
Sepracor Inc.
Banner Marketing
Teva Neuroscience, Inc.
6TP.002 Therapy Program: Multiple
Sclerosis
4/13 Door Drop Marketing
4/13 Door Drop Insert Marketing (2)
Celebration for Research – Main Stage
Residents Scholarship Fund
UCB Inc.
Celebration for Research – NeuroBowl
Stage
Merz Pharmaceuticals Inc.
United Council for Neurologic
Subspecialties (UCNS)
2DS.002 The Dystonias
Residents Scholarship Fund
Neurology
Wolters Kluwer (Lippincott Williams
and Wilkins)
WIFI Access
Exhibit Guide
Shuttle Bus Service
Neurology and Continuum
Zogenix, Inc.
4/12 Newspaper Belly Band
Neurology Now and Continuum
4/13 Exhibit Hall Coffee Break
Exhibit Guide
Shuttle Bus
Book Bags
Pfizer Inc
4/12 Door Drop Insert Marketing
Corporate Therapeutic Update
Exhibit Guide
Current as of 2/10/10
128
Planning Your Trip to Toronto
important annual meeting information
Registration and Hotel Reservation Deadline: March 10, 2010
Registration, Hotel, and Travel Reservations: www.aan.com/am
Registration and Hotel
Travel
Mail:
AAN Registration and Housing c/o CMR
33 New Montgomery, Suite 1100
San Francisco, CA 94105
Airline Reservations:
Carlson Wagonlit Travel
Fax:
Credit card reservations only
(415) 979-2260
Phone:
Credit card reservations only
US/Canada
(800) 676-4226
International
(415) 979-2283
Email:
Registration: aanreg@cmrus.com
Housing: aanhousing@cmrus.com
Phone:
(866) 978-1071
Fax:
(866) 914-2817
Email:
aanparticipants@carlsonwagonlit.com
Hours:
Monday–Friday, 7:30 a.m.–5:00 p.m. CST
Closed weekends and holidays
Hours:
Monday–Friday
6:00 a.m.–6:00 p.m. Pacific Standard Time
Suggest an Education Program for Upcoming Meetings
2011 Annual Meeting: Honolulu
The AAN invites you to submit an Education Program suggestion for the 63rd Annual Meeting, April 9 through
April 16, 2011, in Honolulu. Proposals for new programs are due by May 13, 2010.
Submit a proposal via the Annual Meeting website at www.aan.com/am.
For questions or more information on the Annual Meeting Education Program, contact Amy Nostdahl at
anostdahl@aan.com or (651) 332-8687.
Here are some important things to
keep in mind when planning your trip:
Travel Documents/Passports and Entry Requirements
Visitors must have valid travel documents/passports to enter Canada
to provide proof of their citizenship. Document requirements vary
depending from which country you are traveling, the reason for your
visit, and the length of your stay, and may include passport or a birth
certificate, photo ID, and/or a visa. Learn more about travel documents
and requirements at www.cic.gc.ca/english/visit/index.asp or
www.toronto.ca/metropolis/english/usefulinfo.htm#customs.
NOTE: Special No-Fee Passports for US Federal
Government Employees
In order to attend the Annual Meeting on business, it may be
necessary for US government employees to obtain an official
United States government no-fee passport from their appropriate
agency office. Government employees should contact the
appropriate office within their agency to discuss proposed
dates of attendance and to confirm whether or not they will
need this official passport.
Currency
Toronto’s currency is the Canadian Dollar; currency exchange is
available at banks and kiosks throughout the city and at the airport.
•For denominations under five dollars, the currency is coins
•US dollars are accepted in most Toronto establishments; however
you will receive change in Canadian funds and exchange rates will
differ from merchant to merchant
•Cash machines/ATMs are available in most banks, hotels, and
shopping centers; please note that ATMs at the airport only accept
ATM cards with the MasterCard logo on them
IMPORTANT NOTE: Don’t forget to call your bank and credit card
companies to let them know you will be traveling to Canada.
Customs, Immigration, and Admissibility
Upon entering Canada, you will be required to go through
customs and immigration. Before you land, your flight crew will
distribute a Travelers’ Customs Declaration Card for you to
complete; Declaration Cards are also available at the airport
upon your arrival. For more information, visit
www.toronto.ca/metropolis/english/usefulinfo.htm#customs.
Anyone with a criminal record (including a drunk driving conviction)
may be excluded from entering Canada. If you were convicted of
or committed a criminal offence outside Canada, you may overcome
this criminal inadmissibility by applying for rehabilitation or you may
be deemed to have been rehabilitated if at least ten years have
passed since you completed the sentence imposed upon you, or
since you committed the offence, if the offence is one that would,
in Canada, be an indictable offence punishable by a maximum term
of imprisonment of less than ten years. For more information, visit
www.cic.gc.ca/english/information/applications/guides/5312ETOC.asp.
Health Insurance
Be sure to check with your health insurance provider about policy
coverage away from home—particularly if you're insured by an HMO
and/or Medicare/Medicaid.
Luggage
Restrictions for carry-on baggage policies and weight and size
limits for checked baggage are different for international flights
than for domestic flights. Be sure to check with your individual
carrier as to weight and measurement restrictions and associated
costs for overages.
Measurements
Canada uses the metric system for weights and measures. If you
choose to drive in Canada, be aware the speed limits are posted
in kilometers per hour instead of miles per hour.
Medication
If you are entering Canada with prescription drugs and syringes:
keep the medication in its original, labeled container; include medical
certificate with syringes showing they are for medical use and
have them declared to Canadian Customs officials; bring an extra
prescription in case your medication is lost and/or to attest to your
need to take such prescriptions; and carry the generic name of
prescription medicines.
Mobile Phone Service
Contact your service provider directly to inquire if service is available
and/or the applicable rates.
Safety
Toronto’s universal number for police, fire, and medical
emergencies is 911.
Tax Rates and Tax Rebates
Most goods and services sold or provided in Canada are subject to the
5% Goods and Services Tax (GST). In Toronto (Province of Ontario),
goods are also subject to an additional 8% Provincial Sales Tax (PST).
When you leave Canada, you may be eligible for a tax refund on the
goods you bought in Canada if you export them within 60 days. For
more information, ask for a copy of the publication called Tax Refund
for Visitors to Canada from the Canada Revenue Agency at
www.cra-arc.gc.ca/menu-e.html or call (800) 66VISIT (1-800-668-4748).
Time Zone
Toronto is in the Eastern Time Zone (the same as Detroit, New York,
and Florida).
For more information, visit www.aan.com/am.
130
Non-Profit Org.
US Postage
PAID
Permit No. 3840
Minneapolis, MN
1080 Montreal Avenue
St. Paul, MN 55116
register early
The deadline for registering without incurring increased general registration and Education Program fees is March 10, 2010. Registrations
received after March 10, 2010, will be processed at a higher rate. On-site registration opens at 8:00 a.m. on Saturday, April 10, 2010, at the Metro
Toronto Convention Centre.
Visit the Annual Meeting Online
Upcoming Annual Meeting Dates
Visit the AAN Annual Meeting website at www.aan.com/am to:
2011: Honolulu
April 9–April 16, 2011
ƒƒ Register for the Annual Meeting
ƒƒ Make travel and hotel arrangements
ƒƒ Search the Education Program
ƒƒ Learn more about special events
2012: New Orleans
April 21–April 28, 2012
2013: San Diego
March 16–March 23, 2013
AAN Website: www.aan.com • Annual Meeting Website: www.aan.com/am • Member Services: (800) 879-1960